[{"article": "For ongoing (or chronic) pain \u2014 a sore lower back, say, or the kind of degenerative arthritis that typically develops with age \u2014 ibuprofen still outperforms acetaminophen.\nIbuprofen doesn't have these two problems \u2014 it's less toxic than the others in the doses that give people pain relief.\nThis is why aspirin has its place as a protective agent against strokes and heart attacks for people at a higher risk.\nAcetaminophen, after all, is the most popular over-the-counter painkiller worldwide.\nAnd that's where things get even more interesting: Acetaminophen isn't actually that safe.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story doesn\u2019t mention costs but since these over-the-counter medications have been widely available for a long time it doesn\u2019t seem like an important omission. Because aspirin has been available the longest and is manufactured by literally hundreds of companies, it is by far the cheaper of the three.", "answer": 2}, {"article": "When his heart disease was first diagnosed four and a half years ago, Mr. Del Sontro, now 50, told his cardiologist he wanted to run one more Bay to Breakers race, a century-old 12-kilometer race in San Francisco.\nThat strategy alone, Dr. Biesecker said, has eliminated the vast majority of candidate genes.\nResearchers\u2019 ignorance of these control regions and what many of them do might doom the effort.\nDr. Biesecker acknowledged that there was no guarantee of success.\nStill, Mr. Del Sontro is preparing for the worst.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There\u2019s no telling what any tests or treatments\u00a0commercialized from this research might cost.", "answer": 2}, {"article": "\"We were worried that there'd be too much scar tissue in the retina itself to be able to deliver the material to the correct spot,\" he said.\nShe was optimistic, but nervous, about the surgery.\nTwo months later, it was time for follow-up assessments.\nShe showed encouraging improvement.\nBut after an hour, the surgery's results looked promising.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There was no mention of costs or insurance coverage.", "answer": 0}, {"article": "\u2022 This is the first time tandospirone has be shown to reverse the deficit in brain neurogenesis induced by heavy alcohol consumption\n\u2022 The researchers also showed in mice that the drug was effective in stopping anxiety-like behaviours associated with alcohol withdrawal, and this was accompanied by a significant decrease in binge-like alcohol intake\n\n\"This is a novel discovery that tandospirone can reverse the deficit in neurogenesis caused by alcohol,\" said study leader neuroscientist Professor Selena Bartlett from QUT's Institute of Health and Biomedical Innovation.\n\"While it could possibly have that effect, it might be able to help reboot the brain and reverse the deficits the alcohol abuse causes - both the inhibition to the brain's ability to regenerate, and the behavioural consequences that come from what alcohol is doing to the brain, like increases in anxiety and depression.\"\nIt is commonly used there and shown to be highly effective in treating general anxiety and well tolerated with limited adverse effects.\"\nAlcohol is specifically very damaging for neurons.\n\"This opens the way to look at if neurogenesis is associated with other substance-abuse deficits, such as in memory and learning, and whether this compound can reverse these.\"\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There is no mention within the release as to the cost of this drug, although it is readily available in both China and Japan. Readers have no indication whether the drug is cheap or expensive, an important factor when evaluating its usefulness among those battling binge drinking and alcoholism.", "answer": 0}, {"article": "At Cooper, cardiologist Phillip Koren said he and colleagues have used the Lariat on the left atrial appendage of about 10 patients in the last six months. The closure was unsuccessful in a few of those cases, but in those, there have been no strokes, said Koren, deputy director of the Cooper Heart Institute. None of the 10 patients suffered adverse events from the device.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "This is an unusual story, not directly about a therapy that patients choose or buy. But we still think the price of the device \u2014 at a minimum \u2014 should be included. The cost of the procedure is also relevant, but not reported on.", "answer": 0}, {"article": "\"I've been treating cocaine-addicted patients for something like 25 years, more, and I've never heard of anybody throwing away cocaine,\" says Dr. Charles Dackis of the University of Pennsylvania, who led a pilot study that suggested modafinil more than doubled addicts' chances of going cocaine-free for at least three weeks.\nHundreds of cocaine users are testing whether that legal pill, called modafinil, could help them kick the addiction, and there's early evidence that it may.\nAddiction specialists gave it a look because even though modafinil isn't a classic stimulant, it triggered something in the brain to also improve patients' mood, energy levels and ability to concentrate _ effects that might counter cocaine withdrawal.\nBut for Dr. Nora Volkow, director of NIH's National Institute on Drug Abuse, the narcolepsy medicine tops the list of promising potential therapies.\nThe prospect of that double-whammy has the National Institutes of Health spending $10.8 million researching modafinil as a potential cocaine treatment.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No mention of the cost of taking modafinil daily. ", "answer": 0}, {"article": "One therapy at M.D.\nNow, because drugs are mostly tested on patients whose cancer has resisted previous treatment, it's usually used on tumors advanced to often fatal stages.\nResearchers acknowledge immunotherapy's promise is furthest from realization for bulky solid tumors, perhaps too advanced for the immune system to beat.\nThat's why immunotherapy's greatest successes will come when it can be used early in treatment, they say.\nSuch research already is under way \u2014 a potential antidote for people whose genetics seemingly fate them for cancer.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not mention costs, which are likely to be very high.", "answer": 0}, {"article": "Varicose veins are one of the more unsightly signs of aging. But new, less-invasive treatments are making it easier to remove them painlessly, bypassing a difficult surgical procedure that was often the only option in the past.\n\nAs many as 25% of women and 15% of men suffer from varicose veins; over the age of 50, one out of two people are affected. Heredity plays a part, but obesity, prolonged standing on the job and hormone therapy increase the risks. Sometimes, varicose veins have no signs or symptoms and require no treatment,...", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Applause all around for this fast and efficient cost comparison. \u201cSmaller veins can often be treated with sclerotherapy, which involves injecting a chemical solution into the vein to destroy it, and costs $250 to $500 per treatment. For larger veins, doctors may recommend endovascular procedures, which range in price from $2,500 to $3,000. These involve threading a catheter into the vein and directing a heat source such as a laser or radio-frequency device into the vein to incinerate it.\u201d There was no price put on the \u201cstripping\u201d option of pulling out the veins entirely, but we still give the story a satisfactory score here.", "answer": 1}, {"article": "Colorectal cancer is the third most common cancer diagnosed in both men and women (excluding skin cancers) and a leading cause of cancer death, the American Cancer Society reports.\nA government panel of experts released updated guidelines today spelling out who should be taking a daily low-dose aspirin for heart health, which also offers the added benefit of protection against colorectal cancer.\nThose who would benefit from the regimen, according to the U.S. Preventive Services Task Force, must meet a strict list of criteria -- including a high risk of heart disease and a low risk of bleeding side effects.\nAt this time, the task force reports that more research is needed to assess whether taking aspirin is beneficial for people who are younger than 50 or those who are 70 and older.\nSpecifically, the group recommends that adults 50 to 59 years old who have a 10 percent or greater 10-year cardiovascular disease risk, are not at an increased risk for bleeding, and have a life expectancy of at least 10 years take a daily low-dose aspirin to prevent heart attack, stroke, and colorectal cancer.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "It is universally known that aspirin is cheap, sold widely and in a manner where its cost will not be a barrier to consumption, so the cost information is not necessary to reiterate in this report.", "answer": 2}, {"article": "MORE: The IUD Answer: Why The Best Form of Birth Control is the One No One Uses\n\nThe researchers followed 237 women who were using an implant like Implanon and Nexplanon and 263 women using the Mirena hormonal IUD.\nThe study is still ongoing, and the researchers plan to recruit up to 800 women and ultimately test whether the IUDs and implants were effective for up to three years after their current FDA-approved duration.\nThe benefit of being able to use the implant and IUD for a longer period of time is that it could reduce costs for individuals and insurance.\nThe implants are currently approved for three years, and the hormonal IUD used in the study is approved for five.\nIn a new study published in the journal Obstetrics & Gynecology, researchers discovered that the hormonal IUD and the implant are highly effective a year after they are currently approved for use.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story mentions potential savings, but we would have liked some figures to give us context. We aren\u2019t given the cost of an office visit and procedure to insert either of the devices being studied, and nobody tries to calculate what a year\u2019s extra contraception is \u201cworth\u201d to a typical woman.", "answer": 1}, {"article": "A new study finds that supplementing the Mediterranean diet with more olive oil or more nuts helps diminish age-related decline in cognitive function. Photo: Getty Images\n\nThe Mediterranean diet, supplemented with a handful of nuts or a few tablespoons of olive oil a day, can counteract the effects of aging on the brain\u2019s ability to function, a new clinical study suggests.\n\nThe study, published online Monday in JAMA Internal Medicine, was unusual in that it employed rigorous scientific practices to test the effect of the diet on health. Most previous evidence showing benefits from the Mediterranean diet was gathered through observational studies, a less conclusive research technique.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story mentions neither of two costs that merited discussion: the cost of following a Mediterranean diet and the cost of the study itself. The former is important to anyone who may want to follow the diet if it proves to delay cognitive decline; the latter because it might explain why few such studies exist.\nIt\u2019s also important to note here that the olive oil and nuts were provided to participants in this study free of charge. And the participants consumed a lot of high-quality olive oil \u2014 a liter per week per family. So the costs of replicating this diet would not be trivial, especially for older adults who may be on fixed incomes (i.e. the kind of people enrolled in the study). And that cost might in turn affect how well people outside of the study can adhere to this diet.", "answer": 0}, {"article": "\u201cThere\u2019s some danger of kids getting a rash, and it would be inadvisable to give it to women in the early stages of pregnancy,\u201d he said.\nSome might not have a large enough sample to find a small but statistically significant effect.\n\u201cIf you\u2019re testing the same intervention on the same population using the same outcome measures, then meta-analysis is a very good technique,\u201d Dr. Barrett said.\nThe authors acknowledged certain weaknesses in their study.\nThere are more than 200 species of virus that cause colds, Dr. Coleman said, and a study could test one species against which echinacea proves ineffective, while leaving open the question of whether it works for others.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Since this article is about a treatment whose benefits are disputed,\u00a0it should tell readers how much it costs.\u00a0This would let them\u00a0do a rough cost-vs.-benefit calculation as they consider whether to\u00a0use echinacea.\u00a0 ", "answer": 0}, {"article": "\"It's all these other components,\" Eckel said.\nThe Mediterranean diet isn't just a little extra olive oil, noted Dr. Robert Eckel, an endocrinologist and past president of the American Heart Association.\nPanagiotakos concludes that this pattern of eating can be easily adopted by people of various cultures and populations.\nAside from helping to prevent the metabolic syndrome\u2013 a cluster of risk factors for heart disease and diabetes- a new study in the Journal of the American College of Cardiology says, the diet can have positive global effects on the individual risk factors: low HDL (\"good\") cholesterol, high triglycerides, high blood pressure and a high blood sugar rate, as seen by your doctor through a blood test.\nThe researchers say what's responsible are the antioxidant and anti-inflammatory effects.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "\n\n\n\n\n \nNot applicable. There was no discussion of costs, i.e. how consumption of a \u2018Mediterranean diet\u2019 compared to more typical diets compare in terms of cost to the consumer. But we think most people would have a pretty good grasp of the general costs of the types of foods involved.\u00a0 But where this becomes an issue, for example, is with what the cost of fresh fish can do to a food budget.\n \n\u00a0", "answer": 2}, {"article": "The information entered on this page will not be used to send unsolicited email, and will not be sold to a third party.\nMoving forward, longer term, observational studies are needed to confirm the safety of fetal exposure to tenofovir treatment, says Pan.\nThose with a high viral load should receive tenofovir treatment starting at gestational week 30 until delivery to reduce the risk of transmission to their infants.\nThe current standard of care is to provide vaccine and immune globulin to reduce transmission rates.\nBased on the findings, the investigators recommend that women be tested for HBV viral load at week 28 of pregnancy.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release makes no mention of the cost of the drug in question, Tenofovir.\u00a0 A web search found that the cost for a month\u2019s supply of the antiviral drug averages just over $1,000.\u00a0For some patients, that cost may be prohibitive. The cost is an issue of particular concern for developing countries, but it is also true that the price may be much lower for them than in the United States. Many pharmaceutical companies offer their drugs at steeply discounted rates in poorer countries to expand access to life-saving medicines.", "answer": 0}, {"article": "Vemurafenib, approved in 2011, can cause non-lethal skin cancers.\nDoctors now dare to hope that giving these new drugs in sequence, or in combination, will help people with melanoma live for years while feeling relatively good.\nPatients with a limited time to live may not be so positive, Turnham says.\nMany of the new drugs aim to remove melanoma's \"cloaking device,\" allowing it to be recognized and killed by the immune system, says Roy Herbst, chief of medical oncology at the Yale Cancer Center.\nFor the first time, however, patients such as Herry have options.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Ballpark costs are mentioned in the final take home quote from the executive director of the Melanoma Research Foundation: \u201c\u201dIf you are a patient and someone says, \u2018There is an 85% chance of you spending $120,000 on a drug, and spending four months of your life being sick, with no benefit,\u2019 you\u2019re not going to be so excited.\u201d", "answer": 1}, {"article": "Exercise, and in particular strength-training routines that develop muscles of the trunk and core, can help reduce pain and improve function, though many people avoid them for fear of doing further harm.\nThose in the third group served as \u201cself-care\u201d controls and received a book containing advice on back exercises and ways to reduce pain.\n\u201cMore participants in the yoga and stretching groups were very satisfied with their overall care for back pain.\u201d\n\nDr. Sherman said that like many other therapies for low back pain, yoga probably would not work for everyone.\nThose in the stretching group saw just as much benefit as the people taking yoga.\n\u201cThe smaller studies which hinted that yoga might be helpful all had problems one way or another.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story did not mention the costs or cost-effectiveness of any of the interventions. These are important issues. Individuals who opt for yoga classes, for instance, may have to bear the costs themselves.\n\n\n\n\n\n\n", "answer": 0}, {"article": "Gastric bypass surgery involves making the stomach smaller, and attaching the lower part of the small intestine directly to the stomach, so much of the small intestine is bypassed.\nThe study helps address a knowledge gap about long-term outcomes of bariatric surgery, said Dr. Jon Gould, chief of general surgery at the Medical College of Wisconsin in Milwaukee.\nAt the study's one-year mark, those who had the bypass had lost 31 percent of their starting weight, but the non-surgical patients had lost just 1 percent.\nAnother possible limitation was the loss of patients during the follow-up, which could have affected the results, the researchers noted.\nFor example, the study included mostly men, so the findings may not apply to women.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Cost is not a component of this story.\u00a0 That is an issue, as the story compares three weight-loss surgical options for morbidly obese individuals, and readers might well be interested in the economics. Also, it would be useful to discuss the costs of\u00a0not having surgery in the matched population.", "answer": 0}, {"article": "This website is archived for historical purposes and is no longer being maintained or updated.\nA majority of states have adopted national guidelines that prohibit basic EMS staff from administering the drug as an injection.\nDepartment of Health and Human Services Secretary Sylvia M. Burwell has made addressing opioid abuse, dependence, and overdose a priority and work is underway at multiple HHS agencies on this important issue.\nHHS\u2019 Health Resources Services Administration recently released a grant opportunity aimed at reducing opioid overdose deaths in rural communities through funding for communities to purchase naloxone and train health care professionals and emergency medical staff on its use.\n\u201cMany of these deaths can be prevented by improving prescribing practices to prevent opioid addiction, expanding the use of medication-assisted treatment, and increasing use of naloxone for suspected overdoses.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There is no mention of costs, either of the drug itself or of providing more training to basic EMTs to achieve certification to administer it.", "answer": 0}, {"article": "Therefore, despite pancreatic cancer representing less than 3% of all cancer cases, more people currently die from it than breast cancer.\nA new blood test developed by researchers at Lund University in Sweden, Herlev Hospital, Knight Cancer Center and Immunovia AB, can detect pancreatic cancer in the very earliest stages of the disease.\nSince the immune system is the first to respond to threats like complex diseases, such as cancer, autoimmune diseases and infections, the microarray was designed to mirror this early response.\nFrom those hundreds of markers, 29 markers were selected to detect pancreatic cancer with 96% accuracy at stage I and II.\nThis provides information about the development of tumours long before being visible on CT or detected by ctDNA.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Cost is not mentioned.\nAlthough the blood test is experimental, researchers would likely be able to provide a rough estimate of what such a 29-biomarker assay might cost.", "answer": 0}, {"article": "During a salvage radical prostatectomy, the prostate gland and surrounding tissue are surgically removed to keep the cancer from spreading.\nNow, a University of Missouri School of Medicine researcher has found that a complex procedure to remove the prostate achieves excellent long-term survival for men after radiation therapy has failed.\n\"By studying a national database of prostate cancer cases, we found that a procedure known as salvage radical prostatectomy can greatly increase a man's chance of survival when traditional radiation therapy has failed to eradicate the cancer.\"\n\"Because radical prostatectomy is a complex surgery, there can be a reluctance to undergo the procedure,\" Pokala said.\n\"However, this study shows that it is a viable treatment option.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The news release does not mention costs.", "answer": 0}, {"article": ".\nThis suggests that the blood test could be used by clinicians for up to a week after injury to detect brain injury.\nThe discovery could greatly expand the window for diagnosing concussions, especially in patients who experience a delayed onset of symptoms.\nThe results showed that the blood test was able to detect brain injuries with 94 percent accuracy, nearly as effective as state-of-the art CT scans.\nThe blood test could also dramatically cut down on the need for computerized tomography (CT) scans.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "We were glad to see a very brief mention in the release that if the biomarker research is confirmed in larger studies, it might someday replace what the release calls \u201cexpensive\u201d CT scans used in emergency rooms to try to diagnose concussion. But there is a tacit assumption that the biomarker would replace the use of CT scans. Experience would suggest, however, that new tests tend not to replace existing methods but are simply added to them. We also want to point out that if this new biomarker test became a commonplace screening tool, it could result in over-screening. Tools for screening have to be evaluated very carefully to have the greatest benefit for the right patients.", "answer": 0}, {"article": "In Alzheimer\u2019s disease, this area of the brain is affected early on, when signs of dementia begin to appear.\nDr. Sandra Black, a brain researcher at the University of Toronto who wrote an editorial on the current study, said the findings could have implications for early stage Alzheimer\u2019s disease if tests were developed to identify this process early through imaging or genomics.\nSuzanne Haber, a neuroscientist at the University of Rochester Medical Center in New York who was not involved in the study, said she was \u201cvery excited about the finding,\u201d but she cautioned that the treatment is very invasive, very expensive and unproven in Alzheimer\u2019s patients.\n\u201cAlthough the current evidence is preliminary, is based on small samples and requires replication, the potential application of deep-brain stimulation in amnestic disorders is enticing,\u201d Black wrote.\nThey also saw signs the treatment might have an effect on memory.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "This line of research is so preliminary that we don\u2019t think it\u2019s necessary that stories report specific cost estimates. This story did include a comment about similar treatments being very expensive.", "answer": 1}, {"article": "Women aged 70 to 75 had the greatest risk reduction, reducing the risk of dying from breast cancer by 84 percent.\nThe study, however, has some limitations, Bernik noted.\nThe greater risk reduction in women aged 70 to 75, Otto said, is probably a result of the long-term good effects of screening participation in the earlier target age group, 50 to 69, before the upper age limit for screening was extended in the Netherlands from 69 to 75.\nNearly 36 percent of these women had never had a mammogram.\nThe risk reduction in younger women, aged 50 to 69, was smaller, at 39 percent, but still considered substantial.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There is no discussion of the costs of mammography.", "answer": 0}, {"article": "For Patients and the General Public:", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "No mention is made of the costs of either neratinib or veliparib/carboplatin. Both treatments\u00a0are experimental and so do not have a market price, but it should be possible to give a rough estimate of the price range of new cancer drugs when they gain regulatory approval. Although the trials detailed in the news release are too early stage to talk about impending approvals, given that the release raises the possibility of \u2018promise for patients\u2019 (in the headline), we think it\u2019s not too early to consider how much patients would have to pay.", "answer": 0}, {"article": "\u201cNumerically this is hardly a major risk, just something we need to keep an eye on,\u201d Holman said.\nThe detailed results also showed no increase in hospitalization for heart failure, which had been a particular concern with DPP-4 inhibitors, the class to which Januvia belongs.\nThere were 228 such hospitalizations for Januvia and 229 in the placebo group, according to data also published in the New England Journal of Medicine.\nIt was undertaken after heart safety concerns were raised over other diabetes medicines.\nMerck in April said the study, called Tecos, of 14,724 patients with type 2 diabetes and a history of heart disease demonstrated that adding Januvia to usual care did not increase major heart problems any more than adding a placebo, removing a cloud that has been holding back sales of the medicine and the company\u2019s share price.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There was no discussion of costs in this story. Cost information is available. It costs about $350 for 30 tablets of 100 mg each.", "answer": 0}, {"article": "Essential fatty acids are substances that are not produced by the human body and are only available from diet.\nThe study, published Monday in the journal Reproductive Health, found that taking capsules containing about 1 gram of a blend of three essential fatty acids produced a significant reduction in PMS symptoms.\nAccording to the study, women who took the supplements for six months saw a bigger benefit than those who took them for three months.\nAccording to the study, the 120 women who participated reported few side effects, and most of those were mild and may have been due to sensitivity to mineral oil, the placebo taken by some of the participants.\nThe study, authored by researchers from the Federal University of Pernambuco, is not the first to address the possible link between PMS and essential fatty acids, substances that play a complicated role in a woman's reproductive system.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not mention costs of the supplements.\u00a0 As we\u2019ve reported, about 70% of the stories we reviewed don\u2019t discuss costs.\u00a0 It\u2019s a bad trend, easily corrected, and takes only another few words in a story.", "answer": 0}, {"article": "Prediabetics are at increased risk for developing diabetes, which can damage the eyes, kidneys, nerves and blood vessels and often leads to cardiovascular disease.\nUsing a simple device for eight hours a night to treat sleep apnea can help people with prediabetes improve their blood sugar levels and may reduce the risk of progressing to diabetes, according to a new study published online in the April 21, 2015, issue of the American Journal of Respiratory and Critical Care Medicine.\n\"Assessment of sleep apnea should be considered in patients at high risk for diabetes and cardiovascular disease, since our study shows that treatment of sleep apnea can reduce these risks.\"\nAfter two weeks, blood sugar control, as measured by an oral glucose tolerance test, improved for those in the CPAP group compared to the oral placebo group.\nBefore and after each treatment period, participants' glucose metabolism was assessed by oral and intravenous glucose-tolerance tests.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release doesn\u2019t address costs at all. This is a significant oversight, since testing to see if a person with diabetes has sleep apnea and, if so, should use a CPAP machine to treat it,\u00a0can cost from hundreds to thousands of dollars.", "answer": 0}, {"article": "\u201cWhen people engage in risky behaviors like driving or smoking, they\u2019re encouraged to take measures that minimize their risk, like wearing a seatbelt or choosing cigarettes with filters.\n\u201cAlthough no substitute for systematic lifestyle improvements, including healthy diet, regular exercise, weight loss, and smoking cessation, complimentary statin packets would add, at little cost, one positive choice to a panoply of negative ones,\u201d the scientists write in their paper.\nWhile statins might combat some of the toll that fatty foods take on cholesterol, there\u2019s a lot they can\u2019t negate: \u201csodium content is high, fibres are absent, and caloric load gargantuan,\u201d Messerli said of the fast food the authors looked at.\n\u201cIt makes sense to make risk-reducing supplements available just as easily as the unhealthy condiments (such as salt or ketchup) that are provided free of charge,\u201d Francis said in his report of the research.\n\u201cThey are not a magic bullet.\u201d\n\nA study in June in the Archives of Internal Medicine suggested, in fact, that statins do not save lives in patients without heart disease, although they may prevent some non-fatal heart attacks.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "In this context, the cost discussion works, even though it is only a passing reference. The authors are trying to argue that statins would not cost much for fast food restaurants. \"It would cost less than 5 pence ($0.07) per customer \u2014 not much different to a sachet of ketchup,\" says one of the authors. It would have been nice to have some clarity on whether that is a wholesale cost, retail cost or a British government cost. For this sort of plan to work in the U.S., assuming it even makes sense, the cost likely would be much higher.", "answer": 1}, {"article": "Surgery is considered by some to be the most definitive treatment, and there is evidence from other studies that it has better long-term cancer outcomes than radiation for higher-risk cancers, but it has more sexual and urinary side effects than radiation.\nNewswise \u2014 Faced with the negative quality-of-life effects from surgery and radiation treatments for prostate cancer, low risk patients may instead want to consider active surveillance with their physician, according to a study released Tuesday by the Journal of the American Medical Association (JAMA).\n\u201cMen who had radiation reported more problems with bowel function and hormone side effects compared to men who had surgery, but these differences were only seen within the first year following treatment,\u201d he said.\n\u201cThis study shows that, despite technological advances in the treatment of prostate cancer, both surgery and radiation still have a negative effect on quality of life,\u201d said co-author David Penson, M.D., MPH, Paul V. Hamilton, M.D., and Virginia E. Howd Professor of Urologic Oncology and professor and chair of the Department of Urologic Surgery.\nThree-year survival from prostate cancer was excellent in the study at over 99 percent for patients regardless of whether they chose surgery, radiation or active surveillance.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Typically, we are asking that a release tell us the \u201ccost\u201d of a therapy or drug, but in this case, we wish the release had given some estimate of the cost savings from active surveillance for patients vs. surgery or radiation or both. This is an important point for both individual patients and the broader society since the population of men with prostate cancer is growing and most are likely to be on Medicare.", "answer": 0}, {"article": "The mantra 'time is brain' still holds true.\"\n\"When the irreversibly damaged brain area affected by the stroke is small, we see that clot removal can make a significant positive difference, even if performed outside the six-hour window,\" says co-principal investigator Tudor Jovin, MD, director of the University of Pittsburgh Medical Center Stroke Institute.\nHowever, a pre-planned interim review of the treatment effectiveness after 200 patients were enrolled in the trial led the independent Data Safety Monitoring Board overseeing the study to recommend early termination of the trial, based on pre-defined criteria demonstrating that clot removal provided significant clinical benefit in the studied patients.\n\"These findings could impact countless stroke patients all over the world who often arrive at the hospital after the current six-hour treatment window has closed,\" says co-principal investigator Raul Nogueira, MD, professor of neurology, neurosurgery and radiology at Emory University School of Medicine and director of neuroendovascular service at the Marcus Stroke & Neuroscience Center at Grady Memorial Hospital.\nBut a milestone study with results published today in the New England Journal of Medicine shows that clot removal up to 24 hours after stroke led to significantly reduced disability for properly selected patients.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Although preventing disability in stroke patients will clearly save health care dollars, it\u2019s also possible that the additional costs of imaging to identify patients eligible for clot removal after six hours will add to health care costs. But this issue is not addressed. The release also contains no information about the potential number (and overall percentage) of stroke patients who might benefit from late clot removal, further obscuring the potential savings in dollars as well as disability.", "answer": 0}, {"article": "As measured by an electroencephalogram (EEG), small children's brains show a specific pattern of activity when they look at a picture of a human face.\nJust the reverse happens in children with autism.\nNormal child development depends on interactions with parents and other people.\nWithout such interactions, language and social skills do not develop.\nBut that's not all, researchers Geraldine Dawson, PhD, and colleagues report.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not discuss costs. And we can only assume that two years of therapy would be quite expensive for families and, as yet unproven in multiple trials, likely would not be covered by insurance.", "answer": 0}, {"article": "One of the most frustrating aspects of brain injuries is that they can be difficult to diagnose; emergency rooms can sometimes miss subtle symptoms, leading to improper treatment and potentially catastrophic consequences. Now, researchers are close to identifying so-called biomarkers that may soon make it possible to pinpoint brain injuries with a simple blood test.\n\nPresence of these biomarkers\u2014proteins produced by an injured brain\u2014could end up determining the future treatment of the estimated 1.4 million athletes, car-crash...", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Not applicable in this case because we understand that It\u2019s too early to discuss costs. There is no specific test mentioned, nor are we told which biomarkers would be included in the pivotal study of that test.\nOnce a test has been created, costs will be relevant (and that\u2019s a point the story could have made.)\u00a0 If the test is exorbitantly expensive to perform, its utility would be limited. We could send a helicopter to rush everyone who has a skiing accident to a neuro-intensive care unit, but that would be\u00a0prohibitively expensive. \nIt\u2019s worth noting that\u00a0in practice\u00a0few if any tests lower the cost of care. In routine use, they can be\u00a0applied more\u00a0indiscriminately, including situations where their use is unlikely to contribute to outcomes that lower downstream costs.", "answer": 2}, {"article": "\u2022 Kim TI, Lee YK, Park SG, et al.\n\"This new research adds to the growing body of evidence that suggests compounds in green tea, such as EGCG, may support cognitive health.\"\nEighty-seven volunteers aged 16 to 34 with Down syndrome were enrolled in the phase 2, randomized, controlled trial.\nThe study was conducted at the IMIM-Hospital del Mar Medical Research Institute in Barcelona, Spain.\nHowever, more research is needed to clarify the nature of the beneficial association between the EGCG and cognitive training intervention (ie, synergistic or additive).\"\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release doesn\u2019t mention the cost of the green tree extract used in the study. By going to the manufacturer\u2019s website we found that a bottle of Life Extension Decaffeinated Mega Green Tea Extract with 100 capsules \u2014 about a month\u2019s supply \u2013 is priced at $22.50.", "answer": 0}, {"article": "An epileptic seizure occurs when large groups of neurons in the brain begin firing uncontrollably, disrupting the balance of electrical activity and causing changes in mental function, motor function and behavior.\nIt\u2019s not known what sets off a seizure, but lately scientists like Dr. Devinsky have been gathering evidence that inflammation, the immune system\u2019s response to injuries or foreign organisms, plays a pivotal role.\nResearchers hope that anti-inflammatories may help ameliorate epilepsy\u2019s underlying causes.\nAlthough they give many epileptics a better quality of life, they do not affect the course of the disease, only its symptoms.\nAs Dr. Devinsky noted, seizures in turn may produce further inflammation, perpetuating the cycle.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The cost of taking anti-inflammatory drugs \u2013 steroids or otherwise \u2013 could be significant over a lifetime. Some of those drugs already are on the market and, as the anecdotes in this story indicate, already being used by some doctors to treat epileptic patients. A few calls and a check on Drugstore.com could have provided readers a range of prices.", "answer": 0}, {"article": "To complicate matters, many migraine sufferers can also experience severe bouts of nausea and vomiting.\nIt's not clear how much the patches will cost, but the class of medications known as triptans can be expensive, as much as $300 a month (although sumatriptan now has a generic version), Waltman said.\nResearch involving 800 patients ultimately led to the approval of Zecuity.\nAccording to Dr. Fawad Khan, a neurologist with Ochsner Neuroscience Institute in New Orleans, few drugs are approved for the treatment of acute, symptomatic migraine.\nA nasal spray is available, as is an injection, but many patients aren't comfortable with these options, Khan and Waltman noted.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story says it\u2019s \u201cnot clear\u201d how much the new patch will cost, which is accurate, but Bloomberg was able to provide a ballpark estimate from a company official, who said it would be in the $95 range. Since this HealthDay piece references the same\u00a0Bloomberg story when discussing the planned launch of the new product, we\u2019re not sure why it didn\u2019t pass along the $95 figure as well.\u00a0We\u2019re pleased that the story at least raised the issue of cost, but we\u2019ll fault it for not providing detail that was easily available. You\u2019d also like to see the cost per migraine episode of this medicine vs. alternatives.", "answer": 0}, {"article": "First published on July 1, 2008 at 12:00 am\nThe study's lead author, Dr. Paul M. Palevsky, said the results may lead to a large savings in U.S. health care costs, estimated at $100 million to $250 million a year for this type of patient.\nDr. Bonventre wrote that the study had \"a predominance of male patients,\" so there is a question of whether its results can be applied to female patients.\n\"When a patient transitions from one therapy to another, the dialysis dose is unlikely to be equivalent,\" he said, adding that results could be affected by different methods in the high-intensity and low-intensity groups.\nThroughout the study, patients remained in intensive or less intensive therapy, although as their clinical conditions changed, they could change forms of therapy, Dr. Palevsky said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There was not explicit information in this story about costs to the individual undergoing care, though one could surmise that less intense treatment would cost less. \u00a0The story included estimates of the impact from the results of the study on costs to the health care system.", "answer": 0}, {"article": "EEGs measure brain electrical activity through electrodes attached to the scalp.\nAlso, the study predicted who was at high risk of autism, but it's unknown if those babies actually went on to develop autism, he noted.\n\"If it can eventually be shown that this technique can reliably identify which children will indeed develop autism, then we will have a valuable tool for early detection,\" Ewen said.\nEEGs are also relatively inexpensive, painless and safe, Bosl said.\nDr. Joshua Ewen, a neurologist and director of the clinical neurophysiology laboratory at the Kennedy Krieger Institute in Baltimore, said the study is well done and looks promising, but needs to be replicated.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "By saying that EEGs are \u201crelatively inexpensive, painless and safe\u201d the story skirts the entire issue of screening costs both at the individual level and at the population level. Even basic genetic screenings for couples considering having children are not covered by many insurance plans unless the couple is in a very high risk group for a particular disorder. The assumption that people might be able to just stop into a clinic and have their child scanned for very little money is naive and misleading.", "answer": 0}, {"article": "Prostate cancer cells express up to 100 times more PCA3 RNA than do normal cells.\nThe test, which is approved in some European countries but not in the U.S., detects genetic material -- RNA -- from prostate cancer gene 3 or PCA3.\nThe PCA3 test can do things the PSA test can't, says Jack Groskopf, PhD, of Gen-Probe Inc., which manufactures the test and funded the new research.\nThe PSA test detects prostate-specific antigen, a protein given off by all prostate cells.\nIt showed that the test accurately predicts whether a prostate biopsy will reveal cancer in high-risk men.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "\u00a0There was no discussion of costs, which might be explained by the fact that the test is not yet available in the US. \u00a0However, since it is commercially available in several European countries, those costs should have been mentioned at the very least. ", "answer": 0}, {"article": "\"The endometrium feeds the baby up until the eighth week of pregnancy.\n\"This study has shown that the EFT can also be an important tool for patients with recurrent pregnancy loss,\" he said.\nKliman and the team focused on the nCyclinE molecular marker as a way to assess patients with recurrent pregnancy loss.\n\"The positive results show us that next we need to study progesterone as a treatment for recurrent pregnancy loss with a prospective randomized trial to validate the findings.\"\nThe researchers believe that the progesterone caused the patients' endometrium to produce more endometrial secretions.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release does not discuss costs.\nCost for generic progesterone range from about $20 to $30 for 30 \u2013 100mg capsules, according to GoodRx\u2019s drug prices tracker.", "answer": 0}, {"article": "Researchers from Norway and Harvard University compared the death rates from breast cancer in four groups: one group of women from 1996 through 2005 who were living in Norwegian counties with screening; another group in the same time period who were living in counties without screening; and two similar groups from 1986 through 1995.\nIt concluded the availability of mammography screening corresponded with a reduction in the rate of death from breast cancer, \"but the screening itself accounted for only about a third of the total reduction.\"\n\"Among women in the nonscreening group, there was an 18 percent reduction in the rate of death from breast cancer, as compared with the preceding 10-year period, presumably as a result of increased breast-cancer awareness, improved therapy, and the use of more sensitive diagnostic tools,\" the findings state.\nThe publication notes that in 2002, the World Health Organization concluded that mammography screening for women between ages 50 and 69 reduced the death rate from breast cancer by 25 percent.\nThe study, published in the New England Journal of Medicine, analyzed data from more than 40,000 women with breast cancer.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "", "answer": 0}, {"article": "Vertigo -- episodes of dizziness that can last for minutes or days -- may be triggered by a number of health issues, ranging from an inner ear disorder to tumors.\nThirty-five study participants had this form of vertigo.\nFor the study, researchers recruited 338 people who had vertigo with an unknown cause.\nOf these, one-third saw their symptoms reduced or they recovered completely.\nPreventative medication was given to 20 of the 35 people with the newly detected type of vertigo.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "While this story focused on what researchers believed is a new form of vertigo, they did mention that it could be treated by an unnamed medication.\u00a0 The story should have named the medication, and the cost.", "answer": 0}, {"article": "Learn more about ADHD from the National Institute of Mental Health.\nGhuman said that this study doesn't answer a number of questions, such as whether or not the elimination diet reduces symptoms long-term.\nParents have long suspected that sugary foods might be a culprit in inducing symptoms, but there's not a lot of evidence to support this theory, according to the NIMH.\n\"Since none of the children stayed on the diet beyond five weeks, it is hard to know if this dietary intervention offers sustained benefit,\" he said, adding, \"Since it is more difficult to enforce restricted diets in older children, this approach may not be suitable for the majority of older children with ADHD.\"\nOne group was placed on the restrictive elimination diet, and the other group served as a control group and received advice on healthy eating.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Neither story mentions specific costs. Both stories say that if parents are to embark on this diet, they will need to have their kids monitored. This story says that parents should have their children monitored by \u00a0\u201ca primary care doctor and, if possible, a dietician.\u201d That would make this diet extremely expensive and would require significant out-of-pocket spending given that insurance companies are not currently paying parents to see their doctor for ADHD-related diet monitoring.", "answer": 0}, {"article": "3 Branum AM, Jones J.\nWhen Kyleena is removed, menstrual periods should return.\nThe pregnancy rate calculated as the Pearl Index (PI) in women aged 18-35 years was the primary efficacy endpoint used to assess contraceptive reliability.\nThe clinical trial had no upper or lower weight or BMI limit.\nWHIPPANY, N.J., Sept. 19, 2016 /PRNewswire/ -- Bayer announced today that the U.S. Food and Drug Administration (FDA) approved Kyleena\u2122 (levonorgestrel-releasing intrauterine system) 19.5 mg, a progestin-containing intrauterine system (IUS), for the prevention of pregnancy for up to five years.1 Kyleena will be available by prescription only in October 2016.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Costs are not discussed at all. Given that this release was issued by the manufacturer of Kyleena, the oversight is especially odd. If anyone would be able to speak to potential cost, it would be them. The product appears to be similar to another birth control product also marketed by Bayer, called Mirena. It is not easy to find a clear price for Mirena, but a 2014 story on the site ClearHealthCosts says that Mirena costs in the neighborhood of $700 or $800 \u2014 not including any medical fees related to having the device put into place. It is also not clear whether Kyleena may be covered by insurance plans.", "answer": 0}, {"article": "\"Our results suggest that nonsteroidal anti-inflammatory drug use is associated with lower colorectal cancer mortality among postmenopausal women who use these medications more consistently and for longer periods of time,\" Anna Coghill, a doctoral student in epidemiology at the University of Washington and Fred Hutchinson Cancer Research Center, said in the news release.\nIn the study, researchers examined the use of aspirin and non-aspirin NSAIDs among more than 160,000 postmenopausal women in relation to deaths from colorectal cancer.\n\"The results of our study help to further clarify the importance of different durations of NSAID use over time for the risk for dying from colorectal cancer,\" Coghill noted in the news release.\nStudy participants were enrolled in the Women's Health Initiative, which \"represents a large and well-characterized cohort [group] of postmenopausal women, and the medication data collected in this cohort made it possible for us to investigate multiple types, durations and strengths of NSAID use,\" Coghill explained.\nExperts say that for studies presented at medical meetings, data and conclusions should be viewed as preliminary until published in a peer-reviewed journal.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The costs of over-the-counter drugs like aspirin and ibuprofen are not in question.", "answer": 2}, {"article": "\"It's my job to see that she gets what she needs to protect herself,'\" he says.\nBut some worry that may sends a mixed signal by protecting girls against a sexually transmitted disease while at the same time telling them they shouldn't have sex.\nMillions of Americans have seen the ad blitz for Merck's new drug Gardasil.\nThe FDA only approved Gardasil in June and already, there is talk of making the $360 vaccine mandatory for the 2 million American girls who enter the sixth grade every year.\nBut is it something that we are in position to sort of ramrod down people's throats?\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does mention the cost of the vaccine. The story should have compared this cost to the alternative \u2013 regular pap smears. This is important information given that women will still need regular pap smears even if they are vaccinated.", "answer": 1}, {"article": "If all it requires is to take a closer look at the images, how can we ignore it?,\" he said.\nWhen researchers added 33 asymptomatic women with established CAD, breast arterial calcification was more powerful than both risk assessment formulas, which suggests the presence of subclinical atherosclerosis may be a more important indicator of heart disease than other risk factors.\nMammography, however, is widely used and accepted and, as Hecht said, may provide an opportunity to risk stratify asymptomatic women by breast arterial calcification who might have calcium in the coronary arteries and ordinarily would not have been readily considered for cardiovascular screening.\nBecause the study involved women who received both mammography and CT scan for clinical indications, these women may have been more likely than the average woman to have coexisting conditions, although Hecht said these were unrelated to heart disease.\nFuture prospective trials are needed to see what the prognostic significance of breast arterial calcification might be.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The news release discusses cost in terms of it being a no-cost screen, since the information would be gleaned from a woman\u2019s mammogram for breast cancer. This is not the whole story. The study authors suggested that identification of calcification on breast screening would indicate the need for additional coronary artery screening. And if some 40 percent of women undergoing mammography have breast artery calcification, this will mean a lot of additional coronary imaging tests and possibly additional medications and surgery, all at unknown cost.", "answer": 0}, {"article": "\"What we found is that kids get home from school around 4 p.m.\nThe researchers conclude that afterschool programs and schools can replace energy dense, unhealthy snacks with peanuts to provide a healthier alternative for children (researchers in the study ensured students did not suffer from nut allergies).\nParticipants in the study were part of a larger longitudinal study on a school-based obesity intervention program.\nFollowing the 12-week intervention, students spent 12 more weeks maintaining the healthy snacking habit.\nThe 12-week study was conducted by researchers at the University of Houston Department of Health and Human Performance (HHP), Baylor College of Medicine and Texas Woman's University.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release didn\u2019t address costs, but we won\u2019t penalize it because peanuts cost, well, peanuts.\nThat being said, the release could have been improved by the addition of some context about the high costs of eating well, especially in urban food deserts and among families without the time, transport, and resources to buy, cook, and eat fresh food.", "answer": 2}, {"article": "LDL was 8.3 points lower on the moderate-fat diet without the avocado and 7.4 points less on the lower-fat diet.\n\u201c\n\nAmericans may not be used to eating avocado but Kris-Etherton says it\u2019s easy to add.\nJust an avocado a day can significantly lower your cholesterol and reduce the risk of heart disease, a new study shows.\nAvocados are definitely not low-calorie food.\nAnd it\u2019s one more piece of evidence in favor of adding good fats to the diet.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not address costs. An avocado a day might add up to $30 or more per month, so that\u2019s not irrelevant. Competing stories gave pricing information or at least noted that avocados can be expensive.", "answer": 0}, {"article": "Professor Marianne Thoresen said: \"Even if we account for a lesser severity of perinatal asphyxia, our research has shown that therapeutic hypothermia reduces the number of children who develop epilepsy later in childhood.\nUntil recently, 20 to 30 per cent of these patients would develop epilepsy and many need regular antiepileptic treatment.\nThe study showed that more children had epilepsy when they reached the age of four to eight years with seven per cent on regular medication.\nEven if a lesser severity of perinatal asphyxia is accounted for, cooling therapy has increased the number of healthy survivors and there are very few children with epilepsy needing drug treatment.\nThe study examined how many babies were diagnosed with epilepsy and how many are on regular antiepileptic drug treatment at two and four to eight years of age.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release doesn\u2019t address cost. Given that the cost can run into thousands of dollars, that\u2019s a significant issue.", "answer": 0}, {"article": "\u201cThis is a first step,\u201d he said, \u201cand all these applications will require further work.\u201d But, he added, if the testing is successful, \u201cI think it will be very popular.\u201d\n\nThe idea for second skin originated more than a decade ago when Dr. R. Rox Anderson, a professor of dermatology at Harvard Medical School, was approached by Living Proof, which had been working on a polymer to be used as a hair product.\nThe skin still has to be able to breathe through this stuff.\n\u201cWe were looking for safety, spreadability, adherence, and the right kind of mechanical and optical properties.\u201d\n\nThe \u201cskin\u201d can last for more than a day.\nand a scientific founder of Living Proof, started searching for something that would work.\nOne of the first applications, said Dr. Barbara A. Gilchrest, a dermatology professor who is part of the research team, was on undereye bags, a condition that plagues so many middle-aged and older people.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story doesn\u2019t discuss costs of the would-be product, even though the story emphasizes that the technology is in private product development and data is being gathered for future FDA approval consideration.", "answer": 0}, {"article": "High blood pressure increases the risk for heart attack, stroke and kidney problems.\nThe rate of side effects was no greater among those who took the three-in-one pill than among the usual care group.\n\"Based on our findings, we conclude that this new method of using blood pressure-lowering drugs was more effective and just as safe as current approaches,\" lead author Ruth Webster said in a news release from the American College of Cardiology.\nThe findings, she said, \"should prompt reconsideration of recommendations around the use of combination therapy.\"\n\"Most hypertension guidelines in these countries do not recommend combination blood-pressure-lowering therapy for initial treatment in all people.\"\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story doesn\u2019t say how much the triple pill costs, or how that cost compares with \u201cusual care.\u201d\nOn GoodRx, 30 tablets of a telmisartan/amlodipine combination runs around $60, while 30 tabets of cholorthalidone is about $17. However, all of the dosages available online were twice what was used in the study.\nAccording to a news release, the researchers are evaluating whether the combination pill is cost-effective solution for blood pressure control.", "answer": 0}, {"article": "Rather than estrogen, DMAU uses a male hormone like testosterone.\nResearchers have developed a prototype male pill that appears to be safe in a month-long trial.\n\u201cDespite having low levels of circulating testosterone, very few subjects reported symptoms consistent with testosterone deficiency or excess,\u201d Page said.\nWhile some subjects on all doses experienced mild weight gain and decreases in so-called \"good\" HDL cholesterol, DMAU appeared safe.\nPage has high hopes for the results, calling them \u201cunprecedented in the development of a prototype male pill.\u201d Longer-term studies are the next step toward a once-daily male contraceptive pill, she said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Cost is not discussed. We understand that the pill is not close to coming to market, but there should be some discussion of costs \u2014 even if it is only to mention the costs of birth control pills for women and the fact that the costs of the male pill are not yet clear.", "answer": 0}, {"article": "The U.S. Food and Drug Administration said Tuesday it has approved Cotellic, a drug produced by Swiss biotech company Roche, for use in combination with the vemurafenib medication as a treatment for advanced melanoma.\n\nThe drugs are intended to target the illness after it has spread to other parts of the body or can\u2019t be removed by surgery.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "This story does not address costs at all, even though one half of the drug combination \u2013vemurafenib \u2014 is already being used in treatment and costs $11,000 per month of treatment. \u00a0The combination treatment is reportedly going to cost $17,600 per month,\u00a0and it is not clear whether payers will cover it.", "answer": 0}, {"article": "Chronic idiopathic constipation is a diagnosis given to those who experience persistent constipation and for whom there is no structural or biochemical explanation.\nTrulance should not be used in children less than six years of age due to the risk of serious dehydration.\nThe safety and effectiveness of Trulance have not been established in patients less than 18 years of age.\nTrulance should not be used in patients with known or suspected mechanical gastrointestinal obstruction.\nIf severe diarrhea occurs, patients should stop taking Trulance and contact their health care provider.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Since the FDA evaluates drugs without consideration of cost we\u2019re rating this Not Applicable. But we look forward to the day when FDA news releases include some mention of cost in its message. The value of a new drug is a function not just of how well it works, but its cost-effectiveness.\nPricing information for Trulance is likely to come soon in the wake of the FDA\u2019s approval. For reference, other drugs aimed at the inflammatory bowel/gastrointestinal disorder market have carried high price tags. One such drug costs about $380 for a month\u2019s supply of 30 capsules.", "answer": 2}, {"article": "Being around for my daughter, my son, my wife.\nAbout eight months after a single treatment, 39 percent of patients had no evidence of cancer.\nSandoval is alive today because of an experimental form of immunotherapy called CAR-T.\n\u201cThat\u2019s actually quite remarkable knowing that at best only one out of 10 of these patients could have complete disappearance of their lymphoma with standard chemotherapy,\u201d Locke said.\nDespite chemotherapy and a stem cell transplant, the cancer returned before his daughter\u2019s first birthday.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Cost was not discussed and this was a major oversight.\u00a0Industry analysts and trade stories predict that axicabtagene ciloleucel will cost $250,000 to $300,000 and that the treatment could bring in about $8 billion a year within five years.", "answer": 0}, {"article": "That\u2019s the good news.\nBut the increased risk for strokes and blood clots disappeared and the protective effect for breast cancer persisted.\nIn fact, the women who took the hormone ended up being at somewhat higher risk for fractures.\nBut the Women\u2019s Health Initiative stunned doctors and women when researchers reported that the risks of the hormones outweighed any benefits.\nThere\u2019s some good news and some bad news for women who took estrogen to help them get through menopause until the health risks of taking the hormone were discovered.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "", "answer": 0}, {"article": "It's OK to ask the question,\" Hoberman said.\nBut here's the rub \u2013 diagnosing ear infections in very young children, who tend to squirm, is not easy.\nMuch of the confusion, experts say, has been caused by studies that weren't careful enough about the diagnosis.\nStudy authors and other experts say doctors should be sure the child really is suffering from an ear infection before writing that prescription.\nIf many children in prior studies didn't really have ear infections, then it's not surprising the antibiotics didn't work for them, says Dr. Jerome Klein of Boston University, who wrote an editorial that accompanies the new studies.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Neither the blog post nor the radio piece discussed specific costs, although the blog post did describe the antibiotic in question, Augmentin, as inexpensive. Since these are kids, the suspension would be used (10 days), and the cost according to Drugstore.com is $76.\nBecause the criteria used in both studies may be substantially more stringent than those used clinically for the diagnosis, the costs of office visits also must be considered.\nIn addition, the \u201ccost\u201d in the more abstract sense of how much antibiotic resistance \u201ccosts\u201d society would have been a great addition to the story.", "answer": 0}, {"article": "\u201cIt\u2019s a tough disease because we don\u2019t have a way to bring vision back once it\u2019s lost,\u201d he said.\n\u201cThis makes sense, but we\u2019ll see if it holds up in future studies.\u201d\n\nFuture studies should look at the habits, activities and nutrition that affect lifestyle and glaucoma risks, said Idan Hecht of Tel-Aviv University in Israel, who wasn\u2019t involved in the research.\nThat includes more than three million Americans, only half of whom are aware they have the disease, according to the Glaucoma Research Foundation.\n\u201cPatients can and should be involved and take an active role in the management of their ailments,\u201d Hecht said.\n\u201cExercising, eating healthy and trying novel ways to improve your health is something you should definitely explore and bring up with your physician.\u201d\n\nEnvironmental factors could play a role in glaucoma risk as well, said Dr. Ahmad Aref at the University of Illinois at Chicago.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Tea is widely available and relatively affordable compared to other prepared drinks.", "answer": 2}, {"article": "During transcranial magnetic stimulation (TMS), a doctor places a large magnetic coil against the patient\u2019s scalp, which creates electric currents to stimulate nerve cells.\nThere were no improvements seen in test scores of those who got the other treatment.\nThe overactive brain circuits also improved among people who got the TMS treatment, the study showed.\nTen out of 20 people who faced this problem following a stroke received the magnet therapy daily for two weeks.\nThis is often not enough to make a meaningful improvement.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story notes that TMS equipment is expensive and requires specialized training. However, this story didn\u2019t put a dollar figure on the cost of the machine as Reuters did. And neither\u00a0this story nor its Reuters counterpart attempted\u00a0to quantify the costs of treatment for\u00a0patients and insurers.", "answer": 0}, {"article": "Several studies have found that dark chocolate, with its heart-healthy flavonols, can lower blood pressure and improve cholesterol.\nReid and his team constructed a mathematical model to predict the long-term health effects of eating dark chocolate daily in high-risk people.\nHowever, Reid believes theirs is the first study to model the long-term effects of eating dark chocolate in reducing cardiovascular risk.\nThey did not study actual people eating actual chocolate.\nThe researchers also computed whether it would be cost-effective to spend money on a public education campaign about dark chocolate's benefits.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The study included a cost-effectiveness analysis and the story reported on it.\u00a0 Unfortunately, it didn\u2019t offer any critical analysis of that cost-effectiveness projection.", "answer": 1}, {"article": "Because this important step is out of the way in advance, it completely changes the patient\u2019s day of surgery experience.\u201d\n\nRadar can target abnormality within 1 mm, sparing more healthy tissue\n\nUnlike mastectomy, which treats breast cancer by removing an entire breast, lumpectomy surgery \u2014 also known as breast-conserving surgery \u2014 is used to remove only the tumor and a small amount of tissue surrounding the tumor.\nThe SAVI SCOUT Radar Localization System helps to decrease the time a woman is in the operating room, increase the success rates of lesion removal and reduce the amount of healthy breast tissue that is removed during the procedure.\nIn addition to enhancing the patient\u2019s surgical experience, the more precise localization of the surgical site enable surgeons to plan the procedure better.\n\u201cUntil now, a patient would go to the imaging center to have the thin wire precisely placed in the breast.\n\u201cWhen the marker was inserted near the lump, it was similar to a biopsy.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The cost of new technology is an important consideration in its evaluation by patients and by institutions. The news release neglects to mention that some insurance companies view the Savi Scout device to be experimental despite its FDA approval. In that case, some patients may have to pay out-of-pocket.\nIt\u2019s likely that the real savings comes from reducing the amount of time a woman is in the operating room, leading to decreased down time, but there\u2019s no data on that here either.", "answer": 0}, {"article": "Other ways women can protect their bones as they age include weight-bearing exercise, and osteoporosis drugs for women at high risk for fractures.\nIt's important to note that calcium intakes on food labels are based on adult requirements of 1,000 milligrams per day.\nSupplements are an additional tool to be used when needed.\nCalcium recommendations vary according to age.\nAnyone over 50 will need an additional 200 milligrams.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No costs are mentioned.", "answer": 0}, {"article": "Reiki, a therapy in which hands are placed lightly on the body or just above it, is increasingly being used to reduce cancer-related fatigue, anxiety, nausea and pain. Several studies suggest a benefit to patients, but scientists say more large, rigorous studies are needed.\n\nCancer patients\u2014due to the disease and to side effects of chemotherapy\u2014often suffer from severe mental and physical fatigue, doctors say. Anxiety, nausea and pain are also common. In recent years, many cancer centers have been offering Reiki, a form of...", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "We give the story high marks here for at least addressing the costs at a couple of centers. It says, \u201cAt Memorial Sloan-Kettering, treatment for inpatients is available at no extra charge; outpatients pay $90 to $110 a session. At Norris Cotton, trained volunteers administer treatments free of charge\u2014often while patients are at the hospital receiving intravenous chemotherapy treatments. Insurance typically doesn\u2019t pay for Reiki.\u201d That last sentence is crucial. The reporter might have asked an insurance company for what other sorts of pain relief or anxiety relief treatments insurance does cover and why Reiki didn\u2019t meet the same bar.", "answer": 1}, {"article": "\"Now I feel relieved.\"\nA study of a cross-section of adults enrolled with a health-management organization in southern California shows that the vaccine provides protection for many older adults without many side effects.\n\"People 60 and over can consider talking to their physician about the possibility of receiving the vaccine to reduce their risk, and the doctor can evaluate if they are eligible,\" said Tseng.\n\"I think it's a very good vaccine, and it's a safe vaccine, but obviously there needs to be continuing surveillance of usage of the vaccine to make sure there are no adverse effects that are seen in one in a 100 million cases versus one in five or 10,000 people,\" said Sumaya, also a member of CDC's Advisory Committee on Immunization Practices.\nTseng's team wanted to test the vaccine's real-world performance, so they compared 75,761 vaccinated members of the Kaiser Permanente health plan to 227,283 members who elected not to have the shot.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "\n\n\nThe story reports that the vaccine can cost a couple of hundred dollars and that cost can put the vaccine out of reach for some people and that even people who could afford it may decide it is not as high a priority as other health care items.", "answer": 1}, {"article": "In devising their models, the researchers updated assumptions that have cast doubt on the relevance of existing breast-cancer risk calculators, which relied on the experiences of women who got an earlier generation of screening mammograms and were more likely to die of breast cancer than is currently the case. Here, teams of modelers from Erasmus University in the Netherlands, Albert Einstein College of Medicine in New York and Harvard Pilgrim Healthcare assumed that women were getting digital mammograms, which offer improved cancer detection rates at lower radiation dosages than earlier mammographic methods. They took into account improved rates of breast cancer treatment effectiveness, and changing causes of mortality for women older than 50. They also took account of the fact that breast density decreases in older women.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The article did not discuss costs. Screening mammograms impose a significant cost on the U.S. health care system and insurers, particularly Medicare. Some critics of those suggesting less frequent screening for some groups of women argue that such efforts want to cut costs at the expense of women\u2019s health and lives. Evidence-based guidelines are winning over some hearts and minds, but hardly all.\nIn any case, it behooves news organizations to at least acknowledge the financial\u00a0cost issue and put it in perspective. This article did not and although it noted the improvement in data collection wrought by digital mammograms in recent years, it also did not note the increased cost of digital (and now 3D) mammography over conventional screening methods.", "answer": 0}, {"article": "He whips up a homemade concoction using frozen elderberries, blueberries and honey.\nThe University of Maryland Medical Center says European elder, also called black elder, is the variety most often used for medicinal purposes.\nBut Kevin Brennan says, for his family, the natural alternative seems to be working.\nBefore you start popping elderberries, beware: eating them raw can make you sick.\nOne small study found an elderberry extract called Sambucol could shorten the duration of flu symptoms after a person gets sick by about 3 days.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The brand of elderberry extract mentioned in this story sells for about a dollar a dose at Walgreens. By our calculations, the daily use recommended by the manufacturer and apparently followed by the family highlighted in this story would cost a family of four about $1500 dollars/year.", "answer": 0}, {"article": "But Johannesdottir added that \"we hope that our finding will inspire more research on skin cancer prevention.\nHowever, the team suggested that past investigations into how NSAIDs may affect skin cancer risk, in particular, had key design problems that undercut efforts to nail down any NSAID-skin cancer connection.\nThe authors noted that prior work supported the notion that NSAIDs may offer some measure of protection against cancer (most notably colorectal cancer), by specifically impeding the cancer-causing activities of COX-2 (cyclooxygenase) enzymes.\nMeanwhile, Dr. William Ting, a private practice dermatologist in San Ramon, Calif., praised the study despite agreeing that many factors are at play when it comes to skin cancer formation.\nResearchers noted the number of prescriptions issued per patient and their length of use, with short-term use defined as fewer than seven years.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The cost of NSAIDs is not in question.", "answer": 2}, {"article": "April 14, 2010 (Toronto) -- A decades-old drug made from human plasma appears to slow the decline of mental skills in people with Alzheimer's disease, suggest results from a small preliminary study.\nThe findings were presented at the American Academy of Neurology meeting.\nResearchers believe the drug can replenish a depleted pool of natural antibodies against beta-amyloid protein, which forms the sticky plaques that riddle Alzheimer's patients' brains.\nThe IVIG treatment also appeared to slow the rate of brain shrinkage by about 45%, he tells WebMD.\nIt's a form of intravenous immunoglobulin, or IVIG, drugs that are usually used to treat immune system disorders.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The approach is described as \"expensive \u2014 about $2,000 to $3,000 per treatment. And patients in the study received infusions up to twice a month, depending on the dose, for 18 months.\"", "answer": 1}, {"article": "With advanced heart failure, a leading cause of hospitalizations, blood-pumping ability is diminished as the heart\u2019s left ventricle becomes enlarged and weakened.\n\u201cFor patients, this is a really hopeful thing.\u201d\n\nHenry, who presented the data at the ACC meeting, stressed the need for larger trials to prove the benefit of ixmyelocel-T\n\nFor the treatment, bone marrow is taken from the patient and enhanced over two weeks to increase two types of cells associated with healing.\nHowever, the treatment failed to improve secondary goals of the trial, such as heart-pumping efficiency and six-minute walking distance, and Vericel shares fell more than 31 percent by afternoon trading on Monday.\n\u201cThis is strong evidence in a well-designed trial that we can decrease events,\u201d said Dr. Timothy Henry, the study\u2019s lead investigator and chief of cardiology at Cedars Sinai Heart Institute in Los Angeles.\nAfter one year, the Vericel treatment led to a 37 percent reduction versus placebo in a composite of adverse events, including death, heart-related hospitalizations and unplanned clinic visits related to heart failure.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Stem cell therapy is assumed to be quite expensive, yet there is no mention of potential cost to the patient or health care system. If the new approach is comparable to other approaches\u00a0then the cost of the alternative methods could be cited. Our rule of thumb: If it\u2019s not too early to talk about how well something might work, then it\u2019\u2019s not too early to start discussing what it may cost.", "answer": 0}, {"article": "Nov. 24, 2016.\n\u201cWith standard aggressive chemotherapy, we only see about 20 to 30 percent of these patients achieving remission, which is the critical first step to have a chance to cure patients with additional therapies.\nBut new research indicates that such patients, paradoxically, may live longer if they receive a milder chemotherapy drug.\n\u201cIt\u2019s exciting to think we may have a therapy that has the potential to improve response rates in this group of high-risk patients.\u201d\n\nThe research is supported by an AML-SPORE grant and the Genomics of AML Program Project grant, both from the National Cancer Institute at the National Institutes of Health (NIH), grant numbers P50 CA171963 and P01 CA101937.\nThe current study involved 116 patients treated with decitabine at the Siteman Cancer Center at Washington University School of Medicine and Barnes-Jewish Hospital, and at the University of Chicago.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There is no discussion of cost in this story. Decitabine is an FDA-approved drug and costs are readily available, but nothing is said of the costs or the relative costs of other treatments.\u00a0  ", "answer": 0}, {"article": "The California Walnut Commission offices are located at 101 Parkshore Dr., Ste.\nThis is the first study that evaluates whether walnut consumption can cause changes to micro-ribonucleic acids (miRNA), the nucleotides that are involved in altering gene expression.\nAs this study was conducted on animals, results cannot yet be implied for humans.\n\"While future studies are needed, we're optimistic of the role of miRNAs as biomarkers of disease and prognosis, and may demonstrate a potential therapeutic target for colorectal cancer treatment.\"\nFolsom, Calif., (May 11, 2015) -- A new animal study from Beth Israel Deaconess Medical Center, Harvard Medical School, led by Dr. Christos Mantzoros, indicates that a diet containing walnuts may slow colorectal tumor growth by causing beneficial changes in cancer genes.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "In this very narrow discussion of a small study in mice, the suggestion is that someday maybe walnuts (or some nutritional element of walnuts) could help people by slowing the growth of colon cancer. But while the study doesn\u2019t mention how much (or how little) such a therapy might cost, we think this criterion is Not Applicable here for two reasons: 1. the cost of walnuts is generally well known, and 2. the research is at early enough stage \u2014 and the release establishes the preliminary nature of the study \u2014 that it\u2019s hard to know what any walnut-related therapy might cost.\nFurthermore, while the criteria of cost is integral to what we all agree is good reporting about health outcomes, incorporating information about the potential cost of walnuts \u2014 or any other foodstuffs \u2014 in a release about a study that\u2019s so preliminary might actually reinforce the suggestion of a useful therapy. Including that info wouldn\u2019t improve anyone\u2019s understanding of the importance of the research.", "answer": 2}, {"article": ".\nThe authors said now that this has been shown to be effective in a non-academic clinical setting, there also is potential for insurance companies to reimburse CAMBRA and other preventive therapies for adults, thereby lowering patient costs while increasing profits for dental practices.\nThe findings, which support earlier research demonstrating positive results of the assessment and treatment method in a university setting, have the potential to transform dental care for high-risk patients at a lower cost to both patients and dental clinics and practices.\nCo-authors on the paper were Benjamin Chafee, DDS, MPH, PhD, assistant professor of preventive and restorative dental sciences and director of the Global Oral Health program, and Beate Rechmann, research associate, both from the UCSF School of Dentistry.\nThe researchers said the risk reduction among the control group may have been caused by the fluoride toothpaste enhancing tooth repair, as well as the mouth rinse enhancing saliva flow and having bactericidal effects.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "While the news release says the research is aimed at lowering costs and reducing the burden for low income patients, we are not given any numbers that describes the value of the intervention.\nThe release only gets as detailed on cost as the excerpts below:\nThe findings, which support earlier research demonstrating positive results of the assessment and treatment method in a university setting, have the potential to transform dental care for high-risk patients at a lower cost to both patients and dental clinics and practices. Results appear online Jan. 22, 2018, in Advances in Dental Research.\nThe authors said now that this has been shown to be effective in a non-academic clinical setting, there also is potential for insurance companies to reimburse CAMBRA and other preventive therapies for adults, thereby lowering patient costs while increasing profits for dental practices.\nThe release also doesn\u2019t address the cost of prescription fluoride toothpaste which may actually result in higher costs overall. The number needed to treat was 4, meaning\u00a0that you would have to treat 4 people for one additional person to get benefit. \u00a0This results in the cost of therapy being multiplied by 4 to get the effect found in the study.", "answer": 0}, {"article": "Rheumatoid arthritis, which is felt throughout the whole body, is caused when a person's immune system attacks his or her own tissues.\nThe studies included arthritis patients aged 18 or older who had hip or knee replacements.\nThe findings are published in the Nov. 28 online edition of Arthritis & Rheumatism.\nThe study team found no differences between the two groups of arthritis patients in rates of follow-up surgery, or 90-day blood clot or death risk.\n\"While complication rates are low, there are some cases with serious consequences that include infection, joint dislocation, blood clots and even death.\"\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not discuss the costs of joint replacement.", "answer": 0}, {"article": "The researchers, Drs.\nAlso, he said, erectile dysfunction can also be a factor of aging and can be treated in most cases.\nThere was also a benefit in men whose tumors had low-risk characteristics.\nBut the findings are not likely to be practice-changing, said Dr. Richard E. Greenberg, chief of urologic oncology at Fox Chase Cancer Center in Philadelphia, who was not involved with the study.\n\"Currently, the potential benefit and side effects of treatment needs to be addressed on an individual basis in relation to the risk stratification of disease, patient desires, health status and risk tolerance,\" Danziger added.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There was no discussion of costs. Costs would include treating the double digit rates of incontinence and erectile dysfunction in these younger men who do have surgery. The surgery may help them live longer, but many, especially since younger at time of surgery, live decades with these potential harms and folllowup costs of the surgical choice.\u00a0 This should get at least a line in such stories.", "answer": 0}, {"article": "Each stage was 15 minutes.\n\u201cThese results suggest that non-exercise active thermogenesis, which we call NEAT, can increase movement and calorie burning, and may have the potential to impact health,\u201d said Horswill, the senior author on the study.\nParticipants in the study familiarized themselves with the workstations during one visit.\nActive Ideas LLC, which offers the HOVR device used in study, funded the research.\nOn a second visit, researchers collected metabolic rate and heart rate data during three progressive stages: seated, seated with the device and standing.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "According to the study, the \u201ccommercially available\u201d device referenced in the news release is called the HOVR (the company that makes the HOVR funded the research). While the news release didn\u2019t mention the cost of the device, a quick Google search shows that these devices are available for purchase online and cost between $75 and $150.", "answer": 0}, {"article": "The requested URL /usnews/health/articles/070805/13knee.htm was not found on this server.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story says the implant designed especially for women is \u201cmore expensive\u201d (presumably in comparison to most other options) even though its cost-effectiveness remains unknown. Still, we wish the story included an actual cost estimate of the device and its implantation.\u00a0 Readers aren\u2019t given any idea of whether this is a ballpark of $200, $2,000 or $20,000.  ", "answer": 0}, {"article": "Because obesity is linked to poor outcomes for expectant mothers and babies -- including birth defects, gestational diabetes, high blood pressure, premature birth and even childhood obesity -- efforts to lose weight before pregnancy are important, said Dr. Aaron Caughey, chair of the department of obstetrics and gynecology at Oregon Health and Science University's School of Medicine.\nBut Caughey, who wrote an editorial accompanying the new research, said women considering weight-loss surgery should make the decision based on the long-term health benefits of the procedure -- not on potential pregnancy-related benefits.\nThe investigators didn't examine what might have caused smaller babies among bariatric surgery recipients, or higher stillbirths.\nCaughey agreed with the researchers that any pregnancy occurring after weight-loss surgery merits a higher level of monitoring and should be considered high-risk.\nThe surgical group was also much less likely to give birth to larger-than-normal babies.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story could have addressed the cost of bariatric surgery in several ways. There is the cost of the surgery itself, and then there is the cost of pregnancy/delivery among obese women who have had bariatric surgery or not. The latter issue would seem most relevant to the story at hand, but might also be harder to measure. At least mentioning either issue, with an attempt at quantification, would have earned the story a satisfactory rating here.", "answer": 0}, {"article": "HPV causes cervical cancer, which remains a significant health problem, particularly in less resource-rich areas of the world.\nThe HPV test should become the screening tool of choice for women 35 and older, the researchers said.\nIt could be done less frequently than the Pap test, which could be used only in women who have tested positive for HPV, they said.\nThe HPV test works a step further back in the process, looking to see if women are infected with HPV.\nBy contrast, Pap smears have a callback rate of about 5 to 7 percent, he said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not discuss the costs of the tests or mention the costs of the additional colposcopies that result from the higher callback rate from HPV testing. Although the story claims that the HPV testing strategy is \"cost-effective\", it provides no evidence to support this claim.", "answer": 0}, {"article": "For example, many hips and knees use a combination of metal and polyethylene parts, and continuous motion can wear away small polyethylene particles.\n\"Pre-hab\"\u2014building up strength before the surgery\u2014is just as important as re-hab afterward, they say.\nThe biggest variable is patients themselves.\nPatients say that regaining function after surgery requires enormous mental and physical effort.\nThat said, some patients are determined to push the envelope, and some doctors give their blessing.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story specified the costs of both primary and revision knee replacement operations.\n\n \n", "answer": 1}, {"article": "Aside from hair transplants, which can cost about $10,000 each and do not always look natural, the only current hope for complete replacement is hair cloning, the act of producing entirely new hair from the DNA of an existing one, which researchers have been attempting, unsuccessfully, for years.\n\u201cWe keep on moving back that time, but I think there\u2019s absolutely no doubt that it\u2019s going to be done.\u201d\n\nHe believes hair cloning will be commercially available within 10 years.\napproved a new hair-loss remedy (Propecia, in 1997), so it is understandable that anticipation for a new one might be running high.\nThe result is an enhanced, refortified hairline rather than a brand new head of hair.\nBut the fact is that many men \u2014 and women \u2014 simply do not accept baldness easily.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story\u00a0provided a more\u00a0thorough discussion of costs than we have seen in many stories about cosmetic products.\u00a0It says, \u201cIt is, however, expensive: a month\u2019s supply of Latisse can cost up to $150, and that is in amounts appropriate for use merely on the eyelashes. Rogaine, which is also available over the counter now, costs about $25 a month, and a month\u2019s supply of Propecia runs about $75.\u201d", "answer": 1}, {"article": "\u201cCAR-T is not the EpiPen,\u201d he said.\nSuch results are why the treatment is on track to become the first gene therapy approved by the Food and Drug Administration.\nThe article that appeared in the New England Journal of Medicine in August 2011 created a \u201cfirestorm,\u201d June said \u2014 one that brought them new resources.\nAnd although checkpoint inhibitors are off the shelf, with every patient getting the same drug, CAR T-cell therapy is customized to an individual.\nAnd childhood leukemia is just the start for a field that has attracted intense interest in academia and industry.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story tackles this issue head on, as here: \u201cNovartis has not disclosed the price for its therapy, but analysts are predicting $300,000 to $600,000 for a one-time infusion.\u201d", "answer": 1}, {"article": "It is less common than Type 2 diabetes, which is associated with obesity.\nBurt, who wrote the study protocol, said the research was done in Brazil because U.S. doctors were not interested in the approach.\nBurt and other diabetes experts called the results an important step forward.\nFor now, the new treatment does not apply to the nearly 20 million Americans with Type 2 diabetes, reports CBS News medical correspondent Dr. Jon LaPook.\nBut diabetics are hopeful they'll some day be free of a lifetime of pinpricks and injections.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story doesn't mention costs of this new treatment. ", "answer": 0}, {"article": "[4] Quotes direct from author and cannot be found in text of Article.\nThe score, which uses measures that can be obtained by simple questionnaires without any need for physical examination, such as self-rated health and usual walking speed, could be used by individuals to improve awareness of their health status, and by doctors to identify high-risk individuals for further treatment, say the authors.\nWe hope that our score might eventually enable doctors to quickly and easily identify their highest risk patients, although more research will be needed to determine whether it can be used in this way in a clinical setting.\nThe resource has been open to bona fide health researchers for 18 months.\nThey used a statistical survival model to assess the probability that 655 specific demographic, lifestyle, and health measurements could predict death from any cause and six specific causes, in men and women separately.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Access to an interactive site for purposes of computing a score predicting one\u2019s risk of dying will be free. However, this should have been stated in the release. We can\u2019t rate the release Satisfactory if there\u2019s no mention of cost at all, so we\u2019ll rate it Not Applicable.", "answer": 2}, {"article": "\"Our idea was to find a way to do a quick examination that would allow, during a boxing or American football match for example, to determine whether the athlete can return to the field or if his condition requires hospitalization.\nHis team has developed a rapid diagnostic test (POCT) called TBIcheck, inspired by the principle of pregnancy testing: by placing a single drop of blood on the well of a small 5cm plastic case, the patient knows within 10 minutes whether there is a risk of mild trauma, namely whether or not his H-FABP level is higher than 2.5 nanograms per millilitre of blood.\nThis discovery, described in PLOS ONE, will not only relieve emergency departments, free patients from often long waits, but also save on costly medical examinations.\nYet 90% of these patients will be able to return home safely, as no trauma has been detected.\nToday, the injured patients have to go to the emergency rooms of hospitals equipped with a CT Scan, an expensive examination that sends X-rays to the brain to detect the presence or absence of brain trauma.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The cost of this device isn\u2019t discussed, despite plans to put it on the market. The release noted that the standard way of diagnosing brain injuries are through CT scans. These tests run more than $1,000 a pop, at least in the U.S. The release might have noted how much this test would cost in comparison. Further, if the outcomes of the test are not improved US insurance companies are unlikely to pay for it.", "answer": 0}, {"article": "Differences in mean changes in swallowing at radiotherapy week 4 (\u221215 in the CRT group and \u221225 in the radiotherapy alone group, P = .02), loss of appetite at radiotherapy week 4 (\u221211 in the CRT group and \u221218 in the radiotherapy alone group, P = .03), nausea at week 8 after radiotherapy (\u22127.3 in the CRT group and 0.3 in the radiotherapy alone group, P = .04), coughing at radiotherapy week 4 (7.4 in the CRT group and \u22125.6 in the radiotherapy alone group, P = .02) and at week 8 after radiotherapy (\u22123.2 in the CRT group and 1.1 in the radiotherapy alone group, P = .04), constipation at month 8 (2.6 in the CRT group and \u221219 in the radiotherapy alone group, P < .001), and cognitive functioning at month 12 (\u22127.0 in the CRT group and 4.6 in the radiotherapy alone group, P = .04) were not seen at the other time points.\nThe use of concomitant cisplatin and radiotherapy resulted in a statistically significant improvement in laryngeal preservation compared with radiotherapy alone, with a hazard ratio of 0.46.\nA pharmacologic profile was also performed weekly on patients receiving cetuximab infusion (CRT group).\nOne of the largest randomized clinical trials was designed to evaluate laryngeal preservation compared with radiotherapy alone, concomitant chemoradiotherapy, and induction chemotherapy followed by radiotherapy.13,14 Each treatment group included at least 180 patients, thus providing much greater statistical power than the current communication.\nThe 2.2% and 11.1% absolute improvements in the rates of laryngeal preservation, at 2 and 3 years, respectively, favored CRT compared with radiotherapy alone (Figure 2).\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release doesn\u2019t discuss costs at all. Given that the relevant study compared radiation therapy to the use of radiation therapy in conjunction with cetuximab, that\u2019s particularly problematic. Cetuximab is already on the market (under the trade name Erbitux) for use in treating various cancers. The drug has been the subject of public debate regarding its cost relative to its therapeutic value (e.g., see these articles in the Wall Street Journal and USA Today). Regardless of where one stands on that debate, treatment with cetuximab can cost tens of thousands of dollars, which is worth mentioning. And the likelihood that the combo therapy won\u2019t be covered by insurance (given its nonsignificant results) should have been discussed.", "answer": 0}, {"article": "\u2022 Women with a 20 percent or greater lifetime risk of breast cancer also should undergo screening MRIs.\nBreast cancer risk assessments are typically not a part of standard care for this age group, the researchers noted.\nThe study also found a significant percentage of women would qualify for other breast screening methods, including breast MRI and genetic testing, Plichta said.\nBut the review of female patients between the ages of 40 and 44 found that 50 percent had an above-average risk for breast cancer, and therefore would be eligible to begin screening mammography at age 40, said lead researcher Dr. Jennifer Plichta.\nThe analysis was designed to look at new breast cancer screening guidelines from the American Cancer Society and the American Society of Breast Surgeons.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Costs were not discussed in the story. It is not clear if such a breast cancer risk assessment would be covered under insurance if they asked their doctor for such an assessment.", "answer": 0}, {"article": "The page you are looking for has either moved or is not available (error 404).\n\nPlease return to the homepage or use the search box above to see if the page is available in a new location.\n\nIf you think this message is in error or need assistance, please email the webmaster.", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The news release does not cite costs. This is unfortunate because hydroxyurea treatment would likely be less costly than standard treatment with blood transfusion.", "answer": 0}, {"article": "Uridine, which is produced by the liver and kidneys, is also found in some foods as a part of RNA, which helps make protein in the body.\nWhether Souvenaid will slow the progression of Alzheimer's isn't known.\nTo be effective, all three compounds must be given together, the researchers said.\nIn addition, medical foods for Alzheimer's most likely won't be covered by insurance, he said.\nTo show the drink's effect on the brain, patients underwent electroencephalography (EEG) throughout the trial.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story states \u201cThere are no plans to market Souvenaid, so the cost hasn\u2019t been established.\u201d", "answer": 1}, {"article": "\"It twists on all planes, it goes up, down, sideways and it rotates.\"\nAfter years of cortisone treatments and therapy, wrist replacement became a last resort.\nPotential patients must be evaluated for other causes of pain, Collins noted, because problems with thumbs or other hand parts can make the wrist hurt.\nOccasionally, other conditions must be addressed in addition to joint damage.\nAfter replacement surgery and months of physical therapy, patients can lift no more than 15 or 20 pounds, he said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The article fails to mention the cost of treatment or whether it is covered by Medicare or other insurers.", "answer": 0}, {"article": "For more on aspirin, visit the National Institutes of Health.\nThe potential impact of aspirin on pancreatic, stomach and brain cancer death rates was more problematic to gauge, the authors noted, due to the relative paucity of deaths from those specific diseases.\nAnd while cautioning that more research is necessary to build on this \"proof of principle,\" the authors suggested that people who embark on a long-term, low-dose aspirin regimen in their late 40s and 50s are probably the ones who stand to benefit the most.\nThe protective impact of low-dose aspirin on stomach and colorectal cancer death was not seen until 10 years out, and for prostate cancer, the benefits first appeared 15 years down the road.\nBut the study's lead author, Prof. Peter Rothwell from John Radcliffe Hospital and the University of Oxford, stressed that \"these results do not mean that all adults should immediately start taking aspirin.\"\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The cost of aspirin is not in question. Nevertheless, a broad recommendation to begin taking aspirin daily in middle age would likely be followed by at least hundreds of millions of people, thus the cumulative costs would be large. Also, such widespread use would increase the costs of treating bleeding ulcers and other adverse events caused by aspirin, though hoped-for savings in reduced cancer treatment would be an offestting factor to consider. Still, because the cost of aspirin on an individual basis is low and well-known we won\u2019t insist on this point.", "answer": 2}, {"article": "In Japan, \u201cfood and health care companies have found cosmetic applications for their ingredients, so they are creating skin care brands.\u201d\n\nFor example, Frutarom, a flavor-ingredient house based in Israel, makes Alguard, a purified polysaccharide shield from a red microalgae that it says protects skin from daily assaults and reduces roughness as well as the look of fine lines.\nThere are more than 100 algae-derived ingredients used in cosmetics worldwide, Mrs. Lewis said.\nDr. Dana Sachs, an associate professor of dermatology at the University of Michigan, Ann Arbor, wrote in an e-mail after looking at Algenist\u2019s dossier that \u201cthe claims on cell regeneration and elastin synthesis are based on in vitro models, which is hard to extrapolate to in vivo, and again no statistical significance is presented, so this is a weak claim.\u201d\n\nDr. Day, who has a doctorate in biochemistry, said that statistical significance was found but not included in press materials.\nThe patent-pending alguronic acid in Algenist is a \u201csingle, purified, highly bioactive compound,\u201d said Tony Day, the vice president for research and development at Solazyme, and therefore delivers \u201cmuch higher activity to the skin\u201d than products using only a microalgae extract.\nIt may seem novel for a nonbeauty company to get into skin care, but these days, it really isn\u2019t, Mrs. Lewis said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story says that these products retail for $65 to $95. We would have liked to have seen how long one of those products would last with typical daily use. Is it $95 a month? Every three months?", "answer": 1}, {"article": "\u201cMy nightmare was that nothing would be different from the placebo group, and there would be nothing of interest to talk about,\u201d he says.\nI think resveratrol is an engaging target that\u2019s very interesting and could be pharmacologically manipulated to develop a treatment.\u201d\n\nMORE: Red Wine Not That Healthy After All, Study Shows\n\nThe resveratrol group showed no change in the levels of a protein that builds up in the brains of Alzheimer\u2019s patients.\nThe amounts of resveratrol in the purified doses that the participants took were extremely high and beyond those found on the market currently \u2014 around what would be contained in about 1,000 bottles of red wine.\nWe need more studies to see if it really does have benefit and then it could be turned into more effective drugs that can better target Alzheimer\u2019s.\u201d\n\nCorrection: The original version of this story misstated that all the participants were men.\nPlus, he says, resveratrol supplements currently available over the counter are \u201cunregulated and we don\u2019t know how much is in it.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not mention cost at all. But in this case we\u2019ll rule this Not Applicable since the story clearly indicates that the supplements studied are not on the market.", "answer": 2}, {"article": "''I am of the opinion that every child deserves this diagnostic intervention,\" researcher Lidy Pelsser, PhD, of the ADHD Research Centre in Eindhoven, the Netherlands, tells WebMD.\nThe diet studied, known as the restricted elimination diet (RED), can work, the researchers say, because they believe ADHD symptoms in some children might be affected by eating specific foods.\nIn five weeks of trying the diet, Pelsser says, parents will know if their child is responding or not; if not, they can move on to other treatments.\nU.S. experts had some caveats, saying that the results of the study, which included 100 children, should be repeated in other populations to see if the findings hold up.\nIn the study, published in The Lancet, 78% of children who stuck with the diet did respond by having fewer symptoms.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "This story doesn\u2019t mention specific costs, although it at least makes a passing reference to expense: \u201cIt can be time consuming and more expensive than other diets, experts say.\u201d The story explains that if parents are to embark on this diet, they will need to have their kids monitored by \u201cexperts\u201d or by \u201ca primary care doctor and, if possible, a dietician.\u201d If so, that would make this diet extremely expensive and would require significant out-of-pocket spending given that insurance companies are not currently paying parents to see their doctor for ADHD-related diet monitoring.", "answer": 0}, {"article": "\"I say, 'Go for it!'\nThat's because surgery doesn't touch the root cause of chronic sinusitis.\nShe'd consider a second operation, but Metson says usually that's advised only for patients with nasal polyps that regrow -- not a problem she has.\nForeman wrote a column about her surgery.\nThat, he says, will be the next big advance in sinus treatment.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "A comment about the overall cost of endoscopic sinus surgery, as well as insurance coverage and likely out-of-pocket expenses for patients, would have been appropriate in this story. In addition, the costs associated with the equipment and upkeep are also important considerations. However, the story didn\u2019t mention costs.", "answer": 0}, {"article": "For more information, see www.scripps.edu.\nThe original form of vancomycin is an ideal starting place for developing better antibiotics.\nBoger called vancomycin \u201cmagical\u201d for its proven strength against infections, and previous studies by Boger and his colleagues at TSRI had shown that it is possible to add two modifications to vancomycin to make it even more potent.\nThe antibiotic has been prescribed by doctors for 60 years, and bacteria are only now developing resistance to it.\nEven if the process isn\u2019t streamlined, Boger believes the new vancomycin\u2019s lifesaving powers make its production valuable.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Cost is not addressed at all, likely because so much work remains to be done before the modified vancomycin is clinically relevant. However, if it\u2019s not too early to talk about the clinical relevance of the findings (which the release does), then it is not too early to talk about potential cost \u2014 at least in broad terms.\nGiven that producing the modified vancomycin currently involves a 30-step process (which researchers are hoping to streamline), the cost may be considerable. The release goes so far as to say that \u201cthe new vancomycin\u2019s lifesaving powers make its production valuable.\u201d If they\u2019re willing to say that, it would have been worthwhile to discuss, in a sentence or two, whether this new version of vancomycin may be more expensive than existing antibiotics. At any rate, cost should not have been overlooked completely.", "answer": 0}, {"article": "Dr. David Rosenstreich, director of the division of allergy and immunology at Montefiore Medical Center in New York City, added: \"An objective and fast test for diagnosing asthma would be helpful, and this test seems to be a non-invasive way of sampling for the underlying problem.\nThe electronic nose was able to correctly differentiate healthy people from those with physician-diagnosed asthma in 87.5 percent of the cases.\nWhen combined with another test, called the fractional exhaled nitric oxide (FENO) test, the electronic nose did an even better job at detecting asthma, the study found.\nWhen the electronic nose and FENO were combined, the two tests together correctly identified almost 96 percent of the asthma cases.\nThose with asthma had a history of allergies, and none had been treated with corticosteroids for at least four weeks prior to the start of the study.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Since this device is\u00a0experimental,\u00a0we can accept the fact that the story didn\u2019t put a specific price tag\u00a0on the technology.\u00a0The story did note that cost might limit initial use of the device.", "answer": 1}, {"article": "Patients with untreatable angina who received the injections of CD34+ stem cells in key areas of the heart had significantly fewer chest pain episodes and significantly better performance on exercise tests than patients who got placebo injections.\nThe patients received 10 such injections during a single catheterization procedure.\nPatients were given a drug for several days to increase the number of CD34+ stem cells in the blood.\nResults from a pivotal study of the treatment were reported today in the American Heart Association (AHA) journal Circulation Research.\nThe approach also showed promise in a 2007 pilot study involving fewer than 30 patients.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No discussion of cost.\u00a0 A ballpark could have been given.", "answer": 0}, {"article": "LONDON (Reuters) - British scientists have discovered a \u201crogue gene\u201d which helps cancer spread around the body and say blocking it with the right kind of drugs could stop many types of the disease in their tracks.\nChantry said in a telephone interview the findings mean drugs could be developed in the next 10 years that could be used to halt the aggressive spread of many forms of cancer, including breast cancer, brain, colon and skin cancer.\nIf a drug was developed that deactivated WWP2, he said, conventional therapies such as chemotherapy and radiotherapy could be used on primary tumors with no risk of the disease taking hold elsewhere.\nResearchers from the University of East Anglia said their findings could lead within a decade to the development of new medicines to halt a critical late stage of the disease known as metastasis, when cancer cells spread to other parts of the body.\nIn tests in the laboratory, the UEA team found that by blocking WWP2, levels of the natural inhibitor protein were boosted and the cancer cells remained dormant.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "This is such an early stage finding it would be premature to throw out cost figures, and there are no comparable treatments that come to mind to serve as cost comparators.", "answer": 2}, {"article": "Dec. 14, 2009 -- Every cup of coffee a person drinks per day may lower the risk of diabetes by 7%.\nThey say several studies have suggested that drinking coffee may lower the risk of developing type 2 diabetes and others have shown that decaffeinated coffee and tea may offer similar benefits, but there has not been a recent review of the research on the issue.\nWhen the information from the individual studies was combined, researchers found each additional cup of coffee drunk per day was associated with a 7% lower risk of diabetes.\nThe study also showed that people who drank more than three to four cups of decaffeinated coffee per day had about a one-third lower risk of developing type 2 diabetes than those who didn\u2019t drink any.\nThe results showed that people who drink more coffee, whether it\u2019s regular or decaffeinated, or tea appear to have a lower risk of developing type 2 diabetes.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "\u00a0Costs weren\u2019t discussed, but most people know what coffee and tea costs. ", "answer": 2}, {"article": "The study\u2019s median follow-up was 18.5 months.\nThe Merck drug is awaiting U.S. Food and Drug Administration approval, but Tecentriq was approved by the agency last year, contingent on verification of its clinical benefit.\nMerck announced in October that the second-line bladder cancer study met its main goal and was stopped early.\nAccording to the FDA approval letter, the company has until December to submit the full trial data to the agency.\nThe data, to be presented next month at a meeting of the American Society of Clinical Oncology, follow last week\u2019s announcement that rival drug Tecentriq, from Roche Holding AG, did not improve survival when used as a second-line treatment for bladder cancer in a trial.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The cost of the drug is not discussed, and this is a significant oversight. As we\u2019ve noted in another review of a story on Keytruda, \u201cthe cost is about $150,000 a year.\u201d\nInsurance coverage and high out-of-pocket costs are another issue that could have been addressed.", "answer": 0}, {"article": "Professor Tim Newton from the Dental Institute at King's College London and lead author of the study said: \"People with dental phobia are most commonly given sedation to allow them to become relaxed enough for a short period of time to have their dental treatment performed.\nThe average number of CBT appointments required before a patient received dental treatment without sedation was five.\nCognitive behavioural therapy could help many people with a dental phobia overcome their fear of visiting the dentist and enable them to receive dental treatment without the need to be sedated, according to a new study by King's College London.\nNearly all patients (94%) reported a knock-on effect from problems with their teeth, mouth or gums on their daily living and quality of life.\nThe latest study, published in the British Dental Journal, looked at the characteristics of 130 patients (99 women and 31 men) attending a psychologist-led CBT service and the outcomes of their treatment.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release does not address cost at all. This is not entirely surprising, since the study was done in the United Kingdom, which has a universal health care system. However, the journal article on which the release is based does address cost, at least in terms of the cost to the health care system itself. The article says that the CBT sessions to address dental fears had \u201can average cost of \u00a3810 per patient.\u201d (The cost in British pounds converts to about $1,212.) The article also says, \u201cWhile initially expensive the evidence suggests that patients can then receive dental treatment without sedation thus potentially reducing long-term costs.\u201d For patients in the United States, the cost would likely be significant \u2014 particularly since the researchers report that patients needed an average of five CBT sessions before being able to receive dental care without sedation (and it\u2019s not clear whether health insurance would cover such sessions).", "answer": 0}, {"article": "The company, which says gammaCore is already available in the European Union, expects to start selling it later this year in the U.S.\n\nVagus nerve stimulation is used to treat a range if disorders, including epilepsy, depression and overeating.\nRelated: New Migraine Drugs Would Treat Pain Before it Starts\n\nSilberstein helped test the device, which users press against the neck.\nThe device is a vagus nerve stimulator and it\u2019s not entirely clear how it works.\nThis went up to about a third of patients with so-called episodic cluster headaches.\nBoth approaches are limited \u2014 it\u2019s not safe to use the injection more than twice a day \u2014 and inconvenient.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "One of the first questions a cluster headache sufferer will have about the device is: how much does it cost? The article doesn\u2019t offer any information about the cost of the device, or comparison to the\u00a0costs of other treatment. A company release for British audiences described the device in terms of its savings compared to medications (\u201c25% reduction in costs associated with acute treatments such as zolmitriptan, sumatriptan and inhaled oxygen\u201d) but a search on the actual cost of the device and the cost of replacing the pre-loaded doses came up empty-handed.", "answer": 0}, {"article": "But the F.D.A.\nSo injecting it is an off-label use.\nShe said veins as large as a Sharpie marker can be tackled with foam sclerotherapy.\n\u201cOtherwise they\u2019ll just come back.\u201d\n\nToday, sluggish underlying veins are best addressed with radio-frequency or laser treatment, said Dr. Min, who developed such a laser.\nBut doctors say they should: these veins are not just a cosmetic problem, but can also lead to aches, pain, and heaviness from blood pooling in the legs.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No discussion of costs \u2014 a big hole when we\u2019re talking about\u00a0treatments that are\u00a0highly profitable for specialists and are often\u00a0sought out for cosmetic reasons and not because of any health risk. \u00a0", "answer": 0}, {"article": "\"But at the same time it's something we'll continue to look at, and hopefully confirm absence of risk.\"\nThat means many doctors are likely to charge more than $300 retail, putting the Merck product in league with Prevnar, an expensive Wyeth vaccine that has been widely used in the United States for five years.\nThe vaccine won approval from the Food and Drug Administration on Feb. 3, and some doctors have received supplies of it.\nThe decision means that pediatricians are likely to recommend three doses of the oral vaccine for nearly every child at age 2 months, 4 months and 6 months, beginning almost immediately.\nThe recommendation for universal use of the vaccine was approved at a meeting of the Advisory Committee on Immunization Practices, the federal panel that sets vaccination policy in the United States.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The author states that the vaccine will cost $187.50 for the three-dose series, making it one of the most expensive vaccines ever marketed. Although the author does say that this cost will put a strain on state-sponsored vaccination programs, there is no attempt to try to quantify the magnitude of this strain or comment on the potential cost-effectiveness of this new vaccination program.", "answer": 0}, {"article": "Then, the newly copied viruses break out of the cell, spreading to other cells nearby and repeating the process.\nThe experimental drug worked three times faster than another antiviral drug, Tamiflu, the company told the Journal.\nThe drugmaker plans to apply for approval in the U.S. this summer; however, the drug likely wouldn't be available here until next year.\nJapanese drug regulators could approve the drug for use in Japan by early March, the Journal reported.\nIn a clinical trial, a single dose of the drug made by the pharmaceutical company eliminated the virus from people's bodies in a median time of 24 hours, The Wall Street Journal reported.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No costs are discussed. Given the millions already sickened or at risk of the flu, knowing the cost of the new drug from Shionogi and Co. is a critical piece of information for health care budgets already stretched to the breakpoint for many families and communities.", "answer": 0}, {"article": "Vegetables particularly high in alpha-carotene include yellow-orange vegetables, such as carrots, sweet potatoes, pumpkin, and winter squash, and dark green vegetables, such as broccoli, green beans, green peas, spinach, turnip greens, collards, and lettuce.\nResearchers wanted to see if other carotenoids may also play a role in reducing the risk of disease.\nThe study shows that eating foods rich in antioxidants, like vegetables and fruits, fights disease and may prolong life.\nNov. 22, 2010 -- Eat your veggies and you may live longer, a study suggests.\nAlthough previous studies have suggested eating more fruits and vegetables is associated with a lower risk of disease, studies have not shown that taking beta-carotene supplements reduces the risk of dying from heart disease or cancer.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "\n\n\nNot applicable. Costs weren\u2019t discussed, but the costs of these common foods are well known.", "answer": 2}, {"article": "Bernard M.Y.\nThe reduction in LDL cholesterol from the higher dose ended up decreasing the risk of a major cardiac event by 6 percent, the researchers found, although the statistic in itself was not clinically significant.\nThis applied even if the patients already had low levels of low-density lipoprotein (LDL, or \"bad\") cholesterol, he noted.\nFor this reason, they noted that the incidence of severe muscle disease on 80 mg of Zocor might be an \"underestimate.\"\nThis trial looked at the benefits of statin therapy with 80 milligrams (mg) versus 20 mg simvastatin (Zocor) among 12,000 heart attack survivors.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There was no mention of the costs of these drugs or the cost ramifications of the increased dosages.\u00a0This ought to have included the simple increase in costs due to the increased dosage of the medication and also at least a nod to the costs associated with the increase in adverse events.", "answer": 0}, {"article": "Red and purple fruits owe their colors to...\nAlthough it's a challenge to eat the raw fruit without getting a mouthful of seeds and astringent pith, pomegranates are everywhere now in the form of juice, concentrates and extracts, all heavily promoted for better health.\nThe juice is a beautiful wine-red color and tastes delicious.\nMuch of the popularity is the work of a California-based company, Pom Wonderful.\nIt pays researchers to study the benefits of pomegranate juice, gives doctors information on positive studies and, of course, sells pomegranate products.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There was no mention of the costs of pomegranates or pomegranate containing products or how these costs compare with other fruits and vegetables considered to be similarly rich in anti-oxidants and particularly polyphenolic compounds.", "answer": 0}, {"article": "\"It appears that women who reported taking prenatal vitamins starting three months prior to conception and through the first month after conception seem to have a reduced chance their child will develop autism ,\" says study researcher Irva Hertz-Picciotto, PhD, professor of epidemiology and environmental health at the MIND Institute and Department of Public Health, University of California, Davis.\nChildren who had the high-risk COMT gene form were seven times as likely to have autism as children without it whose mothers did take the vitamins.\nExactly why the prenatal vitamins may protect against autism is not clear, she says.\nTaking prenatal vitamins was found even more protective for mothers and children who had a high-risk genetic makeup .\nThe mothers with the high-risk form of MTHFR had a 4.5 times higher chance of a child developing autism, she says, than mothers without this high-risk form who did take the prenatal vitamins.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There was no discussion of costs, which is unfortunate considering that\u00a0there can be\u00a0big differences in the\u00a0price of prescription prenatal vitamins vs.\u00a0OTC brands.\u00a0Some women may also do fine with a basic\u00a0store-brand multivitamin. Costs can also vary depending on insurance coverage, since some plans may cover the cost of prescription vitamins but not OTC\u00a0products.\u00a0At a minimum, the story should have mentioned the range of costs for a month\u2019s supply\u00a0in order to satisfy the criterion. Some discussion of the other tradeoffs between prescription and OTC brands (varying formulations, tolerability, etc) would also have been helpful.", "answer": 0}, {"article": "\u201cDefinitely it doesn\u2019t look like antidepressants are placebos,\u201d he concluded.\nThe researchers said they couldn\u2019t be sure there would be similar improvements with other types of antidepressants \u2014 especially given the more limited data in kids and the elderly \u2014 or that the longer-term benefits would be as clear.\nIrving Kirsch, who studies antidepressants and placebos at Harvard Medical School in Boston, said the new report didn\u2019t make him more optimistic about the drugs.\nStill, not everyone in the studies improved \u2014 on average, about five people had to be treated with one of the drugs for one person to feel better, and the benefits seemed to be diminished among some of the oldest patients.\nThe findings, he added, \u201craise other questions that need to be followed up (including), what\u2019s going on in the elderly?\u201d\n\nBoth types of Effexor, or venlafaxine, also seemed to help adults with mild to severe depression, with slightly more patients responding to the immediate-release dose.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The costs of antidepressants weren\u2019t discussed, but perhaps that is understandable in this kind of broad overview of a meta-analysis. Fluoxetine (prozac) and venalfaxine (effexor) are now both generic. \u00a0So costs are pretty low.", "answer": 2}, {"article": "Genomic Health Inc. has struck a deal to commercialize a new blood test that can help advanced prostate cancer patients decide whether to try costly new-generation drugs or rely on much cheaper traditional chemotherapy to improve their chances for survival.\n\nThe test, developed by closely held Epic Sciences Inc., San Diego, detects a mutation associated with a poor response to two new drugs, Xtandi from Medivation Inc. and Astellas Pharma Inc. of Japan, and Zytiga from Johnson & Johnson.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Excellent job here. The costs of treatment are a core aspect of the story. The opening paragraph describes how the blood test in question could help determine whether patients should receive \u201ccostly new-generation drugs or rely on much cheaper traditional chemotherapy,\u201d and the specific costs of different therapies are detailed early in the article.\nMuch less information is given about the cost of the blood test itself, though the writer does make it clear that the price is not yet determined. It would have been\u00a0useful to note the costs of\u00a0any\u00a0comparable\u00a0tests already in clinical use, and to\u00a0let the reader know how insurance companies deal with\u00a0new diagnostic tests.", "answer": 1}, {"article": "Researchers around the world are seeking ways to regenerate damaged hearts, spines and skin with stem cells. At an operating table here recently, Kotaro Yoshimura leaned over a 51-year-old woman and put stem cells to use for a different purpose: cosmetic breast surgery.\n\nDr. Yoshimura jabbed the underside of the woman's left...", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story provides a range of the costs of the procedure for cosmetic purposes and also notes cost of additional surgeries that may be needed to correct for fat-grafting that did not survive after an initial procedure.\u00a0 This procedure may not be approved by health insurance for reconstruction due to the lack of evidence for safety and long-term outcomes. ", "answer": 1}, {"article": "Nothing.\nThat may explain why the B vaccine appears to offer some protection against Neisseria gonorrhea.\nClinical trials will need to be conducted to see if the effect researchers have observed is actually due to the meningococcal B vaccine.\nThere are vaccines for several Neisseria meningitidis strains, but designing a vaccine to protect against the B strain was a particularly difficult nut to crack.\nBut the same component is one of several in the Bexsero vaccine, which was used in Quebec when the government decided to vaccinate against meningococcal B disease in a part of the province with a high relative rate of cases a few years ago.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There\u2019s no mention of how much a gonorrhea vaccine might cost. In the U.S. meningitis B vaccine Bexsero, which contains manufactured by GlaxoSmithKline, costs $99 for a pediatric dose and $106 for an adult dose. Two doses are required.\nA discussion of cost and cost-effectiveness is particularly important when considering a widespread public vaccination campaign.", "answer": 0}, {"article": "\"Whether the vaccine is going to look anything like this one I don't know.\nThe results were barely significant on statistical grounds, perplexing for scientific reasons and unanticipated by most researchers.\nIt is unlikely -- but not impossible -- that any country would consider it effective enough to be used as a public health measure against HIV.\nThe study cost $105 million, most of it provided by the National Institutes of Health.\nNevertheless, the first positive result for an AIDS vaccine after two decades of experimentation is being called a milestone.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "At this early phase of research it\u2019s understandable that cost wouldn\u2019t be discussed. ", "answer": 2}, {"article": "\"Six-month IOP Reduction with a Topical Bimatoprost Ocular Insert: Results of a Phase 2 Randomized Controlled Study,\" Brandt, et al.\nThe ring became dislodged in 15 patients but was replaced each time, allowing therapy to continue.\nOphthalmologists at 10 sites nationwide tested the ring in a phase 2 clinical trial on patients with glaucoma or ocular hypertension.\nThe authors noted the device could also be used for non-glaucoma medications, with potential applications for dry eye, allergies and inflammation.\nThe ring is designed to be replaced by an ophthalmologist every six months.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The news release doesn\u2019t mention costs, despite the fact that investors would need to recoup the enormous cost of developing a device and winning Food and Drug Administration approval. It might be too early to estimate the market price of the ring, but the news release could have helped readers understand financial implications by mentioning the typical high cost of new medical devices as well as what it might cost to pay a clinician to insert, monitor and replace a medicated ring at regular intervals. It could have also mentioned costs for existing treatment options, and in more rare cases, the cost of surgeries that are performed when patients fail to adhere to treatment plans.", "answer": 0}, {"article": "A new method for performing a \u201cvirtual\u201d colonoscopy that requires less unpleasant preparation was shown in a new study to accurately detect larger precancerous polyps\u2014and was a better experience for patients.\n\nThe second-leading cause of cancer deaths in the U.S., colon cancer can be prevented if precancerous polyps\u2014known as adenomas\u2014are found and removed during a colonoscopy\u2026.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The Journal skipped the cost question, which was unfortunate. The Boston Globe said, \u201cMedicare doesn\u2019t provide coverage for the imaging test, which Zalis said costs about one-third as much as the traditional scope screening.\u201d Both of the outlets could have mentioned the range of possible costs for a traditional and virtual screening.", "answer": 0}, {"article": "\"But it's a slippery slope to saying 'OK, maybe two is better.'\nThere's no evidence drinking in your 20s or 30s has any health benefits.\nStudies will continue, and not everyone has given up the idea that moderate drinking \u2014 up to two drinks a day for men and one day for women \u2014 might have some cardiovascular benefits.\nFor some people, even moderate drinking is clearly risky.\nBut before you pour your next cocktail, beer or glass of wine, you should know this: the science suggesting a benefit has never been conclusive.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Cost was not an issue here. People generally know what a bottle of wine or other alcohol costs.", "answer": 2}, {"article": "\u2022 Prostate cancer mainly occurs in older men; about 6 in 10 cases are diagnosed in men aged 65 or older.\nWhile the findings need further research, larger clinical trials could give better information on individualized treatment for each prostate cancer type.\nThese genes demonstrated the risk of the disease progression, which was more accurate than the currently used Gleason score test and PSA test.\nThis could lead to a better quality of life and more effective treatment based on which prostate cancer a man is diagnosed with.\nThe researchers said the analysis in their study is better at forecasting how prostate cancer will advance compared to the current diagnostic tests being used for prostate cancer such as the prostate specific antigen test and the Gleason score.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release makes no mention of the cost for an additional genetic test.", "answer": 0}, {"article": "\"Sadly,\" they write, \"we are left in a conundrum.\nBut this isn't the first study to call into question the benefits of mammography and whether women are too often the victims of overdiagnosis.\nAnd yet, a new study published in JAMA Internal Medicine has found something that may seem counterintuitive: More breast cancer screening didn't actually save lives.\nThe trouble with overdiagnosis is that while the cancers doctors find wouldn't have harmed their patients, the treatment and stress that result from the diagnosis probably will.\nWe also need to remember that in medicine, more often than not, we generally overestimate the benefits and underestimate the harms.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There was no discussion of costs in this story or of insurance coverage for mammography. While many readers may understand that screening mammography is generally covered by insurance, it would have been helpful to state explicitly that mammograms in the U.S. are covered by the Affordable Care Act. More broadly, given that this study questions the effectiveness of mass breast screening, it\u2019s worth at least asking what such screening is costing the health care system.", "answer": 0}, {"article": "Nerve cells that communicate and control the voluntary muscles of the body (such as those in the arms, legs and face) degenerate or die.\nIn Pharr's father's case, the progress of disease was rapid.\nUnfortunately, the procedure provided no benefit to patients, though it caused substantial pain to two of the study participants.\n\"He did not want to go on the ventilator,\" she said, adding that many people prefer a \"natural death.\"\nWhat he discovered during that experiment was that none of the patients suffered long-term effects (from either the surgical procedure or the implantation of stem cells), and no unusual acceleration of disease occurred.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There\u2019s no mention\u00a0of how much this procedure costs. Though this is still in its earliest stages, one could simply mention this issue, as it\u2019s likely to be very expensive.", "answer": 0}, {"article": "AMHERST, Mass.\nParticipants in the study contributed more than 1 million person-years of follow-up, during which 2,041 women experienced early menopause.\nDiet was assessed five times over the 20-year study, allowing the researchers to capture within-person variation in changes in food and nutrient intake over times, Boutot explains.\nOthers on the study team were from Brigham and Women's Hospital and Harvard Medical School.\nThe study was supported by a grant from NIH's Eunice Kennedy Shriver National Institute of Child Health and Human Development.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Replacing animal products with plant foods wouldn\u2019t significantly raise a person\u2019s food budget and might actually save money.", "answer": 2}, {"article": "Lung cancer is the No.\n\u201cThis new information adds to the growing body of evidence that metformin may help prevent and inhibit the progression of lung cancer,\u201d Gutterman said.\nMetformin is one of the most widely used drugs for type 2 diabetes, with 41 million prescriptions written in the United States in 2008, the American College of Chest Physicians said in a statement.\n\u201cOur study, as well as other research, suggests an association between metformin and/or TZD use and the risk of developing lung cancer,\u201d said Dr. Peter Mazzone of the Cleveland Clinic in Ohio, who led the study.\nBut Dr. David Gutterman, president of the American College of Chest Physicians, said more research would be needed before this could be proposed.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Costs aren\u2019t quite relevant as there are no regimens to compare yet. In other words, this was not a prospective study comparing different methods to prevent or treat cancer. However, we give a nod because we\u2019re told that generic metformin is cheaper than TZDs.", "answer": 1}, {"article": "And I am a lunch buddy at one of the schools nearby,\" she says.\nThis is why the telescope is implanted in only one eye.\nColby says that's also why patients need to learn to use the implanted telescope eye for near activities.\nFor one, the treatment doesn't work for those who have had cataract surgery.\nThe treatment doesn't work for those who have had cataract surgery.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "This sounds like a lengthy and involved procedure that would require expensive technical expertise during surgery. The device itself has to be very expensive. Because there are lower-tech surgical\u00a0alternatives and\u00a0non-surgical alternatives, insurance companies may be slow to cover this sort of procedure. Given that, it would have been nice to see a ballpark figure for how much this costs. ", "answer": 0}, {"article": "Wolters Kluwer N.V. (AEX: WKL) is a global leader in information services and solutions for professionals in the health, tax and accounting, risk and compliance, finance and legal sectors.\nBefore migraine surgery, the patients had \"extremely poor\" PSEQ scores, indicating a high level of disability.\n\"Our study demonstrates the high functional disability experienced by migraine patients, compared to those with other pain conditions, \" comments ASPS Member Surgeon William Gerald Austen, Jr, of Massachusetts General Hospital.\nDr. Austen and colleagues conclude, \"Chronic pain questionnaires such as the PSEQ add to our understanding of functional outcome after surgery and put pain in migraine surgery patients in perspective to better-known pain conditions.\"\nThe study evaluated the performance of one such questionnaire--the Pain Self Efficacy Questionnaire (PSEQ)--in migraine surgery patients.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The news release did not include the cost of this migraine surgery \u2014 nor did it really say what a migraine surgery entails, except for briefly comparing it to a cosmetic forehead-lift. According to the website linked in the news release, a cosmetic forehead-lift (also called a \u201cbrow lift) costs an average of $3,403. However, a look at anecdotal articles online reveals that the cost can often be much more if not covered by insurance \u2014 up to $30,000 in some cases.", "answer": 0}, {"article": "Brain scans and spinal taps are helpful but they're not certain.\nThere is still plenty of lab work to be done, more rigorous research before it's proven a simple blood test can diagnose Alzheimer's, but those working on the test are hopeful it can be approved for use by 2009, adds Blackstone.\nToday only an autopsy can establish for sure that a patient had Alzheimer's.\nAccording to a paper published in the online edition of the British journal Nature Medicine, preliminary studies by a team of scientists led by a Stanford neurology professor show the test is yielding promising results in predicting which patients with mild memory loss are at high risk of developing Alzheimer's disease.\nCurrently, an early Alzheimer's diagnosis requires complex brain scans.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Potential costs not addressed.\u00a0 However, this is not a commercially available test or even available in most research labs so costs are very difficult to predict.\u00a0 But a story like this also could have touched on the whole issue of the downstream costs associated with testing everyone with some memory loss \u2013 which could be enormous \u2013 and the costs of providing what are now relatively ineffective current drug treaments.\u00a0\u00a0 ", "answer": 2}, {"article": "\"What we observed was a massive improvement in response,\" Baselga said.\nThey looked to see which drug was better at eliminating invasive cancer in the breast and metastatic cells in the lymph nodes.\nThat's the effect on overall survival in using the two-drug approach.\nGlaxoSmithKline, the maker of Tykerb, helped fund the study.\nThose given Tykerb alone had a 25 percent response.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Cost of Tykerb was estimated \u2013 about $4,000/month wholesale.\u00a0 No mention of Herceptin\u2019s cost.\u00a0 Strange to include one but not the other since this was a story about a \u201cdrug duo.\u201d\nCost is always an important consideration in this type of story.\u00a0 This is especially true when the drug costs are so high.\u00a0 The drug costs for the combination regimen approaches $100,000 a year.\u00a0 Since the combination treatment is not standard, insurance coverage will be spotty at best.", "answer": 0}, {"article": "\u201cIt\u2019s not going to be a panacea,\u201d says Thomas.\nImportantly, this vaccine is designed to work against only heroin, not other opioids.\nThe compound, created by chemists at the Scripps Research Institute, works in a way that\u2019s similar to other vaccines.\n\u201cIt\u2019s an avenue that shows some promise.\u201d\n\nAlthough research on humans is not yet planned, study authors Kim Janda and Paul Bremer, chemists at the Scripps Research Institute, are encouraged about this next step.\nThe current study of the vaccine, published in the Journal of the American Chemical Society, follows eight years of laboratory research and studies in rodents that indicated the compound could neutralize heroin at different doses.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Given the level of development, cost is not a consideration at this juncture.", "answer": 2}, {"article": ".\nCherian noted that the study does not prove that the DASH diet leads to a reduced risk of depression; it only shows an association.\n\"Future studies are now needed to confirm these results and to determine the best nutritional components of the DASH diet to prevent depression later in life and to best help people keep their brains healthy,\" said Cherian.\n\"Making a lifestyle change such as changing your diet is often preferred over taking medications, so we wanted to see if diet could be an effective way to reduce the risk of depression.\"\nThe study found that people whose diets adhered more closely to the Dietary Approaches to Stop Hypertension (DASH) diet were less likely to develop depression than people who did not closely follow the diet.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Costs are not discussed. However, the \u201ctreatment\u201d at issue is not a drug or medical technology with clearly defined costs. Rather, the DASH diet focuses on an individual\u2019s food choices. While there are cost constraints associated with any diet, and many people do not have easy access to the fruit and vegetables that are at the heart of the DASH diet, it would be challenging to address those issues in any meaningful way in the context of a news release like this one. That being the case, we\u2019ll rate this as \u201cnot applicable.\u201d", "answer": 2}, {"article": "Previous studies have shown that nitrites \u2014 also found in high concentrations in celery, cabbage, and other leafy, green vegetables like spinach \u2014 widen blood vessels, but researchers say this was the first to find that nitrites also increase blood flow to the brain .\nAn hour later, an MRI scan recorded brain flow in each person\u2019s brain.\nOn the second day, after another 10-hour fast, the participants returned to the lab and ate their assigned breakfasts.\nThe high-nitrate breakfast included 16 ounces of beet juice.\nThen they were sent home with lunch, dinner, and snacks that conformed to their assigned diets.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Not applicable.\u00a0 The costs of these veggies was not discussed, but it\u2019s not in question.", "answer": 2}, {"article": "Diffuse large B-cell lymphoma is the most common type of non-Hodgkin lymphoma in adults.\nArmin Ghobadi, an oncologist at Siteman who was an investigator in the Kite trial, said the new treatment is \u201cjust the first step\u201d and that researchers are working to make it safer and more effective.\n\u201cThese are patients who knew they were out of options,\u201d he said, noting that lymphoma patients who relapse or don't respond to treatment have just a 50 percent chance of surviving for six months.\nThe one-time infusion, known as CAR T-cell therapy, is made by Kite Pharma, which is based in Santa Monica, Calif., and recently was bought by Gilead Sciences for $11.9 billion.\nEven so, Yescarta's cost is likely to stoke the ongoing debate about high drug prices.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story states the cost of this new therapy. It also contrasts it to the other approved drug for CAR T-cell therapy. However, it would have been helpful to know if this cost includes all the related hospital care and services, or is simply the cost of the drug itself. It also would have been useful to compare it to other treatments for this form of cancer, such as chemotherapy or transplantation.", "answer": 1}, {"article": "\u201cOur lab is on an island in the South.\nNot everyone is convinced of the effectiveness of after-sun care.\nA new school of thought in the beauty world is pushing the idea that what you put on your skin after a day at the beach could play a part in reducing sun damage.\nI know that it\u2019s not realistic to say \u2018no sun.\u2019 \u201d\n\nShe is, however, quite knowledgeable about how to be safe when you\u2019re in the sun.\n\u201cThat can make sun-exposed skin feel better,\u201d she said, \u201cBut there\u2019s nothing you can do to reverse sun exposure.\u201d And while Henry Lim, president of the American Academy of Dermatology, believes that the Yale study was important, he cautions that you only have a three-hour window after sun exposure to take advantage of any potential product benefits\u2014and that antioxidants \u201care notoriously not very stable and must be formulated carefully in order to be effective.\u201d\n\nBut believers like True Nature Botanicals\u2019 Ms. Peterson are undeterred.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story mentions the costs of the products it cites.", "answer": 1}, {"article": "MEMPHIS, Tenn., Oct. 26, 2015 /PRNewswire/ -- Imagine.\nThe ongoing refinement of the technology makes treatment more precise and extremely reliable.\nFollowing numerous limited studies, a growing number of women are now being treated with the technique as part of a groundbreaking clinical trial involving leading breast cancer specialists across the country.\nWe are confident that the ICE3 trial can prove certain women can be successfully treated less aggressively than in the past.\nThe ICE3 trial, which began patient enrollment in October 2014, will significantly expand data on the technique as a treatment for breast cancer.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There isn\u2019t a dollar sign anywhere in this release, but other cryoablative therapies cost about $11,000 to $12,000 per session and multiple sessions are sometimes necessary.", "answer": 0}, {"article": "About the Society of Breast Imaging\n\nThe Society of Breast Imaging (SBI), established in 1985, is a professional medical organization dedicated to improving the practice of breast imaging and the quality of medical education in breast imaging.\nWASHINGTON, Sept. 29, 2015 /PRNewswire/ -- The American College of Radiology (ACR), Society of Breast Imaging (SBI) and major medical organizations experienced in breast cancer care continue to recommend that women start getting annual mammograms at age 40.\nThe SBI also provides a medium for the exchange of ideas among those involved in breast imaging.\nThe ACR and SBI believe women 40 and older should have access to mammograms and that Medicare and private insurers should be required to cover them for these exams.\nSeventy-five percent of women diagnosed with breast cancer have no family history or other factors that place them at high risk for the disease.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The average cost of an annual mammogram is relatively easy to find, but this news release didn\u2019t address it. The average out-of-pocket expense, per mammogram visit, is about $33. This is about 1/7th the cost of the full tab (approximately $266), according to a 2011 study in Journal of Women\u2019s Health. ", "answer": 0}, {"article": "Drinking cow\u2019s milk produced at night may be a treatment for anxiety and insomnia, suggests an animal study in the Journal of Medicinal Food.\n\nA glass of milk at bedtime has long been touted as a sleep aid. But the study found that milk collected at night, or night milk, had enhanced sedative effects in mice compared with milk produced during the day. Night milk significantly decreased the rodents\u2019 physical activity, balance and coordination and increased sleep time compared with day milk, the research showed.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Although the cost of night milk is\u00a0not discussed directly, the reader is given a hyperlink\u00a0to the company website of\u00a0Milchkristalle GmbH, a producer of night milk, where the price of night milk may be found. (Though we\u00a0find it strange that a hyperlink of night milk should direct the reader to a specific company selling a night milk product.)", "answer": 1}, {"article": "So you do not get the impression that the world is moving or that you are moving, you actually do not feel anything,\u201d Bergquist explained.\nThe research was led by Associate Professor Filip Bergquist, who said the simple device was similar to the TENS (Transcutaneous Electrical Nerve Stimulation) therapy which is used for pain relief, for example in child birth.\nThe plan is now for the device to be tested in a longer-term study, where patients will be using it at home.\nBergquist said he hoped the device could treat patients for whom the Levodopa drug, which turns into dopamine in the body and increases levels of the chemical, was not enough.\nThe device operates by providing stimulation via patches attached to the patient\u2019s head behind the ears, where the vestibular system is located.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Though the device remains experimental, the story says it is similar to other TENS (Transcutaneous Electrical Nerve Stimulation)\u00a0devices. A typical cost for TENS according to an internet search varies from $40 to $200 \u2014 a figure that the story could easily have provided. Some insurers may cover this cost, but possibly not for conditions where there is not a clearly demonstrated benefit.", "answer": 0}, {"article": "Medical-device makers, venture capitalists and surgeons are racing to turn a once-controversial weight-loss procedure into the next big thing in elective surgery.\n\nOnce dismissed by some surgeons as a gimmick, gastric banding -- in which a silicone band is wrapped around the upper stomach to restrict food intake -- is now the focus of a fierce competition pitting consumer-products giant Johnson & Johnson against Botox maker Allergan Inc. Venture-capital-backed outpatient centers are popping up to implant the bands. Growing...", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story provided several estimates for the cost of gastric banding; it also discussed insurance coverage, i.e. that the procedure was not always covered by insurance.", "answer": 1}, {"article": "By Amy Norton NEW YORK (Reuters Health) - People with multiple sclerosis have long said that smoking marijuana helps ease their painful muscle cramping.\n\u201cSpasticity is a big problem for many people with MS, and the current medications don\u2019t necessarily work for everyone,\u201d said LaRocca, who was not involved in the new study.\nBoth LaRocca and Corey-Bloom said there were limitations to the current study.\n\u201cI think this study shows that yes, (marijuana) may help with spasticity, but at a cost,\u201d said Corey-Bloom, of the University of California, San Diego.\n\u201cWhat effects that might have had on the results is unclear.\u201d\n\nCorey-Bloom said that should not have influenced the spasticity findings, since an independent researcher (who didn\u2019t know whether patients were smoking marijuana or the placebo) rated spasticity using a standard scale.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Somebody had to pay for the marijuana used in the study.\u00a0 And somebody would have to pay something if it were used therapeutically.\u00a0 A cost estimate would have helped.\u00a0 Not everybody knows this stuff.", "answer": 0}, {"article": "And, yes, they do get into the brain,\" Fleming explains.\nAnother surprise was a decrease in serotonin in brains of pigs fed the prebiotic.\nAlthough more work is needed to tackle remaining questions, the study adds to the growing body of research suggesting a strong and potentially modifiable link between the gut and the brain: a link that makers of infant formula should strongly consider.\nThe researchers hypothesize that the prebiotics may alter levels of tryptophan, serotonin's amino acid precursor, but it's too early to say.\nNot necessarily; those pigs didn't show greater anxiety than control pigs during a stress test or poorer performance when given a learning and memory test.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There is no discussion of the associated costs of both formula and prebiotic-enhanced formula which could be considerable considering the amount and length of time an infant would consume it.", "answer": 0}, {"article": "Surgery for a painful, common back condition known as spinal stenosis resulted in significantly reduced back pain and better physical function than treatment with drugs and physical therapy, according to the latest findings from a large federally funded research effort.\n\nThe results from the Spine Patient Outcomes Research Trial, or Sport, echo findings it reported last April involving degenerative spondylolisthesis, another common spinal problem. A separate, earlier report from the same study found nonsurgical treatment for...", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The article reports the costs of surgery ($10,000-12,000) though it does not mention the cost of nonoperative care or compare the costs of the two treatment regimens. It\u2019s unclear from the article whether the surgery costs encompass all aspects of surgery, from surgeon fees through hospitalization.", "answer": 1}, {"article": "CT scanning uses X-rays and computers to produce a clearer image than traditional X-ray techniques, but CT also uses higher radiation doses to generate those images.\nThat\u2019s consistent with the findings of the National Lung Screening Trial in the U.S., which in November released data \u2014 published online in the New England Journal of Medicine last week \u2014 showing that 20 percent fewer middle-aged heavy smokers died of lung cancer when they were screened annually with a CT scan compared to a standard, less detailed chest X-ray.\nMoreover, they warn that while regular screening might help doctors catch cancer earlier, it also comes with a high price tag and added risks to patients.\n\u201cWe now have a technology that can detect (lung cancer) early enough to make some impact,\u201d Berg said.\nWhile doctors ruled out cancer, those patients would have undergone further tests, sometimes including biopsies, which can cause complications including infection and bleeding.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story emphasizes cost several times, including the estimate of a few hundred dollars per scan.", "answer": 1}, {"article": "\u201cFar too many cancers are picked up too late, when it is no longer possible to operate and the chances of survival are slim,\u201d he said.\nResearchers said their results showed promise in the approach of blood screenings for cancer, but noted further \u201cclinical development\u201d was needed.\nThe test was most accurate for diagnosing pancreatic, ovarian, liver and gallbladder cancers, correctly finding the diseases in at least four out of five patients.\nResearchers hope the test will become part of a \u201cuniversal screening\u201d tool that doctors can use to detect cancer in patients.\nA blood test for 10 different types of cancers could one day help doctors screen for the disease before patients show symptoms, researchers at the world\u2019s largest gathering of oncologists have said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Costs are not mentioned.\nAs we\u2019ve reported in the past, one company has marketed their similar test with a $1,000 price point.", "answer": 0}, {"article": "The researchers believe that adding probiotics to the peanut allergens may be important in improving the children\u2019s tolerance to the food, but Dr. Anna Nowak-Wegrzyn, an associate professor of pediatrics at Icahn School of Medicine at Mt.\nThe results are encouraging, allowing the children who were treated to eat peanuts without fear of an allergic reaction.\nBut the new findings provide even more evidence that using peanuts to treat peanut allergy, and to re-train the immune system to be less allergic, can be effective.\nThe Australian team added probiotics to further enhance the gut\u2019s ability to accept the peanuts and not trigger an immune reaction.\nThe study, published in the journal , follows up on children enrolled in an earlier study of an immunotherapy treatment, which combined probiotics with small doses of peanuts that were designed to gradually train the children\u2019s immune systems to accept the peanut allergen rather than treat it as something foreign.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Cost is not addressed. Would this be a relatively inexpensive treatment? A costly one? Is it too early to tell? Readers won\u2019t be informed of this.", "answer": 0}, {"article": "Carl Alexander, a spokesman from the charity Cancer Research UK, said: \u201cThis study is an exciting example of how research can find clues in our genes to help us uncover those more likely to develop the disease.\nBy testing a man\u2019s DNA, researchers can look for genes linked to the disease, which one in seven men in the Western world will be diagnosed with in their lifetime.\nIf it is found to be effective, it could be an important tool for physicians.\nRosalind Eeles, an author of the study at the U.K.-based Institute of Cancer Research (ICR) who specializes in finding genetic variants that increase the risk of prostate cancer, told The Guardian the team is \u201cexcited by the test\u201d because it can be used by doctors to offer patients targeted screenings.\nScientists have developed a spit test that could identify the men most at risk of developing prostate cancer.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There\u2019s no cost data. While this test isn\u2019t on the market \u2014 and might never be \u2014 there are plenty of saliva-based genetic tests that are.\nSays the U.S. National Library of Medicine: \u201cThe cost of genetic testing can range from under $100 to more than $2,000, depending on the nature and complexity of the test.\u201d", "answer": 0}, {"article": "Both show that antibiotics are more effective than placebos in relieving ear-infection symptoms such as fever, poor appetite, decreased activity and irritability and suggested that their benefits warrant their being administered early on, regardless of the seeming severity of a child's symptoms.\nInterestingly, antibiotics were no more effective at reducing pain, as reported by parents or children, than placebos.\nNow two new studies (bolstered by an accompanying editorial) in the New England Journal of Medicine demonstrate what we parents have suspected for years: When it comes to ear infections, antibiotics are in order.\nStill, some of the placebo-group kids required \"rescue treatment\" when their symptoms grew markedly worse.\nEar infections hurt, and waiting for them to run their course can be excruciating.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Although the cost of antibiotics to treat an ear infection may not be a significant\u00a0issue for most families, we think costs always should be addressed.\u00a0 We found an estimate on Drugstore.com of $76 for a 10 day course of treatment. \u00a0 There, that wasn\u2019t difficult, was it?", "answer": 0}, {"article": "Computed tomography coronary angiography (CTCA), is a high-resolution X-ray of the heart that can be used to diagnose the reason for angina, or chest pain, symptoms and clarify what other treatments might be needed.\n\u201cAlthough CTCA removes diagnostic uncertainty and halves the rate of subsequent heart attacks, quality of life can be negatively impacted in those who are worried about their health and are found to have nonobstructive coronary artery disease,\u201d Newby said.\nWhen the CTCA results revealed something less than a blockage, so-called nonobstructive disease, as the cause for the patient\u2019s chest pain, patients\u2019 quality of life got worse in the following weeks and months.\nAlthough getting CTCA is associated with a lower likelihood of having a heart attack later on, its effects on symptoms and quality of life may vary, the researchers note in the journal Heart.\nThis reflects the fact that the cause of the symptoms had been unknown before and in addition they now have heart artery disease that needs treatment, Newby said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not mention the cost of computed tomography coronary angiography (CTCA), which can be a few hundred dollars.", "answer": 0}, {"article": "At the end of the day I don't know that this will be the best technology out there, but it is a step forward to allow continued innovation in this area,\" Foreman said.\nMela Sciences does not plan to ask insurers to cover the device until several years from now, after it is more widely used.\nThe company's study was not intended to show that screening with the device saves lives, only that it can help improve a doctor's ability to spot melanoma.\n\"The diagnosis of melanoma is the most serious one a dermatologist makes, and we have sleepless nights worrying about it,\" said Pariser, who consulted for the device's maker, Mela Sciences Inc. of Irvington, N.Y., on its presentation to FDA.\nRegulators said this week that they ultimately approved the device after Mela Sciences agreed to limit its use to board-certified dermatologists who undergo a specialized training course.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story takes the rare step of talking about costs from three different angles. The cost to the physician. The cost to the patient. And the cost to insursers. \u201cDoctors will pay a one-time fee of $7,500 to lease and receive training on the device. Patients will pay $150 out of pocket for a MelaFind scan, which analysts say may limit use to more affluent patients who are willing to pay extra for the latest medical care. Mela Sciences does not plan to ask insurers to cover the device until several years from now, after it is more widely used.", "answer": 1}, {"article": "1.\nResearchers sought to determine the clinical effectiveness of acupuncture or Alexander Technique lessons compared with usual care for persons with chronic, nonspecific neck pain.\nThe researchers found that acupuncture and the Alexander Technique lessons both led to a significant reduction in neck pain at 12 months compared with usual care alone.\nOver time, both interventions resulted in a greater increase in self-efficacy than did usual care, and these improvements were associated with better NPQ outcomes.\nBoth interventions had a high rate of acceptability, and greater adherence was associated with better pain outcomes.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The news release does not mention the costs of either acupuncture or the Alexander Technique. This is important to include since both therapies probably require the patient to pay out of pocket, at least in the United States. A quick web search found that the median cost of an acupuncture session\u00a0 nationwide is $100. Alexander Technique sessions cost about the same as massage therapy \u2014 around $70 to $100 per 45-minute session. In this study, 12 acupuncture sessions and 20 Alexander Technique sessions were required.", "answer": 0}, {"article": "For more on dietary supplements, visit the Office of Dietary Supplements of the U.S. National Institutes of Health.\n\"This was indeed a small study,\" acknowledged corresponding study author Joe Vinson, a professor of chemistry at the University of Scranton, in Pennsylvania, but he noted that prior research has been conducted in both France and Japan.\nThe study was conducted in India and funded by Applied Food Sciences, the American manufacturer of two green-coffee-extract products.\nEach patient ultimately cycled through each section.\nIn one section, study participants, who were all between the ages of 22 and 26, consumed a capsule filled with 700 milligrams of green coffee extract.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "\u201cGreen coffee-bean extracts are sold online at prices ranging from about $10 to $20 for 60 capsules,\u201d according to the story.", "answer": 1}, {"article": "AstraZeneca PLC's cholesterol drug Crestor sharply lowered risk of heart attacks among apparently healthy patients in a major study that challenges longstanding heart-disease prevention strategies. The findings could substantially broaden the market for statins, the world's best-selling class of medicines.\n\nHeart experts said the findings, presented Sunday at the annual scientific meeting of the American Heart Association in New Orleans, could reshape cholesterol-treatment guidelines used for more than a decade to fight cardiovascular...", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "While the story included a calculation that suggested that the intervention was as cost effective as strategies screening for elevated LDL, the story failed to indicate the actual cost to the consumer. \n\u00a0", "answer": 0}, {"article": "Leukemia is the most common childhood cancer and accounts for about 30 percent of all childhood cancers.\n\u201cBecause the primary goal of public health is prevention of morbidity, health care professionals should be taught the potential health benefits of breastfeeding and given tools to assist mothers with breastfeeding, whether themselves or with referrals to others who can help.\nIn addition, more high-quality studies are needed to clarify the biological mechanisms underlying this association between breastfeeding and lower childhood leukemia morbidity,\u201d the study concludes.\nThe authors suggest several biological mechanisms of breast milk may explain their results, including that breast milk contains many immunologically active components and anti-inflammatory defense mechanisms that influence the development of an infant\u2019s immune system.\nThe many potential preventive health benefits of breastfeeding should also be communicated openly to the general public, not only to mothers, so breastfeeding can be more socially accepted and facilitated.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "While it\u2019s obvious that breastfeeding is free of charge, readers might not appreciate what an advantage this is compared with prepared formulas. This is an especially important consideration in the developing world where a desire for westernization has caused a significant bump in infant formula sales. The average annual cost of a brand-name infant formula is approximately $1200 in the US. Then again, there\u2019s potentially a cost to breastfeeding in terms of work/career advancement for the mother and the labor value of time spent breastfeeding/pumping. Breast pumps can be expensive, too. The news release didn\u2019t need to explore all of this, but some acknowledgment of the issues at play would have been welcome.", "answer": 0}, {"article": "Normally it's the very old or very young that die from flu, but every year there are deaths from influenza A,\" said Gilbert.\nThe initial results are positive, says Peter Palese, professor and chair of microbiology at Mount Sinai School of Medicine, New York, but more research is needed before the new treatment is approved.\nThe vaccine would be an important step in treating seasonal flu, not just pandemics.\nThe results, say Gilbert, are important in developing a new form of protection that researchers hope could spell the end of flu vaccination supply problems.\n\"Whether it's this vaccine or another one someone else develops, I don't think we'll be continuing with the type of flu vaccines that we have at the moment.\"\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Since this vaccine is not yet available, a discussion of costs is not necessary.\u00a0\u00a0\u00a0", "answer": 2}, {"article": "Clostridium novyi flourishes in low-oxygen environments.\nA potentially dangerous bacteria appears to target malignant cells and could provide a new means of fighting cancer, a small, preliminary study reports.\nResearchers have moved on to the next phase, in which patients taking the immunotherapy drug pembrolizumab (Keytruda) will also be treated with a single injection of Clostridium novyi-NT, Janku said.\nPatients in this clinical trial were left with the bacterial infection for one week, and then everyone was given antibiotics to kill off the Clostridium novyi-NT, Janku said.\nThe researchers suspect the two therapies used in combination will create a strong immune response against cancers.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There was no discussion of the potential cost of this therapy. Although it is probably too early in the process to discuss precise numbers, it would\u00a0have been helpful if the story had discussed the big picture. While bacterial therapies may be cheap to develop, the cost of clinical trials and bringing a new product to market tend to be very high. Also, an ongoing trial pairs this therapy with immunotherapy drug pembrolizumab, which can cost about $13,500 per month, according to published reports.", "answer": 0}, {"article": "Medical researchers are well aware that the dummy pills used in clinical trials often provide as much relief as the actual drugs being tested. This is what's known as the placebo effect, and it's quite common in people with Parkinson's, a movement disorder that causes tremors, stiffness and balance problems. A 2008 meta-analysis found that placebos used in clinical trials of Parkinson's treatments improved symptoms by an average of 16%.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The cost of sugar pills is not in question. But the story does explore the cost implications of developing more effective placebos. It says, \u201cTo the extent that doctors can use placebos to improve patients\u2019 symptoms, they can use the real drugs less, which may be expensive or toxic.\u201d", "answer": 1}, {"article": "Then in 2002, the results of the largest randomized clinical trial of hormone replacement, the Women\u2019s Health Initiative (W.H.I.\nstudy actually had nothing to do with menopausal symptoms.\nfindings have been seriously misunderstood and misinterpreted,\u201d and millions of women for whom the benefits clearly outweigh the risks are needlessly being denied treatment.\nDr. Manson is distressed about the large number of women \u2014 about a third of those now on hormone replacement \u2014 who are relying on \u201ccustom-compounded\u201d products that have not been reviewed for safety and effectiveness by the Food and Drug Administration.\nMost of the 27,347 women entering the study were already in their 60s and 70s, already a decade or more past menopause.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Costs are not discussed.", "answer": 0}, {"article": "He says he plays basketball with his granddaughter, works on his farm, and gets on the treadmill for 30 minutes three times a week.\nIt's the first time tissue-specific stem cells, other than bone-marrow cells, have been tested in humans, Hare says.\nThe breakthrough comes just as researchers were becoming discouraged by studies in which bone-marrow stem cells failed to heal damaged hearts.\n\"The reported benefits are of an unexpected magnitude,\" writes Gerd Heusch, MD, PhD, chair of the Institute of Pathophysiology at the University of Essen, Germany, in an editorial in the Nov. 14 online issue of The Lancet.\nThese adult stem cells already are committed to becoming heart cells, but they can transform into any of the three different kinds of heart tissues.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story makes no mention of costs. \n\n\n\nBecause this is a phase 1 study, no costs can be determined at this stage.\u00a0 Needless to say, the costs are likely, however, to be significant. There is widespread concern that when stem cell therapies do become available for some conditions that they will be cost prohibitive. The reason so many stem cell studies have enrolled so few patients is, in part, because research costs are so high, and that translates into higher costs for patients down the road.", "answer": 1}, {"article": "Greek researchers offered fresh evidence of the health benefits of the Mediterranean diet, reporting in a large study that it helps improve several risk factors linked to diabetes, obesity and heart disease.\n\nThe Mediterranean diet is high in monounsaturated fats such as olive oil and also relies heavily on whole-grain cereals, fruits and vegetables, fish and low consumption of animal fats. It has been shown in numerous studies and clinical trials to reduce mortality from such causes as cardiovascular disease and cancer.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Not applicable. There was no discussion of costs, i.e. how consumption of a \u2018Mediterranean diet\u2019 compared to more typical diets compare in terms of cost to the consumer. But we think most people would have a pretty good grasp of the general costs of the types of foods involved.\u00a0 But where this becomes an issue, for example, is with what the cost of fresh fish can do to a food budget.", "answer": 2}, {"article": "\u201cIf screening is going to work, you\u2019ve got to keep at it.\u201d\nThis latest study, published in the journal Lung Cancer, looked at death rates in a different, smaller population of heavy smokers, and estimated that those who received up to two CT scans would have between a 36 and 64 percent lower risk of dying, compared to those who went unscreened.\nA new study finds that regular smokers who received three-dimensional X-rays to look for the presence of early tumors had a significantly lower risk of dying over a 10-year period.\nFurthermore, an April study showed that 21 percent of a patient\u2019s initial lung CT scans show suspicious lesions that turn out not to be cancer, but lead to needless invasive follow-up procedures and radiation exposure, as well as stress and anxiety for patients and their families.\nIt is not clear when or how guidelines for lung cancer screening could be drawn up, and until they are, insurers including government programs such as Medicare are unlikely to pay the average $300 cost of a scan.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "\n\n\n\nThe story reports that this sort of scan costs about $300. The story also notes that if screening is effective, the scans would need to be repeated, though there is no consensus on what schedule would make the most sense. The CDC estimates that more than 45 million Americans currently smoke cigarettes and more than that many are former smokers. \nThe story should have more clearly pointed out that the cost of a screening program is not the cost of a single test, but the cumulative cost of repeatedly screening many millions of people as well as the cost follow-up tests and treatments\u2026 both the treatment of potentially dangerous lung cancers, but also the treatment of the many suspicious lesions that turn out not to be cancer. A separate study found a false positive rate of more than 20 percent, suggesting that follow-up tests (and the costs they incur) would be a frequent added expense. The story should have at least referred to the national costs and the additional testing and treatment costs triggered by false positive scans.\n", "answer": 0}, {"article": "Anderson Cancer Center in Houston.\nThe goal of the vaccine, Hale said, is to educate the body to respond to that HER2-based peptide, so it will recognize the cancer when it recurs and attack it.\nBut until the vaccine is linked to an actual survival benefit or improvement in tumor status, Diamond said, no one can say if it helps the patients in a meaningful way.\nThat is a good thing, Hale said, because \"an increase in these cells has been found to be associated with [cancer] recurrence.\"\nThe science is early, Hale stressed, and it will take at least five years before the vaccine could conceivably be available if ongoing studies bear out.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Costs weren\u2019t discussed, but since this was an early report on an experimental vaccine, that is understandable.", "answer": 2}, {"article": "While the new screen only looks for Down syndrome, Sullivan says that some of the other trisomy birth defects can be more easily identified on an ultrasound exam.\nIt is not a diagnostic test for Down syndrome, she says.\n\u201cThis test looks very promising, but it is also very expensive,\u201d\n\nWhile there are risks attached to amniocentesis and CVS screens, these are minimized when the test is performed by a skilled obstetrician, she says.\nJoyce Fox, MD, the chief of medical genetics at Cohen Children's Medical Center in New Hyde Park, N.Y., definitely sees a role for a test such as the one described in the new study.\nFor now the test just looks for Down syndrome, but \u201ctechnology will advance to the point where noninvasive testing will encompass more of the less common genetic anomalies,\u201d she says.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "We\u2019ll give the story the benefit of the doubt for again leaning on an independent expert who says the technology is likely prohibitively expensive.\u00a0 While no dollar estimate is given, we think this is good enough for now.", "answer": 1}, {"article": "In recent years, surgical techniques, anesthesia and other medical care advanced, and death rates fell.\nEven more impressive: 65 percent survived without any long-term complications \u2014 a \u201cvery, very remarkable\u201d result, Kurlansky said.\nThe studies were reported at an American Heart Association conference this week in New Orleans.\nOverall, 90 percent survived their surgery to leave the hospital.\nEven 90-year-olds are having open-heart surgery, said Dr. Harlan Krumholz, a Yale University cardiologist who has researched older heart patients.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There was no discussion about the costs of the procedures discussed or whether there were additional costs associated with treating the older patient.", "answer": 0}, {"article": "It matters.\nThe current standard treatments for metastatic melanoma -- chemotherapy and interleukin-2 (IL2) -- only have response rates in about 15 percent of these patients, said Dr. Paul Chapman, senior author of a study in which the findings are described.\nThat finding opened the door to potential targeted, molecular therapies for melanoma, which has been sorely lacking in effective treatments.\nOne expert cautioned that it's too early to say whether the drug will actually prolong patient's lives, or if it might be helpful to patients in earlier stages of the disease.\nThe average survival time for someone diagnosed with melanoma is nine to 11 months, added Chapman, who is an attending physician in the Melanoma Sarcoma Service at Memorial Sloan-Kettering Cancer Center in New York City.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story didn\u2019t mention costs, which is somewhat understandable given the early phase of research.\u00a0 But the competing USA Today story, while noting that drug pricing hasn\u2019t been set, at least noted that many new cancer therapies \"cost $5,000 to $7,000 a month.\"\u00a0 This story should have done something like that as well. ", "answer": 0}, {"article": "The F.D.A.\nBut with less than a third of the enrollment goal of 2,500 patients completed, doctors will have a long wait for esults.\nEven stenting proponents worry about overuse of the technology in challenging cases.\nAnalysts estimate that sales of carotid stents, which cost around $3,000 each, have not yet topped $100 million.\nhas also tentatively approved a stent system from the Cordis division of Johnson & Johnson.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Cost of stenting procedure put at $10 -15K; later mention of \nMedicare restriction of coverage criteria.", "answer": 1}, {"article": "For more on chemotherapy, visit the American Cancer Society.\nSpecifically, nearly 70 percent of those in the fish oil group either kept their pre-chemo muscle mass or gained muscle.\nThe finding is based on a small study involving just 40 lung cancer patients.\nThe authors concluded that fish oil supplementation appears to be a safe and effective way to prevent malnutrition among cancer patients, and may ultimately prove to be of benefit for other groups of people, such as elderly patients who also face a significant ongoing risk for muscle loss.\n\"And other similar studies have looked at omega-3 and muscle preservation and have also suggested that fish oil can act to prevent inflammation caused by both disease and hardcore medications, like chemotherapy agents.\"\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No discussion of cost for the mega doses of fish oil used in the study.", "answer": 0}, {"article": "\"We think it will be a very important tool in the toolbag of surgeons and physicians treating obesity and its co-morbidities,\" said Gregory S. Lea, senior vice president and chief financial officer of EnteroMedics. \"When patients leave the diet, counseling and drug world and have nothing more, they turn to surgical procedures, and only 1% to 2% of patients who might be eligible for bariatric surgery are getting it.\"", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story quotes the manufacturer of the device estimating a cost between $20,000 and $30,000 for the procedure. The story further notes that the intervention is not yet covered by private insurers or Medicare, but that the company is negotiating for coverage. The results of those negotiations will play a major role in the availability of the procedure.\nThis is sufficient for a satisfactory rating. We\u2019d add that given the widespread use of cost sharing in today\u2019s health insurance products, a procedure of this type will be quite costly to many by way of deductibles and co-insurance. A middle of the road estimate of these out of pocket costs would have been informative.", "answer": 1}, {"article": "People with abdominal obesity are at higher risk of heart disease and early death than people with slimmer waistlines.\nThat intensity was equivalent to brisk walking for the previously sedentary participants, Ross told Shots.\nThe rest of us want to know how much we have to exercise to see health benefits.\nIn effect, those guidelines say there's no particular benefit from working out harder, other than saving time.\nThat exercise prescription was about the same as in the government guidelines.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Fitting exercise time into a life can be tricky if you are in poverty, working two jobs, or don\u2019t have a safe neighborhood. The story delivers an implicit acknowledgment of such concerns in the first line when it says, \u201cSome people \u2014 who are they? \u2014 have no problem fitting regular aerobic exercise into their lives.\u201d But that\u2019s not quite enough for a satisfactory rating here. The study involved \u201csupervised\u201d training sessions, which we assume means with some kind of trainer. How much would it cost to hire someone like that or join a gym that offers exercise equipment? A quick statement about those costs would\u2019ve earned the story a pass here.", "answer": 0}, {"article": "The findings, reported in the journal Diabetes Care, do not suggest that yoga should replace other forms of exercise for people with type 2 diabetes \u2014 a disease commonly associated with obesity.\nMeanwhile, their average blood sugar levels held steady \u2014 in contrast to the non-yoga-practicing \u201ccontrol\u201d group, whose blood sugar levels rose.\nThey found that, on average, the yoga group\u2019s levels of the chemicals dipped by 20 percent.\nFurther, long-term studies are needed to see whether that is the case, the researchers say.\n\u201cBut,\u201d she added, \u201cit should be noted that yoga controlled the blood sugar levels which otherwise rose in the control group.\u201d\n\nIn addition to that, the study found, signs of so-called oxidative stress declined in the yoga group.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There was no discussion of class costs. How much do yoga classes \u2013 several times a week \u2013 cost?", "answer": 0}, {"article": "The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices.\nEfficacy of Intrarosa, a once-daily vaginal insert, was established in two 12-week placebo-controlled clinical trials of 406 healthy postmenopausal women, 40 to 80 years of age, who identified moderate to severe pain during sexual intercourse as their most bothersome symptom of VVA.\nIntrarosa, when compared to placebo, was shown to reduce the severity of pain experienced during sexual intercourse.\nThe U.S. Food and Drug Administration approved Intrarosa (prasterone) to treat women experiencing moderate to severe pain during sexual intercourse (dyspareunia), a symptom of vulvar and vaginal atrophy (VVA), due to menopause.\nIntrarosa is the first FDA approved product containing the active ingredient prasterone, which is also known as dehydroepiandrosterone (DHEA).\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The FDA evaluates drugs without consideration of cost, so it\u2019s understandable that they wouldn\u2019t comment on it \u2014 and that\u2019s why we\u2019re rating this Not Applicable. We look forward to the day when any news release about a new drug \u2014 even one from the FDA \u2014 includes some mention of cost in its message. After all, the value of a new drug is a function not just of how well it works, but its cost-effectiveness. With the newly approved Intrarosa are we looking at $10 or $100 for each round of treatment?\nIts active ingredient, DHEA, is sometimes used as a dietary supplement. On Goodrx.com, a bottle of 300 25-mg tablets of Natrol goes for $13.29.", "answer": 2}, {"article": "There are three types of omega-3 fatty acids: a-linolenic acid (ALA), eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA).\n\"There is evidence that both omega-3s from plants and marine sources are protective against cancer and we wanted to determine which form is more effective.\"\nBased on the doses given in the study, Ma said humans should consume two to three servings of fish a week to have the same effect.\nProf. David Ma has discovered that marine-based omega-3s are eight times more effective at inhibiting tumour development and growth.\nBesides certain foods containing EPA and DHA, supplements and functional foods, such as omega-3 eggs or DHA milk, can offer similar cancer prevention effects, he added.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The additional cost of adding fish and seafood to the diet aren\u2019t discussed.\u00a0  ", "answer": 0}, {"article": "Nearly a quarter of a million people worldwide have leprosy, which causes disfiguration of the skin and mucous membranes as well as progressive and incurable nerve damage.\nA viable vaccine to prevent and/or treat leprosy is the next step in the effort to bring this disease to an end.\nBased on data generated in preclinical studies, the vaccine candidate, called LepVax, has progressed to Phase I clinical testing in the United States, the first stage of safety testing in human volunteers.\nThe vaccine candidate will serve as part of an overall strategy to end leprosy, which will require detection, prevention and treatment.\nReed, along with scientists from a variety of scientific organizations recently published \"Innovative tools and approaches to end the transmission of Mycobacterium leprae\" in , outlining what is needed to achieve this goal.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Costs aren\u2019t mentioned. We know that it is far too soon to put a specific price tag on the treatment, but the release could have discussed the feasibility of scaling up manufacturing, whether the process is costly or time-consuming, etc. How much could the vaccine, which the release tells us is the first \u201cdeveloped specifically for leprosy\u201d and \u201cproduced by totally synthetic methods,\u201d cost patients? Based on the information in the release, it\u2019s anyone\u2019s guess.", "answer": 0}, {"article": "Natural Cycles uses a woman's body temperature and menstrual cycle data to tell her when she is fertile.\nAnd if the app gives you a \"red day\" \u2013 meaning you could be fertile \u2013 you have to abstain from sex, or use another method of protection such as condoms.\nFor starters, it can only protect against pregnancy, not STIs.\nYou don't actually need an app to practise natural family planning \u2013 although it does cut down on paperwork.\nEven so, the FPA advises that natural family planning is most effective if you\u2019re taught how to do it by a specialist teacher, and you monitor all three fertility indicators \u2013 temperature, menstrual cycle length, and cervical secretions.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The\u00a0story states that the app requires a monthly or yearly subscription, which implies it\u2019s not free. But there is no mention of what the subscription costs, which was easily found by visiting the Natural Cycle website (linked in the article). It\u2019s $5.80 per month or $69.90 per year. (For comparison\u2019s sake, the cost for one\u00a0month\u00a0of the pill can cost up to $50 although it\u2019s often covered by many health insurance companies.)", "answer": 0}, {"article": "Ralph Sacco and Tatjana Rundek of the University of Miami in an accompanying editorial.\n\u201cAlthough this was not a randomized trial and there was no comparison group to assess whether specialized units performed better than nonspecialized (stroke) units, these (newly-reported) risks are substantially lower than expected.\nThe ongoing study, which used previous stroke estimates for comparison, was based on data from 4,789 patients from TIAregistry.org, an international registry designed to follow cases for as long as five years.\nMore than two thirds of the patients in the study had a score of 4 or higher but the researchers caution that \u201climiting urgent assessment to patients with a score of 4 or more would miss approximately 20 percent of those with early recurrent strokes.\u201d\nThe study was also noteworthy because, over the long haul, patients did a particularly good job of taking the medications they were given.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Cost isn\u2019t addressed. Emergency room costs can be expensive, particularly for uninsured patients. And the costs associated with TIA treatment can vary widely, because treatment options can vary depending on the diagnosis. For example, a patient may be given drugs to \u201cbust\u201d a blood clot, or the patient may need to perform a surgical procedure. A 2014 study found that the average hospitalization for stroke in the U.S. cost approximately\u00a0$20,396 \u00b1 $23,256.\nThat\u2019s a lot of variability, and covers all types of stroke \u2014 not TIAs per se. In other words, it\u2019s tricky to nail down any firm numbers for a relatively concise news story. But the costs associated with treatment in a TIA unit could still be discussed (or at least mentioned).", "answer": 0}, {"article": "Of those, 25 had been admitted with a primary diagnosis of \"acute decompensated heart failure\" while another 16 patients had shown no signs of heart failure but did have other cardiovascular issues.\nDr. Gregg Fonarow, a professor of cardiology at the University of California, Los Angeles, said that if further research were able to establish its effectiveness, a breath-driven tool for identifying heart failure would be a helpful diagnostic innovation -- but more so in a doctor's office or clinic than in the hospital.\nThe study authors pointed out that the most common reason American patients are admitted to a hospital is when there is a suspicion of heart failure -- a tough-to-treat condition in which the heart's pumping action grows gradually weaker over time.\nThe investigators stressed that their evaluation is based on a small group of participating patients, and that more extensive research will have to be done to confirm their initial success.\nThis study is really a proof of concept.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "This potential test is in the early stages of development. Almost everything about it, from how well it actually works, or how it compares to alternatives, has yet to be studied. The story does quote a researcher saying the test is \u201ctheoretically cheap.\u201d", "answer": 2}, {"article": "Severely premature babies are more likely to live if they receive intensive-care treatments rather than palliative care to keep them comfortable, according to a U.S. government-funded study published Thursday.\n\nWhether babies born at the extreme edge of viability, generally considered to be 22, 23 or 24 weeks of gestation, should be aggressively medically treated is a controversial issue among pediatric experts. These infants often don\u2019t survive and, even if they do, many have substantial long-term health problems.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Especially in the WSJ, we would expect some mention of the extraordinarily high health care costs that can result from intensive treatment. The decision about which treatment is best in any particular baby\u2019s case should not be driven by costs, of course, but it is important to acknowledge the cost issue for this as well as for other health conditions.", "answer": 0}, {"article": "GAITHERSBURG, Md.\nThe therapy is exciting, AIDS specialists say, even though it is at least three years from market, because it could offer a completely new tool to combat a 25-year-old foe.\nIf approved by the Food and Drug Administration, bevirimat, developed by Panacos Pharmaceuticals Inc., would represent the first in a new class of drugs that uses an unusual approach to block maturation of the virus that causes AIDS.\nThat's why some patients, doctors, and researchers are excited about an experimental drug based on an herb known by the Latin name Syzigium claviflorum that had been used in Taiwan to treat diarrhea and stop bleeding.\nBevirimat is being developed as physicians begin to use drugs from different classes in combination to fight the virus at different steps in its life cycle.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not provide any projections of what the drug might cost. But the story was able to estimate annual sales of the drug for Panacos Pharmaceuticals. If you can give the latter, you should be able to provide the former. ", "answer": 0}, {"article": "Human monoclonal antibodies are naturally occurring human antibodies that are genetically altered in a laboratory, cloned in large numbers and introduced into the patient to target disease sites.\n\"For those patients with elevated LDL who are intolerant to statins, this provides a viable option,\" said Dr. Suzanne Steinbaum, a preventive cardiologist at Lenox Hill Hospital in New York City.\n\"The most interesting aspect of this study is use of a novel approach using monoclonal antibodies -- a subtype of antibodies -- in the management of elevated LDL cholesterol,\" said Dr. Kenneth Ong, acting chief of cardiology at the Brooklyn Hospital Center.\nMONDAY, Nov. 5, 2012 (HealthDay News) -- An experimental drug may help patients who can't tolerate statins lower their cholesterol, a new Australian study suggests.\nThe study was published online Nov. 5 in the Journal of the American Medical Association, to coincide with a planned presentation at the American Heart Association's annual meeting in Los Angeles.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Although this drug is still experimental, the story should have told readers that some analysts predict that this sort of drug, known as a biologic, will cost at least $10,000 a year, compared to less $200 a year for a generic statin. Many observers predict that the extremely high cost of this new type of cholesterol-lowering treatment is likely to mean it would be used only when statins don\u2019t do the job, which means this line of research may never be relevant to most people.", "answer": 0}, {"article": "\"We estimate that use of [Brilinta] instead of [Plavix] for one year in 1,000 patients with acute coronary syndromes and who are planning to undergo an invasive strategy at the start of drug treatment would lead to 11 fewer deaths, 13 fewer myocardial infarctions, and six fewer cases of stent [clotting] without an increase in the rates of major bleeding or transfusion,\" conclude study researcher Christopher P. Cannon, MD, and colleagues.\nAnd in the new study, patients had less bleeding after stent installation.\nAnd since the drugs irreversibly bind to blood-clotting platelets, a patient has to stop taking these drugs for five to seven days before the body can make enough new platelets.\nBoth drugs increase the risk of dangerous bleeding.\nBut there's a problem with Plavix, and with a newer, stronger drug in the same class called Effient.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "\u00a0There was no discussion of costs, although the story did mention that the twice a day dosing of the drug would be required. \u00a0If the drug is as close to FDA approval as indicated in the story, it would suggest that the company has some idea about its pricing.", "answer": 0}, {"article": "For more on irregular heartbeats, visit the U.S. National Library of Medicine.\nIn fact, with this new approach, the study team found that physicians could destroy such cells with 100 percent accuracy.\nThis, they said, is due to the procedure's use of a slender medical device called an endoscope, which when inserted into the target region provides a continuous real-time image of the culprit cells.\nThe current study focused on 27 patients (66 percent men), all of whom were diagnosed with a form of atrial fibrillation.\nThe findings are reported by study author Dr. Vivek Y. Reddy, a senior faculty member in medicine and cardiology at the Mount Sinai Medical Center in New York City, and colleagues in the May 26 online edition of Circulation: Arrhythmia and Electrophysiology.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No discussion of costs \u2013 a recurring and significant oversight. ", "answer": 0}, {"article": "It's a substantial number of women,\" Lyman said.\nThe study, involving nearly 900 women who were treated at 115 sites across the country, found that those who did have their lymph nodes removed were no more likely to survive five years after the surgery than those who did not, the researchers reported in a paper published in the Journal of the American Medical Association.\nThe study provides \"strong evidence\" that many women can safely forgo lymph node removal, they wrote.\nThe researchers noted that the study was limited to women with tumors known as T1 or T2, meaning they were relatively small, had no enlarged nodes that could be felt, and the cancer had not spread elsewhere.\nIn a telephone interview, Gary Lyman of the American Society of Clinical Oncology said the findings will probably prompt the group to revise its recommendations for breast cancer patients accordingly.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There was no discussion of costs.\u00a0 The article does refer to an editorial that accompanied the paper.\u00a0 The editorial observed that women would be spared \u201cunnecessary surgery.\u201d\u00a0 Less surgery should result in lower costs for the patient.", "answer": 0}, {"article": "A large, new study may be reassuring to women considering mastectomies because of a history of breast cancer in their families.\n\nStanford University researchers affirmed that women with mothers and sisters who carry one of the BRCA gene mutations but who aren't carriers themselves don't have an especially heightened risk of breast cancer.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story did not discuss the cost of the BRCA test, which according to the National Cancer Institute can range from several hundred\u00a0to several thousand dollars.", "answer": 0}, {"article": "\"Fast and junk food seem like an easy and affordable option for busy parents, but defaulting to high-fat, high-sugar, high-calorie foods is putting their children's health and future at risk,\" Heller said.\nHowever, to truly understand the effect of diet on children's intelligence, further studies are needed, they said.\nA more health-conscious diet was associated with small increases in IQ, she said.\nThis is particularly true during the first three years of life when the brain is developing rapidly, the study authors explained.\nCommenting on the study, Samantha Heller, a dietitian, nutritionist and exercise physiologist in Fairfield, Conn., said that \"most of us do not realize that the foods we eat have direct consequences on brain growth, function and performance.\"\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There is some research suggesting that diets with a lot of junk food cost less than diets that are rich in fresh fruits and vegetables. This might be a factor that explains why low-income families tend to eat more junk food than families that are well off. Frozen vegetables (and fruits) are also healthy choices and may be a better alternative for low-income families. The story could have brought this factor into the discussion.", "answer": 0}, {"article": "In Rothwell\u2019s study, published in The Lancet, researchers found the 20-year risk of death was reduced by about 10 percent for prostate cancer, 30 percent for lung cancer, 40 percent for colorectal or bowel cancer and 60 percent for oesophageal cancer in those taking aspirin.\nPeter Elwood, an expert on aspirin from Cardiff University\u2019s medical school who was not involved in this study, described aspirin as \u201ca remarkable drug.\u201d\n\n\u201cThis risk of a bleed is so small compared to the benefits,\u201d he told reporters.\nAlastair Watson, professor of translational medicine at the University of East Anglia, said the study was an important step in scientists\u2019 understanding of how to prevent cancer.\nThe findings will fuel an already intense debate about the merits of taking aspirin, which increases the risk of bleeding in the stomach to around one patient in every thousand per year.\nThe researchers added, however, that treatment with aspirin during the trials lasted for only for between four and eight years on average, so the effects on risk of deaths due to cancer may underestimate possible results of longer-term treatment.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "\n\n\nAlthough the story does not discuss costs, the price of aspirin is low and well-known.", "answer": 2}, {"article": "The study described in the article \"Effect of Foeniculum vulgare Mill.\nIn the end, fennel was concluded to be a safe and effective treatment to reduce menopause symptoms without serious side effects.\n\"This small pilot study found that, on the basis of a menopause-rating scale, twice-daily consumption of fennel as a phytoestrogen improved menopause symptoms compared with an unusual minimal effect of placebo,\" says Dr. JoAnn Pinkerton, executive director of NAMS.\nThe study was completed in Tehran, Iran, where the average age of women at menopause is younger than in the United States: 48.2 years versus 51 years, respectively.\nThe study outcomes are published online today in Menopause, the journal of The North American Menopause Society (NAMS).\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Fennel supplements are sold in brick and mortar stores and online. Costs are easily established and should have been addressed in the release along with equivalent doses used in the pilot study.\nWe found 100 mg fennel seed capsules selling on Amazon.com for $9.58 for 100 capsules.\nIt\u2019s not clear that there is a standard way to assess fennel potency. Is the fennel simply ground up and made into a 100 mg tablet? What should a consumer look for when trying to buy it? The release doesn\u2019t offer any guidance.  ", "answer": 0}, {"article": "Even the issues of how much vitamin D adults should take and whether calcium supplements help keep bones strong have been matters of debate.\nStill, this group stressed the risk was very small, resulting in 2 cases of throat cancer in 1,000 people ages 60 to 79, compared with the normal rate of 1 per 1,000.\nAlso missing, Nelson said, are randomized studies that would indicate how often patients should be screened.\nFor Dr. Douglas C. Bauer, a professor at the University of California-San Francisco and a researcher who also treats many osteoporosis patients, the hardest decision is when to stop the drugs in patients who still have low bone density after five years of treatment but are not especially frail.\nHowever, the most extensive study on the calcium question, done by the Women\u2019s Health Initiative as a randomized controlled trial, was inconclusive.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The article did not discuss the costs of various management approaches. A simple statement about the costs of screening and the annual costs of bisphosphonates would have been useful.\n\u00a0\n ", "answer": 0}, {"article": "Highlighting the significance of the findings, the study\u2019s senior author, George A. Macones, MD, the Mitchell and Elaine Yanow Professor and head of the Department of Obstetrics and Gynecology, said, \u201cThis study is a tremendous addition to the literature on preventing surgical-site infections after cesarean.\nBut according to Tuuli, the unique circumstances of a C-section \u2014 that bacteria come from both skin and vagina and that a woman\u2019s immune system is altered during pregnancy \u2014 mean the results of these studies may not apply.\nOf 575 patients who randomly received the iodine-alcohol combination, 42 developed a surgical-site infection.\nThe average cost of treating those cesarean-related infections in the hospital is $3,500 and may be much higher for severe infections.\nBut based on the biological plausibility and the striking reduction in surgical-site infections with chlorhexidine, this is one of those circumstances.\u201d\n\nThis work was supported by a Women\u2019s Reproductive Health Research Career Development grant from the Eunice Kennedy Shriver National Institute of Child Health and Human Development, of the National Institutes of Health (NIH), grant number 1K12HD063086-01; and by the Department of Obstetrics and Gynecology at Washington University School of Medicine in St. Louis.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "We gave the release a passing grade on cost for including context on the cost of an infection.\n\u201cAn estimated 1.3 million women in the U.S. delivered their babies by C-section in 2013, with surgical-site infections complicating 5 to 12 percent of those deliveries. The average cost of treating those cesarean-related infections in the hospital is $3,500 and may be much higher for severe infections.\u201d\nOur wish list for this release might include whether chlorhexidine is any more expensive (or cheaper) than the standard of care and what the cost is for treating an infection outpatient. These are details that would have added to the quality of the release. However, infections are costs that can be prevented, and that is the main issue which the release covers well.", "answer": 1}, {"article": "Coronary heart disease, which causes heart attacks and angina -- chest pain resulting from the heart not getting enough blood -- is the leading cause of death in the United States, with nearly 450,000 in 2005, according to the American Heart Association.\nThis method of intravenous injection means that the procedure theoretically could be performed in a doctor's office or clinic, increasing the accesibility to patients, Karp said.\nThe study is a step forward in a field in which a lot of approaches have been tried in animals and preliminary human trials, but none has been approved for widespread clinical use for heart patients.\nThe phase I results from 53 patients are not definitive proof that the treatment is effective, but do suggest so, Hare said.\nMore broadly, besides bone marrow transplantations, there have not been any major successes in the stem cell field in terms of helping large numbers of patients, Karp said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story reports that harvesting enough stem cells for infusion is difficult and costly, though it fails to cite specific costs. \nFor research in Phase I, any comment on cost might be purely speculative. ", "answer": 2}, {"article": "Breast cancer caused by BRCA mutations is particularly aggressive.\nThe study findings are extremely reassuring to Rebbeck -- no breast cancer diagnoses among women who had double mastectomies after three years of follow-up.\nWhile surgical decisions are up to patients, the findings of this study should help them decide what to do, she says.\nAnd they told Toby her lifetime risk of that type of cancer was as high as 90 percent.\nToby was one of the women researchers from around the country tracked in the study to see how they fared after having this surgery.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "1clip_filelist.xml\"/>\n\n\n\nThis story hints at the financial implications when it notes that the woman featured did not want her last name used because she is worried about her health coverage, but it does not report the cost of testing (which ranges from several hundred to several thousand dollars and may not be covered by insurance) nor the cost of intensive surveillance or surgery.", "answer": 0}, {"article": "To place an electronic embedded link to this study in your story: This link will be live at the embargo time: http://jamanetwork.com/journals/jamasurgery/fullarticle/10.1001/jamasurg.2016.4219\n\nIn a study published online by JAMA Surgery, Daniel E. Hall, M.D., M.Div., M.H.Sc., of the Veterans Affairs Pittsburgh Healthcare System and University of Pittsburgh, and colleagues examined the effect of a Frailty Screening Initiative (FSI) on death and complications by comparing the surgical outcomes of patients treated before and after implementation of the FSI.\nOn the basis of this review, clinicians from surgery, anesthesia, critical care, and palliative care were notified of the patient\u2019s frailty and associated surgical risks; if indicated, perioperative plans were modified based on team input.\n\u201cThis study reveals the feasibility of facility-wide frailty screening in elective surgical populations.\nIt also suggests the potential to improve postoperative survival among the frail through systematic administrative screening, review, and optimization of perioperative plans.\nThe magnitude of improvement among frail patients increased at 180 and 365 days.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "No costs are mentioned.", "answer": 0}, {"article": "Prostate cancer is the most common cancer among men.\nAhmed told Bloomberg that HIFU may also be cheaper than other standard treatments, noting that the cost of the MRI and mapping was an estimated $2,400, plus about $1,600 for HIFU; in comparison, removing the prostate costs about $7,100.\nOverall, about 95% of the men were cancer-free after a full year following the trial.\nWhile the initial results were promising, they need to be replicated; HIFU also needs to be studied long-term and compared with other therapies.\n\u201cFocal therapy of individual prostate-cancer lesions, regardless of whether they are multifocal or unifocal, leads to a low rate of genitourinary side-effects and an encouraging rate of early freedom from clinically significant prostate cancer,\u201d the authors concluded in the study.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story quoted another news source quoting the researcher, who claimed \u201cthat HIFU may also be cheaper than other standard treatments, noting that the cost of the MRI and mapping was an estimated $2,400, plus about $1,600 for HIFU; in comparison, removing the prostate costs about $7,100. Fewer side effects would also lower other health care costs, he said.\u201d\nBut that quote from the researcher may have been an incomplete assessment of costs.\nIt\u2019s unknown if cancers are more likely to recur following HIFU.\u00a0 If they were, then ultimate costs would be higher.\u00a0 In fact, the Lancet article noted that 4 men required retreatment within one year.\u00a0 Additionally, 39 of 41 men had repeat MRI/biopsy after 6 months.\u00a0 While that may have been just part of the research protocol, the extent to which repeat MRI/biopsy are part of clinical practice would also contribute to costs.", "answer": 0}, {"article": "DOI: 10.1016/j.ophtha.2016.01.036.\nHow vitamin C inhibits cataract progression may have to do with its strength as an antioxidant.\nThe research is also the first to show that diet and lifestyle may play a greater role than genetics in cataract development and severity.\nResearchers noted that the findings only pertain to consuming the nutrient through food and not vitamin supplements.\nNewswise \u2014 SAN FRANCISCO \u2013 A diet rich in vitamin C could cut risk of cataract progression by a third, suggests a study being published online today in Ophthalmology, the journal of the American Academy of Ophthalmology.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "No mention is made of the cost of adding more Vitamin C rich foods into the diet, but that would be tough to do, since the cost of foods rich in Vitamin C varies widely across the world.", "answer": 2}, {"article": ".\nAfter five weeks of treatment, subjects receiving dTMS lost more than 3 percent of their body weight and more than 4 percent of their fat--significantly more than controls did, Luzi reported.\nResults of the fecal analysis demonstrated that, after five weeks, dTMS-treated subjects had greatly increased quantities of several beneficial bacterial species with anti-inflammatory properties, such as are found in healthy people.\nThis study expands on the researchers' previous finding that dTMS reduced food cravings and induced weight loss in obese individuals.\nHe and his co-workers studied whether dTMS could improve the gut microbiota composition in obese persons and, if so, by what underlying mechanisms.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Cost of dTMS is not mentioned in this release. After doing a bit of independent information gathering, it seems that even though dTMS may be more cost-effective than other more invasive neurostimulation techniques, each session can cost a patient roughly $400-$500, according to PyschologyToday. Individuals in this study underwent 15 sessions each, which amounts to $6000 to $7500 for five weeks of therapy. We don\u2019t know the long-term effects of dTMS on weight loss, nor do we know if, or \u2013 more likely \u2013 how often these sessions would need to be repeated, but it\u2019s easy to see the price for an individual mounting quickly.\nThe release doesn\u2019t mention insurance coverage but costs for this type of therapy are likely to be out-of-pocket.", "answer": 0}, {"article": "Asthma has complicated Todd Anderson's life ever since he was 3 years old. Doing sports\u2014even stairs\u2014had been difficult. Cigarette smoke, pollen, disinfectants or a passing whiff of perfume could set off a severe asthma attack. \"It feels like your chest is clenching up like a fist,\" says Mr. Anderson, a 29-year-old music teacher in the New York City schools.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "\n\n\nThe story is concise but thorough. In three sentences it reports that few insurers cover the procedure because it is new, that the cost ranges from $12-18,000 and also that some patients with severe asthma may spend a similar amount on standard care (including hospitalizations.) ", "answer": 1}, {"article": "Restless leg syndrome (RLS) is a neurologic disorder causing unpleasant sensations and an urge to move the legs when at rest.\nPatients using the RLS device also reported an 82 percent decrease in sleep loss.\nPilot study published in the Journal of the American Osteopathic Association finds targeted pressure device significantly increased sleep for those with moderate to severe symptoms\n\nAuthors from Lake Erie Research Institute in Pennsylvania report an adjustable foot wrap caused to treat restless legs syndrome (RLS) is 1.4 times more effective than the standard pharmaceutical treatment.\nThe eight-week clinical trial involved 30 otherwise healthy adults with moderate to severe restless leg syndrome.\nResearchers indicate that the pressure produced by the device may also stimulate a dopamine release, similar to massage therapy or acupressure.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release does not mention that this foot wrap sells for $350 per pair. This may be less expensive than the cost of medicines used to treat RLS, something that could have been pointed out as a favorable thing.", "answer": 0}, {"article": "Dr Golam Khandaker, who led the study, says: \"It's becoming increasingly clear to us that inflammation plays a role in depression, at least for some individuals, and now our review suggests that it may be possible to treat these individuals using some anti-inflammatory drugs.\n\"It's too early to say whether these anti-cytokine drugs can be used in clinical practice for depression, however,\" adds Professor Peter Jones, co-author of the study.\nAnti-inflammatory drugs similar to those used to treat conditions such as rheumatoid arthritis and psoriasis could in future be used to treat some cases of depression, concludes a review led by the University of Cambridge, which further implicates our immune system in mental health disorders.\nMeta-analyses of the other types of clinical trials showed similar results.\n\"About a third of patients who are resistant to antidepressants show evidence of inflammation,\" adds Dr Khandaker.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There is no mention of the cost of any of these drugs. A Consumer Report article puts many of these drugs in the range of on average $2,000 a month when treating rheumatoid arthritis. It is unclear if the same doses would treat depression. \u00a0This was also an issue in CNN\u2019s story.", "answer": 0}, {"article": "The Ache: In the digital age, many people spend hours daily bent over computers, phones and tablets\u2014our necks craned forward. Some scientists say this unnatural position can lead to pain, headaches and other symptoms, sometimes collectively called \u201ctext neck.\u201d\n\nThe Claim: Technology itself comes to the rescue. An Android app called the Text Neck Indicator measures the angle of your phone and lets you know when you\u2019re holding it in a favorable viewing position. And a new wearable device, Alex, monitors the angle of your neck...", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "This is a toss-up, since the story tells readers that the wearable device (named Alex) costs $99, but doesn\u2019t tell readers how much the app (named the Text Neck Indicator) costs. A look online tells us the app costs $2.99. For what is essentially a product review, it was an unusual oversight not to include the cost of the app. However, in the event of a toss-up, we try to give the story the benefit of the doubt, so this gets a Satisfactory rating.", "answer": 1}, {"article": "CT scans became popular because they offer a quick, relatively cheap and painless way to get 3D pictures so detailed they give an almost surgical view into the body.\nThat puts them at risk of developing radiation-induced cancer, Brenner and Hall said.\nThe radiation and risk from one CT scan is low, but it carries a dose 50 to 100 times greater than a traditional X-ray, reports LaPook.\nThe report estimates the percentage of cancers caused by CT scans -- currently 0.4 percent -- will increase to as much as 2 percent in a few decades because the number of scans has increased so dramatically, reports CBS News medical correspondent Dr. Jon LaPook.\nA previous study by the same scientists in 2001 led the federal Food and Drug Administration to recommend ways to limit scans and risks in children.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story mentioned that CT scans are faster and better at diagnosing certain problems than are other types of imaging.\u00a0 It did not, however, provide information about the costs of various types of imaging or whether there were differences in terms of costs covered by insurance.", "answer": 0}, {"article": "Filing for approval in the EU has been completed.\nThe primary endpoint of the so-called Tropic trial was overall survival.\nThe clinical trial results will be presented at the 2010 American Society of Clinical Oncology (ASCO) on June 6.\nThe FDA\u2019s review should happen in the third quarter, Sanofi said.\nThe French drugmaker said on Thursday that the combination of the treatments led to an improved median overall survival of 15.1 months against 12.7 months in patients who took a chemotherapy of mitoxantrone with prednisone/prednisolone.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "\u00a0The story included no discussion of costs. If a drug is this far down the pipeline in the EU and the US, somebody has some cost projections. ", "answer": 0}, {"article": "MS can cause many symptoms, including blurred vision, loss of balance, poor coordination, slurred speech, tremors, numbness, extreme fatigue, problems with memory and concentration, paralysis and blindness.\nThose deaths are a major concern, one neurologist said, because MS is not in itself life-threatening.\nBut the treatment can be risky because the patient's immune system has to be wiped out before the stem cells are transplanted, the researchers said.\nThe researchers think these deaths were most likely due to the transplant technology used before 2006, which has since improved.\nA trial that compares stem cell transplants with other therapies to see whether stem cell transplants can become a treatment for patients who have progressive MS is about to start, added Racke, who co-authored an editorial that accompanied the study.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Costs aren\u2019t discussed. And that\u2019s particularly problematic, given the potential costs associated with stem cell treatment. While we\u2019re not aware of any clinically-available stem cell treatments for MS, we can get a rough idea of costs from the stem cell treatments currently available for treating some cancers \u2014 and those costs can reach into the hundreds of thousands of dollars.", "answer": 0}, {"article": "\u201cUsing these multiple, possible endpoints was something unique to this study,\u201d Jaffe said.\nJaffe said the study\u2019s results are significant not only because they indicate adalimumab delays treatment failure, but also because the investigation considered several signs as causes for treatment failure.\n\u201cSince each of these signs can be associated with different types of uveitis, the study\u2019s results broaden the applicability of treatment for patients.\u201d\n\nThe study authors note, however, that patients in the adalimumab group reported serious adverse effects, such as respiratory tract infections and allergic reactions, more frequently than those in the placebo group.\nJaffe said the study focused on time to treatment failure because delaying or preventing inflammation is the key to successful treatment.\nPatients in the adalimumab group were also significantly less likely to experience treatment failure during the duration of the study (80 weeks) and they were at lower risk of treatment failure due to each of the four signs.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "No dollar signs here, which \u2014 as we discovered \u2014 is quite an oversight, given the steep costs of adalimumab.\nPrednisone costs about $0.33 per mg, and chronic uveitis patients take anywhere from 10 mg to 60 mg per day. Looking at the minimum number (which patients are usually tapered to 6 months into their treatment), that\u2019s a cost of more than $1,190 a year.\nIn comparison, the name-brand of adalimumab, Humira, costs about $54.49 per mg. In the study, patients received adalimumab on a bi-weekly basis, receiving some 1,640 mg of the drug over 80 weeks if they didn\u2019t drop out. That adds up to a total of $89,400 \u2014 an average of $58,000 per year or $1,120 per week.", "answer": 0}, {"article": "Multiple neurological disorders, including Parkinson\u2019s disease and dementia with Lewy bodies, involve the abnormal clumping of a protein called alpha-synuclein into brain deposits called Lewy bodies.\nImportantly, test results were available within two days, compared to related assays that require up to 13 days.\nThis research was supported in part by NIH funding awards ZIA AI001086-08, AGO5131, and PHS P30-AG010133.\nThe research findings were published in Acta Neuropathologica Communications.\nScientists from the University of California San Diego, University of Verona in Italy, Indiana University School of Medicine, Indianapolis, and the Case Western Reserve University School of Medicine, Cleveland, collaborated on the project.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There\u2019s no mention of the cost. The study itself says having quicker results \u201cmarkedly enhances the cost effectiveness and practicality\u201d of these tests.", "answer": 0}, {"article": "Lumbar disk herniation is a common, often debilitating, condition that affects the disks that act as cushions between the vertebrae of the lower spine.\nIn 128 patients, the pRF treatment was delivered directly under CT guidance to the root of the nerve.\nThe use of pRF also could improve outcomes for patients set to receive corticosteroid injections.\nPatients who received pRF saw greater overall improvement in pain and disability scores during the first year.\nThe one-year outcomes demonstrated that CT-guided pRF was superior to the injection-only strategy.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Costs are not included.\nComparing the cost of the three treatment options mentioned in the release \u2014 CT-guided pRF, CT-guided steroid injections, and lumbar disk surgery \u2014 would have been appropriate and helpful.\nAn assumption is made that the cost of this procedure is less than a surgical intervention. This is often not the case, and \u201cminimally\u201d invasive approaches can cost more.", "answer": 0}, {"article": "An estimated 25 million to 45 million Americans suffer from irritable bowel syndrome, or IBS, a gastrointestinal condition that can cause miserable symptoms.\nMaking it worse for many patients, there hasn't been a conclusive test to diagnose what's wrong with them.\nShe got the new blood test to confirm her diagnosis, and when it came back positive, she said she felt a sense of relief knowing IBS wasn't all in her head.\nBut that could finally change with the introduction of two simple new blood tests for spotting the disease.\n\"I'm not saying the symptoms went away,\" she said, but she \"started to feel more whole.\"\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No mention of cost, and it\u2019s not clear from the story if the tests are commercially available. Since there\u2019s a consumer website devoted to the tests, we assume they can be purchased, but couldn\u2019t find any cost information on the site. The story could have enlightened us.", "answer": 0}, {"article": ".\nFurthermore, restarting therapy with the new oral anticoagulant dabigatran was associated with a lower risk of recurrent hemorrhage in these cases than the old standby drug warfarin.\nThe risk of dying from any cause or having a stroke was 23 to 34 percent higher in patients who discontinued anticoagulation therapy compared to those who resumed it.\nMore than 1,500 of those people suffered a major bleeding event while using one of the drugs.\nPeople who took dabigatran after their initial bleeding event had nearly half the risk of another major bleeding event within one year compared with those who took warfarin.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There\u2019s no mention of the significant cost difference between the two anticoagulants. A one-month supply for the highest recommended dosage runs about $400 for dabigatran, marketed as Pradaxa, versus $11 for warfarin, which has additional monitoring costs.", "answer": 0}, {"article": ".\nForward looking statements with respect to predicted improved survival described in the poster presentation and video, are based on current expectations from the presented retroactive study and involve inherent risks and uncertainties about the potential health and medical benefits of MR-guided Radiation Therapy for the treatment of patients with locally advanced pancreatic cancer.\nThe early results highlighted above, along with other data obtained using MRIdian will be tested in a multi-center, prospective, single-arm clinical trial for inoperable, locally advanced or borderline resectable pancreatic cancer.\nFurther studies, including the planned prospective multi-institutional study referenced in this press release, as well as patient data covering longer periods of time post-treatment, could lead to different or contrary results from those expressed during ASTRO or in the poster presentation.\nThe trial will be conducted by ViewRay's Clinical Cooperative Think Tank (C2T2), a group of MRIdian medical institutions focused on evidence gathering to support MR-guided radiation therapy.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Costs of the\u00a0MRIdian on-table adaptive radiotherapy in comparison to conventional radiotherapy are not discussed. Given that it is new and more personalized than current treatment options it\u2019s likely to be correspondingly more expensive. Certainly, more frequent MRIs would be very costly.", "answer": 0}, {"article": "\"My reaction was, 'Well, you smoked for 30 years.\nLike many patients his age, he didn't expect there would be any effective treatment.\nAnd, after five years, almost 9 out of 10 patients were alive and cancer free.\nHe was senior author of a study published in the Journal of Clinical Oncology in October.\nThis was the case for Morton Pollner, who is one of Adusumilli's patients.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There is no mention of the costs associated with the surgery.", "answer": 0}, {"article": ".\nThese additional results of the Systolic Blood Pressure Intervention Trial (SPRINT) appear in the current online issue of the Journal of the American Medical Association (JAMA).\nAlthough the standard blood pressure treatment goal is 140 mm Hg, various medical panels have provided inconsistent guidance about what is the optimal blood pressure goal for the senior population.\nThis lower blood pressure goal also reduced the risk of death among this group by 32 percent, compared to a target systolic pressure of 140 mm Hg.\nOther experts have supported keeping the standard treatment goal at 140 mm Hg.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release makes no mention of costs associated with the differing strategies. It states that hypertensive elderly patients receive medication to lower their systolic blood pressure to either 140 mm of mercury or 120 mm of mercury, and that, on average, the patients who had a lower targeted blood pressure required an added medication. But no specific drugs are mentioned, so readers cannot judge whether there would be cost differences between this recommended regimen and their current therapy.", "answer": 0}, {"article": "Professor Norman Ratcliffe said, \"There is currently no accurate test for prostate cancer, the vagaries of the PSA test indicators can sometimes result in unnecessary biopsies, resulting in psychological toll, risk of infection from the procedure and even sometimes missing cancer cases.\nOur aim is to create a test that avoids this procedure at initial diagnosis by detecting cancer in a non-invasive way by smelling the disease in men's urine.\nWith help from industry partners we will be able to further develop the Odoreader, which will enable it to be used where it is needed most; at a patient's bedside, in a doctor's surgery, in a clinic or Walk In Centre, providing fast, inexpensive, accurate results.\"\nAfter further sample testing the next step is to take this technology and put it into a user friendly format.\nEven with detailed template biopsies there is a risk that we may fail to detect prostate cancer in some cases.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There is no mention of the cost of this diagnostic test aside from the implication that it would be inexpensive. A lead researcher of the device states, \u201cWith help from industry partners we will be able to further develop the Odoreader, which will enable it to be used where it is needed most; at a patient\u2019s bedside, in a doctor\u2019s surgery, in a clinic or Walk In Centre, providing fast, inexpensive, accurate results.\u201d\nThe release is clear that this was a pilot study and that the system is not yet available for mass use. That\u2019s good. But the release does speculate that the\u00a0test might mean that \u201cinvasive diagnostic procedures that men currently undergo eventually become a thing of the past.\u201d\nWe think that if it\u2019s not too soon to speculate about these kinds of benefits, it\u2019s not too soon to provide some idea of what the test might cost.", "answer": 0}, {"article": "Learn about diagnosis and treatment of prostate cancer from the U.S. National Cancer Institute.\nThe Hopkins work was described as \"outstanding\" by Dr. William J. Catalona, director of the prostate cancer program at Northwestern Memorial Hospital's Robert H. Lurie Comprehensive Cancer Center, who pioneered the use of the standard PSA test and helped develop the new version of the test.\nThe regimen found unfavorable indications for 39 of the cancers -- meaning progression of cancer grade or tumor size -- and favorable for the 32 others, Veltri said.\nIt is the pro-PSA level that is most valuable as a predictor, Veltri said, but it is only one part of the study.\nThe Hopkins group is trying to identify other biomarkers that would improve the program's predictive value, he said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There is no discussion of costs for this product. \u00a0\nWhile it is currently not approved for clinical use in the US, the story could have extrapolated from princing in Europe.\u00a0 Would it be expected to double screening costs or inflate them by a factor of 10?", "answer": 0}, {"article": "The disease is characterized by an itching, oozing rash that can cover almost all of the skin.\nThe constant itch, to say nothing of the disfigurement, can be so unbearable that many patients consider suicide.\nThere has never been a safe and effective treatment.\nFor some, relief was almost instantaneous.\nWithin a couple of weeks, the ugly red rash that had covered 90 percent of her body was almost gone.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story reports that the company says the price has not been set. It also notes that \u201cIt is a biologic, the most expensive type of drug, and is injected every two weeks.\u201d The story could have offered readers a more detailed picture by noting that a widely prescribed (and heavily advertised) biologic treatment for Crohn\u2019s Disease, Humira, costs about $2,000 per dose or about $50,000 per year. Of course, the amount paid by patients varies widely depending on insurance coverage.", "answer": 1}, {"article": "\u201cThe studies are small and the longest of them lasted only three years.\nAlthough low hormone levels are widely thought to increase a man\u2019s risk of depression, the researchers found that \u201cpsychological symptoms had little or no association with the testosterone level.\u201d\n\nThere are four main approaches to testosterone therapy available in this country: intramuscular injections every one to three weeks; skin applications through a patch or gel; and pellets implanted under the skin that last for months.\nA $45 million study financed by the National Institute on Aging is under way at 12 medical centers to see if a year of treatment with testosterone will help 800 men aged 65 and older with low levels of the hormone and problems with physical functioning, fatigue and sexual or cognitive performance.\nBefore the most recent study, at doses considered normal, the testosterone gel showed little or no effect on cardiovascular risk, the two doctors reported.\nIn a report on the risks of testosterone therapy, written with Dr. Ernani Luis Rhoden and published in 2004 in The New England Journal of Medicine, Dr. Morgentaler noted that testosterone has widespread effects throughout the body, but he and Dr. Rhoden concluded that with proper monitoring, any looming hazards can be readily detected.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Given the controversies about the benefit of testosterone replacement treatment in andropausal men, the costs of care are an important consideration. Testosterone replacement therapies can range from $10 to $300 a month\u00a0not including testing and physician visits.", "answer": 0}, {"article": "Senator Arlen Specter, a Pennsylvania Democrat and longtime advocate for cancer screening, said in an interview: \u201cAnd this Pap smear guideline is yet another cut back in screening?\nDr. Kevin M. Holcomb, an associate professor of clinical obstetrics and gynecology at NewYork-Presbyterian/Weill Cornell hospital, said that when he heard the advice to delay Pap testing until 21, \u201cMy emotional response is \u2018Wow, that seems dangerous,\u2019 and yet I know the chances of an adolescent getting cervical cancer are really low.\u201d\n\nAs with the new mammogram recommendations, women may not readily give up a yearly cancer test.\nIn addition, Dr. Saslow said, doctors in this country have been performing 15 million Pap tests a year to look for cervical cancer in women who have no cervix, because they have had hysterectomies.\nStill, the new recommendations for Pap tests are likely to feed a political debate in Washington over health care overhaul proposals.\nThe doctors\u2019 group also felt it was safe to test women less often because cervical cancer grows slowly, so there is time to catch precancerous growths.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The report does not mention costs. Price should be taken into account whenever population screening is an issue. \nGiven how much emphasis the story puts on the political ramifications for health care reform, the omission is particularly unfortunate.\u00a0 ", "answer": 0}, {"article": "'This is not the end': Using immunotherapy and a genetic glitch to give cancer patients hope\n\nNew shingles vaccine is highly effective \u2014 and in short supply\n\nResearchers use immune-cell 'army' to battle another tough cancer\nShlomo Shinnar, president of the American Epilepsy Society and a neurologist at Montefiore Medical Center in New York, has said the drug will be \u201ca very valuable addition\u201d to the limited options for treating severe childhood-onset epilepsy.\nThe drugmaker is testing other CBD treatments for glioblastoma and schizophrenia.\nFDA Commissioner Scott Gottlieb said the approval was \u201ca reminder that advancing sound development programs that properly evaluate active ingredients contained in marijuana can lead to important medical therapies.\u201d The medication, tested in three randomized, placebo-controlled trials with more than 500 patients, was effective in reducing seizures, the FDA said.\nHowever, it isn\u2019t clear whether such a reclassification would involve CBD products in general, the CBD formulation used specifically in Epidiolex or something else.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Some reports suggest the cost of Epidolex will be high and insurance coverage is unclear. The article should have addressed these issues.", "answer": 0}, {"article": "Studies in mice, dogs, pigs, and monkeys have shown that so-called focused ultrasound waves can be used to heat tiny bubbles that then mechanically push open gaps in blood vessels, allowing drugs to leak out into the brain.\n\u201cIt really opens up a lot to the imagination.\u201d\n\nMost drugs are blocked from entering the brain by the \u201cblood-brain barrier,\u201d which protects against infection, but also makes it tricky to treat brain tumors, diseases like Alzheimer\u2019s, and mental illness.\nHall felt nothing from the seconds-long bursts from 1,024 ultrasound beams aimed at different points around her skull, and an MRI scan confirmed that the brain barrier was successfully traversed.\nBecause the trial was designed solely to determine the safety of focused ultrasound to the brain, the patient was not given a therapeutic dose of doxorubicin and the procedure is not expected to help in her recovery, Mainprize said.\nNew, safe doses of drugs will need to be determined, once medication is not being diverted by the blood-brain barrier, noted Dr. Gordon Li, a neurosurgeon at Stanford.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The article doesn\u2019t mention costs at all. It\u2019s likely a very expensive procedure since interventional radiologists are involved.", "answer": 0}, {"article": "ADVERSE EVENTS \n\nNasal pain, discomfort or burning (10.3%); transient electrical discomfort (5.2%); nosebleed (5.2%); nasal congestion (3.1%); headaches (2.1%); trace blood, dot heme in nostril (2.1%); facial pain (2.1%); sore eye (1.0%); sinus pain (1.0%); periorbital pain (1.0%); runny nose (1.0%); nasal ulcers (1.0%); and light-headedness (1.0%).\nAll device-related adverse events were mild in nature.\nThere were no device-related serious adverse events.\n\"Interestingly, neurostimulation has been used as an approach for a wide variety of disorders for more than 30 years.\nThere have been two clinical studies showing positive safety and effectiveness of the device in the increase of tear production completed with 145 aqueous deficient dry eye adult patients.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Even though this tear stimulator has been approved for sale, no price is mentioned in the release. After an internet search on costs we came up empty-handed. A specialized device like this is expected to cost a few to several hundred dollars. Will it be covered by insurance plans? The release doesn\u2019t say.", "answer": 0}, {"article": "Phentermine is commonly used as a short-term weight loss treatment, and was previously paired with fenfluramine to make the successful but now-discontinued weight loss drug Fen-phen.\nAccording to the manufacturer's study, the two drugs, when taken together, and at controlled-release doses, were very safe.\nThe study was funded by the pharmaceutical company Vivus, which combined the two drugs into one pill called Qnexa, and petitioned the U.S. Food and Drug Administration for approval in October 2010.\nAccording to the report, there were specific concerns about each drug's safety individually; specifically Topamax, which is reported to cause some psychiatric and cognitive side effects and may cause clef palate birth defects if taken while pregnant.\nThe drug could be a good option for some people, but it's most likely not a silver bullet, said Dr. Melina Jampolis, CNNHealth's physician nutrition expert, who is not connected with the study.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Not applicable.\u00a0 The story didn\u2019t discuss cost, but the story was clear that is a drug that has been slowed in its path to marketing approval so that is understandable.", "answer": 2}, {"article": "These forward-looking statements speak only as of the date hereof.\nAdditionally, the test predicts the likelihood of recurrence in a pre-invasive form of breast cancer called DCIS.\nThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the benefits of the test to physicians, patients and payors.\n\"The publication of this clinical utility study clearly demonstrates that the Oncotype DX DCIS Score can play a key role in enhancing cancer care for patients with DCIS, and we believe that these results will support expanded adoption of and access to the DCIS Score.\"\nThe Oncotype DX DCIS Score result provides patients with an individualized estimate of local (in the same breast) recurrence, which could be either invasive breast cancer or DCIS.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release never mentions the cost of the test and there is some concern that insurance carriers may not cover costs for tests of DCIS. Insurance coverage is variable and appeals do not always result in reversal of the denial.", "answer": 0}, {"article": "The dorsal root ganglions are nerve cells, on both sides of each of the spine's vertebra, and are the gateway to pain between nerves in different parts of the body, spinal cord and brain.\nIt shows long-term data that patients experienced significant pain relief and functional improvements, she said.\nFor most patients, the device reduced pain by 33 percent, which was significant, the researchers reported.\nOne pain specialist not involved with the study saw the benefits of this procedure.\nThe treatment has two advantages over spinal cord stimulation, McCarthy said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story did great on this criterion. It said the cost of spine stimulation devices \u201ccan range from $15,000 to $50,000 or more, according to a 2008 report funded by the Washington State Department of Labor and Industries.\u201d It also mentioned the procedure \u201cisn\u2019t covered by all insurance companies, so out-of-pocket costs to patients can be very high.\u201d One quibble we did have is that it isn\u2019t clear whether the device to stimulate the dorsal root ganglion is different in cost than the other types of spinal cord stimulation.", "answer": 1}, {"article": ",org *2014 Journal Citations Report published by Thomson Reuters \u00a92015\n\nElsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress.\nA three-year randomized controlled clinical trial has found that two topical creams are effective in most primary, low-risk superficial BCC, comparing favorably with photodynamic therapy (PDT), as reported by investigators in the Journal of Investigative Dermatology.\n\"The main advantages of noninvasive treatments are good cosmetic outcome, preservation of surrounding tissue, and potential for home application of either creams,\" explained lead investigator Marieke Roozeboom of the Department of Dermatology, Maastricht University Medical Center in the Netherlands.\nThere are over two million cases a year in the U.S. and the lifetime risk of developing a BCC before the age of 85 years is one in five people.\nConsequently, there is no consensus in international BCC guidelines on the first choice of noninvasive therapy for superficial BCC.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The news release notes that \u201cFluorouracil has the advantage of being less expensive than imiquimod,\u201d a statement for which we rank this satisfactory. But it would have been more complete if we had been told how much cheaper, and how the topical treatments compare with the cost of surgical removal or photo-dynamic therapy.", "answer": 1}, {"article": "Lung function got 10 percentage points better, on average, in people who got the drug compared with those taking a placebo.\nBut these results, even with plenty of caveats, suggest the drug is on the right track.\nThe experimental medicine, taken twice a day, goes by the code name VX-770.\nThe improvement at six months was still present almost a year after the study's start.\nThe effectiveness of VX-770 looks \"best case,\" he wrote.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "More explicitly than some other stories we saw, this blog included an estimate that the drug \u201cwould command a very high price, perhaps $250,000 a year.\u201d", "answer": 1}, {"article": "Post-traumatic stress disorder (PTSD) is a term for a broad range of psychological symptoms that can develop after someone experiences or witnesses a traumatic event.\nThis is called 'reconsolidation', and we now plan to test the effect of doxycycline on reconsolidation of fear memories.\nTo treat such diseases, we already have clinically approved drugs that block these enzymes, including the antibiotic doxycycline, so we wanted to see if they could help to prevent fear memories from forming in the brain.\nOur results support this theory, opening up an exciting avenue of research that might help us to find treatments for PTSD.\nA week later, under no medication, participants returned to repeat the experiment.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release makes no mention of costs. It could have addressed cost through information about the relatively inexpensive antibiotic used in the study or by mentioning the social and economic costs of those afflicted with PTSD.\nEven though the research is called a \u201cproof of concept,\u201d we think if it\u2019s not too soon to issue a news release it shouldn\u2019t be too early to include cost implications.", "answer": 0}, {"article": "Cancer is the No.\nThe test is a long way from being used to screen for cancer, but the study shows a way to get there, the team reported in the journal Science Translational Medicine.\nThe blood test detected the majority of cancers in people with four of the biggest cancer killers: breast, colon, lung and ovarian cancer, the team at Johns Hopkins University said.\n\u201cWe have used this approach to examine 58 cancer-related genes,\u201d the team wrote in their report.\nIt was even more accurate in finding late-stage cancers, but the goal would be to catch cancer in its earliest, easiest-to-treat stage.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "This story gets a satisfactory in this category by including, \u201cThe genetic sequencing is also expensive right now \u2013 on the order of several thousand dollars for the 30,000 repeats the team did. But costs are coming down steadily, he said.\u201d", "answer": 1}, {"article": "Coleman RE, Hall A, Albanell J, Hanby A, Bell R, Cameron D, Dodwell D, Marshall H, Jean-Mairet J, Tercero JC, Rojo F, Gregory W, and Gomis RR.\nThe new study, which is published in the journal Lancet Oncology, was part of an international phase 3 clinical trial involving 3,360 women with stage II or III breast cancer.\nWomen who do not carry the gene - approximately 80 per cent of women with breast cancer - were found to benefit from the bone strengthening treatment.\nThousands of breast cancer patients at risk of developing aggressive secondary tumours could benefit from a potential new genetic test.\nThe results need to be confirmed in a second trial, currently underway in the United States, before the test is likely to receive approval for wider use in patients.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There was no mention of the cost of the proposed genetic testing for MAF amplification (MAF is a gene expressed in certain cancers and used as a biomarker for bone metastasis) nor any mention of the cost of treatment with a bisphosphonate. Treatment with a bisphosphonate is often recommended for 5 years so this cost should be included.\nAs is the case with many new genetic tests when they become available, there\u2019s a lag between when a test is approved and when insurance will actually cover the cost.", "answer": 0}, {"article": "In 1992, Harvard neuroscientist Richard Davidson embarked on an unusual research project to study the brains of Buddhist monks who spent thousands of hours meditating.\nThe study looks at adults with chronic low back pain, one of the leading cause of disabilities in the United States and one reason why more and more people are addicted to painkillers.\nThe participants in the small study ranged in age from 20 to 70 and had suffered from back pain for an average of 7.3 years.\nThe study did caution that 30 of the 103, or about one-third, of the participants in the meditation group reported an \"adverse event,\" most often an increase in pain due to yoga.\nLed by Daniel C. Cherkin of Group Health Research Institute in Seattle, the experiment involved randomly assigning 342 adults with the condition to meditate, talk with a psychologist or continue with their normal techniques for addressing the pain, such as medication.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story doesn\u2019t address costs for any of the treatment options discussed. Is MBSR comparable to CBT? Does insurance cover either treatment option?", "answer": 0}, {"article": "(Intralipid infusions are increasingly popular, but the practice was found not to help in a 2016 study of older women with a history of miscarriage.)\nThat patient is now considering an egg donor.\nBut the report doesn\u2019t note that just 1 percent of women have that condition in the first place, making the odds still overwhelmingly in her favor.\nInsurers don\u2019t cover it; after it became clear that patients were balking at the bill, Celmatix cut the price in half.\nFor Smith, who works as a foster parent providing intensive care in Northern California, there\u2019s nothing more important than family.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Cost\u2014since the test is not covered by insurance\u2014gets a prominent spot in this story. Well done.", "answer": 1}, {"article": "Niki Munk, an assistant professor of health sciences in the School of Health and Rehabilitation Sciences at Indiana University-Purdue University Indianapolis and one of the co-first authors of the study, said that the study's findings are important, given the large number of people who suffer low back pain in the U.S.\n\nLow back pain leads all disorders in years lost to disability in the U.S.\nAdditional investigation is needed to replicate the results of the initial study and to conduct a cost-benefit analysis of massage therapy, Munk said.\nWhile the study results are promising, much more work needs to be done, Munk said: \"The fact of the matter is that chronic lower back pain is very complex and often requires a maintenance-type approach versus a short-term intervention option.\"\nMore than 50 percent of those who participated in the study experienced clinically meaningful improvements in their low back pain with disability, according to Munk.\nIn this study, patients were referred by a physician to a massage therapist.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "We give the release credit for stating that massages are generally not covered by insurance and that patients typically pay out-of-pocket. And the release provided some important context about cost with this statement from the lead author: \u201cGenerally, people wonder if it is worth it. Will it pay to provide massage to people for an extended period of time? Will it help avoid back surgeries, for example, that may or may not have great outcomes? These are the types of analyses that we hope will result from this study.\u201d\nWhile massage is now offered in nearly all cities and towns, not all readers know how much they will need to shell out for the 10 sessions used in this study.\nA one hour massage averages $60 an hour nationally, so 10 sessions would cost about $600. That\u2019s something people considering this type of therapy would like to know.", "answer": 1}, {"article": "Vitamin D is found in certain foods and beverages such as fortified milk and cereals, and fatty fish such as salmon.\nThe disease most often strikes adults after age 20, but it can develop in children.\nGrowing evidence has suggested that vitamin D, found in fortified milk, may lower one\u2019s risk of MS. Now, researchers with the Harvard School of Public Health in Boston have shown that it\u2019s possible this protective benefit could begin while a baby is developing in the womb.\nThe study involved more than 35,000 female nurses whose mothers answered questions about their diet habits during pregnancy.\nIt revealed that women born to mothers who had the highest intake of vitamin D had a much lower risk of developing MS as an adult.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "A discussion of cost is not necessary on this topic in this context.\u00a0\u00a0\u00a0\u00a0", "answer": 2}, {"article": "The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.\nThe team of researchers chose to focus on low-dose \"baby\" aspirin, because not only is it inexpensive and readily available as potential means of prevention, but because there are already a lot of people already taking it for prevention of other diseases such as heart disease and even colon cancer.\n\"The study found an interesting protective association between low-dose aspirin and breast cancer,\" said lead author Christina A. Clarke, Ph.D., M.P.H., from the Cancer Prevention Institute of California.\nOther collaborating authors include Alison J. Canchola, M.S., and Lisa M. Moy, M.P.H., from the Cancer Prevention Institute of California, and Susan L. Neuhausen, Ph.D., The Morris & Horowitz Families Professor in Cancer Etiology & Outcomes Research, Nadia T. Chung, M.P.H., and James V. Lacey Jr., Ph.D., M.P.H., from City of Hope.\nIn the ensuing years before 2013, 1,457 of these participants developed invasive breast cancer.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release notes, near the bottom, that low-dose aspirin is inexpensive. That\u2019s enough to earn it a satisfactory rating here since low-dose aspirin is indeed inexpensive. Costs for a bottle of 300 tablets currently range from $3.47 to $12.49 according to an online search.", "answer": 1}, {"article": "CNN Films Presents:\" Glen Campbell ...\nAnd anecdotally, patients who took resveratrol told the researchers that they felt like they were maintaining their mental ability.\nIf resveratrol does pan out in further research, it may add to the medications that are currently available, such as Aricept and Exelon, which slow, but do not halt, progression of the disease, Hendrix said.\nHowever, he added that changes in biomarkers may not necessarily lead to mental and behavioral improvements, which larger studies will address.\nThe main goal of the current study, which included 119 patients, was to find out whether high doses of resveratrol could be safe.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not address cost at all.\u00a0But as with the competing Time coverage, we\u2019ll rule this Not Applicable since the story clearly indicates that the supplements studied are not on the market.", "answer": 2}, {"article": "As examples, smoking rates were highest among those without a graduate education degree certificate and lowest among those with a graduate degree; higher among those living below the poverty level versus above it; and higher among some minorities such as American Indians and Alaska Natives, multiple- race individuals and blacks.\nSix of the eight cases found in the screening were considered potentially curable with surgery.\nFollowing the trial, the National Comprehensive Cancer Network, a nonprofit organization of cancer centers that develop guidelines for cancer diagnosis and treatment, along with the United States Preventive Services Task Force, which makes recommendations for preventive medicine, recommended screening high-risk individuals on a slightly broader scale, which the Lahey and Augusta area screening used.\nThat study also provided the first broad evidence that low-dose computed tomography, or LDCT, was a more effective screening tool than the traditional chest X-ray.\nRates in Massachusetts, where the Lahey screening occurred, are 12.8 to 16.4 percent.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release clearly states that the relevant screening technique would normally cost between $100 and $250, but was free as part of the initiative.", "answer": 1}, {"article": "Dr Allan Pantuck, the lead clinician of the study, added, \"With fixed dose therapy, patients are often switched to other drugs when they no longer respond to treatment.\nThe research team successfully utilised CURATE.AI to continuously identify the optimal doses of each drug to result in a durable response, allowing the patient to resume a completely normal and active lifestyle.\nThis advance is expected to dramatically improve response rates for all combination therapies that are being developed for oncology as well as virtually all other diseases.\nMultiple clinical trials using CURATE.AI-guided combination therapy for oncology and additional applications such as post-transplant immunosuppression are underway.\nThis new study demonstrates that CURATE.AI can optimise multi-drug regimens.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The AI used in this case is called the \u201cCURATE.AI\u201d platform. It\u2019s not clear if the platform is proprietary. If it is, it is not clear what the cost would be for health care providers to access and make use of the platform. It is also not clear what level of training, and associated costs, would be needed for health care providers to be able to use the platform in a clinical setting. Given that the AI platform appears to be designed to create personalized treatments for each patient, the cost could be considerable. It\u2019s hard to estimate, since the release does not address cost in any way.", "answer": 0}, {"article": "Shift workers with chronic sleep deprivation also face an increased risk of accidents.\n\u201cSleep deprivation makes this worse of course, and together with the clock, this conspires to impair our ability to sustain attention to task (e.g., driving), and avoid distraction, and react quickly to external stimuli like traffic lights, brake lights in front of you, road signs, etc,\u201d Mistlberger added by email.\nMore research is needed on the potential of bright light therapy to make exhausted drivers safer, said Dr. Donald Redelmeier, a researcher at the University of Toronto who wasn\u2019t involved in the study.\nExposure to bright light didn\u2019t appear to improve reaction times or sleepiness.\nBeyond its small size, other limitations of the study include the reliance on lab conditions for sleep deprivation and light exposure, which may not match what shift workers would experience on the job, the authors note.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Cost information is not provided, but\u00a0the cost of a bright light is presumably reasonable.", "answer": 2}, {"article": ".\nIt is estimated that one third of women in the United States will get a UTI by the age of 24.2\n\n\"Findings like this,\" adds Dr. Luis, \"give practitioners a viable, inexpensive, non-antibiotic option to help patients reduce the recurrence of an uncomfortable and potentially debilitating infection.\"\nThe review explains that the medicinal properties of cranberries may be attributed to their unique polyphenol, proanthocyanidins - or PACs, for short.\na total of 28 studies showing results from nearly 5,000 patients were considered.\n\"While recommendations for dosage and duration of treatment require further study, the efficacy of the medicinal properties of cranberry products has been well-established.\"\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release notes that \u201ccranberry products are low cost,\u201d which is fair enough and is sufficient to earn this a satisfactory rating. The issue of cost is, however, complicated by the fact that the release offers no information on what sort of cranberry products a patient may use. Is one glass of cranberry juice per day sufficient? Does one need to consume the whole berries? Or should patients take over-the-counter cranberry-based supplements? Costs would vary depending on how one chooses to pursue the vague directions discussed in the release.", "answer": 1}, {"article": "The research team, led by Cleveland Clinic's Eric Klein, M.D., conducted a multicenter prospective study of 261 men scheduled for prostate biopsy at five academic and community centers in the U.S. enrolled between August 2015 and December 2016.\n\"Despite criticism, PSA has transformed the landscape of early detection, screening, and management of prostate cancer in the last few decades,\" said Dr. Klein, chair of Cleveland Clinic's Glickman Urological & Kidney Institute.\nThe IsoPSA test was developed by Cleveland Diagnostics, a company co-founded by Cleveland Clinic, in which it has financial interest.\nDr. Stovsky has a leadership position (Chief Medical Officer) and investment interest in Cleveland Diagnostics, Inc.\n\nCleveland Clinic is a nonprofit multispecialty academic medical center that integrates clinical and hospital care with research and education.\n\"Unfortunately, PSA is tissue-specific but not cancer-specific, leading to overdiagnosis and overtreatment of biologically insignificant cancers, which is widely recognized as a key limitation in its clinical utility.\"\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There is no discussion of costs in this news release \u2014 neither the cost of the test or the potential savings if it decreases false positive results which lead to further testing or treatment.\nA regular PSA test is typically covered by insurance, especially for men over the age of 50. According to Healthcare Bluebook, a PSA test should cost around $48 for patients without insurance, but prices may vary depending on location. This price also does not include the office visit.\nWe feel the news release should give consumers a ballpark estimate of costs, even if it is a new test. Therefore, we give the news release a Not Satisfactory rating here.", "answer": 0}, {"article": "The average age for menopause is 51, with ovulation in most women ending sometime between age 40 and 60.\n\u201cWe developed a statistical model for estimating the age at menopause from a single measurement of AMH concentration,\u201d Tehrani explained in a report on the study.\nWells said Tehrani\u2019s team appeared to have hit upon a \u201cfairly accurate algorithm\u201d for predicting menopause.\nThe test, which measures levels of a hormone produced by cells in the ovaries, was able to predict the age at which women reached menopause to within an average of 4 months, according to data to be presented at the conference of the European Society of Human Reproduction and Embryology in Rome on Monday.\nBut said it would be important to see if the method could also help predict the time when fertility effectively ends.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not mention costs, or potential costs of the test.\u00a0 On one website, the cost was of the test was $183. \u00a0It is unclear whether insurers would pay for this, unless in the setting of an infertility evaluation.http://www.acubalance.ca/ovarian-reserve-testing-including-anti-m\u00fcllerian-hormone-amh.", "answer": 0}, {"article": "\"Clinical chemistry score versus high-sensitivity cardiac troponin I and T tests alone to identify patients at low or high risk for myocardial infarction or death at presentation to the emergency department\" is published August 20, 2018.\nThe authors suggest the score can be useful for standardizing diagnoses and improving safety.\nThe score, published in CMAJ (Canadian Medical Association Journal), can also identify patients at risk of subsequent heart issues after discharge.\nIn this international study, researchers from Canada, Australia, New Zealand and Germany combined common laboratory blood tests available at many hospitals around the world to create a single laboratory score, or clinical chemistry score, to diagnose heart attack.\nAn international team of researchers has developed a simple laboratory score that is safer and faster at diagnosing patients who visit the emergency department with heart attack symptoms.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Although the release characterizes the chemistry tests that make up the scoring system as \u201ccommon,\u201d it offers no information about the cost of each or the likely cost of aggregating them into the recommended scoring system.", "answer": 0}, {"article": "CHICAGO -- Many patients treated with Byetta, a diabetes drug by Amylin Pharmaceuticals Inc. and Eli Lilly & Co., were able to maintain good blood-sugar control and also lose weight after three years on the drug, according to a study.\n\nThe study, described at the American Diabetes Association's annual meeting here, examines clinical data from the longest trial involving Byetta presented to date.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not mention any costs, which is important because this is an expensive treatment and there are less expensive alternatives.\u00a0 ", "answer": 0}, {"article": "Learn more about alcoholism and how it is treated at the U.S. National Institute on Alcohol Abuse and Alcoholism.\nExactly how this drug curbs drinking is not fully understood, but its use may increase blood pressure, heart rate and feelings of sadness and nausea, thereby blunting the pleasurable effects of alcohol, the researchers said.\nChantix costs roughly $3 per pill.\nMore research is needed, he noted, but \"this medication may be helpful for people with a drinking problem who are also smokers.\"\nThe study was funded by the U.S. National Institute on Drug Abuse and the U.S. National Institute on Alcohol Abuse and Alcoholism.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story reports that Chantix costs about $3 per pill.", "answer": 1}, {"article": "\u201cLet\u2019s talk about your test results,\u201d my neurologist said.\n\nShe looked as if she had good news. Instead, it was shocking.\n\nThe carotid artery on the left side of my neck, one of the brain\u2019s two main sources of blood and oxygen, was clogged with fatty plaque, the doctor said. The artery was almost completely blocked.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "While the story reports the cost of scanning carotid arteries to be about $70, it does not discuss the cost of surgery. One analysis of Medicare reimbursements done a few years ago reported hospitals were paid about $11,000 for each patient getting a carotid endarterectomy. An earlier report estimated that in 2008 hospitals charged about $35,000 for the surgery and associated treatment, though the ultimate reimbursements by Medicare were much lower.", "answer": 0}, {"article": "Claudia Kawas, a geriatric neurologist at the University of California, Irvine, said a patient strode into her office soon after the FDA approved the procedure and asked for the \"Alzheimer's test.\" In one hand, he held an article about the approval of Amyvid. In the other, he had a document from a right-to-die group. If the test was positive, he told her, he would get his affairs in order and kill himself within 60 days.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story reports, \u201cLack of coverage for the $3,000 test is the biggest barrier.\u201d", "answer": 1}, {"article": "Over the last decade, the makers of medical devices have developed techniques that have widened diabetes management options beyond pricking the finger several times a day to test blood glucose levels.\nThe study not only indicated that the algorithm system prevented very low glucose overnight, Dr. Hovorka said, but it also indicated that the experimental system was better able to keep blood glucose in an acceptable range.\nAlthough the Lancet study was small \u2014 only 17 children completed the entire protocol \u2014 it is significant because it demonstrated that a computer algorithm could safely interpret glucose data and calculate appropriate insulin doses for a pump, he said.\nEven so, Dr. Kowalski said, using separate devices that are not designed to work in concert poses limits to treatment, particularly overnight.\nIndeed, even if device makers are able to develop fully automated prototypes of combination systems, they are likely to face regulatory hurdles, analysts said, and would have to factor in product liability concerns.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Like its competitors, the Times did not discuss costs\u2013an\u00a0omission\u00a0which perhaps is more acceptable in this story since it clearly indicated that this is not very close to being a marketable product. Nevertheless, we would have liked to have seen some mention of the financial impact.\u00a0\u00a0 Many patients with type 1 diabetes are not using currently available pumps and sensors because of the high cost of these devices.\u00a0It seems likely that this new treatment, if it ever becomes widely available, will be as expensive or more so than the current pump and sensor technology. ", "answer": 0}, {"article": "\u201cWe\u2019ll also advance key parts of our tobacco plan very soon,\u201d he said.\nThe FDA will seek public input and scientific research on the role that flavors such as menthol play in tobacco addiction, and for the regulation of premium cigars, Gottlieb said.\nThe FDA is seeking additional research and data for public review, Gottlieb said, as it tries to develop a nicotine product standard.\nThe move was part of a comprehensive plan the agency announced last summer to regulate tobacco and nicotine, FDA Commissioner Scott Gottlieb said on a call with reporters.\nThe comment period will be open through mid-June, said Mitch Zeller, director of FDA\u2019s Center for Tobacco Products.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "This is a proposal for reformulating a product already on the market. Also the cost is not closely tied to their contents \u2014 cigarettes are among the most highly taxed products in the US.\nIt\u2019s too early to know if cigarette costs would be altered by this proposal, so we\u2019ll rate this as not applicable.", "answer": 2}, {"article": "HDL cholesterol is not fully understood, but essentially sucks cholesterol out of cells, to be flushed from the body through the liver.\nPeople who can\u2019t control cholesterol with diet, exercise and statin drugs could soon have a new option.\n\u201cIt appears to be safe and to not raise blood pressure,\u201d Shah told CNN, \u201cbut it\u2019s not a slam-dunk.\u201d For one thing, despite improved cholesterol levels, patients did not see less inflammation in their blood vessels.\nThe study was sponsored by Merck, the drug\u2019s manufacturer.\n\u201cIt\u2019s like a rocket that landed on Jupiter, rather than the moon.\u201d Still, Eckel warned it\u2019s too soon to say whether ancetrapib would actually prevent disease over the long run.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "\n\n\nThis and other CETP inhibitor drugs are being tested in combination with statins. More than 20 million Americans currently take statins, so an approved drug would be expected to be widely prescribed. Stock market jumps that quickly followed the announcement of these trial results show that market watchers expect a lot of money would be spent. So even though this cholesterol drug is still being tested, if the lead sentence of the story promises people that it may be available \u201csoon\u201d then it is reasonable to expect the story to tell them how much they may soon be paying. Readers would be curious to know if the \u201cjaw-dropping\u201d effects (to quote from an American Heart Association news release) will be accompanied by a jaw-dropping price\u2026 for individuals and for the nation.\n", "answer": 0}, {"article": "Please visit http://www.\nTo gage the effects of lifestyle habits, the researchers developed a score based on the results of the health professionals survey, then applied it to the physicians' study.\nLead author Stacey Kenfield, ScD, of UCSF, and a team of researchers at UCSF and Harvard, focused on this variant of prostate cancer to determine if exercise, diet and smoke-free status might have life-saving benefits.\nIn the study, published today, Nov. 17, 2015, in the Journal of the National Cancer Institute, the researchers analyzed data from two U.S. studies: the Health Professionals Follow-Up Study that tracked more than 42,000 males ages 40 to 75, from 1986 to 2010; and a second, the Physicians' Health Study that followed more than 20,000 males ages 40 to 84, from 1982 to 2010.\nThe researchers also calculated that lethal prostate cancer among American men over 60 would be cut by 15 percent if they consumed at least seven servings of tomatoes per week and that 17 percent would be spared this diagnosis if they consumed at least one serving of fatty fish per week.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The study evaluated the combined effect of six lifestyle habits on prostate cancer mortality. Those six factors were, as described in the journal article: \u201cnot currently smoking or quit 10 or more years ago, body mass index under 30 kg/m2, high vigorous physical activity, high intake of tomatoes and fatty fish, and low intake of processed meat.\u201d It\u2019s tough to put a price tag on those lifestyle choices. How much does \u201chigh vigorous physical activity\u201d cost? How much does it cost to avoid eating processed meat? It would be easy to say this category doesn\u2019t apply. But the release does address the issue, saying the study findings underscore \u201cthe ongoing need for more effective prevention measures and policies to increase exercise, improve diet quality and reduce tobacco use in our population\u2026.It takes co-operation and effort from multiple areas, like insurance companies, employers, policy makers and city planners, to figure out how to creatively support and encourage more exercise into most busy adults\u2019 working day.\u201d Recognizing the need for policies that support these lifestyle changes is important \u2014 and addresses the cost issue in a meaningful way.", "answer": 1}, {"article": "The item you've requested, /cgi-bin/article.cgi?f=/n/a/2006/01/17/national/a130050S19.DTL&type=health, was not found.\n\u2022 the item no longer exists, or\n\u2022 there has been an error on the site.\n\nIf you feel the address you entered is correct you can contact us, mentioning the error message received and the item you were trying to reach.\n\nWe apologize for any inconvenience. From here, you can:\n\u2022 use the menu bar above\n\u2022 select an item from our site index below", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No mention of the cost of\nhernia operations, which may play a role in someone opting for watching waiting.", "answer": 0}, {"article": "March 31, 2010 -- A widely prescribed drug used to shrink enlarged prostates appears to reduce the incidence of prostate cancer in men with an increased risk for the disease.\nWhile the studies suggest a role for Avodart and Proscar in the prevention of prostate cancer, experts tell WebMD that important questions remain about using the drugs for this purpose.\nIn a trial involving more than 8,000 men from 42 countries, those who took the drug Avodart had a 23% lower risk of being diagnosed with prostate cancer over four years of treatment, compared to men who did not take the drug.\nStudy researcher Gerald L. Andriole, MD, says a significant proportion of men screened for prostate cancer fall into this clinically ambiguous category of having elevated PSAs and negative biopsies.\nThe risk reduction was similar to that seen in an earlier large trial of Proscar, another drug in the chemical class known as 5-alpha-reductase inhibitors.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "At the end of the story, an expert is quoted accurately describing the cost of the drug as $4 a day, which is expensive given that it should be taken daily for many years. The article does note that insurance companies would not pay for using dutasteride for chemoprevention unless the FDA approves the indication. \u00a0The article does note that finasteride, a comparable drug, is now available as a generic.", "answer": 1}, {"article": "ET.\nAlthough the results provide evidence that PDE5 inhibitors may benefit heart health, the retrospective study design makes it impossible to ascertain direct cause and effect, Andersson noted.\nA limitation of the study is that the researchers did not assess the effects of untreated erectile dysfunction, or conversely, the effect of having an active sex life without taking erectile dysfunction drugs.\n\"This type of erectile dysfunction treatment is beneficial in terms of prognosis, and having an active sex life seems to be a marker for a decreased risk of death.\"\n\"From the perspective of a doctor, if a patient asks about erectile dysfunction drugs after a heart attack and has no contraindications for PDE5 inhibitors, based on these results you can feel safe about prescribing it.\"\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The study was observational and the number of ED drug doses men took was not reported or calculated. Since the study was conducted in Sweden, it\u2019s possible there was no cost for individual patients but the drugs were covered by the national health system.\nSince this release was issued by the American College of Cardiology to an American audience we think some comment on the cost of ED drugs or the cost of treating heart conditions would be appropriate for readers.", "answer": 0}, {"article": "Italian researchers retrospectively studied 647 kidney transplants, grouping the donors according to whether they were in their 50s, 60s, 70s or 80s.\nA new study has found a kidney transplanted from a deceased 79-year-old can be as effective as one from a person 30 years younger.\nGenerally, guidelines classify donors older than 50 as \u201cextended criteria donors,\u201d but shortages have led to using these donors more frequently.\nOld age is not necessarily a barrier to kidney donation.\nThe study is in the Clinical Journal of the American Society of Nephrology.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story doesn\u2019t discuss costs. Couldn\u2019t the transplant surgery be more expensive for older donors due to increased rate of complications? And just in general, cost is almost always an issue with surgery, and this needed at least a brief mention.", "answer": 0}, {"article": "Male infertility has a range of root causes, from low or abnormal sperm production to blockages to illness.\nThe researchers tested the device on 350 clinical semen specimens in Massachusetts, including both trained and untrained users in their trial.\nThe researchers say the optical attachment could be created by 3D-printing, and the device would only cost about $5.\nThough the system is in the prototyping stage, it could eventually shake up the world of fertility testing by allowing men to evaluate their sperm in their own homes and helping health centers with fewer resources offer easy, cheap testing.\nThe app\u2019s user experience is hard to forget: users can see vivid moving images of their sperm right on the screen.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Only part of the prototype\u2019s projected cost is discussed: $5 for a microchip device. While this sounds good, the cost of the \u201ctiny weight scale\u201d isn\u2019t mentioned, nor is the \u201coptical attachment\u201d that could be 3D-printed. However, a consumer 3D printer can cost $1,000 or more, not including supplies.\nReaders also are\u00a0told male fertility screening is costly, but we\u2019re never told what the cost is.", "answer": 0}, {"article": "A birth-control pill that eliminates women's monthly periods could hit pharmacy shelves later this year, marking the latest effort by a drug company to expand a contraceptive's features beyond preventing pregnancy.\n\nSince \"The Pill\" was introduced nearly a half-century ago, most regimens have mimicked a woman's cycle by having a pill-free week each month when women can have bleeding and other symptoms.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story mentions potential cost savings for women who take the new birth control pill, which is intended to eliminate monthly menstrual-like bleeding, but the cost of the drug itself is not noted. The basis for a claim that the drug may also improve women\u2019s work productivity is not clear either. ", "answer": 0}, {"article": "\"For many women with symptoms and especially with concerns about hormone replacement therapy, trying soy for six to 12 weeks to see if it relieves their symptoms could be a first line of treatment,\" says Melissa Melby, PhD, a professor of medical anthropology at the University of Delaware.\nThe study had no industry funding.\nNow, researchers who took another look at 19 published studies find that soy supplements may help, at least over time.\nTwo co-authors, not including Melby, have ties to the soy industry.\n\"I personally think foods [containing soy] are better.\"\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No discussion of cost.", "answer": 0}, {"article": "A Harvard researcher hopes an old arthritis drug, which he read about in a 19th century German medical journal, could be a cheap new treatment for diabetes.\n\nIn the late 1990s, Steven Shoelson's research suggested that the drug, called salsalate, might also help diabetics. The idea sent him into the basement stacks of a Harvard library to see whether anyone else had pursued the notion.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Although there was no specific price mentioned, the medication was described as \u2018a cheap generic\u2019. \u00a0Further \u2013 there was discussion about a goal being to see it remain inexpensive. \u00a0That said \u2013 it still would have been helpful to include the price since it is a currently available product.", "answer": 1}, {"article": "Charli Scouller \n\nPR Manager (School of Medicine and Dentistry) \n\nQueen Mary University of London \n\nc.scouller@qmul.ac.uk \n\nTel: 020 7882 7943\n\nQueen Mary University of London (QMUL) is one of the UK's leading universities, and one of the largest institutions in the University of London, with 20,260 students from more than 150 countries.\nThe new vaccine, Gardasil 9, is not only safe but will offer greatly improved protection against cervical and other cancers.\nThe new vaccine offers significantly greater protection than the current vaccine, which protects against only two cancer causing types of HPV.\nUntil late last year, there were two available vaccines to protect against HPV related disease (Cervarix and Gardasil).\nA pivotal international clinical trial compared the safety and efficacy of the new vaccine, Gardasil 9, with the current vaccine, Gardasil, in more than 14,200 women aged between 16 and 26 years old.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release is from the UK and likely written for a UK audience, which would expect the cost of the vaccine to be covered under the NHS vaccination program. (The release mentions that the current vaccine is covered by NHS.) However, the release does not provide any detail on what the vaccine costs per person or what the vaccination program costs NHS \u2014 which is something we think even readers in the UK would be interested in and deserve to know. For our U.S. readers, we\u2019d note that\u00a0the vaccine requires three doses and therefore three different office visits. The costs of the visits and the vaccines ($130-140 per dose) bring the total immunization cost to approximately $500. Insurance usually covers a portion of the costs, but patients may have copayments.", "answer": 2}, {"article": "Professor Paul Workman, Chief Executive of The Institute of Cancer Research, London, said:\n\n\"Nivolumab is one of a new wave of immunotherapies that are beginning to have an impact across cancer treatment.\nNivolumab became the first treatment to extend survival in a phase III clinical trial for patients with head and neck cancer in whom chemotherapy had failed - and it did so with fewer side-effects than existing therapeutic options.\nNivolumab will still have to go through approval by the European Medicines Agency and NICE before it is available for head and neck cancer patients on the NHS.\nThis trial found that it can greatly extend life among a group of patients who have no existing treatment options, without worsening quality of life.\nThis phase III clinical trial expands the repertoire of nivolumab even further, showing that it is the first treatment to have significant benefits in relapsed head and neck cancer.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release doesn\u2019t address costs at all. This may be because the study was done in the U.K., where public health care mitigates the cost for patients. However, it is definitely an issue for patients in the U.S. In an NEJM piece published last year, one doctor stated that, when used for treating metastatic renal-cell cancer, nivolumab costs, \u201cby my estimate, around $65,000 for Medicare beneficiaries and up to twice that for commercially insured patients.\u201d Other estimates are that nivolumab treatment \u2014 again, for cancers other than head and neck cancer \u2014 could cost more than $100,000 per patient. That is a huge factor in making treatment decisions, and needs to be addressed.", "answer": 0}, {"article": ".\nAccording to the study authors, this is the first drug shown to improve patients' loss of ability to move their muscles voluntarily.\nStill, pridopidine does not get at the underlying cause of Huntington's disease, Di Rocco said.\nMore than 70 percent of the patients taking the higher dose of the drug showed a significant benefit, according to the researchers.\n\"A well-tolerated drug that produces even small benefits for patients with Huntington's disease would be a very welcome addition to the currently available treatments for this debilitating disorder,\" Andrew Feigin, from The Feinstein Institute for Medical Research in New York City, wrote in an accompanying commentary.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There is no mention of costs in the story. Although pridopidine is an experimental drug, it may have been useful for the reader to know whether pridopidine could be at least a cheaper alternative to tetrabenazine, the only drug currently approved for Huntington\u2019s disease.", "answer": 0}, {"article": "(Reuters) - Medtronic Inc, a manufacturer of pacemakers, heart stents and spine products, has developed a device to tackle another common health problem: erectile dysfunction.\nAfter three months the results were promising, the company said.\nRogers said it could be several years before Medtronic undertakes a much larger late-stage trial.\nHe also noted that men who take certain drugs for heart disease cannot use the popular pills.\n\u201cED is largely a vascular disease and that\u2019s why Medtronic was interested in this,\u201d said Dr. Jason Rogers of UC Davis Medical Center, one of the researchers of the company-sponsored trial.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Sure, it\u2019s early in development.\nBut just as surely, some estimate could have been made of what the stent, the surgery, and followup care would cost.\nIf it\u2019s not too early to report on \u201cpromising\u201d results after ann initial feasibility study, then it\u2019s not too early to start projecting costs \u2013 even in \u2013 or perhaps especially in \u2013 a business story.", "answer": 0}, {"article": "All compared people taking at least 200 milligrams of Vitamin C each day with people taking placebos.\nThe message from the researchers, Senay observed, is that, if your activity profile doesn't match that of people like these, vitamin C won't keep colds away.\nShe explained that a review of numerous studies concluded that vitamin C isn't what it's cracked up to be, failing to help prevent the common cold in any meaningful way, except in some people exposed to extremely high stress.\nIt makes us look toward other methods, aside from vitamin C, Senay concluded.\nBut, she emphasized, this doesn't mean vitamin C is useless, not by a long shot.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Information about how much it would cost to take the\u00a0vitamin prophylactically for a year would have made a useful point\u2013taking vitamin C isn\u2019t just ineffective, it\u2019s costly. It would also have been good to report how much\u00a0money Americans spend on vitamin C products to treat colds\u2013not just the supplements but lozenges, often-expensive vitamin C products marketed for cold treatment, etc.\u00a0 ", "answer": 0}, {"article": "Aromatase inhibitors block an enzyme that the body needs to produce estrogen.\nExperts said the study was significant because some women and their doctors choose to continue aromatase inhibitors past the standard five years.\nThe trial included 1,918 postmenopausal women who had what\u2019s called hormone-receptor positive breast cancer, in which the hormones estrogen or progesterone fuel the proliferation of cells.\nDr. Debra Patt, a breast cancer specialist at Texas Oncology who was not involved in the study, called the difference of a few percentage points in the risk of recurrence (95 percent vs. 91 percent) \u201csubstantial.\nThe study, which was also published Sunday in the New England Journal of Medicine, was partially funded by Novartis, which sells letrozole \u2014 the aromatase inhibitor used in the trial \u2014 as the branded drug Femara.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story mentions costs. Letrozole, the aromatase inhibitor used in the trial, is available as a generic for less than $100 a month.", "answer": 1}, {"article": "Heterosexuals who are HIV negative can significantly reduce their risk of infection by taking a daily dose of an antiviral drug, according to a new study by the Centers for Disease Control and Prevention.\nIn fact, an interim review of the Partners data on effectiveness was so compelling that the trial was stopped early and the placebo arm was discontinued.\nThe CDC says the next step is to fully review all the data and begin to develop guidelines for the use of these drugs in heterosexual men and women here in the U.S.\n\u201ciPrEx provided the first proof of an important new method of HIV prevention that can help slow the global toll of 2.6 million new HIV infections each year.\nClear evidence Baeten said, that PrEP substantially reduces infection risk.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Although these drugs are available cheaply in developing countries\u00a0(less than $1 per pill according to some estimates), even these modest costs can put\u00a0them out of reach in the poorest countries where they are most needed. In the United States, the cost of daily treatment with Truvada (one of the medications studied which contains a\u00a0combination of\u00a0emtricitabine and tenofovir)\u00a0can add up to some $13,000 annually. The story should have referenced cost as one of the obstacles to any large-scale new prevention effort", "answer": 0}, {"article": "That 1.7 percent difference is not considered statistically significant.\nAbbott Laboratories' newly approved Absorb stent comes with one important caveat: it hasn't yet been shown to be safer than older metal implants.\nThe new stent is designed to gradually dissolve over three years.\nDoctors who studied Absorb said it may take several years before its advantages become clear.\nOther complications with the new device include allergic reactions, infections and internal bleeding.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "This piece does an admirable job of providing cost information in the face of reluctance by Abbott Labs, the stent\u2019s designer, to disclose such information. The reporter, instead, offers readers a sense of the typical hospital bill for \u201cstenting procedures.\u201d \u00a0You will not be surprised to learn that such surgery is not cheap at about $30,000.", "answer": 1}, {"article": "\u2022 Pregnant women who were hospitalized with severe cases of flu illness were half as likely to have been vaccinated as women with non-severe illness.\nThe findings also underscore the importance of flu vaccination for this risk group.\nA related editorial commentary by Alan T. N. Tita, MD, PhD, and William W. Andrews, PhD, MD, of the University of Alabama at Birmingham, accompanies the new study in The Journal of Infectious Diseases.\n\"All pregnant women should receive annual influenza vaccination to prevent influenza and associated complications for themselves and their infants,\" the study authors wrote.\nThe current study, based on data from a nationwide flu surveillance network including 14 states, focused on pregnant women hospitalized with laboratory-confirmed flu over four recent flu seasons, from 2010 to 2014.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release focuses primarily on using the antiviral drug oseltamivir to treat pregnant flu patients who have been hospitalized. A course of oseltamivir often costs more than $100. For patients with limited resources, or without good insurance coverage, cost could be a factor. And because the drug is on the market, the release could have addressed this with a sentence or two. The release also discusses the importance of vaccination, without addressing cost.", "answer": 0}, {"article": "The greatest risk was found for drugs that target gonadotropin-releasing hormone: 159.4 cases of diabetes per 1,000 person-years, compared with 87.5 for men who did not have androgen deprivation therapy, as well as a 35 percent increased risk for sudden cardiac death, a comparable increase in heart attack risk and a 22 percent increased risk for stroke.\nAnti-hormone therapy was developed to treat the pain and other problems of advanced prostate cancer, Albertsen said, and so it was generally used for only three to five years.\nPrevious studies have shown potential dangers related to androgen deprivation therapy in older men, Keating said.\nDr. Peter Albertsen, a professor and chief of urology at the University of Connecticut Health Center, said that \"the point of this paper is to help physicians understand that long-term use of this therapy carries consequences.\"\nHormone deprivation therapy is started, Keating said, when levels of cancer-associated prostate-specific antigen (PSA) increase after surgery or radiation therapy, but there are no other indicators of danger.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "\u00a0This story did not discuss costs, yet it could have raised questions about the lucrative reimbursement for hormone therapy as one factor driving its use in situations where it has no proven benefit.", "answer": 0}, {"article": "The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices.\nThe drug is approved for use with a companion diagnostic, the LeukoStrat CDx FLT3 Mutation Assay, which is used to detect the FLT3 mutation in patients with AML.\nThe FDA granted this application Priority Review, Fast Track (for the mastocytosis indication) and Breakthrough Therapy (for the AML indication) designations.\nIf the FLT3 mutation is detected in blood or bone marrow samples using the LeukoStrat CDx FLT3 Mutation Assay, the patient may be eligible for treatment with Rydapt in combination with chemotherapy.\nRydapt should not be used in patients with hypersensitivity to midostaurin or other ingredients in Rydapt.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There is no mention of the cost of this new drug, Rydapt (midostaurin), or of the cost of the diagnostic tool, the\u00a0LeukoStrat CDx FLT3 Mutation Assay, which the FDA approved for use in determining the appropriateness of using this drug. Many patients will need to be tested for this mutation in order to find the individuals who have it and thus may benefit from this new drug.\nHowever, the FDA evaluates drugs without considering costs, which is why they are not discussed in this news release. We rate this one Not Applicable.", "answer": 2}, {"article": "They rated themselves as healthier and were less likely to report problems with mobility, pain, daily activities, social interactions and feelings of depression and anxiety, among other factors that can compromise well-being.\n\u201cMost say they wish they\u2019d done it 10 years sooner.\u201d She explained that the overwhelming majority of patients who undergo bariatric surgery have spent many years trying \u2014 and failing \u2014 to lose weight and keep it off.\nIn reviewing studies that followed patients for five to 25 years after weight-loss surgery, Dr. Twells and colleagues found major long-lasting benefits to the patients\u2019 health and quality of life.\n\u201cI haven\u2019t come across a patient yet who wouldn\u2019t recommend it,\u201d Dr. Twells said in an interview.\n\u201cBariatric surgery is probably the most effective intervention we have in health care,\u201d says Laurie K. Twells, a clinical epidemiologist at Memorial University of Newfoundland.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story tells readers that the bariatric surgery has a \u201ctypical\u201d price tag of $30,000 \u2014 and that some medical insurers, including Medicaid programs in many states, are reluctant to cover the cost of bariatric surgery. That\u2019s good.", "answer": 1}, {"article": "www.petermunkcardiaccentre.ca\nThe CardioMEMS\u2122 HF System is designed to monitor heart failure patients whose condition is serious but who are not so ill that the technology cannot improve their outcome.\nThe first Canadian patient implanted with the heart monitor will be among 25 patients within the Ted Rogers Centre for Heart Research at the Peter Munk Cardiac Centre to be fitted with the device over the next nine months.\nThis technology is a way to directly measure how much fluid is in a patient, allowing us to intervene before they develop symptoms of congestion, before they end up in hospital.\nThe system features a small butterfly-like sensor that then sits inside the pulmonary artery of a heart failure patient.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Although this implant was a first in Canada, the news release could have cited costs of existing alternatives and given a ballpark estimate of the new intervention.\nFor example, an implantable cardioverter defibrillator (ICD) is a battery-powered device placed under the skin to keep track of heart rate. If an abnormal heart rhythm is detected, the device will deliver an electric shock to restore a normal heartbeat. ICDs alone range from $25,000-$32,000, but costs vary widely depending on insurance or financial assistance. Procedure costs depend on the physician and medical facility.\nLike ICDs, it\u2019s probable that CardioMEMS will also cost tens of thousands of dollars for US patients. Since there is no discussion of costs in this news release, we give it a Not Satisfactory rating here.", "answer": 0}, {"article": "Michael Burk found walking increasingly painful last year. Crossing the street and tying his shoes became challenges, and colleagues noticed he was limping at work.\n\nOn a recent morning, Mr. Burk reported to the Hospital for Joint Diseases, part of NYU Langone Medical Center in New York City, for hip-replacement surgery. His surgeon had promised him a better quality of life, and said both the operation and recovery would be quick.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "In a piece that found room to tell us how much the operating tables cost, there is no excuse for not telling us how much the competing procedures cost.", "answer": 0}, {"article": "The average age of people in both groups was 73.\nThe findings, presented Sunday, Nov. 25 at the Radiological Society of North America meeting in Chicago, suggest that doctors may one day be able to use widely available tests to tell people their risk of developing dementia before symptoms arise.\nWhen the researchers focused on specific parts of the brain most likely to show damage, the accuracy rose to 95 percent.\nAlthough there are no drugs available yet to prevent or delay the onset of Alzheimer's disease, identifying those at high risk of developing dementia within the next few years could still be beneficial, the researchers said.\n\"We showed that a single MRI scan can predict dementia on average 2.6 years before memory loss is clinically detectable, which could help doctors advise and care for their patients.\"\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There was no discussion of cost. A brain MRI can be expected to run anywhere from $826 to $4,780, including both physician and imaging fees, according to the web site Healthcare Bluebook. The information in the news release suggests MRIs would have to be repeated every two years or so in order to detect brain changes before the onset of symptoms.", "answer": 0}, {"article": "The fibers within the tendons fray.\n\u201cIt\u2019s not insignificant, but it\u2019s not kidney stones.\u201d\n\nSo the question of whether cortisone shots still make sense as a treatment for tendinopathies, especially tennis elbow, depends, Dr. Khan said, on how you choose \u201cto balance short-term pain relief versus the likelihood\u201d of longer-term negative outcomes.\nBut that cautionary experiment and others didn\u2019t slow the ascent of cortisone (also known as corticosteroids).\nWhy then does a cortisone shot, an anti-inflammatory, work in the short term in noninflammatory injuries, providing undeniable if ephemeral pain relief?\nThe evidence for cortisone as a treatment for other aching tendons, like sore shoulders and Achilles-tendon pain, was slight and conflicting, the review found.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "\nThe New York Times article did not discuss the costs of steroid injections or other treatments. It would have been useful if the article could have pointed out that the long-term costs of steroid injections haven\u2019t been documented.\n", "answer": 0}, {"article": "The requested URL /usnews/health/articles/070311/19clot.htm was not found on this server.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There were no estimates for the costs of either treatment.", "answer": 0}, {"article": "Zinc lozenges appear to influence the common cold through the release of free zinc ions into the oro-pharyngeal region.\nThus, zinc doses of over 100 mg per day do not seem to provide any more benefit.\nThere is no significant difference between zinc acetate lozenges and zinc gluconate lozenges regarding their efficacy in shortening the duration of common colds according to a meta-analysis published in Journal of the Royal Society of Medicine Open.\nPreviously zinc lozenges containing citric acid were shown to be ineffective in treating colds because citric acid binds zinc ions very tightly and no free zinc is released.\nBecause of the somewhat stronger binding, zinc gluconate has been proposed to be less suitable constituent for lozenges.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "No mention is made in the release about how much zinc lozenges cost. Zinc supplements can be purchased at pharmacies\u00a0and most supermarkets\u00a0for less than $10.", "answer": 0}, {"article": "Type 2 diabetes is the most common form of the disease and is linked to obesity.\nZinman, in an interview, predicted the new study would prompt medical societies to recommend that Jardiance be used by type 2 diabetics who have a history of heart disease or who are at risk of cardiovascular events.\nHe has not prescribed Jardiance and similar drugs as frequently as treatments like Januvia, but expects that may change based on the new data.\nThe benefits were especially impressive because they added to protection that patients received from taking cholesterol fighters and other life-saving heart drugs, Zinman said.\nThe vast majority of those patients could be candidates for Jardiance, which costs over $4,000 per year, Morningstar analyst Damien Conover said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The initial version of the story that we reviewed did not address cost.\nAn update to the story, posted after our review, noted the drug costs more than $4,000 annually.", "answer": 0}, {"article": "A growing number of doctors are offering an expensive laser procedure they say zaps away a common fungus that causes ugly, discolored nails. Published data on laser treatment for nail fungus is scant, but early results suggest it is a reasonable option for people who don't want the side effects of oral medications.\n\nOnychomycosis, or fungal infection of nails\u2014most often on the toes\u2014affects about 12% of Americans, according to the American Academy of Dermatology. Some people are genetically prone to it. Others, including swimmers...", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Costs of one treatment course is estimated at $750-1,500 and the story says that some may need one one to four treatments.\u00a0 So up to $6,000 for ugly toenails.", "answer": 1}, {"article": ".\nThe researchers investigated patients enrolled in the randomized, double-blind, comparative, multicenter international phase 3 ACTIVE trial to evaluate the efficacy and safety of 80 micrograms of abaloparatide-SC in preventing fractures in otherwise healthy, ambulatory, postmenopausal women with osteoporosis.\nThe data suggest that abaloparatide appears to be an effective treatment for a broad group of postmenopausal women with osteoporosis.\nOverall, 2,463 patients between 49 and 86 years of age were randomized to one of three treatment arms for 18 months: double-blind 80 micrograms of abaloparatide-SC, blind-matched placebo, or open-label 20 micrograms of subcutaneous teriparatide (an FDA-approved prescription drug known to increase bone density and strength).\nThe results of the pre-specified subgroup analysis within the ACTIVE clinical trial will be presented Friday, April 1, at ENDO 2016, the annual meeting of the Endocrine Society, in Boston.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release doesn\u2019t include any discussion of the financial burden of the disease or estimated costs of treating it. This is a big market for drug makers and there are plenty of data available. Forteo, a similar drug to abaloparatide-SC, a human parathyroid hormone, is already on the market. It is reasonable to assume that the cost structure will be similar. GoodRx.com notes that a 28 day supply costs about $2,400.", "answer": 0}, {"article": "DOI: 10.1016/j.ajog.2017.11.570.\nAdditionally, the app was used to collect all study-related data.\nAcupressure-based features - with instructions on how to administer self-acupressure shortly before and during menstruation - were only made available to the intervention group.\nThe app helped participants to apply simple self-acupressure techniques to three different acupressure points.\nIn contrast to acupuncture, this technique can be used as a form of self-care and is suitable for use at home.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release did not mention it, but the app is \u201cgratis\u201d according to the Luna app website (in German). Most apps of this kind are sponsored and free, and even those that are not free of charge are mostly very inexpensive.", "answer": 0}, {"article": "Boston, MA - Women who eat more high-fiber foods during adolescence and young adulthood--especially lots of fruits and vegetables--may have significantly lower breast cancer risk than those who eat less dietary fiber when young, according to a new large-scale study led by researchers at Harvard T.H.\n\"From many other studies we know that breast tissue is particularly influenced by carcinogens and anticarcinogens during childhood and adolescence,\" said Walter Willett, Fredrick John Stare Professor of Epidemiology and Nutrition at Harvard Chan School and senior author of the study.\n\"This work on the role of nutrition in early life and breast cancer incidence suggests one of the very few potentially modifiable risk factors for premenopausal breast cancer.\"\nOther Harvard Chan School researchers involved in the study included Heather Eliassen, associate professor in the Department of Epidemiology, and Xiaomei Liao, research scientist in the Departments of Epidemiology and Biostatistics.\nThe study will be published online February 1, 2016 in Pediatrics.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "It seems so simple. Add more fiber to your diet to improve health. But one thing many health groups forget to consider when making recommendations for changing one\u2019s diet is the inconsistency in the cost and availability of healthful foods. We\u2019ll rate the release Not Applicable here because most people have a general idea what high-fiber foods will cost. But we wish the release had provided at least a ballpark figure on what the weekly, monthly or annual cost would be to adding more fruit and vegetables to one\u2019s diet. In addition, it needs to be acknowledged more often that there is a large segment of the U.S. population that does not have ready access to grocery stores that sell fresh fruits and vegetables.", "answer": 2}, {"article": "They were then randomized to receive either Forteo or a placebo.\nAfter eight weeks of treatment with Forteo, though, the pain went away and the osteonecrosis resolved, reported the authors, from Austin Health in Melbourne, Australia.\nBut the two papers in the Oct. 16 online issue of the New England Journal of Medicine report success with teriparatide (Forteo) in rebuilding bone.\nAfter six weeks of therapy, patients in the Forteo arm saw greater healing of their jawbone and this continued throughout one year of follow-up.\n\"There was a significant improvement in clinical measures of gum and bone,\" McCauley stated.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There\u2019s no discussion of costs. Forteo at the doses described costs about $250/week. Given the severity of the osteonecrosis described in the letter of a single case, the costs are relatively nominal since the treatments were of fairly brief duration.", "answer": 0}, {"article": "In coherent breathing, the goal is to breathe at a rate of five breaths per minute, which generally translates into inhaling and exhaling to the count of six.\nThe subjects\u2019 saliva was tested at various intervals during the exercise.\nThe findings were published in the journal BMC Complementary and Alternative Medicine in August.\nThe research was presented in May at the International Congress on Integrative Medicine and Health in Las Vegas.\nHere are three basic breathing exercises to try on your own.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Since deep breathing is free, no discussion of costs is warranted.", "answer": 2}, {"article": "The Harvard Medical School affiliates share a clinical staff that delivers inpatient care at Boston Children's Hospital and most outpatient care at Dana-Farber Cancer Institute.\n\"The vast majority of patients with CML do remarkably well on imatinib [Gleevec] and similar drugs: The disease is well controlled and side effects are tolerable,\" says Stuart Orkin, MD, the study's senior author and a pediatric hematologist/oncologist at Dana-Farber/Boston Children's Cancer and Blood Disorders Center.\nEpizyme, a biopharmaceutical company based in Cambridge, MA, recently opened a pediatric trial of an Ezh2 inhibitor for children with rhabdoid and other tumors.\nThe new study grew out of efforts to discover whether different types of cancer are susceptible to Ezh2 inhibitors.\nThe findings, reported online today by the journal Cancer Discovery, raise the prospect that Ezh2 blockers, in combination with Gleevec and similar drugs, could eradicate the disease in some patients in relatively rapid fashion or could be an effective therapy for those who become resistant to Gleevec-like agents, the authors state.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Oddly, the release includes a quote from the study\u2019s leader about how \u201cthe cost savings of such an approach could \u2026 be significant\u201d \u2014 yet treatment cost estimates are completely absent in the release.\nCost deserved more than the nod given in this release. The release mentions the treatment will be a \u201cGleevec-like\u201d drug so it\u2019s notable that the costs may also be \u201cGleevec-like\u201d to start.\u00a0 A 2016 Washington Post article noted that the wholesale cost of Gleevec had risen from $26,400 to $120,000 annually over the 15 years it has been on the market. Even with insurance, a patient might have paid $500-$800 month out-of-pocket for the drug, the Washington Post found. The introduction of generics after the patent on Gleevec expires this year will bring the cost down dramatically.\nIn the chronic phase of the disease, where remission isn\u2019t likely, the average cost for brand-name imatinib per year is $79,000 a year, or $92,000 by a more recent estimate. A large group of physicians wrote in a 2013 cost analysis study in the journal Blood: \u201cWe believe the unsustainable drug prices in CML and cancer may be causing harm to patients.\u201d Fortunately, a generic drug should cost $46,000 a year as Gleevec loses patent exclusivity in 2016, according to a recent study in the Journal of the National Cancer Institute.\nBut that\u2019s just imatinib. Although the release mentions an Epizyme-made Ezh2 inhibitor drug in an unrelated Phase 1 clinical trial, it doesn\u2019t name it.", "answer": 0}, {"article": "CHICAGO\u2014Using whole-brain radiation to treat cancer that has spread to the brain is a treatment that for many patients is worse than the disease, a new study suggests.\n\nResearchers said the technique, when used after a more precise radiotherapy to kill the cancer, resulted in more memory loss and other cognitive deficits than treating with radiotherapy alone. While the more aggressive treatment was better at preventing recurrence of tumors in the brain, it didn\u2019t extend survival.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story doesn\u2019t mention cost. It\u2019s a missed opportunity to discuss the costs associated with whole brain radiation and the savings that could be had by avoiding it.\nBut since the story is focused entirely on not pursuing a course of action \u2014 and there\u2019s no additional treatment specified in place of whole-brain radiation that would involve costs \u2014 we won\u2019t dock points for this omission. We\u2019ll rule it Not Applicable.", "answer": 2}, {"article": "UT Southwestern physicians provide care in about 80 specialties to more than 100,000 hospitalized patients, 600,000 emergency room cases, and oversee approximately 2.2 million outpatient visits a year.\nAnd the exercise needs to be performed four to five times a week.\nPrevious studies from Dr. Levine's research program have shown substantial improvements in cardiac compliance in young individuals after a year of training, but surprisingly little change if the training was started after age 65.\nTwo to three times a week was not enough, the researchers found in an earlier study.\nIn the study, exercise sessions were individually prescribed based on exercise tests and heart rate monitoring.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The intervention proposed is at least a half-hour of exercise 4-5 times per week. With the exception of a recommended 1 or 2 sessions involving weights or exercise machines (which would involve some cost) this intervention would require minimal financial investment. We\u2019ll rate this Not Applicable.", "answer": 2}, {"article": "The F.D.A.\n\u201cThere are very few treatments in all of cardiovascular medicine that could claim that \u2014 I can think of heart transplant, and that\u2019s it.\u201d\n\nThe results were even more notable, he said, because the early versions of the devices were clunky, stiff and difficult to use.\nThe result was a requirement that a hospital should be doing at least 50 surgical aortic valve replacements a year to have access to the technology.\nAnd new data from another large study by Edwards found that patients at intermediate risk did better with the newest version of its valve than would be expected with surgery in the first 30 days, when most deaths occur.\nThe consensus of the group, he said, was that \u201cnot every one of the 1,150 cardiac surgery programs or the 1,600 cath labs in the U.S. should be able to do it.\u201d\n\nIn June 2014, after another company, Medtronic, did similar studies, its device was approved, too, for high-risk patients.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "We\u2019ll award a Satisfactory here with some reservations. Although the article addresses the cost of the procedure, and in particular of the valve, readers should have been told how the cost compares to conventional surgery, rather than just the bottom line risks for hospitals. Here\u2019s how the story presents it: \u201cIt\u2019s a hard proposition when $32,500 goes right out the door to Edwards,\u201d the valve manufacturer, he said. The hospital gets about $40,000 from Medicare, which is fine if there are no complications. But older patients, in their late 80s and 90s, often end up with four-, five- or even seven-day hospital stays. \u201cWe could lose $25,000,\u201d he said.\u201d\nAccording to the Healthcare Blue Book, a reasonable charge to the consumer for heart valve surgery is $50,000.", "answer": 1}, {"article": "Of these, 85 percent were mild or moderate.\nSalloway's study looked at the drug's safety in 194 Alzheimer's patients, most of whom had mild- to-moderate Alzheimer's and participated in a long-term (78 weeks or longer) study.\nThe studies were funded by Pfizer Inc. and Janssen Alzheimer Immunotherapy.\nBecause this study was presented at a medical meeting, the data and conclusions should be viewed as preliminary until published in a peer-reviewed journal.\nThe researchers, who said monitoring of bapineuzumab will continue, are now awaiting the results of a larger Phase III trial on the drug.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "As the drug is still under development, there was no discussion of costs.\nThis is a humanized monoclonal antibody and the story might have mentioned some of the drugs currently on the market to treat other disorders such as bevacizumab (Avastin) or adalimub (Humira). \u00a0This could have led to some discussion about costs because these are not inexpensive medications.", "answer": 2}, {"article": "The California Walnut Commission offices are located at 101 Parkshore Dr., Ste.\nThere are numerous possible active properties in walnuts that may be contributing factors in providing health benefits.\nThe CWC has supported health-related research on walnuts for more than 25 years.\nThis research was supported in part by the California Walnut Commission (CWC).\nSome study limitations should be considered.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Walnuts are reasonably affordable, and most people have some idea of how much they cost.", "answer": 2}, {"article": "Obese children and those with diabetes often suffer from fatty liver, a condition normally associated with alcohol abuse but increasingly common among non-drinkers who gain excessive amounts of weight.\n\u201cThis is causation.\u201d\n\nThe diet he provided the children isn\u2019t considered ideal from a health perspective \u2014 starches are still a considerable source of calories and can contribute to weight gain.\nBut that the rise of the chronic diseases was actually linked to higher sugar consumption is a challenge.\nNow, in a paper published Tuesday, he and his colleagues believe they have come up with the definitive evidence that sugar, as Lustig says, \u201cis toxic.\u201d\n\nIn most lab studies, the doses of sugar that scientists test are quite high; they want to see what the effect is quickly and, depending on the research, they may not have time to wait to study the more gradual effects that might emerge.\n\u201cWe know that a healthy diet and weight loss cause good metabolic changes, and although this study tries to attribute its effects to low fructose, in fact it is impossible to do that because of the study design.\u201d\n\nSome experts are concerned for other reasons.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Many sugar-rich packaged and prepared foods are more expensive than home-made foods.But the study was not designed to compare the costs of diets, and most people know how much different types of food that contain sugar cost. So we\u2019ll rate this Not Applicable. On the other hand, it would have been useful to cite estimates of the cost of treating the disorders\u00a0linked to metabolic syndrome components, such as high blood pressure, as well as the costs of treating the chronic diseases that are a consequence of the syndrome, such as diabetes and heart disease.", "answer": 2}, {"article": "TMS treats conditions by delivering brief, powerful magnetic field pulses that stimulate nerve cells in the brain.\nOverall, 38% of the people with the real device responded to the treatment compared with 11% of those with the sham device.\nThe approval was based on a clinical trial of 100 people with obsessive-compulsive disorder, where roughly half received treatment with TMS and the other half had a sham treatment that didn't deliver the electromagnetic pulses.\nPeople who were taking medication for OCD continued to do so for the trial.\nA response was considered a 30% reduction in the Yale-Brown Obsessive Compulsive Scale (YBOCS) score, which is used to measure the severity of OCD symptoms.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The article does not say how much this treatment cost nor whether insurance covers the costs. Some estimates of TMS put the cost of four to six week courses of five-day-a-week, 20-minute treatments at between $5,000 to $15,000 and up.", "answer": 0}, {"article": "Resveratrol is a naturally occurring compound found in foods such as red grapes, raspberries, dark chocolate and some red wines.\nTurner says the study also found that resveratrol was safe and well tolerated.\nTurner, who treats patients at MedStar Georgetown University Hospital, cautions that the findings cannot be used to recommend resveratrol.\nAn \"investigational new drug\" application was required by the U.S. Food and Drug Administration to test the pure synthetic (pharmaceutical-grade) resveratrol in the study.\nGUMC was one of 21 participating medical centers across the U.S.\n\nFurther studies, including analysis of frozen blood and cerebrospinal fluid taken from patients, are underway to test possible drug mechanisms.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Although resveratrol is found in some foods, it was tested here as an investigational new drug. This means that it is not available commercially in 1-gram pills. The news release points out this fact, which is why we rate this Not Applicable.", "answer": 2}, {"article": "While some teenagers want to switch from insulin injections to pump therapy to gain more flexibility in their lives, doctors said device problems such as a blocked tube can lead quickly to dangerous episodes of high blood sugar.\nParents should be vigilant in watching their children\u2019s use of the pumps, researchers from the Food and Drug Administration wrote.\nBut they called for more study to address safety concerns in teens and even younger children who use the popular pumps.\nAnd they\u2019re a growing segment of diabetes care, with $1.3 billion in annual sales worldwide, said Kelly Close, a San Francisco-based editor of a patient newsletter.\nAt times, the devices malfunctioned, but other times, teens were careless or took risks, the study authors wrote.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The original AP story told readers the cost of devices, approximately $6,000, and monthly supplies, approximately $250.\u00a0 The St. Paul Pioneer Press, in its shortened version of the AP story, left this information out.\u00a0 So our grade is for the Pioneer Press effort, not the original AP story. \u00a0", "answer": 0}, {"article": "\u201cWe believe we can modify this test and make it much easier and simple... (and then) we can have something ready to be introduced into the clinic,\u201d he told Reuters in Nicosia.\nSince amniocentesis carries a small risk of spontaneous miscarriage \u2014 Patsalis put it at around one or two percent \u2014 scientists have been looking for new less invasive ways to test for Down\u2019s and other potential genetic problems.\nDoctors currently use a test known as amniocentesis to check whether a baby is likely to be born with Down\u2019s.\n\u201cSuch a non-invasive approach will avoid the risk of miscarriages of normal pregnancies caused by current, more invasive procedures,\u201d the scientists wrote in their paper.\nPhilippos Patsalis, medical director of the Cyprus Institute of Neurology and Genetics, who led the study, said the results were \u201cvery exciting\u201d and the test now needed to be trialed in a larger study of about 1,000 pregnancies, but could lead to changes in clinical practice within two years.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No discussion of cost. If a story can claim that something \u201cmay soon be\u201d available, it ought to be able to project cost.\u00a0 Of course, it\u2019s probably way too early to project anything meaningful on either count, but therein lies the weakness in such story framing.", "answer": 0}, {"article": "NEW YORK (Reuters Health) - In a small study, people who had chronic pain as a result of damage to the nervous system reported feeling less pain, as well as less depression and anxiety, when they smoked marijuana compared to when they smoked a drug-free placebo.\nThe study\u2019s five-day treatment sessions also leave questions about patients with chronic conditions who might need treatment for months or years.\nDuring each treatment, participants were asked about their pain, sleep patterns, mood, and overall quality of life.\nThere was also no difference in the quality of life or mood scores that participants reported when they were on any of the four treatments.\n\u201cThe trial did not last long ... so the authors cannot really say whether any response would be sustained,\u201d Dr. Henry McQuay, who studies pain and pain relief at the University of Oxford, wrote in an editorial accompanying the study.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "It is less surprising that neither story discussed costs, given that so few stories do. But sample costs could have been obtained by calling any of the numerous medical marijuana outlets in states where it is legal.", "answer": 0}, {"article": "Aneurysms are weakening, or bulging, of blood vessels that can rupture and become life-threatening.\n\u201cI feel very lucky to have benefited from this new and improved surgical technique and for the great doctors who cared for me.\n\u201cThis was a difficult surgery, but I knew I was in good hands,\u201d said Angelino, 85, of Culver City.\n\u201cPrior to gaining approval from the Food and Drug Administration, patients with many types of aneurysms and aortic conditions had limited treatment options,\u201d said Azizzadeh, director of Vascular Surgery at the Smidt Heart Institute at Cedars-Sinai.\nAfter my recovery, I know I will feel stronger and healthier, and will remain forever grateful.\u201d\n\nSince Angelino\u2019s surgery, Azizzadeh who, in conjunction with medical device company Medtronic, served as the national principal investigator in clinical tests of the device \u2013 has performed several additional, successful surgeries.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "No costs were mentioned.", "answer": 0}, {"article": "\"When a body gets used to having a chronic headache suppressor, the patient can experience a rebound in the absence of that suppressor.\nSeven of the patients (about 6 percent) failed to get any benefit from the treatment, the investigators found.\nMandato stressed that no one in the study required sedation to undergo the procedure.\nDr. Richard Lipton, director of the Montefiore Headache Center in New York City, described the findings as \"very dramatic.\"\nThe researchers acknowledged that this procedure is a temporary solution that would need to be repeated.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There was no discussion of costs in the article. A search of 4 percent lidocaine yielded a price tag of $524.25 for 100 mL, suggesting that the costs of the lidocaine itself (they used 2 mL for each nostril, or 4 mL total) would not be significant. The main cost would be the imaging and procedure fees for the interventional radiologist. It\u2019s not clear what those would amount to, but it wouldn\u2019t be a trivial sum.", "answer": 0}, {"article": "Dr Webster added: \"Patients are brought back at frequent intervals to see if they are meeting their targets with multiple visits required to tailor their treatments and dosage.\nDr Ruth Webster, of The George Institute for Global Health, said this was a major advance by showing that the Triple Pill was not only more effective than standard care, it was also safe.\nA new low dose three in one pill to treat hypertension could transform the way high blood pressure is treated around the world.\nA trial led by The George Institute for Global Health revealed that most patients - 70 per cent - reached blood pressure targets with the 'Triple Pill', compared to just over half receiving normal care.\nWith high blood pressure the leading cause of disease burden worldwide, it's expected the findings published in JAMA will change guidelines globally.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The cost of the three-in-one pill is not mentioned.\nTwo similar pills already on the market (Tribenzor and Exforge HCT). They\u2019re also once-daily pills combining an angiotensin II receptor blocker + calcium channel blocker + thiazide diuretic. They both have a retail price of approximately $10 a pill, or $300 per month [Source: Drugs.com].", "answer": 0}, {"article": "Dr. Christopher B. Granger, the study\u2019s lead author and a professor of medicine at Duke University, said, \u201cI think this is a profound trial result that will have a major impact on the practice and management of patients with atrial fibrillation.\nThe study included 18,201 people in 1,034 clinical sites in 39 countries and was consistent worldwide, the sponsors said.\nAlthough the study was financed by the drug makers, which raises the issue of bias, it met the gold standard for medical research as a randomized, double-blinded trial in which doctors and patients did not know who took which pill until the end.\nThe companies\u2019 stock soared after they released a brief statement about the stroke and bleeding benefits in June.\nIt combines both greater efficacy in terms of prevention of stroke with a substantial reduction to bleeding risk, and that package is one that will be particularly compelling.\u201d\n\nWall Street has high expectations, too.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story mentioned that it was expected that the drug reported on would cost $8/day as compared with <$1/day for warfarin.\nOne aspect of costs that were not considered in this story is the difference in monitoring, which would be less with patients using Eliquis. The competing HealthDay story did a better job on this latter point.", "answer": 1}, {"article": "I wouldn\u2019t wish it on my worst enemy, but I have to go through with it.\u201d\n\nDr. Lowy explored the entire cavity from the diaphragm to the pelvis.\n\u201cIt\u2019s maximally invasive,\u201d said Dr. Sugarbaker, who often removes the \u201cspare parts\u201d \u2014 organs a patient can live without, like the spleen, the gall bladder, the ovaries and the uterus.\nMr. S. left the hospital eight days later, happy to have undergone the treatment.\nBut doctors added it may be if it is described merely as chemotherapy.\nThe man\u2019s belly was filled with three liters of saline fluid and the chemotherapy, a generic drug called mitomycin C, heated to 42 degrees Celsius, or nearly 108 degrees Fahrenheit.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Good job on this, stating \u201cThe cost of the surgery and Hipec, including hospitalization, ranges from $20,000 to more than $100,000, doctors said. While Medicare and insurers generally pay for the operation, the heated treatment may not be covered. But doctors added it may be if it is described merely as chemotherapy.\u201d", "answer": 1}, {"article": "Nancy U. Lin and Harold J. Burstein, of the Dana-Farber Cancer Institute and Harvard Medical School in Boston, said: \"EMBRACE provides much needed, high-level evidence for chemotherapy use in patients with heavily pretreated breast cancer.\n\"This global phase 3 study establishes a potential new standard treatment for women with heavily pretreated metastatic breast cancer, for whom there was previously no chemotherapy treatment with proven survival benefit,\" the authors wrote.\nThe study, known as the EMBRACE trial, was funded by Eisai Inc., which markets eribulin.\nThe study included 508 women who were given eribulin and 254 women who received treatment of the physician's choice, which was defined as: any single-agent chemotherapy, hormonal or biological treatment approved for cancer treatment; radiotherapy; or symptomatic treatment alone.\nDr. Javier Cortes, of the Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology in Barcelona, Spain, and colleagues published the findings in the March 3 online edition of The Lancet.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There is no discussion of cost in the article.", "answer": 0}, {"article": "Eli Lilly announced promising data on its efforts to have its Cymbalta depression treatment also used as pain medicine, saying a study showed the drug \"significantly\" reduced chronic lower-back pain.\n\nLilly has been looking at the potential of Cymbalta for relieving the discomfort of fibromyalgia and osteoarthritis pain as well as back pain. The company's results of late have been boosted by the antidepressant, whose second-quarter sales jumped 26% to $654.4 million.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No discussion of cost \u2013 only of sales figures which aren\u2019t much help to the individual consumer. Cymbalta is expensive. ", "answer": 0}, {"article": "The results were published in the New England Journal of Medicine.\nTwenty-two percent of those combination patients had a complete response, meaning no sign of tumor.\nBut after 11 months, more than half of the combination group had yet to see their disease worsen.\nIn a separate group of 33 patients with a mutation of the BRAF gene involved in cancer cell growth, the overall response rate was 52 percent for the combination.\nOverall survival data was not yet available.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story doesn\u2019t address cost at all, and it\u2019s a glaring omission. Yervoy costs around $30,000 per injection \u2014 and the combined cost of treatment with the two drugs would likely cost a patient (or that patient\u2019s insurance provider)\u00a0more than a quarter of a million dollars.", "answer": 0}, {"article": ".\nThe new study, published in The European Journal of Internal Medicine, found cannabis therapy is safe and efficacious for elderly patients who are seeking to address cancer symptoms, Parkinson's disease, post-traumatic stress disorder, ulcerative colitis, Crohn's disease, multiple sclerosis, and other medical issues.\nWhile the researchers state their findings to date indicate cannabis may decrease dependence on prescription medicines, including opioids, more evidence-based data from this special, aging population is imperative.\nMore than 70 percent of patients surveyed reported moderate to significant improvement in their condition.\n\"After monitoring patients 65 and older for six months, we found medical cannabis treatment significantly relieves pain and improves quality of life for seniors with minimal side effects reported.\"\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Cost is not mentioned in this news release. The study involves several different methods of taking cannabis (smoking, infused oils, vaporization) which all involve a wide range of pricing. Moreover, it isn\u2019t clear whether insurance pays for this or whether it represents out-of-pocket payments by patients.", "answer": 0}, {"article": "St. Jude freely shares the breakthroughs it makes, and every child saved at St. Jude means doctors and scientists worldwide can use that knowledge to save thousands more children.\n'Since reduced AIM2 activity in colorectal cancer patients is associated with poor survival, it might be useful to detect the level of AIM2 expression in polyps taken from colonoscopy and use this as one of the biomarkers for prognosis,' Kanneganti said.\nShe said that the findings could have important applications for prevention, prognosis and treatment.\n'However, our work is the first to identify AIM2's role in controlling proliferation of intestinal stem cells.\nThey found that AIM2 deficiency causes uncontrolled proliferation of intestinal cells.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release does not address cost at all. This is not surprising, given that this is an early study, in an animal model, which identifies the role of a particular protein in preventing and, possibly, slowing the progression of colorectal cancer. However, the release explicitly discusses specific therapeutic possibilities, such as interferon therapy to increase AIM2 activity and transferring healthy bacteria into colorectal cancer patients. If you\u2019re going to discuss possible treatment options (even in general terms), it\u2019s worth mentioning what they may cost (even in general terms).", "answer": 0}, {"article": "Airways became less likely to close off after exposure to an allergen.\nThe drug also improved overall airway function, an effect researchers hadn't expected, Israel said.\nPhysical examinations showed that people taking Gleevec actually experienced a slight overall widening of their airways, Israel added.\nTwo generic versions of the drug were launched last year, which could make it less pricey than new-wave asthma drugs headed for the market, Israel added.\nBlood tests showed that Gleevec did reduce mast cell activity in patients, Israel said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "We were glad the story addressed costs, but actual figures would have been more helpful. It says imatinib \u201cmight provide a relatively inexpensive new treatment for asthma patients. Two generic versions of the drug were launched last year, which could make it less pricey than new-wave asthma drugs headed for the market, Israel added.\u201d\nWhile it may cost less than other options, this treatment isn\u2019t what we consider inexpensive, even off-patent. Generic imatinib costs $96.53 to $276.53 per tablet, according to Drugs.com.", "answer": 1}, {"article": "November 16, 2015.\nIn the article the authors offer suggestions to how both individual consumers and the food industry can use seaweed to make our everyday meals healthier.\nHe and the co-authors suggest that seaweed should be added fast food, thus making this type of food healthier.\nAn important feature is also that the seaweed has umami - the fifth basic taste, which is known to promote satiety and hence regulate food intake in addition to reduce the craving for salt, sugar and fat.\nBy adding seaweed to processed foods we can make food healthier.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There is no discussion of costs in this piece. This is odd for two reasons: 1. Seaweed of certain varieties is readily available in grocery stores and a staple of sushi bars and other restaurants. 2. The authors are advocating that seaweed become a regular part of baking and cooking, which means that costs need to be considered.", "answer": 0}, {"article": "A number of new multiple-sclerosis medications are beginning to hit the market that promise to make it easier for patients to control flare-ups of the disease and slow its progression.\n\nThe drugs, designed to be taken orally, represent a new generation of treatment for MS. Currently, people with the disease can choose from a range of drugs that are administered by injection.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "This story lists both the costs of the newest drug \u2013 Gilenya \u2013 and the costs of existing injectable treatments. This is a great bonus for the reader.", "answer": 1}, {"article": "Microcapsules loaded with stem cell-derived insulin-producing cells retrieved after they had been transplanted into a mouse.\nBut experts say the findings provide hope for future treatments for people.\nJust because the system produced strong results in mice does not mean people will respond the same way.\nPlus, donors are in short supply and can\u2019t yield enough cells to treat the millions of people with type 1 diabetes around the world.\nThose drugs are not ideal, because they carry a risk of infection or cancer.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Part of the caution in this story is not linking the research too closely to a potential on-the-shelf treatment. The story says in several ways that a drug therapy would be a good distance away. So we don\u2019t think it appropriate to talk about costs at this point. We rate it Not Applicable.", "answer": 2}, {"article": "This will help for that,\u201d Destounis said.\n\u201cOur results indicate that in 1,000 women screened for 10 years, three breast cancer deaths would be prevented,\u201d Duffy said, adding that most of the deaths prevented would have occurred more than a decade after the screening had started.\n\u201cI think for anybody who was beginning to have their faith shaken in the value of mammography, these data show mammography is quite valuable as a public health approach to reducing deaths from breast cancer,\u201d Smith said.\nHe said the new findings do not speak to the frequency of screening issue, but they do make clear that screening works.\n\u201cEveryone must make up their own mind, but certainly from combined results from all the screening trials, mammography in women aged 40-49 does reduce deaths from breast cancer,\u201d he said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "This story did not mention the cost or insurance coverage for mammograms, though it did allude to the expense of having additional biopsies and tests to distinguish between a cancerous and noncancerous lesion found via screening.\u00a0", "answer": 0}, {"article": "Food sources of vitamin D include milk, breakfast cereals and orange juice fortified with vitamin D, as well as some fatty fish, like salmon and mackerel.\nSome researchers believe that people need more vitamin D than is currently recommended, and that intakes above 2,000 IU per day are safe.\nBut whether vitamin D is the reason for the excess risks \u2014 and whether taking supplements can curb those risks \u2014 has yet to be shown.\nLaaksi said that larger clinical trials looking at different doses of vitamin D are still needed before the vitamin can be recommended for curbing the risk of respiratory infections.\nOn the other hand, a recent study of 162 adults found that those who took 2,000 IU of vitamin D everyday for 12 weeks were no less likely to develop respiratory infections than those given placebo pills.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "1clip_filelist.xml\" rel=\"File-List\"/>\n\n\n\n\n \nThis story does not mention cost. Sure, vitamin pills cost only pennies a day, but treating everyone would cost billions of dollars a year.\n Assuming just a nickel a day for 400 IU of vitamin D (the dose used in this study), the cost of treating everyone in the U.S. would exceed $5 billion a year. That bill has to be compared to the expected benefits of supplements given to healthy people, which in this trial were not statistically significant, so those billions might just be flushed down the drain.", "answer": 0}, {"article": "Dr Douglas Morrison, author of the paper from the Scottish Universities Environmental Research Centre at the University of Glasgow, commented: \"We developed inulin-propionate ester to investigate the role of propionate produced by the gut microbiota in human health.\nThe team found that when volunteers drank the milkshake containing inulin-propionate ester, they had less activity in areas of their brain linked to reward -- but only when looking at the high calorie foods.\nNewswise \u2014 Eating a type of powdered food supplement, based on a molecule produced by bacteria in the gut, reduces cravings for high-calorie foods such as chocolate, cake and pizza, a new study suggests.\nIn a second part of the study, which is published in July edition of the American Journal of Clinical Nutrition, the volunteers were given a bowl of pasta with tomato sauce, and asked to eat as much as they like.\nThis study is filling in a missing bit of the jigsaw -- and shows that this supplement can decrease activity in brain areas associated with food reward at the same time as reducing the amount of food they eat.\"\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Granted, the study is preliminary but the release could have included an estimated cost for the supplement, particularly since a form of inulin powder is already available commercially in supplement shops and online.", "answer": 0}, {"article": "AURORA, Colo. (Nov. 16, 2016) - Researchers at the University of Colorado Anschutz Medical Campus have found that high doses of vitamin D reduce the incidence of acute respiratory illness (ARI) in older, long-term care residents.\nBut Ginde said the primary finding that vitamin D can reduce ARI is a major step forward in treating these dangerous infections.\nThe findings of the clinical trial, published today in the Journal of the American Geriatrics Society, could help reduce one of the leading causes of serious illness, debilitation and death among patients in nursing homes and other long-term care facilities.\nHe cautioned that the study is not definitive proof that vitamin D can prevent ARI but it suggests that it can and at little risk to the patient.\nThey also had over double the incidence of falls, the study said.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There is no mention of costs in the release. Even though we are talking about vitamin D, which can be found at any drugstore for around $20 a bottle, we estimate that it could cost about $10 \u2013 $15 for a 30-day supply.", "answer": 0}, {"article": "And Owens says that people with medical conditions like ulcers, kidney problems, liver problems or bleeding disorders are more vulnerable, as are people who take blood-thinning drugs and NSAIDs.\nAnd while many medical groups recommend daily aspirin to lower heart disease risk, not all federal agencies agree.\nIf people don't have a significantly increased risk of having a heart attack or stroke over the next decade, Nissen says, they may be \"causing more harm than benefit.\"\nThese new recommendations aren't final, and are open to public comment.\nThe Food and Drug Administration actually issued a warning against routinely taking aspirin to prevent heart disease in people without significantly high risk.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Cost is not a component of this story, but it does not appear to be as relevant an issue to this piece compared with other stories.", "answer": 2}, {"article": "Before the introduction of whooping cough vaccine in the 1940s, more than 200,000 cases a year were reported in the U.S. By 1965, that number plummeted to fewer than 10,000 a year. But the disease made a comeback in the 1990s, as the newer \"acellular\" vaccine \u2014 containing only cellular material but not whole cells \u2014 was phased in. While it is safer and has fewer side effects than the old version, studies have found that its protective effects wane more quickly than originally expected.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The cost of a Tdap vaccine for mothers isn\u2019t noted, and it should be: It\u2019s free under any insurance plan, per the Affordable Care Act (sometimes called \u201cObamacare\u201d). For anyone paying out of pocket, though, it\u2019s about $64 per dose.", "answer": 0}, {"article": "Editor's note: Tune in as Dr. Sanjay Gupta explores the signs, tests and lifestyle changes that could make cardiac problems a thing of the past on \"The Last Heart Attack,\" Saturday, August 27, 8 and 11 p.m.\nLead author Dr. David Jenkins, Canada research chair in nutrition and metabolism at the University of Toronto and St. Michael's Hospital, had previously shown the effectiveness of a cholesterol-lowering diet when all the meals were provided to participants.\nJenkins said participants achieved these results even though compliance to the whole grain, vegetarian diet was only about 40%.\nThe study was published Tuesday in the Journal of the American Medical Association.\nTo put the diet to the real-world test, participants received a one-hour counseling session with a dietitian and an illustrated study booklet at the outset and, later, received a 30-40 minute follow up session.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Same problems here as with the competing LA Times story: The\u00a0post doesn\u2019t address how much it will cost to maintain this diet, which includes some pricey soy-based\u00a0components and\u00a0expensive fortified margarines.", "answer": 0}, {"article": "Animal studies have suggested that omega-3 fatty acids may have anti-cancer effects, but the results from human epidemiological studies have been inconclusive.\nThe analysis appears online in The American Journal of Clinical Nutrition.\nThe researchers found no effect in men, and no effect of omega-3 consumption on hyperplastic polyps, which are more likely to be benign.\nA new study has found that consumption of omega-3 fatty acids from fish is associated with a reduced risk for one kind of colon polyp, but only in women.\nAfter controlling for age, race, body mass index, smoking and other factors, the researchers found that women in the highest fifth for omega-3 consumption \u2014 those who consumed three or more servings of fish a week \u2014 were 33 percent less likely than women in the lowest fifth to have adenomatous polyps, a type likely to become cancerous.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Not applicable.\u00a0 The cost of fish in the diet is not in question.", "answer": 2}, {"article": "Trigeminal neuralgia (TN) is a very painful nerve disorder that causes an electrical shock feeling in the face, usually in older people.\nThe authors, from Cleveland Clinic in the US, say considering radiosurgery earlier on could make a big difference to patients' lives.\nImportantly, the benefit of treatment was strongly driven by improvements in pain and discomfort as well as self-care.\nIn the research, radiosurgery helped improve the quality of life for patients with trigeminal neuralgia and reduced their depression, which is often exacerbated by the side effects of other treatments.\nBy considering it earlier as a treatment option, doctors could help improve the lives of patients with TN more quickly.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "We know surgery has many costs involved but none of them are discussed in this news release. The release mentions performing a \u201ccost-based analysis\u201d at the end but this is insufficient to give credit here.", "answer": 0}, {"article": "Dong, an expert in vitamin D and a professor in the MCG Department of Population Health Sciences, says about 15 minutes daily in the \"young\" sun - between 10 a.m. and 2 p.m. - but before your skin starts to get pink, is the best source of vitamin D.\n\nFoods like milk, milk products like cheese and yogurt, fatty fish like mackerel and sardines, some greens like kale and collards and fortified cereals also are good sources.\nParticipants taking 4,000 international units - more than six times the daily 600 IUs the Institute of Medicine currently recommends for most adults and children - received the most benefit, says Dr. Anas Raed, research resident in the MCG Department of Medicine and the study's first author.\nThe test essentially measures the speed at which the blood is moving, and in this case, fast is not good, Raed says.\nVitamin D also reduces inflammation, an underlying mechanism for obesity related development of coronary artery disease, says Raed.\nThe Institute of Medicine currently recommends a daily intake of 800 IUs of vitamin D for those age 70 and older.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release responsibly notes that obtaining more vitamin D is a potentially simple endeavor for most individuals. They can drink more milk, for example, or purchase a relatively inexpensive supplement.", "answer": 1}, {"article": "I didn\u2019t even know I had cancer until after the surgery to remove the tumor,\u201d Hopper told NBC News.\nA modified version of the polio vaccine, infused straight into aggressive brain tumors, helped some patients live for years longer than they normally would have, doctors reported Tuesday.\nBut if the tumor is aggressive, it\u2019s usually fatal.\n\u201cThe nature of the treatment causes side-effects,\u201d Bigner said.\nIt\u2019s not clear why just one in five patients benefits, said Dr. Annick Desjardins, who worked on the study team.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There\u2019s no mention of how much this might cost, but we\u2019ll rate this N/A since the story makes it clear that this concept still requires more research.", "answer": 2}, {"article": "UCSF Benioff Children's Hospital Oakland (formerly Children's Hospital & Research Center Oakland) is a premier, not-for-profit medical center for children in Northern California, and is the only hospital in the East Bay 100% devoted to pediatrics.\nThis was a novel approach, different from the commonly used method of looking at zinc in the blood or using stunting and morbidity for assessing zinc status.\nIn addition to King, the study's other authors are Sarah J Zyba, Swapna V Shenvi, David W Killilea, Tai C Holland, Elijah Kim, Adrian Moy, Barbara Sutherland, Virginia Gildengorin, and Mark K Shigenaga, conducting the research at CHORI's Nutrition and Metabolism Center.\nKing and her team are the first to show that a modest increase in dietary zinc reduces oxidative stress and damage to DNA.\n\"These results present a new strategy for measuring the impact of zinc on health and reinforce the evidence that food-based interventions can improve micronutrient deficiencies worldwide.\"\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Although zinc can be found in everyday foods such as oysters and red meat, the mineral can also be taken as a dietary supplement. A bottle of 100 zinc tablets goes for about $4 to $6 at the local drug store.\nSince there is no discussion of costs in this news release, we give it a Not Satisfactory rating here.", "answer": 0}, {"article": "The majority of smokers who successfully switch to vaping say they have fewer respiratory infections, according to a study led by Queen Mary University of London\n\nThe majority of smokers who successfully switch to vaping say they have fewer respiratory infections, according to a study led by Queen Mary University of London (QMUL).\nFuture studies should assess respiratory symptoms objectively and on unselected samples of vapers.\nDespite the limitations, the researchers say that the study provides a reasonable reassurance that vaping does not promote respiratory infections and may in fact reduce them.\nSome previous cell and animal studies have been interpreted as suggesting that vaping may increase vulnerability to infection, but these studies did not use realistic exposure levels.\nHuman trials have reported no significant adverse respiratory effects associated with e-cigarette use for up to 1.5 years and a follow-up study of smokers with asthma who switched to vaping found significant improvements.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Vaping is a lot cheaper than smoking, but it still isn\u2019t cheap, running into the hundreds or even thousands of dollars per year. The cost of vaping isn\u2019t mentioned. Nor is the cost of other smoking cessation methods. The health costs of e-cigarettes are still unknown.", "answer": 0}, {"article": "\"Ideally, we want to eliminate all staph aureus from the skin of eczema patients,\" said Leung.\nExperts say there is more research to be done, but that the goal of the trial is to discover the best combination of bacteria to clear eczema from the skin and then make it available to patients as a prescription cream.\nResearchers hope that using the bacteria-infused cream will offer a long-term solution where other treatments fall short.\nA new clinical trial is testing a natural treatment that researchers hope will provide a long-term solution for those dealing with the dry, itchy and painful skin that comes with chronic eczema.\nWhile it may seem counterintuitive to treat bacteria with more bacteria, experts say this approach seeks to restore the natural microbial balance of healthy skin.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "This lotion is still in clinical trials. Pricing is most likely unavailable.", "answer": 2}, {"article": "What's more, \"people tended to measure the outcomes very differently,\" Matthews says.\nAnd there wasn't much hard data on psychological, social or economic outcomes, according to the report.\nAnd here's a biggie: There wasn't much information about adverse effects on women and babies, something everyone would certainly want to know.\nBut Matthews says reviewers found few high-quality studies about any treatment.\nUnfortunately, medicines to relieve morning sickness have a checkered history.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There wasn\u2019t any discussion of\u00a0costs of these treatments. The point of the story was tell readers that these treatments couldn\u2019t be recommended on the basis of medical evidence. Even in an overview of available treatments, some cost information is important for readers, especially given the fact that regular acupuncture treatments are going to cost a lot more than vitamin B-6. How much money are people wasting on these treatments?", "answer": 0}, {"article": "Accumulations of neurotoxic beta-amyloid protein can be detected with positron emission tomography, or PET scans, and analysis of cerebrospinal fluid, but these are invasive, inconvenient and costly, making them impractical for routine screening and follow-up evaluation.\nWith the imaging technology's ability to detect autofluorescence signal related to retinal beta-amyloid, these findings may lead to a practical approach for large-scale identification of the at-risk population and monitoring of Alzheimer's, the researchers say.\n\"This is the first study demonstrating the potential to image and quantify retinal findings related to beta-amyloid plaques noninvasively in living patients using a retinal scan with high resolution.\nThe study's first author, Yosef Koronyo, a research associate at Cedars-Sinai and a scientist and inventor at NeuroVision, said the latest findings cap a decade of study that has produced several landmark discoveries.\nThis clinical trial is reinforced by an in-depth exploration of the accumulation of beta-amyloid in the retina of Alzheimer's patients versus matched controls, and a comparison analysis between retina and brain pathologies.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "High up in the release it says:\n\u201cAccumulations of neurotoxic beta-amyloid protein can be detected with positron emission tomography, or PET scans, and analysis of cerebrospinal fluid, but these are invasive, inconvenient and costly, making them impractical for routine screening and follow-up evaluation.\u201d\nWe love this kind of comparison but we expect those comparisons to be backed up. What makes these other diagnostic tools \u201cinvasive, inconvenient, and costly\u201d? How much do they cost? How much does this type of diagnostic cost? Remember, the study was done on deceased people\u2019s brains and retinas. So you can\u2019t get much more invasive than that.", "answer": 0}, {"article": "\"What we found was a very coherent pattern of less cervical cancer among people who\u2019ve used the IUD based on thousands of women \u2014 and the pattern wasn't subtle at all, it was stunning,\" Dr. Victoria Cortessis, the study's lead author and associate professor of clinical preventive medicine at the Keck School of Medicine at the University of Southern California, told BuzzFeed Health.\n\nIUDs are small, T-shaped devices that are placed in the uterus to prevent sperm from reaching an egg. They are a highly effective form of birth control and they can offer protection against pregnancy for up to three, five, or ten years.\n\nThe study is the first of its kind to combine and analyze data from multiple studies to look at the issue. \"We went through all of the relevant human epidemiological data on this topic and narrowed it down to 16 high-quality observational studies of over 12,000 women from all over the world,\" Cortessis says.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The exact cost of an IUD wasn\u2019t mentioned in the story, but it did allude to the low cost of the product. The story also missed an opportunity to articulate the economic issues associated with HPV vaccine availability, namely the manufacturing cost of the vaccines and the profitability focus of the pharmaceutical industry.", "answer": 0}, {"article": "Legumes, beans, whole grains and some seeds have it, as do uncooked potatoes and unripe bananas.\nBut that\u2019s not the case with resistant starches, so named because they resist digestion.\nEven if you heat them up again, they retain their new resistant starches.\nMost intriguing and surprising of all is that so many leftovers contain resistant starch.\n\u201cThe potential for a nutritional lifestyle intervention to counter obesity driven by high-carbohydrate food, though we don\u2019t know yet how significantly, is fascinating,\u201d Arciero says\u2014especially when it\u2019s as simple and delicious as reheating your pasta.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story is dealing with low-cost, widely available foods, so we\u2019ll rate this N/A.", "answer": 2}, {"article": "Please see paper for the complete list.\n\u201cThe magnitude of improvement in these ten patients is unprecedented, providing additional objective evidence that this programmatic approach to cognitive decline is highly effective,\u201d Bredesen said.\nOther collaborators on the study include Edwin C. Amos, Jonathan Canick, Mary Ackerley, Cyrus Raji, Milan Fiala, and Jamila Ahdidan.\nThe study, which comes jointly from the Buck Institute for Research on Aging and the UCLA Easton Laboratories for Neurodegenerative Disease Research is the first to objectively show that memory loss in patients can be reversed, and improvement sustained, using a complex, 36-point therapeutic personalized program that involves comprehensive changes in diet, brain stimulation, exercise, optimization of sleep, specific pharmaceuticals and vitamins, and multiple additional steps that affect brain chemistry.\nAnother patient, a 49-year old woman who noted progressive difficulty with word finding and facial recognition went on the protocol after undergoing quantitative neuropsychological testing at a major university.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The news release does not discuss the cost of this complex intervention or the cost of genetic testing for Alzheimer\u2019s. The costs for adhering to this protocol would quickly add up, but the descriptions are so vague that it\u2019s impossible to make informed projections. It cites \u201cdiet, brain stimulation, exercise, pharmaceuticals, optimization of sleep, specific pharmaceuticals and vitamins,and multiple additional steps that affect brain chemistry.\u201d", "answer": 0}, {"article": "Early iron deficiency can interfere with nerve development, biochemistry and metabolism, hampering both intellectual and fine motor development.\n\u201cIt had an impact across a range of function, including intellectual function, executive function and fine motor function,\u201d factors that could affect a child\u2019s later academic success, Christian said.\nChristian\u2019s team studied 676 school-age children whose mothers had been in a clinical trial in which some got iron and folic acid supplements and other nutrients while they were pregnant.\n\u201cWhat we showed is prenatal iron and folic acid supplementation had a significant impact on the offspring\u2019s intellectual level and motor ability and ability during school age, which was a very exciting finding,\u201d she said.\nShe said many children in poor communities would benefit from better prenatal programs that include the low-cost nutritional supplements.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There is no discussion of costs. This is a problem because even if the individual doses of iron and folic acid are relatively cheap, their application on a large population, including staff time, monitoring and the attendant paperwork, would no doubt become costly quickly. We\u2019re talking about a study of 676 kids, but there are billions of children worldwide who could benefit from this type of intervention. Some nod to costs should have been made here.", "answer": 0}, {"article": "Watson says we don't know for sure, but it's possible the body begins to adapt to those changes, which is why the weight loss is reversed over time.\nThat's when she opted for bariatric surgery.\nFriedman kept the weight off for almost 10 years.\nAnd research conducted over the past decade suggests it works.\nAnd more importantly, she wants to keep the weight off.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story clearly provides the reader with an estimate of the costs of the procedure and highlights issues related to insurance coverage. A strong point in this story.", "answer": 1}, {"article": "\"So many people say `how can cancer screening be harmful?'\nThe last study is a warning to people who get screening tests that aren't recommended, or who question whether screening can ever hurt.\nThe new study was the first big one to examine a newer screening tool, HPV tests, with or without Pap smears in routine practice.\nThe new study gives \"very, very solid support\" for screening less often, Lichter said.\nThe results don't apply to using these tests on women with symptoms of ovarian cancer or abnormal physical exams.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not list the costs of all the screenings mentioned, but we give it a passing grade for at least addressing the issue of costs-versus-benefits. The story says, \u201cHPV tests cost $80 to $100 compared to $20 to $40 for Paps.\u201d", "answer": 1}, {"article": "(Dr. Deland is helping to develop a new ankle replacement device for Zimmer of Warsaw, Ind., which may be submitted for F.D.A.\nEach year about two million Americans visit the doctor for ankle pain from arthritis or fracture.\nThe operation is complex, and many foot and ankle surgeons lack experience.\nThe procedure is among the most difficult that foot and ankle surgeons perform, and one of the biggest challenges is getting proper alignment of the replacement joint.\nDr. Brian Donley, an orthopedic surgeon who is director of the foot and ankle center at the Cleveland Clinic, says patients should always ask their doctor to disclose any financial interest in a device.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "This article does not discuss costs \u2013 a significant oversight.", "answer": 0}, {"article": "As myelin damage continues over the course of the disease, neurons progressively lose their ability to reliably transmit electrical signals, resulting in progressive loss of vision, weakness, walking difficulties, and problems with coordination and balance.\nThe drug tested in the trial, clemastine fumarate, was first identified as a candidate treatment for MS in 2013 by UCSF's Jonah R. Chan, PhD, Debbie and Andy Rachleff Distinguished Professor of Neurology, vice chief of the Division of Neuroinflammation and Glial Biology, and senior author of the new study.\nThe researchers said that the Phase II results, published online on 10 October, 2017 in The Lancet, are the first in which a drug has been shown to reliably restore any brain function damaged by a neurological disease in human patients.\nThe new results are particularly notable, Chan said, because patients in the trial had suffered from MS symptoms caused by injury to myelin for years.\nIn light of previous laboratory studies of the antihistamine compound at UCSF, the researchers said, the drug most likely exerted its effect by repairing damage MS had inflicted on myelin, an insulating membrane that speeds transmission of electrical signals in the nervous system.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Clemastine fumarate, also known by its brand name Tavist, is an antihistamine that can currently be bought over the counter. According to GoodRx.com, 60 tablets of 2.68mg Clemastine go for $33.33. If patients take the clinical trial\u2019s dose of 2 tablets per day, this supply should last 30 days.\nSince costs are not discussed in this news release, we give it a Not Satisfactory rating here.", "answer": 0}, {"article": "America\u2019s ongoing battle with weight-loss that has led to fad diets and invasive surgeries like gastric bypass and stomach stapling.\nDr. Prem Chattoo, a New York based gastroenterologist, told FoxNews.com that the balloon is placed it into the stomach through the mouth.\nChattoo said that even if the balloon were to pop, the saline would be absorbed and pose no harm to the patient.\nThe hope is that patients can train their body to eat in a much healthier fashion without feeling overly hungry.\nIn addition to eliminating the scarring and risks involved with more invasive options, Chattoo said that the recovery time is also much faster.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story clearly notes that the device, known as Orbera, \u201cis not covered by insurance and costs $8,000.\u201d", "answer": 1}, {"article": "...\nSimilarly, BE episodes decreased in the 50- and 70-mg/d treatment groups.\nAt some doses, the medication lisdexamfetamine dimesylate, a drug approved to treat attention-deficit/hyperactivity disorder, was effective compared with placebo in decreasing binge-eating (BE) days in patients with binge-eating disorder (BED), a public health problem associated symptoms of mental illness and obesity and for which there are no approved medications, according to a study published online by JAMA Psychiatry.\nThe one-week BE episode response status was improved in the 50- and 70-mg/d treatment groups, and a greater proportion of participants achieved four-week cessation of BE episodes and global improvement of symptom severity with all lisdexamfetamine dosages.\nThe U.S. Food and Drug Administration has not approved pharmacologic treatments for BED, according to background information in the study.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The news release does not discuss costs for drug, lisdexamfetamine (Vyvanse), that is still under patent. All drugs of the amphetamine class suppress appetite, and those that are generically available might potentially give similar results. The companies that market those generic drugs, however, have little incentive to undertake the expensive testing involved to achieve an FDA approval, since many companies make the generics. That said, lisdexamfetamine is different from the other amphetamines in that it is released more slowly into the blood. Tests show the main neurotransmitter affected by these drugs, dopamine, is released more slowly and doesn\u2019t get to as high a level, so this drug may have\u00a0less potential for abuse and addiction problems.", "answer": 0}, {"article": "\u2022 Using other options to collect urine, such as bedpans.\n\"This program can reduce urinary infections in hospitals if a team is assembled to ensure adoption of best practices and to rapidly correct reasons for failing to comply with these processes,\" she added.\nAs for improving infection control in intensive care units, Huang said, \"further analysis may help us understand why this intervention didn't work.\"\nShe said, \"While we've known the correct care processes for managing urinary catheters, we haven't been able to reliably reduce catheter-related infections.\"\nBut there was no drop in infections or catheter use in intensive care units (ICUs), the study findings showed.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "We\u2019re told that, each year, catheters in hospitals cause 250,000 infections and cost $250 million to treat. That\u2019s important to note and we\u2019re glad it was included. However, the story didn\u2019t tell us how much the intervention costs to implement. But, because this is an intervention that doesn\u2019t have direct consumer costs (unlike, say, a new cancer drug or surgery), we\u2019ll rate this is as N/A.", "answer": 2}, {"article": "Multiple myeloma is the second most common type of blood cancer in the U.S., impacting more than 25,000 people each year and disproportionatly affecting African-American men.\nMore than improving the results of the initial treatment, the MASTER study will treat patients for the necessary time to confirm elimination of minimal residual disease and then discontinue therapy.\nThe hope is that the therapies will eradicate the disease in a significant proportion of patients and measure disease response more accurately than ever before.\nAs it stands, patients with billions of cancer cells in their bodies and patients with true disease eradication will both appear to be in complete remission using current methods to measure disease response to therapy.\nHowever, researchers at the University of Alabama at Birmingham Division of Hematology and Oncology are leading and currently recruiting for a Phase II clinical trial that intends to provide newly diagonosed multiple myeloma patients an innovative treatment plan.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "In some experiments, it may be too early to discuss treatment costs, but this trial involves drugs that are all already approved for other uses, which means their prices are known. Also, while trial participants typically are not charged for experimental drugs, in this case it appears they will be billed for many treatment costs\u2026 and there would likely be costs for some (including travel and\u00a0 lodging) that insurance would not cover. In fact, the lead investigator acknowledged the costs when asked in an interview about what patients should know about the trial:\n\u201c[T]he study, like any other clinical trials, that our components are considered standard of care and they are charged to the patient or to the insurance. For example, the costs of seeing the doctor, the cost of doing the main test for a traditional disease assessment, the cost of stem cell transplant, but there are components that are considered experimental and are covered by the study, in this case, the daratumumab, the carfilzomib and the MRD testing by itself.\u201d\nThe release should have also noted these costs.", "answer": 0}, {"article": "And finally, this is a very real world study.\u201d\n\nThe study was received well by the audience.\nOne of the caveats of the study was that participants were highly motivated people looking for ways to cope with and decrease their blood pressure.\nEngaging patients in such a way could be a very powerful tool in promoting behavioral change, Nolan said.\nParticipants were also largely white and well-educated, with most having a postsecondary education, so the results of the study might not be generalize well to other groups.\nThese tools were carefully chosen to increase in knowledge about and motivation to maintain a heart-healthy lifestyle.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story didn\u2019t mention the estimated cost; we think that would have been a useful detail to both patients and healthcare providers interested in offering this program.", "answer": 0}, {"article": "Dr Gorlanova said: \"As research in this field progresses, we are understanding more and more about the gene-environment interaction for the development of asthma.\nIt is already known that environmental factors have a modifying effect on specific genetic risk, so the aim of this new study was to find out whether this could also be true for breastfeeding and this specific gene related to asthma with the respect to respiratory symptoms in early infancy.\nThis is the first time that we were able to show the effect of the 17q21 variants on respiratory symptoms during the 1st year of life, depending on breastfeeding status.\n\"Our study is the first to show that breastfeeding can modify the effect of asthma-related genetic profiles on respiratory symptoms in the first year of life\", commented Dr Olga Gorlanova, from the University Children's Hospital Basel (UKBB), and the University of Basel, Basel, Switzerland.\nInfants who have a genetic profile linked with asthma risk could be protected against respiratory symptoms if they are breastfeed, according to a new study.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There are two aspects to this release: a genetic mutation which predisposes to asthma and the potential value of breastfeeding in reducing that risk. The release makes no mention of costs in explaining this research. While on the surface breastfeeding carries no economic burden, genetic testing does. The release does not provide any information (as we will note later) about the availability of genetic testing or whether insurance coverage is available.\nIt\u2019s difficult to quantify, but breastfeeding can have financial costs. There is growing awareness that breastfeeding does exact a toll in time and related earning potential, as explained in this New York Times article.", "answer": 0}, {"article": "For instance, yoga may influence brain chemicals known as neurotransmitters (boosting levels of feel-good agents like serotonin), lower inflammation, reduce oxidative stress and produce a healthier balance of lipids and growth factors \u2014 just as other forms of exercise do.\nThe researchers say there\u2019s enough evidence to warrant a larger study on the effects of yoga on mental health, and it should be considered as part of treatment for more disorders.\nSome of the studies included in the analysis even suggested that yoga might affect the body in ways similar to antidepressants and psychotherapy.\nBut while the research is promising, yoga likely won\u2019t be a panacea for mental illness.\n\u201cMost individuals already know that yoga produces some kind of a calming effect.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story did not discuss costs. Yoga is relatively cheap (roughly $10 to $20 per class in the Northeast city where one of our reviewers lives)\u00a0compared with other forms of treatment,\u00a0but it isn\u2019t covered by insurance. So the costs can still add up, especially for those with limited incomes who are already paying for other medical care.", "answer": 0}, {"article": "Muscles all over the body break down as the patient grows up, the heart included.\nTests in mice genetically engineered to have a condition similar to Duchenne muscular dystrophy showed the drug could improve how the heart works, Joseph Beavoa of the University of Washington and colleagues at the University of North Carolina found.\nIt is not clear just how the drug is helping the mice, they reported in the Proceedings of the National Academy of Sciences, but they said it may be worth trying it as a treatment for muscular dystrophy.\n\u201cAlthough PDE5 inhibitors will certainly not cure DMD, the current studies suggest that they could be used in combination with current or future therapies,\u201d the researchers wrote.\nMany patients die of heart failure and most patients with the condition die before age 40.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "\n\n\nEven though this line of research is preliminary, the story should have noted that typical treatment for pulmonary hypertension patients who use the Revatio brand of sildenafil costs more than $15,000 a year and that since the drug does not cure the disease, this sort of treatment might well continue indefinitely. ", "answer": 0}, {"article": "In 1917, two German inventors first used pressurized pure oxygen to treat decompression sickness, which occurs when undersea divers return to the surface too quickly.\nHyperbaric therapy, he said, can return them to full function, even years after the injury.\nPatients typically receive between 40 and 60 hour-long hyperbaric treatments spread over two to three months.\nSpecialists told her the operation probably had caused collateral brain trauma.\nOver the past decade, doctors in the United States and internationally have begun using it to treat mTBIs.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story mentions that \u201cpatients typically receive between 40 and 60 hour-long hyberbaric treatments spread over two to three months\u201d and that a treatment \u201ctypically cost between $200 and $400 per session and is rarely covered by insurance.\u201d", "answer": 1}, {"article": "\"This work is very exciting and promising,\" said Nichols, who added, \"The FVII-deficient dogs tolerated the initial gene therapy infusions very well and have had no adverse side effects over several years of follow up.\nThis success in large animals holds considerable potential for a safe, effective and long-lasting new treatment in humans with the same bleeding disorder.\nThe current study sets the stage for clinical trials in humans.\nOver the past 15 years, CHOP hematology researchers have performed clinical trials of gene therapy for hemophilia B that have helped define efficacy and dosing levels in humans.\nThis gene therapy may especially benefit young children with severe bleeding from factor VII deficiency, such as patients receiving care in CHOP's hematology program.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The news release does not bring up costs, but we\u2019ll rate this Not Applicable since the release is clear that this is early-stage work that is not yet ready for use in humans. Some mention of costs would have been valuable nonetheless. Gene therapy is known to be extremely costly, and when a disease is rare, as this is, that raises questions about what company would find it profitable to pursue the potential treatment. The University of Utah provides some excellent background on the \u201ccommercial viability\u201d of gene therapy.", "answer": 2}, {"article": "\"My impression is, even with the newer band, the results are not significantly better,\" he says.\nBut a spokesman for the company that manufactures Lap-Band says the study is flawed.\nBut some, including the manufacturer of the Lap-Band -- used in a technique called laparoscopic adjustable gastric banding -- take exception to the study, criticizing the small sample size and the number of patients lost to follow-up.\nThe critics also point out that both the device itself and the expertise of surgeons placing it have improved greatly since the patients in the study had their bands placed, in the years 1994 through 1997.\nEven so, a majority of the patients in their small study said they were satisfied with the procedure.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "As with the HealthDay story we reviewed, there was no discussion of costs of the banding procedure nor for regular office visits for band adjustment.\u00a0\u00a0Although these costs were not detailed in the study reported on, this information is readily available.\u00a0\u00a0We think that this is unfortunate given the magnitude of the cost of the procedure. We also would have liked to have seen a comment or two about insurance coverage", "answer": 0}, {"article": "\"Men need to learn as much as they can about the possible outcomes and benefits of the various treatments and the potential side effects, and choose which direction they are most comfortable with,\" Brooks said.\nFor those methods, too, there was too little research to say with confidence which method was superior in preventing deaths from prostate cancer, the researchers said.\nProton beam therapy in particular is expensive, but according to this report, there isn't enough evidence to show it's any better than other option.\nFinally, patients and their doctors should weight the potential debilitating side effects of the treatments, such as incontinence and erectile dysfunction, against how comfortable the man is with holding off on treatment, experts say.\nBrooks said more comparative effectiveness research, which compares different kinds of treatments, is needed.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The only discussion of cost was one phrase deep in the story \u2013 \u201d proton beam therapy in particular is expensive\u201d \u2013 but that was it.\nProton beam therapy and a related approach \u2013 intensity modulated radiation therapy \u2013 are being used more commonly and both are very expensive.\u00a0 Within a story that discusses the lack of evidence, cost certainly deserved more attention.", "answer": 0}, {"article": "March 16, 2010 -- An experimental type of highly focused radiation therapy may control inoperable lung cancer tumors and help people with the deadly disease live longer.\nThis type of radiation therapy has not yet been approved by the FDA as a lung cancer treatment, but this study brings it one step closer.\nResearchers say that rate of tumor control is more than double that found with conventional radiation treatment for inoperable lung cancer.\nIn the study, researchers evaluated the safety and effectiveness of SBRT in treating 55 people with early-stage but medically inoperable lung cancer.\nA new study shows stereotactic body radiation therapy (SBRT) effectively controlled more than 87% of early-stage inoperable non-small-cell lung cancer tumors for up to three years.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not mention costs or insurance coverage. Likely given how experimental the treatment is, insurance will not cover the procedure. Given that it is not an approved treatment, a simple statement about its cost relative to current therapy could have been helpful. For desperate patients and families struggling with the treatment options, uNPRoven treatments that are likely not to be covered by insurance would require out of pocket coverage.", "answer": 0}, {"article": "When that occurs, the next step is to examine the suspicious area, with the physician ordering a biopsy or inserting a scope into the lungs to evaluate further.\nIf perfected, the test could help spare patients the need to undergo invasive procedures such as biopsies when lung cancer is suspected, they predict.\nAccording to Dubinett, about one in 500 chest X-rays shows a lung nodule of ''indeterminant significance.\"\nHe is the senior author on the study, presented at the American Association for Cancer Research-International Association for the Study of Lung Cancer's joint conference in Coronado, Calif.\n\nAbout 219,000 new cases of lung cancer were expected to be diagnosed in the U.S. in 2009, according to the American Cancer Society, and about 159,000 deaths were expected.\n''Currently, 20% to 25% of surgeries done for suspected lung cancer turn out to be benign diagnoses,\" says Steven Dubinett, MD, professor of medicine and pathology and director of the Lung Cancer Research Program at the Jonsson Comprehensive Cancer Center at the David Geffen School of Medicine, University of California, Los Angeles.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Costs are not discussed, as this is an investigational procedure.", "answer": 2}, {"article": ".\nThe data review did not look at any health outcomes associated with pasta consumption except for the ones specified below.\nThe research, \"Pasta Consumption in American Children and Adolescents is Associated with Greater Daily Intake of Shortfall Nutrients as Defined by the 2015 Dietary Guidelines, Improved Diet Quality and Lower Added Sugar Intake,\" was conducted by Nutritional Strategies, Inc. on behalf of the National Pasta Association.\nThe study examined associations between pasta consumption, shortfall nutrient intakes as defined by the 2015 Dietary Guidelines (2015 DG) and diet quality in comparison to non-pasta consumption in U.S. children and adolescents (ages 2-18).\nNPA is the leading trade association for the U.S. pasta industry.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release does not address the cost of including pasta in meal preparation but it\u2019s generally known to anyone who buys food that a box of dry noodles can be purchased for less than $1.", "answer": 2}, {"article": "But overall, the median length of survival was 12.5 months for patients treated with poliovirus, compared with 11.3 months for a similar group of patients treated in the past, the researchers report.\nMuch more follow-up research is needed to better assess and hopefully improve the treatment's effectiveness, the researchers say.\nTwo patients have survived more than six years, Bigner says.\nBut the researchers and other brain-cancer doctors caution the research is at a very early stage.\nSome other researchers praised the results.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There\u2019s no mention of how much this might cost, but we\u2019ll rate this N/A since the story makes it clear that this is early research.", "answer": 2}, {"article": "The Food and Drug Administration does not endorse DHA or fish oil capsules, but recognizes doses of up to 3 grams a day of fish oil as generally safe.\nBut, she adds, epidemiological studies consistently show positive health effects from fish consumption on mortality, cardiovascular risk factors and, now, dementia.\nThe average level of DHA among all the participants was 3.6 percent of all fatty acids, and the top 25 percent of the population had values above 4.2 percent.\nPeople in this top one-quarter in DHA levels had a 47 percent reduced risk of developing dementia, even after controlling for body mass index, diabetes, hypertension, smoking status and other known or suspected risks.\nRisk reduction was apparent only at that top level of DHA \u2014 those in the bottom three-quarters in DHA level showed no detectable difference in risk.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "This story did not include any cost estimates for fish or\u00a0docosaheaenoic acid (DHA)\u00a0containing supplements.\u00a0 It also did not include an estimate for the amount of supplements that would be needed to result in the plasma levels of DHA seen to be associated with lower dementia risk.", "answer": 0}, {"article": "\"If people have high blood pressure and a weight problem, a low-carbohydrate diet might be a better option than a weight loss medication.\"\nA new study shows that a low-carbohydrate diet was equally good as the weight loss drug orlistat (the active ingredient in Alli and Xenical) at helping overweight and obese people lose weight, but people who followed the low-carb diet also experienced a healthy drop in their blood pressure levels.\nResearchers say studies have already shown that the two weight loss methods are effective at promoting weight loss, but it's the first time the health effects of each have been compared head to head.\n\"I expected the weight loss to be considerable with both therapies but we were surprised to see blood pressure improve so much more with the low-carbohydrate diet than with orlistat,\" researcher William S. Yancy, Jr., MD, an associate professor of medicine at Duke University Medical Center, says in a news release.\n\"It's important to know you can try a diet instead of medication and get the same weight loss results with fewer costs and potentially fewer side effects,\" Yancy says.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Cost is particularly important when many patients may have to pay out of pocket for weight loss drugs. The\u00a0story does\u00a0not provide any information about the\u00a0cost of orlistat, the\u00a0cost of the food\u00a0in the\u00a0study diets, or the cost of the counseling provided to study participants.\u00a0\u00a0\nA quotation from one of the study researchers suggests\u00a0that\u00a0a low-carb diet might be a\u00a0cheaper alternative to a low-fat diet plus medication.\u00a0While this is certainly\u00a0possible, it also seems possible that low-carb eating,\u00a0with its emphasis on protein from\u00a0meat,\u00a0would be more expensive than low-fat eating, and that this would cancel out any savings on medication. In any case,\u00a0making any kind of judgment in this area would require\u00a0more hard data, but\u00a0the story provides only speculation.", "answer": 0}, {"article": "\"Those same benefits translate to people seeking to fight off the common cold, flu and other seasonal illnesses.\"\nIndividuals should consult with a professional massage therapist to determine the best massage therapy approach for their specific needs.\nBy meeting or exceeding state training requirements, ascribing to a code of ethics and participating in continuing education, American Massage Therapy Association massage therapists are appropriate additions to any wellness regimen and create specialized approaches based on individual conditions, fitness and goals.\nRegular massages have been shown to make the immune system stronger, according to studies.\nA qualified massage therapist can play an important role in health and wellness.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Since there was no mention of costs in this news release, we rate it Not Satisfactory. It would have been helpful to readers to discuss the approximate cost of a massage session, which can vary widely depending on the region, therapist and setting. The Center for Spirituality & Healing at the University of Minnesota estimates the national average for an hour-long massage to be about $60. Many people may wonder if their insurance policy would cover a massage therapy session. Insurance companies rarely pay for massage therapy, particularly for indications that aren\u2019t backed by science or evidence.", "answer": 0}, {"article": "Wisdom teeth, also called the third molars, are four teeth that grow at the very back of each corner of the mouth.\nA simple surgical extraction for a wisdom tooth that's showing through the gums should run about $230, according to Healthcare Bluebook.\nThe question comes down to which side of the fence medical professionals fall on\n\nIt's worth noting that oral surgeons make a good chunk of their paychecks by removing wisdom teeth, so there is a financial incentive involved.\nThe American Association of Oral and Maxillofacial surgeons says, \"There is no pat answer, cookbook recipe, or flow chart that is universally accepted regarding the decision making process\" in these cases.\nThe American Public Health Association has sided with this argument since 2008, when it formally opposed the preventative removal of wisdom teeth.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "This article talks about the overall costs of removing wisdom teeth \u2014 $3 billion annually, according to the American Public Health Association (which opposes preventative extraction) \u2014 as well as the costs of removing a single molar. A single extraction can range from $230 to $400 according the story source, the Healthcare Bluebook.\nThe story would have added more value if it had mentioned a range of costs associated with surgical complications or treatment for infections following surgery.", "answer": 1}, {"article": "Still, the study suggests that brain stimulation \"not only just helps patients who haven't been able to recover from depression, but it seems to be associated with the absence of relapses.\nDr. Samuel James Collier, an assistant professor of psychiatry at the University of Texas Southwestern Medical Center at Austin, predicted that even if deep brain stimulation turns out to be an effective treatment for depression, it'll be far from the first line of defense.\nAnd for now, the research is preliminary, so it's too early to know for sure if the treatment is appropriate to be used for any kind of depression.\nDeep brain stimulation has been around for more than 20 years, Mayberg said, and is commonly used to treat Parkinson's disease.\nIf patients are interested in deep brain stimulation treatment, they should try to get into the study that's ongoing, Mayberg said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "We would have liked to have seen a little more information on costs, but we are glad that costs are mentioned up high. In the third sentence, the story says, \u201cThe surgery necessary to allow deep brain stimulation is extremely expensive\u201d Later it says, \u201cThe cost of the surgery is about $50,000\u201d. It would have been interesting to note whether deep brain stimulation is covered by Medicare or any insurance companies for treatment of any disorders, including Parkinson\u2019s.", "answer": 1}, {"article": "Their overall risk of death was 30% lower than the sedentary adults, with the risk of cardiovascular and cancer deaths lower by 40% and 18% respectively.\nBut the weekend warriors also saw substantial health benefits if they met the physical activity target too.\nThe findings will reassure people who find it hard to make time for a daily exercise routine and opt instead to break a sweat once or twice a week in the hope of keeping fit.\n\u201cThe novel finding is that it appears the duration, and possibly the intensity, of leisure time physical activity is more important than the frequency,\u201d Ekelund said.\n\u201cA middle aged or older person should do as much as 12 weeks of moderate exercise before introducing vigorous exercise,\u201d he said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "We don\u2019t think that cost is relevant here.", "answer": 2}, {"article": "I was in New York last week, and the air was also not very clean.\u201d\n\nThe protective effect of ectoine was discovered by Prof Jean Krutmann and colleagues at the Leibniz Research Institute for Environmental Medicine, while investigating whether the molecule could protect skin against sun damage.\nBilstein said the inhaler could be useful around the world, as particulate air pollution is not just a European problem: \u201cEspecially in Asia \u2013 China in particular \u2013 the demand for such a product is even higher.\nRussell, who also lectures at Imperial College and Oxford University, said it might also be useful for the treatment of asthma, COPD and other lung diseases, not only prevention.\nThe new inhaler has been developed by German medical devices company Bitop and is based on a molecule called ectoine, discovered in the 1980s in a desert bacterium which uses the compound to conserve water in 60C heat.\nIt is expected to be available as an inexpensive, over-the-counter product.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The expected cost to UK\u00a0consumers is noted ($17 pounds/month).", "answer": 1}, {"article": "-- Icing the bottom of the foot, sometimes using ice to massage the heel area\n\n-- Using cups made of gel in shoes to cushion the heel (and many orthopedic surgeons say expensive custom-made orthotics are not necessary)\n\n-- Wearing a night splint, a simple brace that holds the foot in a flexed position to keep the plantar fascia stretched during sleep\n\n-- Physical therapy, though some studies indicate that some PT practices such as ultrasound and whirlpool are not helpful\n\n-- Use of NSAID (non-steroidal anti-inflammatory) drugs such as ibuprofen and naproxen\n\n-- Corticosteroid injections into the heel, though this is controversial and should not be used repeatedly\n\n-- Backing off activities like running until the pain goes away, and then reinitiating them gradually\n\nAbout 90 percent of sufferers will get better with time.\nBut while inflammation can be involved in plantar fasciitis, it doesn't seem to be the cause, Duggal says.\nSo the hope is that platelet injections will stimulate healing without the damaging effects of shock-wave therapy.\nDuggal says foot specialists don't really know what causes the pain of plantar fasciitis.\n[Other centers use lower-energy shock waves over several treatments.]\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Cost is a major part of the story here and NPR doesn\u2019t gloss over it.\u00a0The cost of shockwave treatment\u00a0can range anywhere from $500 to several thousand dollars, NPR reports, and\u00a0usually is not covered by insurance.\u00a0NPR could have added some useful context\u00a0 by mentioning that\u00a0the shockwave machines themselves can be very expensive to purchase and operate.\u00a0This\u00a0can\u00a0create an incentive for physicians who have bought such a machine to promote\u00a0shockwave treatments to patients who may not need them. In addition, it\u00a0would have been helpful to know how this treatment\u2019s costs differ from those of other common treatments. \u00a0\u00a0", "answer": 1}, {"article": "For more information about the study contact ket.study@unsw.edu.au or call 02 9382 9509.\n\"Not only was ketamine well-tolerated by participants, with none experiencing severe or problematic side effects, but giving the treatment by a simple subcutaneous injection (a small injection under the skin) was also shown to be an acceptable method for administering the drug in a safe and effective way.\"\nAs part of the double-blind, placebo-controlled trial, an active control treatment which causes sedation similar to ketamine, was used to substitute for one of the treatment sessions.\nPrevious studies into ketamine treatments for older people with depression - which are limited to just five case reports - show mixed success, with findings limited by small sample sizes.\nFollowing the RCT, participants also received 12 ketamine treatments in an open-label phase to investigate the effectiveness of multiple doses of ketamine.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release didn\u2019t mention the cost of ketamine infusion therapy. Another way to address costs in the release would have been to include a discussion of the medical and social costs of depression.", "answer": 0}, {"article": "Among them: engaging in regular physical activity, maintaining a healthy weight, and not smoking cigarettes.\nMany other strategies will also reduce the risk of cancer, he says.\nEven so, he says, \"our results provide additional support for the potential benefit of daily aspirin for [reducing] cancer mortality.\"\nThe benefit, however, may not be as great as believed, says researcher Eric Jacobs, PhD, of the American Cancer Society.\nThe new analysis is published in the Journal of the National Cancer Institute.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The cost of aspirin is not in question.", "answer": 2}, {"article": "For more about corneal transplants, try the U.S. National Library of Medicine.\nGriffith said a German study recently found that donated corneas cost about $2,500.\nThe next step in research, Griffith said, is to create a \"new generation\" of cornea implants and test them on a wider variety of patients.\nIn the new study, researchers tested corneal implants that are \"biosynthetic,\" meaning they're created with the help of living tissues.\nArtificial corneas are another option, but they're difficult to implant into the eye and can cause side effects, the researchers said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "This is the only story of the three reviewed to discuss costs. As for cost, Griffith said the biosynthetic corneas \"in theory\" should be cheaper than donated corneas. Griffith said a German study recently found that donated corneas cost about $2,500.", "answer": 1}, {"article": "Unlike some other organs in the body, such as the liver or skin, the brain does not regenerate new connections, blood vessels or new tissue structures.\nThe mice with new neurons showed improved motor behavior, though the exact mechanism wasn't clear.\nThe study was supported by funds from the National Institutes of Health.\nThe gel was eventually absorbed by the body, leaving behind only new tissue.\nThe brain has a limited capacity for recovery after stroke and other diseases.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The featured treatment is a gel in developmental phase. The price is likely unknown, and not including it seems reasonable.", "answer": 2}, {"article": "CHICAGO (Reuters) - Pathway Genomics, a company known for pushing the boundaries of direct-to-consumer genetic testing, on Thursday will launch a cancer screening test designed to detect bits of cancer DNA in the blood of otherwise healthy people.\nSeveral oncology experts said liquid biopsy tests like Pathway\u2019s, while exciting, still require large clinical studies proving they help people beat cancer through early detection.\nThe company is focusing on mutations that are relatively well-understood, and for which there are specific treatments, said Chief Executive Jim Plante.\nRoche-backed Foundation Medicine Inc, Genomic Health Inc, Illumina Inc and Sequenom Inc say they have similar tests in the works.\nDoctors, however, need an indication of how many patients will get a false positive result, something that can only be determined in a very large clinical trial, said Vogelstein.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story mentioned the cost of the test, but the competing Bloomberg story gave a more detailed breakdown of costs. There was\u00a0no mention of insurance coverage, or of total costs of work ups of positive tests and the need for continual testing.", "answer": 1}, {"article": "Many pregnant women who have symptoms of depression worry that taking antidepressants might harm their unborn babies -- so they stop taking their medications, say researchers at the Stanford University School of Medicine.\nThe study included 150 pregnant women diagnosed with major depressive disorder.\nAcupuncture might be a useful alternative, they say, because a study of pregnant women shows that the procedure works in reducing depressive symptoms better than other non-pharmacological techniques.\nRemission rates were not significantly lower in the depression-specific acupuncture group compared to the other two groups.\nSome received depression-specific acupuncture treatments, others had needles inserted in acupuncture points not known to relieve depression, and a third group received massage therapy.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There was no discussion regarding the cost of acupuncture, a particularly important omission since acupuncture is not covered by all insurance companies.\u00a0\u00a0\u00a0\u00a0 ", "answer": 0}, {"article": "People with Type 2 diabetes get an earful of grim lectures about their health prospects and endure much hardship to manage their condition well. But new research offers those who do so a rare reward. A glass of wine every day not only won't hurt, says a new study: It can actually improve cardiac health, help manage cholesterol and foster better sleep.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not report the cost of wine or mineral water, but these drinks are so commonplace that it seems reasonable to assume that readers already know what they cost. So we\u2019ll rate this Not Applicable, but we\u2019d note that a\u00a0typical bottle of wine is 750 ml, which is 5 servings of 150 ml (about 5 oz) that were \u2018prescribed\u2019 in the trial. \u00a0Although the cost of a moderately priced bottle (say $10) every 5 days is not huge, this could be a burden for some people on a fixed income. \u00a0A better choice for them might be more fresh vegetables.", "answer": 2}, {"article": "As we cut calories and lose weight, our resting metabolic rate eventually slows and our bodies become less efficient at shedding mass in a process known as adaptive thermogenesis.\nAnd while it\u2019s common to regain a few pounds after returning to previous eating habits, the two-week dieters kept the pounds off, maintaining a nearly 18-pound loss six months after the study.\nThe experimental group stuck to the eating plan for two weeks, before ditching the diet for two weeks.\nFor the small study just published in the International Journal of Obesity, the team enlisted 51 obese men from the ages of 25 to 54 years old.\nThe dieters ate enough calories to maintain their weight during the off period.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No information was included about the nature of the two diets involved in the study or their costs. Readers might want to know if pre-packaged meals were involved, or liquid meals, for example.\nAs we found after reading the study, the food intake of the dieters was highly controlled, and this would presumably cost money to mimic in real life:\n\u201cMeals were prepared by a commercial kitchen under the direction of a dietician and delivered to the participants homes each week.\u201d", "answer": 0}, {"article": "Nov. 22, 2010 -- Exercising to piano music may help improve balance and prevent falls among the elderly.\n\nA new study shows older men and women who participated in a piano-music-based exercise program were less likely to suffer a fall than those who didn't. Those who exercised to piano music also showed improvements in balance and the manner or style of walking.\n\n\u201cEach year, one-third of the population 65 years and older experiences at least one fall, and half of those fall repeatedly,\u201d write researcher Andrea Trombetti, MD, of University Hospitals and Faculty of Medicine of Geneva, Switzerland, and colleagues in the Archives of Internal Medicine. \u201cExercise can counteract key risk factors for falls, such as poor balance, and consequently reduce risk of falling in elderly community-dwelling individuals.\u201d\n\nResearchers say a large proportion of falls in elderly people occur while walking, so improving gait and balance can have a major impact on fall prevention.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not mention costs. A web search of programs offered in the U.S. show prices ranging from a $200-1000 for a series of sessions which may last several months and include music instruction. \n", "answer": 0}, {"article": "Examining more than 500,000 Facebook posts from both groups, researchers determined which words, post lengths, frequency of posting and timing of posts were most associated with a depression diagnosis. They found people with depression used the words \"I, my, and me,\" as well as such words as \"hurt, tired, and hospital,\" more often than others in the months preceding their diagnosis. Using indicators such as these, they built a computer model that could predict which people would receive a depression diagnosis with comparable accuracy to commonly used clinical surveys.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "This work is early in its development and the story makes that clear.\nHowever, it would still be worthwhile to raise some questions: Who would pay for the development of future modeling tools? Who would pay for the training necessary to make these tools useful to health care providers? Who would pay for the time that health care providers would have to put into the work? None of these things would happen in a vacuum, and it would be useful to raise these issues.", "answer": 2}, {"article": "\"At the end of the day, our findings might modestly over - or under-estimate the health burdens,\" he told us.\nAnd eating more \u2014 or less \u2014 of just 10 types of food can help raise or lower the risk of death from these causes, the researchers found.\nBut, here's the flip side: The researchers also found there's a significant risk in eating too little of certain healthy foods.\n\"This is a remarkable burden, nearly 1,000 deaths each day\" linked to dietary habits, says senior study author Dariush Mozaffarian, dean of the Friedman School at Tufts.\nSo, changing Americans dietary habits could have a significant impact, the authors argue.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story addresses cost at both the individual and societal level, noting that poor diets are \u201clinked to billions of dollars in healthcare spending. For instance, diabetes costs the U.S. $245 billion a year. In the U.S., a women with diabetes incurs, on average, about $283,000 in lifetime health care costs. (Many cost studies don\u2019t separate Type 1 and Type 2 diabetes.).\u201d That\u2019s helpful context..\u00a0", "answer": 1}, {"article": "Then the researchers, led by Dr. Frank Hu of the Harvard T.H.\nThat is, each year, coffee would be keeping 1 person in 1,000 from dying.\nThis same Nurses Health Study, for instance, infamously found a correlation between post-menopausal hormone therapy and lower risk of cardiovascular disease and death, here and here.\nBut given the 2013 research suggesting \u201ctoxicity of high coffee doses\u201d in some people, he said, \u201cto me the most reasonable approach would be to keep coffee intake to two to three cups most days.\u201d\n\nSecond Take: STAT knows better than to get between coffee lovers and their cup o\u2019 joe, so if you want to take this study as permission to keep beating a path to your Keurig, we\u2019re not going to slow you down.\nIf you do want to infer causation from this latest study, know that drinking coffee reduced the absolute mortality risk from 6.8 deaths a year per 1,000 people to, at best, 5.8.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Arguably, most people know how much their java habit costs them every day, and neither this STAT story nor the competing CNN coverage mentioned costs. Like hazelnut cream, some mention of the overall cost of the coffee habit in the U.S. would have added some flavor, but this omission gets a pass.", "answer": 2}, {"article": "Acute myeloid leukemia (AML) is a rapidly progressing cancer of the blood characterized by the uncontrolled proliferation of immature blast cells in the bone marrow.\nVYXEOS was also granted Fast Track designation for the treatment of elderly patients with secondary AML.\nThe trial met its primary endpoint demonstrating a statistically significant improvement in overall survival.\nFurthermore, approximately half of those patients are considered suitable for intensive treatment.\nEven with current treatment, overall survival for AML is poor.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There was no discussion of the costs of the treatment.", "answer": 0}, {"article": "We're sorry, but we seem to have lost this page.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There is no mention in this story of costs, which is a shame. CTs are the preferred diagnostic tool right now and, apparently, are widely used. A switch to MRIs would not only mean the purchasing of a lot of new equipment but also staff training, new protocols and new drugs and dyes to be administered. Are we talking about an extra $1,000 per person? $5,000? More? The reporter spoke with two local medical institutions and could have asked both of them what it costs to buy both sets of equipment and what it costs to administer the exams.", "answer": 0}, {"article": "Researchers said they had identified a family of retroviruses in patients with chronic fatigue syndrome, opening up a potentially promising new avenue of treatment for a debilitating disease that afflicts as many as four million Americans and 17 million people world-wide.\n\nThe finding will likely spur patients with the condition to seek treatment with drugs used to fight HIV, the virus that causes AIDS. Although HIV and the newly identified virus group are different, they are both retroviruses.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story did not discuss the cost of treating chronic fatigue patients with antiretroviral drugs, which are extremely expensive.\u00a0 As one of our medical editors wrote, \"Anti-retroviral drugs are not benign, either clinically or financially.\" ", "answer": 0}, {"article": "Of the men who had a raised platelet count of the same value or higher six months after being diagnosed with thrombocytosis, 18.1% developed cancer, while for women the figure was 10.1%.\nThat, say the researchers, makes testing for raised platelet count a valuable tool, and could speed up cancer diagnosis by at least three months for thousands of patients a year.\nBut it remained unclear whether the condition could signal an increased risk of all cancers, and how it ties in with factors such as age and sex.\n\u201cThis work should begin to change practice, so that GPs should be testing patients with raised platelet counts for cancer, especially those without other potential cancer symptoms,\u201d he added.\n\u201cThis is an excellent study that demonstrates the potential for a commonly used blood test to identify some patients with cancer earlier,\u201d he said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Blood testing costs vary widely, but can run to hundreds of dollars, even for those covered by national or private health insurance. Moreover, there are likely even heavier costs associated with follow up cancer screenings and tests for those considered at risk because of thrombocytosis. The article makes no mention of potential or actual costs, and one suspects that a quote from a UK health information officer may have had costs in mind when she said \u201cmeasuring platelet count in patients who don\u2019t otherwise warrant a blood test is not necessarily a good idea. But if a patient has a blood test for another reason and a high platelet count is found, then one of the possible diagnoses doctors should consider is cancer.\u201d", "answer": 0}, {"article": "Although surgeons can also take X-rays during the posterior procedure, it is much more difficult, and they wait until patients are in the recovery room, where, Bollinger says, \u201cthere\u2019s not much that can be done.\u201d He explains that while the body \u201ctolerates an imperfect alignment pretty well, if a new hip gets dislocated, it\u2019s often because it\u2019s not in perfectly.\u201d\n\nRobert Saunders, a nurse at Alta Bates Summit Medical Center in Berkeley, Calif., sees about 200 hip replacement patients a year.\nMany patients aren\u2019t aware of the option.\nAccording to those who use this anterior technique, the benefits are substantial.\nUnger says that most surgeons have used the posterior approach for years, have fine results, and see no need to switch.\nMichael Bollinger, who operates at Palm Drive Hospital in Sebastopol, Calif., switched methods a few years ago.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There is no mention of costs.", "answer": 0}, {"article": "\u201cIt was a little humiliating, to be honest,\u201d she said of the testing.\nThe preoperative \u201cevaluation\u201d is a fishing expedition of sorts, in which doctors sink an array of electrodes through the top of the skull and wait for a seizure to occur, to see whether it\u2019s operable.\nAll the while, the scientists monitored a handful of \u201chot spots\u201d in the brain which, previous work had shown, were strongly related to memory encoding.\nEach participant carried out the word-memorization tests repeatedly, with different words every time; some lists were memorized with brain stimulation, and other lists with no stimulation, which served as a control.\nThis approach \u2014 called direct neural recording, and piggybacking entirely on the clinical placement of the electrodes \u2014 has become the leading edge of research into the biology of human memory.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story could have noted how much it typically costs to implant electrodes in the brain of a patient. According to the University of Michigan, deep brain stimulation implants and surgery can cost \u201cabout $30,000 plus physician and MRI fees.\u201d Meanwhile, the National Parkinson Foundation states the all-in cost can reach $50,000 and sometimes up to $100,000 (e.g. for implants on both sides of the brain).", "answer": 0}, {"article": "However, men who took three pills daily were more likely to suffer mild to moderate diarrhea: 14% vs. 2% of those who took one pill.\nAt the start of the study, the men's PSA levels were doubling every 12 months.\nThe study was presented at the Genitourinary Cancers Symposium.\nThe new study involved 92 men with cancer that had not spread beyond the prostate and rising PSA levels.\nAfter six months of taking the capsules, it took 19 months for their PSA levels to double.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No discussion of costs for pomegranate-containing products.", "answer": 0}, {"article": "Screening patients for heart disease with a heart-imaging test prompted greater follow-up care but had little to no effect on the number of heart attacks and other cardiovascular events in those patients, a new study found.\n\nResearchers at Johns Hopkins Hospital in Baltimore led the study, which was published online Monday in the Archives of Internal Medicine.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story provided information about the costs for the test.", "answer": 1}, {"article": "A recent study has found evidence suggesting text messages could reduce one\u2019s odds of a second heart attack.\n\nA six-month clinical trial in Australia found that patients recovering from a heart attack were more likely to maintain lower blood pressure, less body fat and lower cholesterol levels than a control group when the patients received text messages asking and giving suggestions about their health routines. Patients receiving the texts also were more likely to be active and to quit smoking than the patients in the control...", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Although the peer-reviewed study on which this story seems to have been based on makes the point that text messages could offer a low-cost strategy for reducing the chances of subsequent heart attacks, the story does not reflect on cost.", "answer": 0}, {"article": "...\nNational Institutes of Health officials say they launched the study because there has never been any evidence that the practice is effective or safe.\nStephen Kopecky, a Mayo Clinic cardiologist who participated in the trial, says he's also concerned about the reliability of its findings.\nThe study was temporarily halted in 2008 because of concerns over ethics and patient safety.\nUnder the best of circumstances, that's not a strong result, says anesthesiologist Kimball Atwood of Newton-Wellesley Hospital in Massachusetts, who has followed the study from its beginning.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story says that chelation therapy costs about $5000 out of pocket.", "answer": 1}, {"article": "The monthly, peer-reviewed Journal of Clinical Sleep Medicine is the official publication of the American Academy of Sleep Medicine, a professional membership society that improves sleep health and promotes high quality, patient-centered care through advocacy, education, strategic research, and practice standards.\nThe improvements were more robust in those who were adherent to PAP therapy.\nThe study is published in the Nov. 15 issue of the Journal of Clinical Sleep Medicine.\nThe American Academy of Sleep Medicine previously identified quality of life as one of three sleep apnea outcome measures that clinicians can track to optimize care for adult patients.\nResults show that there were significant and clinically meaningful improvements in general quality of life and sleep-related quality of life measures after the initiation of PAP therapy for sleep apnea.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Despite touting the benefits of CPAP, the news release made no mention of the costs of CPAP home machines. These machines aren\u2019t cheap\u2013a quick internet search shows that they can run anywhere from $500 to over $1,000, not including other necessary equipment such as face masks and cleaning supplies. While the National Sleep Foundation says that most insurance policies cover CPAP machines, it is likely that someone buying a machine will still have to pay a hefty out-of-pocket sum. This could prove to be an obstacle to many seeking treatment, especially people from lower socio-economic backgrounds.", "answer": 0}, {"article": "Older age and African-American race are risk factors for colon cancer, and there is evidence linking obesity and a sedentary lifestyle to the disease as well.\nAmong these women, HRT use was linked to a 55 percent lower risk of the disease versus non-use.\nHenderson\u2019s team also found that the beneficial effect of HRT was stronger among women who had had a first-degree relative diagnosed with colon cancer.\nThe findings, reported in the American Journal of Epidemiology, support the theory that estrogen offers some protection against colon cancer.\nAs a result, experts now advise that while HRT is effective at relieving menopausal symptoms \u2014 like hot flashes and vaginal dryness \u2014 women should take it at the lowest dose and for the shortest time possible.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The cost of hormone replacement therapy is not in question.\u00a0 ", "answer": 2}, {"article": "\"Previous patients got sick, but it wasn't clear at the time whether it was due to the T cells or an infection,\" said pediatric oncologist Stephan Grupp, who oversaw Emily's care at Children's Hospital of Philadelphia. \"Now we know the main reason they were sick was the cells. But now we can intervene. She taught us.\"", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story did not mention costs. While it\u2019s too early for an exact figure, we know that this sort of treatment with tailoring the patient\u2019s own cells is very expensive. The competing NY Times story went into detail on costs, reporting:\n\u201cBut such drugs tend to be extremely expensive. A prime example is the Novartis drug Gleevec, which won rapid approval in 2001 for use against certain types of leukemia and gastrointestinal tumors. It can cost more than $5,000 a month, depending on the dosage.\nDr. June said that producing engineered T-cells costs about $20,000 per patient \u2014 far less than the cost of a bone-marrow transplant. Scaling up the procedure should make it even less expensive, he said, but he added, \u201cOur costs do not include any profit margin, facility depreciation costs or other clinical care costs, and other research costs.\u201d", "answer": 0}, {"article": "However, \"I don't want women who chose mastectomy to think they did the wrong thing,\" Hwang said.\nThe findings may reverse the mastectomy trend, said Dr. Laura Kruper, co-director of the breast oncology program at the City of Hope Comprehensive Cancer Center in Duarte, Calif., who was not involved in the study.\nThe study is scientifically sound in many ways, Kruper said.\nHwang believes the study does arm women with valuable information.\nThe study was observational, Hwang stressed.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There was no discussion of the differences in cost between the two options.", "answer": 0}, {"article": "\"Just telling people to do things doesn't work,\" says Sean Duffy, CEO of Omada Health.\nNot every Omada Health participant makes the progress they're aiming for.\nAnd he says the convenience of having the program delivered on a smartphone was key, too.\nThat's promising, because there's evidence that a 7 percent body weight loss cuts the risk of developing diabetes by about 60 percent.\nThere is some evidence that these kinds of programs are working.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No mention of cost in an article about a technology-based treatment program for improving diet and exercise. Readers learn that one person received a body weight scale when he signed onto the program, which raises a big question \u2014 how much does this program cost? What happens cost-wise if you don\u2019t succeed? The program includes personal coaching as well. We always want health stories to mention costs, and for this story on a new, relatively untested weight loss plan, cost seems especially important.\nThe company\u2019s website doesn\u2019t make this information easy to learn either, but does mention that the cost might be covered by health insurance.", "answer": 0}, {"article": "The item you've requested, /cgi-bin/article.cgi?f=/n/a/2006/03/12/national/a180226S32.DTL&type=health, was not found.\n\u2022 the item no longer exists, or\n\u2022 there has been an error on the site.\n\nIf you feel the address you entered is correct you can contact us, mentioning the error message received and the item you were trying to reach.\n\nWe apologize for any inconvenience. From here, you can:\n\u2022 use the menu bar above\n\u2022 select an item from our site index below", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Cost of Plavix is included in the story. ", "answer": 1}, {"article": "In addition to Chang, other authors on the all-MD Anderson study include: Stephen Hahn, M.D., Ritsuko Komaki, M.D., Pamela K. Allen, Ph.D., Zhongxing Liao, M.D., Steven H. Lin, M.D., Ph.D., Daniel Gomez, M.D., James Welsh, M.D., Melenda Jeter M.D., James Cox, M.D., Michael O'Reilly, M.D., Ming Li, M.D.\nOf note, said Chang, no patients developed the most severe, or grade five, toxicities, as seen in patients who receive standard of care.\nToxic effects of treatment in both the acute and late settings also were analyzed.\nWhile the study's survival, recurrence rates and toxic effects are still favorable when compared to rates associated with the most advanced traditional photon radiation therapy, intensity modulated radiation therapy (IMRT), technology to diagnose and stage the disease, as well all treatment modalities have significantly improved.\nIn contrast, the historical OS rate with standard of care concurrent chemotherapy and traditional radiation was 16 months at the time when the study was designed.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "We\u2019re not talking about a few pills a day here. We are talking about ongoing expensive treatment for five years. The costs needed to be explained as well as whether those costs are typically covered by insurance, especially in the kind of political climate we are in now, where health care coverage is the subject of hot debate. It is important for studies such as this to begin addressing the cost of care.", "answer": 0}, {"article": "\"It's clearly muddying the waters,\" he said.\nBut Kopans noted that mammography is still the only test that has been proven to reduce the death rate from breast cancer and that this study should not divert attention away from that fact.\nIn other words, breast cancer screening was associated with a reduction in death -- but only accounted for 10 percentage points of the difference.\nBut since the advent of routine mammograms in the 1990s, the rate of death from breast cancer has dropped 30 percent, he observed.\nThe analysis, published in the Sept. 23 issue of the New England Journal of Medicine, raises new questions about the benefits versus risks of screening mammography and is already reigniting tensions over its frequency of use in the United States.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "This is a big one to miss. Mammograms usually are covered by insurance, but because of the conflicting guidelines, there is a concern that some insurance companies won\u2019t want to cover mammograms for women under 50. Also, if a woman doesn\u2019t have insurance and falls into the right demographic, they will need to foot the bill. It would not have been difficult to find out how much they cost and even to find someone to estimate how much is spent every year in the U.S. on mammograms.", "answer": 0}, {"article": "I think there is a greater capacity to be open-minded and let science dictate our conclusion, not politics,\u201d Grob said.\nGrob\u2019s study looked to see whether psilocybin could help ease some of the anxiety of dying cancer patients.\nThe treatments were given in random order and neither the doctors nor the patients were told which compound was administered.\nThe pilot study of 12 cancer patients was designed to prove that hallucinogenic drugs could be studied safely as a way to relieve the distress of advanced cancer.\nIt revives a promising field of study lasting from the 1950s to the early 1970s that suggested some patients experienced powerful and sustained improvement in mood and anxiety from hallucinogens.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There would have been two ways to approach costs in this case. The first would be to ask\u00a0local, state or federal law enforcement sources for\u00a0ballpark estimates of the street value of the drugs involved. The second would be to ask the researchers how much they spent to obtain the drugs.", "answer": 0}, {"article": "Our technology keeps the cells in the body under immune surveillance, so immune suppression is not necessary,\" said Sen, who also is executive director of Ohio State's Comprehensive Wound Center.\nWith this technology, we can convert skin cells into elements of any organ with just one touch.\nTNT doesn't require any laboratory-based procedures and may be implemented at the point of care.\nThe procedure is also non-invasive.\nThe cargo is delivered by zapping the device with a small electrical charge that's barely felt by the patient.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There are no discussions of cost, but because this is a technology already being touted as a \u201cbreakthrough\u201d with wide applications costs should have been broached as part of the description.", "answer": 0}, {"article": "BLOOMINGTON, Ind.\n\"While concerns about prescribing medications to treat ADHD that have the potential for abuse are understandable, this study provides further evidence that the use of these medications is not associated with increased risk of substance use problems in adolescence or adulthood,\" Quinn said.\nThe results, based upon nearly 3 million people with ADHD in the United States, are reported in the American Journal of Psychiatry.\n\"The results also highlight the importance of careful diagnosis and compliance with treatment.\"\n\"Rather, this and other recent studies find that the risk of such problems is lower during and after periods of use of these medications.\"\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There was no discussion of costs. It would have been helpful to include the average cost of ADHD drugs with and without insurance. A 30-day supply of generic Adderall averages $25, according to GoodRx.", "answer": 0}, {"article": "\"We have the side view and the back view,\" said Kaufman.\nSuch highly specific screening may allow doctors to detect more abnormal growths, called polyps, when they are as small as .10 mm, so they can be removed before they become full-blown cancer tumors.\nMore routine DNA tests and stool sampling, which show signs of bleeding caused by irregular growths, can also help detect colon polyps and indicate that the need for a full colonoscopy.\nIt may need to be followed with the physical colonoscopy later, as well.\nRegular colonoscopy physically examines the colon by inserting a lighted probe into the intestine and requires a sedative.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Cost should always be a consideration in a discussion of a new technology. Screening tests are no exception There are approximately 100 million adults in the US over the age of 50 years according to the 2010 census report. That is a lot of screening, and the financial implications can loom very large. Although the cost of the test, in this case virtual colonoscopy, is important, it is only one piece of the equation. The removal of suspicious lesions cannot be done in the virtual world, so suspicious lesions identified virtually would require a physical colonoscopy, adding to the overall cost. According to the\u00a0\u00a0Colon Cancer Alliance, a CT colonoscopy costs between $400 \u2013 800. This cost is not covered by Medicare and most commercial insurance companies.", "answer": 0}, {"article": "An experimental drug has proved effective at treating an aggressive form of breast cancer in patients who aren't responding to the widely used drug Herceptin, giving hope to women with otherwise limited treatment options, said drug maker GlaxoSmithKline PLC, presenting the results Saturday at the American Society of Clinical Oncology meeting in Atlanta.\n\nWhen taken with a standard chemotherapy treatment in a clinical study, the new drug, Tykerb nearly doubled the time to 8.5 months before the average patient's breast cancer...", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not mentioned the proposed cost of lapatinib.", "answer": 0}, {"article": "Given in the abdomen, AMG145 reduced low-density lipoprotein (LDL) cholesterol levels among a group of healthy volunteers.\nFormer AHA President Dr. Ralph Sacco said that it is too early to make any predictions about what role, if any, this therapy will have in lowering cholesterol levels, but it could one day fill an important void.\nThe new drug did hit its target, PCSK9, and decreased levels of LDL cholesterol by up to 64 percent.\nThe study was funded by AMG145 manufacturer Amgen Inc.\n\nHigh cholesterol is a major risk factor for heart disease.\nNow, researchers are testing the new shot in people who have high cholesterol.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story did not mention\u00a0costs. This is an important deficiency,\u00a0since\u00a0drugs like AMG 145, which are called\u00a0monoclonal antibodies, are typically among the most expensive drugs in the world and are an important source of rising health care expenditures.", "answer": 0}, {"article": "Some see Qnexa as a test of the FDA trying to recalibrate how it weighs risks and benefits for weight-loss drugs.\nThe setbacks put a spotlight on how the FDA handles these drugs.\nBut some say the agency's aversion to accepting any risks is outdated.\nAs the FDA works through this, many are watching how the agency handles Qnexa.\nQnexa's rejection came amid a flurry of failed attempts by drug companies to win approvals of new weight-loss drugs.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No mention of Qnexa\u2019s cost. As the New York Times reported, \u201cThrough a regulatory loophole of sorts, many obesity doctors prescribe two separate drugs that, when taken together, are essentially the same medicine.\u201d So, at least some estimate of the cost of those components could have been given.\u00a0 Or analysts could have helped project what expected Qnexa costs would be.", "answer": 0}, {"article": "Complications can include fluid buildup around the heart, called cardiac tamponade, which makes it difficult for the heart to pump blood.\n\"Of concern is that complication rates are still higher than desirable for this procedure, and there was suboptimal use of stroke-preventing anticoagulation [anti-clotting] therapy after the procedure,\" added Fonarow, who was not involved with the study.\nAtrial arrhythmias in the first three months after ablation were classified as early recurrences and not considered as failures, Arbelo said.\nHe said, \"Relief of symptoms in patients with atrial fibrillation can be challenging.\"\nAblation was successful in 74 percent of patients, Arbelo said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does mention the procedure is often covered by insurance. But it didn\u2019t discuss the costs without insurance (or to the health care system). Estimates put it at roughly $10,000 for the procedure, and quite a bit more once hospital costs are factored in.", "answer": 0}, {"article": "New research analyzing more than 22,000 U.S. cases of aortic aneurysm repair is likely to hasten the trend toward more procedures being done with a device called a stent-graft instead of the typical surgery that requires up to eight weeks of recovery.\n\nThe study by doctors at Harvard Medical School and the federal Centers for Medicare and Medicaid Services found the death rate in surgery, 4.8%, was four times that of the 1.2% death rate in placing stent-grafts to seal off the aneurysm. Surgery tended to provide a more permanent...", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There was no discussion of costs associated with either procedure.", "answer": 0}, {"article": "\"Now they tell me, 'You never say 'What?'\nOften, it meant only being able to do one thing at a time, explained the mother of three young children.\nThe implant is permanent.\nEven with one implant, Merlo called the results \"surreal.\"\nIt contains a battery that must be replaced in about seven years.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No discussion of costs. Cost of any new device is important as is insurance coverage.\u00a0 Neither are addressed in the story, an oversight we find difficult to understand.\u00a0 According to the manufacturers website the cost of the surgery and the device in $33,000.\u00a0 Insurance does not cover the device at the moment.\u00a0 The battery, said to need replacing every 7 years, costs approximately $6,000 and may need to be performed as early as every 3 years depending on usage per day and other factors.\u00a0 Again, these costs are not covered by insurance.", "answer": 0}, {"article": "Prescribing testosterone for age-related deficiency \u2014 which is only vaguely defined \u2014 took off in 2000. The trend was driven not by solid scientific evidence, but by the introduction of convenient, rub-on testosterone products, the first being Androgel. Many men are put on testosterone with no tests of their levels or despite tests showing normal levels, a study of Medicare claims found.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Although this article\u00a0mentioned that rub-on testosterone products are readily available, it did not explicitly mention the cost of those products, or compare them to existing, approved treatment for anemia and low bone density in men.", "answer": 0}, {"article": "No doubt you have heard that yogurt is teeming with bacteria--and no doubt you try not to think about that as you dig into a cup of the stuff. Yes, they're supposed to be good bacteria, ones that not only don't make you sick but actually improve your health. Still, a spoonful of critters with unlovely names like Lactobacillus reuteri, Lactobacillus rhamnosus and Bifidus regularis will never sound like a palate pleaser to even the most dedicated health nut.\n\nWhether or not you've ever developed a taste--or even a tolerance--for living things in your lunch, more are on the way. Food...", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There was no mention of the costs of probiotic containing products; there was no discussion of whether there is any sort of price differential between traditional products and those to which probiotics or additional probiotics have been added.", "answer": 0}, {"article": "The researchers thank the Biotechnology and Biological Sciences Research Council (Grant 324594, Systems Biology studentship for J.M.H.\nThe research could also lead to substantial improvements in cancer survival rates, suggests co-researcher Dr Isolda Romero-Canelon:\n\n\u201cCurrent statistics indicate that one in every two people will develop some kind of cancer during their life time, with approximately one woman dying of ovarian cancer every two hours in the UK according to Cancer Research UK and two deaths every hour from bowel cancer.\n\u201cIt is clear that a new generation of drugs is necessary to save more lives and our research points to a highly effective way of defeating cancerous cells\u201d.\nThis can lead to a wide-range of side-effects from renal failure to neurotoxicity, ototoxicity, nausea and vomiting.\u201d\n\n\u201cExisting platinum-based cancer treatments often become less effective after the first course, as cancer cells learn how they are being attacked, but our new osmium compound with its different mechanism of action, remains active against cancer cells that have become resistant to drugs such as Cisplatin\u201d.\nOur new compounds work by attacking the energy balance in cancer cells\u201d.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release speculates that FY26 could be cheaper to produce than platinum-based chemotherapy drugs. That may well be true, but the release didn\u2019t provide any evidence or reasoning as to why this would be the case. Nor does it explain that cheaper \u201cproduction\u201d might not mean cheaper pricing for patients. We know that platinum is expensive, but then again new drugs are typically far more expensive than existing generic treatments. We\u2019d need more than a general claim that the drug \u201ccould be cheaper\u201d to award a Satisfactory rating here.", "answer": 0}, {"article": "Paul J.D.\nThe techniques developed by the interdisciplinary team can be used by dermatologists and will reduce safety concerns in laser dermatology by improving laser transmission through surface layers of the skin.\nWhiteside, a doctoral candidate in the MU Division of Food Systems and Bioengineering, devised a system that will not only improve the process, but will be safer for both clinicians and patients.\nThe team is in the planning stages of developing a start-up company to commercialize the technique.\nThe sonoillumination research was funded in part by a 2015 Fast Track grant from the University of Missouri System.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "While it could be argued that the work on this combination laser-ultrasound device is at too early a stage to demand a comparison to the cost of existing laser devices, a quote in the release claims, \u201cwe\u2019re hopeful that the procedure will be available widely in the near future,\u201d which implies the developers must have some sense of how much their device might cost when they achieve their stated goal of commercialization.", "answer": 0}, {"article": "\u2022 Prostatectomy, the surgical removal of the prostate gland, which can be done with minimally invasive techniques and robotic assistance;\n\u2022 Brachytherapy, in which doctors implant numerous small radioactive seeds about the size of a grain of rice into the prostate gland using multiple large needles inserted through the skin in the operating room.\nOther clinical trials at the UTSW Department of Radiation Oncology are seeking to expand the application of SBRT to high-risk (Stage III) prostate cancer patients.\nDr. Timmerman, Director of Image-Guided Stereotactic Radiation Therapy, Medical Director of Radiation Oncology, and holder of the Effie Marie Cain Distinguished Chair in Cancer Therapy Research, has served as the lead investigator in several national trials designed to evaluate the efficacy and safety of SBRT to treat other types of cancer, including cancer in the lung, liver, and spine.\nThe study - the first trial to publish five-year results from SBRT treatment for prostate cancer - found a 98.6 percent cure rate with SBRT, a noninvasive form of radiation treatment that involves high-dose radiation beams entering the body through various angles and intersecting at the desired target.\nTo reduce the side effects associated with SBRT, current clinical trials at UTSW are using a unique and biodegradable rectal spacer gel to protect the rectum.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release does not discuss costs. We find this disappointing, but also ironic. In a very quick search, we discovered that one of the major topics regarding SBRT is its low-cost relative to the existing therapies. In the Journal of Oncology Practice, authors in 2012 directly compared it cost-wise to another method and concluded: \u201cSBRT for low- to intermediate-risk prostate cancer has great potential cost savings for our health care system payers and may improve access to radiation, increase patient convenience, and boost quality of life for patients.\u201d", "answer": 0}, {"article": "A new study has an intriguing finding: Advanced cancer patients who received early palliative care in conjunction with standard care for their disease not only reported better quality of life, but lived a few months longer than patients who received only standard care.\n\nThe research, published in the New England Journal of Medicine, included 151 patients diagnosed with metastatic non-small-cell lung cancer who were randomly assigned to one of those treatment plans. At 12 weeks, 86% of those who were still alive filled out assessments \u2026", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "This issue\u00a0is alluded to obliquely in the quote that ends the article,\u00a0which\u00a0suggests that\u00a0palliative care\u00a0may help address \"critical concerns regarding the use of health care services at the end of life.\" This is not\u00a0specific enough to satisfy the criterion.", "answer": 0}, {"article": "Nerve cells in the brain die, and in a few short years, children lose the ability to walk or talk.\nThey usually die within five years of diagnosis.\nFor the first time, doctors have used gene therapy to stave off a fatal degenerative brain disease, an achievement that some experts had thought impossible.\nThe patients were children who had inherited a mutated gene causing a rare disorder, adrenoleukodystrophy, or ALD.\nOne of medicine\u2019s greatest villains: HIV.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story tackles this issue head on, though what they report may not be comforting for those affected. Here\u2019s how they address the issue: \u201cThe results of the new study also give rise to a concern that is becoming a regular feature of gene therapy work and other new biotech therapies: How much will this treatment cost? Bluebird Bio is not saying\u2026[but one scientist involved in the study] expects the price to be similar to the hundreds of thousands of dollars it costs for a bone-marrow transplant.\u201d", "answer": 1}, {"article": "A rare form of blindness inched closer to a cure, after two groups published preliminary studies on replacing the bad gene that causes the condition. The results are likely to boost the prospects of gene therapy, a technique that shows promise but has yet to prove it can be used to cure many diseases.\n\nAbout 2,000 people in the U.S. have Leber's congenital amaurosis No. 2, caused when a child inherits a certain flawed gene from both parents. Patients with the bad gene can't make a protein that is supposed to nourish the eye's...", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Costs are not discussed but it is understandable that they might not be known after an experiment on only 6 people. ", "answer": 2}, {"article": "Lack of F.D.A.\nThere was a great need, the authors concluded, to \u201cimprove awareness of this important advice.\u201d\n\nThe fact that fish oil is also sold as a nutritional supplement has made it harder for some doctors to regard it as a powerful drug, experts said.\nThis summer, a critical review of existing research in BMJ, The British Medical Journal, \u201ccast doubt over the size of the effect of these medications\u201d for the general population, said Dr. Roger Harrison, an author of the paper, \u201cbut still suggested that they might benefit some people as a treatment.\u201d\n\nDr. Harrison said he believed that people should generally increase their intake of omega-3 acids, best done by eating more fish.\nThe fact that heart patients receive such different treatments in sophisticated hospitals around the world highlights the central role that drug companies play in disseminating medical information, experts said.\nMarylou Rowe, a spokeswoman for Reliant Pharmaceuticals, which owns the license for the drug in the United States, said that further trials of Omacor would be needed for it to be licensed for heart attack patients in the United States.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "This story did not discuss the costs of any of the means to increase dietary omega-3 fatty acid intake. ", "answer": 0}, {"article": "The median age was 75 years (range 41to 94).\nPatients were treated with SBRT for early-stage lung cancer between 2004 and 2014 and followed for a median of 1.7 years.\nThe study evaluated safety and efficacy outcomes of 1,083 patient reports collected in a multi-institutional database.\n\"In addition to providing important support for using SBRT to treat early-stage lung cancer in elderly patients, these findings highlight the value of multi-institutional collaborations and large data sets that can provide statistically meaningful answers to critical questions about treatment outcome and guide clinical decision making.\"\nElekta (EKTA-B.ST) today announced new data demonstrating stereotactic body radiation therapy (SBRT) is a safe treatment option for early-stage lung cancer patients aged 80 or older.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There are no costs mentioned in the release. There have been a number of studies on the cost-effectiveness of different radiation therapies, including SBRT.  ", "answer": 0}, {"article": ".\nOne for the Guys Men, too, have an option for a faster, less painful procedure than vasectomy to tie the vas deferens -- the tubes that carry sperm from the testicles to the penis.\nThe biggest drawback, Whitaker says, is the need for X-rays three months after the procedure to confirm the fallopian tubes are blocked.\nUntil then, the patient must use another form of birth control.\nWomen can undergo the procedure in 35 minutes in their doctor's office, under local anesthesia; they are advised to rest for 24 to 48 hours before resuming normal activity.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not mention costs of Essure compared to tubal ligation.", "answer": 0}, {"article": "Gluck et al.\nObesity 4 Nov.\n\nNIDDK Research Clinical Psychologist Marci Gluck, Ph.D., is available to comment on this study.\nMore study is needed to confirm the safety and effectiveness of tDCS for weight loss.\nThen for three days, they unknowingly received either active or sham (fake) transcranial direct current stimulation, or tDCS.\nOn each visit, the participants ate a weight-maintaining diet for five days.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The news release does not provide any information on what the experimental therapy, known as transcranial direct current stimulation, might cost if and when it is available to the public. We\u2019ll rate this Not Applicable because it\u2019s too early to know what it might cost and the release doesn\u2019t make it sound like the technology will be available imminently. However, we\u2019d note that a close cousin of this method, transcranial magnetic stimulation, is FDA approved for major depression and migraine. Sessions cost about $300 each and may include 20 or more sessions and run several thousand dollars. The release could have mentioned this.\u00a0", "answer": 2}, {"article": "\"We're always searching for simpler things to do,\" Brooks said.\nBrooks said it would be nice to have a very simple, accurate screening test -- whether that means a breath test or blood or urine tests.\nIt's all based on studies showing that breath samples from cancer patients tend to have a distinguishing pattern of so-called volatile organic compounds (VOCs).\nAnother big question, he added, is whether breath analysis could pinpoint people with colon polyps.\nNow, a small pilot study suggests such a test could be developed.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Costs were not mentioned, but since this test is in an early stage of development, it would be difficult to provide an accurate cost figure.\u00a0That figure would have to include both the cost of the test and any unnecessary follow-up tests and procedures\u00a0due to false-positive results. \u00a0We\u2019ll rule it not applicable.", "answer": 2}, {"article": "Ray added: \u201cThis is the strongest evidence yet that statins reduce the risk of heart disease and death in men with high LDL.\n\u201cThis legitimises current guidelines which recommend treating this population with statins.\u201d\n\nRay said people with lower levels of cholesterol, around 4mmol/L, who otherwise appear healthy, should also be treated with statins.\nResearchers from Imperial College London and the University of Glasgow found impressive results among those on statins, who were given the widely-prescribed type pravastatin.\nStatins cut the risk of dying from heart disease by 28% among men, according to the longest study of its kind.\n\u201cIt shows the enduring and long-term benefit of taking statins, including the extent to which they reduce the risk of dying from heart disease, which can only be seen in a study of this length.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Costs were not discussed. However, statins cost between roughly $313 (generic) to $1,428 (name-brand) per patient per year in the US, according to a 2012 study in Pharmacoptherapy. The costs are much less in the UK: $164 (generic) and $509 (name-brand) per patient per year.", "answer": 0}, {"article": "But at this stage, the company itself has been careful not to promote its device directly to consumers since its F.D.A.\nHourlong treatments are best spaced out by two months, said Dr. Dover, who charges $700 per spot.\nThat said, a doctor with a Zeltiq device isn\u2019t hard for patients to find.\nAfter reviewing Erchonia Medical\u2019s clinical study, Dr. Brian M. Kinney, a plastic surgeon in Los Angeles, said, \u201cI can\u2019t prove that it works.\u201d His concerns are that the tape measure method of gauging circumferential changes \u201cisn\u2019t consistently reliable.\u201d What\u2019s more, study participants and the placebo group were assessed only two weeks after their last treatment, not long enough to measure adequately whether results last.\nPart of the reason the device has made inroads during these strapped times is that doctors don\u2019t buy it outright, but pay per use.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story states the price for the Zerona device: $1,700 to $3,800 for six sessions. The price of Zeltiq is also reported but is not as clear:\u00a0We learn only that one doctor charges \"$700 per spot\"\u2013but not how many treatments are provided or needed, what constitues as \"spot,\" and so on.\u00a0 ", "answer": 1}, {"article": "\"I'm not sure I'd want to sign up for that one before I had longer-term results,\" Califf said.\nBut he echoed the thought that a longer-term and larger test is needed to determine the incidence of some possible major side effects, such as impotence.\nIf eprotirome does pass all the anticipated tests successfully, its use at first probably would be in combination with a statin, Angelin said.\nUse as a single drug treatment for elevated cholesterol levels could follow, first in selected patients, then more widely, he said.\nThe trial's researchers were careful to list indications of possible harmful side effects, such as a reduction in levels of HDL (\"good\") cholesterol, Califf said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There was no discussion of costs \u2013 not even a projection.\u00a0 If you can label something as an \"alternative to statins\" in the headline, then you can certainly at least project for readers what this \"alternative\" might cost.\u00a0 ", "answer": 0}, {"article": "Texas rep expects Trump to make case for a border wall at State of the Union\n\n\"We're going to keep working to secure the border, and not blink until we either get it done or the voters get to speak in 2020\"", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No costs are mentioned. According to the website for the STAR trial, the cost of raloxifene is about $75 per month, while tamoxifen costs about $100 per month. Because these drugs have to be taken for long periods of time, cost is an issue. ", "answer": 0}, {"article": "Autism is a spectrum disorder that includes repetitive behaviors and impairments in language, communication and social skills.\nThis test costs no more than a standard MRI, which runs around $1,500, Hirsch noted.\nFurther work is needed to refine the test, Hirsch added.\nHirsch noted the study is preliminary and, as such, has some limitations.\nThere are important limitations to the study, Adesman said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story deserves high marks for noting the high costs of an MRI. \u201cThis test costs no more than a standard MRI, which runs around $1,500, Hirsch noted.\u201d", "answer": 1}, {"article": "Psoriasis is a chronic autoimmune-related skin condition in which thick, scaly patches appear on the skin.\nFurther analysis showed those who lost the most excess weight a year after surgery showed the biggest improvements in their disease activity.\nAccording to the study's authors, the findings suggest that losing excess weight may improve symptoms in people who have these lifelong conditions.\nPatients who underwent surgery saw significant reductions in their disease severity scores at post-surgical follow-up -- according to a 0 to 10 rating scale -- with disease severity scores in patients with psoriasis dropping from 5.6 to 4.4, and scores falling from 6.4 to 4.5 for those with psoriatic arthritis.\nThe researchers found 55 percent of patients with psoriasis and 62 percent of patients with psoriatic arthritis reported improvements in their disease.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release contained no cost information related to bariatric surgery and its potential complications. Bariatric surgery has become commonplace but it is costly and carries risk. The release should have also mentioned the theoretical costs related to better symptom control for psoriasis sufferers who have undergone bariatric surgery. These could include a possible reduction in costs of anti-inflammatory drugs or other therapies.", "answer": 0}, {"article": "The Merck drug boceprevir and Vertex Pharmaceutical\u2019s similar drug telaprevir are expected to win FDA approval within months, following phase III trials showing that both drugs boosted cure rates to around 70% when used with standard therapy.\nThe drugs will be used in patients with HCV genotype 1 -- the hardest to treat form of the viral infection.\nAdding one of the drugs to the current two-drug regimen of peginterferon and ribavirin will make the treatment of hepatitis C more complex, but it will also cure a lot more people, hepatitis C specialist Donald M. Jensen, MD, of the University of Chicago Medical Center, tells WebMD.\n\u201cTriple-drug therapy represents a major advance in the treatment of hepatitis C for patients,\u201d he says.\nResults from two phase III boceprevir trials are published in the New England Journal of Medicine.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story merely quoted one hepatitis C specialist saying, \u201cThis is a very expensive drug, and I would imagine some insurance companies would not pay for it.\u201d\u00a0 But why not give specific cost estimates?\u00a0 Even a framework for what \u201cvery expensive\u201d\u00a0means.\nAs we wrote on our blog (a piece that commented on how inconsistently some journalists deal with drug cost information), \u201cIt\u2019s probably safe to say that the cost will be in the thousands per month. The costs of existing treatment is about $70,000 for 48 weeks of treatment.\u201d\nYou better believe that any company that expects drug approval within a month knows what its pricing will be.\nAlso, the story could have mentioned the specific cost of erythropoietin, since the trials found that many participants require it to combat the anemia that often results from the treatment.\n", "answer": 0}, {"article": "The quality of what you get can differ from one practitioner to another,\" said Manber.\nA response rate was defined as a 50 percent reduction in depression symptoms, Manber said.\nBut, she cautioned that \"acupuncture is not a substitute for the appropriate use of antidepressant therapy especially in women with a prior history of response to antidepressants.\"\nThe depression-specific protocol was designed just for this study, and the control acupuncture was specifically designed to avoid using acupuncture needles in any areas known to affect depression.\nMONDAY, Feb. 22, 2010 (HealthDay News) -- Women who experience depression during pregnancy may have another treatment option, new research suggests.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story makes no mention of costs or insurance coverage for acupuncture in the context of partum depression. Costs could be a significant barrier to getting the treatment for many women. The story points out that it is important that women are fully treated into remission, yet it makes no estimate of the cost of the full 12 sessions as described in the study.", "answer": 0}, {"article": "\u201cThe key question is, will the consumer view as credible that ingesting a pill will prevent (sun) damage?\u201d\n\nIn another experiment, Laboratoires Inneov scientists gave the tanning pill to 80 women and asked them to sunbathe as they normally would over the summer, applying sunscreen at their discretion.\nHe pointed out it was hard to draw any conclusions from this part of the study because it didn\u2019t include any data.\nOf more than a dozen researchers and dermatologists contacted about the quality of this study, only Schalock agreed to comment.\nAnd what if the company selling the product did the tests?\nWhat exactly did they tell Laboratoires Inneov?\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Costs not discussed and it could have been frosting on this story. ", "answer": 0}, {"article": "PHILADELPHIA - Patients with atrial fibrillation (AF), a rapid irregular heartbeat caused by pooling blood in the heart which can lead to heart failure and stroke, are often treated with an ablation, a minimally invasive procedure used to remove the tissue which causes the pooled blood.\n\"These are patients who were actively seeking, preparing for and are committed to the alternate treatment method, and who are informed about how to diligently and effectively monitor their pulse throughout the day.\"\n\"It is extremely common for patients with AF to seek treatment that does not involve the use of chronic oral anticoagulants therapy, as there are other risks associated with their long term use,\" said co-author Francis E. Marchlinski, MD, FHRS, director of Electrophysiology for the University of Pennsylvania Health System and Richard T. and Angela Clark President's Distinguished Professor in the Perelman School of Medicine at the University of Pennsylvania.\n\"This kind of approach to anticoagulation therapy requires an open line of communication between the patient and the care team, and calls for a specific type of patient.\n\"The goal of this study was to find a safe and effected treatment option, and our initial results support 'as-needed' blood thinners and pulse monitoring as the alternative.\"\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Since we don\u2019t know which drugs were used in the study we don\u2019t really have an idea what the costs, or costs savings would have been. Obviously if patients start taking their novel anticoagulants on an \u2018as needed\u2019 basis then a lot of money could be saved. These drugs, it should be noted, are typically a lot more expensive than warfarin, the current standard of care in AF.", "answer": 0}, {"article": "Ann Thorac Surg 2015;100:785-93. doi:10.1016/j.athoracsur.2015.05.021\n\nFull text of the article is available to credentialed journalists upon request; contact Cassie McNulty cmcnulty@sts.org at +1 312 202 5865\n\nAbout The Annals of Thoracic Surgery\n\nThe Annals of Thoracic Surgery is the official journal of STS and the Southern Thoracic Surgical Association.\nAs part of the PARTNER-I trial, Vinod H. Thourani, MD, from Emory University in Atlanta, and colleagues from 12 other institutions in the United States found that transcatheter aortic valve replacement (TAVR) is a safe and effective way to treat aortic stenosis in nonagenarians who qualify for the surgical technique.\nOur study shows that age alone should not preclude referral for TAVR in patients age 90 years and older.\"\n\"Compared with an age-sex-race-matched US population, the TAVR patients had a comparable risk of mortality, and quality of life improved within 6 months of the procedure.\nWhile the current study did not evaluate other alternative options for TAVR, these techniques may include transaortic, transcaval, transcarotid, or trans-subclavian.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release does not mention cost or that this requires hospitalization. The article highlights that patients spent on average 5 days in the hospital.", "answer": 0}, {"article": "This is in line with some of our recent studies which indicate that the GI tract microbiome in Alzheimer's is significantly altered in composition when compared to age-matched controls, and that both the GI tract and blood-brain barriersbecome significantly more leaky with aging, thus allowing GI tract microbial exudates (e.g.\nIn a new clinical trial, scientists show that a daily dose of probiotic Lactobacillus and Bifidobacterium bacteria taken over a period of just 12 weeks is enough to yield a moderate but significant improvement in the score of elderly Alzheimer's patients on the Mini-Mental State Examination (MMSE) scale, a standard measure of cognitive impairment.\nFuture research, on more patients and over longer time-scales, is necessary to test if the beneficial effects of probiotics become stronger after longer treatment.\nIn mice, probiotics have indeed been shown to improve learning and memory, and reduce anxiety and depression- and OCD-like symptoms.\nEven though this increase is moderate, and all patients remained severely cognitively impaired, these results are important because they are the first to show that probiotics can improve human cognition.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The cost of the intervention isn\u2019t mentioned, and there\u2019s no assessment of how the cost might compare with other medications prescribed to treat the cognitive symptoms of Alzheimer\u2019s disease. It should also be noted that this intervention, if it were available to purchase, would likely be a long-term, continual investment. Probiotic bacteria are known to be transient \u201cpassers through\u201d in the gastrointestinal tract, so a person would need to continue to purchase and consume the beverage for as long as they hoped to see results. Probiotics also tend to be relatively expensive, with the capsules now on the market typically costing about 50 cents to $1 per pill.", "answer": 0}, {"article": "Doctors who have turned surgery into a popular treatment for obesity are setting their sights on a burgeoning new market: diabetes patients.\n\nA growing amount of research suggests that bariatric surgery, which shrinks the stomach and sometimes reroutes the intestines, has a lasting effect on the most common form of diabetes, and not just because patients lose weight. Studies have found that more than 75% of patients with this type of diabetes who undergo the surgery see their disease disappear. They can go on to live diabetes-free...", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The report states that\u00a0the operation is costly, about $25,000, and that insurance coverage is not guaranteed. It also indicates that at this time surgery\u00a0purely to treat diabetes, not reduce body weight, is\u00a0unlikely to be covered.\nThe report adds useful context by\u00a0stating that\u00a0conventional diabetes care costs $10,000 per year.\u00a0", "answer": 1}, {"article": "CHICAGO (Reuters) - Two new drugs using very different scientific approaches can extend survival among patients with the deadliest form of skin cancer, offering the first new hope for real progress in many years.\nShe and others expect vemurafenib to be approved this year.\nThe five-year survival rate for the aggressive cancer is just 15 percent.\nBristol-Myers\u2019 Yervoy was approved in March for patients with inoperable or metastatic melanoma, based on a previous study which showed the drug given alone extended survival by four months in patients who had failed other treatments.\nDr. Paul Chapman of Memorial Sloan-Kettering Cancer Center in New York and the study\u2019s lead investigator called the results an \u201cunprecedented level of difference\u201d for patients with advanced melanoma, who typically survive just eight months on current treatments.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No discussion of costs \u2013 only of potential sales volume.\nIsn\u2019t the significant cost of both drugs worth at least one line a story like this?", "answer": 0}, {"article": "Heart disease is still the leading killer of Americans \u2014 790,000 people have heart attacks each year \u2014 and stenting is a mainstay treatment in virtually every hospital.\nThe devices are lifesaving when used to open arteries in patients in the throes of a heart attack.\nMore than 500,000 heart patients worldwide have stents inserted each year to relieve chest pain, according to the researchers.\nSometimes patients get stents when they have no pain at all, just blockages.\nTheir study focused on the insertion of stents, tiny wire cages, to open blocked arteries.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story says the procedure to insert stents costs from $11,000 to $41,000 in the U.S.", "answer": 1}, {"article": "Kisco, N.Y.\nMore of those undergoing lap-banding, however, needed repeat surgeries (13 percent vs. 2 percent).\nMore people in the bypass group had complications right after the surgery.\nAnd certain procedures may still be preferable for certain patient populations, added Roslin, such as bands for patients with lower BMI who don't have so many metabolic challenges.\nThere are various theories to explain why gastric bypass may be superior, including one that attributes the success to changes in hormones that control the metabolism of blood sugar.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story notes that the average cost of weight loss\u00a0surgery is about $30,000. It would have been helpful to include a comparison of the different procedures discussed in the story, but this is good enough.", "answer": 1}, {"article": "In an email, Gunter said she frequently prescribes high-frequency TENS (pulses between 50 and 120 hertz at a low intensity) to treat patients who suffer through their periods: \"I have done so for more than 15 years.\nJen Gunter, an OB-GYN and pain medicine specialist, noted that the idea of using TENS for menstrual pain is actually very sound.\nFor now, it's only possible to preorder the device (at a cost of $85) and wait six months for it to ship.\nGunter's main question about Livia is whether it will be significantly different from the already available and effective TENS devices, which usually cost around $35.\nHe explained that the key to the device is TENS (transcutaneous electrical nerve stimulation), those electronic nerve stimulators you've probably seen in strip malls that hook up to the body to treat neck or back pain.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "We were pleased to\u00a0see cost discussed\u00a0in the story. The story points out that the projected retail cost of the Livia device ($149) and the pre-order price ($85) is more than\u00a0similar devices (as low as $30 on Amazon).", "answer": 1}, {"article": "(Reuters) - U.S. health regulators said on Tuesday they approved a stent by Abbott Laboratories that is the first designed to be absorbed into the bloodstream after it is implanted.\n\u201cThere are no longer going to be permanent metal implants in the artery.\u201d\n\nAbsorb releases the drug everolimus to combat the growth of scar tissue that can form within a stent and cause the artery to narrow again, the U.S. Food and Drug Administration, which approved the stent, said.\nAbbott plans to roll out the device to about 100 hospitals in the next several months as it trains surgeons on the implant procedure before ramping up sales, said spokesman Jonathon Hamilton.\nAnalysts have predicted Absorb will gain a market niche but not surpass drug-dispensing metal stents such as Xience in share until longer-term data show more favorable clinical results.\nAbsorb\u2019s appeal is that it allows the blood vessel to return to a natural state, free from a permanent metal implant.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "A reader would be hard-pressed to determine the cost of this new stent.\u00a0 The only cost information provided sits in the last paragraph of the story, where it notes that the dissolvable stent will apparently cost more than Abbott Lab\u2019s drug-coated metal stent, marketed under the name Xience. (See our review of the AP story to see how much more in-depth they covered costs.)", "answer": 0}, {"article": "A tiny balloon is inflated to flatten the clog and a mesh scaffold stent is usually placed.\nNeither treatment proved better for any subgroups like smokers, diabetics, or older or sicker people.\nAlso, the clogs treated with angioplasty are not the really dangerous kind.\nHalf of these low-risk patients received stents and medication.\nIn the study, only one-third of the people treated with drugs ultimately needed angioplasty or a bypass.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "While the story does describe the cost of stenting, it does not provide the cost of the medication for comparison.", "answer": 0}, {"article": "Some of the stem cells did become heart muscle, Hare said; they also triggered the heart to produce more of its own stem cells which became new heart muscle as well, he said.\nThe study shed new light on a question of prime interest to cardiologists: whether the injected stem cells actually transformed themselves into heart muscle, or improved heart function in some other way.\nBy implication, it almost certainly improves the patient's health, although that was not directly measured in the small, early study.\nThe trial was primarily about the safety of the procedure, and all eight patients came through without significant side effects, he said.\nIt worked in patients such as Eaton, whose heart attack was 11 years ago, Hare said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Since this treatment is not available, a discussion of costs is not warranted.\n", "answer": 2}, {"article": "\u201cDid you somehow get a biased sample of people, and is that why you\u2019re seeing this difference?\u201d\n\nHer 2008 study analyzed data from nearly 64,000 people who were melanoma-free at the beginning of the investigation, then followed them for a few years to see who developed the disease.\nNow, a smaller study that asked people with melanoma and those without the disease to recall their use of NSAIDs has found that taking these drugs - particularly aspirin - at least once a week for more than 5 years may have offered some protection against the deadly disease.\nThe findings are interesting, but should not lead people to conclude that popping a few painkillers will reduce their risk of skin cancer, cautioned Dr. Maryam Asgari of Kaiser Permanente Northern California and the University of California San Francisco, who co-authored the 2008 study.\nOverall, regular use of NSAIDs for more than 5 years appeared to reduce the risk of developing cancer by more than 40 percent, the authors report in the Journal of Investigative Dermatology.\n\u201cI think the jury is still out.\u201d\n\nThere\u2019s reason to hope NSAIDs might offer some protection against this type of cancer, however - earlier this year, a review found that people who use painkillers such as ibuprofen on a regular basis may be less likely to get bladder cancer.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Costs aren\u2019t discussed, but everyone should know the costs of aspirin, ibuprofen or related painkillers.", "answer": 2}, {"article": "For further information or interview requests contact Sandy Fleming at the University of Kent Press Office.\nThe team individually tailors rehabilitation programmes to support people in returning to sport and exercise activities after injury or surgery.\nAn eight week return to running programme using the anti-gravity treadmill was individually designed by Dr Hambly.\nNot only does the tailored anti-gravity treadmill programme provide a great environment for healing, it also helps the person restore their belief that they can make a successful return to the sport they love.\nPatients recovering from knee operations are being helped back to sport and exercise through expert rehabilitation at the University of Kent.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release makes no mention of costs of the \u201cspace age\u201d treadmill device. We found at least one anti-gravity treadmill has been around since 2005. The machines sell for between $24,500 and $70,000. Most people who would want to use them would be referred to a rehabilitation clinic where it may cost about $80 to run on one for 55 minutes.", "answer": 0}, {"article": "Currently, people who do not have HIV but are at substantial risk of getting it--because they have multiple sexual partners, for example, or an HIV-infected partner--can receive antiviral medications to prevent disease, a strategy called pre-exposure prophylaxis (PrEP).\nThis is why researchers continue to look for other ways to control the virus--and broadly neutralizing antibodies could prove to be part of an alternate treatment strategy.\nAlthough these patients were found to have some resistant virus in their blood, further research in the lab showed that those viruses were still sensitive to other broadly neutralizing antibodies, including 3BNC117, that target different parts of the pathogen.\nIn an effort to accomplish this, the investigators are looking into modified variants of the antibodies with prolonged activity, so that they would need to be given less often in the PrEP setting.\nThe purpose was to determine whether the antibody was safe and whether it had antiviral activity in humans.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "This new process sounds very expensive but the release doesn\u2019t give us any clues as to how costly it might be. Biologic therapies used for other indications are very expensive. It would be helpful if the release had at least mentioned cost, even to say that they are as yet unknown.", "answer": 0}, {"article": "On the other hand, longer treatment was tied to a 24-percent decrease in hip fractures, which along with wrist and spine fractures affect about half of all people with osteoporosis.\nThe findings add to earlier concern over the medicines, called bisphosphonates, whose U.S. labels have been required since October to include a warning about the thighbone fracture risk.\nBut some experts worry that negative media coverage might have led to more fractures and possibly deaths by dissuading patients from taking the drugs.\nAnd the actual risk of having one of the unusual fractures was low, said Laura Y. Park-Wyllie, of St. Michael\u2019s Hospital in Toronto, who worked on the new study.\nAfter taking bone drugs for five years, about one in 1,000 women went on to suffer a thigh fracture over the next year.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The cost of a year\u2019s treatment should have been included. The story only says the drug are \u201ccheap.\u201d\u00a0 Cheap to one woman may be a financial burden to another.", "answer": 0}, {"article": "But from other research \"we know it's safe to place an electrode in the nucleus accumbens, it's safe to stimulate it electrically, and we expect to be able to tune [the electrode] as we already do with DBS.\nThe current study used a brain stimulation device already approved for hard-to-treat epilepsy.\nTrouble is, the moderation wore off in a few days, and the DBS also interfered with the animals' social behavior.\nThat got Halpern thinking about a newer system \u2014 one that doesn't stimulate continuously, like DBS, but switches on briefly only after sensing a trouble signal, much like a pacemaker monitors and responds to abnormal heart rhythms.\nThe intermittent system controlled overeating much better than the continuous or random protocols \u2014 and nearly as well as in a separate group of mice that got zapped manually by a researcher watching their behavior on video.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Although the article might have been strengthened by including the costs of alternative therapies, it clearly notes the high cost of the implantable device.", "answer": 1}, {"article": "The requested URL /usnews/health/articles/070603/11back.htm was not found on this server.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The study does not mention direct or indirect costs (such as loss of productivity), a significant oversight when comparing surgery to nonoperative treatments. ", "answer": 0}, {"article": "In a study recently published in the European Journal of Applied Physiology, Seeley and a group of BYU colleagues, as well as Dr. Eric Robinson from Intermountain Healthcare, measured inflammation markers in the knee joint fluid of several healthy men and women aged 18-35, both before and after running.\nBYU professors Sarah Ridge and Ty Hopkins were also coauthors on the study.\nSpecifically, they're looking to do similar tests on people who have suffered ACL injuries.\n\"Instead, this study suggests exercise can be a type of medicine.\"\nWhen the same fluids were extracted before and after a non-running condition, the inflammation markers stayed at similar levels.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There is no cost mentioned, but typically, running does not have any cost requirement except for good shoes. This category is not applicable for this research.", "answer": 2}, {"article": "The beneficial effects of traditional acupuncture, according to the researchers, did not appear to be associated with changes in levels of hormones that trigger menopause and its associated symptoms.\nAfter 10 weeks, the women in the traditional acupuncture group had significantly less severe hot flashes and mood swings than those who'd gotten the fake treatment.\nThe research included 53 postmenopausal women, with about half receiving traditional Chinese acupuncture twice a week and the others given sham acupuncture treatments.\nThe findings were published online March 7 in Acupuncture in Medicine.\nThough the researchers acknowledged that they did not monitor how long symptom relief lasted, they suggested that traditional acupuncture may offer an alternative for women who can't or don't want to use hormone replacement therapy to ease menopause symptoms.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No discussion of cost.\u00a0 Women in the study were treated for 10 weeks.\u00a0 How much would that cost?\u00a0 Not a trivial issue.", "answer": 0}, {"article": "While smoking is a public health scourge, the nicotine in cigarettes may have some promise in treating another growing problem, mild cognitive impairment (MCI), which can be a precursor to Alzheimer\u2019s disease or other forms of dementia.\nMORE: Is Nicotine a \u2018Gateway\u2019 to Cocaine Addiction (and Cancer)?\nHowever, when clinical experts rated overall general change in the patients, they did not see a significant difference between the two groups.\nAbout half the participants were former smokers.\nThe authors conclude, \u201cThis initial study provides evidence for nicotine-induced cognitive improvement in subjects with MCI; however, whether these effects are clinically important will require larger studies.\u201d\n\nThe study found no problematic side effects associated with the nicotine patch and none of the patients had withdrawal symptoms when it was stopped.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story didn\u2019t mention cost. The nicotine patch is readily available over the counter.\u00a0 We found a range of prices online, including one big chain\u2019s patch for roughly $2.70 a day.", "answer": 0}, {"article": "Follow her on Twitter @drfernstrom.\nBut that\u2019s a misleading association because a variety of illnesses can also cause drop in cholesterol, which is unrelated to diet.\nEat less saturated fat for better heart health: that\u2019s been the conventional wisdom based on decades of scientific study.\nWhile the study has many limitations because it doesn\u2019t take into account genetic or lifestyle factors that are proven important in both heart disease risk and longevity, it suggests that blood cholesterol levels are only one factor.\nIn fact, the study found that the lower the cholesterol, the greater the risk of death.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Since this is about affordable and widely available cooking oils, this is N/A.", "answer": 2}, {"article": "\u201cBut even without that firm answer at this point I don\u2019t see the harm in supplementing.\u201d\nMore studies need to replicate and confirm the role that omega 3 fatty acids might play in fertility, but for now, Skaznik-Wikiel says that there isn\u2019t much harm in consuming more omega 3 fats.\nThe study, presented at the American Society of Reproductive Medicine annual meeting, was in mice, so more research needs to be completed before omega 3 foods or supplements become part of treatment for infertility.\n\u201cBased on this study, it looks very encouraging that omega 3s can potentially improve fertility,\u201d says Skaznik-Wikiel.\nBut other studies Skaznik-Wikiel has done with mice suggests that these fats may lower levels of inflammation that can adversely affect ovarian function.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The article includes no discussion of the cost of adding either omega 3 supplements or foods high in omega 3 fats to an individual\u2019s diet. Omega 3 supplements may not be especially\u00a0expensive,\u00a0but the story doesn\u2019t address this issue either.", "answer": 0}, {"article": "For nine months, the developing fetus is attached to its mother by the umbilical cord.\nNow, research suggests there may be benefits to keeping mom and baby attached a few minutes longer.\nAndersson's study marks the first time researchers have followed children to see whether the clamping makes a difference later in life.\nIron is essential to the developing brain, he said, and deficiencies during early months \u2014 perhaps linked to early clamping \u2014 could affect nerve and muscle control, making it harder for the child to later control a pen or interact comfortably with peers.\nThose benefits, researchers say, likely have to do with iron.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The difference of slowing down the clamping of the newborn\u2019s umbilical cord does not seem to add any cost to care for a delivery. The story might have talked about potential \u201csavings\u201d if widespread use of this new technique made iron-deficiency for babies less common in US. But any benefit would be difficult to quantify.", "answer": 2}, {"article": "Acupuncture designed to treat depression appears to improve symptoms in pregnant women, suggesting it as an alternative to antidepressant medication during pregnancy, a study found.\n\nThe study, published Monday in the journal Obstetrics & Gynecology, is the largest to date examining the effectiveness of acupuncture to treat depression in pregnant women. It was funded by a grant from the government's Agency for Healthcare Research and Quality. \"Acupuncture that we have tested works for pregnant, depressed women,\"...", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The study makes no mention of costs or insurance coverage. Because insurance coverage for acupuncture varies widely, out-of-pocket expenses for the 12-session regimen could be a substantial barrier to many women getting the treatment.", "answer": 0}, {"article": "Anderson Cancer Center.\nIf such a test were developed, it would likely be used first to test patients at high risk for pancreatic cancer.\nThe new finding could lead to a blood test that would allow doctors to screen for pancreatic cancer much more effectively.\nThe researchers found that the presence of the protein could distinguish with 100 percent accuracy whether patients had early stage pancreatic cancer or chronic pancreatitis, a major risk factor for the cancer.\nLevels of the protein were markedly lower after surgical removal of a patient's tumors.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The study includes no mention of costs for the screening test. While it\u2019s noted that the test has not yet been developed, it would be possible to give a ballpark figure based on similar screening tests.", "answer": 0}, {"article": "Images on paint can display on the left, a cancer free mouse; image on right illustrates how the tumor paint shows cancerous cells even after the cancerous organ has been removed.\n\nWhen treating cancer with surgery, there's nothing as important as making sure that every last bit of the disease has been removed. That's not always possible, since tumors have nasty habits of embedding themselves within healthy tissue and of breaking away and spreading malignancies to other parts of the body. But Researchers at Seattle's Fred Hutchinson Cancer Research Center have come up with an innovative way of giving surgeons the upper hand against these wily tumors. They have created a molecular \"paint\" that coats cancer cells so doctors can see the wayward cells that they may otherwise miss.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There was no mention of costs of the \"paint\" nor of the equipment needed to visualize where the \"painted\" cells are localized.\nFrom the website of the company that made the imaging equipement, it was not apparent that an apparatus was even available that would accomodate a \"patient\" larger than a rodent.", "answer": 0}, {"article": "No more than a few days later, the samples were transported to labs at the university, where they remained frozen until they were processed by researchers. This ensured that none of the bacteria had a chance to grow or change from the time the sample was collected. Also, it guaranteed that all samples were treated the same way.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "These were not\u00a0\u201ctreatment\u201d studies so discussing costs is not relevant. However, the way the story is written could make readers think they should start buying more wine and coffee, which isn\u2019t what the findings\u00a0showed.", "answer": 2}, {"article": "Though CA125 is valuable to look for recurrence of cancer, it is not recommended for screening because it can surge, for example, during menstruation. However, guidelines from the American College of Obstetricians and Gynecologists and the National Comprehensive Cancer Network (NCCN) recommend a CA125 test plus vaginal ultrasound imaging for a woman with nonspecific symptoms that could signal ovarian cancer, such as bloating and pain. A CT or MRI scan may be added, although these are expensive. A biopsy is usually avoided because it could spread cancer cells.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Costs are mentioned reasonably\u00a0early in the story, and with specificity. This was good\u00a0to see.", "answer": 1}, {"article": "Some prostate cancers evolve to use energy from lipids (fat).\nPrevious work shows that metabolizing lipids helps prostate cancer escape anti-androgen therapy.\n\u201cThis finding may have a huge impact on patients with CRPC that had very few options before,\u201d says Schlaepfer.\nA University of Colorado Cancer Center study published today [May 3] in Oncotarget shows that combining a CPT1A inhibitors with anti-androgen therapy increases the cancer\u2019s sensitivity to the anti-androgen drug enzalutamide.\nIn part, this is due to the cancer\u2019s ability to resist anti-androgen therapy.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The drug in question, enzalutamide, is advertised and sold as Xtandi. The cost of the drug could easily have been included in the news release. According to GoodRx, the out-of-pocket cost for 120 capsules of 40 mg Xtandi is roughly $11,000.\nRanolazine (marketed as Ranexa), the other drug discussed, is priced at about $350 for a 60 day supply of 500-mg tablets.", "answer": 0}, {"article": "Visit http://www.\nThe study, New Multiple CT Assessment of Acute Stroke Patients: Are We Ready for Prime Time?, shows that recent advances in imaging software in the angiosuite give neurointerventionalists the essential details required to diagnose a patient with large vessel occlusion (LVO) for an endovascular thrombectomy (EVT).\nThis study suggests that in the future, stroke patients can bypass the CT scan or emergency department and go directly to the angiosuite for imaging and proper care.\nPreliminary results show that the cone beam imaging software compares favorably with baseline and follow-up CT scans.\nThe lead PI on this study, Professor Vitor Mendes Pereira, concluded by saying, \"By reducing intra-facility transfer times, patients can receive EVT treatment sooner, which can significantly impact patient outcomes\".\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Costs are not addressed, either of this form of CT imaging compared to standard, or to the overall cost of care for acute stroke management. Nor does the release outline any factors that may influence potential cost. Is software the only thing new here? Or is new hardware also needed? This part is confusing. The release tells readers that the relevant study is titled \u201cNew Multiple CT Assessment of Acute Stroke Patients: Are We Ready for Prime Time?\u201d This indicates that the software relies on CT scans. The release further states that \u201crecent advances in imaging software in the angiosuite give neurointerventionalists the essential details required to diagnose a patient [with a particular type of stroke]. This study suggests that in the future, stroke patients can bypass the CT scan\u2026\u201d But, if they are bypassing the CT scan, what images is the software working with?", "answer": 0}, {"article": "Wasting syndrome is characterized by a loss of weight and muscle atrophy, and largely found in patients who suffer from cancer, kidney disease, chronic obstructive pulmonary disease, and heart failure.\n\u201cWe tested these compounds in sedentary mice and found a dramatic improvement in exercise endurance and a mild increase in muscle size of certain muscle groups,\u201d Sah says.\nThe intellectual property associated with this discovery was recently licensed by the UI Research Foundation to Innovus Pharma, an over-the-counter consumer goods and specialty pharmaceutical company that commercializes non-prescription medicine and consumer care products.\nThe discovery was a \u201cserendipitous finding\u201d in the lab of Rajan Sah, M.D., Ph.D., assistant professor of Internal Medicine and Molecular Physiology and Biophysics at the University of Iowa.\n\u201cThis same calcium signal also activates signaling pathways to increase skeletal muscle endurance and also skeletal muscle size.\u201d\n\nSah\u2019s research team hypothesized that low level calcium cycling induced by these natural compounds might promote improved exercise capacity and overall metabolic health associated with healthy muscle mass.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There is no mention of the costs for the compounds referred to in this release. Nor are the compounds themselves identified which might give some idea of the cost of acquiring them.\u00a0 The release suggests an over-the-counter drug was being developed but no information was provided on what the cost might be to patients.\nGiven that this is pre-clinical research, we have no idea about what the process of isolating the active compounds would be, which would impact cost.", "answer": 0}, {"article": "Anorexia has one of the highest mortality rates of any psychiatric disorder and is among the most common psychiatric disorders in girls aged between 15 and 19 years.\nCommenting on the results of this small trial, Janet Treasure and Ulrike Schmidt of King\u2019s College London\u2019s Institute of Psychiatry said the technique looked promising and would give hope to patients with especially pernicious forms of anorexia.\nThis success, in a small study designed as a pilot to test the safety of the technique, suggests larger trials will confirm the effectiveness of the deep brain stimulation (DBS) device, the researchers wrote in the medical journal The Lancet.\nImplanting the DBS device requires minimally invasive surgery which can be completely reversed if problems occur, the researchers said.\nAndres Lozano, who led the study, said the results were encouraging because they pointed to a genuine therapeutic effect, rather than a placebo or hunger-increasing effect.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No discussion of costs, which are significant.\nIn this 2008 Chicago Tribune blog post, the cost of\u00a0DBS was estimated at $150,000 or more per patient in some uses.\u00a0There would also be additional costs for ongoing monitoring and follow-up once the device\u00a0was\u00a0implanted.", "answer": 0}, {"article": "\u201cI wouldn\u2019t use the word excited too much,\u201d said Anthony Fauci, director of the NIH\u2019s National Institute of Allergy and Infectious Diseases.\nSo it\u2019s difficult to think about how a single shot might work against all the different HIV subtypes circulating around the world.\n\u201cThe mosaic strategy is one way to attempt to deal with the global virus diversity.\u201d\n\nA word of caution, though: We\u2019re only in the early phase of human testing, and the vaccine could ultimately fail to prevent the virus from spreading among people.\nBut so far, the HIV community is carefully watching the Ad26 vaccine research because the approach seems quite promising.\nBut scientists may be inching toward a vaccine that could tackle HIV\u2019s genetic diversity and prevent the virus from taking hold in people.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "While it might be premature to speculate about the exact costs of an experimental vaccine, offering no discussion at all is a major flaw in this story.\u00a0Cost is a central, vital part to this narrative because any health technology developed to be used in the world\u2019s poorest countries are only going to matter to those people if it is affordable.", "answer": 0}, {"article": "Too much LDL cholesterol circulating in the blood can lead to the thickening of artery walls, making them less flexible and therefore impairing their function and increasing the risk of heart disease.\nIn this phase one clinical trial, which is designed to determine if a drug is safe, researchers found that using a monoclonal antibody (lab-produced protein) called REGN727, was not only safe, but effectively blocked PCSK9 and therefore signficantly reduced bad cholesterol in healthy patients as well as those also taking the popular cholesterol-lowering drug Lipitor.\nTwo arms used 72 healthy volunteers who were either injected with a single dose of the drug in increasing amounts to test for side effects, which is the purpose of a phase one clinical trial.\nThe cost of this drug will also play a role in determining which patients might use it, Fong and Young say.\nAll of those subjects were also receiving treatment with the statin Lipitor.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story noted that two editorial writers \u201ccaution that it will remain unclear how important this\u00a0class of drugs will be. The cost of this drug will also play a role in determining which patients might use it.\u201d\nBut better cost context could have easily been provided.", "answer": 0}, {"article": "However, contrary to the popularly held belief that a greater number of concussions are linked to CTE , no connection was found between levels of CCL11 and reported number of concussions.\n\"This may be one of the abnormalities [of the disease], but it may take 2-3 to be useful to diagnose CTE,\" said McKee.\nAn early step in the right direction\n\nMcKee also cautioned that this is still early research.\n\"The findings of this study are the early steps toward identifying CTE during life.\nPublished in the journal PLOS One, researchers have found a protein that can be a marker of this devastating disease.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The relevant research finding is so far removed from a clinical diagnostic tool \u2014 and the story makes that clear \u2014 that it\u2019s tough to expect much from the story in regard to cost.", "answer": 2}, {"article": "Referring to Lozano's second clinical study, Dr. Nader Pouratian, a neurosurgeon and DBS researcher at UCLA, comments, \"The recent deep brain stimulation trial for Alzheimer's disease clearly demonstrates the safety of this approach for trying to treat the progression of disease.\nGiven that so few people have had electrical stimulation applied to memory circuits, perhaps the most significant finding was that both the surgery itself and DBS of the fornix appear safe.\nThe technique is also approved for obsessive-compulsive disorder and is being looked at for a number of other brain disorders, including depression, chronic pain and, as in Lozano's work, dementia.\nUsing a 3-dimensional brain mapping technique called standardized low-resolution brain electromagnetic tomography, or sLORETA, Lozano's group uncovered an explanation for the unexpected findings.\nYet the fact that the therapy can in some people rescue recollections \u2013 albeit random ones \u2013 and possibly induce new neuron growth in memory regions of the brain seems reason enough to pursue it further.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not discuss what this treatment might cost, even though DBS is widely used for other conditions. A DBS surgery for Parkinson\u2019s, for example, can cost a minimum of $35,000, including hospital and physician fees, according to the National Parkinson Foundation.", "answer": 0}, {"article": "But it is also relevant to anyone who takes their weight management seriously and wants to stay lean and healthy.\"\nHowever, we also showed that a vegetarian diet is much more effective at reducing muscle fat, thus improving metabolism.\nThe vegetarian diet was found to be almost twice as effective in reducing body weight, resulting in an average loss of 6.2kg compared to 3.2kg for the conventional diet.\nHowever, subfascial fat was only reduced in response to the vegetarian diet, and intramuscular fat was more greatly reduced by the vegetarian diet.\nThis finding is important for people who are trying to lose weight, including those suffering from metabolic syndrome and/or type 2 diabetes.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There may be cost implications in maintaining a balanced vegan or vegetarian diet. This is especially true for people whose conventional meat-based diet currently includes a lot of processed foods and they find they need to shop for expensive veggie burgers and soy-based meals at the Whole Foods or Trader Joe\u2019s to round out their vegetarian diet. It would have been good if the release had at least mentioned there may a cost consideration.", "answer": 2}, {"article": "BOSTON (Reuters) - If you\u2019re checking into the hospital for surgery, doctors may soon be swabbing your nose in an effort to prevent an infection from appearing after your operation.\nThe research team, led by Dr. Lonneke Bode of Erasmus University Medical Center in Rotterdam, estimated that 250 patients would need to be screened to prevent one infection.\n\u201cPreventing one infection will pay for thousands of these screenings,\u201d Dr. Henri Verbrugh of Erasmus, a coauthor of the study, said in a telephone interview.\nThe new study, published in the New England Journal of Medicine, used a rapid test to identify which patients, most of whom were scheduled to undergo surgery, had the bacteria in at least one nostril.\nAlthough his team did not evaluate enough patients to study the problem directly, \u201cWe feel this technology is capable of preventing those types of infections as well,\u201d Verbrugh said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not adequately discuss costs, an important consideration. Cost benefits are briefly mentioned.\u00a0 But those cost-saving implications are not validated in any way in the story. And no estimates of absolute costs were disclosed. Independent assessment of the cost implications would have been preferable.", "answer": 0}, {"article": "They found that Chinese women who ate the most soy were also less likely to die of lung cancer, the No.\nIt wouldn\u2019t be difficult to eat enough soy to be protected, Patel noted.\nStudies have shown that supplements containing soy protein don\u2019t have much health benefit.\n\u201cPeople should consider eating a diet that is healthy.\n\u201cThis finding, along with our previous observation of an approximately 40 percent reduction in risk of incident lung cancer associated with high intake of soy food, provides further support for the role of soy food intake in lung cancer development and prognosis,\u201d the researchers wrote.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The cost of soy foods is not in question.", "answer": 2}, {"article": "\u201cAre patients better off getting these much broader tests?\u201d he said.\nEven among all appropriate candidates who are sent for genetic testing, only nine percent will test positive for the BRCA mutations, so an additional four percent who have non-BRCA mutations is a significant number, Ellisen said.\nThough these results indicate that additional genetic screening is clinically useful, some genetic test results will be uncertain, and it can be psychologically difficult for patients to deal with this uncertainty, Ellisen said.\nAnd for many, family testing would be recommended for first-degree relatives, according to the report in JAMA Oncology.\nEarlier this year, 17 genetic experts argued against testing for a wider panel of breast cancer-related gene mutations until they are proven to be valid and useful in clinical practice (see Reuters story of May 27, 2015 here: reut.rs/1TvOoDf).\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The article mentions that the tests themselves \u201care not more expensive than testing for the BRCA mutations alone,\u201d but it doesn\u2019t state what those BRCA-only panels cost. In addition, insurance coverage for panel testing is not as uniform as it is for BRCA 1/2 testing. There are established guidelines for BRCA 1/2 testing from the National Comprehensive Cancer Network that most insurance companies honor. There are not yet established guidelines for panel testing.\u00a0We appreciate the nod to cost, but we thought a little bit more detail was needed here for a Satisfactory rating.", "answer": 0}, {"article": "Using the gentler technique, called laparoscopy, a surgeon makes small cuts in the abdomen before inserting a tiny camera inside, then performing the operation by watching a television monitor.\nOn average, it cost $17,594, compared to $12,125 for the laparoscopic surgery.\nYet again, the patients who had laparoscopy fared much better than those who had conventional surgery.\nIndeed, those who had laparoscopy were younger and usually had less severe disease, which could have biased the results in favor of the minimally invasive procedure.\nWith his colleagues, he looked back at some 40,000 such surgeries done at dozens of academic medical centers in the U.S. \u2014 roughly 14,000 open procedures and 26,000 laparoscopic ones.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Nice job on this.\u00a0 The story states:\n\u201cFor uncomplicated cases of appendicitis, in which the appendix is still intact, the tabs for the two surgeries came out about the same, at just over $7,800. \u2026When the appendix had burst, however, the open surgery racked up a considerably higher bill. On average, it cost $17,594, compared to $12,125 for the laparoscopic surgery.\u201d\n\u00a0", "answer": 1}, {"article": ".\nThe findings, which are published in BJU International, could change the way men are treated for low testosterone.\nOver five months, patients had 10 clinic visits with one overnight stay.\nAs this study has shown in a randomized, double-blind, double-dummy, placebo-controlled manner, exogenous testosterone therapy with Androgel can clearly decrease sperm production and potentially impact fertility,\" said Dr. Kim.\nThe Company's website can be accessed at http://www.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The news release doesn\u2019t give the cost of either of the drugs that are compared in the study.", "answer": 0}, {"article": "A 33-year-old Queens woman who was treated by Batzofin last week fits that bill. Married for two years, she failed to get pregnant through intercourse, with and without drugs. When Batzofin told her about his new procedure, she said, \"Let's go for it.\"", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does compare average costs of one course of IVF treatments with one course of IVM treatments. Given the lack of proven success with IVM, multiple rounds of treatments may be necessary to conceive.\u00a0 This is not specifically stated and the focus of the story is promoting IVM as a more cost-effective method of fertility treatments. This emphasis is misplaced.\u00a0 \nThere NO evidence that anyone has data that directly compares IVF and IVM, let alone understands cost per cycle, conception, or healthy pregnancy. \n\u00a0\nKathie, confused here and not sure if we should ding given that they did list the cost of each treatment?\u00a0", "answer": 0}, {"article": "May 23, 2011 -- Researchers in Europe say a fermented dairy product containing a specific bacterium known as a probiotic did not relieve constipation in children more than a dairy product without a probiotic.\nBut in a new study the kids who consumed the fermented dairy product did no better, based on number of stools produced, than youngsters in a comparison group.\nThe study examined 159 children with constipation for at least two months with a defecation rate of less than three times per week.\nThe finding is significant, the researchers say, because probiotics have helped some adults with constipation.\nAbout half were given the probiotic product twice daily for three weeks; children in the comparison group were given a dairy product without the probiotic.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There was no mention of costs. How much would it cost to give kids such a probiotic product twice daily for three weeks as they did in the study?", "answer": 0}, {"article": "\u201cOurs is probably a bottom estimate,\u201d Dr. Cahill said.\nWhile use of the products in such operations has since fallen, one expert said the new report should convince doctors to stop using them in anterior cervical fusions, as the procedure is known.\nHe added that the study also confirmed how quickly physicians had adopted the proteins both for approved and unapproved uses.\nBy 2006, just four years after such products were first sold, the proteins were used in about 25 percent of all spinal fusions, the review found.\nMarybeth Thorsgaard, a Medtronic spokeswoman, said the company was close to completing a clinical trial involving the use of Infuse in anterior cervical fusion.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "\n\n\nWhile this story reported that one manufacturer of bone-growth proteins had an estimated $760 million dollars worth of sales of the products in 2008, it did not include the higher hospital charges highlighted in the study published in the Journal of the American Medical Association. According to the study authors, the median hospital charges for spinal fusion procedures using the bone-growth proteins was $46,112, about 40 percent higher than the $31,179 median charge for procedures that did not include the proteins.", "answer": 0}, {"article": "Zeitzer was on the committee that removed jet lag as a \u201cdisease\u201d from the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), the guide that psychiatrists use to diagnose mental illnesses.\n\u201cFor moving your system to an earlier time, such as would be necessary when traveling West-to-East, light during the last few hours of the night is ideal.\u201d\n\nThe night flashes require special technology and equipment, beyond just a smartphone, which are still in development, Zeitzer said.\nIn a previous study, the short flashes of light at night did not interrupt sleep or reduce its quality, he added.\n\u201cHowever, the treatments that are developed for jet lag can be used for less prevalent, though far more significant societal problems including delayed sleep in teens (in whom we have an ongoing clinical trial using the flash technique) and shift workers who try to flip between a night time schedule for work and a day time schedule for leisure,\u201d he told Reuters Health by email.\n\u201cThis clock remains synchronized with the external day through regular exposure to light.\u201d\n\nNighttime flashes change the timing of the circadian clock, he said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "While no costs were discussed, the suggestion that the device might be expensive was made: \u201cThe night flashes require special technology and equipment, beyond just a smartphone, which are still in development, Zeitzer said.\u201d We\u2019ll consider this nod in the direction of cost sufficient for a Satisfactory rating, since it would be difficult to say exactly how much such a device would cost at this stage.", "answer": 1}, {"article": "Outside of heart attacks, doctors are often too quick to use a common $20,000 procedure to treat patients suffering from coronary artery disease, a new study suggests.\n\nAbout 600,000 angioplasty procedures, which almost always involve placement of a tiny metal tube called a stent, are done in the U.S. each year. Roughly 70% of these procedures are performed on patients suffering symptoms of a heart attack and aren't medically controversial. But the remainder are done on stable patients who are suffering mild symptoms or no symptoms...", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The $20,000 procedure cost is in the first sentence. Many stories never get there at all.", "answer": 1}, {"article": "\"Current FDA-approved treatments for depression fail for millions of people because they don't work or don't work fast enough,\" said senior author Ruben Abagyan, PhD, professor of pharmacy.\nBut ketamine has not been tested in a large clinical trial, and all evidence of its antidepressant effects has come from anecdotes and small studies of fewer than 100 patients.\nThat control group eliminated the possibility that people who take ketamine have less depression because they have less pain.\nAccording to Abagyan, it is possible that another factor common to patients taking ketamine was driving the antidepressant effect, such as the fact that ketamine also relieves pain.\nFor financial and ethical reasons, ketamine has never been tested for its safety and effectiveness in treating depression in a large-scale clinical trial, but it reportedly works much more rapidly than standard antidepressants.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release does not specify cost, but says ketamine is \u201crelatively inexpensive and is covered by most health insurance plans if three other antidepressants fail.\u201d If prescribed it is done so \u201coff-label\u201d since ketamine is not FDA approved for depression, and thus not covered by health insurance. At least one ketamine treatment center says the drug is not covered by insurance.\nThe release also doesn\u2019t specify which ketamine formulation it assessed. When given by infusion, which is how depression is treated clinically with the drug, it can cost several hundred dollars per treatment.", "answer": 0}, {"article": "Acupuncture, a popular form of alternative medicine, involves inserting ultra-thin needles into the skin.\n\"The symptoms don't (normally) get better by that much that quickly.\"\n\"We are now designing a randomized clinical trial to further evaluate acupuncture after prostate cancer treatment,\" Ashamalla added.\nThe question is whether the acupuncture reduced the hot flashes or a placebo effect played a role, said Freedland, who's familiar with the study findings.\nThey received acupuncture twice a week for 30 minutes over four weeks.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story could have easily provided some cost estimate for four weeks of twice-weekly acupuncture sessions. But it didn\u2019t.", "answer": 0}, {"article": "1 Sperling RA, Aisen PS, Beckett LA, et al.\nThese imaging findings can help spur beneficial lifestyle changes in patients to reduce risk for Alzheimer's disease.\nThe concept that cognitive decline can be identified early and prevented by applying quantitative brain imaging techniques is the focus of \"Hot Topics in Research: Preventive Neuroradiology in Brain Aging and Cognitive Decline,\" a review published online in American Journal of Neuroradiology (AJNR).\nSuch work is already happening at UCLA and other institutions that meld these approaches into novel ways to improve patient care.\n\"We are working closely with neuroradiologists to redefine how we can reduce risk for Alzheimer's with quantitative neuroimaging that helps us pinpoint symptom-relevant volume loss in the brain and subsequent targets for tracking our lifestyle-based interventions,\" says Dr. David Merrill, a geriatric psychiatrist at UCLA Medical Center.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There is no mention of costs in the release, but overuse of medical technology such as MRI scanning is one major reason for soaring health care costs. According to personal finance website Nerdwallet.com, median prices of a brain MRI range from $525 in Atlanta to a whopping $3,310 in Milwaukee.", "answer": 0}, {"article": "Urothelial carcinoma is the most common type of bladder cancer and occurs in the urinary tract system, involving the bladder and related organs.\nTherefore, today the FDA also approved the Ventana PD-L1 (SP142) assay to detect PD-L1 protein expression levels on patients' tumor-infiltrating immune cells and help physicians determine which patients may benefit most from treatment with Tecentriq.\nThe Ventana PD-L1 (SP142) assay companion diagnostic for Tecentriq is marketed by Ventana Medical Systems, based in Tucson, Arizona.\nTecentriq is the first FDA-approved PD-L1 inhibitor and the latest in the broader class of PD-1/PD-L1 targeted biologics approved by the FDA in the last two years.\nThe FDA granted the Tecentriq application breakthrough therapy designation, priority review status and accelerated approval for this indication.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release does not mention cost. The FDA evaluates drugs without consideration of cost, so it\u2019s understandable that they wouldn\u2019t comment on it \u2014 and that\u2019s why we\u2019re rating this Not Applicable. But let\u2019s be real here: The value of a new drug is a function not just of how well it works, but its cost-effectiveness. So we look forward to the day when any news release about a new drug \u2014 even one from the FDA \u2014 will include some mention of cost in its message.", "answer": 2}, {"article": "Traditionally, patients with leukemia, lymphoma and myeloma have first tried to find an adult bone marrow donor either from a close relative or from a national bone marrow registry.\nAt that point, Mumford said, his choices were to continue chemotherapy and live for, maybe, another year and a half.\nAnd patients still must endure months of recovery.\nEven siblings are not a sure thing, with the chance of matching a brother or sister only 25 percent.\nIn that case, other matching blood is made available free of charge.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The costs of donation are discussed, but not transplantation \u2014 the treatment discussed. It\u2019s not cheap, and it may not be completely covered by insurance.", "answer": 0}, {"article": "Dr. Andrew Adesman is chief of developmental and behavioral pediatrics at Cohen Children's Medical Center of New York, in New Hyde Park, N.Y.\nTHURSDAY, Jan. 22, 2015 (HealthDay News) -- A therapy involving \"video feedback\" -- where parents watch videos of their interactions with their baby -- might help prevent infants at risk for autism from developing the disorder, a new study suggests.\nThe goal of the therapy -- delivered over five months while the infants were ages 7 to 10 months -- was to improve the infant's attention, communication, early language development, and social engagement.\n\"Children with autism typically receive treatment beginning at 3 to 4 years old,\" he explained.\n\"Although it would be wonderful if a relatively simple, video-based intervention could reduce the recurrence risk of autism spectrum disorder in later offspring, further studies are needed to examine this very issue,\" he said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "This story did not discuss costs of the video intervention. However, other high-end, intensive therapies now in use add substantially to the cost of caring for a child with autism. For example, after only a brief online search, we found information suggesting that the Early Start Denver Model (ESDM), a behavioral therapy, costs around $5,560 per month. It is our belief that anything that is judged to be good enough to be headlined as \u201cmay curb autism\u201d is also worthy of a cost estimate, even by estimating the cost of something somewhat comparable.", "answer": 0}, {"article": "The requested URL /usnews/health/articles/061015/23addict.b.htm was not found on this server.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There was no estimate provided for the cost of the drug.", "answer": 0}, {"article": "Keytruda thereby met its main goal of the study.\nSafety of Keytruda was consistent with what had been seen in previous trials among lung cancer patients, Merck said in a release that included only summary \u201ctopline\u201d information from the results.\nPatients whose tumors had especially high levels of PD-L1 also went longer without a progression of disease than those taking docetaxel, Merck said.\nMore detailed data from the study will be provided soon, Merck said, adding that it will ask the U.S. Food and Drug Administration later this year to add the new data to the drug\u2019s package insert label.\nThe approval was contingent on the company providing more detailed data in the future on Keytruda\u2019s safety and effectiveness.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not mention cost at all. Given that this is as much a business story as a health story, and that Keytruda has already been approved for use by regulators, this is a significant oversight. Previous news coverage of Keytruda in other news outlets says that Keytruda will cost $12,500 per month, and that median use of the drug is 6.2 months \u2014 or $77,500. If a patient takes it for a year, that comes to $150,000. That\u2019s worth noting.\nIt would also have been worth noting what the estimated costs of\u00a0docetaxel are, for comparison purposes.", "answer": 0}, {"article": "Shares in Angle, which has a market cap of about 50 million pounds, rose 2.2 percent to 68 pence.\nThe performance of the test would now be validated in another study designed to meet European CE Mark and US FDA regulatory requirements, he said.\nIt also had the potential to identify targets on the tumor that could be used to inform treatment strategies, he said.\nAngle founder and chief executive Andrew Newland said the study had demonstrated the ability to correctly detect cancer, and importantly correctly detect the absence of cancer.\nHeadline results from a study of 400 patients in Europe and the United States showed the test to detect cancerous cells in the bloodstream correctly identified cancer in up to 95 percent of cases, the company said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Cost is not discussed here.\u00a0Cost is always a consideration when discussing a new testing method. The existing blood tests (CA-125 and OVA-1) are relatively inexpensive ($60 and $650 respectively). \u00a0Although this new method may be more sensitive and specific, its cost effectiveness is uncertain at the moment.", "answer": 0}, {"article": "In 2016, breast cancer accounted for 29 percent of all new cancers identified in the United States and was responsible for 14 percent of all cancer-related deaths.\nThe study reports breast cancer is the most commonly diagnosed malignancy among females and the leading cause of death around the world.\nThe researchers were able to isolate relevant data to more accurately identify breast cancer biomarkers using two different electronic nose gas sensors for breath, along with gas-chromatography mass spectrometry (GC-MS) to quantify substances found in urine.\n\"Our new approach utilizing urine and exhaled breath samples, analyzed with inexpensive, commercially available processes, is non-invasive, accessible and may be easily implemented in a variety of settings.\"\n\"We've now shown that inexpensive, commercial electronic noses are sufficient for classifying cancer patients at early stages,\" says Prof. Zeiri.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The news release never gives readers an estimate for the cost of a combination breath and urine screening test for breast cancer. The release does state that the technologies used for both urine and breath are \u201cinexpensive\u201d but doesn\u2019t give us a concrete number to justify that claim.", "answer": 0}, {"article": "She also said the survival benefit was observed across key subgroups, including those with varying levels of a protein called PD-L1 that can help tumors avoid detection.\nAnalysts from Baader Helvea said its announcement completes an \u201calready robust\u201d set of data for regulators who now must sign off on Tecentriq\u2019s use as an initial treatment of lung cancer.\n\u201cWe continue to see Roche efficacy more than sufficiently competitive to grant a 43 percent market share in the indication, translating in 4.9 billion francs Tecentriq peak sales and 1.2 billion francs in 2018,\u201d Baader\u2019s Bruno Bulic said.\nWhile Roche did not provide specific overall survival data, the headline result helps its bid to catch up to better-established immunotherapies from Merck and Bristol-Myers Squibb and its shares rose about 1 percent in early trading.\nThis could help Roche make the case that its cocktail is suitable for broad patients groups, not just those with specific biomarkers.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Not discussion of costs. Some estimates have put the monthly cost of Tecentriq alone at $12,500. Adding the three other drugs brings it to about", "answer": 0}, {"article": "According to the FDA, \"Testosterone products are FDA-approved only for use in men who lack or have low testosterone levels in conjunction with an associated medical condition.\nThe findings may sway the ongoing debate over testosterone therapy's benefits and risks, especially for the heart.\nWhile the new study results do seem to advocate for testosterone replacement therapy, Barua stresses the need for \"appropriate screening, selection, dosing, and follow-up of patients to maximize the benefit of testosterone therapy.\"\nDr. Rajat Barua, the paper's corresponding author, says the study is also noteworthy because of its finding that administering the right dose is critical: Treating \"low T\" but not restoring levels to normal doesn't appear to impart much benefit, at least in terms of cardiovascular risk.\nTestosterone isn't prescribed with the goal of improving heart health, but that is a consideration in many cases.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Cost is not mentioned in this document. Generic testosterone is relatively inexpensive, which suggests that if these results reflect a real benefit, the treatment might actually be cost saving.", "answer": 0}, {"article": "\"We don't want to treat any man unnecessarily with that type of treatment.\nThese findings are good news for some men, since the effects of short term of hormone therapy are reversible, D'Amico said.\nBut when the researchers looked closely at those findings, they found that patients with low-risk prostate cancer did not need hormone therapy because the chance they would survive with radiation alone was already almost 99 percent, Jones said.\nOverall, hormone therapy reduced the risk of dying from prostate cancer over 10 years from 8 percent to 4 percent, Jones said.\nAnd while short term hormonal therapy is \"not very toxic, there are [still] some toxicities,\" Jones noted.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There was no discussion of costs.\u00a0 Over and over again \u2013 more than 70& of >1,500 stories we\u2019ve reviewed fail to adequately discuss costs.\u00a0 This has to change.", "answer": 0}, {"article": "Autologous CD34?\nThe researchers concluded that for \"no option\" patients with class III/IV angina refractory that was unresponsive to conventional medical therapy and who were not candidates for revascularization, injection of CD34+ cells resulted in persistent improvement in angina at two years post-treatment.\nOutcomes from the \"ACT-34-CMI\" study, a two-year, phase II, randomized, double-blind, placebo-controlled clinical trial, will be published in an upcoming cardiac issue of Cell Transplantation.\nEncouraging early clinical trials suggest that cell therapy is an attractive treatment option for these patients, especially trials in which subjects were transplanted with autologous (self-donated) CD34+ cells.\"\nAccording to the researchers, the study demonstrated that CD34+ cells have the ability to restore the microcirculation and improve myocardial tissue perfusion.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release does not discuss costs at all. Given that this was a phase II study, meaning it is still at least one step removed from clinical use, we don\u2019t necessarily expect a release to give a precise cost to the treatment. However, we do expect cost to be addressed in at least some capacity. For example, is there an expectation that this treatment would be comparable in cost to other treatment options for angina? Given that this was industry-funded study, the release could have addressed this in at least broad terms.\nAs the release appears to be comparing this procedure to bypass surgery, it would be helpful to know exactly what is involved in obtaining \u201cautologous\u201d (self donated) cells and \u201cintramyocardial delivery into the ischemic zone\u201d later referred to as \u201cinjected.\u201d\u00a0 It is unclear if this is a surgical procedure, inpatient hospital treatment or clinic visit, all of which would influence the final cost.", "answer": 0}, {"article": "JACC is ranked No.\nProgram, researchers in Madrid implemented a three-year healthy lifestyle intervention for 3 to 5 year olds that used their school, teachers and families to promote cardiovascular health through healthy diet, increased physical activity, understanding of the human body and managing emotions.\nThe largest positive changes in body fat were seen in the 3-year-old group that received three years of interventions.\nThe study and editorial are part of a comprehensive Population Health Promotion issue of the Journal of the American College of Cardiology focusing on issues that broadly impact public health and the prevention of cardiovascular disease and related conditions.\nIn an accompanying editorial, Deepak L. Bhatt, M.D., M.P.H., executive director of interventional cardiovascular programs at Brigham and Women's Hospital Heart and Vascular Center and professor of medicine at Harvard Medical School in Boston, said the program is groundbreaking, and follow-up studies to further pinpoint the exact mechanisms by which the program achieved positive effects on young children's health will be vital for implementing the program in other areas and informing the design of future global programs.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The news release does not talk at all about costs, and this three-year intervention including education for 3-5 year-old children sounds as if it could have had substantial cost.", "answer": 0}, {"article": "Larry Holzman \u2014 avid mountain-biker, skier and guitarist in a band \u2014 plays hard.\nBishop says the benefit of the FlexBar, which costs between $16 and $33, over traditional hand weights is that it helps people strengthen without recreating the symptoms.\nAnd the FlexBar makes it simple to do this kind of stretch.\nHis physical therapist quickly diagnosed it as tennis elbow.\nIt usually happens when people grip things too hard or too long.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story states that the FlexBar costs between $16 and $33. It could have compared this cost with that of some other treatment options, which can be quite expensive.", "answer": 1}, {"article": "Suvorexant is part of a class of drugs called Dual Orexin Receptor Antagonists or DORAs, which work by blocking chemical messengers called orexins.\nSo far, Merck has not seen any cases of narcolepsy, a sleep disorder marked by daytime sleepiness, in its late-stage clinical trials, Renger said.\nExperiments in animals suggest Merck\u2019s sleep drug Suvorexant, now before the U.S. Food and Drug Administration, may avoid these side effects, the company said.\n\u201cThese treatments work by forcing the brain to go to sleep,\u201d said study leader Jason Uslaner of Merck in an interview on the website of Science Translational Medicine, which published the study.\nOrexins originate in a specific region of the hypothalamus, so targeting them may have less impact on other brain functions, Renger said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Even though the drug maker has already applied for FDA approval to market a similar drug, there is no discussion of how much it will cost.", "answer": 0}, {"article": "Adult brains contain oligodendrocyte progenitor cells (OPCs), which are stem cells that generate myelin-producing cells.\nIn the current study, Dr. Tesar wanted to see if drugs already approved for other uses were able to stimulate OPCs to increase myelination.\n\u201cOff-label use of the current forms of these drugs is more likely to increase other health concerns than alleviate multiple sclerosis symptoms.\nUsing this technique, they were able to quickly test the effects of hundreds of drugs on the stem cells.\nNCATS and Dr. Tesar have an ongoing collaboration and plan to expand the library of drugs screened against OPCs in the near future to identify other promising compounds.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "While one could argue that we should give the release a pass given the early stage of the research,\u00a0the drugs discussed are commercially available and it would have been easy to provide cost information.", "answer": 0}, {"article": "An experimental drug designed by Roche Holding AG's Genentech unit against a new cancer target yielded encouraging results against two rare tumors, researchers said, potentially opening up a new front in the battle against the disease.\n\nIn a small study, the drug, known as GDC-0449, shrank tumors in 18 of 33 patients, or 55%, with an advanced form of a skin cancer called basal cell carcinoma. In addition, the drug had a dramatic, though temporary, effect on a 26-year-old patient who had undergone multiple surgeries, chemotherapy...", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The drug has only been tested in a phase I trial and a discussion of cost is not applicable at this time.", "answer": 2}, {"article": "Sigmund Freud often included one of his dogs in psychoanalysis sessions.\nBut the popular embrace of pets as furry therapists is causing growing discomfort among some researchers in the field, who say it has raced far ahead of scientific evidence.\nCherry-picked positive results also are a problem, as he says happens in promotional materials from the Human-Animal Bond Research Initiative (HABRI).\nIn other words, people are recognizing that anecdote isn\u2019t enough.\u201d\n\nUsing animals in mental health settings is nothing new.\nCertainly, the groups offering up pets think this, as do some mental health professionals.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Cost is not discussed, but this is an important factor to consider when evaluating any intervention\u2013and especially one that can be expensive. For example, Autism Service Dogs of America (a group that promotes the use of service dogs for patients with autism) estimates that \u201cthe full cost to breed, raise and train an ASDA service dog is over $20,000.\u201d Another organization that trains dogs to work with autism patients estimates the cost at $30,000 (though it does not charge the client \u2014 the expense is paid through fundraising initiatives). We don\u2019t claim that these are costs that individual patients would necessarily be responsible for, but they do offer some insight into the potential expenses associated with the care, training and upkeep of therapy animals. It\u2019s not negligible, and it\u2019s worth mentioning.", "answer": 0}, {"article": "Consultant hematologist John Snowden said: \u201cThe immune system is being reset or rebooted back to a time point before it caused MS ...\n\u201cWe want people to be aware that HSCT is an aggressive treatment that comes with significant risks.\n\u201cThe MS Society has recently funded a study looking into the impact of HSCT on the immune system and we\u2019d like to see larger trials in this area.\nThe treatment has traditionally been used to treat bone and blood cancers.\u201d\n\nBasil Sharrack, a consultant neurologist at Sheffield teaching hospitals NHS foundation trust, said: \u201cThe new treatment is showing some remarkable results in the small number of patients we have treated so far.\nThis is not a technology you can patent and we have achieved this without industry backing.\u201d\n\nEmma Gray, the head of clinical trials at the MS Society, said: \u201cOngoing research suggests stem cell treatments such as HSCT could offer hope, and it\u2019s clear that in the cases highlighted by Panorama, they\u2019ve had a life-changing impact.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Low in the story, one patient is identified as having spent \u00a330,000 (approximately $42,500) on the treatment. We\u2019ll give credit for this nod in the direction of cost, but it would be hard for a reader to generalize from that.\u00a0It isn\u2019t clear whether this is covered by insurance or not. It also isn\u2019t clear whether the price paid by this one patient is also the cost for the others. At the least, some context for that reference would have been helpful.\u00a0 We don\u2019t think of UK patients as paying out of pocket for health care. And since this is the U.S. edition of the Guardian, the info should be tailored for a U.S. audience.", "answer": 1}, {"article": "Most head and neck cancers are linked to alcohol consumption and to smoking.\nInterestingly, the protective effect of coffee was not diminished in drinkers and smokers.\nThough there weren't enough data on decaf drinkers to draw conclusions, drinking tea -- even massive quantities -- was not protective.\nDrinking less than five cups of coffee a day had a smaller but statistically significant protective effect: about 4% lower odds of mouth and throat cancer for each cup drunk daily.\nThat's probably not what University of Milan researchers Carlotta Galeone, ScD, PhD, and colleagues thought they'd find when they analyzed nine studies comparing 5,139 people with head and neck cancer to 9,028 people without cancer.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Not applicable \u2013 the cost of coffee is not in question. ", "answer": 2}, {"article": "In rural or underserved areas, doctors sometimes must rely on a patient's symptoms or use their own judgement in looking at test sample color results to determine whether a patient has an infection.\nThe work could lead to faster and lower-cost lab results for fast-moving viral and bacterial epidemics, especially in rural or lower-resource regions where laboratory equipment and medical personnel are sometimes not readily available.\nThe WSU researchers found that their portable smartphone reader worked nearly as well as standard lab testing in detecting 12 common viral and bacterial infectious diseases, such as mumps, measles, herpes, and Lyme Disease.\nIf they send results off to a lab in a distant city, the doctors sometimes must wait for days -- by which time the infection may have become widespread.\nThe researchers tested the device, which is about the size of a hand, with 771 patient samples at Hospital of University of Pennsylvania and found that it provided false positives only about one percent of the time (was 97. to 99.9 percent accurate).\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The news release reports that the device would probably cost less than $50 to manufacture. However, the cost of a lab device is only part of the cost of infectious disease testing. What sort of training is needed to accurately interpret results? Would the device be able to replace conventional lab tests or would it be used as a preliminary test, that would then be checked by conventional tests? It is possible that in real world circumstances, the device could lead many more people into testing, potentially increasing the total cost of testing programs. The health benefit could be worthwhile, but the news release should not claim that a device would reduce costs without evidence of total costs in real world use.", "answer": 0}, {"article": "The requested URL /usnews/health/articles/070506/14healthwatch.lede.htm was not found on this server.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not mention costs of the treatment.", "answer": 0}, {"article": ".\nThe experience supports a growing body of research showing good outcomes with surgery for chronic temporal headaches.\nThe simplified approach using the Gillies incision combines the advantages of other approaches to chronic temporal headache surgery while minimizing the disadvantages, Dr. Peled believes.\nHe hopes his new technique will \"lower the bar to adoption\" of effective surgical treatment for patients with this debilitating headache condition.\nIt's unclear why the three remaining patients didn't have good improvement, although Dr. Peled notes that two of the three had had temporal headaches for decades before surgery.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There is no discussion of costs in the news release. Surgery to treat chronic severe headaches could prove to be expensive (ie. thousands of dollars), since the intervention may also require anesthesia, operating room facilities and a hospital stay.\u00a0 Although costs may vary widely depending on the hospital and region, we believe a ballpark estimate would have been helpful.", "answer": 0}, {"article": "Hialeah bucket list: All the things you need to do in Hialeah before you die\n\nYou can spend your whole life working on this list.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story tells readers the scans cost about $200-$400 and are generally not covered by insurance.\u00a0 ", "answer": 1}, {"article": "What if doctors had a pill that prevents breast cancer and nobody wanted to take it? That has pretty much been the situation with tamoxifen, an estrogen-like drug that was proved in 1998 to cut in half the chance of developing breast cancer if taken for five years by women with increased risk of the malignancy. The trouble is, tamoxifen also triggers menopausal symptoms like hot flashes and slightly increases the chances that a woman will develop blood clots and uterine cancer. As a result, women haven't been too eager to take the medication--nor have many doctors been all that enthusiastic...", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The cost of treatment is provided in a side bar: raloxifene is about $75 for a month\u2019s supply, while tamoxifen is about $100. Story notes that medication is taken daily for 5 years. ", "answer": 1}, {"article": "More than six million children in the United States have asthma, according to the Centers for Disease Control and Prevention, as do more than 330 million children and adults worldwide, according to the Global Asthma Network.\nAn editorial in the same journal by an expert who was not part of the study praised the research, saying it was well designed and carefully performed.\nDr. Bisgaard said it was not possible to tell from the study whether pregnant women could benefit from simply eating more fish.\nThe author of that editorial, Dr. Christopher E. Ramsden, from the National Institutes of Health, said the findings would help doctors develop a \u201cprecision medicine\u201d approach in which fish-oil treatment could be tailored to women who are most likely to benefit.\nThe research was paid for by the Danish government and private foundations.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story did not discuss cost. There are dozens of fish oil supplements on the market and their cost varies widely. The story could have given some sense of the financial impact that this regimen would have.", "answer": 0}, {"article": "It\u2019s of phenomenal significance in that regard,\u201d he told Reuters.\nExperts described the study results as phenomenal and said the device, developed by German researchers, could eventually change the lives of up to 200,000 people worldwide who suffer from blindness due to a degenerative eye disease called retinitis pigmentosa.\nZrenner said further trials of the implant should be completed in two to three years and if those proved successful the device could be on the market and available for thousands of patients in about five years\u2019 time.\nThe implant device, which sits completely within the eye, is a tiny plate, measuring just 3 mm squared and a 10th of a millimeter thick, which has around 1,500 tiny light sensors connected to amplifiers and electrodes.\nEberhart Zrenner, chairman of the University of Tuebingen Eye Hospital in Germany and director of a small company called Retinal Implant AG which is developing the device, said the trial results were a \u201cproof of concept\u201d and would now be taken into further trials in around 25 to 50 patients in Europe.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story makes no mention of costs. Instead by saying, \u201ccould be on the market and available for thousands of patients in about five years\u2019 time\u201d it leaves readers with the impression that cost is not an issue. This is exactly the kind of device that an insurance company might put on its \u201cineligible\u201d list.\u00a0A quick review of the business media suggests the cost of the device will exceed $75,000 if it becomes commercially available. according to this Medical Device Technology Alert. It is hard to imagine why this important fact was overlooked in the story.", "answer": 0}, {"article": "[Seriously, why does anyone under 18 still have access to a tanning bed?]\nThat said, the agency warned Wednesday that the new drug can cause serious side effects, including trouble swallowing or nerve damage to the jaw that can result in an uneven smile or muscle weakness in the face.\nThe FDA warned, however, that the treatment also has the potential to kill other types of cells, such as skin cells, if injected improperly.\nKeith Leonard, chief executive of Kythera, the California-based firm that developed Kybella, said at a conference last month that he believes the new treatment \"can drive a very large market and leave very satisfied patients.\"\nPatients can receive as many as 50 injections of the drug in a single treatment, the agency said, with up to six treatments administered no less than a month apart.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story says that the company would not discuss the \u201cpotential cost\u201d of the drug until after its launch next month, and that the\u00a0sales of the anti-wrinkle drug Botox exceed $2 billion per year. That\u2019s enough for a Satisfactory rating. The story could have further informed readers by noting that insurers won\u2019t pick up the tab.", "answer": 1}, {"article": "The American Cancer Society has more on lymphoma.\nPeople whose physical activity was greater than normal before diagnosis were less likely to have died from lymphoma, or from any other cause, than were those who'd been less active, the study found.\nBut the study couldn't prove that more exercise actually caused death risk to drop.\nThat finding comes from a new study by Mayo Clinic researchers of nearly 4,100 people with lymphoma, a cancer that starts in the white blood cells that normally help fight infection.\n\"Our findings show that physical activity can have a positive impact on survival in lymphoma patients,\" she said in a Mayo news release.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Cost is really not applicable here. The story (and the relevant research) focuses on general levels of physical activity, not specific forms of physical activity.", "answer": 2}, {"article": "Dr. William Nelson, co-vice chair of the SU2C Scientific Advisory Committee and director of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins in Baltimore, Maryland, said:\n\n\"Understanding the link between prostate cancer and DNA repair mutations is incredibly important for patients and their families.\nThe trial is a milestone in cancer treatment as the first to show the benefits of 'precision medicine' in prostate cancer - with treatment matched to the particular genetic characteristics of a man's tumour.\nIts efforts have helped produce a 20-fold increase in government funding for prostate cancer.\nThe trial, called TOPARP-A, received support from a wide range of funders including Cancer Research UK, the Prostate Cancer Foundation, Stand Up To Cancer, Prostate Cancer UK and the Movember Foundation.\nThe next trial includes only men with these mutations in their tumours, with the aim of proving that olaparib is highly effective for them.\"\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release provides no cost information on the drug and the additional testing and additional radiographic work that would be part of this treatment.", "answer": 0}, {"article": "Sumathi Reddy has details on Lunch Break.\nBut some researchers are investigating the beneficial bugs for conditions that have nothing to do with the digestive tract.\nThey are live microorganisms\u2014or \"good\" bacteria\u2014that when consumed in capsules or yogurt are said to confer a health benefit.\nOne of the fastest-growing dietary supplements, probiotics are now prominent on drug and big-box store shelves.\nProbiotics, believed to help with digestion, are increasingly being studied to treat wide-ranging conditions, from colic to cholesterol and the common cold.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story tells us that probiotics sales totaled $770 million last year, but it doesn\u2019t break\u00a0that figure\u00a0down as far as what the individual can expect to pay. A quick search on one of the products mentioned showed that a 1-2 month supply will set you back about $68. This is important as many people may not have the resources to pay for their medications prescribed by their physicians.", "answer": 0}, {"article": "Researchers conducted a randomized, double-blind, placebo-controlled study of 40 postmenopausal women ages 45 to 65 with high blood pressure.\nThe improvement, the scientists write, was moderate compared with that of blood pressure medicines.\nThe lead author, Sarah A. Johnson, a postdoctoral researcher at Florida State University, said she saw no reason for people to radically change their diet, but that if they are not eating blueberries, they might want to try them.\nBut, they say, eating blueberries in larger amounts or for longer periods could increase the effect.\nThere were no significant changes in the placebo group.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Blueberries are expensive, and the featured study utilizes \u201cfreeze-dried blueberry powder,\u201d which is more of a supplement than something you\u2019d find in a grocery store. Some back-of-the-envelope calculations based on prices from this supplier suggest that the daily powdered blueberry regimen could cost as much as $50 a month.", "answer": 0}, {"article": "AMD, the No.\nResearchers have discovered that patients who take the drug L-DOPA are significantly less likely to develop AMD, and if they do get AMD it's at a significantly older age, according to the study published online Nov. 4 in the American Journal of Medicine.\nMARSHFIELD - A drug already used safely to treat Parkinson's disease, restless leg syndrome and other movement disorders also could delay or prevent the most common cause of blindness affecting more than 9 million older Americans - age-related macular degeneration (AMD).\nThe next step in this research is to perform a clinical trial to determine the ability of this drug to prevent AMD.\nThese provocative results were then confirmed in a much larger data set of 87 million patients where similar results were observed and the study expanded to include prevention and delay of \"wet\" AMD, the most devastating form of the disease.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "While the release is relatively cautious, it fails to mention the costs of its suggested treatment in any way. One assumes from the release that patients would be taking L-DOPA for a considerable length of time, which could represent a substantial expense. L-DOPA has been prescribed for patients with Parkinson\u2019s disease and other maladies for years and offering an estimate of yearly costs of the drug should have been easy, and would have helped readers gauge the value of this research in terms of patient care. Levodopa is generally prescribed in combination with another drug or drugs but the treatment cost of L-DOPA alone is several thousand dollars annually.", "answer": 0}, {"article": "U.S. doctors do at least two stenting procedures these days for every coronary bypass operation.\nNow the biggest collection of cases so far comes out in favor of surgery on the all-important question of mortality.\nBut Dr. Laura Mauri says in an accompanying editorial that the new study can't settle any debates.\nThat can call into question the ultimate relevance of the findings.\nSo the new data may be the best that doctors and patients in this situation can expect for the foreseeable future.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "This story, along with the Associated Press and Wall Street Journal stories we reviewed, did not include information about costs.", "answer": 0}, {"article": "Whitcomb, whose research on the determinants of fertility and pregnancy outcomes usually involves studying biomarkers at the molecular level, adds, \"Lifestyle is definitely relevant to these outcomes because it can have an effect at the molecular level.\nWhitcomb says, \"We don't know what to make of the finding that high intensity physical activity may have different biological effects than walking, but our study doesn't offer enough detail to get at why vigorous activity would work differently than other levels.\"\nFurther study is necessary to clarify possible mechanisms through which walking and vigorous activity might affect time-to-pregnancy.\"\nWhitcomb says another way in which this study is distinct from other work in this area has to do with who was included in the study.\nModerate activity, sitting and other activity categories were not associated with fecundability overall or in BMI-stratified analyses, they add.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The news release states:\nWalking has great potential as a lifestyle change because of its low cost and availability\nFair enough.", "answer": 1}, {"article": "We could not find the requested page.\n\nPlease visit our home page to explore our services.", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "This technology seems to still be in the experimental stage.", "answer": 2}, {"article": "Caused by defective genes, cystic fibrosis affects multiple organs.\nAlthough HGH not a cure for the disease, which afflicts 30,000 people in the U.S., the researchers found that it reduced the number of hospitalizations among those who have the disease.\nA daily injection can be difficult for a child who is already taking several other medications, White said, but going to the hospital fewer times might make up for it.\nHuman growth hormone is a promising tool in treating cystic fibrosis, a new University of Connecticut study suggests.\nWhile the study offers insights on managing the disease, there's not enough evidence yet on whether HGH treatments could extend the lives of those with cystic fibrosis.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does mention that human growth hormone is expensive; however, it would have been preferable if it reported an\u00a0actual dollar amount, as this information is readily available. \u00a0", "answer": 1}, {"article": "She turned to RESTASIS\u00ae because she didn\u2019t want to keep worrying about constantly using eye drops.\nThe quiz on Restasis.com can help individuals learn whether they\u2019re a candidate for the drug.\nOn Restasis.com, you can take the brand\u2019s \u201cdry eye quiz\u201d\u2014 for every quiz taken, Allergan has agreed to donate $1 to the organization.\nAfter toting around eye drops, Tomei said she has found a solution with Allergan\u2019s prescription drug RESTASIS\u00ae, which works by increasing the eyes\u2019 natural ability to produce tears.\nShe decided to partner with Allergan not only because she found the prescription improved her quality of life but also because of the company\u2019s relationship with Guide Dogs for the Blind.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Costs are not mentioned in this story. A quick internet search shows that two packets of 30 vials of Restasis costs more than\u00a0$300. For comparison purposes, a bottle of generic artificial tear drops costs about $10. Also, there is no mention of the issue of insurance coverage for the cost of Restasis. Some insurers limit coverage for topical cyclosporine or require cumbersome prior authorization to approve coverage.", "answer": 0}, {"article": "Both studies appear in the Feb. 2 issue of The New England Journal of Medicine.\nUlipristal acetate is the active chemical in the emergency contraceptive sold in the U.S. as Ella, but the daily doses taken by the fibroid patients in the studies were much smaller than those in the contraceptive.\nIn one study, the drug ulipristal acetate proved to be much more effective than a placebo for shrinking the non-malignant uterine tumors.\nIf trials now under way in the U.S. prove positive, New Jersey-based Watson Pharmaceuticals Inc. and Swiss-based PregLem hope to market ulipristal acetate as a fibroid treatment under the trade name Esmya, says Watson spokesman Charlie Mayr.\nIn another, ulipristal acetate was found to be as effective as monthly injections of the drug Lupron for reducing heavy bleeding in women with uterine fibroids.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No mention of costs.\u00a0 If the drug is awaiting marketing approval in Europe, some estimate could have been obtained.\u00a0 And, since the drug has the active chemical of the Ella contraceptive drug \u2013 only in smaller doses \u2013 at least the cost of Ella could have been cited.", "answer": 0}, {"article": "Fish-oil supplements don't appear to help pregnant women prevent post-partum depression or boost the baby's brain development as previously believed, according to a large trial published Tuesday in the Journal of the American Medical Association.\n\nThe 2,400-woman, randomized study complicates the advice for pregnant women. It adds to a body of mixed research on some potential benefits of the popular omega-3 fatty acid known as DHA, or docosahexaenoic acid. DHA, which can move from the mother to the baby during pregnancy, accumulates...", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There was no discussion of costs and we always think there should be \u2013 even if inconsequential. ", "answer": 0}, {"article": "For further information, please contact:\nThe previously unrecognized PMS/PMDD benefit of PS Plus came about when 2,000 volunteers received and consumed Lipogen's PS Plus for brain health and stress management.\nAccording to the Medical University of South Carolina, current available treatments include SSRIs and other drug treatments that treat side effects and can cost from US$60.00 - US$535.00 per month.\nThese symptoms qualify as PMS in 20% to 30% of pre-menopausal women.\n\"We also have begun an ongoing, double-blind, randomized, placebo-controlled clinical trial with daacro GmbH, Trier, Germany, to learn more how Lipogen's formulation can help alleviate PMS and PMDD symptoms.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Although the release points out the\u00a0high costs of selective serotonin re-uptake inhibitors (SSRIs) and other drug treatments for PMS cost $60 to $535 per month, it fails to mention that a 30-day supply of its product costs $54.95.\nAccording to a website showing the product patent application,\u00a0 it appears to be a combination of\u00a0phosphatidylserine (PS) as the active ingredient along with phosphatidic\u00a0acid\u00a0(PA) and magnesium. These products are available from other manufacturers for purchase on the internet for varying costs.\nOf interest, the patent application (but not the news release) states that various formulations were given \u201cfour times a day\u201d\u2026\u201dfrom three weeks before the expected monthly menstruation until the commencement of menstruation.\u201d\u00a0 That would amount to more than 80 pills or tablets per cycle, which would be quite expensive compared to daily dosing of other medications.", "answer": 0}, {"article": "\"So before we activated the device, we have all sorts of problems\u2026 This is basically your brain saying, 'I'm not breathing.'\nFor Siravo, she said her memory is back to 100 percent.\nIt's only for moderate to severe cases, and like any surgery, there is risk of infection.\nExhausted, the 59-year-old could barely do her job as a nurse \u2013 and she knew something wasn't right.\n\"And then that didn't work.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Here\u2019s what the story says in regard to cost: \u201cThe device costs around $20,000 not including the surgery.\u201d\nThis doesn\u2019t adequately address two key points.\nThe first problem here is that an invasive surgery, such as this one, could be extremely expensive. Does it require the patient to be put completely under by anesthesia? Is it out-patient surgery, or would patients have to spend at least one night in a hospital? Details like that can make a huge difference in terms of cost.\nThe second, bigger problem is that the story doesn\u2019t make clear that this is not a one-time cost. Inspire implants can malfunction, and the batteries in the implants will need to be replaced. For example, a 2010 study published in Sleep Medicine Reviews found that, out of eight patients, five experienced device malfunctions more than six months after implantation. There may have been improvements in the technology since that study was published, but there is still no acknowledgment that Inspire\u2019s internal power supply would need to be replaced periodically \u2014 and neither the new battery nor the related medical procedure is likely to be free.", "answer": 0}, {"article": "Want to embed a link to this report in your story?\nWhy The Research Is Interesting: Much is known about the short-term outcomes of bariatric surgery for weight loss but relatively little is known about its long-term effects.\nStudy Conclusions: The association between bariatric surgery and a lower rate of death from any cause adds to the limited literature describing the beneficial outcomes of these surgical procedures for obese patients.\nSome previous research has been limited by a number of factors, including the lack of a comparison group of obese patients who did not undergo bariatric surgery.\nBottom Line: Obese patients who underwent weight-loss surgery had a lower rate of death from any cause compared with obese adults who received nonsurgical care to manage their obesity.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Three types of bariatric surgery (laparoscopic banding, Roux-en-Y gastric bypass, laparoscopic sleeve gastrectomy) are the primary interventions evaluated in this study. The costs for these common weight loss procedures are not mentioned in the news release.\nSome information \u2014 even broad cost ranges of bariatric surgery compared to nonsurgical care \u2014 is warranted.", "answer": 0}, {"article": "While the function of sweating is to prevent overheating, those affected sweat even when the body does not need cooling.\n(Reuters) - Dermira Inc said its experimental topical therapy for excessive underarm sweating was successful in two late-stage studies, bringing it one step closer to providing an easy-to-use therapy for the often embarrassing condition.\nIn the first trial, a significant improvement in the severity of sweating was seen in 52.8 percent of the patients treated with the drug, compared with 28.3 percent patients in the control group, on a scale designed by the company.\nAbout two-thirds of the total 697 enrolled in the two trials for the company\u2019s topical treatment, DRM04, were treated with wipes containing DRM04, while the rest were not.\nFor instance, a class of drugs called anticholinergics are commonly used off-label for this purpose, but they are linked with the risk of dementia.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The product is not yet on the market, and is defined as experimental, so we\u2019ll rate this as N/A. But readers would still benefit from seeing the\u00a0projected steps\u00a0needed to get on the market, which isn\u2019t made clear here.", "answer": 2}, {"article": "\u201cThere is a larger program we are putting into place.\u201d\nBYL719 plus fulvestrant cut risk of death or progression in those patients by an estimated 35 percent, Novartis said.\nEven though PIK3CA mutations are the most common genetic change in hormone-receptor positive breast cancer, trials of agents seeking to put a brake on this pathway to tumor growth have largely disappointed including on safety issues.\nSamit Hirawat, head of Novartis\u2019s cancer drug development, said in an interview the side-effects profile of alpelisib held up.\nOther drugmakers including Roche have seen similar investigational medicines stumble, making Novartis\u2019s progress here hopeful news, doctors involved in the trial said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Although\u00a0BYL719/alpelisib has not been approved by the FDA, it\u2019s safe to assume that the drug will be costly, and there should have been some discussion of this. The only PI3K inhibitor approved as a cancer treatment, for certain types of lymphoma, is an injection and retails for about $4,700 per vial.\u00a0Many vials may be given over the course of treatment.", "answer": 0}, {"article": "Compared with the 35 stroke patients who got clot-dissolving medicine alone, the 35 who got the two-pronged treatment were nearly twice as likely to regain some neurological function after three days. Imaging results revealed that for those who got both treatments, 100% of the brain tissue initially affected by a clot had blood flowing to it after 24 hours. Among the subjects who only got alteplase, the median level of restored blood flow was 37%.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "We aren\u2019t provided with any numbers, but the story does speak to the issue of cost. \u201cBut many centers, citing mixed findings on the devices\u2019 benefits, have either abandoned or have been reluctant to offer the treatment, which is costly and complex to provide. Insurers, too, have been skeptical of the procedure\u2019s value, and many refuse to reimburse for it.\u201d \nCost would be difficult to pin down precisely for this procedure, since it varies by device type and by hospital, but it would have been helpful to provide a ballpark figure.", "answer": 1}, {"article": "\"In some cancers, a part of the TRK gene has become attached to another gene, which is called a fusion.\nThe larotrectinib research was supported by Loxo Oncology Inc., the National Institutes of Health, the Cancer Prevention and Research Institute of Texas, the National Center for Advancing Translational Sciences, and Alex's Lemonade Stand Foundation.\nLarotrectinib is the first cancer drug to receive FDA breakthrough therapy designation for patients with a specific fusion of two genes in the cancer cell, no matter what cancer type.\nThe results of the larotrectinib trial in adult patients - a 75 percent response rate - were published last month in the New England Journal of Medicine.\nThe selectivity of the drug means it does not cause the severe side effects associated with many traditional cancer treatments, and none of the patients with TRK fusions had to quit the study because of a drug-induced side effect.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release doesn\u2019t offer any cost projections.\nAlthough larotrectinib is not yet FDA approved and therefore not available for sale in the US, its ultimate approval seems likely. In fact, the company that makes larotrectinib, Loxo Oncology, has pursued a partnership agreement with Bayer Pharmaceuticals to market the new drug in the US.\nGene-targeted oncology drugs that have already hit the market, some of which are now available in generic form, have remained very expensive therapeutic options.\u00a0 An added expense with larotrectinib is that genetic testing for the oncogenic mutations NTK1, NTK2, and NTK3 is not yet commonplace.\u00a0 All of these factors suggest that larotrectinib will be an expensive treatment.", "answer": 0}, {"article": "According to Dr. Anthony L. Komaroff, a Harvard internist and epidemiologist who has written a commentary to accompany the study, \"For many years medical scientists have speculated that the symptoms of ME/CFS might be caused by cytokines, molecules that the immune system use to wage war against foreign invaders of the body.\nWhat's more, the findings also point to possible treatment with immune-modifying or anti-inflammatory therapy.\nSo why do routine lab tests that doctors order often come back negative or not informative in ME/CFS patients?\nThis is significant because symptoms in these patients and findings from other studies also suggest that chronic inflammation plays a major role in the illness.\nKomaroff also notes a recent increase in research funding by the National Institutes of Health, which has included a comprehensive in-house study aimed at unraveling the underlying causes of the condition.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story talks about work to develop a commercially available test, but there is no discussion of what such a test might cost. A story needs to at a minimum discuss what is known about the costs of diagnosing and potentially treating a cytokine-based condition.", "answer": 0}, {"article": "\"It is not going to be reimbursed by insurance, at least for the first generation and certainly for the foreseeable future,\" he said.\nThe device doesn't change the stomach's natural anatomy, according to the FDA.\nBut the device can only be used for six months at a time, and it is not likely to be an alternative for people who require lap-band surgery, stomach stapling or other forms of bariatric surgery, said Dr. Mitchell Roslin, chief of obesity surgery for Lenox Hill Hospital in New York City.\nPatients who did not receive the device lost about half that amount of weight -- just over 3 percent of their total body weight, the FDA said.\nThe balloons take up space in the stomach, which presumably makes people feel fuller faster, the FDA said in its announcement Tuesday.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does discuss costs. The discussion would be better if it included the cost of implanting the device. The story only told the price of the device in Europe \u201caverage price is about $6,200, according to the manufacturer.\u201d But it was not clear whether that price includes fees to the doctor and clinic for insertion and removal. And readers/consumers should also think about this: given the high likelihood of \u201cintolerable\u201d nausea, what is the impact this might have on lost work time?\nWe are not given context of prices for other procedures related to this one \u2013 such as bariatric surgeries.\n\u00a0", "answer": 1}, {"article": "With the FDA's announcement, drugs like pembrolizumab have also begun to change the way that physicians, patients and government regulators think of cancer. No longer will they see all cancers of the lung, breast, colon, brain, liver, pancreas and prostate as distinct from one another. Instead, they will look for the common genetic mutations that give rise to cancers no matter where they're found. And they'll treat those cancers with a drug that uses that common signature as a homing beacon, either for the immune system or for targeted cancer drugs to attack.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Readers have to get deep into the story, but they are eventually told about \u201cKeytruda\u2019s $100,000-per-year price tag.\u201d", "answer": 1}, {"article": "Packaged in powder form and mixed with liquid, alginate expands in the stomach to form a thick gel, mimicking the effect of a large meal.\nAccording to the researchers, the higher sodium content of the alginate drink \u2014 a little over one gram per dose, or about half a teaspoon of salt \u2014 could have offset any potential blood-pressure reducing effect of the supplement.\nFor Mette Kristensen, one of the study\u2019s authors, the message seems clear: \u201cIf you actually comply with the treatment, you do have the improvement in weight loss.\u201d\n\nHowever, effects on blood pressure were less promising.\nAmong people who stuck with the trial, those on the fiber supplement lost 15 pounds, on average, compared to 11 pounds in the placebo group.\nFive people taking the fiber gel left the study due to problems with stomach bloating, nausea and diarrhea.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story explained that alginate as an aid to weight loss is already available in pill form, selling for around $45 for a seven-day supply.", "answer": 1}, {"article": "Modern water dispensers may be more effective than old-fashioned water fountains since water quality and cleanliness may deter kids from using older fountains, and they're not as efficient at serving large numbers of children, experts noted in an accompanying editorial.\nThe editorial, entitled \"Power of a Simple Intervention to Improve Student Health: Just Add Water,\" said the study's findings are significant.\nThe study, published in JAMA Pediatrics, analyzed data collected from 1,227 elementary and middle schools across New York City - some with and some without \"water jets.\"\n\"The study by Schwartz and colleagues in this issue of JAMA Pediatrics adds to a growing body of evidence supporting the importance of providing drinking water access in schools.\nIn this study, the findings demonstrate that water access in schools can promote healthy weight outcomes among students,\" Turner and Hager said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The CBS article does not mention any costs associated with the installation of a water dispenser. The JAMA Pediatrics article states that water jets are \u201crelatively low-cost\u201d interventions, with a one-time cost of about $1,000 per machine. There are also ongoing maintenance expenses, as well as additional costs for disposable cups. In addition,\u00a0if the jets affect sales of milk and other beverages on school grounds, the costs would actually be higher still.\nWe believe the water jet cost should have been covered in the story, since researchers in the original journal article emphasized the association between a \u201crelatively low-cost water availability intervention and decreased student weight.\u201d That\u2019s why we give the CBS article an Not Satisfactory rating here.", "answer": 0}, {"article": "In February, the World Health Organization offers a prediction \u2014 based on surveillance and laboratory and clinical studies \u2014 and then each country uses that prediction to approve vaccines in its jurisdiction.\nSo, yes, the flu vaccine can prevent illness, but it's hard to detect major effects on public health in the data.\nThat seems to be the same conclusion that other studies have drawn \u2014 the flu vaccine is modestly helpful, and doesn't hurt.\nSo, as this Cochrane review notes, it's impossible to draw firm conclusions on the effectiveness of the flu vaccine for those over 65 because the data is so biased and poor.\nOn the other hand, the evidence suggests that there's no harm in getting a flu shot, either.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "While the story only touches on the costs of flu shots in passing, saying that they\u2019re relatively cheap, we\u2019ll give them the benefit of the doubt on this category.\u00a0 At least at two points in the story, the issue of costs are raised.\u00a0 We would have liked it even better had the story mentioned the actual range of possible costs for the flu vaccine.\u00a0 A quick web search shows the prices ranging from $10 to $30, based on information from the CDC.\u00a0 And free shots are regularly available at public health centers as well.", "answer": 1}, {"article": "\u201cNot everything that is natural is safe,\u201d she said.\nResearchers would still need to conduct pre-clinical trials to test its medicinal benefits.\nHer lab at Emory is doing additional research to confirm the safest and most effective way of using the plant extract.\nIts leaves and bark are used to treat wounds, ulcers, burns and skin infections, Quave said.\nThe plant extracts didn't harm the skin tissues or the normal, healthy bacteria found on skin.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story didn\u2019t discuss costs. But if\u2019s not too early to state that the plant extracts \u201ccould help fight deadly superbug,\u201d then it\u2019s not too early to discuss costs of said extracts.\nLess savvy readers may think that treatment with this plant involves crushing up some\u00a0berries and putting them on your skin rash, a very inexpensive process. However, more thorough reporting would have said something about the need for\u00a0complex and expensive clinical trials, which would drive up the price of any final drug.", "answer": 0}, {"article": "At that point, a valve designed to open on its own, allowsthe balloon to empty and be excreted naturally from the body,eliminating the need for endoscopy or another procedure.\nimmediate pastpresident of the ASMBS and vice-chair, UC Irvine Department ofSurgery and chief of gastrointestinal surgery, who was not involvedin the study said the device is not a permanent solution to weightloss, but has the potential to help those individuals who areoverweight or have obesity and are not candidates for bariatricsurgery.\nAllurionTechnologies, the manufacturer of the device called Elipse\uf0d4, whichis not yet commercially available, is studyingwhat it says is the \u201cfirst procedureless gastric balloon\u201d inpatients with a body mass index (BMI) of 27 or more.\nThe Agency for Healthcare Research andQuality (AHRQ) reported significant improvements in the safety ofmetabolic/bariatric surgery due in large part to improvedlaparoscopic techniques.\nNewswise \u2014 Anew gastric balloon that can be swallowed like a pill and then filledwhile in the stomach, helped patients lose more than 37 percent oftheir excess weight over four months, according to new researchpresented here at ObesityWeek 2015, the largest international eventfocused on the basic science, clinical application and prevention andtreatment of obesity.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release doesn\u2019t suggest what the procedure might cost. It could be more than the gastric balloons already on the market due to the use of new technology or it could be less since it is less invasive than surgery. It would be useful to provide readers with some idea of how the procedure will be priced in comparison to similar procedures. A web search found prices for gastric balloon procedures ranging from $6,000 to $10,000 across the United States.\nWhereas the Eprise gastric balloon pill would be available to those with a BMI of 27 and above, according to the release, it is not a permanent weight-loss solution. Not exactly a bargain then?", "answer": 0}, {"article": "A moderate dose of MDMA was found to significantly increase feelings of loving, friendliness and playfulness, the researchers said, whereas the low dose of MDMA boosted feelings of loneliness.\nThis effect, the Bedi and his team suggested, could help people improve their social skills by shielding them from the negative emotions of others.\nEach session lasted at least 4.5 hours, or until all effects of the drug had worn off.\n\"More controlled research is needed to establish whether MDMA can safely and effectively add to psychotherapy for some conditions and, if so, what the mechanisms of these effects are,\" Bedi said.\nAll said they had taken MDMA for recreational purposes at least twice in their lives.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No mention of costs. What would be the cost of overcoming \u201ctrouble connecting with others socially\u201d?", "answer": 0}, {"article": "Elective Caesarean-section deliveries can increase problems for a newborn if done too early -- even when the baby has technically reached full term, according to a large new study.\n\nThe findings could help diminish a widely popular practice -- now about one in every 14 births -- in which mothers choose to schedule c-sections, or surgical removal of the baby. The study, published in the New England Journal of Medicine, found that about a third of elective c-sections are done too early -- before 39 weeks. Although a fetus is considered...", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No data comparing costs of c-section vs. vaginal birth is provided. \nThis is surprising, given the fact that one reason experts discourage elective c-sections is high cost. ", "answer": 0}, {"article": "A new generation of treatments for severe eczema is on the horizon, which doctors say could help millions more patients gain relief from chronic outbreaks of the oozing, itchy and sometimes debilitating rashes that come with the disease.\n\nAt least two new eczema medicines could be approved by the U.S. Food and Drug Administration in 2017, and a half-dozen more drugs are being tested in clinical trials.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The costs of these two new medications is not addressed. \u00a0Given their possible availability by 2017, the dearth of cost information is a real disservice. Many currently available treatments are very inexpensive, so\u00a0it is important to know\u00a0the costs of the newer medications in order to assess if they are a viable alternative for\u00a0people and\u00a0for health systems.", "answer": 0}, {"article": "BMI is a calculation of body fat based on height and weight, and a BMI of more than 30 is considered obese.\nCaution is vital when using any drug that has been approved for one condition for another, Sandon said.\nBut they also suffered more side effects than patients not taking the medication.\nThe authors said such side effects were typically \"mild.\"\nAll study participants followed their treatment plan for one year.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Zonisimide\u2019s cost is known. It is already being used as an antiseizure medication. The story could have discussed its cost in that setting. Instead, this is one of the 70% of stories we review that include only claims (\u201cshows promise\u201d in this case) but nothing about what the promise costs.", "answer": 0}, {"article": "Actually, nitrous is making a comeback in U.S. maternity circles. It has remained a staple of childbirth in Canada, Australia, and Britain \u2014 Catherine, Duchess of Cambridge (the former Kate Middleton), who welcomed her third royal baby, Louis Arthur Charles, last month, reportedly has used it. But it basically disappeared in the United States in the 1970s. American women preferred to be numbed below the waist with epidural anesthesia, or at least that became the gold standard for pain relief.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The cost of nitrous oxide for use during labor in one facility ($250) is included. It\u2019s also mentioned that most insurance plans won\u2019t cover it.\nA bonus that may have been appreciated by readers would have been comparing its price to the two most common approaches for managing labor pain (in the US): epidurals and IV narcotics.", "answer": 1}, {"article": "A growing number of doctors who treat the estimated 6.4 million American children diagnosed with A.D.H.D.\nYet Dr. Bertin has recently changed the way he talks about medication, offering parents a powerful argument.\nThe question is whether these effects can last once the drugs have left the bloodstream.\nDr. F. Xavier Castellanos, director of research at the New York University Child Study Center, called assertions that stimulants are neuroprotective \u201cexaggerated,\u201d adding: \u201cThe best inference is that there is no evidence of harm from medications \u2013 normalization is a possibility, but far from demonstrated.\u201d\n\nA.D.H.D.\nIn an email, Dr. Wilens said he had not received \u201cany personal income\u201d from the pharmaceutical industry since 2009.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The costs of ADHD medications and other common therapies are readily available. The story would have been better if it had included at least a brief reference to these costs", "answer": 0}, {"article": "\"For black tea lovers, there may be a new reason to keep drinking it,\" she said.\nThe new study also concluded that both green tea and black tea have different effects on liver metabolism.\nThe new findings show that black tea polyphenols, which are too large to be absorbed in the small intestine, stimulate the growth of gut bacterium and the formation of short-chain fatty acids, a type of bacterial metabolites that has been shown to alter the energy metabolism in the liver.\nThe findings build on a 2015 UCLA study that demonstrated that both green tea and black tea helped prevent obesity in mice that consumed a high-fat, high-sugar diet.\nDr. Zhaoping Li, director of the UCLA Center for Human Nutrition, chief of the UCLA Division of Clinical Nutrition and the study's senior author, said the findings suggest that the health benefits of both green tea and black tea go beyond their antioxidant benefits, and that both teas have a strong impact on the gut microbiome.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There is no discussion of the costs of black, decaffeinated tea.\nWhile one might argue that the cost of tea is relatively well known, remember that this was an animal study. We don\u2019t know how much a person would have to drink in order to achieve the equivalent dosage for humans. The release could have clarified this point.", "answer": 0}, {"article": "Furthermore, a study from the University of Rochester, published in March in Environmental Health Perspectives, found that men with shorter anogenital spans had lower sperm counts, poorer quality sperm, lower sperm concentrations and lower motility.\nBut one urologist said the the finding is too preliminary to introduce into clinical practice, however.\n\"This paper also provides new data on infertile men, who have shorter (less masculine) anogenital distance.\"\n\"Together the two studies make a strong case that this simple measure (the anogenital distance) reflects early genital development and predicts semen quality and fertility,\" she said.\nFurther research is needed to compare techniques for measuring anogenital distance and assess their accuracy, he and his colleagues said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Not applicable.\u00a0 The cost of such an approach is not in question.", "answer": 2}, {"article": "Glover acknowledges that \"it's not a perfect solution.\nThough the immunotherapy treatment is simply a matter of gradually increasing your tolerance to peanuts, you could have a severe reaction at home.\nThere are more than a few caveats when it comes to the treatment regimen.\nStill, if it had taken twice the amount of time, she would have done it: \"It's peace of mind.\"\nThe tipoff: a skin reaction around her mouth after she was given food with a small amount of peanuts in it.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not mention costs \u2014 particularly important since the treatment might have to be taken for life. It\u2019s reportedly due to come on the market next year. ", "answer": 0}, {"article": "Hernias occur when part of an internal organ, such as the intestines, bulges out through muscle.\nThe traditional approach may be appropriate when it's too risky to place patients under general anesthesia, Brunt said, such as in elderly patients and those with multiple health problems.\nRecurrences decreased to 0.5 percent and 4 percent, respectively, if the procedures were performed by experienced surgeons.\nThe other approach is older and is performed through a 2- to 2.5-inch incision in the groin, Brunt said.\nThe study authors didn't examine a third approach, known as \"patch and plug,\" he said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "We\u2019ll give credit to the story for attempting to compare the relative costs of the two procedures, but we thought the language used was just too vague to support a satisfactory rating. The story says the costs of the two procedures are \u201ccomparable,\u201d but that \u201cthe laparoscopic procedure may cost more.\u201d Unfortunately, it\u2019s difficult to tell from this description if the procedures cost about the same or whether the laparoscopic procedure is, in fact, more expensive. Attaching a specific dollar figure to each procedure would have made the meaning more explicit.\u00a0 Given the nature of the long-term follow-up presented, one could have discussed both the short-term medical costs of the two procedures and then whether there were differences in care over the ensuing 5 years that may have changed the short-term comparison.", "answer": 0}, {"article": "\"My back, my legs were just covered with a hot red rash,\" Vinnedge said.\nThe researchers hoped that by choosing T cells more selectively and cloning only those judged most likely to vanquish their foe, the treatment would be more effective.\nIn a bid to make cancer immunotherapy more effective, researchers report they have succeeded in halting the progress of aggressive melanoma in its tracks \u2014 at least briefly \u2014 in seven patients treated with an army of cloned cancer-fighting immune cells.\nIn one of those patients, the treatment resulted in complete remission of his metastatic melanoma and evidence that his immune system stands ready to fight any return of the cancer after three years.\nHis research group is making plans to try the technique on patients with advanced ovarian cancer and sarcomas \u2014 rare tumors that arise from connective tissue in bones and muscle.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "An early experiment of immunotherapy against melanoma may be too early to allow for a cost estimate.", "answer": 2}, {"article": "According to Kramer, \"This randomized study concludes that [aspirin's] use is not only effective for reducing the incidence of preeclampsia at term, but also preterm.\nThere were no serious side effects for expectant mothers, or adverse events for the babies related to aspirin use during pregnancy, the researchers noted.\nThe reduction in risk was even greater for early deliveries.\nAbout 1,600 women completed the double-blind, placebo-controlled study.\nACOG already recommends that women who are at high risk of preeclampsia take a low-dose baby aspirin beginning between 12 and 28 weeks of pregnancy.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "We\u2019ll consider this N/A since generic aspirin is very affordable. Still, we never think it\u2019s a bad idea to acknowledge the cost of a treatment. Also, there is the potential for significant cost savings to individuals and society by reducing the financial burden of treating pregnancy and childbirth complications using only a very affordable medication. We\u2019d be curious to see an estimate.", "answer": 2}, {"article": "MayoClinic: Find out more about melanoma\n\nOne study presented at the American Society of Clinical Oncology's (ASCO) conference on Sunday focused on the experimental drug vemurafenib.\nNearly 90% benefited from this new targeted drug, Schuchter said.\nResearchers compared this new drug, which comes in pill form, to the only FDA-approved chemotherapy drug for melanoma, dacarbazine: It has been used to treat melanoma patients since 1975, but is only effective in about 10% of patients.\nYervoy takes a while to work, and some patients may not have that time, study author Chapman said.\nHe also points out that both drugs do have side effects so patients have to be monitored.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Not a word about costs \u2013 difficult to comprehend given the estimates the New York Times provided of $120,000 per course of treatment for one and \u201cat least tens of thousands\u201d per year for another.\nIs this not an issue worthy of a line?", "answer": 0}, {"article": "NEW YORK (Reuters Health) - Considering having a surgeon remove your cancerous prostate using a robot?\nIn the current study, Murphy and his team looked at 68 studies of robot-assisted laparoscopic surgery to better understand its downsides.\nAnd while some studies showed low complication rates, the researchers add, those rates went up when doctors used a standardized approach to reporting complications.\nFinally, the researchers note, expenses associated with the procedure\u2014the robot costs at least 1.8 million ($2.6 million) to install, 100,000 ($145,000) a year to run, and 1,500 ($2,200) extra for each surgical case-mean the procedure is \u201cprohibitively\u201d expensive \u201cfor many hospitals and indeed many countries.\u201d\n\nThe researchers conclude: \u201cThe significant learning curve should not be understated, and the expense of this technology continues to restrict access to many patients.\u201d\nAlso, the researchers add, robot-assisted surgery is no easier to perform and has no better outcomes in patients with conditions that can worsen surgical outcomes, such as being obese, having a large prostate, or having had previous surgery in the area.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "\u00a0The story indicated that the robotic procedure was more expensive than a standard surgical prostatectomy. In addition, it included information about the expenses associated with obtaining and running the equipment.", "answer": 1}, {"article": "\"It's premature to make any conclusions,\" he said.\nBut Dr. Anthony D'Amico, chief of radiation oncology at Brigham and Women's Hospital in Boston, said that this study was too small to reach any definitive conclusion about the value of vitamin D in fighting prostate cancer.\nThe findings also need to be replicated in a much larger number of patients, D'Amico said.\nMONDAY, March 23, 2015 (HealthDay News) -- Vitamin D supplements may slow or prevent low-grade prostate cancer from progressing, a small new study suggests.\nD'Amico stressed that men should not start taking vitamin D supplements in hopes of slowing or curing prostate cancer.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story doesn\u2019t address cost. While it can be argued that most patients have a rough idea of the price of vitamin D supplements, a quick word on the monthly cost of supplements, or the potential cost-effectiveness of supplementation as part of a larger watchful waiting approach, would have been useful. The article does point out that vitamin D is available in fortified dairy products and directly from El Sol.", "answer": 0}, {"article": "But plasma insulin response was sharply lower in fructose drinkers, which may affect what we eat, according to the senior author, Dr. Kathleen A.\n\u201cInsulin is released when we consume glucose,\u201d she said.\nAs they did so, they rated their hunger using the scale.\n\u201cDon\u2019t stop eating fruit.\nBefore having their drinks, the participants rated their desire to eat on a one-to-10 scale from \u201cnot at all\u201d to \u201cvery much.\u201d Then they drank the liquids and had functional magnetic resonance imaging brain scans while looking at images of food and of neutral objects like buildings or baskets.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "It\u2019s hard to assess cost in this situation \u2014 there is no specific medication or treatment to put a price tag on. We\u2019ll give this a \u201cNot Applicable.\u201d", "answer": 2}, {"article": "Read more: Trump Health Exam: President Still Taking Hair Loss Drug Even After Research Revealed Link to Erectile Dysfunction and Depression\n\nIn the U.S., the National Institute of Mental Health estimates 16.2 million adults experienced at least one major depressive episode in 2016.\nPooling data from 522 trials including nearly 120,000 patients, researchers found all drugs analysed were more effective than placebos in the treatment of adults with acute depression.\nIn the U.K, where a number of the study authors are based, at least one million more people could benefit from drugs or psychotherapy, senior author John Geddes said.\nJames Warner, an Imperial College London psychiatrist, added: \u201cDepression causes misery to countless thousands every year and this study adds to the existing evidence that effective treatments are available.\u201d\nWhile these results should reassure many people with depression that antidepressants can be effective, \u201cthis does not necessarily mean antidepressants should always be the first line of treatment,\u201d he said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Without mentioning any numbers, the story does say that the costs of antidepressant drugs tend to be lower than the other major treatment approach for depression, which is talk therapy.\nThe story would have been stronger with cost data. For example, the four drugs found most effective\u00a0 in the analysis\u2013 mirtazapine, escitalopram, venlafaxine, and sertraline \u2014 cost $8 to $12 for 30 tablets, according to the web site GoodRx. The study says, \u201cAll of the most effective antidepressants are now off patent and available in generic form.\u201d\nIt also doesn\u2019t mention that talk therapy may have more value for some patients because it can equip people with tools for life, and severe depression needs to be treated by a combination of drugs and talk therapy.", "answer": 1}, {"article": "; Francesca Cesari, MSc., Ph.D.; Anna Maria Gori, MSc.\nIn an editorial accompanying the study, Cheryl A. M. Anderson, Ph.D., M.P.H., M.S., an associate professor of preventive medicine at the University of California, San Diego, in California, wrote that there were similarities between the two diets that may explain the results.\nMost participants were able to stay on both diets.\nAnderson, who was not involved in the study, added that promoting both diets by healthcare professionals \"offer a possible solution to the ongoing challenges to prevent and manage obesity and cardiovascular diseases.\"\nThe association has strict policies to prevent these relationships from influencing the science content.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "At first glance it might seem appropriate that costs are not mentioned. However, the comparative costs of these two diets could vary considerably depending on what part of the world you live in (ie. in some locations, a Mediterranean diet is either not feasible or prohibitively expensive).\nAlso, the subjects in this study received both nutritional counseling and diet plans which, may not only have influenced the outcomes of this study, but also would carry a price tag in the real world.", "answer": 0}, {"article": "Kychman is an advisor to Boehringer Ingelheim and serves on their speakers' bureau, services for which he is compensated.\nThe findings come from phase III clinical trials that drugmaker Boehringer Ingelheim hopes will convince the FDA to approve flibanserin for the treatment of hypoactive sexual desire disorder (HSDD).\nIn the 24-week \"Bouquet\" studies (each of the Boehringer Ingelheim-funded studies is named after a flower), there were few drug-related side effects.\nData suggest that the drug begins to affect sexual satisfaction after four weeks of continuous treatment.\nSome 15% of women on flibanserin, and 7% of those on placebo, stopped treatment due to side effects.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Cost data for flibanserin is not provided.\u00a0 Some projection of cost should be available for any drug this far along in Phase III trials \u2013 and for which the company has already begun marketing campaigns.\u00a0 If not from the company, then from stock analysts. ", "answer": 0}, {"article": "Other scientists and companies have long sought ways to measure risk from multiple, additive gene effects \u2014 the \"poly\" in polygenic \u2014 and Myriad Genetics has begun selling a type of polygenic test for breast cancer risk.\nBut specialists in heart disease and genetics who weren't involved with the research called the new findings exciting because of their scope.\nInstead, Kathiresan can calculate risk scores for those five diseases \u2014 eventually maybe more \u2014 simply by reanalyzing the kind of raw data people receive after sending a cheek swab to companies like 23andMe.\nEach variation alone would have only a tiny effect on health.\n\"This is the first time polygenic scores have really been shown to reach the level of precision where they can have an impact\" on patient health.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does say that the new approach \u201cdoesn\u2019t require the most sophisticated type of genetic testing\u201d \u2014 which is considerably expensive \u2014 adding that they (the researchers) can calculate \u201crisk scores for those five diseases \u2014 eventually maybe more \u2014 simply by reanalyzing the kind of raw data people receive after sending a cheek swab to companies like 23andMe,\u201d\u00a0an at-home genetic test kit currently available. But it fails to point out that such kits themselves can be relatively expensive and currently wouldn\u2019t be covered by most medical insurance plans.", "answer": 0}, {"article": "Symptoms of heart failure include fatigue, breathlessness and swelling in the limbs.\nBut the study was small, and the stem cells had only a minor impact on patients' heart function.\nThat's in contrast to many past studies, where researchers have injected stem cells -- often from patients' bone marrow -- into the heart.\nIt takes later-phase trials -- where some patients receive the treatment, and others do not -- to prove that a therapy actually works.\nBut it's not clear whether the stem-cell tactic was actually effective, said Gorodeski, who was not involved in the study.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Costs aren\u2019t addressed. This is a tricky one, given that this work is still so far removed from being used in clinical practice (and therefore having an established cost). However, stem cell therapies in general are notoriously expensive, so it\u2019s certainly an issue worth noting. If it\u2019s not too early to talk about benefits, it\u2019s not too early to talk about costs.", "answer": 0}, {"article": "Hupin D, Roche F, Gremeaux, et al.\nDr Hupin emphasised that the widespread acceptance of this message would encourage more elderly people to include even \"low doses\" of physical activity in their usual daily activities, without experiencing high levels of fatigue or of pain.\nThese differences in risk were statistically significant.\nAs a simple rule for the elderly Dr Hupin recommended that at least 15 minutes of physical activity for five days a week would be a suitable first target for the elderly.\nBased on the results, Dr Hupin said that a revision of the recommendations for physical activity in the elderly may thus be warranted and beneficial - low dose physical activity can significantly reduce mortality.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Cost is always a concern. But in this case, the release mentions \u201cbrisk walking, cycling, swimming or gymnastics\u201d as physical activities, not some fancy exercise devices. So we\u2019ll rate it Not Applicable, although we\u2019d note that some of these activities might not be accessible without a gym membership or other equipment.", "answer": 2}, {"article": "[Watch how the body\u2019s \u2018serial killers\u2019 stalk and attack cancer cells]\n\n\"This is a first in class agent, a brand new therapy,\" Harrington said.\nWhen the latest trial was started, Harrington explained, there was no standard of treatment for melanoma -- so it's compared to a treatment that no one expected to outpace T-VEC.\nBut this is the first time a modified virus has been successful in carrying out that treatment.\nNow that other therapies -- ones that target specific mutations in patients' cancer cells -- are showing more success than what was available when the trial was formed, researchers will have to see how T-VEC compares.\nBut there's more work to be done to determine just how T-VEC can fit into the cancer-treatment landscape.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There is no discussion of the costs of this drug. Genetically modified drugs are often extremely expensive and because there is no discussion of alternative therapies, it is difficult to know anything about the cost, actual or comparative.", "answer": 0}, {"article": "Trisha Bradbury was one of the participants allocated to the FIT study, and she explains: \"I lost my mum at 60, and being 59 myself with a variety of health problems, my motivation was to be there for my daughter.\n\"As well as being delighted by the success of the study in the short term, there are very few studies that document weight loss past the end of treatment, so to see that people continued to lose weight despite not having any support shows the sustainability and effectiveness of this intervention.\"\nIn addition, users of FIT lost 4.3cm more around their waist circumference in six months - and continued to lose weight after the intervention had finished.\nThe study showed how after six months people who used the FIT intervention lost an average of 4.11kg, compared with an average of 0.74kg among the MI group.\nFIT goes one step further than MI, as it makes use of multisensory imagery to explore these changes by teaching clients how to elicit and practice motivational imagery themselves.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Both MI and FIT rely on patients engaging in multiple sessions with a trained therapist. Whether done in a for-profit country like the United States or a country that partially or fully subsidizes health care, there are cost considerations. The cost of those sessions, and follow-up consultations, was not mentioned.", "answer": 0}, {"article": "Actinic keratoses are typically red, scaly skin lesions that can over time develop into a type of skin cancer.\nThe new study was funded by Picato manufacturer LEO Pharma.\nBecause the new gel is only used for a few days, any irritation is usually short-lived.\n\u201cThe shorter application period is what makes ingenol mebutate a breakthrough in the treatment of actinic keratosis,\u201d researcher Mark Lebwohl, MD, says in a news release.\nOther available topical treatments must be used for several weeks, and often irritate the skin.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No mention of the cost of the gel. We quickly found online estimates of $699 for one tube at .05% dosage.", "answer": 0}, {"article": "People who experience them see or hear things that are not there (hallucinations) and/or have false beliefs (delusions).\nNo drug in this class is approved to treat patients with dementia-related psychosis.\nThe U.S. Food and Drug Administration today approved Nuplazid (pimavanserin) tablets, the first drug approved to treat hallucinations and delusions associated with psychosis experienced by some people with Parkinson\u2019s disease.\n\u201cNuplazid represents an important treatment for people with Parkinson\u2019s disease who experience these symptoms.\u201d\n\nAn estimated 50,000 Americans are diagnosed with Parkinson\u2019s disease each year, according to the National Institutes of Health, and about one million Americans have the condition.\nNuplazid was granted for the treatment of hallucinations and delusions associated with Parkinson\u2019s disease.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The news release makes no mention of Nuplazid\u2019s cost. An online search for the anticipated cost of the drug revealed only that market analysts predict the drug will reach blockbuster status \u2014 meaning it will have sales of at least $1 billion. The drug will no doubt be much costlier than competing generic anti-psychotics.", "answer": 0}, {"article": "\u201cBut it does give us hope.\u201d\nOne of the study\u2019s limitations is its small size, and researchers cautioned that families should not try to replicate the treatment at home.\nChildren without autism were used as a control for the study, the news release reported.\nThe research team surmises the disparity is due to antibiotics prescribed within the first three years of life.\nResearchers also asked the children\u2019s doctors to perform pre- and post-diagnostic evaluations, which suggested lasting benefits.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The short story does not discuss the costs of the experimental fecal transplant. In some patients, the donor stool material is introduced using a colonoscopy or other mechanical procedure, which can cost $2,000. This story does not explain how the stool was given to the children, so the costs are further confused by that.", "answer": 0}, {"article": "MORE: With Early Breast Cancer Treatment, Less May be More: Studies\n\nCertain fruits seemed to confer the biggest protection against breast cancer \u2014 apples, bananas and grapes were associated with the greatest reduction in risk while kale and oranges in adulthood also contributed to reduced breast cancer risk.\n\u201cThis study also has an important message for schools and the need to provide students with the opportunity to consume more fruits and vegetables as part of the school meal program.\u201d\n\nFarvid wasn\u2019t able to document a strong relationship between vegetables and lower breast cancer risk, but says that may be because the study wasn\u2019t powered enough to detect an effect.\nIn the study, Farvid and her team could not find any significant relationship between fruit juice and breast cancer risk; that may be because fruit\u2019s anti-cancer effects may have to do with the fiber found in the whole fruit, which is stripped out of juice.\nThe results also underscore the importance of eating whole fruit, rather than fruit juice.\nThe findings are among the first to look at how diet during adolescence can affect health later, and highlights the importance of establishing healthy habits from a young age, especially since many of the chronic diseases occur over many years and get rooted early in life.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Cost was not discussed, and because this is about fruit, we\u2019ll rate this N/A. However, it is worth pointing out that fresh fruit isn\u2019t something that all consumers can take for granted, since it can be expensive and hard to find in areas known as \u201cfood deserts.\u201d", "answer": 2}, {"article": "The requested document is forbidden. Please try your operation again .", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There was no discussion of costs.", "answer": 0}, {"article": "If the child said a word, the parent repeated it and added something.\nNevertheless, for parents of children with autism, even a modest reduction would be worthwhile.\u201d\n\nDr Max Davie, of the Royal College of Paediatrics and Child Health, said it offered \u201ca hugely cheering message for families\u201d, while Uta Frith, emeritus professor of cognitive development at University College London, called it \u201ca remarkably positive story, because the intervention itself was neither intensive nor invasive\u201d.\n\u201cThese results at follow-up are pretty consistent in showing the benefit of this early intervention for autism across a range of measures.\nThe success of the preschool autism communication trial (Pact) has surprised even the researchers who designed it.\nMy impression is that this is an intervention that reduces the severity of autistic symptoms, rather than curing autism.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The article does a good job of noting the social, health, lost productivity and educational costs of autism in the UK and the United States,\u00a0but it did not note the cost of the interventional program itself, and the time challenges that caregivers of autistic children face in pursuing this kind of intervention.", "answer": 0}, {"article": "The requested URL /usnews/health/articles/070723/23healytip.htm was not found on this server.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story did not contain any information about the costs of the various statin medications.\u00a0 Although not entirely germane to the main topic, since individuals might make choices about which specific statin to take based on claims of enhanced LDL lowering, it would seem that cost information should have been included.", "answer": 0}, {"article": "\"We always assume there's luxury,\" Wright said.\nHe also believes the test will be used by specialists for Parkinson's patients who \"do not exhibit a very typical symptomatology\" or do not respond as expected to treatment.\nWhen validating a new biomarker for disease, \"one should always analyze at least two different (groups of patients and controls) to make sure that the results are reproducible,\" said Hansson, who added that participants should also include both early- and late-stage patients established at different clinics.\nHowever, the test cannot distinguish between the different atypical disorders, which doctors must rely on symptoms to diagnose.\nThough other symptoms will show up eventually and help in diagnosing the patient, in the meantime, the patient will be receiving the wrong medicines.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Costs are not included. Presumably a blood test would be cheaper than a test of spinal fluid, which requires a lumbar puncture.", "answer": 0}, {"article": "The item you've requested, /cgi-bin/article.cgi?f=/n/a/2006/02/15/national/a141001S34.DTL&type=health, was not found.\n\u2022 the item no longer exists, or\n\u2022 there has been an error on the site.\n\nIf you feel the address you entered is correct you can contact us, mentioning the error message received and the item you were trying to reach.\n\nWe apologize for any inconvenience. From here, you can:\n\u2022 use the menu bar above\n\u2022 select an item from our site index below", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No cost of calcium and vitamin D supplements was provided.", "answer": 0}, {"article": "The Ache: Common cholesterol-lowering drugs called statins can have unpleasant side effects, including muscle aches and weakness.\n\nThe Claim: An extract from a bitter, fragrant citrus fruit called bergamot, commonly known as a flavoring in Earl Grey tea, can lower cholesterol with minimal side effects, some scientists say. It also boosts good cholesterol, reduces fatty deposits in the liver and lowers blood sugar, they add.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There are bergamot supplements on the market, but the price was not discussed. The cost of statins is also excluded.", "answer": 0}, {"article": "Between 12% and 20% of women in the 35 countries in the Organisation for Economic Co-operation and Development suffer from perinatal depression, and 20-35% in poorer countries.\nThe study found that women who had least social support such as those who were not living with or near their mother or mother-in-law, benefited most from the therapy intervention, both in the short and long term.\nCognitive behavioural therapy has significant positive effects on a mother\u2019s mental health, income, employment and parenting skills even seven years after the birth of the child, according to the first study of its kind.\n\u201cThis is an important study for the impact on mothers with depression but there are global implications for the treatment of all human beings suffering from depression.\nWhile studies have highlighted the short-term benefits of CBT, until now question marks have been raised about whether it can have long-term effects.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "We were glad that this short story mentioned the societal cost estimate for depression but still find it lacks any \u201ccost\u201d for the therapy under discussion.\nFor the clinical trial, the researchers used an existing system of Lady Health Workers who are specially trained to do the intervention, so the cost would be whatever it cost to add this training and time to their work. (Likely minimal.)\nSo, we think the story should have added a line or two acknowledging that it was a relatively affordable intervention where it was implemented\u2013in Pakistan\u2013but is likely to be of widely varying costs depending on where it\u2019s used. In the U.S., for example,\u00a0cognitive behavioral therapy typically requires 8-12 weeks of visits to a professional who charges between $180 and $250 per hour in the United States, according to Consumer Reports. Some of this might be covered by some insurance.", "answer": 0}, {"article": "Necator americanus, the New World hookworm, is as long and thin as a vermicelli noodle.\nAnd because of the risks associated with parasites, going around infecting people isn't a viable treatment option.\nThe doctor wanted to know whether there might be a connection between the dramatic success of deworming programs around the world and the rise of immune system problems like asthma and celiac disease.\nOnly so many people are willing to have a parasite put inside them for science.\nIt was an intriguing result, but it's difficult to scale that kind of study.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story speculates at length about potential benefits of this treatment, before ever establishing that this is preliminary research. Our guideline is \u201cif it\u2019s not too early to talk about benefits, then it\u2019s not too early to talk about costs.\u201d This story didn\u2019t\u00a0do so.", "answer": 0}, {"article": "Our trial showed no difference between the two in protecting entire communities.\"\nThe original intention of the study was to show that nasal spray vaccines would provide better protection than flu shots, but Loeb says the conclusions of the study are now especially important, given the ACIP's recommendations.\nDr. Mark Loeb, lead author of the study, says his team's findings challenge the ACIP's recommendations towards flu shots, or inactivated vaccines.\nPublished today in the scientific journal Annals of Internal Medicine, the study shows that the nose spray had a similar effect to the standard flu shot.\nLoeb says his team will continue to study herd immunity with different vaccine formulations by vaccinating children.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "This release doesn\u2019t discuss\u00a0costs in its comparison of influenza shots versus nasal sprays, although both modes of immunization have been around for a long while and the costs for both are easily known. \u00a0While\u00a0flu immunizations are often free through public health clinics and such, some\u00a0people receive their immunizations from their family physicians and carry a specific cost.\u00a0 Knowing the difference in costs between the two types\u00a0is useful information both for people and public health officials.", "answer": 0}, {"article": "Chemotherapy and other cancer therapies can wreak havoc on the taste buds and olfactory senses, depriving recipients of the intricate interplay between taste and smell that is critical to grasping flavors and enjoying foods.\nThe team's findings will make it possible for cancer patients to taste foods properly and to enjoy a healthier appetite, enabling more optimal nutrition during a critical period of recovery.\nTheir most recent study builds on the previous body of work through the application of lactoferrin supplements in treating taste and smell abnormalities.\nAlthough TSA is widespread and a frequent complaint of cancer patients, until now, there have been no established therapies that reliably prevent or treat this problem.\nThis research could help us develop TSA-targeted biomarkers and strategies for improving quality of life during chemotherapy.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The cost of lactoferrin supplements is not mentioned.\nThe 250 mg capsules used in this study were supplied by Jarrrow Formulas who list the capsule price as 50 cents. Therefore, three-a-day dosing \u2014 as tested in the study \u2014 would cost $1.50.", "answer": 0}, {"article": "Georgetown University Medical Center (GUMC) is an internationally recognized academic medical center with a three-part mission of research, teaching and patient care (through MedStar Health).\nWASHINGTON -- Consuming soy foods (such as soy milk, tofu and edamame) and cruciferous vegetables (such as cabbages, kale, collard greens, bok choy, Brussels sprouts, and broccoli) may be associated with a reduction in common side effects of breast cancer treatment in breast cancer survivors, say a team of scientists led by Georgetown Lombardi Comprehensive Cancer Center.\nPhytochemicals, or bioactive food components, such as isoflavones in soy foods and glucosinolates in cruciferous vegetables may be the source of the benefit, researchers say.\nThe lead author on the study, Sarah Oppeneer Nomura, PhD, of Georgetown Lombardi, said that while further research is needed in larger study populations and with more detailed dietary data, this project addresses an important gap in research on the possible role of lifestyle factors, such as dietary habits, in relation to side effects of treatments.\nIndeed, in this study, Chinese breast cancer survivors ate more than twice as much soy and cruciferous vegetables.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "While dietary interventions often are considered inexpensive, they are not free. The cost of adding cruciferous veggies and soy products to the shopping lists of potentially millions of women is worthy of a mention.", "answer": 0}, {"article": "Also, scar tissue often builds up around intravenous wires, a process that can make removing and replacing them difficult or dangerous.\nBut Dr. Bardy estimated that the device could work in about 25 percent of patients who now get a defibrillator.\nDr. Bardy said the cost of the new device is about the same as a standard defibrillator.\nDr. Douglas P. Zipes, a professor at the Indiana University School of Medicine in Indianapolis, said the new device could someday displace existing models used in many patients Every month, about 10,000 patients in this country get a defibrillator, either for the first time or as replacements for devices whose batteries have worn out.\nHowever, he said it could help reduce health care costs, because implanting it is much simpler.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "\nThe story notes that the cost of the device would be similar to that of existing devices, but that implantation is simpler, which might make those costs lower. It would have been helpful to specify the estimated cost of existing implantable defibrillators.", "answer": 1}, {"article": "Kilmer McCully of the V.A.\nThe findings follow a number of disappointing studies testing vitamins and other dietary supplements for health reasons.\nThe new findings undermine a theory that taking B vitamins to reduce levels of an amino acid in the blood called homocysteine could protect against heart attacks and strokes.\nThe new study, involving more than 15,000 high-risk patients, did not find any overall benefit and even suggested the combination may be dangerous for some patients.\nAlthough the new studies did show that the vitamins cut homocysteine levels, that did not translate into a reduction in the risk for heart attacks or strokes.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Since this story doesn\u2019t make claims about efficacy, costs don\u2019t seem applicable. ", "answer": 2}, {"article": "\"For example, we know that certain changes in the retina, like thinning tissue [due to cell loss] or weakening electrical activity, occur alongside loss of brain tissue and reduced brain activity in patients with neurological disorders like multiple sclerosis and Parkinson's disease.\nA tiny skin electrode was placed on the skin under the eye to record the retina's electrical activity.\nThe results show the device accurately indicated reduced electrical activity in the retina in multiple cell layers in the participants who had schizophrenia, including in cell types that had not been studied before in this disorder.\n\"However, since every prior study has found that people with schizophrenia exhibit reduced retinal wave forms and slowed retinal responses, our research shows that we closing in on an accurate test that is faster, less invasive, inexpensive and more accessible to patients.\"\nWe and other researchers are now investigating whether retinal changes are related to brain structure and function changes in schizophrenia.\"\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There was no discussion of the cost of this device (or the cost of a test using the device). One news release put the cost at \u201cless than $15,000.\u201d", "answer": 0}, {"article": "For more on stroke, visit the National Stroke Association.\nArora explained that tenecteplase is not widely used in the United States for heart attack patients because these patients are typically treated with angioplasty or heart bypass surgery.\nAmong more than 200 stroke victims, TNKase (tenecteplase) was about twice as effective as alteplase in restoring blood flow to the brain, and it also resulted in less disability, the scientists found.\nIn this study, patients were given the drugs within 4.5 hours after the onset of a stroke, Campbell said.\nCampbell said tenecteplase is more effective than alteplase because of differences in the enzymes in each drug.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story explained that tenecteplase costs about $5,800 in the U.S. compared with about $8,000 for alteplase.", "answer": 1}, {"article": "Scientists still haven\u2019t discovered a cure for the common cold, but researchers now say zinc may be the next best thing.\nAlthough a majority of trials have shown some benefit from zinc, many of them have been criticized for failing to \u201cmask\u201d the treatment, meaning the participants most likely knew they were using zinc, which may have skewed the results.\nIn some of the cited studies, the benefits of zinc were significant.\nWhile the findings are certain to send droves of miserable cold sufferers to the drugstore in search of zinc treatments, the study authors offered no guidance on what type of zinc product to buy.\nAt the same time, many of the trials that showed no benefit from zinc have been criticized for using formulations that may have contained ingredients that blunted the effectiveness of zinc.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Although researchers have not reached a consensus about the optimal dose or formulation, the story could have provided cost information for the various over-the-counter zinc products. In addition, this story could have been enhanced by a brief discussion of the general costs of treatment and the cost of lost work days, school absenteeism, and physician visits.\n", "answer": 0}, {"article": "CT scans, however, are considered overused - with more than 80 million performed in the U.S. during 2011.\nDr. Sumit Majumdar, who wrote an editorial accompanying the new study, said a lower threshold for bone density would catch most cases of osteoporosis and limit \u201cincidentaloporosis\u201d - incorrect osteoporosis diagnoses \u201cdiscovered\u201d while doctors were looking for something else.\nThe researchers, who published their findings in the Annals of Internal Medicine on Monday, compared patients\u2019 CT scans to their dual-energy X-ray absorptiometry (DXA), which is traditionally used to diagnose osteoporosis.\nDespite DXA scans being safe and cost effective, Pickhardt and his colleagues say the test is underused.\nPickhardt said the screenings would have to target the right groups of people to prevent overdiagnosis.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story explained the cost of DXA tests and CT scans.", "answer": 1}, {"article": "About the University of Louisville Physicians Group and The James Graham Brown Cancer Center:\n\nThe James Graham Brown Cancer Center is a key component of the University of Louisville Health Sciences Center.\nIRE was successfully administered to all patients.\nThe data was presented at the American Surgical Association annual meeting in San Diego.\nThe NanoKnife\u00ae IRE system is approved by the U.S. Food and Drug Administration for the surgical ablation of soft tissue.\n\"The STAR data adds to the growing body of evidence that IRE ablation may represent a new treatment paradigm for patients with locally advanced pancreatic cancer,\" said Robert Martin, M.D., Ph.D., F.A.C.S., director of the Division of Surgical Oncology, and Professor, Department of Surgery, University of Louisville, James Graham Brown Cancer Center.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Costs aren\u2019t discussed, but secondary sources suggest each NanoKnife machine (which can be used over and over again) costs between $200,000\u2013$300,000. The one-use needles, which are used to\u00a0zap or ablate cancerous pancreatic tissue, cost about $2,000 each\u2013but it\u2019s not said how many sessions are required. Nor is the cost\u00a0of\u00a0doctors, hospital stay, etc. discussed. Plus, it\u2019s unknown if insurance will cover this.", "answer": 0}, {"article": "\u201cYou could not have convinced me that I would ever have done this or continued with this,\u201d she said.\n\u201cThe mind-body connections set it apart from other exercises,\u201d she said, adding that doctors are seeking \u201canything we can offer that will make patients say \u2018I can really do this.\u2019 \u201d\nDr. Solomon and other experts cautioned that bigger studies with other masters and approaches were necessary.\nAnd Dr. Gloria Yeh, a Beth Israel Deaconess internist and co-author of the editorial, said others \u201cwill say, \u2018It\u2019s too slow, I can\u2019t do that.\u2019 \u201d\n\nBut she said it offered a \u201cgentler option\u201d for patients deterred by other physical activities.\nStill, patients, who received twice-weekly tai chi classes and a DVD to practice with 20 minutes daily, showed weekly improvement on an established measurement, the Fibromyalgia Impact Questionnaire, improving more than the stretching-and-education group in physicians\u2019 assessments, sleep, walking and mental health.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "\u00a0At a minimum, the reporter could have found out how much the master used in the study typically charges and how much the DVD costs. Still, unlike most of the stories, this reporter did write, \"Dr. Shmerling said that though tai chi is inexpensive compared with other treatments, some patients would reject such an alternative therapy.\"", "answer": 1}, {"article": "\"We adjusted for as many of those differences as we could,\" Wong said.\nOther experts expressed skepticism, saying the study's design may have missed another explanation for the lower death rate among men who were treated: They were probably healthier in ways that doctors can tell only by examining them, not by looking at their medical records, which is what the study's authors did.\nThe research, published in today's Journal of the American Medical Association, is the first to directly examine what has become conventional wisdom: that many older men need not treat early prostate cancer because it tends to grow so slowly that they will probably die of something else first.\n\"For many years, the thinking has been that observation or 'watchful waiting' was the safest option for elderly patients with early prostate cancer,\" said Yu-Ning Wong of the Fox Chase Cancer Center in Philadelphia, who led the study.\nThe findings prompted debate among specialists, who said the results could have potentially far-reaching implications because they address one of the central quandaries about prostate cancer and because the disease is so common.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The article does not provide any cost information, and there are clearly wide variations in costs among the various prostate cancer treatment options.\u00a0 ", "answer": 0}, {"article": "\"There are a number of components that lead to a man having normal fertility potential,\" Brannigan said.\nAt-home sperm tests are a fairly new idea, Imler said, but SpermCheck Fertility is not the first one.\nAlthough it's not the first ever at-home test, SpermCheck Fertility is the first one to use the lateral flow assay method, Lopez said.\nThe test is not intended to be a complete semen analysis or an overall indicator of a man's fertility, Lopez said.\nSpermCheck Fertility is the only FDA-approved home sperm test currently on the market and available in retail stores, Lopez said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story says, \u201cThe test costs about $40; the average cost of a semen analysis in a doctor\u2019s office is about $100.\u201d As a comparison, the story says, \u201cThere are also several at-home sperm analysis kits available online. They each include a microscope and cost at least $80.\u201d", "answer": 1}, {"article": "A compound in raspberries is being touted as the next new fat burner. But people looking to lose a few pounds may not want to go running to the produce aisle just yet. Scientists say there are no major human studies to support the idea that a berry holds the secret to weight loss.\n\nRaspberry ketones, the organic compounds that give raspberries their aroma, raised hopes as a weight-loss aid after a 2005 study by Japanese researchers found the ketones boosted fat-burning processes in rat cells in a laboratory as long as those...", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story gives pricing information for some of the supplements mentioned \u2014 $3.79 for a month\u2019s supply of one ketone\u00a0capsule product, and\u00a0$68 for a month\u2019s supply of ketone/coffee bean extract combo.", "answer": 1}, {"article": "Having a large waistline, high blood pressure, high blood sugar, low levels of HDL (good) cholesterol and high levels of triglycerides, are among the factors that make up metabolic syndrome.\nSahebkar said most of the clinical benefits reported for curcumin have been achieved when curcumin was added to a standard drug therapy regimen, and patients should be careful not to replace their prescribed drugs with curcumin without prior consultation with their physician.\nThe study team also analyzed data from eight previous studies and confirmed that curcumin had shown a significant reduction of CRP concentrations in a total of 281 patients.\nThey found that the people who took curcumin had improved blood levels of all three biomarkers as well as reduced fasting blood sugar and hemoglobin A1c, a measure of long-term blood sugar levels.\nIn the eight-week trial, researchers found significant reductions in signs of inflammation, such as C-reactive protein and other blood markers.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story fails to mention or discuss cost at all. A quick online search found that the price of curcumin supplements can vary significantly from as little as $8 for 90 one-gram doses (the size of the dose used in the study) to as much as $45 for 60 doses. The story also notes that \u201cmost of the clinical benefits reported for curcumin have been achieved when curcumin was added to a standard drug therapy regimen.\u201d Adding a potentially high-cost supplement to an existing drug routine could tip the scales of any cost-benefit analysis.", "answer": 0}, {"article": "Not a single cancer was undetected that became palpable,\" she said.\nHowever, with breast cancer remaining a major cause of cancer death in women, there is good reason to pursue the search for improved screening methods, according to the study's lead author, Christiane Kuhl, M.D., chair of the Department of Radiology at RWTH Aachen University in Aachen, Germany.\nThe new study showed that, consistent with previous research, breast MRI can depict these rapidly growing cancers with high reliability.\nAccording to Dr. Kuhl, the results suggest that MRI can serve as a useful supplemental screening tool for women at average risk, especially those with dense mammographic tissue, and that MRI is superior to supplemental ultrasound for this purpose.\nThe results also highlight the ability of MRI in the detection of more aggressive types of cancer.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Although the news release does not specify the exact price tag, it makes the reader aware that MRI screening is often avoided due to higher cost than other screening options:\n\u201cMRI screening has not been considered necessary for women at average risk, and there has been resistance to expansion of MRI into this population due, in part, to concern over higher costs.\u201d\nIt would have been helpful if the release had stated whether or not this rapid MRI will have a lower cost than traditional breast MRI.", "answer": 1}, {"article": "Bone-health experts are making a new push to reduce rates of osteoporosis, with a particular focus on controlling the bone-wasting disease in men.\n\nAn important goal is to get greater numbers of men to be tested for osteoporosis when they come to a hospital or clinic with a fracture to the wrist, vertebrae or other bones that wasn\u2019t from a major accident or trauma. Doctors call this a fragility fracture\u2014one that results from a decrease in bone density.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There is not enough discussion of costs in the story \u00a0The costs one needs to consider \u2014 in addition to the cost of the initial bone scan \u2014 are any treatment-related costs (e.g. drug therapy), as well as follow-up care, monitoring, etc. These would be offset by potential savings in terms of less need for future treatments for a new fracture. The story does mention that hip surgeries cost\u00a0$25,000 or more, which may help explain why hospitals are not clamoring to set up screening programs for men to prevent fractures.", "answer": 0}, {"article": "How miserable is combing a child's hair, lock by lock, to pick off head lice? So miserable that some parents are buying $30 shampoos and other washes that promise to ward off the tiny, grayish bugs.\n\nThe parents get peace of mind that they are doing something. Conveniently for the product makers, there's no way to tell if they kept lice at bay, or if children wouldn't have gotten lice anyway. Makers say sales are growing fast.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story includes the cost of some of the products in question.", "answer": 1}, {"article": "Cardiac hybrid imaging combines coronary computed tomography angiography (CCTA) and myocardial perfusion imaging with single photon emission tomography (SPECT) to provide information on both stenosis and perfusion.\nThe study supports CCTA use for an initial, noninvasive evaluation of patients with known or suspected stable coronary artery disease.\nDr. Kaufmann said that hybrid imaging findings could help guide treatment decisions, such as whether or not a patient should have a revascularization procedure such as bypass or angioplasty.\nThe shear stress information could help identify lesions that do not yet have an impact on ischemia but will in the future.\nThe results show that cardiac hybrid imaging is an excellent long-term predictor of adverse cardiac events in patients evaluated for coronary artery disease.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There is no discussion of the cost of the hybrid imaging approach compared with the standard approach.", "answer": 0}, {"article": "It's a success story you might dream of when you start, but it actually seeing to happen is a great feeling.\"\nLead author Claudia Buntrock, a PhD candidate in clinical psychology at Leuphana, says that because the study only tracked participants' mental health over the course of 12 months, the long-term effectiveness of the intervention is unknown.\nOther experiments with online therapy have found that people didn't continue it if it wasn't guided by an actual human.\nSimilar programs have been used to treat depression, but this may be the first one tested to prevent it, the researchers say.\nThe study, which was conducted by researchers from Leuphana University in Lueneburg, Germany, recruited 406 people with subthreshold depression, which is defined as having some symptoms of depression but not enough to be diagnosed with major depressive disorder.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Cost is not addressed in a meaningful way. The story simply refers to online programs for mental health problems as \u201clow cost.\u201d Given that the online programs used in the study involved generating feedback from online trainers for each session and for each patient, the cost may not be negligible. And it\u2019s not clear whether insurers in the U.S. would be willing to pay for preventive mental health treatment. The research was done in Germany, which has a different health care system than the U.S., but the issue of cost should have been addressed more fully.", "answer": 0}, {"article": "\"But I will say that I don't know of any study looking at acupuncture and vision.\nChildren, however, often have trouble adhering to patch therapy, the treatment can bring emotional issues for some and a reverse form of lazy eye can also take root, the researchers said.\nThere are studies based on symptomatic things such as pain, and I think there's pretty good evidence that it does have benefit in that respect.\nThe team nonetheless pointed out that their study's tracking period was relatively short, and that acupuncture is a complicated system that may lend itself to different success rates, depending on the skills of the particular acupuncturist.\nMONDAY, Dec. 13, 2010 (HealthDay News) -- Acupuncture may be an effective way to treat older children struggling with a certain form of lazy eye, new research from China suggests, although experts say more studies are needed.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story mentions that acupuncture\u00a0may not be\u00a0be covered by many insurers, but it never provides even a ballpark\u00a0estimate of what a typical office visit for acupuncture would cost.", "answer": 0}, {"article": "Guidelines also suggest that pregnant women not drink more than two cups a day.\nI\u2019m also not suggesting that people start drinking coffee by the gallon.\nMost of us aren\u2019t drinking coffee because we think it will protect us, though.\nI can\u2019t think of any other product that has this much positive epidemiologic evidence going for it.\nBut it\u2019s way past time that we stopped viewing coffee as something we all need to cut back on.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There is no discussion of costs, but we\u2019ll rate this Not Applicable since most coffee consumers would have some idea of how much their habit costs them.", "answer": 0}, {"article": "Independent committees look at the details of the patients and how well they are doing in drug trials like these.\nKeytruda, approved October last year for lung cancer and in 2014 for melanoma, is pricey \u2013 costing about $150,000 a year for a course of treatment.\nThe company now can ask the Food and Drug Administration if it will approve Keytruda to use as the first treatment a lung cancer patient tries.\nThe researchers wanted to see how it worked against the standard chemotherapy cocktails.\nKeytruda was being tested for the first time in 305 lung cancer patients who had not been treated at all yet.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story notes the costs and puts the costs in perspective, too. It says, \u201cKeytruda, approved October last year for lung cancer and in 2014 for melanoma, is pricey \u2013 costing about $150,000 a year for a course of treatment. It\u2019s approved for use with a specific test for PD-L1 activity.\u201d", "answer": 1}, {"article": "\u201cIt isn\u2019t \u2018grin and bear it for a few months\u2019 and it will all pass, as many women suffer severe symptoms for five-plus years,\u201d she said.\nIn addition, very few women were receiving vaginal estrogen therapy for sexual symptoms.\nVaginal estrogen preparations are very safe and effective for this problem but were prescribed to less than 5 percent of the women, the authors say.\nDr. Wulf H. Utian, medical director of the North American Menopause Society, agrees that many reasons may underlie the lack of treatment.\n(Reuters Health) - Many women with severe menopausal symptoms are not being treated for them even though safe, effective remedies are available, a study from Australia suggests.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The cost of therapies for menopausal symptoms is not discussed.\u00a0Prempro\u00a0(the common oral estrogen/progesterone tablet) is $1.65\u00a0per pill on an online pharmacy price checker, and must be taken daily \u2014 so the cost implications of some options are significant.", "answer": 0}, {"article": "PSA is a protein produced by cells of the prostate gland.\nIn the study, researchers used data on more than 5,500 men in their 60s and 70s who took part in a drug trial for a prostate cancer prevention drug.\nThe whole issue of prostate cancer screening -- including the PSA test, the digital rectal exam and PSA velocity -- has been controversial, said Dr. Otis Brawley, chief medical officer of the American Cancer Society (ACS).\nHigh levels of PSA can be a marker for prostate cancer, although it's far from a perfect screening tool, experts say.\nAs for PSA velocity, the ACS doesn't have a position on what PSA velocity warrants a biopsy.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story did not discuss the costs of PSA tests or provide estimates of the costs for following up an increase in PSA with a biopsy. These are significant cost issues, which warranted at least a line in the story. ", "answer": 0}, {"article": "\u201cThat\u2019s something that we almost never see in someone who\u2019s manifested the degree of disease one needed to have in order to get into the study,\u201d Smith said.\nThe duration of response to the autoimmune inflammatory disease, along with the quick response to initial therapy, suggests fewer infusions may be just as effective, \u201cbut future studies will sort that out,\u201d Smith said.\nThis eye condition usually lasts one to two years and often improves on its own, according to NIDDK.\nHowever, while only 10 percent of patients who received the drug had double vision before the study, that rose to 50 percent by 24 weeks.\nThe typical treatment for Graves\u2019 eyes is glucocorticoids, which are not always effective and also have side effects, the study team notes.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There is no mention of the potential price of teprotumumab, an important piece of context for the story. Will patients be able to afford this new therapy if it becomes available? Even if exact numbers numbers can\u2019t be pinned down, we know that there are other treatments used to treat the eye bulging that often comes with Grave\u2019s disease and those cost figures should be available. Some suggestion as to whether the new drug might be cheaper or more expensive than are current approaches would be helpful for readers.", "answer": 0}, {"article": "Susan Pisano, a spokeswoman for the Association of Health Insurance Plans, the largest trade group, said insurers would wait for guidance from the FDA, but adds, \"If the FDA pulls back its approval for this particular indication, it would trigger a review of plan policies.\nDoctors told Gilbert she'd be lucky to be alive in five years, but with chemotherapy and radiation, she fought off the cancer, again.\nA few years later, she felt chest pains, and doctors thought she was having a heart attack.\nBut gratitude is tinged with worry, because the Food and Drug Administration is considering the unusual step of revoking its approval of Avastin as a treatment for metastatic breast cancer.\nBut some physicians, including Perez, say the issue is getting harder to ignore.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "", "answer": 1}, {"article": "Collaborating with Dr. De Giglio were Francesca Tona, M.D., Francesca De Luca, Psy.D., Nikolaos Petsas, M.D., Ph.D., Luca Prosperini, M.D., Ph.D., Valentina Bianchi, Psy.D., Carlo Pozzilli, M.D., Ph.D., and Patrizia Pantano, M.D.\nThe results suggest that video-game-based brain training is an effective option to improve cognitive abilities of patients with MS.\nIn the future, the researchers hope to study whether the plasticity induced by video games in MS patients is also related to improvements in other aspects of their daily lives.\nAt follow-up, the 12 patients in the video-game group had significant increases in thalamic functional connectivity in brain areas corresponding to the posterior component of the default mode network, which is one of the most important brain networks involved in cognition.\nThe modifications in functional connectivity shown in the video game group after training corresponded to significant improvements in test scores assessing sustained attention and executive function, the higher-level cognitive skills that help organize our lives and regulate our behavior.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release makes no mention of the cost of this video game/training program although that would be a key immediate question in the minds of both MS patients and their families. Moreover, this cost may not be covered by health insurance whereas other forms of cognitive training, for example performed by occupational therapist, may be. The release also fails to mention the cost of other equipment required to play the video game. Together, the game and player can cost hundreds of dollars, depending on the model purchased, and while that cost may not be overly prohibitive, readers deserve to know it when considering the value of this study\u2019s information.", "answer": 0}, {"article": "Mayta-Apaza AC, Pottgen E, De Bodt J, et al.\nHowever, the new study does suggest that Montmorency tart cherries can be added to the list of gut-friendly foods.\nWhile previous studies on Montmorency tart cherries have ranged from heart health and exercise recovery to sleep, this is the first study to explore the potential gut health benefits.\nWhile the dietary intervention was based on a limited number of human volunteers and more research is needed to support these conclusions, the results help build the foundation for future research and suggest Montmorency tart cherries can play a role in positively shaping the microbiome and maintaining gut health.\nAn international team of scientists found that Montmorency tart cherries helped to positively impact the gut microbiome - a collection of trillions of bacteria and other microbes that live in the intestinal tract.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The cost of Montmorency tart cherry juice is not mentioned.\nWalmart sells a quart of concentrate for about $16.", "answer": 0}, {"article": "Biopsies may be performed via open surgery on the breast or with a less invasive core-needle biopsy in which a small sample of breast tissue from the affected area is removed through a special needle inserted through the skin.\nThe results showed that core needle biopsies were about as accurate as open surgery at detecting cancerous vs. noncancerous breast lesions.\nThey say additional studies are needed to find out what factors affect the accuracy of core-needle breast biopsy.\nA new review of more than 80 studies on the two breast cancer screening methods shows breast needle biopsy was able to distinguish between cancerous and noncancerous breast lesions with about the same accuracy as surgical biopsy and less than half the risk of complications.\nIn addition, the study showed women initially diagnosed with breast cancer with needle biopsy were more likely to be treated with a single breast cancer surgery than those initially diagnosed by open surgical biopsy.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not mention the individual or general health care cost of the different types of biopsies, or if the core needle biopsy guided by x-rays or ultrasound will ultimately cost less than surgical biopsy. The story also was silent on (unaware of?) the big tug of war between surgeons (who get paid for open biopsies) and radiologists (who get paid for the stereotactic biopsies).\u00a0 ", "answer": 0}, {"article": "Some recreational swimming pools and homeowners with backyard pools have manual treadmills that are water-safe and can be plunked right in the water.\nSo, even older patients with limited mobility and balance don\u2019t have to negotiate getting down into a pool.\nWhether you call it water running, aqua jogging or hydrotherapy, you can\u2019t beat a workout in water for an array of health benefits, many experts say.\nBudd Coates, training director at Runner\u2019s World magazine, said runners don\u2019t just plunge into water\u200b therapy when they\u2019re injured; it\u2019s a great conditioning method for healthy athletes, too.\nCoates said the beauty of water running (or even walking) is that it\u2019s great for any age and any level of ability, from elderly stroke survivors to Olympic athletes.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Cost is not discussed, which is a significant oversight. At least some idea of what the out-of-pocket costs are for this kind of therapy is important.\nWhile we wouldn\u2019t expect the story to necessarily address all the following issues, these are the kinds of questions people have when considering what kind of therapy to receive.\nFirst, the treadmill systems: It is difficult for consumers to find a cost for underwater treadmills, as most of the companies that sell them tell potential customers to contact the company for a quote. However, the treadmill company mentioned by name in the article quotes $65,000 in the example on how its leasing program works. And a 2013 story in USA Today says that underwater treadmill systems range in price from $33,000 to $270,000. A 2014 story in Runner\u2019s World says that insurance may cover the use of such a treadmill system at a physical therapist\u2019s office, if the system is being used for injury recovery. The CBS story doesn\u2019t even give us that much information.\nSecond, this story also mentions pools that have a \u201cwater flow system you can work against.\u201d Again, it\u2019s not clear what the costs of such a system would be, but one such company notes that its least expensive therapy pool options start at $7,400 (yet, the same company notes that its standard system \u201cstarts at $22,900\u201d).\nThird, the story also refers to simply exercising in a pool with a foam vest or foam handbells. This is, of course, far more affordable for most people.\u00a0But it\u2019s not clear, at all, how comparable the benefits of this sort of activity are to the use of the high-end systems discussed in the rest of the article.\nLastly, for a story like this, it would be great to know how water-based physical therapy compares in cost to standard PT. It may not be covered by a patient\u2019s insurance and result in higher out of pocket costs, for example.", "answer": 0}, {"article": "Traditionally, highly sensitized patients in need of a kidney have languished on waiting lists because it's so hard to find a compatible donor.\nResearchers found that the treatment -- dubbed IdeS -- quickly wiped out the dangerous antibodies, allowing all but one of 25 patients to have a successful transplant.\nBut the findings mark another step forward for patients like these, according to Jordan, who is medical director of the kidney transplant program at Cedars-Sinai, in Los Angeles.\nThose patients were all successfully treated with standard anti-rejection drugs, according to the researchers.\nNow the new research suggests a simple approach -- an infusion of a particular enzyme hours before the transplant -- could offer a better alternative.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Although the article notes that current desensitization efforts involving time-consuming immune system drug infusions to stifle rejection antibodies add up to $30,000 to the cost of a transplant, it does not make any estimate of the cost of the enzyme infusion that was the subject of the \u201cnovel\u201d approach described in the new study. Based on later comments, it is presumed to cost about $65,000.", "answer": 0}, {"article": "With knee-replacement surgery on the rise, more patients with two bad knees are opting for a controversial procedure that replaces both at the same time.\n\nSimultaneous bilateral knee replacement, as the surgery is known, is a subject of debate among orthopedic surgeons, with conflicting evidence about the risks and benefits. Proponents say it eliminates the need for a second hospital stay and grueling rehabilitation period, reduces time spent under anesthesia and costs less.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "This is an essential part of the story, since cost is presented as one of the most significant benefits of performing bilateral knee replacement. The story cites a 2013 study that \u201cestimated the cost of bilateral surgery at $43,401 compared with $72,233 for two separate surgeries staged over time.\u201d One addition that would have made the story a bit stronger: since many patients requiring knee replacement surgery are older adults, it might have been useful for readers to know the extent to which Medicare might defray related costs. Still, the story tackles cost head on, and gets a solid Satisfactory here.", "answer": 1}, {"article": "The hormone progesterone also feeds uterine fibroids, so blocking its effects may help treat painful fibroids.\nAlthough EllaOne is not available in the U.S., an FDA advisory panel recently voted that it should be.\nIt is effective for up to five days after unprotected sex.\nAs of now, EllaOne is used in Europe as a morning-after pill because it blocks the effects of key hormones -- namely progesterone -- involved in ovulation.\nThe new drug is manufactured by HRA Pharma, a European pharmaceutical company, which provided funding for the new study.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not describe costs of the drug.", "answer": 0}, {"article": "Melanie Ashton continued, \"We found that people who had a better-quality diet, a diet with anti-inflammatory properties, or a lower BMI, showed better response to add-on nutraceutical treatment than did those who reported a low-quality diet, or a diet including foods that promote inflammation, or who were overweight.\nNow a group of Australian, German and American scientists have shown those who have a high quality diet, a less inflammatory diet, and/or a low BMI (Body Mass Index) may respond better to an add-on nutraceutical treatment provided as part of a clinical trial.\nThese are early results, but if replicated may mean that treatment of some mental health problems could benefit from the inclusion of dietary advice.\nResearchers measured BMI at the beginning of the study, and then measured depression and how a person is able to function in their day to day life.\nParticipants received the study medication in addition to any stable treatments they were already receiving.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The study investigated three interventions: 1) A combination treatment of over a dozen \u201cmitochondrial enhancing agents\u201d (including N-acetylcysteine, or NAC); 2) NAC alone; 3) placebo.\nNAC is the only intervention that is routinely used as a treatment. Its cost is not included. According to Amazon.com a 600 mg tablet costs roughly $0.10 \u2013 $0.30 (but the dosage used in the study is not mentioned).", "answer": 0}, {"article": "In 2016, he was ranked the No.\nThese results, published today online ahead of print in the American Journal of Medicine, with an accompanying editorial by the editor-in-chief, show that Plaque HD\u00ae, produced statistically significant reductions in dental plaque and inflammation throughout the body as measured by hs-CRP.\nThe results released today from a randomized trial of a novel plaque identifying toothpaste, (Plaque HD\u00ae), show statistically significant reductions in dental plaque and inflammation throughout the body.\nThis large scale randomized trial will test whether Plaque HD\u00ae reduces risks of heart attacks and strokes.\nIn addition, the product's proprietary formulation contains unique combinations and concentrations of cleaning agents that weaken the core of the plaque structure to help the subject visualize and more effectively remove the plaque.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Plaque HD toothpaste is very expensive: $16.95 plus $5.75 shipping for a single 4.1-ounce tube, according to the manufacturer\u2019s website, compared to less than $5 for a similar amount of conventional toothpaste. Also, plaque disclosing tablets can be bought for about 10 to 25 cents each. These don\u2019t have to be used every day, just on a periodic basis to determine effectiveness of brushing.\nConsidering the big price difference, consumers would want to see strong evidence that this brand of toothpaste really provides health benefits over other toothpastes and other ways of showing plaque on teeth.", "answer": 0}, {"article": "Reductions were seen of 35 percent at 10 weeks, and just over 22 percent at one year, for those given real acupuncture, compared with 24.5 percent and 5 percent, respectively, for those given sham acupuncture, the researchers said.\nAccording to the study authors, nine out of 10 patients try some form of alternative therapy, such as massage or acupuncture, in addition to their regular pain medication.\nHowever, although taking less pain medication, acupuncture patients were using higher levels of antidepressants after one year, which may have artificially boosted the positive results, he said.\nFibromyalgia treatment usually starts with medications such as the nerve pain medication Lyrica (pregabalin), and if that fails or is only partly effective, doctors might add acupuncture to the mix, Rances said.\n\"Although it was allowed for the participants to continue with the pharmacological [drug] treatment they were taking beforehand, when the study was finished, the patients who received individualized acupuncture were taking less medication than the group on sham acupuncture,\" Vas said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story offers an estimate of the cost of an acupuncture session at $125. The study participants received nine separate sessions, which would, by this estimate, total $1,125. The story also mentions that some insurance carriers will pay for acupuncture treatments.", "answer": 1}, {"article": "Paul is on Procter & Gamble's advisory board but holds no stock in the company and will not profit financially.\nThere were no side effects in the two other groups.\nThe current study shows that Vaporub is more effective than placebo.\"\nThat night, 30 minutes before bedtime, Vicks or petroleum jelly was rubbed onto the child's chest and neck.\nThe next day parents were questioned about their child's symptoms overnight.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "\n\n\n\nOne could say that the cost of VapoRub is not an important factor, but given how easy it would be to note the price of VapoRub, especially for the amount used in the study, we think the story should have included it.", "answer": 0}, {"article": "Early menopause is often a side effect for women treated with chemotherapy for breast cancer, but a new study reveals some guarded promise for preventing early menopause breast cancer patients.\nFor younger women still hoping for children, these treatments can cause devastating short-term or long-term loss of menstrual periods, and loss of fertility.\nPatients were randomly selected to be treated with chemotherapy alone or with chemotherapy and triptorelin, a drug, called a GnRH analogue, that prevents the ovaries from releasing eggs.\nThey conclude that using assisted reproductive technology \u2013 such as storing eggs before chemo, is \u201cthe most effective option for fertility preservation.\u201d\nAn accompanying editorial by Dr. Hope S. Rugo and Dr. Mitchell P. Rosen of the University of California-San Francisco says that trptorelin therapy should not be recommended as a standard treatment and should be approached with caution in women with hormone-sensitive disease.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Costs of the treatment are not mentioned in the article; rather, the costliness of an alternative, storing eggs prior to treatment, is emphasized.\n", "answer": 0}, {"article": "June 28, 2010 -- Cholesterol-lowering statin drugs appear to reduce the risk for prostate cancer recurrence in patients who have had a surgical procedure called radical prostatectomy.\n\u201cStatin users may see their doctors more often and may be more health conscious in general, and it has been suggested that this could explain the observed reduction in risk,\u201d Freedland tells WebMD.\nBut the fact that the fewest recurrences were seen in men who took the highest statin doses is compelling, says senior investigator Stephen J. Freedland, MD, of the Duke Prostate Center.\nThose who took the highest doses saw their recurrence risk drop by half.\nThe research does not prove that taking cholesterol-lowering drugs directly slows the growth and progression of prostate cancer.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The lack of cost information is particularly troublesome in this case because there are so many statins on the market, and cost information would be easy to find.", "answer": 0}, {"article": "In the 1960s sitcom Leave It to Beaver, Beaver Cleaver was so impressed by his dad's tales of ice cream and pretty nurses that he schemed to have his tonsils out, even though he didn't need it.\n\"\n\nRosenfeld disputes Obama's claim, saying insurers usually pay a surgeon $200 to $300 for tonsil surgery.\nToday, the most common reason for the surgery is \"sleep disordered breathing,\" a broad diagnosis that includes sleep apnea and snoring.\nSo the doctor recommended tonsillectomy.\nThey'd recommend surgery if a child has five or more throat infections a year for two years, or three or more in three years.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Oddly, the story mentions physician reimbursements for tonsil surgery but makes no mention of patient costs. \u201cRosenfeld disputes Obama\u2019s claim, saying that insurers usually pay a surgeon $200 to $300 for tonsil surgery.\u201d", "answer": 0}, {"article": "The P-Cure team is committed to enabling all oncology centers and hospitals globally to establish cost-effective proton therapy services for the best possible care and cure,\u201d said Dr. Marash.\nIn addition to the clinical benefits of P-Cure\u2019s solution, there are also significant economic advantages to treating patients in a seated position.\nThe P-Cure gantry-less system significantly reduces many factors associated with proton therapy including the capital cost of equipment and construction, the size of a single room center or multi-room expandable center and the time from center planning to treatment.\nThe P-Cure system is based on a diagnostic-quality computed tomography (CT) enabling treatment planning, positioning and treatment delivery for cancer patients in a seated position.\nP-Cure is the innovative provider of image-guided solutions for better clinical effectiveness of proton therapy at a fraction of the current capital and operating costs.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "We were pleased to see the potential economic impacts of this therapy raised in the release. The release says, \u201cIn addition to the clinical benefits of P-Cure\u2019s solution, there are also significant economic advantages to treating patients in a seated position.\u201d However, the cost savings refer to the reduced capital investment for the proton beam center, not the cost for patients. The release is basically arguing that the device will decrease the cost for the center per patient treated, and will accomplish this by making it easier to get treatment done and make it more accessible, affording extra time to bring in more patients. This is not exactly the cost that the patient is thinking about.\nWe give the release credit for raising the financial issue but at least one cost-related number is needed here.", "answer": 0}, {"article": "Parkinson\u2019s disease is a progressive neurological disease that causes symptoms including muscle tremors, shaking, and stiffness.\nThe study doesn\u2019t prove that berries (or flavonoids in any other food) prevent Parkinson\u2019s disease.\nThe findings should be considered preliminary as they have not yet undergone the \"peer review\" process, in which outside experts scrutinize the data prior to publication in a medical journal.\nNor is it clear why the results differed for men and women.\nThis was an observational study and therefore can\u2019t establish cause and effect.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Not applicable. The costs of the flavonoid-containing foods mentioned in the story is not in question.", "answer": 2}, {"article": "In nonsurgical spinal decompression, a patient is placed on a special type of table with harnesses on the pelvis and rib cage.\nIt is designed for patients who have not had surgery.\nIt is less than half the cost of surgery but is rarely covered by insurance.\nThe treatment, which includes several 20-minute procedures and rehabilitation, costs between $3,500 and $4,000.\nI would say a quarter of my patients fall asleep.\u201d\n\nThe decompression therapy is used to treat herniated discs, ruptured discs, sciatica, bulging discs, degenerative discs, posterior facet syndrome and spinal stenosis/arthritis.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does mention the cost of the treatment, which is not covered by insurance. The story should have compared the cost to other available treatments. Nonetheless we\u2019ll give it the benefit of the doubt and score it satisfactory. ", "answer": 1}, {"article": "New vertebral fractures occurred less frequently in the active treatment groups vs placebo: in 0.58 percent (n = 4) of participants in the abaloparatide group; in 0.84 percent (n = 6) of participants in the teriparatide group; and in 4.22 percent (n = 30) of those in the placebo group.\n\u201cFurther research is needed to understand the clinical importance of risk difference, the risks and benefits of abaloparatide treatment, and the efficacy of abaloparatide vs other osteoporosis treatments,\u201d the authors write.\nOverall, there were no differences in serious adverse events between the treatment groups.\n: This study was funded by Radius Health.\nAdditional therapies are needed for prevention of osteoporotic fractures.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There is no discussion of costs in the release. At a minimum it could have mentioned the cost of the existing FDA-approved comparator drug.", "answer": 0}, {"article": "Dec. 21, 2009 -- A fatty substance found naturally in the lungs may provide a natural defense against respiratory syncytial virus (RSV) infection.\nNew research suggests the substance, a lipid known as POPG, may prevent RSV infection as well as limit the spread of the virus once infection has occurred.\nTherefore, together with the results of this study, researchers say the compound merits further research as a treatment for RSV infection in humans.\nApplying POPG to the cells after RSV infection also inhibited the spread of the virus to neighboring healthy cells.\nIn addition, the study showed treating infected mice with POPG dramatically reduced infection and prevented the spread of the inflammatory cells into the lungs.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Costs weren\u2019t discussed and we can understand why with something that is only in the pre-human testing phase. ", "answer": 2}, {"article": "Worldwide, more than 10 million people have impaired vision or blindness as a result of corneal damage, but only a small fraction ever receive transplants from cadaver donors.\nIn a newly released study, investigators from Canada and Sweden reported results from the first 10 people in the world treated with the biosynthetic corneas.\nNine of the 10 experienced cell and nerve regeneration, meaning that corneal cells and nerves grew into the implant.\n\u201cWe are still in the prototype stage, but this shows that regenerating a human cornea is possible.\u201d\n\nTwo years after having the corneas implanted, six of the 10 patients had improved vision .\nIt has been 10 years since Griffith and colleagues first reported the development of a material with the potential to grow healthy new tissue in people with damaged corneas.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "One of the few ways this story fell down. Because donor corneas and plastic corneas are already on the market, at least a range of costs for those treatments and assessment of whether this would be a more or less expensive treatment would have been important information to include.", "answer": 0}, {"article": "Media campaigns, increased tobacco and tightening of smoking laws have all had an effect as well.\n\u201cPatient compliance is a very big issue,\u201d said Dr. Richard Hurt, director of the Nicotine Dependence Center at the , who was not involved in the study.\nDr. Hurt said products like nicotine gum and patches \u201care absolutely essential, but we use them in combinations and doses that match treatment to what the individual patient needs,\u201d unlike smokers who are self-treating.\nDoctors who treat smokers said that the study findings were not unexpected, given the haphazard way many smokers used the products.\nThe use of replacement products made no difference, whether they were taken for the recommended two-month period (they usually were not), or with the guidance of a cessation counselor.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "All three stories at least mentioned the total amount of money being spent on nicotine replacement products or the growth in that spending. None of the stories actually explained how much these products cost or compared them to the costs of cigarettes. The cost of an 8-week regimen of nicotine patches is $160-200.", "answer": 1}, {"article": "The GI tract is also home to the intestinal microbiome, a complex population of roughly 100 trillion microorganisms (more than ten times the number of cells that make up the human body) that interacts with the mucosal lining of the GI tract.\nAnd a new study from Baltimore's Sheppard Pratt Health System, conducted by a research team led by Faith Dickerson, finds that a probiotic supplement may reduce inflammation of the gut, which is known to exacerbate bipolar disorder.\nWith this in mind, researchers developed a probiotic supplement aimed at reducing inflammation caused by microbial imbalances in the gut.\nA group of patients recently hospitalized for mania participated in a 6-month study to track the effects of probiotic treatment on both their mood and the status of their immune system.\nThe beneficial effects were most pronounced in those patients who exhibited abnormally high levels of inflammation at the beginning of the study.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Neither the cost, composition, or dosing of the intervention \u2014 a probiotic preparation of strains of a Lactobacillus and Bifidobacterium \u2014 is provided.", "answer": 0}, {"article": "Pneumonia is a leading cause of death for elderly patients, with over 90 percent of pneumonia-related deaths among those 65 and older.\nOMT also reduced the in-hospital mortality rates of those with the highest severity of illness.\n\"This study should encourage physicians to use their osteopathic techniques when treating older patients with pneumonia.\"\nDisclosures: The basis for this analysis, The Multicenter Osteopathic Pneumonia Study in the Elderly (MOPSE) clinical trial, was funded by a consortium of foundations including the Foundation for Osteopathic Health Services.\nPrevious studies have also shown that OMT can improve the efficacy of antibiotics in pneumonia patients.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release does not address the costs of osteopathic adjunct therapy even in general terms. Readers would have no idea, for example, if medical insurers might cover the cost for in-hospital or post-discharge osteopathic care. And it might have been highly useful to include easy-to-get information about the average cost of an extra day or two in the hospital for pneumonia treatment. Given that payment for patients hospitalized with pneumonia is typically based upon a bundled fee, the costs of providing OMT may be offset if length of stay is reduced.", "answer": 0}, {"article": "\u201cA.A.\nDespite the largely negative findings, John F. Kelly, a clinical psychologist at Harvard, said he still believed that A.A. and other 12-step programs were effective.\n\u201cAlthough the randomized controlled trial is the gold-standard methodology in comparing between conditions,\u201d said Thomas G. Brown, an assistant professor of psychiatry at McGill University, \u201cit washes out a factor that may be important in potentiating A.A.\u2019s benefits, namely patient choice and preference.\u201d In other words, having a patient choose the form of treatment, rather than being assigned to it as in most studies, could be an important factor.\nBut observational data can.\u201d\n\nIt is unlikely that substance abuse experts will widely reject A.A. on the basis of these findings.\nThe review covered only carefully controlled trials.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The cost of treatment is not provided. It would be important to note that A.A. might be a preferred option for relapse prevention because it is free, meetings widely-available, and it is not time-limited, like many forms of psychotherapy.", "answer": 0}, {"article": "When treating a patient suffering from depression, Brent Forester considers which anti-depressant to prescribe\u2014ideally, one that will ease psychic pain without side effects.\n\nIt can be a tough call.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story makes clear that the test is expensive and that Medicare and some other insurance plans cover it.", "answer": 1}, {"article": "Zied is also the author, with Ruth Winter, of a book titled \"So What Can I Eat?\"\nNow, there's new information showing how important folic acid is.\nBut a few small lessons now can turn out to be valuable later in life.\nIt's a tremendous challenge for parents to teach their teenagers and \"tweens\" everything they ought to know.\nDr. Emily Senay discussed it on The Early Show Tuesday.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There was no mention of costs in this piece.\u00a0 It would have been very easy to note that it is CHEAP!", "answer": 0}, {"article": "In his study published in the International Journal of Radiation Oncology, Biology, Physics, he and his colleagues found, \"in circumstances where surgery may result in significant neurologic or organ dysfunction, patients can be treated definitively with radiation therapy alone.\nWhile the findings were written for health care professionals and very technical, Tracy was encouraged.\nThere was photon therapy available in San Francisco, but, in my research, I found out the photon beams don't stop at the tumor and have a greater possibility of affecting surrounding organs, too.\nDr. Kabolizadeh explained, \"Image guidance allows doctors to visualize tumors during therapy to assess response and make sure the tumor is treated correctly every day.\"\nThe San Francisco radiation oncologist not only shared Dr. Kabolizadeh's research paper, but also his contact information.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Cost is not mentioned. A visit to the website of the organization that issued the release offered little additional information about cost, noting only that \u201cmany insurance plans will cover\u201d proton beam therapy.\u00a0 And many will not. Finding cost information online was surprisingly difficult. According to a 2017 story on MedPage Today, the cost of proton beam therapy can range from $30,000 to $120,000. Those are significant numbers, and the failure to address cost in the release is a significant oversight.\nSince these multi-million dollar machines (which can cost in excess of $200 million) are available in a very limited number of locations, many patients, including the one profiled in the release, have to travel for proton therapy treatment so prospective patients would need to add travel expenses to overall treatments costs.", "answer": 0}, {"article": "The retina is the light-sensing nerve tissue at the back of the eye.\nThe stem cell injection resulted in 130 days of preserved vision in laboratory rats, which roughly equates to 16 years in humans.\nFrom there, clinical trials will be designed to test potential benefit in patients with later-stage age-related macular degeneration.\nThis work was supported by the Simon and Beathrice Apple Stem Cell Fund for Eye Research, the David and Janet Polak Foundation Stem Cell Core Laboratory; National Institutes of Health (R01 EY020488), Department of Defense (W81XWH-12-1-0617), Foundation Fighting Blindness and the Knights Templar Eye Foundation Inc.\n\u201cThough additional pre-clinical data is needed, our institute is close to a time when we can offer adult stem cells as a promising source for personalized therapies for this and other human diseases.\u201d\n\nNext steps include testing the efficacy and safety of the stem cell injection in preclinical animal studies to provide information for applying for an investigational new drug.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "At no time during the release is the potential cost of a possible treatment ever mentioned.\u00a0 That\u2019s understandable since the work is only being done in animal models and far-removed from eventual clinical use.\u00a0 But the release suggests that\u00a0human use is close at hand.\u00a0 If the procedure were ready for clinical use in humans, it would involve costly eye surgery as well as the very costly and complicated manipulation of human skin cells so that they become stem cells.\u00a0 While the cost of these processes will inevitably\u00a0fall,\u00a0it\u2019s likely to remain substantive.", "answer": 0}, {"article": "The California Walnut Commission offices are located at 101 Parkshore Dr., Ste.\nCo-authors with Dr. Falk are Liana C. Del Gobbo, PhD, Robin Feldman, MBA, Kara Lewis, PhD, and Dariush Mozaffarian, MD, PhD.\nThis study was supported in part by funds from The International Tree Nut Council Nutrition Research and Education Foundation.\nOf 1,301 articles surveyed, 61 trials met eligibility criteria for this systematic review and meta-analysis, totaling 2,582 unique participants.\nAdditionally, results showed that tree nut consumption may be particularly important for lowering the risk of heart disease in individuals with type 2 diabetes.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "We won\u2019t ding the story for not mentioning costs, although walnuts certainly are expensive. Each one of us passes by bags of walnuts every time we go to the grocery store and probably have at least a vague idea of what they cost.", "answer": 2}, {"article": "There are two common surgical approaches for a total hip replacement: anterior, which involves entering surgically through the front of the hip, and posterior, or entering surgically through the side or buttocks.\nDr. Roy Davidovitch, director of NYU Langone's Hip Center, said he performs around 400 hip replacements a year and approximately 40 percent of those patients will go home the same day.\nAnd to be quite honest, if the pain is controlled and the patient is healthy and medically completely stable there is no reason for them to be in the hospital.\nHowever, not every surgeon is embracing the same-day trend.\nThose who have risk factors must plan on staying overnight in the hospital, not going right home.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There is no discussion of the costs of hip replacement, even though it is a common procedure and its costs are widely discussed. For example, a Blue Cross Blue Shield report noted an average cost of about $30,000, but with wide variations, ranging between \u201c$11,327 in Birmingham, Alabama, and $73,987 in Boston.\u201d", "answer": 0}, {"article": "Allergy shots may be used for hay fever when antihistamines and other allergy medications do not control a person\u2019s symptoms adequately, or for people who want to reduce their reliance on medication.\nIn addition, the long-term effectiveness of the grass-pollen tablets is not yet fully clear.\nDr. Harold Nelson, an allergist at National Jewish Health in Denver, said that the body of evidence indicates that sublingual immunotherapy beats antihistamines and other medications used to control hay fever symptoms.\nStill, Nelson said that if sublingual products do win approval in the U.S., they will likely boost the number of hay fever sufferers who want to use under-the-tongue immunotherapy.\nNo sublingual immunotherapy products have yet been approved in the United States, however.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "1clip_filelist.xml\" rel=\"File-List\"/>1clip_themedata.thmx\" rel=\"themeData\"/>1clip_colorschememapping.xml\" rel=\"colorSchemeMapping\"/>\n\n\n\n \nThe story concedes that the \u201cultimate cost-effectiveness of sublingual immunotherapy has\u2026yet to be determined.\u201d Based on cost in the U.K., the story reports that treatment may be $3.50 per day, adding that it should be \u201ctaken daily, starting several months before the start of the next grass-pollen allergy season and continuing for three years thereafter.\u201d\u00a0 \u00a0\u00a0\n", "answer": 1}, {"article": "Commenting, Professor Andreas Meyer-Lindenberg, Central Institute of Mental Health, Mannheim and member of the ECNP executive board, said: \"This work builds on previous studies that have shown a critical role of excessive activity of subregions of the temporal lobe in the generation of voice hallucinations in schizophrenia.\nTo move this into treatment, controlled trial such as the one by Dollfus and coworkers are important.\nThis is the first controlled trial to show an improvement in these patients by targeting a specific area of the brain and using high frequency TMS.\nFor the first time, scientists have precisely identified and targeted an area of the brain which is involved in \"hearing voices\", experienced by many patients with schizophrenia.\nThey have been able to show in a controlled trial that targeting this area with magnetic pulses can improve the condition in some patients.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Cost is not discussed. TMS therapy is already available for the treatment of other mental health conditions, including depression, so cost estimates should not have been difficult to come by. And since costs can reach into the thousands of dollars, depending on the length of treatment, it is not an insignificant issue for patients and their families.", "answer": 0}, {"article": "Tuberculosis is a chronic bacterial infection that's spread through the air and usually infects the lungs, although other organs of the body can be involved.\nThe test, known as the \"Xpert MTB/RIF\" test for Mycobacterium tuberculosis and resistance to rifampin (RIF), appears to be more than 97 percent accurate and is even able to diagnose drug-resistant TB, researchers said.\nFurther trials of the new test are planned, the researchers said.\nThe machine costs around $30,000, but would be priced under $20,000 in poor countries, he told the AP.\nThe test diagnosed tuberculosis in 99.2 percent of the patients, the researchers found.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "This story does more than pay lip service to cost, flagging it as the key to making this test available in the developing world.\u00a0It notes the price tag of\u00a0the diagnostic machine itself and says that the $63 cost\u00a0per test may be discounted by more than half in developing world countries.\u00a0It fails\u00a0however to compare the\u00a0cost of the new test with\u00a0the existing TB test. Even more important, it fails to explain that a $20 or $30\u00a0expense,\u00a0which might sound modest to U.S. readers, would actually represent a huge cost burden in many developing world countries, where\u00a0annual per capita health care expenditures are sometimes less than $30.\u00a0A close call, but since the story made a good-faith effort to address this issue, we\u2019ll award a satisfactory with deficiencies noted. \u00a0\u00a0\u00a0", "answer": 1}, {"article": "Their average age was 69.\nAn editorial accompanying the study said which drug is selected may be less important than identifying and starting an approved treatment.\nThere needs to be a large head-to-head trial between Forteo and abaloparatide, she said, to really see which drug is better.\nAbaloparatide works differently from Forteo and improves bone density more than Forteo, Miller said.\nForteo is covered by Medicare, Miller said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Although it is not known how much abaloparatide will cost at this stage, the article does discuss\u00a0the cost\u00a0of its would-be competitor, Forteo, which costs about $2,500 a month for those without insurance.", "answer": 1}, {"article": "For more information, visit fredhutch.org or follow Fred Hutch on Facebook, Twitter or YouTube.\nBecause of the data from this clinical trial, avelumab (brand name Bavencio) has become the first systemic therapy approved by the FDA for MCC, and the first treatment of any kind approved for metastatic MCC.\nAvelumab is the first FDA-approved treatment for metastatic MCC and the first disease that the drug has ever been approved to treat.\nTom Judd, who lives near Portland, Oregon, knows what it is like to be diagnosed with a deadly cancer for which there is no approved drug.\nHe is a consultant for EMD Serono Inc. and receives funding from Bristol-Myers Squibb to perform biomarker studies in MCC clinical trials.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There is no mention of costs in this piece. Even though it calls out the drug avelumab (marketed as Bavencio) by name, the release does not talk about what a typical regimen of that drug or any other would be.\nBloomberg reports that avelumab will be priced at $13,000 a month, or $156,000 for a year of treatment.", "answer": 0}, {"article": "They were then monitored for 24 hours.\nThe study shows that within hours of drinking it, beet juice lowered systolic blood pressure (the top number in a blood pressure reading) by an average of 4-5 points among a small group of healthy men .\nAmong both men and women, the results showed a trend to lower systolic blood pressure six hours after drinking the beet juice.\nIn this case, Coles says it may be partially explained by the fact that the women in the study tended to be older, and many were on prescription medications, such as oral contraceptives.\nBut researchers say this is the first study to look at the effects of adding beet juice to a heathy person\u2019s diet without making any other diet or lifestyle changes.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story did not discuss the cost of beetroot juice. We saw some products advertised on Amazon for $8-10 for a 32 oz jar (about 2 days\u2019 worth of juice at the dosage studied).\u00a0Cheaper versions are probably available, or you could juice your own, but the story could have addressed this either way.\nIn keeping with the spirit of this criterion, ALL health care interventions cost something.\u00a0 Only about 30% of the stories we review ever adequately address this issue.\u00a0 Americans spend a greater percentage of their GDP on healthcare than any other country.\u00a0 Costs matter.", "answer": 0}, {"article": "Flublok is an exact copy of the influenza virus coat protein and is not subject to the egg-adapted mutations associated with low vaccine effectiveness (see Skowronski et al.\nFDA approved the quadrivalent formulation (\"Flublok Quadrivalent\") in October 2016 that will be commercially available for everyone over 18 years for the 2017/18 influenza season.\nThis data satisfies both pre-specified criteria for non-inferiority and superiority of Flublok over the traditional egg-based quadrivalent inactivated vaccine.\nFlublok Quadrivalent is FDA approved for adults 18 and older.\nFlublok contains three times more active ingredients than traditional vaccines and produced significantly higher immune responses to the A strains of influenza (especially H3N2) in the Flublok Quadrivalent study.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Costs aren\u2019t discussed at all. Given that this release comes from the manufacturer, and that the drug was approved by the FDA in October 2016, it\u2019s not clear why this information isn\u2019t available.", "answer": 0}, {"article": "Those are also symptoms of a deficiency of B12, a key nutrient needed to make red blood cells and DNA and keep the nervous system working right.\n\nVitamin B12 deficiency is officially considered rare, affecting about 1 in 1,000 Americans, according to a 2005 study. But the incidence...", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The costs of vitamin B12 supplements were not discussed and whether they are often covered by insurance was not explored.", "answer": 0}, {"article": "Radiation oncologist Dr. Richard Stock, of Mt.\n\"With four treatments left, I have 98 percent of my vision left,\" Rianta said.\nJust weeks later, Rianta was getting the therapy and the tumor was shrinking.\nIt's the most expensive device in medicine today.\nThe technology is two decades old, but Mass.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does a good job of describing the problem of the costs of proton beam therapy.", "answer": 1}, {"article": "Dying tumor cells release cell-free DNA (cfDNA) into the blood, where cancer-specific methylation changes can be detected at any disease stage.\nI am therefore very encouraged with the results of this study, showing that EpiCheck has the ability to identify both non-small-cell and small-cell lung cancer at early stages, with a high level of sensitivity and specificity.\nSuch promising results combined with the simplicity of the test, could allow us to detect lung cancer at the early stages and hence improve 5-year survival from about 15% to about 50-70%.\nTherefore, a screening test aimed at the entire risk group to assist in the early detection of the disease is highly needed and can dramatically increase lung cancer survival.\nTo date, there is no adequate screening process for the early detection of lung cancer, bringing 5-year survival rate to approximately 15%.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There\u2019s no discussion of cost. While we understand that this news release is touting a product in the early stage of development, it would still be beneficial to give readers some idea of the projected cost.", "answer": 0}, {"article": "Other researchers contributing to this study include: Robert L. Coleman, M.D., Alpa M. Nick, M.D., Pedro T. Ramirez, M.D., Lois M. Ramondetta, M.D., Diana Urbauer, Jack L. Watkins, all from MD Anderson; Susan K. Lutgendorf, Ph.D. from University of Iowa; Sanjeev Kumar, M.B., B.S.\nBeta-blockers may also reduce cancer-related psychological distress in newly diagnosed patients, according to the study authors.\nThere are currently two clinical trials, one led by MD Anderson, evaluating the combination of chemotherapy and propranolol (a type of NSBB) on cancer biology and on stress modulators in patients with newly diagnosed EOC.\nFuture trials will seek to identify patients who would benefit most from beta-blocker use and the best beta-blocker for a specific tumor type based on adrenergic receptor expression.\nWith further research, they may also prove beneficial in conjunction with other treatment regimens and across other cancer types.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release doesn\u2019t mention cost at all. Beta-blockers are currently available, and a monthly prescription can run patients from 10 to hundreds of dollars. The non-selective beta-blockers mentioned in the release are all available as a generic product and are relatively inexpensive as compared to the selective agents", "answer": 0}, {"article": "But they can have large effects on muscles and joints, often making muscles work as much as 50 percent harder for the same movement and increasing stress on joints by a similar amount.\nThe findings were somewhat puzzling: While the group that used inserts had about half as many injuries \u2014 defined as pain that kept them from exercising for at least half a day \u2014 there was no obvious relation between the insert a soldier chose and his biomechanics without it.\n\u201cI guess the main thing to note is that, as biomechanists, we really do not know how orthotics work.\u201d\n\nOrthotists say Dr. Nigg\u2019s sweeping statement does not take into account the benefits their patients perceive.\nThey added, though, that the research was inadequate for them to have confidence in those conclusions.\n\u201cThe vast majority of our patients are happier having them than not,\u201d he said about orthotics that are inserted in shoes.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "It would have been useful to discuss the relative costs of off-the-shelf and custom shoe inserts. The former are generally less than $50 while the latter can run into many hundreds of dollars. The article mentions the expensive price-tag of custom-made orthotics. It didn\u2019t, however, discuss the overall costs of off-the-shelf shoe inserts, which have to be replaced with regularity.\n\n \n", "answer": 0}, {"article": "Currently, the U.S. Preventive Services Task Force recommends that biennial screenings start at age 50 for most women, while the American Cancer Society advises that annual screenings begin at age 45.\nPort noted that screening guidelines tend to be based on the ability of mammograms to save lives and how often they give a false positive result.\nAnd the women who were screened earlier had smaller tumors.\nAnd Dr. Len Lichtenfeld, deputy chief medical officer for the American Cancer Society, noted that this was an observational study that only looked at the experience of one institution.\nPort also looked at the 40- to 49-year-old age group, and found those who had never had a mammogram were much more likely to need chemotherapy.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The article did not discuss costs. Screening mammograms impose a significant cost on the U.S. health care system and insurers, particularly Medicare.", "answer": 0}, {"article": "\u201cIf we can do the same for other patients, that would be an amazing accomplishment that many decades of work and research on glioblastoma have never done,\u201d says Badie, whose own father passed away a decade ago from glioblastoma.\nIf the patient had not received the CAR T therapy, he likely would only have survived a few weeks after his cancer recurred, says Badie.\nThis is the first time that immune cells have been injected into these brain regions, because introducing anything into the ventricles can cause dangerous and possibly deadly inflammation.\nBased on this man\u2019s case, his team is hoping to now inject not just the tumor site but also the ventricular space in the brain, since that may help control spread of the cancer.\nBut after being treated with the immune therapy, his cancer did not grow or recur for nearly eight months.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Although there may not yet be any accurate prediction of the cost of the particular therapy described for this single patient, it is generally well established and well documented that immunotherapies\u2013particularly those that involve modifying a patient\u2019s own immune cells\u2013 are many times more expensive than standard treatments, sometimes running to annualized costs in the hundreds of thousands of dollars. This story says nothing about this.", "answer": 0}, {"article": "Michael T. Lotze, a professor of surgery and bioengineering at the University of Pittsburgh, said that \"the work is heroic.\nResponse by others in the field was positive but not effusive.\nAnd cancer sometimes returns even after that much time has elapsed.\nThe report, published online by the journal Science, is the latest result of a three-decade effort by surgeon Steven A. Rosenberg to find ways to manipulate the human immune system to fight cancer.\nA team of researchers from the National Cancer Institute reported yesterday that they have successfully treated two cancer patients using gene therapy, the introduction of genes into the human body for medical purposes.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There was no estimate of the costs for this kind of individualized cancer treatment.", "answer": 0}, {"article": "\"Started looking in the cupboard and I saw pie pans and I said, 'These are perfect.\nThe last thing John Kanzius thought he'd ever do was try to cure cancer.\nHere's the important part: if clinical trials pan out - and there's still a long way to go - the Kanzius machine will zap cancer cells all through your body without the need for drugs or surgery and without side effects.\nWell it's true, and if you think it sounds improbable, consider this: he did it with his wife's pie pans and hot dogs.\nThat's what 60 Minutes wanted to know, so Stahl went to his garage laboratory to find out.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The costs at this point would be purely speculative, as it\u2019s not clear what kind of nanoparticles would be used, what the machines would cost to build, the many factors which will likely complicate the process even before it reaches human testing. \nIt\u2019s not necessary in this case for the story to mention costs. ", "answer": 2}, {"article": "\"They say, 'Oh my God, this has changed my life.\nShe said for her it wasn't about increasing the quantity of sex she was having, but rather the quality.\nDoctors who treat women with low libidos tore apart the JAMA study.\nIn their editorial, Woloshine and Schwartz said Sprout and others put pressure on FDA to approve the drug.\n\"I should be able to choose whether the side effects are worth the benefit,\" she wrote.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No cost information, whatsoever.", "answer": 0}, {"article": "The requested URL /usnews/health/articles/061105/13healy.htm was not found on this server.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not mention the cost of the scan, an important piece of information for the consumer given that insurance is unlikely to cover it.", "answer": 0}, {"article": "Dr Arthur Roach, Director of Research at Parkinson's UK, which funded the study said:\n\n\"People affected by Parkinson's, their carers, and health and social care professionals have said that preventing falls and improving balance is the biggest unmet need for people living with the condition, other than finding a cure.\n\"This trial shows that there may be drugs already available, being used for other purposes, that can be tested to help treat Parkinson's.\nScientists have discovered that a commonly prescribed dementia drug could hold the key to helping prevent debilitating falls for people with Parkinson's.\nThis is a real breakthrough in reducing the risk of falls for people with Parkinson's.\"\nDr Henderson and her team at the University of Bristol studied 130 people with Parkinson's who had fallen in the past year.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release doesn\u2019t mention the drug\u2019s cost but we won\u2019t dock points for that omission since the release is from the UK where cost would be less of a concern for readers than it is in the U.S. This drug is common enough in the United States and is available in generic form.", "answer": 2}, {"article": "Generalized anxiety disorder (GAD) is one of the most common anxiety disorders in older adults and is associated with poor quality of life, increased health care utilization and impaired memory.\nTelephone CBT consisted of up to 11 sessions (nine required) and focused on, among other things, anxiety symptom recognition, cognitive restructuring, relaxation, coping statements and problem solving.\nHowever, older adults who live in rural areas can face a number of barriers, including living in an area where psychotherapy is not available, so alternate methods of providing treatment could increase utilization, according to the study background.\nThese two trends are inextricably linked in the area of geriatric mental health and our search for better, more effective treatments with greater reach.\u201d\n\nThe author made conflict of interest disclosure.\nTo place an electronic embedded link to this study in your story Links will be live at the embargo time: http://archpsyc.jamanetwork.com/article.aspx?doi=10.1001/jamapsychiatry.2015.1154 and http://archpsyc.jamanetwork.com/article.aspx?doi=10.1001/jamapsychiatry.2015.1306\n\nTelephone-based cognitive behavioral therapy was better at reducing worry, generalized anxiety disorder symptoms and depressive symptoms in older adults who live in rural areas, where access to mental health treatment may be limited, according to an article published online by JAMA Psychiatry.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "At no point in the release was cost mentioned.\u00a0 Psychotherapy and counseling can be costly, especially for the elderly on fixed incomes.\u00a0 Readers would be well-served with some estimate of the costs of the services provided through this trial.\u00a0 Also, a mention of a comparison between the costs of office visits for such therapy versus that delivered via telephone would be useful to give readers a fuller picture of the practical potential for this approach.\u00a0Medicare requires in person contact for payment. \u00a0That\u2019s why the cost issue is important in this case. We think news releases can and should address these matters.", "answer": 0}, {"article": "He is an associate professor in the department of infection and obesity at the Pennington Biomedical Research Center in Baton Rouge, La.\nThe research was funded by the American Egg Board, and will be presented at the19th European Congress on Obesity in Lyon, France.\nScientists suspect that egg protein may be better at making people feel full longer compared to the protein found in wheat.\n\"This study shows that diets with higher protein quality may enhance satiety, leading to better compliance and success of a weight loss diet,\" researcher Nikhil Dhurandhar, PhD, says in a news release.\nMay 11, 2012 -- Starting your day off with an egg may help curb your appetite better than cereal, new research suggests.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The cost of eggs and cereal is not in question.", "answer": 2}, {"article": "With brachytherapy, also known as internal radiation therapy (RT), implants are surgically inserted in or near cancerous tissue to deliver a curative radiation dose directly to the tumor while limiting exposure for surrounding healthy tissue.\nAt an average of nearly three years following treatment, cancer control rates were favorable and the toxicity profile was highly favorable.\nAll patients received a single, 19 Gy fraction of HDR brachytherapy.\nThree patients experienced recurrence or progression, yielding an estimated three-year cumulative biochemical control rate of 93 percent.\nToxicity rates were extremely low, with essentially no major complications encountered in this initial group of 58 patients.\u201d\n\nWhile findings highlight the potential tolerability of a single fraction of HDR brachytherapy for localized prostate cancer, the article also emphasizes the need for additional follow-up to compare long-term cancer control rates with conventional treatment approaches, which generally administer larger cumulative doses than the 19 Gy dose used in this trial.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There was zero mention of cost, which is unfortunate because presumably a single treatment would entail fewer costs than one that involved multiple procedures.", "answer": 0}, {"article": "There were 812 deaths (32.2 percent) among heart failure patients not treated with Plavix and 709 deaths (28.1 percent) among heart failure patients treated with Plavix.\nA randomized study comparing conventional heart failure therapy with and without Plavix \"is needed urgently,\" the editorial writer concluded.\nMONDAY, March 22, 2010 (HealthDay News) -- The anti-clotting drug Plavix is of modest benefit in cutting the odds of death in patients with heart failure and heart attack who don't undergo angioplasty, a new study finds.\nHe said the benefit of the drug found in this study is \"of unquestionable practical importance,\" and added that the positive outcomes seen in a relatively short follow-up suggests potentially even better long-term survival.\nThe study appears online March 23 and in the March 30 print issue of the Journal of the American College of Cardiology.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "\u00a0There was no discussion about the cost of this drug.", "answer": 0}, {"article": "In one study, researchers found that people who have long telomeres, the small strips of DNA that cover the ends of chromosomes, have a 30 percent increased risk of developing colon cancer.\nAccording to Ahlquist, Cologuard is the first noninvasive test to detect pre-cancerous polyps, he added.\nDr. Floriano Marchetti, an assistant professor of clinical surgery in the division of colon and rectal surgery at University of Miami Sylvester Comprehensive Cancer Center, said the new test could be an important adjunct to colon cancer screening if it proves itself in further study.\nSavings over time on a more accurate test done fewer times could justify the higher cost of the Cologuard test, Ahlquist said.\nAhlquist noted that the test still needs to be refined.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "A hesitant satisfactory score.\u00a0 The story stated, \u201cthe cost of the test has not yet been established. It is expected to cost more than a fecal occult blood test, but far less than a colonoscopy. A fecal occult blood test can cost as little as $23 while a colonoscopy can total $700.\u201d\u00a0 It is expected by whom to cost in that range?\u00a0 What\u2019s the source? (Reuters reported a $300-400 cost estimate from the company.)", "answer": 1}, {"article": ".\nBy activating the bitter taste receptors in the uterus, the bitter substances relaxed the contracted uterine muscle tissue more completely than the current drugs used to prevent preterm labor in humans.\n\"The biological mechanism of labor initiation remains unknown, and a large percentage of preterm pregnancies do not respond well to current medications,\" said Ronghua Zhuge, Ph.D., associate professor within the University of Massachusetts Medical School's Department of Microbiology and Physiological Systems in Worcester, Massachusetts.\n\"The bitter taste receptors that we have found on uterine muscle could be one more piece of the puzzle to understand the onset of labor, both at term and preterm, and develop new therapeutics for preterm labor.\"\nSubmit to The FASEB Journal by visiting http://fasebj.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There is no discussion of the cost of this treatment. If it\u2019s not too early to send a news release touting a potential new treatment \u2014 even one that is in the earliest stages of development \u2014 it\u2019s not too early to address cost.\nChloroquine, the unnamed substance in the release, when used to treat malaria costs about $4 a tablet. The release doesn\u2019t say whether the drug would be given as an injection or tablet when used to stop early contractions.", "answer": 0}, {"article": "Thirty women each received real acupuncture that also included a bit of an electric buzz or the inactive placebo pill, 32 women got sham acupuncture, and 28 women received gabapentin (Neurontin).\nInterestingly, sham acupuncture came in second place for effectiveness, the researchers said.\n\"There is a component of behavior of doing a sham procedure, so it psychologically may trigger a different kind of reaction from patients versus taking the placebo pill.\"\nDeng pointed out that clinicians have come to realize that the placebo effect is very important in treatment.\nThe study was published Aug. 24 in the Journal of Clinical Oncology.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There is no discussion of costs of any of the treatments studied.", "answer": 0}, {"article": "Send your questions to Julia via the submission form or @juliaoftoronto on Twitter.\nAnd a lot of running (i.e., ultramarathon training) can well be harmful, while the same is never true for walking.\nIn many ways, Sarah is a perfect case study in how to think about the benefits and risks of running versus walking.\nThere's even evidence that running can have positive effects on tension, depression, and anger.\nAll this research, while illuminating, didn\u2019t offer up any clear conclusions on whether running or walking was better for you overall.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not mention costs,\u00a0but both walking and running are inexpensive and widely accessible, so we\u2019ll rate this N/A.\nHowever, cost does play a role here, albeit minor, so\u00a0we think the story would have been stronger if it had included a couple points: Most running experts acknowledge that wearing cheap (often lower-quality) running shoes increases the likelihood of injury, and even those who are walking for exercise need shoes that provide good arch and ankle support. Also, many people do not live in neighborhoods conducive to outdoor exercise (from high traffic and/or pollution, or safety issues), and end up spending money at a gym or on buying a treadmill.", "answer": 2}, {"article": "Vegetable and canola oils, soybeans, flaxseed, walnuts and vegetables including spinach, kale and salad greens are also a source of omega-3 fatty acids.\nThe only people who should avoid DHA are patients on a blood thinner like Cumadin, he added.\nTan said the next step in the research is to follow these people to see if the risk factors they observed translates into a higher rate of cognitive deterioration.\nTan\u2019s team studied 1,575 people with an average age of 67 who were free of dementia.\nThe study was published Tuesday in the print edition of the journal Neurology.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The recommendations quoted in this story \u2014 get 1000 mg/d of DHA \u2014 are only achievable by taking supplements, so the story should have included a comment about how much these cost.", "answer": 0}, {"article": "Dr Iain Foulkes, Cancer Research UK's executive director of research and innovation, said: \"It's exciting to see how Cancer Research UK's partnerships with both academia and industry are bringing urgently needed new tests and treatments to patients.\nUltimately, a candidate molecule called ICEC0942 suppressed tumour growth in a wide range of cancer types in lab tests.\nIn a bid to come up with new forms of treatment that work in a distinct way from established ones, chemists, biologists and clinicians at Imperial College London collaborated on creating a new drug, the properties of which are reported in the journal Molecular Cancer Therapeutics.\nThe drug may not become available to patients for a number of years yet, but researchers believe that if clinical trials are successful, it could be used to tackle a variety of treatment-resistant cancers.\nLicensing of the technology to Carrick Therapeutics was led by Cancer Research UK's Commercial Partnerships Team and Imperial Innovations, the Technology Transfer Office of Imperial, with support from Emory University.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There\u2019s no discussion of costs here, either of initial research funded by the charity Cancer Research UK or of the potential cost to patients and payers if this drug ever goes on the market. While an exact price isn\u2019t something we\u2019d expect, the news release could have described the financial arrangement under which Carrick obtained the license to this therapy and mentioned the high costs that new cancer drugs typically command.", "answer": 0}, {"article": "Excluding prostate cancer, researchers found about a 12 percent reduction in overall cancer occurrence and said the protective effect seemed to be greater in people who had previously battled cancer.\nThe protective effect of the daily pill was described as \u201cmodest\u201d by the trial investigators who emphasized that the primary use of vitamins was to prevent nutritional deficiencies.\n\u201cIt doesn\u2019t seem like there is any particular risk associated with taking a vitamin and there might be a small benefit,\u201d said Dr. David Weinberg, chief of the department of medicine at Fox Chase Cancer Center in Philadelphia.\n\u201cOur trial took a very commonly used multivitamin that has basically low levels of all the different essential vitamins and minerals.\u201d\n\nThe findings suggest that the biggest health benefit may come from a broad combination of dietary supplements, he said.\nThe U.S. Physicians Health Study II included nearly 50,000 male doctors aged 50 and older and spanned more than 10 years.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Not applicable. The story didn\u2019t mention costs, but most people know that a daily multivitamin isn\u2019t very expensive.", "answer": 2}, {"article": "Feb. 10, 2011 (Los Angeles) -- Giving clot-busting drugs to people with mild strokes could prevent more than 2,000 of them from becoming disabled each year, researchers say.\nIn fact, one in three people who suffer a mild stroke are disabled three months later, Khatri says.\nBut people with mild strokes are typically denied tPA because the studies that established its effectiveness excluded mild cases, says Pooja Khatri, MD, of the University of Cincinnati.\nIt's been assumed that people with mild strokes \"generally [do] well and the risk of tPA treatment, which includes a slight but significant risk of life-threatening bleeding in the brain, would not be worth the benefit,\" she says.\nMild strokes -- characterized by such symptoms as clumsiness in the hand, weakness of an extremity, some slurred speech, temporary loss of vision, and/or dizziness -- account for more than half of strokes in the U.S.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story states that the drug costs about $2,000.", "answer": 1}, {"article": "A new study confirms that long-acting forms of contraception such as intrauterine devices and implants are better than birth control pills and patches at preventing pregnancies, giving doctors new ammunition to recommend these methods.\n\nThe study, to be published Thursday in the New England Journal of Medicine, involved about 7,500 women in a project promoting long-acting birth control to reduce unintended pregnancies. There are an estimated three million unplanned pregnancies a year in the U.S., often because of incorrect or...", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There is no discussion of the costs of long-acting methods (IUDs, implants, and long-acting injections) compared to alternatives such as the birth control pill, patch, or ring, although there is acknowledgement that insurance may not cover long-acting methods.\u00a0 It only briefly addresses IUDs and implants with this line: \u201ccan cost patients several hundred dollars if not paid for by insurance.\u201d", "answer": 0}, {"article": "For more details and to read the full study, please visit the For The Media website.\n\u201cGreater confidence in these outcomes may result from larger confirmatory studies of longer duration,\u201d the authors write.\nSeveral measures of quality of life also improved compared with those in the sham laser group, including general vision and independence.\nA limitation of the study was its small sample size and short follow-up period.\nChirag P. Shah, M.D., M.P.H., and Jeffrey S. Heier, M.D., of the Ophthalmic Consultants of Boston, randomly assigned 52 patients (52 eyes) to receive YAG laser vitreolysis (n = 36) in one session or a sham (placebo) laser treatment (control; n = 16).\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Cost does not make an appearance.\u00a0 Given the ubiquity of these floaters, some reflection on cost is warranted, as laser treatment of both eyes can run into the thousands of dollars.", "answer": 0}, {"article": "\"Our finding is so exciting because there is already an approved drug against RANKL called \u201eDenosumab\u201d.\nScientists at the University of Maryland School of Medicine in Baltimore have already tried the preventive use of a RANKL blocking drug in mice.\nThe second group received RANKL blockade treatment for prevention with the result that virtually no malignant changes in breast tissue could be observed even over a longer period of observation.\nCareful phase III clinical trials are now needed to confirm the efficacy in humans.\nA multinational research effort now made the discovery that RANKL is also the main driver of BRCA1 mutation-driven breast cancer.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The cost of the treatment in question, denosumab, (trade name: Prolia) is not mentioned.", "answer": 0}, {"article": "The resource you are looking for might have been removed, had its name changed, or is temporarily unavailable.", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The website reveals that the materials for this diet plan cost almost $50, including shipping. This price should have been included in the release.\nThe news release says that the diet is based on common food items, implying the food cost wouldn\u201dt be substantially more expensive than the dieter\u2019s regular diet. However, this impression cannot be checked without reviewing the plan materials.", "answer": 0}, {"article": "Insurance coverage varies, and doctors often only offer this testing to women at higher risk because of things like advanced maternal age.\nSeitz, in Alabama, thought it was a bonus that getting this new blood test would tell her if she was having a boy or a girl.\nStudies have shown that the new fetal DNA tests do a better job, says Norton.\n\"Approximately 1 in 700 pregnancies there's an extra X or extra Y,\" she says, noting that these are mild conditions that would normally go undetected, unless a woman had an invasive test like an amnio.\nThe results she did get from the fetal DNA test were reassuring.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story mentioned that insurance coverage of the new tests varies, but no indication of an actual dollar amount was given.", "answer": 0}, {"article": "\"The Suboxone got me far enough away to look and say 'wow, look at your life.\nIt's an orange pill that's dissolved under the tongue.\nThe hope is one day that Suboxone can do for painkiller addiction that drugs like Prozac did for depression: convince the public that addiction is a brain disease, not a character flaw.\n\"I didn't know how bad being on opiates affected me,\" he said.\n\"None,\" he said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The focus of the segment is, properly, the high costs of addiction to painkillers. Still, it fails to state how much Suboxone costs. ", "answer": 0}, {"article": "Trials were conducted on nine healthy individuals in a blinded comparative study on absorbable versus fermentable carbohydrates.\nNew trials of a breakthrough swallowable sensor have revealed the device is 3,000 times more accurate than current technology used to diagnose many gut disorders.\nThe findings show the revolutionary gas-sensing capsule developed by researchers at RMIT University in Melbourne, Australia, could surpass breath testing as the benchmark for diagnosing gut disorders, paving the way to solving previously undiagnosed conditions.\n\"Importantly this test is non-invasive and allows the patient to continue with their daily life as normal.\"\nThe vitamin pill-sized capsule, currently being commercialised by Atmo Biosciences, provides real time detection and measurement of hydrogen, carbon dioxides and oxygen in the gut.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The news release makes many bold claims about the accuracy and clinical utility of this device. And if it\u2019s not too early to make such claims,\u00a0it\u2019s not too early to give readers some idea of what this type of technology might cost.", "answer": 0}, {"article": "Furthermore, erectile dysfunction is reported in 21 to 85 percent of all prostate cancer patients, while urinary incontinence is reported in 24 percent of men with this disease.\n\"Despite these figures, we found that a structured yoga intervention in the form of twice-weekly classes is feasible for patients during a six- to nine-week course of outpatient radiotherapy for prostate cancer,\" said Vapiwala.\nThe new, first-of-its-kind study, led by Neha Vapiwala, MD, an associate professor in the department of Radiation Oncology at PSOM and Penn's Abramson Cancer Center, found that general quality of life and measurements of side effects often experienced by prostate cancer patients--including fatigue, sexual health, and urinary incontinence--were stable throughout a course of outpatient radiation therapy among the men participating in an intensive yoga program.\nOther studies have demonstrated beneficial health and quality of life effects from yoga interventions in cancer patients.\nThe possible explanation for the benefits of yoga seen in the study stems from physiologic data demonstrating its ability to help reduce cancer- as well as treatment- related fatigue and to strengthen pelvic floor muscles and increase blood flow.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The news release did not say how much the yoga classes cost, but that is not a fatal flaw, given that the classes are offered daily to millions of downward dog fans in health centers, living rooms and parks around the world. We\u2019ll rate this Not Applicable.", "answer": 2}, {"article": "He explained: \"When teixobactin was discovered it was ground breaking in itself as a new antibiotic which kills bacteria without detectable resistance including superbugs such as MRSA.\nThe Lincoln team has successfully synthesized new simplified versions of teixobactin which harness the same powerful antibiotic effects in a way that could be produced on a commercial scale.\nWe have been investigating a way to simplify the design while retaining the high potency against resistant bacteria such as MRSA.\nScientists working to develop a 'game-changing' new antibiotic have made a significant advance towards creating commercially viable drug treatments by producing two simplified synthetic versions of the substance which are just as potent at killing superbugs like MRSA as its natural form.\nThe breakthrough by researchers at the University of Lincoln, UK, marks another important step to realising the potential of teixobactin in aiding the global fight against antibiotic-resistant pathogens.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "A key point of the release is that the researchers have developed a form of the teixobactin antibiotic that could be commercially viable. This statement implies that they made some rough calculations of the potential cost of manufacturing the drug. Even though it may be too early to guess at a market price (which depends on many factors other than actual manufacturing cost), it would have been nice to see some comparison to the production costs of other antibiotics.", "answer": 0}, {"article": "score of 0.9 or higher at the age of 50.\nStill, the absolute risks for men with elevated scores were lower than might be expected.\nThey still have a very low individual risk of dying from prostate cancer, judging from the new data.\n\u201cThere\u2019s a strong case that they should be exempted from screening.\u201d\n\nThe advice is less clear for men with scores between 1.0 and 2.0 at the age of 60.\nFinally, some new research offers simple, practical advice \u2014 at least for men 60 and older.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "\u00a0There was no discussion of costs, though this doesn\u2019t seem relevant to this particular discussion.\u00a0", "answer": 0}, {"article": "More women are undergoing genetic testing after a diagnosis of breast cancer, and improvements in both mastectomy and breast-reconstruction techniques have made the option of a double reconstruction less daunting.\nThough the researchers had limited information about the patients, Dr. Tuttle suggested that younger women might be choosing the procedure because their cancers tended to be very aggressive, and they had more years ahead of them in which a second cancer might develop.\nThe numbers were much higher among women who had the breast with cancer removed, rather than a lumpectomy.\nSeveral developments may be driving the trend toward prophylactic mastectomies, experts said.\nHe and other experts emphasized that though the removal of the healthy breast sharply reduced the risk of a new cancer developing in that breast \u2014 the risk is not zero because some tissue can remain \u2014 it was the cancer that had already been diagnosed that posed the greatest threat to a patient\u2019s life.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not list the additional cost of surgical treatment and reconstruction for the prophylactic mastectomy. While the focus of the story was to report the increase in these procedures, the story could list the average cost and the time spent recovering from bilateral mastectomy and reconstruction. \n\u00a0\n", "answer": 0}, {"article": "Common symptoms are abdominal pain and diarrhea, and it can lead to bowel perforations.\nHe said a 100-point drop in the CDAI was clinically meaningful to patients.\nThe intravenous biotech drug met the primary goal of the study as almost 40 percent of patients who received the 6 milligrams per kilogram of weight dose of Stelara achieved a clinical response \u2014 defined as a 100-point reduction in the Crohn\u2019s Disease Activity Index (CDAI) \u2014 after six weeks of treatment.\nPatients in the study on average started at 320 or 325 on the CDAI scale, researchers said.\n\u201cIt\u2019s effective in the patient population that has the greatest unmet need at this point in time,\u201d Sandborn said of patients who do not respond to anti-TNF drugs.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "While we\u2019re given the size of the market, we don\u2019t get the costs of the drug itself. It\u2019s a biologic treatment and it ain\u2019t cheap.\u00a0 Even if this story is targeted at a business audience, patient costs are extremely relevant.", "answer": 0}, {"article": "\"It's not.\"\nThe investigators further noted that even eight months after treatment launch, no serious adverse effects were directly attributable to the new drug.\nTo test the drug, Kappos and his team recruited patients aged 18 to 55 seeking MS treatment in 79 centers in 20 countries.\nAnd I see no major advantage of this drug versus that older drug.\nTUESDAY, Nov. 1, 2011 (HealthDay News) -- Multiple sclerosis patients may eventually benefit from a novel treatment that takes aim at the abnormal behavior of a specific type of immune cell, preliminary research suggests.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "It may have been understandable that costs wouldn\u2019t be discussed at this early stage of research.\u00a0 However, when the Mayo expert weighed in at the end about a comparable drug, this provided the perfect and easy opportunity for the story to include ballpark costs of drugs in this category. And a ballpark cost of the comparable drug is somewhere around $20,000.", "answer": 0}, {"article": "We are actively seeking the best-suited licensees having resources and marketing expertise to maximize sales for each of our products in the U.S. and globally.\"\nAfter 48 hours, the average pain reduction for OsteoRx\u2122 users was nearly three times greater than for patients using the competing brand.\nAt 72 hours, OsteoRx\u2122 results were nearly five and a half times better.\nAfter just 24 hours, patients using OsteoRx\u2122 experienced an average improvement in range of motion that was more than twice as large as the competition.\nEach HSRx OTC drug product is proven in independently conducted clinical studies to provide superior treatment outcomes.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release does not contain any cost information of interest to people suffering from joint pain. The chief financial officer, Frank Parise, mentions money only in relation to his company\u2019s fundraising efforts:\n\u201cWe are actively seeking the best-suited licensees having resources and marketing expertise to maximize sales for each of our products in the U.S. and globally.\u201d\nA bottle of 120 tablets of Osteo-Rx sells for $19.99 on the company\u2019s website.", "answer": 0}, {"article": "\u201cBut this is a small study, a proof of concept.\nBut they stressed that the trial was small, so far larger studies are needed to confirm the results.\n\u201cWe must bear in mind that this is a pilot study with a small sample,\u201d Anna Fenton, co-editor of Climacteric, said in commentary on the work.\nGenazzani said the results showed DHEA has potential, especially for those women who may have problems in taking more conventional HRT.\nFor this trial, a team of researchers led by Andrea Genazzani of the University of Pisa followed a group of 48 post-menopausal women with troubling symptoms.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Costs are missing from the story, and, given that these are well established products, cost information could have been explained.\n\u00a0", "answer": 0}, {"article": "Rates are rising, in part because tanning became fashionable.\nNew data about to be released to a meeting of cancer specialists shows that 40 percent of the patients who have been taking the drug are still alive three years later.\nIt was bad enough for 8 percent of patients that they stopped taking it.\nThat compares to about 5 percent of patients given the standard therapy, interleukin, the American Society for Clinical Oncology (ASCO) says.\nThe drug, called Keytruda, takes a new approach to treating cancer by stopping tumor cells from cloaking themselves against the normal, healthy immune system response.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The video claims the cost is about $150,000 a year and is \u201ccovered by insurance.\u201d The text story notes how pricey it is and states \u201cKeytruda costs about $12,500 a month, or $150,000 a year.\u201d", "answer": 1}, {"article": "But it\u2019s not proof,\u201d Broderick said.\nThe results of the clinical trials, presented this week at a meeting in Hawaii, shocked and surprised stroke physicians.\nThe other half of the patients got standard treatment, which didn\u2019t include the procedure.\nRemoving the clot wasn\u2019t better than standard care in either group \u2014 those with a lot or a little brain tissue to lose.\nOne study took eight years to complete because it was so difficult to enroll patients willing to take the chance that they would be randomly assigned to get the older treatment.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Nice job on this.\u00a0 The story reported:\n\u201cInsurance companies and Medicare, the health insurer for the elderly, already cover the endovascular procedure. It costs about $23,000 compared with $11,000 for acute stroke treatment using intravenous clot-dissolving drugs, known as thrombolytics.\u201d\n(and)\n\u201cWill it change practice? That\u2019s a good question,\u201d said Koroshetz. \u201cThe payers may look at this and wonder if they should continue paying for these procedures. If it gets to that point, then clearly things will change.\u201d", "answer": 1}, {"article": "Also, mice that received the drug had slower blood clot formation than untreated mice, but the treated mice did not bleed longer than untreated mice.\nThe serpent-medicine connection isn't new, one cardiologist noted, since venom typically kills by disrupting the blood's clotting mechanisms.\nStill, experiments in animals often don't translate to success in humans, so further research is needed.\nThe snake's venom contains a protein called trowaglerix, the researchers explained.\n\"The potential development of a new agent based on snake venom that could have similar beneficial effects on preventing blood clotting, and potentially cause less bleeding side effects, is an exciting discovery that warrants future investigation,\" Marzo added.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story did not discuss costs, but our rule of thumb is: If it\u2019s not too early to speculate about benefits, it\u2019s not too early to talk about what the cost might be.", "answer": 0}, {"article": "Drs.\nSo for up to two years the new study followed more than 5,000 Group Health patients who started taking an antidepressant.\nBupropion should be considered the first-line drug of choice for people who are overweight or obese, Dr. Simon said.\nBut patients should consult their doctor about which medication is right for them, before making any changes, including starting, switching, or stopping medication.\nPrior research on antidepressants and weight change was limited to one year or shorter.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "A quote from one of the study\u2019s co-authors\u00a0mentions \u201ccosts\u201d and \u201cpatient preferences\u201d as sensible considerations in first choice of antidepressant therapy, but the release offers no information about the comparative costs of the drugs that were studied or even the estimated average annual cost of such therapy. The release would have been strengthened by such data.", "answer": 0}, {"article": "A serious mood disorder that affects as many as 1 in 7 women after childbirth, postpartum depression can lead to panic attacks, inconsolable sadness, and deep feelings of inadequacy.\nOne of the drug\u2019s most promising features: It appears to work quickly \u2014 some women in the study started experiencing relief after 24 hours.\nThe company has not submitted study data to federal regulators and isn\u2019t at this point seeking approval of the drug, known as SAGE-547, for postpartum depression.\nSage\u2019s drug is designed to change the traffic patterns in the brain.\nHe wrote the book \u201cEverything You Need To Know About Prozac\u201d in the early 1990s, in part to counter fear-mongering about the antidepressant.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The drug is still in early experiments, but it would have been nice to give readers some indication of how the eventual price of this drug might compare to available antidepressants.", "answer": 2}, {"article": "Error code 404. Something went\n\nwrong and we can't seem to find\n\nthe page you're looking for.\n\n Report a broken link.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There\u2019s no discussion of costs, although the story does mention that insurance coverage varies.", "answer": 0}, {"article": "\"And I thought, 'If we could do that in people, this is going to be amazing.'\nWhat Belvin didn't know at the time was that a revolutionary treatment for melanoma had begun testing in clinical trials.\nAllison's treatment was still experimental, but if it worked, it had the potential to save Belvin's life.\nBelvin was the first recipient of the immunotherapy that Allison had ever met.\nAn immunologist named Jim Allison, now at the University of Texas MD Anderson Cancer Center, had figured out that if the immune system was tweaked just right, it could do a better job of killing the cancer than the usual treatments.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story doesn\u2019t address cost. Given that ipilimumab treatment can cost $120,000 (according to this 2012 paper in the journal Pharmacy & Therapeutics), and is not necessarily covered by insurance, that\u2019s a significant oversight. A\u00a0quick acknowledgement of the steep price tag would have made helped readers more fully understand what this treatment involves.", "answer": 0}, {"article": "The ancient art of applying suction cups to the body has gotten a boost from several new studies that show it helps relieve a variety of painful conditions. But scientists say larger, more rigorous studies are needed.\n\nCupping, as the practice is called, was performed traditionally in China and other countries, and is now available from acupuncturists, and some chiropractors and massage therapists in the U.S. In the traditional method, called fire cupping, a ball of burning cotton is briefly placed inside a glass cup to heat...", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The article mentions that the cost of cupping \u201cvaries widely, from $40 to $100 or more for a half-hour session.\u201d", "answer": 1}, {"article": "Other texts might include something like, \"Hi, Elizabeth.\nNot only does this research provide evidence that a text-based program can improve heart disease risk factors, but it also shows that a bunch of bells and whistles aren't required for successful health outcomes.\nIt can't tell us whether text messaging could eventually lead to fewer subsequent heart attacks among the patients receiving those messages or whether the positive health outcomes would continue past the six-month study window.\nIt can be hard to view those everyday decisions in light of more distant consequences, like having another heart attack or not living as long a life as desired.\nThere's a lot of hype over mobile health interventions these days, Chow says.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "This is a tricky one. The story does not explicitly address cost, except to call text messaging \u201ca scalable and affordable approach.\u201d For many (or most) patients, the cost of receiving four text messages a week would likely be negligible \u2014 covered by an individual\u2019s phone plan or by nominal text rates. However, not everyone owns a mobile phone, a fact that makes access (and cost) a more significant issue.\u00a0However, the story does deliver on this point. The story discusses both the number of U.S. adults who own mobile phones (90 percent) and the fact that text messages are more accessible than other forms of mobile health communication (such as apps, which require patients to own smartphones or other smart devices). So, while we\u2019d prefer a more in-depth discussion here, we\u2019ll award\u00a0a Satisfactory rating for the story\u2019s nod in this direction.", "answer": 1}, {"article": "Anderson.\nThe benefits were greater in women aged 45 to 49, vs. those aged 40 to 44, the researchers said.\n\"Mammography has been shown in study after study to reduce breast cancer deaths in women aged 40 to 49,\" Obel added.\nTo further stir the pot, a Norwegian study released last week found that routine mammograms accounted for only about one-third of the decline in breast cancer death rates seen recently.\nThe study, done in Sweden, found that women who were screened cut their risk by 29 percent.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not discuss the costs of annual mammography screening, or even provide a range of costs.\u00a0 The story does not discuss any health care policy cost repercussions of breast cancer screening recommendations.\u00a0 The story does not discuss the cost of unnecessary biopsies or other treatments for women who have a false positive diagnosis via mammography (greater in women 40-49). ", "answer": 0}, {"article": "Mammograms, for example, prevent 25 percent of breast cancer deaths, and the PSA test for men has not been shown to prevent prostate cancer deaths.\nDr. Ransohoff and other screening experts say patients should continue to have the test, because it is still highly effective.\nStill, he said, that does not mean that patients should have more frequent colonoscopies.\nCT colonoscopies, so-called virtual colonoscopies, are not a solution, some screening experts said.\nOne solution, supported by six studies, is to be sure there is just a short time between when patients finish taking the strong laxative that cleanses their bowel and the colonoscopy, Dr. Rex said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story refers to colonoscopies as being \u201chugely expensive.\"\u00a0 It would have been better to tell readers exactly how much they cost. ", "answer": 0}, {"article": "In macular edema, fluid from those damaged vessels leaks into the macula, the part of the retina that is responsible for the straight-ahead vision important for driving, recognizing faces and reading.\nAbout 1 percent of those getting Lucentis injections suffered an inflammation of the eye from an infection.\nThe steroid treatment did not improve eyesight more than laser therapy alone and caused side effects.\nThe trial involved 691 patients, some of whom had both eyes treated, resulting in 854 total eyes.\nThe fourth group got laser therapy plus a sham injection.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "\u00a0Kudos! \u00a0This story reported on the costs of the drug Lucentis as well as the less expensive Avastin.", "answer": 1}, {"article": ".\nThis study also confirmed that SecA inhibitors have the potential for being broad-spectrum antimicrobials, can directly block virulence factor production and can null the effect of efflux pumps.\nTheir study showed that small molecule analogs that target the functions of SecA, a central part of the general bacterial secretion system required for viability and virulence, have potent antimicrobial activities, reduce the secretion of toxins and can overcome the effect of efflux pumps, which are responsible for multi-drug resistance.\nHe co-led the study with Phang C. Tai, Regents' Professor of Biology at Georgia State, who is an expert on the functions of SecA in bacteria.\nATLANTA--A novel class of antimicrobials that inhibits the function of a key disease-causing component of bacteria could be effective in fighting methicillin-resistant Staphylococcus aureus (MRSA), one of the major drug-resistant bacterial pathogens, according to researchers at Georgia State University.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Even though it\u2019s \u201cearly days\u201d for this strategy we\u2019d like to see some mention of costs, if not for the proposed therapy then a related one, or the societal costs of combating MRSA. The release didn\u2019t shy away from forecasting potential treatment benefits based on this early research \u2014 so we\u2019d like to see the same approach applied to costs.", "answer": 0}, {"article": "Hot flashes are a sudden rush of heat, followed by facial flushing and sweating, often followed by chills and clamminess.\nThe alternative therapy reduced hot flashes by as much as 74% in the study conducted by researchers at Baylor University\u2019s Mind-Body Medicine Research Laboratory and funded by the National Institutes of Health.\nA total of 187 postmenopausal women who reported having at least seven hot flashes a day, or 50 a week, were recruited for the trial.\nOnly hormone therapy, which many women can\u2019t take or want to avoid, is more effective for treating the most common symptom of menopause, says researcher Gary R. Elkins, PhD.\nThe women were also given a recording of the hypnotic induction, and they were asked to practice self-hypnosis at home daily.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not detail the costs of the weekly sessions of therapeutic hypnosis, which are likely to be high.", "answer": 0}, {"article": "But \"that trial is never getting done, nor should it be done,\" Golden said.\nAs to whether circumcision reduces sexual sensitivity, Perera said there's no evidence that it affects sensation when performed on adults.\nThe highest-quality studies, known as randomized controlled trials, don't report whether infant circumcision affects sensation, she said.\nBut another from the United States gives more weight to findings from Africa that show the procedure, when it's performed on adult men, makes a major difference in preventing such diseases as AIDS.\nShe said that circumcision poses problems from a mental point of view, potentially causing \"significant anger or feeling incomplete, hurt, frustrated, abnormal or violated.\"\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "This story did not discuss the cost of circumcision or its coverage by insurance companies. Currently, some state Medicaid programs do not cover its cost. ", "answer": 0}, {"article": "The Mount Sinai Hospital is in the \"Honor Roll\" of best hospitals in America, ranked No.\nMore specifically, the non-wire electrodes were less traumatic, causing less injury and minimizing fractures inside the inner ear.\nThe results, published in the June 23, 2017, online edition of The Laryngoscope, may transform how doctors approach cochlear implant procedures to give patients the best possible outcomes.\nThe research also determined that the best surgical approach for cochlear implant procedures did not involve drilling into the bone around the ear.\nThis research was supported by the National Institute on Deafness and Other Communication Disorders the National Center for Advanced Translational Sciences.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Surgery can be costly itself as well as all the related expenses that follow from it so knowing the overall costs is very important. No costs are mentioned.", "answer": 0}, {"article": "Rick lost 20 pounds, and Nina said she feels 20 again.\nIt's a lifestyle change.\nLike many on the various detox plans, she couldn't stomach the all-liquid diet and craved solid food.\nBecause of that promised quick fix, the detox diet business is booming.\nEfron lasted only four days.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There was no discussion of costs.", "answer": 0}, {"article": ".\nOnly one incision is required because Lee and other doctors can use a device called a trocar, which has holes for each instrument and the endoscope.\nTechnically known as single-port cryosurgery, the technique is used only for cancers no bigger than an inch and a half wide that haven't spread beyond the kidney, Lee said.\nThis technique, which Lee helped develop and has been using for about a year, represents a big advance over conventional kidney-cancer surgery, which can require a foot-long incision and, sometimes, removal of a rib so the doctor can reach the malignancy, according to experts.\nThat was what happened to Davis, who had gone to a hospital for a kidney stone.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story makes no mention of the cost of cryotherapy or how it compares to other available treatments.", "answer": 0}, {"article": "Journal of Child and Adolescent Psychopharmacology.\nBoth findings reaffirm the potential that mindfulness therapy could bring to the table.\n\"These integrative approaches expand traditional treatments and offer new strategies for coping with psychological distress,\u201d said the study\u2019s co-author Sian Cotton, director of the UC's Center for Integrative Health and Wellness, in a statement.\n\"Mindfulness-based therapeutic interventions promote the use of meditative practices to increase present-moment awareness of conscious thoughts, feelings, and body sensations in an effort to manage negative experiences more effectively.\u201d\n\nChildren who are at a high risk for bipolar disorder or other anxiety disorders, such as the participants, often have poor coping skills when confronted by stress, and only a lucky few get help.\nThe therapy was also able to increase brain activity in the insula, a part of the brain that helps monitor how the body feels psychologically.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Cost is not discussed at all. How much does cognitive therapy cost for children with anxiety disorders? Does it require long-term treatment with multiple sessions? Is it usually covered by health insurance providers? These are all important questions for families who have a child experiencing an anxiety disorder \u2014 and this story doesn\u2019t address them.", "answer": 0}, {"article": "\"So, yes, one of the limitations of this kind of study is always the question of its generalizability to other populations,\" he cautioned.\nRamsden acknowledged that the Sydney study had been narrowly focused on a specific group of people: middle-aged men with a history of heart disease, who were asked to consume linoleic acid in quantities far exceeding both AHA guidelines and the dietary habits of most Americans.\nBut an updated look at the study indicates that heart disease patients who follow this advice may actually increase their risk for death.\nThe first group was told to consume linoleic acid, in the form of safflower oil and safflower oil polyunsaturated margarine, at levels equal to 15 percent of total calorie intake.\nBut he also suggested that his team's rigorous look back offered valuable insights into how nutritional science has evolved.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The cost of vegetable oil and other sources of linoleic acid is not really in question.", "answer": 2}, {"article": "Studies of adults find that social jet lag is associated with higher BMI, insulin resistance, depression, and a higher likelihood to engage in dangerous behaviors like smoking.\nBut even if later school start times only improve sleep time, that\u2019s a positive step for public health.\nFor one, teens need more sleep than adults: about eight or nine hours a night, compared with about the six or seven their parents require.\nBut it\u2019s not a foregone conclusion that later start times will ensure teens sleep more.\nWhen it made its recommendation, the Academy of Pediatrics admitted \u201cit is clear that additional research is needed to further document the effects of changes in school start times over time.\u201d\n\nWell, there\u2019s some new (but still incomplete) evidence that later start times do help teens get more sleep.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Although specific, numerical costs are not mentioned, the story does a good job of reflecting on the kinds of costs that school districts would incur if they went to a later start time.", "answer": 1}, {"article": "Asthma on the Rise in U.S.\nSymptoms completely disappeared in 94% of patients taking kampo herbs after an average of 16 days, Shimoide says.\nThe study did not look at possible side effects of kampo herbs.\nNorth American allergy experts tell WebMD that although they find the preliminary findings fascinating, further study is needed before they would recommend the herbs.\nHerbs used in the current study include Scutellaria root, Coptis rhizome, gardenia fruit, hoelen, cinnamon bark, and Glycyrrhiza (aka licorice) root.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No discussion of the cost of kampo, nor of any comparison with current asthma medications.", "answer": 0}, {"article": "Asked if the 34% improvement in cognitive decline is meaningful to a patient, Carrillo said, \"I have a family member with AD.\nThe results really became clear when the researchers looked only at those patients with mild, early-stage disease.\nLarger studies in many more patients are needed before the drug will be available, though, she says.\nThere was even a hint that the drug helped to slow the decline in functioning.\nThe benefit is small and studies have been inconsistent, says researcher Rachelle Doody, MD, head of Alzheimer\u2019s disease research at Baylor College of Medicine.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Though it is too early to have a firm price, the story notes that similar drugs can cost hundreds of dollars per month. This price reference is more specific than the one in the AP story.", "answer": 1}, {"article": "Weight training or cardio?\nLosing weight is generally recommended for those with obesity, but preserving muscle - while losing fat - is particularly important for older adults in order to maximize functional benefit, Beavers said.\nThe findings, \"Effect of Exercise Type During Intentional Weight Loss on Body Composition in Older Adults with Obesity,\" appear in the November issue of the journal Obesity.\nCo-authors on this paper included W. Jack Rejeski and Anthony Marsh, co-principal investigators of the CLIP-II study, and Jessica Sheedy, Beverly Nesbit and Jill Gaukstern, all of the Wake Forest University Department of Health and Exercise Science; and Walter Ambrosius, Michael Walkup, Jonathan Burdette and Barbara Nicklas of the Wake Forest School of Medicine.\nThis is the latest study from the Cooperative Lifestyle Intervention Program (CLIP-II), a single-blind, randomized controlled trial.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The news release does not make any mention of costs. Although weight training isn\u2019t like a medication with a certain price, the release could have added information about the cost of local weight training classes at senior centers, YMCA classes, etc. There are also many articles online that discuss tips on weight training for seniors for free.", "answer": 0}, {"article": "Among the women who initially had no heart disease and did not take any dietary supplements, 3.4 percent had heart attacks, compared to 2.6 percent of the women who took multivitamins plus other supplements; this translated to a 27 percent lower heart attack risk with vitamins.\nBut vitamin pills seemed to have less of an effect in women with heart disease, Dr. Susanne Rautiainen of the Karolinska Institutet in Stockholm, Sweden, and her colleagues found.\n\u201cIt is very important to keep in mind that multivitamin users tend be \u2018healthier\u2019 in general.\nSimilar studies have been done in men, with some confirming the current findings and others contradicting them, Rautiainen said.\nThe women ranged in age from 49 to 83 at the study\u2019s outset, and about 60 percent in each group used some type of dietary supplement.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "\u00a0There was no insight about the costs of various multivitamin formulations.", "answer": 0}, {"article": "Through its divisions in 54 subfields of psychology and affiliations with 60 state, territorial and Canadian provincial associations, APA works to advance the creation, communication and application of psychological knowledge to benefit society and improve people's lives.\nThis study is the first to examine similar positive effects from college courses taken by older adults, said Lenehan, of the University of Tasmania.\nThe participants who took college classes volunteered for the study so they probably had a greater interest in continuing education that the general senior population, the journal article noted.\nThe participants completed the same cognitive tests each year during the four-year study, with 92 percent of the college-studies group displaying a significant increase in cognitive capacity, while the remaining 8 percent generally maintained their cognitive capacity.\nPrior research has shown that college study earlier in life may increase cognitive capacity, and it appears the same may be true for older adults, Lenehan said.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Costs were not mentioned in the article and we think that they should have been. Although costs for tuition in Australia are fixed,\u00a0the lowest tier is approximately $5,000 US dollars annually. That is a considerable sum for elderly retirees.", "answer": 0}, {"article": "Injections of botulinum toxin, best known as a wrinkle treatment, are now being used increasingly to prevent chronic migraine sufferers. Scientific data are mixed, but two large recent studies show Botox can reduce the number of headache days in chronic sufferers.\n\nMigraine headache is a debilitating neurological condition that manifests itself as an intense throbbing pain on one or both sides of the head, according to the Migraine Research Foundation, a New York nonprofit. Some 14 million people experience migraine attacks...", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The article gave a bare-bones estimate about the costs of Botox. However, it didn\u2019t provide any real-world estimates of the total long-term costs of the injections and any ancillary services from specialists.\nSince chronic migraines can be a life-long complaint, the total costs may be jaw-dropping. The article also did not address the cost-effectiveness of Botox for chronic migraines. Will patients and insurers be interested in paying steep prices for meager clinical results?\n\n \n", "answer": 0}, {"article": "For the study, the researchers followed 57,872 women in B.C.\nThe study, published today in the British Medical Journal Open, found that low-income pregnant women who receive care from a midwife compared to a physician are less likely to go into early labour, to have a baby with a low birth weight, or to have a small-for-gestational age birth, meaning a fetus or infant that is smaller or less developed than normal for the number of weeks in pregnancy.\nThey used maternity, medical billing and demographic data to investigate the odds of small-for-gestational age birth, pre-term birth and low birth weight for low-income women receiving care from a midwife, GP, or OB.\nAfter controlling for differences such as age, previous pregnancies, where they lived and pre-existing medical conditions, the researchers found that low-income women who were receiving prenatal care from a midwife had 29 per cent lower odds of a small-for-gestational age birth compared to women who received care from a GP.\nMcRae said the findings add new evidence in support of midwifery care, and support the development of policies to ensure midwives are available and accessible, especially for low-income women.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There\u2019s no discussion of how much it costs to use midwives in Canada or who pays for their services. The release did note that all of the 57,872 women included in the study had received medical insurance premium assistance.\nIn general, midwifery care is less costly than that provided by specialists in obstetrics and gynecology and general practitioners.", "answer": 0}, {"article": "Colorectal cancer is the third most common cancer in men and women, and strikes 1.2 million people each year.\nThis is not the first study to suggest Celebrex and similar drugs \u2014 known as COX-2 inhibitors - may reduce the risk of developing colon cancer, he said, but people need to balance that potential benefit with the higher risk of cardiovascular complications.\nOnly half of the people who originally agreed to participate in the study remained after 5 years, and it\u2019s unclear how this might affect the results, noted Chan, whose own research suggests aspirin could prevent deaths from colorectal cancer.\nThe study, published in the American Journal of Gastroenterology, received financial support from Pfizer, which sells Celebrex.\nAs a result, he said he suspects most people would choose to rely on regular colonoscopies to catch the disease in its early stages, rather than take a potentially risky drug for years.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story manages to work costs into the discussion: \u201cAt a cost of several dollars per day, depending on dosage, [Celebrex]\u00a0is much more expensive than older pain relievers such as ibuprofen.\u201d", "answer": 1}, {"article": "Master said each participant was asked to carry an accelerometer to record movements and an iPod Touch loaded with an app that would ping them prompts at intervals during each day to report any symptoms they were feeling. They also completed activity questionnaires and summaries. In addition, they wore a device called an ActiGraph to monitor sleep.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The intervention, rest, does not have any obvious costs. (Unless one is working, wherein prescribed rest can result in loss of income.) The tool used to track activity and symptoms could presumably cost\u00a0money if it\u2019s ever made publicly available.", "answer": 2}, {"article": "Powers said, \"I think what's going to happen is that we will develop systems of rapid triage and rapid transport.\nAll of these studies showed that the device can safely and effectively stop a stroke by removing blood clots, he added.\nThat last point is especially important, because the stent retrieval device will not fit into the smaller blood vessels that branch out further into the brain, Powers said.\nThe major risk of using the device is that it could tear an artery and cause bleeding in the brain, particularly since it will be used on people who have already received very potent blood thinners, Kandzari said.\nStent retrieval devices make that quick hospital transfer even more important, since the gadgets provide a crucial backup for tPA but are more tricky to use.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The article does not mention, even generally, what removing a clot using these devices might cost. In a broader way, we would have welcomed discussion of how much treating strokes costs the entire health system and how risks versus benefits of different strategies may have large effects throughout the health system. For example, if this new intervention prevents disability for more patients, might it save the system those costs?", "answer": 0}, {"article": "Digital tomosynthesis (DBT), or 3D mammography, does slightly better, detecting approximately 25 percent more cancers, or roughly 5 cancers in 1,000 women screened.\nBased on the preliminary results at Penn Medicine, the cancer detection rate of AB-MR screening is 25 cancers per 1,000 patients.\nTo put this in perspective, the cancer detection rate of mammography is roughly 4 cancers in 1,000 women who have a mammogram.\n\"Based on the literature and our results, women with dense breast tissue who desire supplemental screening, these results suggest that AB-MR may be a better option than other supplemental screening tests such as whole breast ultrasound.\n\"Having dense breast tissue makes it more difficult to detect a cancer on a mammogram,\" said the study's lead author, Susan Weinstein, MD, an associate professor of Radiology and the director of breast MRI at Penn Medicine.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There was no discussion of costs of the abbreviated breast MRI and it was unclear if this type of procedure is commonly covered by insurance for asymptomatic women.\nThe release also refers to women who \u201c\u2026request additional screening after a negative mammogram\u2026.\u201d \u00a0Requesting additional costly screening adds to overall healthcare costs and may also lead to over-diagnosis.", "answer": 0}, {"article": "Among parents of children with autism, Mr. Frank said, \"some will say, 'Come on, who are you kidding?'\nThe Children's Institute plan would be taking what is arguably a fringe movement into the mainstream: It would be the first autism treatment of this kind staged in an American hospital setting.\nWith roots in autism treatment theories that until now have lived mostly on the Internet, the pediatric clean room plan would be the first of its kind in a mainstream American hospital environment.\nWith so many doubts -- and so few answers -- about effective autism treatments among the growing community of families affected by the condition, the institute said openness is vital to the experimental method's success.\nAt the outset, patients would be only the sickest children, who have not responded to other treatments.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "This article does report costs estimated\u00a0to design the clean room, $500,000, and that a minimum of $1 million dollars annually will be needed to support operating expenses.\u00a0 Cost of the experimental approach were not reported and may not be available at this time because the project is still in the planning stage; however, it is estimated the operational costs will support the experimental approach for only\u00a0four to six experimental subjects per year.\u00a0 ", "answer": 1}, {"article": "Doctors tell patients who are at risk of developing stones to drink lots of water and avoid foods rich in oxalate, such as rhubarb, okra, spinach and almonds.\nThis finding could lead to the first advance in the treatment of calcium oxalate stones in 30 years.\n\"HCA shows promise as a potential therapy to prevent kidney stones,\" the researchers wrote.\nThe head-to-head studies of CA and HCA determined that while both compounds inhibit the growth of calcium oxalate crystals, HCA was more potent and displayed unique qualities that are advantageous for the development of new therapies.\nThe most effective inhibitors reported in the literature simply stop the crystal from growing.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release could have mentioned the price of the supplement used by researchers. The product is sold as a weight loss aid. The manufacturer\u2019s recommended dose of two capsules taken three times a day costs about $17 per month.", "answer": 0}, {"article": "Matthews: \u2018It\u2019s only going to get better\u2019\n\nIn his first game with the Pacers, he only made two shots but they came in the fourth quarter to pull out the victory vs. the Hornets.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There was no mention of treatment costs.", "answer": 0}, {"article": "Folic acid is naturally present in green, leafy vegetables and legumes.\nO\u2019Connor, of the University of Toronto and the Hospital for Sick Children in Ontario, Canada, called the findings \u201cpretty significant.\u201d\n\nStill, she said, you can\u2019t be sure if the kids who performed better had a better diet in general or if some other hidden factor could explain the results.\nWhen all their grades from ten core classes were added up, there was a clear difference between teens who got the most and the least folic acid in their diets.\nThe researchers looked at 386 15-year-olds who were finishing up ninth grade.\nThe differences remained even after the researchers accounted for gender, smoking, the mothers\u2019 education and which schools the kids went to.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Not applicable.\u00a0 Costs weren\u2019t mentioned, but we didn\u2019t think that was a necessity in this case.", "answer": 2}, {"article": "Grocers shelves add new coconut-water products regularly.\nIn the past couple of years a couple of brands have figured out the right angle \u2014 electrolytes and hydration.\u201d\n\nCraven estimated the coconut-water market at about $100 million annually right now, but companies are doubling their sales year after year.\nEven so, Little, a coconut enthusiast, doesn\u2019t recommend loading up on coconut fats.\nIt\u2019s the whole coconut that needs to be talked about.\u201d\n\nEntrepreneurs are talking about the whole coconut these days.\nIt\u2019s simple all the way around.\u201d\n\nOne tablespoon of coconut oil contains 120 calories and 14 grams of fat, 12.5 grams of which is saturated.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "For a story that attempts to wow readers with unsupported claims from third hand sources about the big money to be made in coconuts, this story is very light on any cost information for consumers. The story says, for example, that while the coconut water market sits at \u201c$100 million annually right now,\u201d one company alone will do \u201c$100 million in sales\u00a0or more in sales\u201d next year. But there is not a single price provided for any specific products nor any \u00a0mention of how\u00a0these prices compare to other foods and beverages that contain similar nutritional value.", "answer": 0}, {"article": "Atopic dermatitis (AD) is a chronic inflammatory skin condition characterized by red, swollen and cracked skin with intense itching.\nThe successful results of the Phase 2 trial of MM36 have been published by the Journal of the American Academy of Dermatology (JAAD), the leading peer-reviewed journal in dermatology.\nMM36 is expected to be the 2nd topical PDE4 inhibitor in the market after the potential approval of Anacor Pharmaceuticals' crisaborole product.\n\"Based on the results of this study, it appears that MM36 could address an important unmet need in dermatology.\"\nAbout MM36\n\nMedimetriks has sole, exclusive US rights to MM36.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release discloses the total 2015 sales of Otsuka, the drug maker, but offers not a penny\u2019s worth of information about the costs of current therapies or whether the new product would be more or less expensive. Although there is no pricing for an investigational new drug still in clinical trials and not yet FDA-approved for sale, it would be helpful to consumers to know if part of the novelty of the product will be its availability and cost.", "answer": 0}, {"article": "Jay Konduros used to rush home several times a year after accidentally cutting or bumping himself.\nThe treatment also \u201cnearly universally eliminated\u201d the need for preventive infusions of clotting factor a few times a week, the scientists said.\nFor example, a separate Spark gene therapy for a rare type of childhood blindness, which is on track for Food and Drug Administration clearance soon, could cost $1 million per patient for infusions in both eyes, according to some Wall Street analysts.\nPorteus noted in his editorial that the hemophilia therapy resulted in savings of about $200,000 a year per patient because of the elimination of clotting-factor infusions.\nStill, the therapies can produce at least some offsetting savings.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Although this therapy is not yet available for patient use, the story makes a point of noting that the cost may well be \u201cstratospheric,\u201d should it make it to market.\nIf approved, such treatments are expected to command stratospheric prices. For example, a separate Spark gene therapy for a rare type of childhood blindness, which is on track for Food and Drug Administration clearance soon, could cost $1 million per patient for infusions in both eyes, according to some Wall Street analysts.\nStill, the therapies can produce at least some offsetting savings. Porteus noted in his editorial that the hemophilia therapy resulted in\u00a0savings of about $200,000 a year per patient because of the elimination of clotting-factor infusions.", "answer": 1}, {"article": "Tremors limited to the hand and forearm, for instance, might respond better than tremors that also affect the shoulder.\nLarger studies, of more-diverse groups of MS patients, are needed, he said.\nThe study\u2019s lead researcher agreed on the need for more work.\nMuscle weakness was the most common side effect in this study, van der Walt said.\nIf Botox is eventually approved for this MS symptom, LaRocca said it will be important for doctors to get training in how to give the injections \u2014 since the drug has to go into carefully chosen locations in the muscle.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story explains: \u201cthe cost could range from $500 to $1,000 Australian dollars, which are roughly equal to U.S. dollars. In the U.S., Botox treatments can cost $455-$575 per injection site.\u201d", "answer": 1}, {"article": "In 37 years as a police officer, Edwin Michel coped with a plane crash, a sniper, wildfires and three bullet wounds.\n\nNothing much rattled him until he was diagnosed with prostate cancer in November 2016. His doctor said the cancer wouldn\u2019t kill him but Mr. Michel, now 76 years old, wasn\u2019t entirely reassured. He felt more confident after a genomics test later revealed his prostate cancer was very low risk. The test, known as Oncotype DX, takes a sample from a prostate biopsy and analyzes 17 genes in it to estimate how aggressive...", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story offers clear information on the cost of the genetic tests by saying,\u201dThe various genomics tests, which have a list price between $3,800 and $5,000, generally are covered by Medicare and some private insurers.\u201d\u00a0 To its credit, it mentions the costs fairly early in the story.", "answer": 1}, {"article": "Prostate cancer is very common, showing up in 240,000 U.S. men every year.\n\u201cOur findings with Western diet and prostate cancer-specific mortality, however, were surprising, in part because there are very little data regarding how diet after diagnosis may impact disease prognosis.\u201d\n\nThe findings could be important for many men.\nIt\u2019s yet another piece of evidence showing that the so-called Western diet can worsen the risks for cancer, as well as all sorts of other diseases from heart disease to Alzheimer\u2019s.\n\u201cOur results suggest that the same dietary recommendations that are made to the general population primarily for the prevention of cardiovascular disease may also decrease the risk of dying from prostate cancer among men initially diagnosed with nonmetastatic disease (cancer that has not spread),\u201d said Dr. Jorge Chavarro of Brigham and Women\u2019s Hospital and Harvard Medical School, who led the study.\n\u201cWe found that men diagnosed with nonmetastatic prostate cancer whose diet was more \u2018Westernized,\u2019 i.e., contained processed meats, refined grains, potatoes, and high-fat dairy, were more likely to die of prostate cancer,\u201d Chavarro said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "We\u2019ll rule this Not Applicable. The article could have noted that a Mediterranean-style diet heavy with fish, olive oil, fresh vegetables, fruit, and whole grains is almost always more expensive than the typical fast, french-fried, and burgered Western diet. But we won\u2019t penalize the story for not mentioning this fact. The report does notes that it \u201cdoesn\u2019t take a whole lot of adjustment\u201d to lower risks with a better diet, and it takes some pains to note that a prudent diet already is widely recommended to ward off other disorders.", "answer": 2}, {"article": "\u2022 Try to stay indoors, and avoid mowing lawns or raking leaves.\nOver-the-counter treatments should not take the place of professional care \u2014 especially if you have never been formally diagnosed with allergies, if you have additional medical problems or if your symptoms persist or worsen, Eghrari-Sabet and Sublett say.\nIt's a myth, he adds, that older, sedating antihistamines, such as Benadryl, are extra effective against nasal allergies.\nThe non-prescription steroid nasal sprays are selling for about $17 to $23 for a one-month supply (at the typical two-squirts per nostril adult starting dose).\nBut you can also tell by the ads: TV spots selling remedies for drippy, congested noses, itchy eyes and other symptoms are in heavy rotation.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story goes above and beyond our standard here. There is a whole section on costs, which tells consumers to \u201cexpect to pay more.\u201d Insurers will no longer cover the cost, the article says, so expect to shell out $17 to $23 for a one-month supply of non-prescription steroid nasal spray. The story also discusses the costs of antihistamines and says store-brand versions are a cheaper alternative to steroid sprays. An example is Walmart\u2019s Equate loratadine tablets, which cost $7 for 60 24-hour doses.", "answer": 1}, {"article": "CAM2038 has the potential to alter the current treatment paradigm for opioid dependence,\" said Sharon Walsh, Ph.D, Professor of Behavioral Science and Director of the Center on Drug and Alcohol Research, University of Kentucky, \"Because of its long acting properties, CAM2038 may decrease patient and physician burden, improve access to treatment, and obviate public health concerns about illicit diversion of buprenorphine.\"\nThe CAM2038 products are designed for administration by healthcare personnel to ensure proper delivery that minimizes the risks of diversion, abuse, misuse, and accidental exposure.\nAbout CAM2038\n\nThe investigational CAM2038 buprenorphine subcutaneous injection products for treatment of opioid use disorder are being developed as once-weekly and once-monthly formulations, each with multiple doses, to cover all phases of treatment from initiation through maintenance.\nFurthermore, CAM2038 was well tolerated across the course of treatment.\nThe CAM2038 products have been evaluated in three Phase 1/2 clinical trials, which evaluated the safety and tolerability as well as pharmacokinetic and pharmacodynamic properties of the products in a total of 176 individuals (opioid-dependent patients and healthy volunteers under naltrexone blockage).\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "No mention is made of the projected cost of the treatment and it is likely to be significant. In addition to the cost of the medication, if it requires a health care professional to administer it \u2014 that will add to the cost. It is also not clear how long the treatment might last. If the treatment is successful, the cost/benefit may be fine, but who pays for the treatment will be an issue.", "answer": 0}, {"article": "In the 1970s, the FDA required warnings on drugs containing progesterone, as 17-HP does, because of an increased risk of birth defects.\nEveryone in this field is mindful of the long-running tragedy of vaginal and other cancers and male urinary disorders that resulted from the last drug thought to prevent premature birth \u2013 a synthetic estrogen called diethylstilbesterol, or DES.\nAnd even for the 30,000 or so women who are eligible, 17-HP, which will be marketed as Makena, isn't a magic bullet.\nInterestingly, the drug is not new \u2014 it's just taken a long and circuitous route to approval.\nFleischman, the March of Dimes official, says there's no such risk from 17-HP, partly because it's not used before the 16th week of pregnancy, when fetal organs have already formed.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No discussion of costs, something we always look for and wish would be provided.", "answer": 0}, {"article": "It defines low birthweight as being when a baby is born weighing less than 5 pounds, 8 ounces.\nRelated: Too Many Babies Die on Their First Day\n\nCharpak\u2019s team found the babies randomly assigned to get this treatment were 39 percent more likely to live into adulthood.\nThey exhibited less antisocial behavior, which might be associated with separation from the mother at birth,\u201d they added.\nBut overall, the findings support the benefits of kangaroo mother care, the team concluded.\nIts key features are: early, continuous and prolonged skin-to-skin contact between the mother and the baby; exclusive breastfeeding (ideally); it is initiated in hospital and can be continued at home; small babies can be discharged early; mothers at home require adequate support and follow-up,\u201d WHO said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The costs of this intervention or of the control, a neonatal minimal care unit in which infants remain in an incubator while they gain weight, aren\u2019t mentioned.", "answer": 0}, {"article": "Our new test is therefore a potential game changer,\" says Professor James Paton, Director of the University of Adelaide's Research Centre for Infectious Diseases.\nThe team has now engineered a harmless portion of the toxin to enhance its specificity for the cancer glycan and used this to detect it in blood samples from women with ovarian cancer.\nThe new blood test has the potential to dramatically improve early detection of the disease, although it will require further testing before it is available for clinicians.\nThe team is currently seeking scientific and commercial partners to further test the technology with larger numbers of patient samples and to adapt it for mass screening.\nA paper published this month in Biochemical and Biophysical Research Communications has shown that the new test detected significant levels of the cancer glycan in blood samples from over 90% of women with stage 1 ovarian cancer and in 100% of samples from later stages of the disease, but not in any of the samples from healthy controls.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Cost is not mentioned and, according to the published study, the high costs of the sensors used in detecting the cancer have proven to be a major drawback.", "answer": 0}, {"article": "HPV, a sexually transmitted disease, can be transmitted through vaginal, anal, and oral sex and has been linked to genital warts as well as cervical, vaginal, vulvar, oral, penile, and anal cancers.\n\u201cThe most salient message is that the [Gardasil] vaccine can prevent HPV infection on the external genital region, which means that we can now prevent most cases of genital warts if the boy is vaccinated at a sufficiently early age,\u201d says study researcher Joel Palefsky, MD, a professor of medicine at the University of California, San Francisco.\nThe Gardasil vaccine has also received FDA approval for prevention of genital warts.\nThese vaccines are now on the CDC\u2019s routine childhood vaccine schedule for girls starting at age 9.\nBoth of these vaccines are recommended to prevent cervical cancers.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "We wish the story had provided the cost of roughly $375 for the Gardasil vaccine involved in the study. But the story did a much better job on deadline than the competing HealthDay story of posing the deeper question of the overall dispute and society-level debate over universal vaccination.\nIt quotes one researcher saying only: \u201cThe main disadvantage is cost, because thus far the vaccine appears to be safe. It\u2019s less cost-effective because most of the serious diseases such as cervical cancer occur in women, not men.\u201d\nSo why not provide the cost figures?", "answer": 0}, {"article": "Steroids can cause severe weight gain, acne and the weakening of bones, among other side effects.\nMore patients on the drug had the required improvement in symptom severity.\nThe company said high levels of the protein might spur the immune system to attach the body\u2019s own tissues.\n\u201cAnd we are in a field where we haven\u2019t even had anything fair.\u201d\n\nBenlysta, which is given by infusion once every four weeks, inhibits the action of a protein in the body called B-lymphocyte stimulator, which helps B cells in the blood respond to infections.\n\u201cWe knew the drug was safe and biologically active,\u201d H. Thomas Watkins, chief executive of the company, said in an interview.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The article comments that Benlysta will be far more expensive than current treatments but doesn\u2019t give an order of magnitude. Nonetheless, we\u2019ll give it the benefit of the doubt. ", "answer": 1}, {"article": "Diseases like Alzheimer\u2019s start years, even decades, before the first symptoms of memory loss shows up.\n\u201cBut what\u2019s nice about it is that it\u2019s a nice non-cognitive, motor factor so it\u2019s looking at another aspect of brain function.\u201d\n\nMORE: This Alzheimer\u2019s Breakthrough Could Be a Game Changer\n\nPetersen suggests that every physician should get this information on their patients at age 65; that way, they can have a baseline against which to compare any changes as their patients age.\nFor now, even if doctors identify patients around age 65 who might be at higher risk of developing cognitive impairment, there isn\u2019t much they can do to interrupt the process.\nMORE: New Test May Predict Alzheimer\u2019s 10 Years Before Diagnosis\n\nWhile his test is a possible solution to that problem, he acknowledges that the results need be repeated before it\u2019s recommended on a wide scale to physicians across the country.\nPetersen believes that the test they came up with could become a useful tool for any physician, even those without special training in the brain.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does note that current, more sophisticated methods of testing are expensive. But it doesn\u2019t really address the cost of new test, except to imply that it would be cheaper. That may well be true, but the cost of adding a\u00a0separate battery of tests to every patient 65 years and older, as the story suggests, could be enormous.\u00a0The \u201csimple\u201d tests defined in the research involve a detailed medical and social history as well as standardized testing for anxiety and depression and gait. \u00a0This testing along with interpretation takes time, and in today\u2019s environment, time is money.", "answer": 0}, {"article": "SIR Annual Scientific Meeting, March 17-22, 2018.\nAs part of the study, researchers will follow patients for up to two years, and new trials to investigate the effectiveness of the drug in treating advanced cancer in the liver are being planned.\nPatients were given escalating doses of T-VEC, up to the maximum FDA-approved dose for melanoma.\n\"This minimally invasive treatment offers patients a novel way to directly and indirectly attack the cancer cells.\"\nResearchers found the patients tolerated the treatment well with expected side effects, including temporary flu-like symptoms.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There was no discussion of how much this therapy might cost. The reported cost of T-VEC for a round of melanoma therapy has been $65,000.", "answer": 0}, {"article": "Insulin may have a relationship with cancer.\nThis adds credence to the idea that metformin's value is in its ability to lower overall insulin levels in the body, Cantley said.\n\"The evidence in diabetic humans is very convincing and very strong,\" added Dr. Phillip Dennis, a senior investigator with the U.S. National Cancer Institute and senior author on the lung cancer paper.\nOthers believed that the finding might influence the choice of drugs in people with diabetes.\nAt this point, no one knows if metformin is safe in non-diabetic populations but some clinical trials are starting to look at the issue, Lippman said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story explains that \"Metformin (originally marketed as Glucophage, though it is now available as an inexpensive generic) has been in use for more than two decades and is currently prescribed to 40 million Americans.\" Good enough to get a satisfactory score. ", "answer": 1}, {"article": "Dr. Adolfo Llanos, a neonatologist at Nicklaus Children's Hospital in Miami, who was not involved with the new study, said the \"quality of this analysis is very good.\nAnd any breast-feeding appeared to reduce the odds of the serious eye disease by 46 percent, the research showed.\nIn re-evaluating the studies, Chen's team found that breast-feeding in any amount appeared to reduce the risk of ROP.\nWhen they do, the screening and treatments are not as good, Chen said, so blindness may be more likely.\nHe added that in China, a previous study showed the incidence of ROP was 50 percent in infants with a birth weight under 1,000 grams (2.2 pounds).\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Cost is not a relevant criterion in this case as the comparison is made between breast milk and formula. Both feeding methods entail costs, both financial and other, that we feel are beyond the scope of the coverage.", "answer": 2}, {"article": "First published on June 22, 2006 at 12:00 am\nDr. Julia Zehr, a Michigan State University researcher who led the study, said the findings suggest that biological factors may influence those behaviors, not just the psychological effect of changes in body composition during puberty.\nBut Dr. George Merriam, a professor of medicine at the University of Washington, cautioned that much more study is needed to determine whether the medication should become widely available to help counteract the effects of aging.\nDr. Merriam said Merck and other companies also are investigating similar treatments.\nThe study did not examine whether the medication improved cognitive functioning.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not provide the cost of growth hormone for the purpose of improved physical functioning in the elderly. ", "answer": 0}, {"article": "\"It was the end of our world and we didn't know why, because this child was a perfectly normal healthy child, Never had a problem,\" Miller says.\nFDA said it asked the company to dig deeper into its data on Singulair for evidence of possible links to suicide.\nThe agency said it has not established a \"causal relationship\" between Merck's drug and suicidal behavior.\nFDA said it is reviewing a handful of reports involving mood changes, suicidal behavior and suicide in patients who have taken the popular allergy and asthma drug.\nThe company said none of the 11,000 patients enrolled in 40 Singulair trials has committed suicide.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The price of the drug is not reported. ", "answer": 0}, {"article": "\u201cIt\u2019s a mixed bag,\u201d Elliott says.\nCharges for patients can range from $10 to $75 per session, says Edo Zylstra, CEO of KinetaCore, a company that offers intensive three-day weekend courses in dry needling to physical therapists.\nTestimonials like that are a big reason dry needling has caught on with some physical therapists, athletes and other patients, Briggs says.\nBurgoon\u2019s group has persuaded some states to bar physical therapists from the practice.\nHe says many acupuncturists do exactly what the physical therapists describe, with the same kind of needles.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story nicely calls out different questions that readers might have, including whether insurance will pay for the therapy. It answers, \u201cMany will not. Charges for patients can range from $10 to $75 per session, says Edo Zylstra, CEO of KinetaCore, a company that offers intensive three-day weekend courses in dry needling to physical therapists.\u201d", "answer": 1}, {"article": "Severe obesity is associated with serious physical and psychological conditions affecting quality of life.\n\u201cThe median BMI reduction of 10 kg/m2 with the lap band is a good result when compared to BMI reduction using the few medications available or lifestyle measures, which is around 1-3 kg/m2,\u201d says Dr Pe\u00f1a.\n\u201cAlthough gastric banding has been controversial and is currently less used in adults with severe obesity, lap band surgery is one of the most studied surgeries for obesity management, has a high safety record and can be a temporary option to manage severe obesity during adolescence,\u201d says Mr Khurana, who is also a Senior Lecturer in the University of Adelaide\u2019s Discipline of Paediatrics.\nHowever there is no data available in Australian adolescents beyond 24 months post-surgery.\nLed by University of Adelaide researchers, in collaboration with Flinders Medical Centre, and published in the journal Obesity Surgery, the study is the first to show medium to long-term follow-up (3-5 years) of lap band surgery in Australian adolescents.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The cost of this surgical procedure is missing in action in this release. This is a problem, because costs in the US, as of 2015, average more than $14,000.", "answer": 0}, {"article": "Oxytocin is produced naturally in the bodies of humans and animals.\n\"Many families are using it with success and reporting improvement,\" said Wendy Fournier, president of the National Autism Association.\nResearchers who were not involved in the study praised the work, saying the findings were promising and could lead to the first effective treatment for the central problems affecting people with autism.\nAlthough more research is needed to confirm and explore the findings, the results are the latest in a growing body of evidence indicating that the hormone could lead to ways to help people with the often devastating brain disorder function better.\nBut Sirigu was among those who said the finding should encourage more research on the potential benefits of oxytocin itself, especially for children.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "If a story is not going to challenge an advocate saying, \"Many families are using it with success and reporting improvement,\" then it certainly can tell us how much it\u2019s costing those families. \n", "answer": 0}, {"article": "Knee replacements were first offered in the 1960s, and hip replacements began in the 1940s, so many boomers are facing the same surgeries their fathers and mothers underwent.\nThe average age of patients listed in the American Joint Replacement Registry is about 66.\nWhile physical activity obviously plays a role in joint deterioration, genetics may be the biggest factor in determining who needs a replacement and when, he said.\nAnd, he promised, \u201cI will get on the skates again.\u201d\n\nLike Smith, many boomers endured months or years of pain before surgery, pain caused by \u201cbone-on-bone\u201d friction when cartilage deterioration eroded their bone cushioning.\nBut having had the procedures, many say they wish they\u2019d done it sooner.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story states: \u201cThe procedures can cost up to $50,000 for knees and $40,000 for hips, though the prices vary widely among Medicare and private insurers, which typically bear the bulk of the cost.\u201d", "answer": 1}, {"article": "\n\u2022 People who have had Type 2 diabetes for up to 10 years can reverse their condition\n\nA new study from Newcastle University has shown that people who reverse their diabetes and then keep their weight down remain free of diabetes.\nIn fact, after 6 months a thirteenth patient had reversed their diabetes.\nThe group included many people with longer duration diabetes, defined as more than 8 years and ranging up to 23 years.\nThis caused international interest, but the study was very short as it was only eight weeks and the question remained whether the diabetes would stay away.\nParticipants in this study had Type 2 diabetes for between six months and 23 years.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release makes no mention of cost and while the diet changes, including diet shakes and vegetables, may not exceed the cost of a regular diet, the individualized weight management program for a half-year could represent additional costs for people not in the study, something of which readers should be reminded.", "answer": 0}, {"article": "Their median age was in the mid-50s, and they were followed for a median of 6.3 years.\nBut Dr. Carlson said that some of his colleagues, even after hearing the new study results, still thought the nodes should be removed.\nBut doctors have continued to think that even microscopic disease in the lymph nodes should be cut out to improve the odds of survival.\nNor is it known whether the findings could be applied to other types of cancer.\nIf any are positive, the disease could become deadly.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Clearly, the costs involved in cancer treatment already are high. By removing a layer of treatment from an estimated 40,000 patients, those costs would have to drop, but it is unclear from the story by how much. Also, it would have been worth mentioning whether this is likely to affect how insurance companies handle lymph node removals.", "answer": 0}, {"article": "GlaxoSmith Kline and Eli Lilly supplied Lovaza and Raloxifene, respectively.\nThese findings may help to support future research looking at the direct effect of omega-3 supplementation on breast cancer incidence in obese women.\nThe researchers plan to test the effect of DHA alone in obese subjects, potentially in combination with weight loss, in a future trial.\nThe study included 266 healthy postmenopausal women with high breast density detected by routine mammograms.\nAt the conclusion of the two-year study, the researchers found that increasing levels of omega-3 in the blood were associated with reduced breast density\u2014but only in women with a body mass index above 29, bordering on obesity.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release makes no mention of costs although omega-3 fatty acid supplements are readily available across the market.\u00a0 A quick web search shows that a month\u2019s supply of Lovaza, the omega-3 fatty acid used in this study, will cost about $280 per month, or $3.360 a year, a hefty price for most Americans.", "answer": 0}, {"article": "\u2022 A plant-based vegetarian diet is not associated with statistically significant changes in triglyceride levels in observational studies or in clinical trials.\nFor clinicians concerned about spending extra time in and outside of the exam room, the study authors encourage time-strapped health care providers to refer patients to registered dietitians who can help with the transition to a plant-based vegetarian diet.\nWe hope to empower patients with new research about the long-term cardiovascular health benefits of a vegetarian diet, which include a reduced risk of a heart attack, stroke, and premature death.\"\nWhat I've found is that if you want your patients to make significant health changes, you have to make them yourself.\nCharles Ross, D.O., a member of the nonprofit Physicians Committee and a former emergency department physician, has firsthand experience with putting a plant-based diet into practice.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release gives a brief nod to costs, acknowledging that the diet would fit into \u201cnearly every\u201d budget. But we\u2019d like to see a bit more. The costs of adhering to a plant-based vegetarian diet could be prohibitive for some, particularly those without easy access to fresh produce markets. While it would take some effort to estimate the annual cost of eating this way for a person or family, the cost consideration could at least be acknowledged.", "answer": 0}, {"article": "Before treatment recommendations are made, doctors put most prostate tumors through other tests, too, like the Gleason score, and they look at the percentage of biopsies that are positive for cancer cells.\nThey say what's really needed is a set of tests that classify prostate tumors by what genes are turned on or off in the cells.\nThe new study discrediting the test, coupled with persistent questions about how useful prostate screening is for most men anyway, add up to a whole lot of discussion points patients should take to their doctors.\nOnce this is sorted out, doctors treating prostate cancer will be less like the blind men who try to guess what kind of creature they're dealing with when they grasp the elephant's trunk or tail.\nEven so, Andriole says, the findings may not make too much difference in the real world.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There was no discussion of costs.\u00a0 What does clinical staging add to a man\u2019s bill?\u00a0 Especially if this is a \u201cwakeup call to those who are over-relying on the clinical staging system\u201d \u2013 as the story states \u2013 what impact could that have on costs?", "answer": 0}, {"article": "\"Most people, especially athletes, when they had hip symptoms, usually they just got diagnosed as a chronic groin pull,\" said J.W.\nAnd they've found that it can be fixed using arthroscopic surgery, which uses narrow instruments inserted through smaller incisions than traditional surgery.\nBut those experiencing hip pain or stiffness have had more-limited options.\nThis is a marked uptick from a decade ago, when Ochiai said the single course in hip arthroscopy was nearly canceled due to lack of interest.\nDoctors say FAI is not something a patient is born with; rather, it develops in adolescence, for unknown reasons.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "\n\n\n \nThe story does not mention the cost of hip arthroscopy or other methods to treat labral tears and femoroacetabular impingement (FAI).", "answer": 0}, {"article": "\"This may simply indicate that some of the causes for preterm birth may not pre-exist before the pregnancy,\" Graves said.\nThe test may cost $150 to $250, Graves said.\nThe test wasn't as effective at 24 weeks of gestation.\nPhysicians will \"be able to use a simple blood test and then know that this woman is at increased risk or reduced risk of a preterm birth,\" said Graves, whose laboratory performed the research in the study.\nWu said the study results are promising, but more research is needed to confirm that the test is reliable.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story included an estimate that \u201cThe test may cost $150 to $250.\u201d", "answer": 1}, {"article": "Drinks such as POM have become increasingly popular with consumers in recent years, thanks in part to public health campaigns against soda that have been prompted by the obesity epidemic.\nThat's the paradox of products such as POM, Silverglade says: The health claims on these products strain the imagination, yet studies have repeatedly shown that health claims sell food.\nHealth.com: 14 health products you probably don't need\n\nIffy health claims don't mean that products like pomegranate juice should be avoided at all costs, says Keri Gans, R.D., a spokesperson for the American Dietetic Association.\nAs long as consumers limit themselves to 8-ounce servings and products with no added sugar, juice can be an excellent source of vitamins and other nutrients, Gans says.\nHealth.com: 25 diet-busting foods you should never eat\n\nNot all of the products were drinks, but \"the beverage category stands out,\" says Bruce Silverglade, director of legal affairs at the Center for Science in the Public Interest, a consumer advocacy group based in Washington, D.C. \"At first blush it seems that beverage products are certainly a large proportion of food products that make bogus health-related claims.\"\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story says a bottle of POM costs $4, meeting our standard for a satisfactory. It could have specified that\u00a0the $4 cost refers to 16 oz bottle and not a larger package.\u00a0There also is no information about how often you\u2019d need to drink the juice to obtain the claimed benefits, so we don\u2019t know if people\u00a0are supposed to drink a\u00a0bottle a day or a bottle a week \u2014 which would make a big difference on the\u00a0cost front. (The latter problem may not be the\u00a0fault of the article, as a quick perusal\u00a0of the POM website turned up no specific information about serving recommendations from the manufacturer.) .", "answer": 1}, {"article": "His doctor prescribed a C.P.A.P.\nIt is also more expensive, and it doesn\u2019t work for every patient.\nBut not everyone finds that Provent alleviates their apnea.\nIn those people, Provent typically doesn\u2019t work.\nDr. Lee A. Surkin, a cardiologist and sleep medicine specialist in Greenville, N.C., said patients typically start with a 10-day trial pack that costs $27.50.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story offered one of the most thorough discussions of costs we have seen in a description of an emerging device. It provides a price for a 30-day supply of the patches and for a 10-day trial pack. It also points out, helpfully, that \u201cUnlike C.P.A.P., Provent is not covered by Medicare and most major insurers, though some doctors say they expect that will change in the near future.\u201d", "answer": 1}, {"article": "Renal vein surgery can often be managed with minimally invasive laparoscopic techniques, but this is not typically advisable for an IVC thrombus (a fibrous clot), which is surgically far more complex with potentially fatal complications that can occur in the course of removing the thrombus and reconstructing the IVC.\n\"Using robotic nephrectomy, our complication rate and lack of mortalities compare reasonably with open series with no grade III to V complications, according to the Clavien system, in any patient, including no deaths.\"\nEach surgeon performed between one and ten procedures for IVC tumor thrombi which ranged from one to 11 cm in length on preoperative imaging.\nThe first known procedure using robotic surgery of renal tumors with IVC tumor thrombi was performed in 2008.\nNone of the operations was converted to open surgery and all but two patients were ambulatory on the day of or day after surgery.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "No mention is made of the cost of the robotic procedure, nor is there any mention of how much the open procedure costs. As we\u2019ve noted in previous reviews and posts, robotic surgery can be very expensive compared to traditional laparoscopic minimally invasive surgery. In some cases, the costs of the robot and the disposables used during a surgical procedure can be in excess of the reimbursement to the sponsoring hospital and those costs are eventually passed on to the consumer. The cost-effectiveness of robotic-assisted minimally invasive surgery is still an open question that we think deserved some discussion in the release.", "answer": 0}, {"article": "\u201cHe said, \u2018Doc, give me what I got last time.\nUntil there are answers, Zarate of the mental health institute said ketamine should be a last-resort treatment for depression after other methods have failed.\n\u201cIt truly has revolutionized the field,\u201d changing scientists\u2019 views on how depression affects the brain and showing that rapid relief is possible, said Yale University psychiatrist Dr. Gerard Sanacora, who has done research for or consulted with companies seeking to develop ketamine-based drugs.\nThere are about 150 U.S. ketamine clinics, compared with about 20 three years ago, said society co-founder Dr. Megan Oxley.\nThe company filed a new drug application in September.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story said one woman paid $3,000 \u201cso far\u201d for her treatments and \u201cscrambles to find a way to pay for another one\u201d as the effects wear off.\nIt also reported that a \u201ctypical\u201d treatment at one clinic \u201cinvolves six 45-minute sessions over about two weeks, costing $550 each. Some insurers will pay about half of that\u2026.\u201d", "answer": 1}, {"article": "Hospitals take over with more sophisticated cooling equipment.\nThough it's not unusual to have debate over new therapies, the benefits of induced hypothermia is not a new discovery.\nBut MetroHealth and Cleveland EMS officials say they aren't convinced the therapy is proven enough to rewrite the book on cardiac arrest treatment.\nWith more than 300,000 deaths a year in the United States from cardiac arrest, Rosenbaum said the focus should be on preventing deadly rhythm disturbances and improving access to defibrillation.\nColumbus is already part of the program, called Cardiac Arrest Registry to Enhance Survival.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There was no information about the costs for the treatment nor the investment in the infrastructure to support the availability of this treatment.\u00a0 Puzzling given the public policy and city/regional planning aspects of the issue. ", "answer": 0}, {"article": "May 14, 2012 -- Acupuncture may allow people with the lung disease COPD (chronic obstructive pulmonary disease) to breathe a bit easier.\nIn a new study of 68 people with COPD, some got acupuncture, along with their daily medication, for three months.\nMany people with COPD have problems getting optimal nutrition because of their condition.\nThe study showed that acupuncture may improve stomach function, making it easier for people with COPD to eat a healthy diet and maintain a normal weight.\nOthers got a sham acupuncture treatment, in which the needles did not enter their skin.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not detail the costs associated with an acupuncture treatment (which may often entail out-of-pocket expenses), or how many treatments are necessary before the patient sees a noticeable benefit.", "answer": 0}, {"article": "\"The band has a spotty history,\" Deveney said.\n\"[I] therefore think patients will continue to ask for the procedure.\"\nBut he cautioned that patients undergoing band surgery should do so knowing that they need to commit themselves to rigorous long-term follow-up.\nThe current observations stem from a research effort led by Dr. Jacques Himpens, of the European School of Laparoscopic Surgery at the Saint Pierre University Hospital in Brussels, whose team assessed the status of 82 patients that had undergone the procedure known as \"laparoscopic adjustable gastric banding\" (LABG) more than a decade prior to the study launch.\nAlmost 50 percent had to have the bands entirely removed, while 60 percent needed to undergo subsequent surgery.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Although not discussed in the study precipitating the story, the costs for gastric banding and appropriate follow-up care are readily available.", "answer": 0}, {"article": "When considering where to give birth, most parents-to-be and doctors in Western nations believe a hospital is the best place.\n\nNot so Jean Stevens, 32, who chose to deliver two children at home in the U.K. She says her two labors were nearly pain-free.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not address cost at all. The story is focused primarily on childbirth practices in the U.K., which has a significantly different healthcare system from that in the U.S. However, the story does discuss childbirth practices in the U.S., and speaks to U.S. experts on the subject. Home births are often significantly less expensive than hospital or birth center deliveries, but there are still costs involved. The story would have been stronger if it had addressed this, even in broad terms.", "answer": 0}, {"article": "The American Congress of Obstetricians and Gynecologists, for example, recommends that regular screenings begin at age 40, while the American Cancer Society calls for women to start yearly screening at age 45 and then move to screening every two years starting at age 55.\nFran Visco, president of the National Breast Cancer Coalition, said the task force's guidelines for women in their 40s \u2014 that they should discuss whether to get mammograms with their doctors and make individual decisions \u2014 come closest to following the evidence accumulated over the past three decades.\nThe task force first suggested in 2009 that breast cancer screening begin at 50 instead of 40, touching off enormous criticism.\nSeveral groups that lobbied for congressional action said in a statement last month that the task force recommendations conflict with those of other organizations.\nIn releasing its final recommendations, the task force confirmed an earlier guidance it issued that said screening mammography had the greatest benefit for women ages 50 to 74.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does address how the USPSTF recommendations may affect insurance coverage of mammography screening, as well as related congressional action mandating that insurers cover such screening. However, the story does not tell readers the bottom line: how much would a mammogram cost if it were not covered by insurance? While we found varying estimates, a 2011 paper stated that the overall cost of a mammogram was $266 \u2014 a considerable sum, and likely out of reach for many women. This was a shortcoming of both the Washington Post and New York Times stories.", "answer": 0}, {"article": "Dr Carol Routledge, from Alzheimer's Research UK, said: \"The diseases that cause dementia begin in the brain up to 20 years before any symptoms start to show, presenting a vital window of opportunity for us to intervene before widespread damage occurs.\nThe Alzheimer's algorithm was able to teach itself to recognize patterns in brain scans that indicated disease.\n\"This study highlights the potential of machine learning to assist with the early detection of diseases like Alzheimer's, but the findings will need to be confirmed in much larger groups of people before we can properly assess the power of this approach.\"\nIt proved to be 100 percent accurate at detecting Alzheimer's disease many years before the patient was later diagnosed.\nThe system was able to identify dementia in 40 patients an average of six years before they were formally diagnosed.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Cost is not mentioned. Nor that the type of scan was specifically a PET scan.\nAccording to this survey of six Veteran Affairs hospitals, the cost of a PET scan using FDG is approximately $1,900.\nWithout insurance (and without the FDG tracer) CostHelper lists the cost of a brain PET scan as $6,700.\nUsing the AI would presumably add additional costs.", "answer": 0}, {"article": "\"I called the doctor back in and said, 'We're doing the chemo.'\nThe drawback of that study, Dr. Glick notes, is that it was not a large prospective randomized clinical trial, the gold standard in medicine.\nAnd while some, including Dr. Winer, predict that the use of chemotherapy will almost certainly decline in the years ahead, for now most doctors are sticking with the current guidelines, waiting for expert advice from national panels on what to do.\nThe study is ethical, said Dr. Larry Norton of Memorial Sloan-Kettering Cancer Center in New York, because the only women whose treatment will be decided at random are those in a kind of gray area, not women for whom chemotherapy would be a clear benefit or clearly unnecessary.\nThat has led doctors to feel most at ease giving very aggressive treatments to almost everyone.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There is no discussion of the cost of chemotherapy and no mention of potential cost savings for women who might not benefit as much from treatment; however, this is not very relevant to this story, as there is a suggestion that less treatment might be better, with a cost savings implied. ", "answer": 1}, {"article": "For ella, \u201cwhile you\u2019re going to have to go and get a prescription for it, it gives you a little bit more leeway in terms of putting your ability to put your life on hold and get this healthcare need taken care of,\u201d said Amy Allina, program and policy director for the National Women\u2019s Health Network.\nIf it is approved, it should be clearly labeled as an abortifacient, which would limit its distribution, the American Association of Pro Life Obstetricians & Gynecologists said in a letter to the FDA earlier this month.\nIf approved, Watson Pharmaceuticals Inc would sell the drug in the United States.\nHRA Pharma\u2019s drug, approved last year in Europe under the name ellaOne, has re-ignited debate over \u201cmorning-after\u201d pills in the United States, where reproductive issues are a constant political issue.\nHRA is not seeking to sell ella without a doctor\u2019s prescription.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not mention costs. Although it is hard to say definitively how much the drug would cost in the US since it is not yet available, the story could have mentioned the cost of the drug in Europe or provide an estimate from the drug manufacturer or even from an analyst.", "answer": 0}, {"article": "Source: Brightling C, et al.\nBy measuring the sputum eosinophil \u2014 the inflammation marker that shows how white blood cells increase during asthma attacks \u2014 the researchers were able to track the effects of the drug.\nWe already know that using treatments to target eosinophilic airway inflammation can substantially reduce asthma attacks.\u201d\n\nUltimately, the researchers hope that the drug \u201ccould likewise help to stop preventable asthma attacks, reduce hospital admissions and improve day-to-day symptoms \u2013 making it a \u2018game changer\u2019 for future treatment,\u201d said Brightling.\n\u201cMost treatments might improve some of these features of disease, but with Fevipiprant improvements were seen with all the types of tests.\nThe drug, known as Fevipiprant (QAW039), was shown to reduce asthma symptoms as well as inflammation, and it improved lung function and repaired airway linings.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not address how much fevipiprant might cost or the cost of currently available treatments.", "answer": 0}, {"article": "Only 30-50 people with type 1 diabetes in the UK currently receive an islet transplant each year, owing to a lack of donors and the difficulty of extracting islets from pancreatic tissue.\nThe pre-clinical results have encouraged CGT and Aberdeen University to create a spin-out company, called Islexa.\nInsulin shots could become a thing of the past for type 1 diabetes patients thanks to a technology being developed by Cell and Gene Therapy Catapult, a London-based not-for-profit organisation, and Aberdeen University.\nIslexa will use CGT\u2019s labs at Guy\u2019s and facilities at Aberdeen University.\nGrowing islets will \u201csignificantly increase the number of patients who can receive the treatment,\u201d Keith Thompson, CGT\u2019s chief executive, told the World Stem Cells and Regenerative Medicine congress in London on Wednesday.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Since the premise of the piece is about pre-clinical efforts, it\u2019s too early to discuss specific costs, so we\u2019ll rate this N/A. However, the article could have been enhanced by noting the cost of other cell-based therapies, islet cell transplants, insulin treatment and the amount of investment being sought.", "answer": 2}, {"article": "Since 1998, the Food and Drug Administration has required that breakfast cereals, breads, rice, pasta and other grain products made with enriched flour come fortified with folic acid.\n\"The story of folic acid is one of the great public health stories of \u2014 ever,\" says Dr. R.J. Berry, who works with the Division of Birth Defects and Developmental Disabilities of the Centers for Disease Control and Prevention in Atlanta.\nBut there's one notable exception to this success story \u2014 Hispanic women \u2014 and researchers think the reason may lie in a staple of their diet: tortillas.\nSo a coalition of groups including the March of Dimes Foundation and the National Council of La Raza has petitioned the FDA to change its stance and allow corn masa flour to be fortified with folic acid.\nSo why does the FDA currently ban dosing corn masa flour with folic acid?\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not talk about any costs. There are a few places where cost might have been valuable. The story could have discussed whether refining corn flour by a different method would cost more than the existing method. The story might have included whether fortified corn flour would be equal or higher in price for consumers than unfortified.\nWe also would have welcomed some comment on the cost of caring for a baby born with a neural tube defect.", "answer": 0}, {"article": "The Claim: Red palm oil, a deep orange fat pressed from the palm tree fruit, is a superfood\u2014packed with healthy antioxidants and good for the heart, say companies who sell it.\n\nThe Verdict: The colorful oil is rich in tocotrienols, nutrients in the vitamin E family, and carotenoids, which the body converts into vitamin A. Several studies suggest possible benefits in stroke and liver disease from vitamin extracts made from the oil, but so far there isn\u2019t proof that consuming the oil can ward off disease, scientists say.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story mentions some specific brands and prices.", "answer": 1}, {"article": "\"This is the holy grail,\" says Suresh S. Ramalingam, MD, associate professor and director of the lung program at Emory University's Winship Cancer Institute in Atlanta.\nBut that test has caused controversy because it falsely detects cancer in about one out of four people, leading to further invasive procedures.\n\"The whole field is focused on using something that's readily available that does not involve an expensive surgery or scan that would allow us to find early cancers,\" says Ramalingam, who is developing technology that aims to replicate the ability of dogs to smell trace amount of chemicals produced by cancerous tumors.\nIn its early stages, lung cancer has few symptoms, making it difficult for doctors to catch it early, when it's still treatable.\nHe was not involved in the research.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not mention costs. At the very least, what does it cost to train dogs?\u00a0If you can let someone call this the \u201choly grail,\u201d you can tell people how much the search for the grail costs.", "answer": 0}, {"article": "After the cap is placed on the patient's head, it is attached to a vacuum pump that sucks the air out of the cap, jamming the tiny grounds together to form a rigid layer that conforms closely to the shape of the patient's head.\nThey have designed a \"granular jamming cap\" filled with coffee grounds that does a better job of tracking patient head movements than current methods.\nIn this case, the cap proved to have 66 percent lower error rates than the headband.\nOn the strength of these results, Vanderbilt University has applied for a patent on the design and the technology is available for licensing.\nIn essence, that is what a team of Vanderbilt University engineers are proposing in an effort to improve the reliability of the sophisticated \"GPS\" system that surgeons use for these delicate operations.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There\u2019s no discussion of how switching to the coffee-filled cap might affect costs. A silicone swim cap and six cups of coffee grounds run less than 20 bucks. But it\u2019s safe to say this device will cost much more given the need for a potential investor to recoup the cost of clinical trials and other expenses related to getting a medical device to market. The news release suggests the cap may save time or prevent errors during surgery, which could reduce some health care costs.", "answer": 0}, {"article": "\u201cThe length of statin use, both greater than six months and greater than five years of use was associated with reduction in colorectal cancer risk.\u201d\n\nThe group of statins that showed the greatest effect in reducing risk are classified as lipophilic: atorvastatin (Lipitor), fluvastatin (Lescol), lovastatin (Altocor, Altoprev, Mevacor), pitavastatin (Livalo), and simvastatin (Zocor),\n\nColorectal cancer is the third most common type of cancer in the U.S.; 102,900 new cases of colon cancer are diagnosed in men and women every year, and about 39,670 new cases of rectal cancer are diagnosed annually.\n\u201cOur findings suggest that randomized controlled trials designed to test the hypothesis that statins reduce the risk of colorectal cancer are warranted.\u201d\n\nThis study was presented at a medical conference.\nAlso, the longer patients used statin drugs, the greater their reduction in risk for colorectal cancer.\n\u201cObservational studies have suggested that long-term use of statins is associated with reduced risk of several cancers, including breast, prostate, lung, pancreas and liver,\u201d says Samadder in the news release.\nThe findings should be considered preliminary as they have not yet undergone the \"peer review\" process, in which outside experts scrutinize the data prior to publication in a medical journal.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "\u00a0Even though both brand name and generic versions of statin medication are available, there was no information about costs in this story. Why this is so \u2013 in a story that suggests a possible future expanded market for these already widely-used drugs, is a puzzle.\u00a0\u00a0", "answer": 0}, {"article": "The National Institutes of Health, as well as the Michael J.\nCollier is already looking for funding for the next phase of his research and hopes to lead a human clinical trial using the drug in the future.\nIn a proof-of-concept study, published in the journal Neurobiology of Disease, the drug nortriptyline, which has been used to treat depression and nerve pain, stopped the growth of abnormal proteins that can build up in the brain and lead to the development of the disease.\nCollier and collaborator Katrina Paumier, an assistant professor of molecular medicine, began looking at previous patient data to see if individuals who were on antidepressants experienced any delay in their need to go on a standard Parkinson's therapy called levodopa.\n\"What we've essentially shown is that an already FDA-approved drug that's been studied over 50 years and is relatively well tolerated could be a much simpler approach to treating the disease itself, not just the symptoms,\" Collier said.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The story is about a proof-of-concept study, which is the very earliest step in research. But if it\u2019s not too soon to issue a news release, it\u2019s not too soon to address cost impacts. The release could have mentioned the cost of the medication, nortryptiline, or alternatively, the economic burden of Parkinson\u2019s.", "answer": 0}, {"article": "\"These are children who could have died from a teaspoon of milk before,\" Wood said.\nNo one should try the approach on his own, because the treatments themselves can trigger potentially life-threatening reactions.\nIt remains far from clear, however, what proportion of children will benefit, how long the benefit might last and what proportion will need to continue to consume at least some milk or peanuts every day to maintain their protection.\nThe strategy is being tested in a handful of small studies that are part of a surge of research in a field that for years showed little progress.\nAlthough the approach appears to be highly effective for some children with milk and peanut allergies, the researchers conducting the studies and others caution that much more research is needed to prove and perfect the approach and that it is far from ready for widespread use.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story didn\u2019t mention any potential costs, but it did make clear that these were small, early studies.\u00a0 So it\u2019s understandable that costs aren\u2019t yet known.\u00a0 Nonetheless, we wish the story would just say that \u2013 and make the safe prediction that since this treatment will involve multiple visits over a protracted period the costs will likely not be inconsequential.\u00a0", "answer": 2}, {"article": "\n\u2022 Read this story at www.uab.edu/news\n\u2022 The UAB News Studio is available for live or taped interviews with UAB experts.\nThere are more than 30-plus new dry eye basic, translational and clinical studies being funded by the NEI/National Institutes of Health to further explore these lipids and proteins, with more than 50 papers being published monthly.\n\u201cFunding from NIH is helping the optometry world make significant strides in understanding the cause and treatment of dry eye,\u201d Nichols said.\nShe focused on the cause and potential therapies for dry eye that are being funded through the National Eye Institute and in private industry.\nResults from inferior corneal staining tests \u2014 used by physicians to detect abrasions on the cornea \u2014 showed improvement in three of the four studies.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The news release does not mention cost. We were unable to find any cost information online after a brief Google search. ", "answer": 0}, {"article": "They find that there are real deleterious side effects but that they are manageable, and conclude the drug is worth using under the proper circumstances,\" he said.\nOverall, Avastin, like several other targeted agents have led to therapeutic advances in lung cancer, he added.\nOverall, 3 percent of the patients died due to adverse events associated with Avastin.\nHowever, several issues remain to be determined, including the optimal dose and the role of maintenance therapy with Avastin, he said.\nThe researchers reported few clinically significant adverse events, meaning that most were no greater than what one would expect in the general population.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "\u00a0There was no discussion about the cost estimates for adding Avastin to treatment, nor any mention of the route of administration.", "answer": 0}, {"article": "Learning skills for positive emotions result in less HIV in blood and less anti-depressant use\n\u2022 Positive emotions are possible even with stress of chronic health problems\n\u2022 Men using positive emotion skills learned to cope with their stress, while control group went on anti-depressants\n\nCHICAGO --- When individuals recently diagnosed with HIV were coached to practice skills to help them experience positive emotions, the result was less HIV in their blood and lower antidepressant use, reports a new Northwestern Medicine study.\nThe HIV study is part of a larger body of positive affect research being conducted by Moskowitz.\nBased on the study results, the intervention is promising for people in the initial stages of adjustment to any serious chronic illness.\nThis is believed to be the first test of a positive emotion intervention in people newly diagnosed with HIV.\nThe positive emotion intervention also improved mental health.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "We did not find any discussion of the cost of bringing patients in for five sessions of what is called \u201cpositive skills intervention.\u201d While it may be low-cost, we need some mention of that to help evaluate the practicality of this therapy.\nThe study itself devotes space to cost analysis.\n\u201cThe [intervention] was quite time intensive for both the study team and the participants which lessens the likelihood that it can go to scale in this format.\u201d\n\u201cWe have begun work on translating the intervention to a self-guided online format that would significantly reduce the cost.\u201d\nIf the news release had included these details, it would have added some practical context for readers.", "answer": 0}, {"article": "Sorry. The page you requested is not available", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The article is silent on the price of Rituxan. Since the company is investing a significant sum to research an additional use, the price is worth mentioning.", "answer": 0}, {"article": "\"We have no right as parents or as physicians or adults to strap them down and chop off a normal part of their body.\nAt that time, the group, which represents about 60,000 pediatricians nationwide, concluded that there was no clear evidence for or against circumcising newborns.\nSome think the academy's position is long overdue, and that the group should have gone even further and more forcefully recommended circumcision.\n\"There is clear evidence that supports the health benefits of circumcision,\" said Susan Blank, who led the 14-member task force that formulated the new policy being published in the journal Pediatrics.\nChapin and other critics argue that the scientific evidence is questionable.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Cost was mentioned as a barrier for some people but no actual cost estimates were given in the story.\u00a0 AP\u2019s story gave a CDC estimate of nationwide costs ranging from $200-600.", "answer": 0}, {"article": "Feb. 1, 2010 -- Twelve weeks of fish oil pills made teens at high risk of psychosis much less likely to become psychotic for at least one year.\nIt's also not clear how fish oil might prevent psychiatric disorders.\nIt's not clear whether the fish oil pills help people with established psychosis.\nAmminger and colleagues warn against over-interpretation of their findings.\nThat's the same level of efficacy seen with antipsychotic medications, note study researcher G. Paul Amminger, MD, of the University of Vienna, Austria, and colleagues.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There was no mention of the cost of dietary fish oil supplements.\u00a0 ", "answer": 0}, {"article": "U.S.-listed shares of Novartis closed up 1.2 percent .\nAfter 48 weeks of therapy, 84.5 percent of the 1,048 participants treated with Tremfya showed 90 percent improvement in disease symptoms, as measured by the Psoriasis Area Severity Index, compared with 70 percent on Novartis\u2019s Cosentyx, J&J said.\nOn a media briefing following the release of J&J\u2019s trial results, Novartis said it expected the data to have \u201climited clinical relevance\u201d and no impact on plans to expand the Cosentyx label.\n(Reuters) - Johnson & Johnson said its drug, Tremfya, was found to be more effective than a rival medicine from Novartis AG in reducing the severity and affected area in adults with moderate-to-severe plaque psoriasis in a late-stage study.\nAbout 7.5 million Americans live with plaque psoriasis, of which 20 percent have moderate-to-severe form of the disease, J&J said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "A cost comparison of the two drugs highlighted in the study \u2014 Johnson & Johnson\u2019s Tremfya and Cosentyx from Novartis AG \u2014 wasn\u2019t provided and would have been helpful.\nThe list price of a 100-mg dose of Tremfya (to be given once every two months) is about $10,000. For Cosentyx, around $4,700 (unclear if dosing is equivalent to Tremfya).\nRegardless, drug costs for severe cases of psoriasis can quickly get into the tens of thousands of dollars for some patients.", "answer": 0}, {"article": "2.\nBut there is a menu of options beyond colonoscopies \u2014 and they\u2019re not necessarily any better or worse, according to the USPSTF\u2019s recently finalized updated recommendations for screening among average-risk adults.\n(Wender doesn\u2019t recommend the OTC tests that are available.)\nBut that lack of trial data is why the Canadian Task Force on Preventive Health Care earlier this year recommended against using colonoscopy as a first-line screening method.\nAccording to public health experts, that\u2019s a bad thing.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "We\u2019ll give this story a Satisfactory rating in this category since it does mention the $1,000 cost of a colonoscopy and that one of the two at-home screening tests costs about $25.\u00a0 But readers would benefit more by knowing the average costs of the two alternatives, rather than just the cost of one.", "answer": 1}, {"article": "Low sperm count, or oligospermia, is a main cause of male infertility.\nAs SpermCheck\u2019s website puts it, a \u201ctrip to a fertility clinic for a semen analysis is not for everyone.\nFor women who are having trouble getting pregnant, the test may very well be one they \u2014 and not their squeamish partners \u2014 snap up along with over-the-counter ovulation kits.\nBy addressing the issue, SpermCheck will join a crowded infertility market that includes more than 20 types of female-fertility tests in Walgreen stores alone.\nThese tests can be expensive (costing hundreds of dollars and not typically covered by insurance), inconvenient and are often embarrassing.\u201d\n\nMORE: \u2018Sonicated\u2019 Sperm: Could Ultrasound Be the Next Male Contraceptive?\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story states that the cost of the test will be $39.99.\nAlthough the story does provide information about the cost of the test (which may have come directly from a news release), it fails to note that the standard approach requires two separate tests as established by the World Health Organization.\u00a0 At a minimum then the real cost of the test is $80.", "answer": 0}, {"article": "But from the beginning, Mr. Hladik resisted.\nHe wanted to be able to go to the beach.\u201d\n\nA nephrologist at the University of North Carolina School of Medicine, Dr. Hladik understood better than most how kidney dialysis could consume a patient\u2019s days.\nGerald J. Hladik was 74 when the day long anticipated by his doctors arrived: His kidneys, damaged years earlier by a viral infection, had lost 85 percent of their function.\nHis father\u2019s eventful medical history included a serious stroke and coronary bypass surgery.\nSo after considerable discussion, Mr. Hladik decided to skip the three weekly trips to a renal center, along with the resulting fatigue and dietary and travel restrictions.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The article could have included some quick facts about the cost of dialysis, as well as the costs of transportation, hospital time and nursing costs that are all involved in being treated as an out-patient at a renal clinic. There was one reference to costs when the story says that, in terms of time, dialysis treatment was \u201cthe equivalent of holding down a part-time job.\u201d", "answer": 0}, {"article": "Eat as you dare.\nNow here\u2019s the interesting part: eating more foods thought to be less healthy \u2014 those typical of Western diets \u2014did not link to an increase in heart attacks, strokes, or deaths.\nA new study of over 15,000 people in 39 countries explored the benefits of this diet for one special group: those already diagnosed with heart disease.\nScientists believe this style of eating offers some protection against mental aging, and, above all else, it is heart healthy.\nThat said, Stewart notes his study has limitations, including a lack of strict guidelines about portion size and no measure of total calories.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not talk about costs. Eating fresh fruits and vegetables\u2013and fresh seafood, especially\u2013is associated with higher costs in many countries.", "answer": 0}, {"article": "\"Because of this, we can take advantage of the 'side effect' and decrease involuntary sweating associated with hot flashes, and decrease the hot flashes as well,\" he explained.\nAnd oxybutynin doesn't interfere with the metabolism of tamoxifen, Leon-Ferre said, calling that an important consideration for breast cancer survivors.\nChemotherapy may induce early menopause, and drugs that reduce estrogen levels may make hot flashes worse, the research team noted.\nThe drug could be game-changing for certain women, said Dr. Alice Police, regional director of breast surgery at Northwell Health Cancer Institute in Sleepy Hollow, N.Y.\n\n\"This is a really important advance in survivorship and compassionate cancer care,\" added Police, who wasn't involved in the study.\nHowever, he cautioned that its long-term effects aren't known.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Using the lead researcher as a source, the article states that most insurers cover oxybutynin; that a month\u2019s supply can range from $21 to $42; and that the cost could be less, depending on the type of insurance a patient has.\nKudos to HealthDay for explicitly addressing cost.", "answer": 1}, {"article": "A qualified claim means there is evidence supporting the claim, but it is not conclusive.\nA new powdered peanut product is the first food item allowed to claim it may reduce peanut allergies in infants, though parents of susceptible babies are urged to consult a doctor before trying it.\nThe Food and Drug Administration allowed the new item, developed by a physician, to make the claim just months after the nation\u2019s top allergy experts reversed longstanding advice on preventing peanut allergies, dropping recommendations to withhold all peanut-containing foods in early childhood in favor of early, frequent exposure, starting with peanut powder or extract for infants beginning to eat solid food.\nWhile many foods like whole grains, nuts and supplements carry qualified health claims stating that they may reduce the risk of diseases like cancer or heart disease, this is the first time a food product label will be allowed to make a qualified claim that it reduces the risk of an allergy, officials said.\nThe label warns that evidence is limited.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story cites the product\u2019s cost: $25 for the introduction kit and and $20 for the maintenance kit, which lasts for about three weeks. The story does not indicate how many weeks that proper use entails, but the randomized trial cited by the AAP in forming their recommendations (the\u00a0Learning Early about Peanut Allergy (LEAP) study) continued peanut exposure until age 5. If Hello, Peanut! was used for the same duration, the total tab would be just over $1,900, a not-insignificant expense. Other less costly alternatives to include mixing smooth peanut butter into pureed fruits and vegetables \u2013 which is suggested by the AAP in the new guidelines. Yet, this alternative is not mentioned by the NYT.", "answer": 1}, {"article": "Transcendental meditation involves shutting out the outside world and focusing thoughts inward, or resting while remaining alert.\nBut while the magnitude of those results is remarkable, the study involved a relatively small number of participants, and did not reveal how meditation may be lowering heart disease risk.\nPrevious studies have linked better health outcomes among heart patients who practiced meditation compared to those who did not, but none of those trials could definitively credit the brain-focusing program with the better health results.\nMORE: Medical Meditation: Say Om Before Surgery\n\nAfter roughly five years of follow-up, the researchers found a 48% reduction in the overall risk of heart attack, stroke, and death from any cause among members of the meditation group compared to those from the health education group.\nIn the latest trial to address those limitations, however, meditation does appear to have an effect on reducing heart attack, stroke and even early death from heart disease, at least among African-Americans.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "This story did not attempt to put a price tag on meditation therapy, which as HealthDay pointed out can be expensive.\u00a0 It could also be pointed out that the mean household income of the participants was less than $18,000 annually.\n\u00a0", "answer": 0}, {"article": "Use of osteoporosis drugs, once heavily advertised by celebrity spokeswomen, has dropped by more than 50% in recent years amid reports of such serious side effects as sudden bone fractures.\n\nYet many experts say the benefits of the drugs, known as bisphosphonates, far outweigh the risks for many users.\n\nAn analysis in the New England Journal...", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story is clear on this point, stating: \u201cAll the bisphosphonates are now available in generic form, for as little as $5 a month.\u201d The only point of confusion is that the story also refers to \u201cnewer osteoporosis drugs retailing for hundreds of dollars or more a month.\u201d However, it doesn\u2019t tell us anything else about these drugs, other than their names. (We\u2019ll get back to that in the \u201cCompare Alternatives\u201d section.)", "answer": 1}, {"article": "Behind that common piece of advice is a complex series of physiological processes that calm the body, slow the heart and help control pain.\n\nBreathing and controlling your breath is one of the easiest ways to improve mental and physical health, doctors and psychologists say. Slow, deep and consistent breathing...", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story states early on that the cost of Spire is $150. The story also mentions the costs of the breathing classes offered by Dr. Belisa Vranich. Readers who are interested in taking the classes or purchasing Spire know what to expect in terms of cost.", "answer": 1}, {"article": "Unlike common polyps, they tend to be flat and the same color as the colon lining.\nThe DNA stool test methods were developed at the Mayo Clinic.\nIt's important for people with IBD because they are at much higher risk for colorectal cancer than the general population.\nSome of the study authors and the Mayo Clinic have a financial interest related to technology used with this research.\nTUESDAY, May 4, 2010 (HealthDay News) -- Noninvasive stool DNA testing can detect two types of colorectal precancers and could play a larger role in colon cancer prevention, say two new studies.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No discussion of costs.\u00a0 ", "answer": 0}, {"article": "For more information go to GetAwair.com.\nIf you already have a smart device system for your home, Awair is working on partnerships with several connected devices like Nest thermostat and other smart appliances so you can manage the air quality in your home or office when you're not there.\nThe app also provides Mayo Clinic \u201cmessage cards\u201d that give relevant information and recommendations for ways to keep your indoor environment healthy.\nEvery room in your house could be susceptive to some form of an air pollutant, but now there is a new device and app that says it can help you breathe easier by tracking air quality.\nBased on your air score, the monitoring gadget will send personalized alerts and advice to the user via its corresponding Awair mobile app.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story states that the Awair app is free, but that each air monitoring device costs $199 dollars. Presumably, one would need multiple devices to monitor air quality throughout a residence.", "answer": 1}, {"article": "They then matched each statin user \u2014 who was aged over 40 when first prescribed a statin between 1995 and 2006 \u2014 with up to five non-statin users for comparison.\nDouglas noted that since this study looked at patients who were already taking statins when they developed pneumonia, a full randomized clinical trial was needed to find out whether starting a statin at the time of diagnosis has a similar effect.\nPrevious studies have suggested statins, which are also available as cheaper generics, may be linked to better outcomes after bacterial infection.\n\u201cStatins are safe, cheap, and an easy intervention in terms of delivery,\u201d said Ian Douglas, a lecturer in epidemiology at the LSHTM who led the research.\n\u201cGiven the potential low number needed to treat to prevent a death suggested by this study, we believe that a strong case exists for randomized trials of statins in people with serious infection to determine if a simple and practical intervention at the point of diagnosis of pneumonia has a beneficial effect.\u201d\n\nDouglas\u2019s team, whose research was published in the British Medical Journal, used data from computerized medical records of doctors\u2019 practices in Britain to identify statin users.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Notwithstanding one researcher\u2019s comment that statins are \u201ccheap\u201d (which might not be the case if we\u2019re talking about drugs that are still on patent),\u00a0there was no specific mention of the cost of treatment with statin drugs. These include the costs of the drug itself as well as ongoing monitoring.", "answer": 0}, {"article": "Allergan Inc. said that two large human tests of its Botox drug, best known for smoothing wrinkles, showed that periodic injections prevent headaches in adults who suffer from chronic migraines.\n\nEven though details of the study weren't released, the announcement, which surprised many physicians and investors, sent Allergan's shares soaring 11%, or $5.95, to $60.53 at 4 p.m. in New York Stock Exchange composite trading. Botox has been used to treat severe headaches for many years, but some researchers have long been skeptical...", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The study does not mention the costs of the injections nor does it comment on whether insurance would be likely to cover it for migraines.", "answer": 0}, {"article": "Depression presents an enormous disease burden, with a reported 350 million people worldwide suffering from the disease, but traditional SSRI treatments carry a burden of their own - in dollars and side effects.\nTheir results showed that magnesium is safe and effective and comparable to prescription SSRI treatments in effectiveness.\nThe study team found that in 112 participants with analyzable data, consumption of magnesium chloride for six weeks resulted in a clinically significant improvement in measures of depression and anxiety symptoms.\nIn addition, these positive effects were shown quickly, at two weeks, and the supplements were well tolerated and similarly effective regardless of age, sex, or use of antidepressants, among other factors.\nNew clinical research published today in PLoS One shows that over-the-counter magnesium appears safe and effective to treat mild to moderate depression.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Despite claiming the low cost of magnesium supplements as a benefit, the release doesn\u2019t include the cost. A quick google search shows that magnesium tablets can be bought online or in stores for less than $15 per bottle.", "answer": 0}, {"article": "Labovitz also points out that the group of men who had fewer strokes were younger, had lower blood pressure and smoked less than the group more prone to stroke.\nTomatoes could contribute to reducing stroke in other ways, Willett says, because they are a good source of potassium, which is known to reduce blood pressure.\nIn other words, perhaps better health habits - not necessarily just the lycopene - lead to fewer strokes.\nThough the study looks promising, experts say that we can't necessarily give all of the credit to lycopene.\nHowever, daily intake of tomatoes may give better protection.\"\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The cost of tomatoes, or other food sources of lycopene, is not in question.", "answer": 2}, {"article": "\"Our meta-analysis of RCTs characterizes how cocoa flavanols affect cardiometabolic biomarkers, providing guidance in designing large, definitive prevention trials against diabetes and cardiovascular disease in future work,\" said corresponding author Dr. Simin Liu, professor and director of the Center for Global Cardiometabolic Health at Brown University who worked with epidemiology graduate student and lead author Xiaochen Lin.\nAll studies were small and of short duration, not all of the biomarkers tracked in these studies changed for the better, and none of the studies were designed to test directly whether cocoa flavanol consumption leads to reduced cases of heart attacks or type 2 diabetes.\nBut taking into account some of these heterogeneities across studies, the team's meta-analysis summarizing data from 19 trials found potential beneficial effects of flavanol-rich cocoa on cardiometabolic health.\nThere were small-to-modest but statistically significant improvements among those who ate flavanol-rich cocoa product vs. those who did not.\n\"We found that cocoa flavanol intake may reduce dyslipidemia (elevated triglycerides), insulin resistance and systemic inflammation, which are all major subclinical risk factors for cardiometabolic diseases.\"\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There is no discussion of costs in the release. We didn\u2019t expect to see chocolate bar prices. But there are existing dietary cocoa flavanol products on the market that could easily have been referenced.\nOnly 7% of the releases we\u2019ve reviewed so far adequately address cost. It has to start somewhere. Each news release writer can say to him/herself, \u2018Not in this case.\u2019 And in 93% of cases so far, cost is inadequately discussed.", "answer": 0}, {"article": "Both Prozac and Celexa belong to a class of antidepressants known as selective serotonin reuptake inhibitors, or SSRIs.\nTaking Prozac (fluoxetine) doubled the chances that a patient would show overall improvement, measured by their clinicians.\nWhen taking Prozac, Hollander says, \u201cPatients acknowledge experiencing less discomfort.\nThose drugs carry significant risk for weight gain, diabetes and movement disorders.\nIt is not known if the differences between these studies are due to differences between the medications or other factors.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "It\u2019s\u00a0 not that costs are high, it\u2019s just that they weren\u2019t discussed. The costs of Prozac are well known and could have been included in this story. Taking just one pill a day for 30 days would cost $214 through Drugstore.com.Prozac is generic at $10 for 3 months at one big box chain. There are also medical followup costs and possibly costs of managing adverse effects.\n\u00a0", "answer": 0}, {"article": "[1] Quotes direct from authors and cannot be found in text of Article.\n[1]\n\nIn this study, the researchers compared the diagnostic accuracy of the new RDT against the benchmark RT-PCR test (altona Diagnostics) being used for clinical diagnosis in the field reference laboratory run by Public Health England at Port Loko in Sierra Leone.\nThis new rapid diagnostic test (RDT) could cut back on the lengthy process usually required to confirm if a patient has EVD, help identify case contacts, and ultimately curb the spread of Ebola.\nSurprisingly, the findings also revealed that the standard altona RT-PCR test, under the conditions deployed in the field, was itself an imperfect reference standard.\nThe study is the first to show that a point-of-care EVD test (ReEBOV Antigen Rapid Test; Corgenix) is faster than and as sensitive as a conventional laboratory-based molecular method used for clinical testing during the recent outbreak in Sierra Leone.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "We don\u2019t see any dollar signs in this release, either for the new test or RT-PCR. According to a New York Times blog post, they cost $60-$200 each.", "answer": 0}, {"article": "In nonblood-based tumors, such as melanoma, only about one-half of patients have T cells in their tumors that can be harvested, and only about one-half of those harvested cells can be grown.\nFor the clinical trial, the Johns Hopkins team enrolled 25 patients with newly diagnosed or relapsed multiple myeloma, although three of the patients relapsed before they could receive the MILs therapy.\nOne year after receiving the MILs therapy, 13 of the 22 patients had at least a partial response to the therapy, meaning that their cancers had shrunk by at least 50 percent.\nAdditionally, the scientists found that patients whose bone marrow before treatment contained a high number of certain immune cells, known as central memory cells, also had better response to MILs therapy.\nNoonan says the research team has used these data to guide two other ongoing MILs clinical trials.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release, while loaded with information about the research, fails to mention costs related to this new approach at any point. This is in spite of the fact that the paper provides what\u2019s necessary\u00a0to fulfill this criterion. The study authors wrote: \u201cThe easy access to the tumor site, the absence of the need for surgical removal of the tissue containing the T cells, the numbers of cells obtained with the harvest, and the ability to expand products in all patients with a relatively short process at a reasonable cost contrast sharply with several limitations of TIL ACT\u201d (a current therapeutic approach to the disease).", "answer": 0}, {"article": "Everyone loses some bone with aging - women abruptly at menopause when estrogen levels decline, men more slowly as male hormones decline over time.\nBut remember: Not exercising also puts you at risk.\nIf a person simply stands, the muscles accommodate and do most of the work, he said - with no benefit to the bone.\nOther exercises - such as front and lateral raises with free weights - focus on the spine at chest level.\n\"Anything that makes bone bear weight is good for bone quality,\" said Dr. Kirkham Wood, head of orthopedic spine surgery at Massachusetts General Hospital.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "not applicable in this case", "answer": 2}, {"article": "\u2022 43% had at least 50% fewer arthritis symptoms, compared to 19% getting a placebo.\nNobody is exactly sure of the role Syk plays in rheumatoid arthritis.\nNow Harvard researcher Michael E. Weinblatt, MD, reports results from a phase II clinical trial in which 457 patients with active rheumatoid arthritis despite methotrexate treatment received R788 or placebo for six months.\nThe drug does have side effects.\nIn a pilot study, the drug appeared to reduce symptoms of rheumatoid arthritis.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not discuss costs, which is a shame. Arthritis is a chronic condition, meaning that any drug that gives people significant relief likley will become a lifelong medication. Even if a per-pill cost is low, the cost per year can be huge. Without this information, it is difficult to gauge the true value of the drug.", "answer": 0}, {"article": "Varenicline contains no nicotine.\nResearchers did not test nicotine gum because it delivers a less consistent flow of nicotine to the user, she said.\nAnd given how difficult it is to kick the habit, smokers need all the help they can get to succeed the first time they try, Lerman said.\nAbout 70 percent of smokers give up the daunting effort during the first week of trying.\nThe patch, worn on the skin, delivers a steady flow of the drug, she said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Applause for mentioning cost, but we would have liked some actual numbers. A 56-tablet bottle of Chantix, which is discussed in the story, costs around $250 this week according to an easy-to-use online price comparison tool. A direct comparison is not quite fair, since different smokers use these medications at different rates, but a possibly comparable amount of patches that provide medication through the skin is around $50. The story also could have asked the study author to estimate the potential savings in some way. In addition, the story does not acknowledge that adding a blood test to identify slow vs. normal metabolizers will add cost to smoking cessation efforts. How much is unclear.", "answer": 0}, {"article": "Dr. Henderson stated, \"Misconceptions about ketamine abound among psychiatrists, particularly related to possible chemical dependence problems.\nThrough a handful of ketamine infusions directed by Theodore Henderson, MD, PhD, refractory depression symptoms can be relieved significantly and persistently.\nThe study also challenges concerns about neurotoxicity and a recent hypothesis that patients must experience hallucinations during ketamine infusion in order to have an anti-depressant benefit.\nAnother conclusion Dr. Henderson highlights is ketamine infusions can relieve refractory depression symptoms persistently, perhaps for years.\nWhile controversial in academic settings, Dr. Henderson said his direct experience supports a different strategy for multiple-infusion treatment regimens and his clinical experience shows ketamine can invoke long-lasting effects often with less than six infusions.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The news release makes no mention of the cost of the infusions, nor does it say whether insurance pays for them. Given that they are not approved as safe and effective by the U.S. Food and Drug Administration (FDA), any cost would likely be borne by the patient.\nThe only person cited in the release, Dr.\u00a0Theodore Henderson, is co-founder of Neuro-Luminance Ketamine Infusion Centers. The center\u2019s website states that infusions start at $745 each, with discounted rates available for multiple-infusion packages.", "answer": 0}, {"article": "Now she's sharing their secrets with back pain sufferers across the U.S.\n\nAbout two decades ago, Esther Gokhale started to struggle with her own back after she had her first child.\nIn fact, Mummaneni says, stronger muscles might be the secret to Gokhale's success.\nSo indigenous people around the world don't have a magic bullet for stopping back pain.\nAnd it doesn't bother her that the method hasn't been tested in a clinical trial.\nBut Gokhale didn't see those two big curves in people who don't have back pain.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story doesn\u2019t mention cost at all. And cost could be a significant factor for anyone interested in pursuing the Gokhale Method. According to the Gokhale Method website, a 45-minute initial consultation (in person or via online video) costs $165. For maximum value, the story could have provided some discussion of the Gokhlae method cost vs. comparison of other strengthening programs \u2014 e.g. physical therapy, Pilates, yoga, working with athletic trainer.", "answer": 0}, {"article": "The American Heart Association has more on heart failure.\nResults were even more heartening at higher doses, where participants had an 88 percent decrease in risk for death, cardiac transplant, hospitalizations and other outcomes, the study authors said.\nAt both six months and a year later, the patients who had received the new gene saw their risk for death, cardiac transplantation, worsening heart failure and hospitalization decline by half.\nThe enzyme regulates calcium cycling, which, in turn, is involved in how well the heart contracts, the researchers said.\nThe study authors hope that, if replicated in larger trials, the gene-therapy treatment could actually delay or obviate the need for heart transplants in patients with heart failure.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Although this gene therapy has barely begun the long road of clinical trials and so we won\u2019t hold this story to the expectation that it discuss costs, the story could have offered readers at least some general comments about how the costs of this sort of gene therapy might compare with conventional treatments for heart failure.", "answer": 2}, {"article": "\u201cIn the Northern hemisphere, the body\u2019s testosterone production naturally declines from November through April, and then rises steadily through the spring and summer with a peak in October.\u201d\n\nLow sexual desire can affect significant numbers of men after the age of 40, with studies finding that up to 25 percent of men report problems.\nBut after treatment, the group exposed to the bright light was scoring sexual satisfaction scores of around 6.3.\nFagiolini\u2019s team recruited 38 men diagnosed with either hypoactive sexual desire disorder or sexual arousal disorder \u2013 both characterized by a lack of interest in sex.\n\u201cBefore treatment, both groups averaged a sexual satisfaction score of around 2 out of 10.\nIn contrast, the control group only showed an average score of around 2.7 after treatment.\u201d\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "How much does a light therapy box cost? The story doesn\u2019t say. Using an online search, we found models ranging from $40 to $300, depending on size and features. It would be helpful to know the duration and intensity of light treatment in the study as well, as this can influence cost.", "answer": 0}, {"article": "Dr Sheraz Markar, an NIHR Clinical Trials Fellow from Imperial College London, under the supervision of Professor George Hanna, told the Congress: \"At present the only way to diagnose oesophageal cancer or stomach cancer is with endoscopy.\nThis study suggests that we may be able detect these differences and use a breath test to indicate which patients are likely to have cancer of the oesophagus and stomach, and which do not.\nThe new research, involving more than 300 patients, showed that the test could diagnose cancer with an overall accuracy of 85%.\nThis will assess the ability of the test to pick up cases within a group that is likely to contain only a small percentage of cancers.\nOver the next three years, the researchers will continue with a larger trial, using the test with patients who are being given an endoscopy for gastrointestinal symptoms but not yet diagnosed with cancer.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "This research is only at its earliest stages, so is it too early to expect cost information? If it\u2019s not too early to promote a technique in a news release it\u2019s not too early to provide a ballpark cost. The release does tout potential savings from avoiding \u201cunnecessary\u201d endoscopies but without also considering that an easy test could send many healthy into further testing or even treatment they didn\u2019t need.\nA 20% false positive rate, which this test apparently offers, could translate into a huge number of expensive endoscopies.", "answer": 0}, {"article": "Weight gain is a common side effect of Zyprexa.\nThose on medication gained an average of 20 pounds during the study.\nThe scale rates severity of more than a dozen symptoms, including suspiciousness, grandiosity and bizarre thoughts.\nIn the first year of a two-year trial, 5 of the 31 of those on medication developed full-blown psychosis, compared with 11 of 29 of those who were taking dummy pills.\nThe new study was intended in part to clarify the trade-off between the risks and the potential benefits of preemptive treatment.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No mention of the cost of Zyprexa and no mention of how long this medication would need to be taken to prevent a severe psychotic break in susceptible adults. These drugs cost around $200/month. Add in physician visits and monitoring for onset of diabetes, weight gain, and hyperlipidemia and you can easily come up with $300/month. ", "answer": 0}, {"article": "The requested URL /usnews/health/articles/070408/16healy.htm was not found on this server.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There is no mention of the costs of hormone therapy.", "answer": 0}, {"article": "Most people turning to surgery for weight loss are probably concerned with how many pounds they can expect to shed.\nAlso, at two years after surgery, data were available for less than half the patients.\nThe cost of the surgery was about $30,000, which exceeds the savings observed directly.\nA year after surgery more than 80 percent of patients were no longer taking any of the diabetes medicines they had been on before the operations.\nThe Johns Hopkins researchers also calculated the effects of surgery on health costs for the patients.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "1clip_filelist.xml\"/>\n\n\n\n1clip_filelist.xml\"/>\n\n\n\nHealth care spending before and after the surgery is a key point in this story. The story also includes an estimate of the cost of stomach-reduction surgery. However, neither the story nor the study offer a comparison of the spending of these patients to that of people who do not have this type of surgery.", "answer": 1}, {"article": "Dr. Len Lichtenfeld, deputy chief medical officer of the American Cancer Society, said it's clear that \"some women with metastatic breast cancer have benefited from Avastin, but others not only have not benefited, they've been harmed.\nThe results of those studies were a bitter pill for patients thriving on Avastin and researchers excited by the promise of the early data.\nThursday's announcement is only a first step in removing the FDA's approval for this drug in treating breast cancer patients.\nThe announcement does not affect Avastin's status as an approved therapy for lung cancer, kidney cancer, colorectal cancer and brain cancer.\nBased on the new data, an FDA advisory panel voted 12-1 to reverse the accelerated approval in July.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The several facets of costs are addressed, including the rationing charge. The story gets a shout out for talking about both sides of this third-rail issue with Avastin.\nIt would have been nice to explain Dr. Sparano\u2019s important comment that doctors will still be able to use Avastin for breast cancer for patients who can afford it. It\u2019s because insurance companies, including Medicare, tend not to pay for drugs when used for reasons the FDA hasn\u2019t approved. So if Avastin does lose its indication for breast cancer, docs can still prescribe it \u201coff-label\u201d for that use, but patients will need to step in and pay for it all.", "answer": 1}, {"article": "[3] Quote direct from author and cannot be found in text of Article.\nLoss of grip strength is unlikely to lie on a single final common pathway for the adverse effects of ageing, but it might be a particularly good marker of underlying ageing processes, perhaps because of the rarity of muscle-specific diseases contributing to change in muscle function.\"\nFurther research is needed to establish whether efforts to improve muscle strength are likely to reduce an individual's risk of death and cardiovascular disease.\"\nThe study, published in The Lancet, also found that grip strength is a stronger predictor of death than systolic blood pressure, and the authors suggest that it could be used as a quick, low-cost screening tool by doctors or other healthcare professionals to identify high-risk patients among people who develop major illnesses such as heart failure and stroke.\nBut until now, information on the prognostic value of grip strength was limited, and mainly obtained from select high-income countries.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release says that grip strength is low-cost, but a dynamometer is not something used routinely in clinical practice.\u00a0Why not provide a cost estimate for both the dynamometers, the cost of administering the test in the clinical setting, and the cost of potential widespread risk-stratifying use? \u00a0Would this still be low-cost? Maybe so, but some projections are possible IF you deal with real numbers, not just the researchers\u2019 value judgment that it is \u201clow-cost.\u201d", "answer": 0}, {"article": "Mannitol pulls water out of the tightly packed cells lining the capillaries so that they shrink and pull away from one another, opening up gaps through which drug molecules can pass into the brain.\nThat means a lot to me.\u201d\n\nDr. Boockvar said: \u201cAvastin may not be the best drug for this delivery technique.\nDr. Boockvar said microcatheters should increase the odds of success by delivering a high dose of the drug directly to where it was needed most.\nBut a scan found a brain tumor nearly the size of a golf ball.\nMr. Sugrue said he was all for it, even though Dr. Boockvar warned him that the drug was no magic bullet.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Costs of the treatment were not mentioned. But we can understand that in an article about an experimental approach so far from clinical use. \n\u00a0", "answer": 2}, {"article": "Investigators evaluated the effect of the USPSTF guideline on the number and distribution of new prostate cancer diagnoses in the U.S.\nThe study showed that 12 months after the draft guidelines were published diagnoses of new low risk cancers had fallen by 37.9%, and continued to fall more rapidly than other disease risk strata, suggesting that, in this regard, the USPSTF recommendation had its intended effect,.\nBy contrast, the number of monthly colon cancer diagnoses remained stable.\nThis study helped quantify the potential benefits (reduced harms of over diagnosis and overtreatment of low risk disease and disease found in elderly men) and potential harms (missed opportunities to diagnose important cancers in men who may benefit from treatment).\n\"While some of the effects of this guideline may be beneficial in terms of reducing harms of over diagnosis and overtreatment, the reduction in intermediate and high risk cancer diagnoses raises concern for delayed diagnoses of important cancers associated with inferior cancer outcomes,\" noted Dr. Barocas.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There is no mention about the costs of PSA tests or of the resulting low-risk cancers that may be unnecessarily irradiated, surgically extracted, or robotically removed. Similarly, there\u2019s no mention of the costs of treating advanced cancer \u2014\u00a0both for health care (advanced cancer treatments can be extremely expensive\u2013e.g., Provenge) and life years lost.", "answer": 0}, {"article": "The amygdala and hypothalamus are regions of the brain that control several memory and emotional functions.\nThe research, published online Jan. 19 in the American Journal of Geriatric Psychiatry, examined the effects of an easily absorbed curcumin supplement on memory performance in people without dementia, as well as curcumin\u2019s potential impact on the microscopic plaques and tangles in the brains of people with Alzheimer\u2019s disease.\nThe double-blind, placebo-controlled study involved 40 adults between the ages of 50 and 90 years who had mild memory complaints.\nThe people who took curcumin experienced significant improvements in their memory and attention abilities, while the subjects who received placebo did not, Small said.\nTheravalues Corp. provided the curcumin and placebos for the trial, as well as funds for laboratory testing and for Small\u2019s travel to present preliminary findings at the 2017 Alzheimer\u2019s Association International Conference.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There\u2019s no discussion of costs in the news release. A quick google search for Theracurmin capsules reveals that \u2014 at the dosages used in the study \u2014 a month\u2019s supply would cost somewhere between $75-$100 dollars.", "answer": 0}, {"article": "\"We can get that whole process of what a meal does without actually having the meal,\" he said.\nThat makes it much safer than, say, systemic stimulants that also rev up the heart and other parts of the body and cause strong side effects, according to the research.\nExperts rightfully caution against relying on miracle diet drugs, but a new study offers a novel approach that bears watching.\nOther researchers are working on similar approaches, he said, but this drug, so far, passes harmlessly out of the intestine after doing its work.\nBetter yet, the drug, fexaramine, works only in the intestine, never entering the bloodstream.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Although we often don\u2019t expect to see firm cost estimates in stories about experimental treatments, a story that exudes such confidence that a new treatment is likely to succeed should at least begin to ask how much it might cost. Is it a chemical that can be produced at relatively low cost or is it more like the sort of exotic treatments that are sold for thousands of dollars a year? Several new obesity drugs have been approved in recent years. The story could have mentioned the price of these drugs to give us some idea of what a new drug might possibly cost.", "answer": 0}, {"article": "Feifel recalls one patient whose depression would disappear like magic after a dose of ketamine.\nAnd ketamine's safety record is so good that it's often the painkiller of choice for children who arrive in the emergency room with a broken bone.\nAnd Paul has spent much of his adult life searching for a treatment that would give him some relief.\nHe didn't qualify for most research studies because of his suicidal thoughts.\nAnd they're doing this even though ketamine lacks approval from the Food and Drug Administration for treating depression.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Nice detail here. The story reports that each treatment can cost $500 to $1000 and it is usually repeated every few weeks. The story also reports the treatment is generally not covered by insurance.", "answer": 1}, {"article": "These new drugs \"could be for someone who needs an addition to statin, or it could be instead of statin,\" Martin said.\nResearchers analyzed 24 randomized control trials to assess the efficacy and safety of the new drugs, called PCSK9 antibodies, in adults with high cholesterol levels.\nThe results, published in the Annals of Internal Medicine, also show that the drugs have a significant effect on reducing heart attacks and overall mortality.\nOthers have such high cholesterol that taking statins alone is not enough.\nIn an editorial published along with the study, experts note that although the results are promising, more long-term research is needed to make definitive conclusions about the drug.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not mention costs \u2014 and antibody-based drugs are typically on the more expensive end of the drug-price spectrum. Some experts estimate that these drugs may cost in the $10,000-per-year range, which, extended over the lifespan of millions of patients, may be a tremendous burden for the system.\nIn addition, the difference in costs with statin medications is going to be striking. For those at very high risk in whom statins aren\u2019t enough, adding this medication may be appropriate. The challenge is defining use in those who cannot tolerate statins, since \u201ctolerate\u201d is a relative term. Many patients can be successfully switched from one statin to another. Having the new agent may result in providers and patients trying less hard to find the right medicine. Given the number of individuals who have elevated cholesterol, the cost implications could be staggering.", "answer": 0}, {"article": "Many more stroke victims than previously thought can be saved from disability or death if doctors remove blood clots that are choking off circulation to the brain, a new study has shown.\nOnly about half the patients who were screened qualified for treatment, known as thrombectomy, which uses a mechanical device to pull clots out of a blood vessel.\nThe researchers used a special type of brain imaging to identify the patients who still had live brain tissue that could be saved if the blood supply was restored.\nHowever, the findings do not apply to every stroke victim.\nThe study showed that the time window could be expanded to 16 hours.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There\u2019s no mention of how much the special imaging and surgical procedure will cost patients.", "answer": 0}, {"article": "\"Done haphazardly and irregularly, it is probably worse than no breast self-exam at all,\" Steiner said.\nBut finding a lump also is no reason to panic, given the limited accuracy of the self-test.\nSome evidence does suggest that self-exams done properly could make a difference.\nShe stopped routinely teaching self-exams to patients after the large trials in China and Russia showed no benefit.\nFurther, decades of research still have not produced good evidence that self-exams make any difference in breast cancer survival.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "It doesn\u2019t cost anything to do a breast self-exam. \nThe story does mention potential harms of increased doctor visits and unnecessary diagnostic procedures triggered by self-exams, with additional cost implied. ", "answer": 1}, {"article": "Celgene\u2019s drug Abraxane prolonged the lives of patients with advanced pancreatic cancer by almost two months in a clinical trial, researchers reported Tuesday, signifying an advance in treating a notoriously difficult disease but not as big a leap as some doctors and investors had hoped.\n\n\u201cIt was not the breakthrough we were anticipating,\u201d said Dr. Andrea Wang-Gillam, an assistant professor and pancreatic cancer specialist at Washington University in St. Louis, who was not involved in the trial.\n\nStill, Dr. Wang-Gillam and others said any progress was welcome against metastatic pancreatic cancer, which has defied most treatments, with patients tending to live only about six months after diagnosis.\n\nPancreatic cancer is the fourth most common cause of cancer death, with 38,000 Americans expected to die this year, almost as many deaths as from breast cancer, according to the American Cancer Society. Yet there are only 45,000 new cases of pancreatic cancer a year compared with more than 230,000 new breast cancer cases.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story reported that Abraxane \u201cwill cost $6,000 to $8,000 a month\u201d for pancreatic cancer patients. And then placed the cost and potential benefit into context: \u201cHow much of an extension of life is meaningful to patients is a matter of some debate, especially with cancer drugs costing thousands of dollars a month.\u201d", "answer": 1}, {"article": "PHILADELPHIA - According to a new study, women experiencing difficulty with time management, attention, organization, memory, and problem solving - often referred to as executive functions - related to menopause may find improvement with a drug already being used to treat attention deficit hyperactivity disorder (ADHD).\nThe Penn-led team administered a once-daily dose of LDX for four weeks to 32 healthy, non-ADHD-diagnosed women between the ages of 45 and 60 experiencing difficulties with executive functions as a result of mid-life onset menopause, and as measured using the Brown Attention Deficit Disorder Scale (BADDS).\n\"Reports of cognitive decline, particularly in executive functions, are widespread among menopausal women,\" said lead author, C. Neill Epperson, MD, professor of Psychiatry and Obstetrics and Gynecology at the Perelman School of Medicine at the University of Pennsylvania, and director of the Penn Center for Women's Behavioral Wellness.\n\"It is also important for clinicians to confirm that a woman's complaints of worsening memory are in the executive function domains, are temporally related to the transition to menopause, and are not indicative of some other pathological cognitive impairment before prescribing a trial of LDX.\"\n\"Although we observed that short-term use of LDX was well tolerated and effective in several subjective and objective areas, long-term studies of menopausal women receiving LDX are needed, similar to those conducted for ADHD patients,\" said Epperson.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There is no mention in the release as to the cost of LDX although, since it is routinely prescribed for ADHD, the cost for users should be easy to provide.\u00a0 A cursory search of the internet suggests that a 30-day supply could cost between $100 and $300, depending on the provider and insurance coverage.\u00a0 Nor is it clear from the release how long women would need to take the drug to ward off any cognitive decline, since the trial the release reports on only continued for several weeks.\u00a0 Providing that information would allow readers to accurately gauge the value of the treatment.", "answer": 0}, {"article": "Food sources of vitamin E include wheat germ, nuts such as almonds and hazelnuts, vegetable oils such as sunflower and safflower oils, and some green vegetables, such as spinach and broccoli.\nIt is unlikely that people could get too much vitamin E from food.\nAnd it supports findings from some previous research that dietary vitamin E, in particular, might be related to a lower risk of dementia.\nWhen Breteler\u2019s team considered a number of other factors \u2014 including participants\u2019 age, education, weight, and smoking and drinking habits \u2014 high vitamin E intake was linked to a one-quarter reduction in dementia risk.\nExperts advise that adults consume no more than 1,000 mg of vitamin E per day.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The costs of foods containing vitamin E is not really in question, so we\u2019ll call this one not applicable.", "answer": 2}, {"article": "\"It's a very important trial,\" added Dr. Angeles Alvarez Secord, associate professor of gynecologic oncology at Duke Comprehensive Cancer Center in Durham, N.C. \"I've been using [the IUD] clinically for several years now for this purpose in patients who desire future fertility and some patients who cannot undergo surgery or who are at high risk for surgical complications.\nThe IUD was removed at the end of the year if there was no evidence of cancer.\nHowever, all the women were alive and seemingly cancer-free by the end of the study after further treatment (either the IUD and GnRH treatment or a hysterectomy), the study reported.\nNine of the women in the study successfully delivered babies.\nIn background material, the researchers stated the progestin-releasing IUD should be effective in treating AEH and also early endometrial cancer, as long as those patients were evaluated with laparoscopy, ultrasound and MRI to make sure their cancer had not spread and there was no simultaneous ovarian cancer.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not mention any costs of the IUD or other treatments.", "answer": 0}, {"article": "Unlike the 2012 campaign, which aired for 12 consecutive weeks, the 2014 campaign aired in two phases, from February 3 to April 6 and from July 7 to September 7.\nWith a year-round campaign we could save even more lives and money.\u201d\n\nTips, the first federally funded anti-smoking paid media campaign, features former smokers talking about their smoking-related illnesses.\nThe latest outcomes measuring the impact of CDC\u2019s national tobacco education campaign are as strong as those achieved in its first year, and suggest that three years into the campaign, the ads were still having a significant impact.\n\u201cThe Tips campaign is an important counter measure to the $1 million that the tobacco industry spends each hour on cigarette advertising and promotion,\u201d said Corinne Graffunder, Dr.P.H., director of CDC\u2019s Office on Smoking and Health.\nMore than 1.8 million smokers attempted to quit smoking because of the nine-week-long 2014 Tips From Former Smokers ( Tips ) campaign.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "We give the release credit for providing some detail on the costs of smoking-related illnesses. However, the intervention here was a national anti-smoking campaign and the cost of that campaign was described in obscure terms:\n\u201cThe Tips campaign is an important counter measure to the $1 million that the tobacco industry spends each hour on cigarette advertising and promotion,\u201d said Corinne Graffunder, Dr.P.H., director of CDC\u2019s Office on Smoking and Health. \u201cThe money spent in one year on Tips is less than the amount the tobacco industry spends on advertising and promotion in just 3 days.\u201d\nOne can deduce based on the numbers given that the campaign costs less than $72 million ($1 million an hour for three days), but why spin it to this extent when it would have been easy to give us an actual number?", "answer": 0}, {"article": "CT (computed tomography), sometimes called CAT (computed axial tomography), is performed by computerized machines that scan patients with X-rays to create three-dimensional cross-sectional images of organs and other parts of the body, providing far greater detail than standard single X-rays.\nBecause it would take decades to follow a large number of patients who have undergone CT scans to determine the exact risks posed by the exams, there are no direct data demonstrating the danger.\nA child's risk may run as high as one case of cancer for every 500 scans, experts say.\nSome say part of the blame lies with physicians who have financial interests in imaging facilities.\nThere are many reasons for the increase, including improvements in the technology that have speeded the procedure, a growing list of uses and a proliferation of the machines.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not discuss the costs of the scans.", "answer": 0}, {"article": ".\nIn this context, the phase III \"Helix\" study is being carried out in more than 30 hospitals in Spain, Germany, Estonia, Portugal, Slovakia and Italy, in 300 patients to evaluate the efficacy of this compound in the treatment of the sign and symptoms of dry eye syndrome.\nWe currently have a robust therapeutic program in ophthalmology with two candidates under development in Phase II and III studies for glaucoma (bamosiran) and ocular pain (SYL1001) , respectively.\nThe therapeutic application of targeted siRNAs is booming given the specificity of gene silencing for a particular protein in a given tissue and the lack of side effects.\nIt must be empathized that this pathology affects more than 5 million in Spain, between 10% and 20% of the population, mostly women, and almost 100% of these being elderly , .\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There is no discussion of the potential cost of this new medication, tivanisiran. We do know, however, that current other treatments for dry eyes can be expensive. Cyclosporine A drops, for example, may run as high as $400 a month. There is no indication that tivanisiran might be more affordable to patients, or if insurers might cover the cost of this news drug.", "answer": 0}, {"article": "Personal sound amplification products (PSAPs) are less-expensive, over-the-counter devices not specifically labeled for hearing loss treatment, but some are technologically comparable with hearing aids and may be appropriate for mild to moderate hearing loss.\nAccording to nationally representative estimates, less than 20 percent of adults with hearing loss report hearing aid use.\nNicholas S. Reed, Au.D., of the Johns Hopkins School of Medicine, Baltimore, and colleagues compared five of these devices (costs, approximately $350 to $30) with a conventional hearing aid (cost, $1,910) among 42 adults (average age, 72 years) with mild to moderate hearing loss.\nThe researchers found that the change in accuracy in speech understanding from unaided to aided varied by device.\nA limitation of the study was the modest number of participants.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The cost of the prescription hearing aid used in the study is noted ($1,910), as is the cost range of five different PSAPs tested (ranging from $30 to $350).", "answer": 1}, {"article": "Tiotropium bromide (Spiriva)) belongs to a class of drugs called anticholinergics, which work by enlarging the airways to allow for easier breathing.\nThese drugs carry a note on their labels warning of the possibility of severe adverse events, including death, he noted.\nIn addition, Spiriva's safety profile among asthmatics still needs to be studied, he said.\nHowever, the study authors and an outside expert stressed that these are early findings and much longer, larger clinical trials are needed.\nIn addition, the combination of an inhaled steroid and Spiriva was not less effective than using an inhaled steroid plus Serevent, they said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Costs aren\u2019t discussed and should be.", "answer": 0}, {"article": "Menstrual cramps, known by the medical name dysmenorrhea, typically begin just before or at the start of a woman's menstrual period and can last several days.\nAnd since the study period lasted only two months, there was no way to tell whether such a high dose produced any toxic long-term effects.\nExperts wondered if women with higher blood levels would experience such dramatic cramp relief as observed in the study.\nThe cost of vitamin D supplements would be roughly comparable with both of these remedies.\nGraham and Rabin agreed that much larger trials should be done before they would recommend vitamin D3 use to any of their patients for cramp relief.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story did explain that \u201cThe cost of vitamin D supplements would be roughly comparable with (NSAIDS or birth control pills).\u201d\u00a0 It didn\u2019t give a ballpark cost, but we\u2019ll give it the benefit of the doubt for nodding in the direction of addressing cost.\n\u00a0", "answer": 1}, {"article": "It also shrank waistlines and resulted in weight loss, both in total body fat and trunk fat, but not in muscle mass.\nThe researchers said further investigation will determine whether the benefits of the diet can continue for several months.\nPeople in the second group were placed on a three-month test of the fasting-mimicking diet.\nThe phase II trial, conducted by researchers at the USC Leonard Davis School of Gerontology, demonstrated a host of benefits from the regimen.\nThe research team found that the beneficial effects -- from weight loss, smaller waistlines and lower glucose, blood pressure and IGF-1 levels -- were sustained.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "While the release discloses that meals during the low-calorie diet periods were provided by a nutrition company, there is no discussion of the cost of following this special diet. We thoroughly scoured L-Nutra\u2019s pages describing the ProLon meal kits containing \u201cproprietary plant-based soups, bars, drinks, snacks, herbal teas, vitamins, and supplements\u201d but no costs were to be found despite the site claiming the meal kits are available. The site invites potential customers to create an account and request more information.", "answer": 0}, {"article": "\"It's very exciting,\" Klein says.\nAt the current recommended prescription dose -- 120 milligrams taken up to three times per day, for example up to 360 milligrams daily -- about 70 percent of users experience gastrointestinal complications, Klein says.\nWhile Americans spend an estimated $1 billion on nonprescription weight loss products, few if any of those products have undergone the rigorous testing that is required by the FDA for prescription medications.\nBut it's important to know that the weight loss that's typical for users of the drug -- 5 to 10 percent of total weight -- will be less than many dieters expect.\nThe company says that 22 million people in 145 countries have taken the drug.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Estimates cost to be $2-3 /day.", "answer": 1}, {"article": "FDA approves first drug aimed at women with inherited breast cancer\n\nU.S. regulators have approved the first drug aimed at women with advanced breast cancer caused by an inherited flawed gene.\n\nThe Food and Drug Administration on Friday approved AstraZeneca PLC\u2019s Lynparza for patients with inherited BRCA gene mutations who have undergone chemotherapy.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story says Lynparza \u201cwill cost $13,886 per month without insurance, according to AstraZeneca.\u201d It mentions that the manufacturer is offering financial assistance to pay for it.\nHowever, the story does not compare the cost to other treatments or address the question of whether insurance companies are expected to cover it, which are important questions now that the drug has been approved for use in breast cancer patients.\u00a0Many patients with metastatic disease worry about reaching their lifetime insurance caps.\nAstraZeneca also does not specify whether the financial assistance that will be provided will cover the full cost or some percentage of the cost, and how the degree of financial assistance provided will be determined.", "answer": 1}, {"article": "Jason Dragoo\u2019s Stanford University research team gets 100 to 200 inquiries every day from people interested in joining its clinical trial studying the use of stem cells to treat knee injuries.\n\nThe interest highlights a growing demand for the use of stem cells derived from a person\u2019s own bone marrow or fat to treat orthopedic injuries. Osteoarthritis, a degenerative joint disease where the protective tissue or cartilage around a joint wears down, is a particular focus of inquiry.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "While the story mentions that stem cell treatments are often not covered by insurance, they should have said how much these treatments typically cost.", "answer": 0}, {"article": "In a transvaginal ultrasound (TVU), sound waves emitted from a probe placed in vagina help a physician check if Essure has been placed properly.\nAll physicians who offer Essure are expected to be trained to perform the TVU confirmation test by mid-2016, the company said.\nThis test is an alternative to the generally-prescribed modified hysterosalpingogram (HSG) test in which an x-ray of the uterus and fallopian tubes is used to check for proper device placement.\nBut since its approval in 2002, women using the device have sent the FDA more than 5,000 complaints, ranging from pain and menstrual problems to pregnancies and even deaths.\nEssure is a small metal coil inserted into woman\u2019s fallopian tubes.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The article does not mention the cost of a TVU or whether a separate charge will be applied for this procedure. In general, TVUs can be costly if not covered by insurance. Depending on the insurance status, who does it, or where (geographically) it is done, the procedure could cost between $250-1,000. \u00a0It is in interesting to note that the cost of a HSG is typically higher (can be anywhere between $800-3,000).", "answer": 0}, {"article": "Drugs such as aspirin and ibuprofen treat inflammation, the body's immune response to infections or pathogens.\nKhandaker said that five of the 20 studies focused on one specific cytokine.\nTwo clinical trials examined by Khandaker focused on another drug blocking the action of a different cytokine, and both studies showed it improved symptoms of depression.\nTheir potential side effects also must be investigated, Khandaker said, adding that \"we and other research groups from both sides of the Atlantic are currently planning and conducting such randomized control trials.\"\nLooking to the future\n\n\"Evidence at this point suggests that cytokine antagonists -- which are much more specific in their anti-inflammatory effects than drugs like aspirin -- show modest antidepressant effects in individuals with depression and increased inflammation,\" said Raison, who did not participate in in Khandaker's research.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Information on the steep costs of some of these drugs is readily available, along with data on whether insurers will pay for them. There is no discussion of costs in the story about this, nor does the story mention a single one of the drugs by name\u2013adalimubab and etanercept are two\u2013so that readers can look for themselves.\nIt is particularly important to mention cost in this case because biologics (the drug class in question) are notoriously expensive (adalimubab is estimated around $1,600 a month) while most first-line generic treatments for depression, like SSRIs, are much more affordable (often less than $20/month).", "answer": 0}, {"article": "Body temperature, heart and breathing rate normalize more quickly.\nAnd if mothers or babies are very sick and have to be isolated, Gray suggests mothers take any opportunity to hold their infant skin to skin.\nAt Ronald Reagan UCLA Medical Center where Ali was born, the technique is routinely practiced for healthy mothers and newborns.\nOne of the first places to show how this technique can help preemies was Colombia in the 1990s.\n\"The baby gets landed in a trusting environment,\" he says, reassuring them that life outside the womb can also be \"soft, comfortable and warm.\"\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There is no cost associated with this practice, especially for healthy full-term babies where less parental training is needed. However, it would have been useful to discuss the high costs of NICU care, and how kangaroo care might affect those costs.", "answer": 2}, {"article": "Unlike the more common obstructive sleep apnea, in which the airway partially collapses and causes pauses in breathing, central sleep apnea (CSA) occurs when the brain fails to control breathing during sleep.\nAbout a third of patients in the treatment group reported therapy-related discomfort that was resolved with some reprogramming of the device.\nBetween six and 12 months of follow-up, all patients received the neurostimulation treatment.\nIn the randomized study, 151 patients were implanted with the device.\nThe study was funded by Respicardia.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There was no mention of cost. Surgery to implant a device is likely to be quite costly and it will require maintenance.", "answer": 0}, {"article": "Medtronic Inc. and Eli Lilly & Co. agreed to collaborate on an early stage research project for a potential Parkinson's-disease treatment that involves delivering medication directly to the brain\u2014a goal that has long eluded drug makers.\n\nThe pact, announced Tuesday, adds to Medtronic's roster of projects aimed at using implantable drug pumps and catheters to circumvent the blood-brain barrier. The tightly packed network of cells in brain capillaries only lets certain substances through, such as key nutrients, making brain-based...", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Not applicable.\u00a0 There was no discussion of costs but that is understandable at this early stage.", "answer": 2}, {"article": "Vitamin D is called the \"sunshine vitamin\" because human bodies produce it when the sun's ultraviolet rays strike the skin.\nHowever, colon cancer patients shouldn't try to boost vitamin D levels beyond the normal range, one expert said.\nBut vitamin D also influences cellular function in ways that could be beneficial in treating cancer, Ng said.\nThis increase in progression-free survival is the most compelling evidence indicating that vitamin D makes a difference in colon cancer, said Dr. Smitha Krishnamurthi, an associate professor of hematology and oncology at Case Western Reserve University School of Medicine in Cleveland.\n\"These findings are interesting, and show that vitamin D may have a role in improving outcomes in cancer care.\"\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "This story does not discuss cost. However, most people generally understand that vitamin supplements are affordable, so we\u2019ll rate it not applicable.", "answer": 2}, {"article": "In the U.K., women are advised not to drink at all during the first trimester of their pregnancy and to drink no more than a drink or two a week after that.\nIndeed, many of the women included in the \"light drinkers\" group had no more than a drink or two during their entire pregnancy.\nWomen were defined as light drinkers if they had no more than one or two drinks a week.\nA drink was defined as a very small glass of wine, a half pint of beer, or a small single measure of spirits, says study researcher Yvonne Kelly, PhD, of University College London.\nMothers were first asked about their alcohol use when the kids were 9 months old.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "This does not seem to apply.", "answer": 2}, {"article": "\"There was a trend toward less severe psoriasis severity in people taking statins,\" says researcher Adam Perry, a fourth-year medical student at Emory University in Atlanta.\nAnd no one should start taking statins in an attempt to ward off psoriasis symptoms, doctors stress.\nBut the findings, presented at the American Academy of Dermatology annual meeting, raise an interesting possibility worthy of further study, experts agree.\nThe study is preliminary and doesn't prove cause and effect.\nMarch 8, 2010 (Miami Beach, Fla.) -- Once again, cholesterol-lowering statin drugs have been shown to be good for more than the heart.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "\u00a0There was no discussion of costs.", "answer": 0}, {"article": "Parkinson's disease is a degenerative condition that affects the central nervous system.\nHe also said it will be important to confirm these findings in other studies and learn the mechanism of how berries and other flavonoids appear to offer some protection against Parkinson's disease.\nAlso, recollections of dietary intake may be faulty, and it's possible that other properties of fruits and vegetables might have influenced the results, the authors said.\nBut, when the researchers looked at the dietary compounds individually, it was clear that berries could benefit both men and women, lowering the risk of Parkinson's disease by about 25 percent for those who had at least two servings of berries a week.\nThe researchers looked at dietary intake of five major flavonoid sources: tea, berries, apples, orange juice and red wine.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The cost of berries and other foods rich in antioxidants is not in question.", "answer": 2}, {"article": "\"You start doing research on that type of tumor, and you're saying, 'Oh my God, you're history.'\nStill, he cautions that the targeted treatments can't be considered cures.\nThe chemo failure was the latest in a string of personal setbacks.\nShe's been in the clinical trial for a year now, and continues to take Zelboraf (or vemurafenib generically) daily.\nAnselmo's successful treatment shows how precision medicine \u2014 tailoring therapy to each patient's genetic needs \u2014 is beginning to transform cancer care.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The article generalizes some costs, e.g. \u201cZelboraf is expensive,\u201d but no hard numbers are shared. (E.g. As of 2011, a common, six-month course of Zelboraf costs about $56,000.) With costs varying widely\u2013and astronomically\u2013among treatments, and name-brand vs. generic, this is critical and pertinent information to include. Another missing cost-related discussion regards the oral chemotherapy drug called temozolomide (which was alluded to in the article but never named). Temodar, the name-brand form of the drug, costs about $100,000 a year, while the generic alternative costs less than $10,000 a year\u2013a 10-fold difference. The cost of genetic testing ($4,000 sequencing costs per tumor) was mentioned in the on-air piece but not in the online body copy.", "answer": 0}, {"article": "CRISPR stands for \"clustered regularly interspaced short palindromic repeats.\"\nDr. Kmiec said the lung cancer work reflects an approach adopted by the Gene Editing Institute to move cautiously in developing medical applications of gene editing.\nDr. Kmiec said there are chemotherapies that have helped patients achieve remission or at least live longer and enjoy a better quality of life by significantly slowing the progress of the disease.\nHe said using CRISPR to do things like improving drug response represents the \"low-hanging fruit\" of CRISPR patient applications.\nDr. Kmiec said that as a CRISPR research program that treats patients from across the economic spectrum, his scientists are keenly aware of the challenges of making cutting edge medical treatments accessible and beneficial for all patients.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The news release mentioned this as a potential \u201caffordable\u201d way of making lung cancer treatment more effective, and that it can \u201chopefully help contain costs\u201d and provide reliability that \u201cincreases the chance that insurance companies will provide coverage.\u201d\nHowever, it doesn\u2019t mention the cost of either gene editing or chemo.", "answer": 0}, {"article": "Radiotracers work by injecting a small amount of a compound tagged with a radionuclide into patients.\nHe noted that, as of now, doctors typically rely on results of the PSA blood test and/or standard diagnostic scans to help guide treatment decisions.\nTwo prostate cancer experts said the tool, if borne out in patients, could prove very useful.\nThe researchers pointed out traditional bone scans are unable to differentiate between malignant and nonmalignant lesions.\nThe study also revealed the radiotracer could help identify cases where prostate cancer had spread to the bone.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Certainly an estimate of the cost of the radiotracer and PET scan could have been provided.\u00a0 PET scans are already in use in a number of applications \u2013 and their use is not inexpensive", "answer": 0}, {"article": "\"Women should recognize that CAD comes with some potential risks,\" Fenton said.\nDr. Daniel Kopans, a professor of radiology at Harvard Medical School and senior radiologist in the breast imaging division at Massachusetts General Hospital, said the study provides additional information to doctors and women, but has some limitations.\nWhile he calls finding more DCIS with computer-aided detection also ''likely a good thing,\" he acknowledged the debate about the possibility that a very early cancer in an elderly woman may not cause a problem in her lifetime.\nCAD is becoming more widespread, said Dr. Joshua Fenton, an associate professor of family and community medicine at the University of California, Davis, and lead study author.\n\"The good news is the use of CAD was related to finding invasive cancers at smaller sizes and earlier stages than before the CAD era,\" said Kopans, also a member of the American College of Radiology's Breast Imaging Commission.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story points out that Medicare pays an additional $11 for mammography readings that use CAD. \u00a0It would also be useful for readers to know that women can\u2019t choose whether to have their mammograms read using CAD or not using CAD.", "answer": 1}, {"article": "\"We were pleased by the results of this first clinical study,\" he says.\nThe research was presented at the American Association for Cancer Research's special conference, Colorectal Cancer: Biology to Therapy.\nAt the meeting, Ahlquist presented the results of the first clinical evaluation study, which enrolled 1,100 patients.\nAt the same meeting, other researchers reported that they have new clues about how DNA characteristics can help predict colon cancer risk.\nAlthough colon cancer is the second leading cause of cancer death for men and women in the U.S., many adults don't undergo the screenings once they reach age 50 (or earlier for those with a family history), Ahlquist told a news conference.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No mention of possible or projected costs. Other stories estimated in the $300 per test ballpark.", "answer": 0}, {"article": "\u201cShe sent me a picture of Giovanni playing in his front yard,\u201d Kefalis said.\nOne sign: Dr. Biffi is now head of the gene therapy program at Dana-Farber/Boston Children\u2019s Cancer and Blood Disorders Center.\nAnd when Kefalis learned about the Italian trial, and the fact that Amy Price had to keep going back to Milan with Giovanni and Ceci, it was clear she would use the money to help families get to Italy.\nTeichner asked, \u201cDo you believe that gene therapy is finally coming into its own?\u201d\n\nThe MLD trial, she thinks, demonstrates what\u2019s possible -- offering promise to the 30 million Americans who suffer from some 7,000 rare diseases.\nIf it hadn\u2019t been for Liviana, Amy and Brad Price would never have known to have their other children tested.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Gene therapies are astronomically expensive; Glybera, the only approved gene therapy in the world, costs around $1 million and has only been used once.\nNowhere\u00a0is the potential cost of the treatment mentioned by the reporter, despite\u00a0interviewing a woman financially supporting families to get their children into the clinical trial.\nAlthough it is impossible to say how much the experimental treatment would cost if approved, the likelihood of an extremely high price tag\u00a0should have been mentioned.", "answer": 0}, {"article": "\u201cBut there\u2019s never before been data saying how harmful stopping shortly before surgery can be.\nThe scientists had no data on how long patients had been taking statins, but only on when they stopped.\nResearchers looked at 3,021 heart surgery patients, most of whom were taking cholesterol-lowering statins.\nAfter controlling for many preoperative health and behavioral characteristics, they found that compared with other patients, those who took statins on the day of surgery had a 48 percent reduced risk of dying in the next 30 days.\n\u201cWe already knew that people on statins before surgery had a decreased risk of death,\u201d said a co-author, Dr. Yi Deng, an assistant professor of anesthesiology at Baylor College of Medicine.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There is no mention of costs in this story, but statins are not free, nor is heart surgery. A quick note about how much they cost would have been helpful.", "answer": 0}, {"article": "Autism is a group of complex brain developmental disorders characterized by impairments in social interaction, communication, and stereotypical and repetitive behaviours.\nIt is also the first clinical trial investigating the efficacy, tolerability and safety of intranasal-administered oxytocin in young children with autism.\nThe study, led by researchers at the University's Brain and Mind Centre, is thought to be the first evidence of a medical treatment for social impairments in children with autism.\nA five week treatment with the synthetic hormone oxytocin significantly improved social, emotional and behavioral issues among young children with autism, according to University of Sydney research published today in Molecular Psychiatry.\nStudy co-author and co-director of the Brain and Mind Centre, Professor Ian Hickie noted the new results were a critical first advance in the development of medical treatments for the social deficits that characterize autism.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release doesn\u2019t mention the cost of the oxytocin nasal spray sold as a generic, or under the brand names Pitocin and Syntocinon. Medical-grade oxytocin shouldn\u2019t be confused with the numerous brands of non-medical grade oxytocin sprays that are sold over-the-counter and online.", "answer": 0}, {"article": "The new research, reported Oct. 10 in the journal Nature Communications, was led by Charles Brenner, PhD, professor and Roy J.\nThe information from the mouse study subsequently helped Brenner's team design the formal clinical trial.\nMore than a decade of research on NR metabolic pathways and health effects in mice and rats had convinced him that NR supplementation had real promise to improve human health and wellness.\nThe study showed for the first time that oral NR is superior to nicotinamide, which is better than niacin in terms of the total amount of NAD+ produced at an equivalent dose.\nThe experiments also revealed more detail about NAD+ metabolic pathways.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The news release does not discuss costs. A 30-day supply, consisting of 60 125-mg tablets, is available on Amazon for $45.99, or $1.53 per day. There is just one manufacturer \u2014 ChromaDex \u2014 licensing the patented product to various companies, which package and sell it under their own labels. As a result, there is no real price competition.", "answer": 0}, {"article": "Watch Sanjay Gupta MD Saturday at 4:30pm and Sunday at 7:30am ET.\nAgatston thinks the coronary calcium scan should be routinely scheduled at age 50, like a colonoscopy, or earlier for people with family histories of heart disease.\nAgatston says relatively new imaging tests give real-time pictures showing whether plaque is building up in key blood vessels, alerting doctor and patient to an increased risk of a potentially deadly heart attack.\nThe other imaging test Agatston recommends is an ultrasound of the carotid artery, looking at plaque in the main blood vessel leading to the brain.\n\"There is a large group in the middle called intermediate risk, which may be as much as 50% of the population,\" said Dr. Erin Michos, a cardiologist at the Ciccarone Center for the Prevention of Heart Disease at Johns Hopkins University\n\nA good candidate for a coronary calcium scan, she says, would be a 50-year-old man with slightly elevated cholesterol and a father who had a heart attack.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does discuss costs. However, it low-balls what people may be actually charged for the scans, which may include facility fees, reading charges and other costs. For example, one insurance company cost calculator (https://www.alegent.com/body.cfm?id=4735) estimates the cost of heart CT scan for calcium to be more than $600 and a carotid ultrasound to be about $700 for people paying for their own scans, so instead of the \u201cless than $100 for both\u201d figure reported in this story, a person getting both scans might be hit with a bill for well over $1000. Also, the statement that these scans are \u201coften covered by insurance\u201d is misleading, since insurers are likely to cover the scans only for patients considered to have an elevated risk, not for everyone. For example, Aetna, one of the largest insurers in the United States, considers coronary calcium scoring investigational, not medically necessary. See http://www.aetna.com/cpb/medical/data/200_299/0228.html\n \n\u00a0", "answer": 0}, {"article": "But this is important enough and impressive enough to tell people about,\" said Robert Temple of the Food and Drug Administration, who spoke to reporters about the findings.\nAll new drugs are tested on pregnant animals to see whether they cause malformations, but those tests can be misleading.\nIt's considered unethical to include pregnant women in studies of new drugs unless the medication is intended to treat pregnancy-related conditions.\nAs a consequence, the labels on nearly all medications carry a statement saying their safety to fetuses has not been established.\nExposure to ACE inhibitors early in pregnancy nearly tripled the risk of birth defects, the study showed.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There was no cost comparison for ACE inhibitors and the other medications that might be used in the management of hypertension. However, since the point of the story was to point out risks, not to promote further use, costs are less of an issue in this story. ", "answer": 2}, {"article": "July 14, 2010 -- An experimental weight loss drug that targets the brain\u2019s hunger center was shown to be safe and effective for helping dieters shed pounds in a two-year study, researchers say.\nBy the end of year one, 55% of the patients in the placebo group and 45% of those taking the diet drug had dropped out of the study.\nThe company hopes to win FDA approval to market the new drug later this year.\nHe says that all the patients in the study were monitored closely for heart valve irregularities, and no difference was seen in the two treatment groups.\nThe study appears in the July 15 issue of the New England Journal of Medicine.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There is no mention of costs. If the drug works similarly to fen-phen. Why not at least mention what that drug cost? If you have to take it twice a day for a year to see any results, what might that long term therapy add up to?", "answer": 0}, {"article": "Trachoma is an eye infection caused by chlamydia and is the leading cause of preventable blindness affecting millions of people in many resource-poor regions of the world.\nThis is why the promise of a vaccine would be extremely beneficial, says David Bulir, co-author of the study.\nCo-author and McMaster PhD student, Steven Liang, explains, \"not only is the vaccine effective, it also has the potential to be widely protective against all C. trachomatis strains, including those that cause trachoma.\"\n\"Vaccination would be the best way to way to prevent a chlamydia infection, and this study has identified important new antigens which could be used as part of a vaccine to prevent or eliminate the damaging reproductive consequences of untreated infections.\"\nThe results look very promising, said senior author James Mahony, a professor of Pathology and Molecular Medicine for McMaster's Michael G. DeGroote School of Medicine and a researcher at St. Joseph Healthcare Hamilton's Research Institute where the work was performed.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Because the release is presented as if the study were conducted in humans, we would expect to see some explanation of what the vaccine might cost.\nA better news release might have commented on the potential costs (and time)\u00a0required for\u00a0testing a new vaccine and bringing it to market.", "answer": 0}, {"article": "Dr Weaver said: \"We have shown that all our patients in the study had their insulin doses reduced after taking metformin and have not suffered any serious adverse effect.\n\"The results, which indicate that metformin, a drug commonly used in the treatment of Type 2 diabetes, could also have a powerful effect in people with Type 1 diabetes is unexpected.\n\"For the first time, this study has shown metformin has additional benefit beyond improving diabetes control when given to patients with relatively well controlled Type 1 diabetes.\nResearchers studied a treatment group of 23 people aged 19-64 who had Type 1 diabetes for up to 23 years and had no evidence of heart disease.\nShe believes this new research is a major development in understanding the best ways to further improve treatment in Type 1 diabetes.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release makes no mention of costs at all, although the unit cost of the drug is both quite low and readily available.\u00a0 Diabetic patients already spend a substantive amount for their medications over their lives and knowing that the addition of this other drug would not be an undue financial burden would be a welcome piece of information. Since the study was done in the UK, one might have expected some comment on the effect of the use of this drug in a large number of type I diabetics on the health care system.", "answer": 0}, {"article": ".\nThe solution was a special device made by Kurve Technology that delivers a spray of insulin deep into the nose.\nThe problem was to find a way to get more insulin to the brain but not to the body.\nAnd patients would need a special device to get it deep into the nose.\nThe lower dose seemed more effective than the higher one.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story did not mention the cost of insulin. This information is readily available and would have provided valuable context. There will also be the cost of the specialized inhaler.", "answer": 0}, {"article": "\"More fish, more brain, less Alzheimer's,\" he tells WebMD.\nSeveral studies have linked a diet rich in certain fish to a reduced risk of Alzheimer's disease.\nThis benefit is thought to come from the omega-3 fatty acids in fish, although studies of fish oil supplements have produced disappointing results in people who already have Alzheimer's.\nNov. 30, 2011 (Chicago) -- Older people who eat baked or broiled fish at least once a week may be boosting their brain health.\nAnd people who ate baked or broiled fish at least weekly and didn't lose brain cells were much less likely to develop Alzheimer's disease or mild mental impairment, says Cyrus Raji, MD, PhD, of the University of Pittsburgh School of Medicine.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The cost of fish is not in question.\n ", "answer": 2}, {"article": "\u201cIt all depends on how you approach risk,\u201d Dr. Zelen said.\nThe question was, Did the program of mammograms and optimal new treatment with coordinated teams of surgeons, pathologists, oncologists, radiologists and nurses lower the breast cancer death rate?\nBut, cancer experts said, no one would do such a study today when mammograms are generally agreed to prevent breast cancer deaths.\nMarvin Zelen, a statistician at the Harvard School of Public Health and the Dana-Farber Cancer Institute, who was a member of the research team said even though the mammography benefit is small, if he were a woman he would get screened.\nBut, he said, whatever the effect of mammograms is, \u201call the signals here are that it is much smaller than we believed.\u201d\n\nDr. Laura Esserman, a professor of surgery and radiology at the in , said it tells her that \u201cif you get the same treatment and the outcome is the same if you find it earlier or later, then you don\u2019t make a difference when you find it early.\u201d\n\nAnd screening has a cost, Dr. Welch said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "\n\n\nThe story does not mention the costs of screening or follow-up tests or treatment \u2013 to the individual or, collectively, to society.\u00a0 Those costs are significant.\u00a0 ", "answer": 0}, {"article": "\"Not every cancer cell becomes a metastatic cancer cell.\nIn the new study, if even one cell was detected in the bloodstream, a woman had a greater chance of her cancer recurring and of dying.\nThe more tumor cells a woman had in her bloodstream, the higher the likelihood of relapsing or dying, according to the report.\n\"This may help with prognosis and staging of the cancer and, in the future, with targets for breast cancer treatments,\" said study lead author Dr. Anthony Lucci, a professor of surgery at the University of Texas MD Anderson Cancer Center, in Houston.\nAnd in an accompanying comment article, Justin Stebbing, a professor in the department of surgery and cancer at Imperial College in London, said that \"despite increasing evidence supporting the use of [circulating tumor cells] as biomarkers, how this information can be integrated into present practice is uncertain.\"\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No information is given about the projected cost of the test, despite the projection that \u201cthe test may not be far off in terms of clinical practice.\u201d", "answer": 0}, {"article": "?\nTo prove it is effective in reducing hot flashes, the Mayo team needed to demonstrate that it was superior to sham, or placebo, treatment.\nExperts in women's health say they are one of the most common ailments for which women use alternative medicine and that interest in non-hormonal treatments has increased as a result of the WHI findings.\nThat's because hot flashes have a high placebo-response rate: Symptoms often improve, at least temporarily, with a dummy treatment.\nThe 2,000-year-old treatment is widely used around the world, according to the National Center for Complementary and Alternative Medicine (NCCAM), part of the National Institutes of Health (NIH).\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The article does not include any information on the cost of acupuncture or on whether insurers cover this for any indications. ", "answer": 0}, {"article": "It also triggers the release of the stress hormone norepinephrine, as well as the mood regulator serotonin.\nAnd because hormone treatment for breast cancer typically makes the hot flash experience even worse, Razzini added, acupuncture could be a useful tool for helping such patients \"stay on their therapy and improve their quality of life.\"\nRazzini didn't know how much American patients might have to pay for such treatment, but added, \"Compared to other effective treatments such as antidepressants, (acupuncture) should be less expensive, and, for sure, more safe and feasible.\"\n\"Acupuncture together with enhanced self-care for three months is effective in reducing hot flashes in women with breast cancer,\" said study author Giorgia Razzini, a clinical trial project manager in the oncology unit of Ospedale di Carpi (Carpi Hospital), in Bologna, Italy.\nThose in the acupuncture group also seemed to have a generally higher overall quality of life in terms of both physical and mental health, with no serious side effects, the study authors said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does address cost, but doesn\u2019t say how much that cost might be. As the story states: \u201c[the researcher] didn\u2019t know how much American patients might have to pay for such treatment, but added, \u2018Compared to other effective treatments such as antidepressants, (acupuncture) should be less expensive, and, for sure, more safe and feasible.'\u201d\nWhile we always try to give the benefit of the doubt in cases where the story at least attempts to address cost, the characterization here seems debatable enough to merit a Not Satisfactory rating.\nA quick internet search finds that acupuncture therapy costs anywhere from $50 to more than $120 per session. That\u2019s not insignificant (and it wasn\u2019t hard to look up). Given that the study in the story had patients go through 10 acupuncture sessions, this could cost a patient at least $500, and possibly more than $1,200.\nAlso, while other methods for treating hot flashes, such as medication, are covered by health insurance, acupuncture is not necessarily covered.", "answer": 0}, {"article": "Median follow-up was 61 months.\nIn low-risk patients, the cancer control rates was superior to historical controls.\nActuarial five-year nadir+2 RFS was 97.1 percent for all patients, representing 97.3 percent of low-risk and 97.1 of intermediate-risk patients.\nAt five years following SBRT, 97 percent of patients were free from prostate cancer progression.\n\u201cAfter following patients for more than five years, we found that serious side effects from a brief course of SBRT were uncommon and that cancer control rates were very favorable compared to historical data.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The news release quotes lead researcher Robert Meier, MD, saying previous studies have shown SBRT to be \u201ca cost-effective and faster alternative to IMRT\u201d but does not provide any detail as to the specific costs of either procedure. In fact, the difference is substantial. A 2014 study in the Journal of Clinical Oncology examined Medicare claims data showed a mean treatment cost of $13,645 for SBRT versus $21,023 for IMRT. And a 2012 study in the Journal of Oncology Practice concluded that SRBT has \u201cgreat potential cost savings\u201d for the health care system, with an average cost of $22,152 versus $35,431 for IMRT.\nOne could also consider the cost of side effects as well as need for future treatments.", "answer": 0}, {"article": "Why?\nThe current study, she added, shows that \u201chigh quality (stroke) care is available in hospitals on the weekends and weekdays.\u201d In fact, care might even be more aggressive on weekends.\nOverall, Kazley added, this study offers \u201cgood news that indicates that the quality of care is similar regardless of when patients present at the hospital for treatment.\n\u201cEven in a country with universal health insurance coverage (such as Canada), disparities in resources, expertise, or the number of healthcare providers working during weekends\u201d may affect the stroke mortality rate, the researchers concluded.\nIn fact, that authors note that patients who received tPA were more likely to die in the hospital.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "As with the HealthDay report, this article did not mention costs.", "answer": 0}, {"article": "Antidepressants frequently prescribed to help treat bipolar depression do little to help patients recover, according to a new study that adds fuel to a long-running debate over how to best treat an affliction that affects an estimated eight million Americans.\n\nBipolar disorder, also known as manic depression, is a serious mental illness that involves dramatic swings in mood, including frequent and lengthy periods of depression. Along with mood-stabilizing drugs like lithium, many physicians also treat the disorder with common...", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not mention the cost of medication to treat bipolar disorder; however, the story and evidence from the study cited\u00a0are advocating fewer anti-depressant medications.\u00a0\u00a0 So cost seems less of an issue in this case.\u00a0 However, the story missed an opportunity to talk about the cost of bipolar disease (90 million work loss days annually in the U.S) and associated health care/treament costs.", "answer": 2}, {"article": "Botox is now being used by men, some of whom did not even run for President. The number of men in the U.S. who paid to get a series of tiny injections in their face nearly tripled from 2001 to 2007--to 300,000, or about 7% of the total Botoxed population. And despite the recession, those numbers aren't going down yet; one of the many things the laid-off cannot afford is to look their age.\n\nMen usually get Botox to remove those two vertical lines between their eyebrows that make them look angry and confused and thus, one could argue, masculine. They...", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story states that Botox treatment costs $500 to $600 per \"session\" when provided by one Palm Springs-based, housecall-making doctor. \nThe cost of Botox varies geographically, and the terms \"injection,\" \"treatment\" and \"session\" mean different thing to different practitioners. Actual price paid to get a certain result can vary widely. The article should at least have implied this.\u00a0 ", "answer": 0}, {"article": "At the end of the study, the group of volunteers who had used the dapivirine ring had 27% fewer HIV infections than a control group who had a placebo ring with no drug, the study found.\nBut it\u2019s now known that, when taken properly, Truvada cuts new cases of HIV by at least 92%.\nOne of the new studies, published today in the New England Journal of Medicine, tested the ring in more than 2,600 women in four countries \u2014 Malawi, SouthAfrica, Uganda, and Zimbabwe \u2014 over nearly two years.\nBut 1 in 3 infections were prevented overall \u2014 and that\u2019s huge.\u201d\n\nWarren noted that other rings with antiretrovirals are also being developed, as well as rings that could offer multipurpose protection, against not only HIV but pregnancy.\n\u201cThat individual control of prevention is so powerful.\u201d\n\nThe dapivirine ring has been in development for more than a decade, and the the new studies are the first to show that it prevents HIV transmission.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story would have benefited by spending even one sentence on cost, since HIV is especially prevalent in countries with few resources. Will the ring be cheaper or more expensive than the pill? If the ring must be replaced monthly, what does that mean for the cost, and will people be more likely to fail to buy the replacements because of cost?\nThere was a lost opportunity here to compare the cost of the vaginal ring versus Truvada, the currently available option for pre-exposure prophylaxis.", "answer": 0}, {"article": "Data were collected for eight years, ending in 2014.\nSince pain relief from rTMS increases a few days after treatment, weekly treatment sessions were selected to try to sustain pain relief at treatment intervals that could be maintained on an outpatient basis.\nIn 2014, a review[2] suggested that there is probable efficacy (a level A recommendation) for short-term rTMS treatment of neuropathic pain, including central post-stroke pain, but did not speak to long-term efficacy.\nOf 18 patients in the open-label series, 11 patients achieved satisfactory-to-excellent pain relief.\nOnce that phase had shown that rTMS did reduce the patients\u2019 pain, an open-label treatment phase began.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The FDA approved the use of rTMS for chronic depression several years ago, so it should have been easy to approximate the costs of a 12-week \u00a0course of therapy. The usual cost of the use of rTMS for depression is $6,000 to $10,000 for 4 sessions per week for 5 weeks. So, continuing with treatment weekly for an ongoing basis (the approach advocated here) would appear to be relatively costly.", "answer": 0}, {"article": "\"If you have your choice, you want to get poked with a needle or you want to try this?\nAnd the patch can be administered by people who aren't trained health professionals.\nGomaa's hope is that vaccine patches will cost less than vaccinations do now.\nA number of the people in the flu patch study applied it to themselves.\nA flu vaccine patch is not yet available to the public.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The article provides information about the cost of both the flu vaccine patch and the jet-injector. The cost of giving flu vaccine by nasal spray isn\u2019t provided.", "answer": 1}, {"article": "Eventually, the overwhelmed system leaves these sugars, in the form of glucose, to build up in the blood, which can lead to obesity, damage the heart, and cause other metabolic problems.\nThat\u2019s because experts believed that once the pancreatic islet cells, the body\u2019s insulin-making factories, were compromised, they couldn\u2019t be made to work again.\nMore work will be needed to confirm what benefit betatrophin might have on diabetic patients before that might be possible, however.\n\u201cThat\u2019s a huge difference.\u201d\n\nWhat\u2019s more, it appears the cells are relatively long-lasting, which could indicate they are robust enough to bring glucose levels in diabetics under control.\nWhat\u2019s more, they also surmised that only a specialized set of beta cells were equipped to make insulin, and that once diabetes set in, too few of these cells remained to pump out the critical hormone.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Not applicable.\u00a0 This research is so preliminary that there\u2019s no telling what any treatment resulting from it might cost.", "answer": 2}, {"article": "An electromagnetic wave then agitates water molecules in the surrounding tumor tissue, producing friction and heat that eventually destroy the tumor.\nU.S. researchers say the technique certainly shows promise.\nIn a preliminary study, the technique, called microwave ablation, eliminated lung tumors in 19 of 28 patients.\nThe findings were presented here at the annual meeting of the Radiological Society of North America.\nThe procedure, which costs about $2,000, takes about an hour, and the patient is typically kept overnight in the hospital for observation.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story says that the procedure \u201ccosts about $2,000, takes about an hour, and the patient is typically kept overnight in the hospital for observation.\u201d That\u2019s good information. Whether most insurance companies cover the therapy would have been good additional context. And the story could have included the costs for complications from the procedure \u2013 with 8 of the patients experiencing partial lung collapse with respiratory symptoms, this drives up the cost substantially.\nNonetheless, we\u2019ll give the story the benefit of the doubt on this criterion.", "answer": 1}, {"article": "High cholesterol levels can increase the risk of heart attack.\n\"And so I would caution against anybody in the U.S. increasing their selenium intake based on what we found, because we also know there's an increased risk for type 2 diabetes when you increase selenium intake if you are already at a high level of blood selenium levels.\"\n\"Overall, the evidence is inadequate to establish a protective role of selenium in cardiovascular disease or to recommend selenium supplementation to improve cardiovascular health,\" he said.\nThe finding comes from a six-month examination of the impact of various dosages of the supplement on the cholesterol levels of healthy people in England.\nHowever, the safety of selenium has not been studied, and the authors said the findings weren't significant enough to recommend supplementation of the trace mineral.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The cost of selenium supplements probably isn\u2019t a big issue for most individual consumers, but across our society the costs are\u00a0substantial. Some discussion\u00a0of this would have been appropriate.", "answer": 0}, {"article": "At the heart meeting in March, researchers will also provide details on risk reduction for each of the components, such as non-fatal heart attack, non-fatal stroke, and heart-related death.\nThe company said Repatha would be well on its way to becoming a $1 billion seller if all prescriptions written had been filled.\nNo new safety problems cropped up in the 27,500 patient study called Fourier, Amgen said.\n\u201cThese results show unequivocally the connection between lowering LDL cholesterol with Repatha and cardiovascular risk reduction, even in a population already treated with optimized statin therapy,\u201d Amgen research chief Sean Harper said in a statement.\nThe primary goal also included need for a new artery-clearing procedure and hospitalization for angina.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "To its credit, the story mentions the high cost of the drug Repatha \u2014 $14,000 per year \u2014 and cites reluctance on the part of some insurers to cover that cost without more substantive data on its efficacy. \u00a0The news release issued by the drug\u2019s manufacturer, Amgen, didn\u2019t include either point.", "answer": 1}, {"article": "Previous studies have found that aspirin users enjoyed a lower risk of colon cancer; a trial published earlier this year concluded that people who take a daily aspirin have as much as a 46% lower risk of colon, lung and prostate cancers, compared with non-users.\nBut given the growing body of data linking aspirin use to lower cancer risk, the researchers say it may be worth factoring in the drugs\u2019 anticancer effects when patients and doctors discuss options for pain relievers.\nIt\u2019s not the first study to show a potential anticancer effect of aspirin and other similar painkillers \u2014 a class of medications known and nonsteroidal anti-inflammatory drugs, or NSAIDs.\nAn aspirin a day could keep skin cancer away, according to a new report in the journal Cancer.\n\u201cGiven the high skin cancer incidence and the widespread and frequent use of NSAIDs, a preventive effect of these agents may have important public health implications,\u201d the authors, led by Sigrun Alba Johannesdottir from Aarhus University Hospital in Denmark, wrote.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The cost of aspirin and other NSAIDs is not in question.", "answer": 2}, {"article": "\"The work by [first author] Price et al.\nTesting the effect of resveratrol on SIRT1 in mice was difficult, Sinclair said.\nWe should be very careful about claiming the importance of resveratrol for medical purposes.\nWhile studies involving animals can be useful, they frequently fail to produce similar results in humans.\nInstead, the goal is to develop synthetic resveratrol compounds that activate SIRT1 and could be taken as medication.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Not applicable.\u00a0 It\u2019s understandable that costs were not discussed at this early animal-model stage of research.", "answer": 2}, {"article": "A sticky mucus clogs organs, particularly the lungs and liver.\nIn an editorial accompanying the study, Dr. Pamela Davis, of Case Western University paraphrased Winston Churchill, \u201cThis study is also a great victory in the war against genetic diseases and marks the end of the beginning for the treatment of the cystic fibrosis defect.\u201d\n\nIvacaftor has been submitted to the FDA for approval, and could be available next year, according to Konstan.\nAbout 1,000 new cases are diagnosed each year, according to the Cystic Fibrosis Foundation, and the average person with the disease dies before age 40.\nThat trial is ongoing and the treatment is at least four or five years away from approval, but if it works, Beall says, it could help 90% of the people with cystic fibrosis.\nThere is no cure for this disease and existing treatments just help alleviate some of the symptoms.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "\n\n\nAlthough the company that wants to sell this drug has yet to announce a price, blogs that follow pharmaceutical companies quote a Wall Street analyst who predicts the drug will cost about $150,000 a year. That massive price tag for a drug that patients likely would have to continue to take for their entire lives is certainly something that readers should be told about.", "answer": 0}, {"article": "Magnetic resonance imaging measured cortical thickness and resting-state functional connectivity (rsFC) before training, after training and three months post-training.\nThe findings, published in Brain and Behavior, further suggest that changes in cortical thickness and neural network connectivity may prove an effective way to quantitatively measure treatment efficacy, an ability that has not existed until now.\nBuilding upon previous research, the study challenges the widely held belief that recovery from a TBI is limited to two years after an injury.\nThe knowledge-based training group learned information about the structure and function of the brain as well as the effects of sleep and exercise on brain performance.\nOver an eight-week period, the strategy-based training group learned strategies to improve attention and reasoning.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The news release does not mention how much the brain training costs. The release could have stated that the cost of cognitive training usually includes repeat visits to a therapist.", "answer": 0}, {"article": "Platelet-rich plasma (PRP) is blood that has been spun in a centrifuge to separate the blood cells.\n\u201cPRP is probably the best treatment for chronic refractory lateral epicondylitis if it is used after classical types of treatment like rest, braces, nonsteroidal anti inflammatory drugs, cortisone injections or physiotherapy have all failed,\u201d Thanasas said.\n\u201cWhole blood treatment is a god alternative in remote areas or in health systems that do not support financially the use of PRP,\u201d he told Reuters Health in an email.\n\u201cThere is now a solution for patients suffering from unrelenting \u2018tennis elbow,\u2019\u201d said Christos Thanasas from Henry Dunant Hospital, Athens, who led the study.\nThanasas added that further studies are needed to see how and when the PRP therapy is most effective, adding that he and his colleagues are about to start trials of PRP therapy in which different concentrations of white blood cells are used to see how this affects the regeneration of tendons.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story made no mention of costs. Given that platelet-rich plasma already is being used for a variety of conditions, including tennis elbow, it would not have been difficult to get a range of costs. A basic Google search reveals a number of sources declaring that insurance plans do not typically cover plasma injections. This all would have been good information for the story.", "answer": 0}, {"article": "Most thyroid cancers can be treated successfully, but advanced cases can be difficult to treat, especially if they do not respond to radioactive iodine (RAI) therapy.\nIn blocking this activity, these new immunotherapy drugs help T cells get back to work in protecting the body.\nThe work is being presented at the American Society of Clinical Oncology (ASCO) Annual Meeting which begins tomorrow in Chicago.\nAs well, at least when used as single agents, these agents tend to confer side effects that patients find much more tolerable than those associated with chemotherapy.\nThis appears to be due to increased use of technology to detect thyroid nodules that may not otherwise been found previously.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release doesn\u2019t mention cost. Immunotherapy drugs like Keytruda that are already on the market have received wide attention specifically because of their high prices..The cost of Keytruda is easily obtainable and is approximately $5,000 per 50mg single use vial. Although the dose was 10mg every two weeks, that would require two vials at approximately $10,000 per month drug costs or $240,000 for the two-year treatment program.", "answer": 0}, {"article": "The investigators found that the less salt people ate, the more likely they were to die of heart disease \u2014 50 people in the lowest third of salt consumption (2.5 grams of sodium per day) died during the study as compared with 24 in the medium group (3.9 grams of sodium per day) and 10 in the highest salt consumption group (6.0 grams of sodium per day).\nBut, Dr. Alderman said, the new study is not the only one to find adverse effects of low-sodium diets.\nLowering salt consumption, Dr. Alderman said, has consequences beyond blood pressure.\n\u201cThey do not tell you what will happen if you change peoples\u2019 sodium intake.\u201d\n\nWhat is needed, Dr. Alderman said, is a large study in which people are randomly assigned to follow a low-sodium diet or not and followed for years to see if eating less salt improves health and reduces the death rate from cardiovascular disease.\n\u201cThe low-salt advocates suggest that all 300 million Americans be subjected to a low-salt diet.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "", "answer": 2}, {"article": "Toenail fungus causes nails to become thick, yellow and brittle in a way that looks pretty ugly and can be painful.\n\u201cI\u2019ve had patients come in who have had laser procedures and not seen long-term success.\u201d\n\nFirestone also says that over-the-counter antifungal nail creams and ointments rarely work because they can\u2019t penetrate the nail root.\nIn this case, there is a chance.\u201d\n\nEven John Strisower, the founder of PinPointe USA, says patients should expect at least a minimal reinfection within five years after laser treatment.\nThe treatment, in which the podiatrist aims a laser beam at the patient\u2019s toenails to kill the organisms that cause the fungus, costs about $1,000 and is not covered by insurance because it is considered an aesthetic procedure.\nThere\u2019s no one route of infection, but sources include pedicures and locker room showers.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story did a good job on this point. It noted that one treatment \u201ccosts about $1,000 and is not covered by insurance.\u201d It put this into a larger context by saying, \u201cLast year, Americans spent $354 million on prescription and over-the-counter treatments for toenail fungus, according to IMS Health, a health-care information company.\u201d And it described at the end of\u00a0the story how one patient\u00a0has tried to fend off reinfection by buying a $130\u00a0sterilization kit for his shoes.", "answer": 1}, {"article": "EULAR aims to promote, stimulate and support the research, prevention, and treatment of rheumatic diseases and the rehabilitation of those it affects.\n\"Findings from our study have shown that adopting a TNFi dose reduction strategy can still meet this objective, with no compromise on symptom control for the patient and offering a more cost-effective option by substantially reducing the high drug costs associated with TNFi maintenance therapy.\"\nIn some cases however, patients maintained a clinical response after stopping the TNFi altogether.\nTo be eligible, patients had to demonstrate stable low disease activity (DAS28 less than 3.2) for over three months.\n\"The optimal management of RA involves achieving the lowest possible disease activity - ideally remission, and then maintaining this level of control,\" said lead author, Dr. James Galloway, Department of Rheumatology, King's College Hospital NHS Foundation Trust, UK.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The news release includes a quote from the lead author, Dr. James Galloway, saying that his study findings offer \u201ca more cost-effective option\u00a0by substantially reducing the high drug costs associated with TNFi maintenance therapy.\u201d\u00a0But it does not specify how much the drug costs or how much might be saved with the new strategy.", "answer": 0}, {"article": "But the F.D.A.\nOther companies, still doing their studies, did not yet have data to examine.\n\u201cThe 20 percent who had amyloid, though they were still statistically in the normal range, did worse on every memory test than the control group.\u201d\n\nWhat, Dr. Skovronsky asked, did that mean?\nThe tests, though, were not necessarily specific for Alzheimer\u2019s and none had been studied to see if they accurately predicted plaque on autopsy.\nWhat if the same pattern occurred in people without Alzheimer\u2019s?\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There is one glancing reference to cost. \"The type of scans used in this study, PET scans, are expensive and patients have to go to a scanning center, get injected with a radioactive dye, wait for the dye to reach their brain and then have a scan.\" How expensive? (The average cost\u00a0 of a PET scan is $3-6,000.) And, if this scan is truly the revolution that this story is making people believe it is, every person in America will want to have this scan done when they turn 50, maybe younger. What would that do to health care costs?", "answer": 0}, {"article": "Cannabidiol, or CBD, is a compound in the cannabis plant that does not contain psychoactive properties that induce a high.\nThis new, randomized, controlled clinical study eliminated those concerns as participants and their physicians did not know if they were on CBD or placebo, say the study authors.\nThe study included a liquid pharmaceutical formulation of CBD, called Epidiolex, which is manufactured by GW Pharmaceuticals and has not been approved by the U.S. Food and Drug Administration.\nThe new study confirms results from a December 2015 open-label expanded access program led by Dr. Devinsky that reported reductions in seizure frequency.\nFor the study, 120 children and adolescents with Dravet Syndrome between the ages of 2 and 18 years were randomized across 23 sites in the United States and Europe to receive either CBD 20 mg/kg or placebo added to their existing treatment over a 14-week period.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There was no mention of the cost of the drug but the NYT reported last year that Epidiolex could cost from $2,500 to $5,000 per month. Since the drug isn\u2019t FDA approved, it\u2019s too soon to know whether its cost will be covered by health insurance.", "answer": 0}, {"article": "While the disease is rare, with about 3,100 new diagnoses and 330 deaths in the United States each year, it often goes undiagnosed until it affects vision. Sacks \u2014 known for books including Awakenings and The Mind's Eye, in which he tells the story of his own cancer \u2014 said his symptoms hit suddenly, wiping out a triangular chunk of the vision in his right eye.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story provides no information about costs, in part because the patient who is the focus of the story was participating in a clinical trial and likely received the treatment at no cost. Even if that was the case, however, the story should have discussed how much this type of treatment would cost, if it became available outside the context of a clinical trial.", "answer": 0}, {"article": "\u201cThis wakes up the immune system and says, \u2018Hey!\n\u201cAfter that, there were no side effects.\u201d\n\nSuch muted side effects point to a major benefit of this new approach, doctors and patients said.\nJohn O\u2019Donnell, a retired math teacher in Piscataway, N.J., was one of those who tried the combination therapy, but ultimately responded only to Imlygic.\nApproved by the Food and Drug Administration on Tuesday for treating advanced-stage melanoma, the virus \u2014 called Imlygic, which was developed in part in a Massachusetts lab \u2014 is a modified version of the herpes virus that both attacks the cancer and sparks the immune system into action against tumors.\n\u201cThis is huge for the whole field, and for cancer patients,\u201d said John Bell, a senior scientist at the Ottawa Hospital Research Institute in Canada.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story nods to costs when it says the company will charge the patient $65,000 for a treatment. But they actually will be trying to charge insurance companies this amount.\u00a0\u00a0How widely will it be covered and when? How many courses of treatment will be necessary? We\u2019ll give the benefit of the doubt here but the story could have done more to clarify.", "answer": 1}, {"article": "There are many factors that cause obesity but there is a growing weight of evidence that shows obesity is not just caused by a behavioural disorder, such as a lack of self-control, but that many overweight people are physically addicted to foods rich in fat and sugar.\n\"It has been shown to reduce impulsiveness in a variety of disorders such as alcohol dependence, schizophrenia and ADHD.\n\"Modafinil was found to have an effect on impulsivity in healthy individuals and so would be able to have an even bigger effect on food addicts, who are lacking in certain types of dopamine,\" said Professor Vlaev.\nThe drug, which is sold under a wide variety of brand names around the world, was one of two drugs tested by researchers, the other being Atomoxetine.\nThere is mounting evidence to show that there is a substantial number of obese people who are food addicts because they have an inability to control their impulsive actions and this drug has shown it can give them more control, which will help overweight people lose weight and so improve their health.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There was no mention of the cost of Modafinil. According to GoodRx, a supply of 30 tablets containing 200 mg ranged from $86 at Safeway to $141 at Target on the day of our web search.", "answer": 0}, {"article": "A drug-coated stent made by Abbott Laboratories that is awaiting U.S. regulatory approval is as safe as, and potentially more effective than, the market-leading version of the heart device made by Boston Scientific Corp., according to findings presented Tuesday at the EuroPCR conference in Barcelona.\n\nClinical-trial data analyzed by Abbott two years after its Xience V stents were implanted in patients are likely to reassure investors and regulators about the product's long-term safety and could restore some investor confidence...", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story did not project any cost of this new stent; it did provide estimates for the amount of sales revenue generated by those drug-eluting stents that are currently available to consumers. \u00a0(The story also did not provide information about how much these stents cost consumers either.) \u00a0There was no discussion of associated costs for the medications that need to accompany the use of these drug eluting stents.", "answer": 0}, {"article": "As the ovaries curb production of the hormones estrogen and progesterone in the years leading up to menopause and afterward, women can experience symptoms ranging from irregular periods and vaginal dryness to mood swings and insomnia.\nFor women who started hormones in their 60s or 70s, however, there wasn\u2019t a meaningful difference in death rates according to whether they got the treatment or a placebo during the initial years of the study.\nAfter 18 years, including both the treatment period and a decade or more of follow-up, women\u2019s age when they joined the study no longer appeared to significantly influence death rates.\nWith additional years of follow-up, it also appears that the increased heart attack risk associated with HRT in the initial results from the WHI trials is limited to older women, McNeil added.\n\u201cWomen seeking treatment for distressing hot flashes, night sweats or other menopausal symptoms may find the mortality results reassuring,\u201d said lead study author Dr. JoAnn Manson of Brigham and Women\u2019s Hospital and Harvard Medical School in Boston.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No information is given on the cost of a typical course of treatment.", "answer": 0}, {"article": "\"However, if your child is overweight or obese I recommend that you consult your primary care physician for advice, and consider having their vitamin D levels tested.\"\nChildren who took vitamin D had a significantly lower BMI, the researchers found.\n\"Although these initial findings indicate that vitamin D could be used in the treatment of obesity, there remains a lack of evidence on the safety and long-term effects of supplementation, particularly if there is no vitamin D deficiency,\u201d said Charmandari.\nThe researchers randomly assigned 117 children with supplements containing 50,000 IU vitamin D for six weeks, while the others acted as the control group.\nIn their next investigation, the team will study whether vitamin D supplements can improve the health of obese children and adolescents who have been diagnosed with disorders linked to obesity, such as high cholesterol, high blood sugar levels, and high blood pressure.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The cost of Vitamin D is not mentioned, but the cost is so low we\u2019ll rate this N/A. (The study says about 100 of the 200 participants were given 50,000 IU of the vitamin per week, which works out to about 20 cents per month.)", "answer": 2}, {"article": "Researchers from Leeds Metropolitan University in the U.K. steeped thyme, marigold, and myrrh in alcohol to make what's called a tincture, and then tested them on the bacteria that cause acne.\nBut some U.S. dermatologists are quick to caution that while intriguing, this research is still preliminary, and thyme-tinged acne treatments are not yet ready for prime time.\nThey all had greater antibacterial effect after five minutes compared to lab specimens exposed to plain alcohol, but thyme was the most potent.\nIn fact, the thyme tincture was more powerful than standard concentrations of benzoyl peroxide, which is the active ingredient in many acne products.\nThe new findings were presented at the Society for General Microbiology's Spring Conference in Dublin.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The cost of thyme \u2013 or the proposed tincture \u2013 is not in question for the moment.", "answer": 2}, {"article": "Oxytocin,which is produced in abundance when a mother is breast-feeding her baby, is known as the \"bonding\" hormone.\nAlso, scientists would need to come up with a different method of delivery, Young said.\nWhile there are drugs for the secondary symptoms of autism, such as irritability and aggression, doctors have nothing yet for the core symptoms in the areas of language, social interaction and intellectual deficits.\n\"It's not clear whether this would be effective at all in children or in young adults who had intellectual problems,\" warned Young.\n\"I really want to encourage clinical trials in this area because of its potential significance, but we have to be very careful in terms of safety data,\" Lajonchere said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Although this is a very preliminary study, some mention of costs should have been included, even if simply to note that the cost of potential treatments is unknown at the present time.", "answer": 0}, {"article": "For more information on Down syndrome, visit the U.S. National Library of Medicine.\nIf larger clinical trials confirm the results, the test could become standard practice, Patsalis said.\nIt also can identify Down syndrome in the 11th week of pregnancy, early enough for a woman to end her pregnancy if she chooses, Patsalis said.\n\"With our method we identify all normal and all Down syndrome [pregnancies],\" Patsalis said.\nDr. Brian Skotko, clinical fellow in genetics at Children's Hospital Boston and a spokesman for the National Down Syndrome Society, said this study has widespread implications for the incidence of Down syndrome.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Only mention of cost was the researcher\u2019s quote:\u00a0\u201cThe cost is much lower than the invasive procedures.\u201d\u00a0 Oh?\u00a0 What is that cost?\u00a0 How much lower?\u00a0 We\u2019re not told.", "answer": 0}, {"article": "Infection with H. pylori is associated with increased risks of stomach and throat cancers.\nThe findings, reported in the Canadian Medical Association Journal, give some extra weight to fecal occult blood testing (FOBT) as a valid option for early detection of colon cancer.\nBut as far as cutting the risk of death from colon cancer, stool testing is similarly effective, according to the U.S. Preventive Services Task Force.\nImmunochemical FOBT is now largely replacing the older test.\nA screening colonoscopy averages around $3,000.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Costs of FOBT and of colonoscopy were included.", "answer": 1}, {"article": "The requested URL /usnews/health/articles/070520/28diet.b.htm was not found on this server.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "\nAlthough the brief does not mention costs, calcium supplements are available without a prescription and consumers can easily determine their costs.\n", "answer": 2}, {"article": "Schafer Cardiovascular Research Fund, the Johns Hopkins Magic That Matters Research Fund for Cardiovascular Research, grants from the National Center for Advancing Translational Sciences (UL1-TR-000040 and UL1-TR-001079), and contracts from the National Heart, Lung, and Blood Institute (HHSN268201500003I, N01-HC-95159, N01-HC-95160, N01-HC-95161, N01-HC-95162, N01-HC-95163, N01-HC-95164, N01-HC-95165, N01-HC-95166, N01-HC-95167, N01-HC-95168 and N01-HC-95169).\nThus, even though their calculated heart disease risk is relatively low and their blood pressure is below traditional cutoffs for treatment, the researchers say people in this category with calcium over 100 are high risk and may benefit from more aggressive blood pressure treatment.\nIn the study, published on Jan. 10 in Circulation, the researchers say these calcium scores allow physicians to go beyond the traditionally calculated risk factors to determine which blood pressure treatment strategy may be most appropriate for a particular patient.\nUsing data from a national study, Johns Hopkins researchers determined that using heart CT scans can help personalize treatment in patients whose blood pressure falls in the gray zone of just above normal or mild high blood pressure.\nPreviously, the appropriate blood pressure treatment for these patients used risk calculations and some guesswork, potentially leaving many vulnerable to heart disease or taking drugs they don't need.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The news release says that coronary artery calcium scans \u201caren\u2019t usually covered by insurance and can range in cost from $100 to $400.\u201d", "answer": 1}, {"article": ".\nAlthough there is ongoing debate regarding the safety and effectiveness of vaginal laser surgery, a new study suggests that it may be effective, especially after multiple treatments.\nThe results of this small, retrospective, non-sham-controlled study demonstrated that this type of laser surgery was particularly effective in reducing the intensity of dyspareunia (painful sex) and dryness.\nStudy results are published in the article \"Microablative fractional CO2 laser for the genitourinary syndrome of menopause: up to 12-month results.\"\n\"This study adds to the literature on vaginal laser therapy for GSM.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The cost of CO2 laser therapy is not mentioned.\nMuch of the CO2 laser treatment in the US is applied to skin \u2014 often for wrinkles, scars, discolorations, or people who want to look younger. According to WebMD such \u201claser skin resurfacing\u201d cost an average of $2,330 in 2016.\nHowever, it\u2019s unclear if vaginal laser therapy would be comparable in terms of duration, equipment involved, or cost.", "answer": 0}, {"article": "A widely anticipated study suggests that hormone therapy started soon after menopause can ease depression, anxiety, hot flashes and other adverse symptoms that many women face, without increasing risks for cardiovascular disease.\n\nThere was no increase in breast cancer, stroke, heart attack or blood clots, but the study's researchers said the sample size was too small and the study time too short to draw firm conclusions.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not detail costs associated with estrogen and progesterone hormone therapies. For example, are low-dose estrogen pills or transdermal estrogen patches comparable in price?", "answer": 0}, {"article": "\"Everyone heals differently.\nThere also isn't a great deal of information on how effective medications or home exercise programs are for treating neck pain, the researchers noted.\nThere are different pathways to healing, and whether you feel you're better off with chiropractic, home exercises or medications, this study shows that all three are basically just as effective.\nThe goal of the home-exercise program was to improve movement in the neck area.\nAll three experts said anyone experiencing neck pain needs to have it evaluated to make sure there isn't a serious or correctable cause of the pain.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "It\u2019s too bad this story didn\u2019t mention costs. Considering that the trial found only small differences in the effectiveness of the treatments, it seems that cost might be a key deciding factor for many people with neck pain. It\u2019s notable that two educational sessions about home exercise were as effective as 15 chiropractic sessions.", "answer": 0}, {"article": "AsthmaNet is a nationwide clinical research network created by the NHLBI in 2009.\nAsthmaNet studies are currently being conducted in 14 states.\nThe study, funded by the National Heart, Lung, and Blood Institute's (NHLBI) asthma network (AsthmaNet), appears in the August 18, 2016, issue of the New England Journal of Medicine.\nThe Division of Pediatric Pulmonology and Allergy/Immunology at UH Rainbow is currently recruiting for a number of asthma-related clinical trials.\n\"Previous observational studies had suggested that acetaminophen use was associated with asthma symptoms,\" says Kristie Ross, MD, MS, Clinical Director, Division of Pediatric Pulmonology, Allergy/Immunology and Sleep Medicine at University Hospitals Rainbow Babies & Children's Hospital (UH Rainbow) and co-author on the study.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Like the Boston Children\u2019s Hospital news release, the University Hospitals Case Medical Center news release does not address costs. The acetaminophen medication used in the study, Little Remedies, costs about 50 percent more than Children\u2019s Advil \u2014 $8.86 for 4 fluid ounces versus $4.96, respectively \u2014 at Walmart. It would have been helpful to include the costs of the generic versions of these drugs which could be significantly lower than brand name drugs.\nSince costs are not mentioned in the news release, we give it a Not Satisfactory rating here.", "answer": 0}, {"article": "But their results were greeted with skepticism by some experts who say they may have overestimated the benefit.\nThe study\u2019s conclusions contrast with those of a report last year by the United States Preventive Services Task Force, an independent group that issues guidelines on cancer screening, questioning the benefit of screening women younger than 50.\nThe new study took advantage of circumstances in Sweden, where since 1986 some counties have offered mammograms to women in their 40s and others have not, according to the lead author, Hakan Jonsson, professor of cancer epidemiology at Umea University in Sweden.\nThe study\u2019s authors include Dr. Stephen Duffy, an epidemiologist at the University of London, and Dr. Laszlo Tabar, professor of radiology at the University of Uppsala School of Medicine in Sweden, who have long been advocates of mammography screening.\nResearchers reported Wednesday that mammograms can cut the breast cancer death rate by 26 percent for women in their 40s.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "\n\n\n      \n\n \n \nThe story does not discuss the costs of annual mammography screening, or even provide a range of costs.\u00a0 The story does not discuss any health care policy cost repercussions of breast cancer screening recommendations.\u00a0 The story does not discuss the cost of unnecessary biopsies or other treatments for women who have a false positive diagnosis via mammography (greater in women 40-49).\n ", "answer": 0}, {"article": "\"Doing that could be a lot easier than nudging children about going to bed,\" Raine said.\nThe researchers also want to add to this current observational study to establish, through randomized controlled trials, that eating fish can lead to better sleep, better school performance and other real-life, practical outcomes.\n\"We have found that omega-3 supplements reduce antisocial behavior, so it's not too surprising that fish is behind this.\"\nGiven the young age of this study group, Liu and colleagues chose not to analyze the details participants reported about the types of fish consumed, though they plan to do so for work on an older cohort in the future.\nIf it also improves cognitive performance -- like we've seen here -- even better.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "No details are provided that would let a reader estimate the cost of including more fish in a diet such as type of fish or the amount to be consumed.", "answer": 0}, {"article": "The requested URL /usnews/health/articles/070805/13folate.htm was not found on this server.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Although costs weren\u2019t mentioned, most people know the costs of the foods and daily multivitamins mentioned in the story as sources of folate. ", "answer": 2}, {"article": "Researchers have found strong evidence that adenotonsillectomy \u2014 the surgery to remove the tonsils and adenoids \u2014 can help relieve childhood behavioral or attention problems, including attention-deficit hyperactivity disorder, or A.D.H.D.\nFinally, a child psychiatrist determined which children's difficulties merited the diagnosis of attention-deficit hyperactivity disorder.\nAbout half of the patients undergo the procedure to control chronic throat or ear infections.\nBut no cause-and-effect relationship has been established.\nAll the children spent one night in a sleep laboratory to record their sleep and breathing patterns.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There is no mention of costs.", "answer": 0}, {"article": "\"We should offer all women the possibility of a cure.\"\nThe possibility of a 50 per cent cure rate would be a significant improvement over the current 20 per cent survival rate resulting from more conventional treatment options offered to patients, which consist of a combination of different methods including: chemotherapy before surgery; post-operative chemotherapy delivered intravenously to the whole body (as opposed to localized into the abdomen); and surgery that leaves minimal residual disease in the abdomen, rather than removing all visible cancer cells.\n\"Women need support to endure surgery and the rigours of intraperitoneal chemotherapy, but should be encouraged to do so whenever possible, considering the potential survival benefits,\" said Narod.\nBased on an analysis of existing evidence, published in an opinion article in the Nature Reviews Clinical Oncology journal on January 20, Dr. Narod argues that to achieve a cure, rather than simply delay progression or reoccurrence of the disease, women should be first treated with aggressive surgery to remove all clinically-detectable cancer cells, followed by targeted chemotherapy to the abdomen (intraperitoneal chemotherapy).\nUp to half of women with advanced-stage ovarian cancer might be cured, compared to the current 20 per cent survival rate, argues Dr. Steven Narod, senior scientist at Women's College Research Institute, who calls for a new standard of treatment for women with late-stage ovarian cancer.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release doesn\u2019t discuss cost at all. This may be due to the fact that the researcher who wrote the opinion piece, and the institution that wrote the news release, are based in Canada, which has socialized health insurance plans. However, given the expense associated with surgery and chemotherapy, and the fact that the release was promoted through a U.S.-based online science news service (and thus, theoretically, aimed at least in part at U.S. audiences), there should have been at least some effort to address the cost. Even if the cost of the proposed standard of care is comparable to other treatment options for advanced stage ovarian cancer, it could have said that.", "answer": 0}, {"article": "After adjusting for non-modifiable stroke risk factors (such as age and family history), researchers found stroke risk among women who breastfed their babies was on average:\n\u2022 19 percent lower in women who had breastfed for up to six months.\nHowever, because the Women's Health Initiative is large, researchers were able to adjust for many characteristics, and the effects of breastfeeding remained strong, Jacobson said.\nThe Association has strict policies to prevent these relationships from influencing the science content.\nThis is among the first studies to examine breastfeeding and a possible relationship to stroke risk for mothers, as well as how such a relationship might vary by ethnicity.\n\"Some studies have reported that breastfeeding may reduce the rates of breast cancer, ovarian cancer and risk of developing Type 2 diabetes in mothers.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Breastfeeding is not an option for all mothers, whether because of medical/physical limitations or because of socioeconomic ones. However, breastfeeding is also not a medical intervention that one can easily place a price tag on. As such, we rate this criterion as not applicable.", "answer": 2}, {"article": "\"The concept of controlling tumor growth by preventing a stress or inflammatory response is not novel,\" said Dr. Cathie Chung, a medical oncologist and an assistant professor of oncology at the City of Hope National Medical Center in Duarte, Calif.\n\nFor instance, other research has found that women with breast cancer who regularly take aspirin, which is an anti-inflammatory, may have a decreased risk of recurrence.\nAs in other retrospective studies, he said, more research is needed to verify the potential link.\nOther experts called the results interesting, but preliminary.\nPowe is due to present the findings Friday at the annual European Breast Cancer Conference in Barcelona, Spain.\nPowe said he plans to do another study to validate the results.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There was no discussion regarding the cost of beta blockers. ", "answer": 0}, {"article": "But if we tailor treatments to the individual biology of the tumor and characteristics of the patient, we'll get the best results,\" Wolf says.\nThe non-responders who were immediately referred for surgery had better outcomes too.\nThe non-responders can be referred immediately for surgery.\nAs part of a Specialized Program of Research Excellence, or SPORE, grant, the team was already maintaining long-term follow-up data on patients.\nOver 10 years, 153 stage 3 and 4 laryngeal cancer patients were treated at Michigan Medicine, with about half receiving the induction chemotherapy.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "This is the one area the release fails to address at all. Cost is simply not addressed.", "answer": 0}, {"article": "Follow us: twitter.com/CocoaHealthSci\n\nIn 1911, Frank C. Mars made the first Mars candies in his Tacoma, Washington kitchen and established Mars' first roots as a confectionery company.\nThis study, conducted by researchers from Italy's University of L'Aquila and Mars, Incorporated, reinforces the results of several recent cognitive studies--throwing more light on the important role diet plays in maintaining cognitive health.\nDr. Giovambattista Desideri, lead author on the paper, said, \"The results of this study are encouraging--they support the idea that diet, and specifically a diet rich in cocoa flavanols, can play an important role in maintaining cognitive health as we age.\"\nDr. Catherine Kwik-Uribe, human health and nutrition director at Mars, Incorporated, and co-author on this latest study, said, \"Since the brain is a heavily vascularized tissue, we might also be looking at vascular improvements as underlying the observed improvements in cognitive function.\"\nNote to Editors: This research trial was carried out with a special cocoa flavanol test product, designed to deliver a standardized amount of flavanols within a nutritionally suitable drink.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "One might say that everyone knows what a piece of chocolate costs. But this study isn\u2019t about chocolate. It\u2019s about a special concoction made out of the flavanols found in cocoa beans. As the release says, \u201cthe nutritionally matched drinks were specially prepared\u201d using either \u201cMars\u2019 patented Cocoapro process\u201d or \u201ca highly processed alkalized cocoa powder.\u201d We have no idea what that would cost for a typical U.S. consumer to replicate in the kitchen, but if the cognitive benefits of this concoction are to be believed, then it would make sense to mention the possible costs.", "answer": 0}, {"article": "Unfortunately, our previous study indicated that, despite their benefits, many patients on statins discontinue their treatment,\" Chodick said.\nA previous study on the same group indicated that persistent use of statins was associated with substantially lower all-cause mortality, which could not be explained only by the prevention of cardiovascular disease, he said.\n\"Although the study does not have immediate clinical implications, our findings may suggest that patients who were prescribed statins and take it persistently may benefit from the many effects of statins, which go far beyond cholesterol reduction, including the reduction of rheumatoid arthritis risk,\" Chodick said.\nAmong those taking statins, there was only a small, short-term reduction in risk of development of osteoarthritis.\nThis work received no outside or corporate finding, the researchers noted.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "\n\n\nThere is no mention of costs in this story, either the direct costs of the drugs or the associated costs of testing and monitoring.", "answer": 0}, {"article": "This signal is passed to a computer that decodes it, and the resulting instruction is then sent to a sleeve he wears on his forearm that stimulates the muscles that move his wrist and fingers.\nFor starters, the device that records the brain signals will need to be much smaller so it's fully implanted under the paralysed person's skin.\nThat's why the device requires training every time Burkhart uses it.\nThere are still many challenges to be overcome to bring this work out of the lab and into the lives of the millions of people who are paralysed.\n\"It will be years until a paralyzed patient will be able to control neural prostheses independently from caregivers, but there is nothing that should make this improvement impossible.\"\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "It is too early in the development of this experimental technology to begin talking about what the price of such a system might be. But readers would have gotten a clearer idea of the preliminary state of this work if the story had noted that the brain mapping, device implantation, sophisticated equipment and hundreds of hours of training probably cost hundreds of thousands of dollars.", "answer": 2}, {"article": "But study author Anna Giuliano believes that, \"vaccinating males would have a direct benefit that men would receive, as well as a community benefit.\nAccording to a study presented last year by researchers at the University of Maryland, just one-third of teen girls and young women who start the three-dose series actually finish, and almost three-quarters don't start it at all.\n\"This well-designed study reinforces the idea that there is value in vaccinating young men against a virus that is nearly ubiquitous among sexually active individuals.\"\nWEDNESDAY, Feb. 2, 2011 (HealthDay News) -- A large international trial finds that the Gardasil vaccine shields young men from human papillomavirus (HPV) as well as it protects young women.\nThis study involved more than 4,000 boys and men aged 16-to-26 from 18 different countries who were randomly assigned to get the vaccine or not.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Yes, the story provides the retail price of the vaccine. But we would have liked mention of the deeper economic questions. Are insurers covering it for young men? Does the overall economics of paying for young men to get it makes sense for society?\u00a0 Cost is part of the reason that only a minority of young women have chosen to get Gardasil, even though it is both available and recommended (by many) for them. Cost is a central issue in how these vaccines will or won\u2019t achieve medical goals of prevention. When writing about vaccination programs, these larger system-wide costs and benefits are an important part of public discussion.\nThe editorial that accompanied the published study in the journal provides additional information on the cost effectiveness of HPV vaccination in boys and girls \u2013 which could have been tapped.\u00a0 ", "answer": 0}, {"article": "In postpartum depression, the GABA pathway may play a key role in regulating hormones that researchers believe can lead to PPD.\nNewswise \u2014 CHAPEL HILL, NC \u2013 UNC researchers say the results from the multi-site phase 2 and 3 trials of brexanolone injection are not only promising, but could change the way postpartum depression (PPD) is treated.\nA unique dose group of brexanolone 60 \u00b5g/kg/hr in one of the studies was not included in the integrated efficacy analysis, but was included in integrated analyses of safety.\n\u201cWith our latest results, we believe that brexanolone, if approved, could provide relief for women with a range of postpartum severity.\u201d\n\nThe paper, published in The Lancet, includes a new integrated analysis of results from three double-blind, placebo-controlled trials that took place at 30 sites in the U.S., including UNC\u2019s Perinatal Psychiatry Unit.\n\u201cWith current anti-depressant SSRIs (selective serotonin reuptake inhibitors) it could take four to six weeks to get a treatment response.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The news release does not mention costs. While a new therapy may not have an established price, the release could have stated \u201cno price is available for this drug.\u201d What would be even better is some context for what women suffering from postpartum pay typically for counseling and medications.", "answer": 0}, {"article": "\"It's kind of amazing that something so simple could be an answer,\" Paul said.\nOne local pediatrician said she wouldn't discourage parents from trying honey with their children, but more studies are needed to draw solid conclusions.\n\"(Honey) is a cheap and effective treatment,\" said Dr. Ian Paul, lead investigator for the study.\nPaul's group tested buckwheat honey instead of the lighter, more popular varieties because it's known to have more antioxidant and antimicrobial effects, which have been shown in other studies to help wounds heal.\nHoney may suppress cough because its sweetness causes salivation that coats the throat, authors of the study suggested.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Other than to describe honey as \"cheap\" the story does not discuss costs. However, because honey is a food product, prices are dependent on the store and source.", "answer": 2}, {"article": "In an interview, Sakoda said, \"Metformin use was not associated with lung cancer risk when we looked at all patients with diabetes.\nThe researchers conducted this study to further clarify the association between metformin use and lung cancer risk.\nAssiamira Ferrara, Charles Quesenberry Jr., and Laurel Habel, coauthors on this study, have received research funding from Takeda to Kaiser Foundation Research Institute for a study of pioglitazone and cancer and from Sanofi through a subcontract from University of North Carolina to Kaiser Foundation Research Institute for a study of insulin glargine and cancer.\nNonsmokers who used metformin for five years or longer had a 52 percent reduction in lung cancer risk, but this finding was not statistically significant.\nSome laboratory studies and a number of observational studies suggest that metformin may prevent cancer, but the data from human studies, however, are conflicting, explained Sakoda.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There is no discussion of the cost of metformin, which is available as a generic and is comparatively cheap. Nevertheless, since diabetes often requires a lifetime of drug use, costs of metformin versus other drugs would be useful to readers, especially in cases such as this when the drug under study is suspected of providing additional benefits or bringing negative side effects.", "answer": 0}, {"article": "To address this gap, researchers conducted a randomized controlled trial including 352 healthy infants from 3 pediatric outpatient clinics, including 7 physician practices, who received scheduled vaccinations in their first year of life.\nThe study was conducted by researchers at SickKids, the University of Toronto, York University and several Toronto-based pediatricians.\n\"The effects of consistent pain management on the development of preprocedural anxiety (fear), hypersensitivity to pain and compliance with future vaccination warrant future investigation,\" they recommend.\nThe infants were randomized to 1 of 4 groups: placebo control; video instruction to parents on how to soothe their baby; video plus oral sugar solution; and video, oral sugar solution and lidocaine applied to the skin.\nFor babies under age 1 year, lidocaine cream, combined with a small amount of sugar given by mouth and infant soothing, can help relieve pain from routine vaccinations, according to a study in CMAJ (Canadian Medical Association Journal).\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "No dollar signs here, though an over-the-counter tube of lidocaine cream usually costs under $10. We\u2019re not sure from the release if an OTC cream was used or one of the proprietary, prescription-only products.", "answer": 0}, {"article": ".\nThis new radionuclide drug shows strong binding to the protein PSMA and is readily and safely taken up by malignant PSMA-positive tumors.\nPSMA-617 could represent a watershed moment for prostate cancer theranostics.\nPositive response to therapy was verified via combined PET and computed tomography (PET/CT), a hybrid imaging system that shows both functional and structural aspects of the body.\nDiagnostic imaging was followed by a therapy-grade radionuclide, lutetium-177, which delivers a more powerful dose of radiation that penetrates and destroys the cells and tissues of tumors when combined with PSMA-617.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Nothing at all is said about the cost of this treatment either for imaging or treatment. Granted, the drug is in the very early stages of development, but that didn\u2019t stop the release from claiming that the approach \u201cpersonalizes cancer imaging and therapy,\u201d \u201coffers new hope for advanced prostate cancer,\u201d and may have \u201ca major impact.\u201d If it\u2019s not too early to make such bold statements, then it\u2019s not too early, in our view, to give some idea of what this treatment might cost.", "answer": 0}, {"article": "Fibromyalgia is a syndrome marked by widespread pain \u2014 including discomfort at specific \u201ctender points\u201d in the body \u2014 along with symptoms such as fatigue, irritable bowel and sleep problems.\nIn addition, the control group received no active therapy to serve as a comparison.\nThe study, of 45 women with fibromyalgia, found that those who learned a technique called \u201caffective self-awareness\u201d were more likely to show a significant reduction in their pain over six months.\nNone of the women in the control group had a comparable improvement.\nPart of that, according to the researchers on the new study, may be because standard treatments do not specifically address the role psychological stress and emotions can play in triggering people\u2019s pain.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Chronic pain\u00a0takes a huge financial toll in terms of\u00a0direct medical costs and lost productivity,\u00a0but the\u00a0story didn\u2019t \u00a0cover this angle. It would have been interesting to hear how costs of this psychotherapy compare with those of drug therapy. Also, no\u00a0word on whether the costs would be covered by insurance or borne out of pocket by patients. \u00a0\u00a0", "answer": 0}, {"article": "Traditional heart catheterization through a vein in the neck can take 20 minutes or longer.\nBut because it's self-contained, the catheter theoretically should provide little margin for contamination that can lead to infection.\nHe plans to bear the cost of any prostheses the veterans need to work on the catheters.\nReavill plans to hire 13 to 20 disabled vets to get the production off the ground \u2014 with the goal of hiring up to 18,000 if the device goes national.\nHe recently procured a bank loan agreement and is hoping the award recognition and hospitals' willingness to try the catheter will attract a venture capitalist.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There is no discussion of how much the \u201cbreakthrough\u201d approach will cost.", "answer": 0}, {"article": ".\nHow the Study Was Conducted and Results: Patnaik, Shapiro, and colleagues enrolled 225 patients with a variety of types of advanced cancer in the phase I clinical trial designed to evaluate the safety and preliminary efficacy of abemaciclib.\n\"The results of the trial supported the FDA decision to grant breakthrough therapy designation to abemaciclib (previously known as LY2835219) for patients with refractory hormone receptor-positive advanced or metastatic breast cancer,\" added Patnaik.\nMultiple clinical trials have already been initiated to evaluate abemaciclib as a treatment for certain groups of patients with breast cancer and NSCLC, as well as children with primary brain tumors and adults with brain metastases, she noted.\nAuthor Comment: \"These data show that abemaciclib is an oral drug that can be taken on a continuous schedule and achieve durable clinical activity against multiple tumors including breast and lung cancers,\" said Shapiro.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "While one could say it is far too soon to start talking about the cost of a drug that is only beginning to be tested in people, the release compared abemaciclib to a somewhat similar drug, palbociclib (brand name: Ibrance) that is listed at approximately $10,000/month. The release could have referred to the costs of similar drugs\u2026 and perhaps included some mention of how long researchers anticipate patients would be treated with this sort of drug. As an aside, the Wall Street Journal reported a fascinating story on how Pfizer set the (just under) $10,000/month list price of Ibrance.", "answer": 0}, {"article": "Atrial fibrillation (also called AFib or AF) is a quivering or irregular heartbeat (arrhythmia) that can lead to blood clots, stroke, heart failure and other heart-related complications.\nThe results must be replicated in larger studies before Botox injections are routinely used to prevent AF after bypass surgery, researchers said.\nAbout half of those patients will develop AF after surgery.\n\"Atrial fibrillation is also always associated with lengthened hospitalization and that means increased healthcare costs.\"\nBut complications from the bypass surgery were similar in both groups, including time in intensive care and on a breathing machine, and infection rate.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The story rightly points out that the development of atrial fibrillation after coronary artery bypass surgery has significant financial implications: \u201cAtrial fibrillation is also always associated with lengthened hospitalization and that means increased healthcare costs.\u201d But we would have liked to have seen some attention paid to the cost of the intervention, namely multiple injections of botulinum toxin.\u00a0 We calculate the cost of one 4mls vial of Xeomin (incobotulinumtoxinA) to be approximately $1000. This cost is likely to be rather small in comparison to the cost of extended hospitalizations, antiarrhythmic therapies and lost productivity from atrial fibrillation.", "answer": 0}, {"article": "Heart researchers have long known that plaques in coronary arteries start out as pimplelike bumps but get waxy and hard and filled with calcium as time passes.\nAccording to today\u2019s guidelines, half had risk scores high enough that a statin would be recommended or should be considered.\nIt turned out that the actual incidence of heart attacks or disabling chest pain in those with zero calcium was half or less than what the risk calculator predicted.\nCurrent guidelines have vastly increased the number of people who are eligible to take statins.\nAll had heart scans, and half had no calcium visible on the scans.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story reports that a CT scan looking for calcium in coronary arteries \u201ctypically costs between $75 and $100. Still, it is generally not covered by insurance and so is not often used to assess risk.\u201d That\u2019s enough information to clear our bar handily, although we\u2019d note that such scans can also turn up lung nodules that require additional follow-up and related costs.", "answer": 1}, {"article": "Previously, no treatment was available for these patients.\"\nThis trial provides evidence that regorafenib is the first systemic treatment for patients whose HCC progressed during treatment with sorafenib, the only other drug with proven clinical benefit.\nThe success of this trial opens the field for testing drugs in third-line treatment of HCC and provides a rationale to test regorafenib as a first-line treatment or in combination with therapies administered directly into the tumor or diseased liver in patients in an earlier stage of HCC, according to Dr. Llovet.\n(New York, NY - January 18, 2017) An international phase 3 trial has found that the drug regorafenib improved survival in patients with advanced hepatocellular carcinoma (HCC), a form of liver cancer, giving people who previously had no other options a better chance at survival.\nThis study tested regorafenib's effectiveness as a second-line therapy on 573 patients previously treated with sorafenib, 194 of whom were given a placebo.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Cost is not addressed at all. This is particularly problematic because regorafenib (brand name Stivarga) has already been approved, and is on the market, for treating other forms of cancer. For example, an online price guide shows that 84 40-milligram tablets of regorafenib cost $15,817. This is a fair estimate of the cost of treatment, given that the initial treatment regime for patients in the clinical trial receiving regorafenib was 84 40-milligram tablets (four 40-milligram tablets per day for 21 days).", "answer": 0}, {"article": "Measuring blood levels of the recently discovered hormone irisin may improve diagnosis rates of teenagers with polycystic ovary syndrome, according to research presented today at the 55th Annual European Society for Paediatric Endocrinology Meeting\n\nMeasuring blood levels of the recently discovered hormone irisin may improve diagnosis rates of teenagers with polycystic ovary syndrome, according to research presented today at the 55th Annual European Society for Paediatric Endocrinology Meeting.\nLifestyle changes and different exercise-related signals that regulate the secretion of irisin could provide a potential option for the management of PCOS.\nThe findings suggest that irisin could be a marker for PCOS allowing the condition to be diagnosed more easily.\nThe findings may reduce the number of unnecessary treatments prescribed to otherwise healthy girls.\n\"If high irisin levels in teenagers with PCOS is established, this could lead to the development of treatments for PCOS.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release doesn\u2019t address costs at all. Given how far this is removed from widespread clinical applications, that\u2019s somewhat understandable. Then again, if a clinical application is so far away, it\u2019s hard to understand why one would claim in the headline that this test \u201cmay reduce teenagers wrongly diagnosed with PCOS.\u201d\nThe researchers presumably know the general cost of measuring irisin levels in a blood test. Is it relatively inexpensive? Even a modest indication of general cost would have been welcome. The release could have acknowledged that the cost of the test in a research setting might be quite different from the cost of a clinical test.", "answer": 0}, {"article": "J Natl Cancer Inst.\nThese key benefits of 3D MAMMOGRAPHY\u2122 could lower the costs associated with needless follow-up exams, and improve patient experience for women seeking a more accurate screening mammogram.\nGenius\u2122 3D MAMMOGRAPHY\u2122 exams have been available in the U.S. since 2011, and are only available on the Hologic Selenia\u00ae Dimensions\u00ae mammography system.\n\"This new analysis confirms that Genius\u2122 3D MAMMOGRAPHY\u2122 exams reduce unnecessary follow-up exams in dense-breasted women.\nThere can be no assurance the systems will achieve the benefits described here, or that such benefits will be replicated in any particular manner with respect to an individual patient.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "No discussion of costs or whether the addition of the 3D mammography\u00a0is covered by insurance policies. This is a huge oversight considering the release touts the potential for significant cost savings. For example, the release states:\n\u201cThis has the potential to provide health systems and insurance companies with significant cost savings, reduce patient stress and expenses, and alleviate challenges for referring physicians who are tasked with relaying mammography results to their patients.\u201d\nA quick online scan of the cost for this newer technology finds that although the 3D test is FDA-approved, it still isn\u2019t covered by most insurance plans.\u00a0 At least one large clinic using the 3D technology asks patients for an an out-of-pocket payment of $60 and then the 2D portion of the imaging test is billed to insurance. The patient is liable for any outstanding balance after insurance has paid.", "answer": 0}, {"article": "\"Here in the U.S., we do things differently,\" he said.\nEven though the ephedra-containing herbal is not readily available in the United States, the M-Y herbal formula is available in many countries besides China, including Korea, Japan, India and Germany, the study authors noted.\nHowever, finding the medicine in the United States is difficult, if not impossible, given that it contains the stimulant ephedra.\nCao and Wang, who specialize in infectious diseases and clinical microbiology, said the herbal recipe -- known as maxingshigan-yinqiaosan (M-Y) -- is easily accessible throughout China and much less expensive than Tamiflu (oseltamivir).\nPer World Health Organization (WHO) recommendations, in most instances, Tamiflu was the treatment of choice, where it was available.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story says the herb mixture is much less expensive than Tamiflu. But how much does Tamiflu (and the related physician visit) cost?\u00a0Providing an actual\u00a0price tag would have dispelled any uncertainty.", "answer": 0}, {"article": "\"When people have serious injuries, whether from accidents or violence, and when they have severe hemorrhage they can bleed to death.\nThe drug, tranexamic acid (TXA) is cheap, widely available around the world and easily administered, experts said.\n\"I think people should consider it [TXA] following trauma on the basis of this study,\" he said.\nIn fact, a trial to see whether TXA can reduce postpartum bleeding has started, the team noted.\nDr. Jerrold H. Levy, deputy chair for research at Emory University School of Medicine in Atlanta and author of an accompanying journal editorial, said that, \"these data are really neat, because any therapy to reduce mortality in trauma is, I think, a major finding.\"\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story notes that TXA is cheap, but we wish it had put\u00a0a dollar amount on it the way competing coverage did. The cost of the medication was\u00a0cited\u00a0in the press release put out by the London School of Hygiene and Tropical Medicine and could easily have been included. \"Cheap\" is relative.\u00a0 And, pertinent to this issue, what\u2019s \"cheap\" in the West may not be so cheap in developing countries. ", "answer": 0}, {"article": "Both drugs could win approval from the Food and Drug Administration by this summer.\nExecutives at CVS Health, a leading pharmacy benefits manager, recently said that PCSK9 inhibitors might cost $7,000 to $12,000 a year and would strain health care budgets because so many people might use them.\nAnalysts say the drugs will have billions of dollars in annual sales and will be taken by millions of people who cannot lower their cholesterol enough using statins alone or cannot tolerate statins.\nStill, the findings could help smooth the way for regulatory approval, wider use of the drugs by doctors and possibly reimbursement by insurers.\nBy a measure known as the hazard ratio, the risk of cardiovascular events was reduced by 53 percent.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "It\u2019s difficult to estimate costs for drugs that haven\u2019t yet been approved by the Food and Drug Administration, so we feel this article did an exceptional job discussing the projected costs of PCSK9 inhibitors. The piece quoted executives at CVS Health who said these drugs may cost $7,000 to $12,000 a year, which may strain health care budgets if many people use them. Furthermore, insurers may be hesitant to pay for PCSK9 inhibitors until there is proof that they prevent heart attacks, strokes and death, it said.\nDespite the potential high costs, analysts estimated the drugs will have billions of dollars in annual sales, the article added.", "answer": 1}, {"article": "\u201cThe person has to be wanting to quit smoking,\u201d he said.\nUsing acupuncture methods to treat addictions such as smoking is not new, White said, but there is still no clear evidence that treatment with needles has any therapeutic effects either.\nPinto says that Innovative Laser Therapy follows up on the success of all of its clients a month after the treatment for clinical evidence that will be part of the package of data presented to the FDA.\nHis company charges $350 for a one-time treatment that takes less than an hour, and offers free extra treatments to patients who are still struggling with quitting in the following 6 months.\nThe clinic uses low-level lasers - similar to those sometimes used to treat arthritis-related pain - to target specific acupuncture points on the body related to addiction, metabolism and stress, and claims that most patients can quit smoking after one session.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story explains that the company profiled \"charges $350 for a one-time treatment that takes less than an hour, and offers free extra treatments to patients who are still struggling with quitting in the following 6 months. Other companies do a few shorter therapy sessions as part of their regular treatment plan.\"", "answer": 1}, {"article": "In a related editor's note, Mitchell H. Katz, M.D., a deputy editor of JAMA Internal Medicine, writes: \"Of course, no study is perfect.\nMiguel A. Mart\u00ednez-Gonz\u00e1lez, M.D., of the University of Navarra in Pamplona and CIBEROBN in Madrid, Spain, and coauthors analyzed the effects of two interventions with the Mediterranean diet (supplemented with extra virgin olive oil [EVOO] or nuts) compared with advice to women to follow a low-fat diet.\nThe study was conducted within the framework of the large PREDIMED (Prevenci\u00f3n con Dieta Mediterr\u00e1nea) trial, which was designed to test the effects of the Mediterranean diet on the primary prevention of cardiovascular disease.\n\"The results of the PREDIMED trial suggest a beneficial effect of a MeDiet [Mediterranean diet] supplemented with EVOO in the primary prevention of breast cancer.\nThis one has a small number of outcomes (only 35 incident cases of breast cancer), the women were not all screened for breast cancer with mammography, they were not blinded to the type of diet they were receiving, and all were white, postmenopausal and at high risk for cardiovascular disease.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release makes no mention of the cost of the supplemented diets compared to what might be expected for a normal daily diet.\u00a0 Some brands of extra-virgin olive oil can cost considerably more, comparatively,\u00a0than other available cooking oils. \u00a0And you\u2019d have to buy lot of olive oil to match this diet \u2014 participants received a whopping 1 L per week per family. Other foods in the Mediterranean diet (e.g. fish and nuts) are also relatively expensive. So the release fails at this category, although it is a minor failure in this case considering the relative strength of the rest of the release.", "answer": 0}, {"article": "Lung cancer kills more Americans than any other type of cancer, nearly 160,000 last year.\nJanne, also a professor at Harvard Medical School, said more research is needed before lung cancer patients should be routinely treated with Opdivo, Keytruda or similar drugs.\nFor other patients, researchers expect other drugs will be needed, too.\nThe study, in 234 patients, was the largest trial of the drug in lung cancer.\n\"It is early days for the successes of immune therapy,\" said Mark Fishman, president of the Novartis Institutes for BioMedical Research, a research arm of drug company Novartis, which is taking a different approach to turning the immune system against cancer.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not mention costs at all. Other media reports have quoted the company as saying it will charge\u00a0an average of $12,500 a month for Opdivo.", "answer": 0}, {"article": "JACC is ranked No.\nThe mission of the College is to transform cardiovascular care and to improve heart health.\nThey also looked a several early indicators of heart disease.\nResearchers from Emory University Hospital in Atlanta set out to learn more about the relationship between depressive symptoms and heart disease.\n\"Our findings highlight the link between worsening depression and cardiovascular risk and support routinely assessing depression in patients to determine heart disease risk.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "It\u2019s hard to put a price tag on regular exercise as there are so many ways to get your physical activity on and many of them are free. So we\u2019ll say this category doesn\u2019t apply.", "answer": 2}, {"article": "For more fitness, food and wellness news, follow us on Facebook and Twitter, or sign up for our newsletter.\nHowever, the data do begin to shed light on why babies born through vaginal birth may have fewer health risks than babies born by C-section.\nThe finding suggests that the arduous experience of labor \u2014 that exhausting, sweaty, utterly unpredictable yet often strangely exhilarating process \u2014 may give children a healthy start, even when it\u2019s interrupted by a surgical birth.\nThe findings are a reminder that although C-sections are appropriate in some circumstances, they are a poor substitute for labor.\nBut babies delivered by a planned C-section, which is usually scheduled to take place well before the first pang of labor, may miss out entirely.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The article does not include any discussion of costs. We believe that information could have added a further dimension to the topic.\nCesarean delivery is estimated to cost 50% more than vaginal delivery, in an analysis from 2013 of US births. [http://www.medscape.com/viewarticle/803426_2]\nAt a time when health-care costs are important drivers of policy, this is not a small factor. Health insurers, including the government\u2019s Medicaid program, could adjust policies to discourage elective C-sections.\nThe story could have added this dimension to the discussion of impact.\u00a0Unwarranted variation in procedures of any kind that carry risk and may not always improve care should raise questions.", "answer": 0}, {"article": "\"I think this may be changing in health care,\" said Spears, \"but because migraine affects women more than men, there is a stigma around the stereotype of a patient who comes in with multiple complaints, calls frequently and wants to see the doctor frequently.\" Men, on the other hand, have been stereotyped as going to the doctor \"only when something he has is real.\"", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The cost of the drug is not discussed. Other media coverage of this new proposed drug, fremanezumab, sets its price as high as $8,500, although it\u2019s not clear if that is for a year\u2019s treatment or a single administration.", "answer": 0}, {"article": "\u201cIt\u2019s easier to pop a pill,\u201d Dr. Altman said.\nBut a number of new controlled trials and meta-analyses like Dr. Moore\u2019s suggest that topical Nsaids are as effective as their oral counterparts for treating osteoarthritis in the knee and hand as well as musculoskeletal injuries like soreness and tendinitis.\n\u201cSuddenly there were tons of folks who thought topical Nsaids were a good idea.\u201d\n\nDr. Roy D. Altman, a rheumatology professor at the David Geffen School of Medicine at the University of California, Los Angeles, said the drugs might be especially helpful for \u201cthe elderly or those taking multiple medications, who were not getting treated but who can now use topical Nsaids and get some benefit.\u201d\n\nAnother leading pain researcher, Dr. Roger Chou, an associate professor of medicine at Oregon Health and Science University, noted that the skin creams delivered \u201cvery high joint concentrations of the topical Nsaid, higher than with standard oral doses, with very low blood levels\u201d \u2014 less than 5 percent of those found with oral Nsaids.\nStill, in one of the only head-to-head trials between topical and oral Nsaids, subjects taking the pills had a much higher rate of indigestion, diarrhea, abdominal pain, abnormal liver tests and anemia than those using the creams.\nIn clinical trials, the skin creams are linked to a higher rate of redness, irritation and rash.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "1clip_filelist.xml\"/>\n\n\n\nThe story says that the average copayment for a month\u2019s supply of some of the topical NSAID medications is around $30. It would have been nice to include the cost of comparable oral medications.", "answer": 1}, {"article": "And tobacco kills one in 10 people worldwide, according to the World Health Organization.\nSmokers who took the pill, sold as Chantix in the U.S. and Champix elsewhere, were much more likely to quit after cutting back on cigarettes than smokers who didn\u2019t use the drug, the study found.\nOther treatments, such as nicotine patches and gum, can also help some smokers cut back gradually, she said.\n\u201cThis is very strong support for changing clinical practice to include gradual reduction aided by medication.\u201d\n\nSmoking is the leading cause of preventable death in the U.S., according to the Centers for Disease Control and Prevention.\nTo see if Chantix, which is manufactured by Pfizer, could help smokers quit without going cold turkey, Ebbert and colleagues randomly assigned 1,510 people at 61 centers in 10 countries to receive either the drug or a placebo for 24 weeks.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not tell us how much the smoking cessation drug costs or whether insurance companies will pay for it.", "answer": 0}, {"article": "\"Although we do not know why the men who took saunas more frequently had greater longevity (whether it is the time spent in the hot room, the relaxation time, the leisure of a life that allows for more relaxation time, or the camaraderie of the sauna), clearly time spent in the sauna is time well spent,\" Redberg wrote.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "For most Americans, access to a sauna would require membership in a health club or community center swimming pool, which is out of reach for many families. The story could have easily mentioned cost.", "answer": 0}, {"article": "Patients taking briakinumab had more serious infections and more cancers than those taking methotrexate.\nGordon was not involved in the current study, but he has been involved in research of the drug and has been a paid consultant and investigator for Abbott.\nBut as successful as the drug appears to be for some patients, it may come with a significant risk.\n\"This drug has had, in this trial, the highest efficacy we have ever seen with any biologic in psoriasis before,\" says study researcher Kristian Reich, MD.\n\"Many of us were disappointed it was withdrawn because there would be a subset of patients who wouldn't respond to anything else and it would have been nice to have for them.\"\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "At this stage of development, the cost of briakinumab is impossible to determine. However if the costs will be anything like other biologics such as Stelara \u2013 which the story mentioned \u2013 then the cost could be as much as $1,500 to 2,000/month.\u00a0 So some attempt could have been made to address the important cost issue in this field of drug development.", "answer": 0}, {"article": "\"So we thought, 'What if we change that by injecting the therapy drug into the metastatic lesions and change the microenvironment of the cancer?'\nThe research showed that using the immunotherapy drug pembrolizumab and the experimental agent SD-101, a sequence of nucleic acids that mimics a bacterial infection, altered the microenvironment around the tumor in a way that enabled the immune system to more effectively attack the cancer.\nThe research was an early-stage study, conducted to test the side effects and best dosage of a potential new combined therapy, and the findings were published today in the journal Cancer Discovery.\nThe study highlights the need for more research into combination therapies like this one, because many people with cancer do not respond to immunotherapy or experience a reoccurrence of their tumors after treatment.\nThe other 13 people in the study had previously received a type of immunotherapy before the study.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The experimental drug does not yet have a cost.\nThe news release does not state that Keytruda costs about $12,500 a month (it is given intravenously every three weeks) or $150,000 a year. It would have been relevant to discuss\u2013since this new drug would be in addition to this very expensive treatment.", "answer": 0}, {"article": "Partial replacements, also known as unicompartmental replacements, are suitable for people who have arthritis in just one side of the knee, usually the inner.\n\u201cIf we see surgeons carrying out this procedure more often, the proportion of knee replacements that are partials would increase from the current figure of 9% and we would see an increase in future economic and population health gains.\u201d\nResearchers from the Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDORMS) publishing in the BMJ Open journal found that the less invasive procedure was being used less than it could be.\nThose surgeons who carried out more partial replacements had better outcomes from them than surgeons who did fewer.\n\u201cThis has allowed us to provide strong proof that partial knee replacements are both better for patients and cheaper for the NHS.\u201d\n\nWhether people had a partial or total replacement varied by surgeon, as did the success of the operation, the researchers discovered.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "This story ran in the U.S. edition of the Guardian. Generally, we expect those stories to acknowledge that the U.S. patients have to pay for their healthcare, and what those costs might be. However, in this case, because the research is looking at some benefits specific to the UK\u2019s National Health Service, we\u2019ll rate this N/A. It does include a small mention on this topic: \u201cPartial replacements are also cheaper, say researchers from Oxford University.\u201d", "answer": 2}, {"article": "Article reference: Thomas L. Jang, Neal Patel, Izak Faiena, Kushan Radadia, Dirk F. Moore, Sammy E. Elsamra, Eric A.\nAnother interesting finding from the research was that slightly more than half of men diagnosed with the disease did not receive combination therapies for their prostate cancer.\nThey found that 10 years after treatment, 89 percent of the prostate removal plus radiation group was still alive.\n\"This important study demonstrates that many men with high-risk prostate cancer derive a survival advantage through a multi-modality approach to their disease.\n\"For high-risk prostate patients we started the use of aggressive radiation therapy after surgery 20 years ago,\" said Adam Dicker, Senior Vice President and Chair of the Department of Enterprise Radiation Oncology at Jefferson Health, who was not involved in the study.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There was no discussion of the cost of any of these treatments. One survey\u00a0from 2014 found uninsured patients were charged an average of $34,720 for prostate removal surgery, plus an average of $8,280 for physician costs. Some hospitals provided discounts for prompt payment.\nAny comparison between these options\u00a0could consider not only the costs of the initial treatment but also any subsequent costs associated with side effects or progressive disease.\nIt\u2019s also worth noting that Jefferson Health offers robotic surgery, which is substantially more expensive.", "answer": 0}, {"article": "When Downing expressed concerns about the drug, she said the doctor blew her off: \"He said, 'What are you worried about?\nThe screening, unsurprisingly, found that Caroline's emotional problems were linked to her sister's death.\nCandace's treatment, Downing said, involved a one-size-fits-all approach to mental health that sees medications as a magic pill.\nThe therapy had an immediate and beneficial impact and turned Mathy Milling Downing, a skeptic about some kinds of mental health treatment, into a fan of mental health treatment done right.\nThe idea of a psychiatric evaluation sent chills down the spine of Caroline's mother, Mathy Milling Downing, who believed that her younger daughter, Candace, had committed suicide because of an adverse reaction linked to a psychiatric drug -- the antidepressant Zoloft.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There was no indicating of treatment costs or whether it was commonly covered by insurance. \u00a0", "answer": 0}, {"article": "ORMD-0801 goes from the gut to the liver, while injected insulin circulates throughout the body before it gets there.\nA safe and effective oral insulin, if approved, is expected to become a multibillion-dollar product.\nThe 28-day study involved patients whose type 2 diabetes was not adequately controlled by metformin.\nThe positive results must be replicated in a larger Phase III trial before the drug, known as ORMD-0801, can be submitted for approval.\nThose who received the oral insulin had a mean night-time glucose reduction of nearly 6.5 percent compared with a placebo.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "A comparison of cost to currently available long-acting insulin would have been informative, but the report is on a trial for safety and efficacy, so this is preliminary.", "answer": 2}, {"article": "WASHINGTON -- A new study shows patients taking the anticlotting drug Plavix along with a type of drug used to block stomach acid have an increased risk of a subsequent hospitalization for heart trouble.\n\nThe study, which is being published in this week's Journal of the American Medical Association, adds to other recent studies that suggest proton pump inhibitors like Aciphex, Nexium, Prevacid and Protonix reduce the effectiveness of Plavix, which is marketed by Bristol-Myers Squibb Co. and Sanofi-Aventis SA.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There was no discussion of cost. \u00a0The cost implications are important. \u00a0The results of the study question the routine use of a costly drug, and cautions that the PPI only be used in select patients and not those who are on Plavix. \u00a0\nIt would been of interest to note that the alternative medications for the treatment of \u2018heartburn and certain stomach problems\u2019 are less costly than the PPI that appears to be problematic.", "answer": 0}, {"article": "The Site is down for maintenance.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Not applicable.\u00a0 Too early to discuss costs.", "answer": 2}, {"article": "Additional UT Southwestern researchers include lead authors Dr. Wenfang Chen, Haley Hill, Alana Christie, and Min Soo Kim, as well as Eboni Holloman, Andrea Pavia-Jimenez, Farrah Homayoun, Dr. Yuanqing Ma, Dr. Nirav Patel, Dr. Guiyang Hao, Qurratulain Yousuf, Allison Joyce, Dr.\nHIF-2 inhibitors also are the target of UTSW's recent $11 million SPORE (Specialized Program of Research Excellence) award.\nIn 2014, the first HIF-2 inhibitor, an oral drug known as PT2385, entered clinical trials in patients with advanced or metastatic renal clear cell carcinoma.\nResearchers surprisingly found a subset of tumors that do not respond to the drug, but were able to identify biomarkers that, once verified, would help determine which patients are more likely to benefit from HIF-2 therapies.\nPart of the SPORE grant, one of just two directly related to kidney cancer in the nation, is focused on further researching HIF-2 inhibitors.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "No costs mentioned. If a release claims that a drug is \u201cmore effective and better tolerated than the standard of care drug,\u201d it should also be prepared to give some cost specifics.", "answer": 0}, {"article": ".\nThat is why patients need a CT scan to confirm the type of stroke before receiving tPA.\nThe findings bordered on statistical significance, suggesting that future clinical trials with a greater number of patients are needed to show similar benefits.\n\"Treatment then needs to happen as quickly as possible, and a mobile stroke unit may allow that to happen.\"\n\"Time is brain in acute stroke after vascular collaterals fail, and faster treatment yields better outcomes,\" said May Nour, M.D., Ph.D., lead researcher, interventional neurologist and director of UCLA's Mobile Stroke Rescue Program.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release briefly mentions the issue of costs with this statement: \u201cIts better outcomes could offset the increased costs of a mobile stroke unit.\u201d\nWe thought the release would have been better if it had noted the nominal cost of clot busting drugs as well as the cost of a CT scanner and additional personnel essential to mobile stroke units, which would be considerable.", "answer": 0}, {"article": "\"This is a multi-channel implantable device,\" Peckham explains.\nAnd I do a little twitch with my muscle in here.\nBack then, she couldn't even wipe the tears from her eyes \u2014 and there were plenty of tears shed.\n\"She could tell you it was tough.\"\nThat's what happened to Annette in 2002 when a car accident left her paralyzed.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not mention costs.", "answer": 0}, {"article": "It's the first study to specifically examine...\nNow, it may be good for the brain as well.\nNow, it may be good for the brain as well.\nWe've long known that the Mediterranean diet is good for the heart.\nWe've long known that the Mediterranean diet is good for the heart.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Not applicable.\u00a0 The cost of a Mediterranean diet is not in question.", "answer": 2}, {"article": "A growing body of evidence suggests that weight-loss surgery is more effective than diet and exercise at getting rid of Type 2 diabetes.\n\nA small but rigorous randomized trial published Wednesday in JAMA Surgery provides the latest evidence showing the superiority of bariatric surgery over lifestyle changes in resolving the chronic condition involving high blood sugar.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The article carries no information about the cost of bariatric surgery, particularly some of the newer, more minimally invasive procedures. Costs are not trivial, particularly because the overall economic costs of type 2 diabetes aren\u2019t either. The piece cries out for\u00a0some dollar signs.", "answer": 0}, {"article": "Sept. 26, 2017.\nThe research, published Sept. 26 in the Journal of the American Medical Association, reports results from the clinical trial known as GIFT (Genetics Informatics Trial of Warfarin to Prevent Deep Venous Thrombosis).\nUnlike prior studies, GIFT took into account genetic variants in three genes for 11 days of warfarin therapy.\nOf the 789 patients who were dosed in the traditional manner, 116 experienced at least one adverse event (14.7 percent).\nCompared with patients receiving traditional warfarin dosing, patients dosed with the genetic approach had a 27 percent reduction in adverse events, which was statistically different.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Although the release doesn\u2019t give actual costs of warfarin versus some of the newer drugs, or factor in the cost of the usual monthly blood testing required of those taking the drug, it does note the cost of the gene testing used for the study, and that the $200 price tag is now less than a month\u2019s prescription of one of the newer anti-coagulants on the market.", "answer": 1}, {"article": "\u201cThat would be the quickest path to insolvency,\u201d he said.\nBut some also want Sarepta to make the drug available to more patients on a compassionate basis even before approval.\nEteplirsen, which Sarepta says has shown no side effects so far, is vying with a similar drug being developed by GlaxoSmithKline to become the first medicine that works by directly countering the cause of the disease.\nAlso, eteplirsen would be appropriate for only about 13 percent to 15 percent of Duchenne patients, those with the particular genetic mutation the drug is meant to counteract.\nEteplirsen could also be the first drug to reach the market for Sarepta since it was founded 32 years ago.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Not applicable. The drug is in early stages of development and as such, identifying the potential cost is premature", "answer": 2}, {"article": "Since 2013, the American Academy of Pediatrics endorses a wait-and-see approach, seeking to let more earaches heal on their own without antibiotics.\nMoms have flooded https://www.facebook.com/ClearPop with glowing testimonials for this simple drug-free solution that:\n\n-can be given along with analgesics or antibiotics.\nClearPop for Rapid Earache Relief has been shelved by Raley's (CA, NV) select RiteAid locations, and is available at boutique drugstores and Amazon.\nCLINICAL TESTS\n\nChildren diagnosed with Acute Otitis Media, or ear infection, consumed the xylitol and Vitamin C-based product in pediatric offices.\nFull study report at http://clearpop.com \n\n\n\nEAR INFECTION AND ANTIBIOTICS\n\nEar infections are the Number One reason kids aged 5 and under receive oral antibiotics.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The news release\u00a0does not discuss costs, which is surprising. On Amazon, the cost is\u00a0$12 for two ClearPop lollipops, more than you might pay out of pocket if you have insurance that covers antibiotics but still relatively cheap.", "answer": 0}, {"article": "Researchers said no Aimovig patients stopped treatment due to side effects, while around 1 percent of placebo patients discontinued because of side effects.\nReuter said the 17-point gap between the treatment and placebo groups was in line with previous Aimovig studies.\nHe said previous studies excluded patients who had tried more than two other treatments.\nThe drug, a monoclonal antibody, was given monthly by injection at a dose of 140 mg for the trial.\nAnalytics firm GlobalData has forecast that CGRP antibodies will generate combined sales of $4 billion by 2026.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story did not discuss costs except to mention a $4 billion sales estimate. This doesn\u2019t help consumers. According to some estimates, pricing for the drug will start around $8,500/year. That\u2019s not chump change.", "answer": 0}, {"article": "Observers measured the symmetry of their smiles, checked for drool and listened to them read sentences.\nDr. Papas, an adviser to Novalar and an investigator in its clinical trials, said she thought the drug would appeal especially to those receiving cosmetic dentistry \u201cwho like to look good when they leave the dentist\u2019s office.\u201d\n\nNovalar said its surveys showed great interest in the product among consumers and among dentists, some of whom said they would mark up the price of the drug as a source of profit.\nNovalar and some dentists who advise the company said it might be useful for children, who can injure themselves by biting their lip or tongue without knowing it.\nWith about 300 million anesthesia injections given by dentists each year, company executives say the drug could easily achieve sales of hundreds of millions of dollars a year.\nThose patients would be expected to have lingering pain, and should not get Oraverse, Dr. Moore said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The article reports the company will sell the drug to dentists for $12.50 per injection. It also says some dentists will mark it up to make profit.\u00a0 How big that markup may be is the key question for consumers.\u00a0 ", "answer": 1}, {"article": "Oral and injectable medications are also prescribed.\nHowever, previous research led by Dr. Zhovtis-Ryerson's group found extending the dose up to 8 weeks did not negatively affect the medication's efficacy in a retrospective sample of 2,000 people.\nThe authors are planning prospective efficacy studies of extended dose natalizumab.\nThe new research showed that extending dosing of natalizumab from every 4 weeks to every 5 to 12 weeks significantly reduced the risk of developing progressive multifocal leukoencephalopathy (PML), a rare but potentially fatal brain infection.\nThe new study, however, reports safety data through up to 72 months, or 6 years, when the extended dosing regimens were applied, with risk reduction for PML as high as 94 percent.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The cost of infusing natalizumab is not mentioned, but this study found the 2-year cost to be $72,120.", "answer": 0}, {"article": "It is high in polyphenols--compounds with strong antioxidant activity that in test-tube and animal models show anticancer and heart-protective effects.\nGood clinical studies are few, however, and although I and other physicians tell our patients to drink green tea, there hasn't been any definitive proof of the value of that advice.\nThere's a growing body of research to suggest that both are probably good for you.\nWe've heard a lot about the health benefits of tea, especially green tea.\nThat's why I was so interested in a report last week in the Journal of the American...\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There are no costs mentioned with the type of tea recommended in the article (gyokuro or matcha) though the article suggests vendors of these types of tea. If the story can suggest sellers, it can cover costs, which can vary widely with these products. ", "answer": 0}, {"article": "Not so long ago, in 2000, the American Academy of Pediatrics recommended that allergenic foods be kept away from infants until they were at least a year old, and often older.\nEarly introduction didn\u2019t seem to make a difference for autoimmune diseases, at least according to the available evidence; eating gluten young wasn\u2019t associated with the risk of developing celiac disease.\nThat warning was especially strong for those with a family history of allergies.\nThat advice has been amended, and newer evidence has shown that introducing foods earlier is actually better for preventing food allergies.\nMore research is necessary to figure out the ideal amounts of these allergens, the optimum times of introduction and the reasons behind the link.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Cost does not apply to in this example of eating habits. However, the story would have been stronger with some context about how much money is spent on treating child food allergies.", "answer": 2}, {"article": "\"Daniel's obstruction was both at the level of the soft palate and at the back of the tongue,\" Thaler says.\nA sleep study confirmed Sheiner had one of the worst cases of apnea his doctors had ever seen.\nSheiner is one of only about a half-dozen patients to have this robotic surgery for apnea.\nSheiner suspected he had sleep apnea because it ran in his family.\nAnd even then, success rates aren't high; they're effective only 20 to 30 percent of the time.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No mention of costs \u2013 not on the robotic surgery, not on CPAP.", "answer": 0}, {"article": "Symptoms can include sadness, insomnia, difficulty concentrating and making decisions, feelings of shame or guilt, as well as difficulty bonding with the baby or thoughts about harming the baby.\nBy midway through the study, 37 new moms had received at least one call from a peer counsellor.\n\u201cThis study, while small, suggests that peer phone counseling could be a very effective, widespread public health intervention.\u201d\nEven though the small study had several women drop out and lacked a control group of moms who received different treatment, the results are consistent with previous research that has proven peer counseling works, said Dr. Ruta Nonacs, a psychiatrist at the Center for Women\u2019s Mental Health at Massachusetts General Hospital in Boston.\nOn average, the women spoke more than eight times and the calls typically lasted about 38 minutes, the researchers reported in the Journal of Advanced Nursing.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "We want to rule this satisfactory. The story notes that the peer phone counseling is run by volunteers with nurses on call, and is thus cheaper than professional counseling, which is \u201cexpensive.\u201d But we need some kind of quantification to know what the story means by \u201clow-cost\u201d vs. \u201cexpensive.\u201d", "answer": 0}, {"article": "Nuts, seeds, whole grains, legumes and even dark chocolate are high in fiber\u2014as are vegetables.\nSonnenburg was not involved with this study, but research from his lab also suggests that fiber plays a big role in promoting good bacteria.\n\u201cThat means if you\u2019re not eating dietary fiber, your immune system may be existing in kind of a simmering pro-inflammatory state,\u201d he says\u2014the very state that predisposes us to different Western diseases.\nLoading up on fiber-fortified processed foods isn\u2019t likely a good way to increase the kind of fiber that benefits the gut.\nYou can increase these bacterial populations by eating fiber, Cani\u2019s research suggests, which acts as a prebiotic in the gut and has a beneficial effect on some bacteria.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not mention cost. However, the intervention being discussed here is increasing one\u2019s dietary fiber intake. And the cost of high-fiber foods is widely variable. While some high-fiber foods may be costly (e.g., fresh vegetables are not readily available for those in urban \u201cfood deserts\u201d), others \u2014 such as beans \u2014 are not. We\u2019ll rate this Not Applicable.", "answer": 2}, {"article": "When it comes to health, I\u2019m skeptical of willpower. Sure, I talk to my students about personal responsibility, but when it comes to the health of populations, I look for big fixes more than for small acts of will.\n\nThat\u2019s why my ears perked up when I heard that two old physician friends had decided to start taking, as a preventive measure, some of the medications often included in what the field has dubbed the \u201cpolypill.\u201d My friends are both top doctors in their 60s, with good diet and lifestyle, and this is now part of their...", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There aren\u2019t specifics on cost. The story states that the various individual medications that might go in a polypill are \u201ccheap,\u201d but we have no evidence that a combined pill would also be cheap. The story links to a \u201cless comprehensive\u201d polypill available online by prescription, but doesn\u2019t tell us how much it costs.\u00a0", "answer": 0}, {"article": "Evofem\u2019s Amphora gel works by regulating vaginal pH within the normal range of 3.5 to 4.5, creating a hostile environment for sperm and certain viral and bacterial pathogens that can cause sexually transmitted diseases.\nThe rate stands at about 91 percent for oral pills and intrauterine devices, according to brokerage Roth Capital Partners.\nAmphora was found to have an 86 percent efficacy rate in avoiding pregnancies and no serious side-effects were observed in the study, which evaluated about 1,400 healthy women belonging to the age group 18-35 years, Evofem said.\nThe company plans to resubmit the marketing application for Amphora in the second quarter next year and if approved, plans to launch the product in January 2020.\nEvofem is also testing Amphora as a preventive treatment for chlamydia and gonorrhea - two of the world\u2019s most common sexually transmitted infections.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not mention what the cost might be for the new birth control gel. It\u2019s a useful bit of information in the birth control market with products ranging from a couple dollars for a condom and hundreds of dollars for an IUD. Reporters can ask for estimates or cost-comparisons even for products that are not yet approved or on the market.", "answer": 0}, {"article": "\u201cThey showed it was safe and tolerable treatment at least for this small number of people,\u201d Fargo said.\nAnd, McCracken says, the company is working to figure out just what it is in the plasma that might affect aging and disease.\nThere was no measurable effect on memory or thinking, the team told the Clinical Trials on Alzheimer\u2019s Disease conference in Boston.\nResearchers trying to answer the question say they found the treatments are at least safe.\n\u201cThere is a theory that there is an inflammatory process that is driving the disease and the plasma is helping that,\u201d she said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There is no mention of the cost of this new approach in this story.\u00a0 The story does state that whatever product is potentially developed, it will not be whole plasma.\u00a0 Since we know what the cost to patients would be for current whole plasma transfusions, and for whole blood transfusions as well, it seems\u00a0plausible for some estimate to be made based on what patients are now charged for either plasma or whole blood transfusions.", "answer": 0}, {"article": "U.S. prisons are experimenting with a high-priced monthly injection that could help addicted inmates stay off opioids after they are released, but skeptics question its effectiveness and say the manufacturer has aggressively marketed an unproven drug to corrections officials.\nThe drug\u2019s manufacturer hopes prisons will be the gateway to a larger market.\nThe drug has no street value or abuse potential.\nWhen the injections stopped, many in the study relapsed.\n\u201cThere\u2019s been pushback with other medications, people saying, \u2018We\u2019re just changing one drug for another.\u2019 That argument goes out the window when you\u2019re talking about a blocker\u201d like Vivitrol.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The high cost of these regular injections is front and center in this story.", "answer": 1}, {"article": "A new study shows women who drank the equivalent of a beer or small glass of wine each day were less likely to develop chronic diseases like heart disease, cancer, and diabetes as they got older compared to nondrinkers or those who drink four or more drinks at one time.\nResearchers then analyzed health status information collected after the women turned 70.\nIn the study, researchers looked at the effects of drinking alcohol at midlife on the risk of diseases commonly associated with aging in a group of 13,894 women enrolled in the Nurses' Health Study.\nAfter taking into account other factors that might affect health and disease risk, like smoking, researchers found women who drank light or moderate amounts of alcohol were less likely to develop chronic diseases as they aged.\nFor example, compared to nondrinkers, women who drank up to one alcoholic drink per day were 20% more likely to be disease-free at age 70 than nondrinkers.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The cost of alcohol is not in question.", "answer": 2}, {"article": "Whether you've been relatively inactive or fairly athletic, age is the enemy of one of the most important sets of muscles in the body: the group of four known as the rotator cuff that surround the ball of the shoulder joint.\n\nAbout 54% of adults older than 60 have a completely or partially torn rotator cuff, compared with just 4% of those between 40 and 60. But tears are most frequently caused by degeneration of the tendon due to age, rather than injury from sports or trauma. Studies show that tears can be managed without...", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There are no dollar figures at all in this story. The story touts \u201clower costs\u201d of repairing a torn shoulder \u201cearlier rather than later\u201d but never delivers the data. The story should have\u00a0compared costs of\u00a0surgery to non-surgical alternatives and factored in the possible six-months of rehabilitation following surgery. From the available evidence, it appears the only reference to costs in the story is at best an overstatement. It says \u201cthat repairing a tear earlier rather than later may result in better patient outcomes, earlier return to work and lower costs.\u201d", "answer": 0}, {"article": "\"It's a very fragile organ to begin with,\" Kavaler said, \"and if you start to do all these things to it you can disfigure it...\nLong-term vacuum treatments did not appear effective, producing no significant physical changes after six months, Gontero said, but did provide a degree of psychological satisfaction.\nThese devices yielded average flaccid length increases of between 0.2 inches and 1 inch, Gontero said, and men achieving better results noted their satisfaction.\nDr. Elizabeth Kavaler, a urologist at Lenox Hill Hospital in New York City, said functional issues resulting from conditions such as birth defects or prostate cancer surgery may warrant penile surgery, but such cases are unusual.\n\"No study has, however, specifically addressed the extent and type of sexual bother in this patient category.\"\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No cost information was provided, leaving a big hole in the story. The range in costs here is wide, and some of the more invasive procedures would be quite costly. None would be covered by insurance unless necessitated by a medical condition.", "answer": 0}, {"article": "\"People say, 'What's the harm in screening?'\nThe task force and other groups concluded previously that it was unclear whether the benefits of the prostate-specific antigen, or PSA, test outweigh the risks.\nMen younger than 75 should be carefully counseled about the potential risks associated with the test and the lack of evidence about any benefit before getting it, the panel said.\n\"The benefit of screening at this time is uncertain, and if there is a benefit, it's likely to be small,\" said Ned Calonge, who chairs the 16-member U.S. Preventive Services Task Force.\nThe blood test that millions of men undergo each year to check for prostate cancer leads to so much unnecessary anxiety, surgery and complications that doctors should stop testing elderly men, and it remains unclear whether the screening is worthwhile for younger men, a federal task force concluded yesterday.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There was no discussion of the costs associated with prostate cancer screening. \u00a0However, as the cessation of routine prostate cancer screening for men over the age of 75 was the new recommendation by the task force, cost is not really germane to the discussion.\nIt might have been helpful to include some mention of the potential costs to screening older men and/or cost saving with cessation of screening older men. \u00a0There are those that are going to interpret the recommendation against routine screening as a cost saving effort.\u00a0", "answer": 2}, {"article": "But she added, \u201cThe community hopes that if telaprevir is approved by the F.D.A.\nBut experts hope that eventually several of the pills now in development could be used together, much as AIDS is treated, doing away with the need for interferon.\nBut analysts expect the drug to cost tens of thousands of dollars for a course of treatment.\nThat shorter time line, plus a higher chance of success, could entice more people to be treated, experts say.\nIf approved, telaprevir would have to be used initially with the existing drugs to prevent the virus from evolving resistance.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "If you can estimate that a drug is going to\u00a0have sales of\u00a0\"$3 billion a year by 2015,\" then you can estimate how much it is going to cost patients and how much more it is going to cost over existing treatments. This story does neither.", "answer": 0}, {"article": "A three-year-old Silicon Valley start-up, Counsyl Inc., won the Bronze Innovation Award for its simple, low-cost genetic test that can alert prospective parents who might be carrying genes that could cause hereditary diseases in their children.\n\nCounsyl's technology promises a \"high quality-of-life impact for families at risk for conceiving children with familial diseases,\" says Larry Bock, an Innovation Awards judge and special limited partner at venture firm Lux Capital. \"This technology bundles previously...", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "\u00a0This story is particularly complete, if brief, on the subject of costs. The story explains that previously, a single genetic test might cost anywhere from $500 to $1,000. The company\u2019s new test, which covers approximately 100 different genetic conditions, costs about $350. The story also points out that most insurance plans will cover the fee. That has not been the case with previous tests.\u00a0 The does not address the down stream costs. For example, if one of the tests is positive, does it need confirmation or is the specificity of the test adequate? If a patient is really at high risk based upon her/his family history, is a negative test sufficiently sensitive to be sure that person does not have the genetic defect?", "answer": 1}, {"article": "Two new just-released studies offer fresh insights into the best way to lose weight and keep it off. Jennifer Corbett Dooren has details on The News Hub. Photo: Bloomberg\n\nA diet based on healthy carbohydrates\u2014rather than a low-fat or low-carbohydrate diet\u2014offers the best chance of keeping weight off without bringing unwanted side effects, a study published Tuesday in the Journal of the American Medical Association suggests.\n\nStudy participants following a low-glycemic-index diet, which is similar to a Mediterranean diet and focuses on fish, fruit, vegetables, nuts and whole grains, also saw improved cholesterol levels and other important markers that lower the risks of developing heart disease...", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Although diets with more animal protein (e.g. Atkins) are likely to cost more, we don\u2019t think that\u2019s a major consideration with weight loss diets. We\u2019ll call it not applicable.", "answer": 2}, {"article": "Elevated sweat chloride confirms that an infant actually has CF.\nThe findings, published in the journal ACS Central Science, shed new light on the underlying mechanisms of CF and could lead to improved prognosis and better therapies for a disease which is quite variable, affecting different children in different ways, say researchers.\nThe biomarkers also point to other underlying mechanisms that contribute to the progression of CF and could lead to better therapeutic interventions earlier in life.\nBut there are some obstacles that complicate clinical decision-making, explains Britz-McKibbin, because sweat chloride can result in ambiguous diagnoses in some borderline cases and does not reveal how the disease might progress for individual patients.\nTesting for these biomarkers could be done in cases in which the chloride sweat test result is unclear, say researchers.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The study does not address costs. The method used to identify the new biomarkers is described as \u201ca specialized technique developed at McMaster [University]\u201d (where the research was done), making it difficult or impossible to estimate what the cost may be.", "answer": 0}, {"article": "\"I've been through it, it was the past, time to move on,\" he said.\nThis new treatment is still experimental, but it's a step forward in the strategy of manipulating a person's own immune system to fight cancer.\nBut then his doctor offered an additional step: an experimental treatment called immunotherapy, in which antibodies that target the cancer are injected into the bloodstream and attach to the tumor cell.\nBut seven years ago, his parents were concerned by an unusual number of bumps on his head, reports CBS News correspondent Dr. Jon LaPook.\nAfter several trips to the doctor, the Mullins received the worst possible news.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Even though this is an experimental approach, it is possible to make some estimate of costs and this should have been included in the story.\u00a0 The story reports on two years of research results.\u00a0 You can be assured that somebody is tracking costs after two years. ", "answer": 0}, {"article": "Attorney James Tuffin followed his usual daily routine last week: He ran five miles and drove to his office on suburban Long Island. In between, he stopped at Advanced Radiation Centers in North Hills, N.Y. There, he drank a quart of water, lay down on a treatment table and watched as a high-tech linear accelerator rotated around him for 90 seconds, blasting his cancerous prostate with radiation.\n\n\"On a good day, I'm in and out in a half-hour,\" says Mr. Tuffin, 54 years old, who was midway through his scheduled 45...", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story states that \"The cost of RapidArc is similar to other radiation therapies. \u00a0It is covered by Medicare and most insurers\". But that doesn\u2019t tell us the cost, and it seems to suggest that since it is covered by insurers, the consumer need not worry about the costs. \u00a0In fact, the acquisition of this sort of equipment is quite expensive and the doctors investing in the technology will need to recover their costs, which may lead to unnecessary treatments.\u00a0 That\u2019s why actual cost is a big deal and should have been in the story. ", "answer": 0}, {"article": "Psilocybin acts on the serotonin system, suggesting it could be developed for treating depression.\nA small-scale pilot study of psilocybin\u2019s use in cases of treatment-resistant depression showed it was safe and effective, the British researchers said.\nRobin Carhart-Harris, who led the study at Imperial College London\u2019s department of medicine, said the results, published in the Lancet Psychiatry journal, were striking.\nMany patients described a profound experience, he said, and appeared to undergo a shift in the way they perceived the world.\nOf 12 patients given the drug, all showed some decrease in symptoms of depression for at least three weeks.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Costs are not broached in this story. The story signals an\u00a0early phase of research with phrases like \u201cpilot study,\u201d but this is overshadowed by the headline and the lead sentences, which create an expectation of benefit.\nEven at a very high level, for example, the story could have told us whether this is something that could be patented and commercialized by a drug company. The price tag for such a treatment would likely be much greater than if the compound were in the public domain.", "answer": 0}, {"article": "What to do?\nOver seven years, more than 42 percent of eligible women aged 65 to 74 were not screened, Amarath's team found, nor were nearly 57 percent of those older than 75.\nHowever, the study also found that those risk factors -- a small body frame, a history of fractures, or taking medications that could thin bones -- had only a slight effect on a woman's decision to get her bones tested.\n\"DXA screening was underused in women at increased fracture risk, including women aged 65 years and older.\nA team led by Dr. Anna Lee Amarnath of the University of California, Davis, examined the medical records of nearly 51,000 women, aged 40 to 85, living in the Sacramento area.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The study makes no mention of the cost of the screening test or whether it\u2019s typically covered by insurance. That\u2019s what we\u2019d look for here to warrant a bare-minimum Satisfactory grade. We also wonder how much money is being wasted on tests for women who don\u2019t need them, or how much money could be saved by screening more smartly.", "answer": 0}, {"article": "People with hypertension have traditionally been advised to stay away from alcohol because excessive drinking can increase blood pressure.\nBOTTOM LINE: Having one or two drinks a day may be beneficial for men with high blood pressure, but studies like these shouldn't be used to justify excessive drinking.\nThe forthcoming study on men doesn't include an MRI component needed for a more complete comparison.\nCAUTIONS: The study included only male healthcare providers, so it might not be generalizable to a broader population.\nBOTTOM LINE: Exposure to negative stereotypes can actually cause people to perform more poorly.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not mention the cost of having one or two drinks a day, but most people know what the tab can be.\u00a0 So we consider this criterion not applicable for this story. ", "answer": 2}, {"article": "Ellison says she tried meditation, but her mind kept wandering.\nOn the other hand, Rabiner says, neurofeedback may offer something other treatments can't.\nBut it will take better research to figure out whether neurofeedback can live up to that promise, Rabiner says.\nIn the meantime, he says, the study has shown that it is possible to do neurofeedback research that involves a placebo.\nUntil a large study comes along using this sort of approach, parents and consumers will have to decide for themselves whether neurofeedback is worth the time and effort.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story sidebar estimates that a full course of treatment can cost $3000 or more. It could have added that this treatment is unlikely to be covered by many insurance companies.", "answer": 1}, {"article": "About Milken Institute School of Public Health at the George Washington University: Established in July 1997 as the School of Public Health and Health Services, Milken Institute School of Public Health is the only school of public health in the nation's capital.\nVery little help is provided to pregnant smokers who want to quit so the study's findings are important, especially if the strategy can be adjusted to be more effective, Abroms says.\nThe researchers recruited pregnant women who were already enrolled in an established text messaging program called Text4baby.\nThe more intensive intervention did seem to help two subgroups quit smoking at least in the short run, Abroms says.\nThe combo of Text4baby and Quit4baby helped women age 26 and older and those in the second and third trimester of pregnancy quit through the delivery date and in some cases beyond.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "It is not made clear what costs would accompany this kind of mobile health message strategy, and whether the costs would be absorbed by health plans and health care providers that use the service, or by individual patients.\nWide use presumes thousands of app downloads and significant infrastructure costs on the part of those maintaining the service.\nIt\u2019s assumed there is profit motive, given the licensing agreement.\u00a0 ", "answer": 0}, {"article": "Autistic children are prone to seizures.\nLupron therapy grew from the mercury camp.\nGeier's promotional materials said he has treated hundreds of children with Lupron and has launched nine ASD Centers in eight states.\nThe drug is not approved for children \u2013 except a rare few with premature puberty \u2013 because it can impair bone development crucial to growth, said Dr. Gary Berkovitz, chief of pediatric endocrinology at the University of Miami medical school.\nLupron critics said autism parents may not understand the dangers.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story says that Lupron costs about $5,000 a month but is seldom covered by insurance. Good job to address both points. ", "answer": 1}, {"article": "The World Health Organization estimates that more than 300 million people suffer from clinical depression world-wide. But cost, time, stigma, distance to travel, language barriers and other factors prevent many from seeking help.\n\nNow, a growing group of health-care providers are betting that technology\u2014from web-based courses to mobile apps that send prompts via text\u2014can help bridge that gap.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "We\u2019re rating this one a cautious \u201cSatisfactory.\u201d\u00a0 The story offers no information about the cost to a patient of a digital therapist, but it does reflect on the cost of creating and maintaining a similar app.", "answer": 1}, {"article": "\"That helps explain the false positives,\" Audeh said.\n\"Despite poorer performance compared with women without a prior history of breast cancer, overall screening mammography was effective at detecting the majority of breast cancer in women with a [history] at an early favorable stage, with the majority of tumors being diagnosed as ductal carcinoma in situ or stage 1,\" Smith said.\n\"Screening mammography does work well in women with a history of breast cancer, so they should continue to get their annual screening mammogram,\" said Diana Miglioretti, senior investigator at Group Health Research Institute in Seattle and a co-author of the new research.\nThe interval cancer rate was 3.6 per 1,000 screenings in those with a history and 1.4 per 1,000 in those without, the investigators found.\nMammograms had detected 76.5 percent of the cancers in women who had never had breast cancer and 65.4 percent in those who had previously had the disease.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The article does not include information about the psychological and financial costs\u00a0of biopsies for\u00a0women with a false positive diagnosis of breast cancer.\u00a0 Among women with a personal history of breast cancer, 1.7 %\u00a0were referred for\u00a0biopsies that determined there was no second\u00a0breast cancer while 1% of the women without breast cancer had false positive determinations.\nThe article does point out that 18% of women with a personal history of breast cancer were called back for additional imaging or biopsies compared with 8.3% of those without breast cancer but there is no discussion of the psychological or financial costs connected with the additional imaging.", "answer": 0}, {"article": "No question,\u201d he said.\nStill, further studies will be needed to build the case, including testing Erbitux alongside other types of chemotherapy, he added, noting the Phase II study did not meet its primary objective of proving a greater than 20 percent response rate.\nThe Phase II study included 173 women whose cancer had spread and who had received other treatments.\nIt is the first time researchers have shown that a drug like Erbitux, which targets a protein called epidermal growth factor involved in cancer cell growth, can provide substantial benefit in difficult-to-treat \u201ctriple negative\u201d breast cancer.\nDr. Fabrice Andre from Institut Gustave Roussy in Villejuif, France, who was not involved in the research, said the results were \u201cextremely important\u201d but echoed the view that the findings now had to be confirmed in larger-scale clinical tests.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "According to the story, sales for this drug were $1.7 billion last year; however, we don\u2019t know how much an individual person can expect to pay \u2013 information it would have been easy for Reuters to find and to include in the story.\u00a0 ", "answer": 0}, {"article": "Doctor Challenges Cause Of MS And Treatment\n\nOne day 7 years ago, after a long walk with his dog along the Hudson River in Manhattan, Marc Stecker noticed he was limping.\nStecker says if he had it to do over again, he would have waited for more research.\nRobert Zivadinov of the Buffalo Neuroimaging Analysis Center in New York says that not only is the procedure unsafe and costly to many patients, it is impeding necessary research.\nAlthough the doctor who treated him in New York found a significant blockage, he was unable to correct it, Stecker says.\nBut he says he was eager to try something that offered him the first real glimmer of hope for a cure.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story mentions that some patients have flown to Europe and spent their life savings on the procedure, and an expert calls the procedure \u201ccostly to patients.\u201d\u00a0So we can probably assume that\u00a0the procedure is unlikely to be covered by major insurers or Medicare (who would cover those with chronic disability), and that the costs will run into the tens of thousands of dollars or more.\u00a0This is important information for the typical patient who isn\u2019t wealthy enough to\u00a0carry this kind of cost burden.\u00a0The story could have been more explicit about all of this\u00a0and provided more specifics\u00a0about the financial aspects of the procedure. However, we think the main point\u00a0to convey here is that the surgery is expensive and patients will have to pay their own way. The story does this \u2014\u00a0though barely \u2014 so we\u2019ll award a satisfactory.", "answer": 1}, {"article": "Inside the brightly lit storefront in Brooklyn, N.Y., business was brisk as employees combed, washed and blow-dried little heads.\n\n\u201cDo I have a lot of lice?\u201d a boy asks the woman combing his hair slathered in Pantene conditioner.\n\nIt\u2019s the busiest time of the year for companies like Lice Busters, a family-run business Dalya Harel started in...", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The article does a good job of noting the cost of the combing salons, as well as\u00a0cost of the medicinal shampoos and other drug treatments, specifically noting also that insurance may not cover the costs.", "answer": 1}, {"article": "Side effects including shaking, headaches, vomiting and swollen gums\u2014as well as unwanted hair growth.\nAn existing drug used to treat a common bone disorder could hold the key to the cure for baldness, according to a new study.\n\u201cThis research has been tested on human tissue, which is promising, but not on humans themselves, so there is still some way to go.\nDr. Hawkshaw said in a statement: \u201cThe fact this new agent, which had never even been considered in a hair-loss context, promotes human hair growth is exciting because of its translational potential: It could one day make a real difference to people who suffer from hair loss.\u201d\n\n\u201cClearly though, a clinical trial is required next to tell us whether this drug or similar compounds are both effective and safe in hair-loss patients.\u201d\n\nA British Association of Dermatologists spokesperson said in a statement the results were interesting.\n\u201cFor individuals with hair loss, treatments can be very hit and miss, there isn\u2019t one which is universally effective.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Arguably it\u2019s too early to know anything about how much this treatment might cost. But, if it\u2019s not too soon to speculate about a \u201ccure,\u201d it also could be argued that it\u2019s not too soon to address cost impacts. This was a tough call, but we went with N/A because of how early the research is.", "answer": 2}, {"article": "October 26, 2017 - For younger patients with severe damage to the rotator cuff muscles, a \"reverse\" shoulder replacement provides lasting improvement in shoulder function, according to a study in The Journal of Bone & Joint Surgery.\nWith refinements in technique and components in more recent years, the procedure has been used in younger, more active patients.\nBut there are concerns about how well the results of RTSA will hold up over time in this group of patients.\nThe improvement was similar for patients with and without prior shoulder surgery.\nThis group of patients typically gets limited benefit from shoulder replacement with conventional implants, which rely on the rotator cuff muscles to provide shoulder movement.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There is no mention of the cost of this surgical procedure in this news release.\u00a0 A quick search online reveals that such procedures can range in cost from $7,000 to $21,000 while an average cited by a study from Johns Hopkins placed the typical cost at around $10,000.\u00a0 Joint replacement operations are typically expensive and their costs should be provided in any story or news release promoting their use.", "answer": 0}, {"article": "Women are considered obese at a BMI of 30 and morbidly obese at 40 (which is typically about 100 pounds over a woman's ideal body weight), yet almost a third of women presenting for bariatric surgery did not identify themselves as obese.\nThe study speaks both to the benefits of bariatric surgery and to the tremendous toll obesity takes on health.\nThe study looked at the effects of bariatric surgery in a relatively short timeframe, one to three years after surgery.\nWhile the study speaks to the transformative effect bariatric surgery can have, Modesitt urged people to avoid gaining weight in the first place and for those seeking to lose weight to exercise and eat more healthily before turning to surgery.\nModesitt, of the UVA's Division of Gynecologic Oncology in the Department of Obstetrics and Gynecology, was most surprised by the dramatic changes seen in the patients' metabolic profiles derived from the gut microbiome, the population of microorganisms living inside us.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There is no mention of costs in the release (or in the study).", "answer": 0}, {"article": "Their symptom score dropped by 29 percent and the number of hot flashes by 35 percent, according to Dr. Yan-bin Ye of Sun Yat-sen University in Guangzhou.\n\u201cThe majority of them are showing no benefit,\u201d said William W. Wong, a nutrition researcher at Baylor College of Medicine in Houston who wasn\u2019t involved in the new work.\nThe work was supported by Frutarom Netherlands, which also donated the supplements.\nHe said it was \u201chard to believe\u201d that soy would have an effect on these women.\nBut a U.S. expert wasn\u2019t convinced by the results, which run counter to other published studies.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Soy supplements are over the counter so the price may vary.\u00a0 Story cites estimate.", "answer": 1}, {"article": "Stress tests measure the heart's response to exertion, letting doctors see or hear any disease.\nEven more surprising, the rate of bad outcomes among the heart patients studied were extremely low.\nThe first showdown pitting 3-D, heart-imaging exams against older stress tests atop treadmills or stationary bikes found that among 10,003 heart patients, their rates of eventually having serious heart events were the same \u2014 no matter which method doctors used to check their tickers, researchers said.\nThe 10,000-plus patients, who visited 193 health centers in the U.S. and Canada, had no prior diagnosis of coronary artery disease.\nResults of the federally funded trial \u2014 Prospective Multicenter Imaging Study for Evaluation of Chest Pain (PROMISE) \u2014 were presented at the American College of Cardiology\u2019s 64th Annual Scientific Session in San Diego.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Costs do not surface in this story.\u00a0 Since one would assume that a CT scan would be considerably more expensive than traditional stress tests, this seems to be an important omission. \u00a0A bit of digging would have made apparent another type of cost between the two kinds of tests: A 2011 observational comparison of these two modalities among Medicare patients (published in the Journal of the American Medical Association) found that heart-related health-care spending was substantially higher among patients who received coronary CT angiography compared with traditional stress testing.", "answer": 0}, {"article": "An inexpensive drug therapy far surpassed a conventional laser procedure in fixing a leading cause of blindness in babies born prematurely, according to a new study.\n\nThe results of the study, to be published this week in the New England Journal of Medicine, were so significant that the 15 hospitals participating in the research have stopped using lasers in favor of the drug, Avastin, which is injected into the eyes of the affected newborns. Avastin, made by Roche Holding AG's Genentech unit, is designed to be used for treating...", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "It gets credit for discussing the costs of Avastin.\nIn this review, we\u2019ll keep coming back to the lack of context for the comparison to Lucentis. This article doesn\u2019t discuss the use of Lucentis in this condition. Is it a real, off-label alternative or a hypothetical one?\u00a0Since the study compared Avastin and a laser, the latter\u2019s price tag would\u2019ve been more relevant instead.", "answer": 1}, {"article": "Phentermine quickly suppresses appetite, while the controlled-release topiramate decreases appetite and increases satiety throughout the day.\nOverall, people who took the combination pill lost more weight than their counterparts who were given a placebo.\nTopiramate also has blood pressure-lowering effects, she says.\nThe people who took the lowest dose of the drug dropped about 5.1% of body weight at six months, and, on average, gained some back by one year.\nThose who took the medium dose of the pill lost 8% of their body weight at six months and 8.2% by one year.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "\u00a0There was no discussion of costs.", "answer": 0}, {"article": "\"It took quite a bit of time to get approval,\" Mithoefer says.\n(All of the participants received additional therapy sessions that did not involve the drug.)\nOn two separate occasions, 12 of the people took a dose of MDMA and then spoke for several hours with a pair of trained therapists.\nThe resulting sense of euphoria and emotional warmth seems to help patients connect with their therapists, says Michael Mithoefer, M.D., the lead author of the study and a Mount Pleasant, South Carolina-based psychiatrist who specializes in PTSD.\nConducting a study with an illegal drug is a complex process.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "At a minimum, the story could quote the DEA, FBI or other law enforcement source on a price range for a typical dose of MDMA. The reporter also could have asked the authors how they obtained MDMA\u00a0and how much it cost them.", "answer": 0}, {"article": "By far, the lowest incidence of colorectal cancers was seen in pesco-vegetarians, people who eat fish at least once a month but eschew all other types of meat. Compared to omnivores, pesco-vegetarians were 43% less likely to be diagnosed with these cancers during the course of the study.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Dietary changes can affect budgets. But the general dietary changes discussed in this story, and in the study it is based on, don\u2019t lend themselves to an analysis of costs. We\u2019ll rate this as not applicable.", "answer": 2}, {"article": "Lower disk herniation results when the insulating disks that sit between spinal vertebrae tear open, allowing jelly-like material to protrude and exert pressure on surrounding nerve roots.\nHe noted that because \"the majority of people with back pain improve with time and exercise alone,\" it remains an open question as to whether the pRF procedure really cured the condition.\n\"Steroid injections are effective only in portion of the patients, and generally require more sessions,\" he noted.\nAnd the new research suggests the treatment could prove a boon to back pain patients for whom standard therapies have failed to do the trick.\nThe therapy is not new, having first received U.S. Food and Drug Administration approval in the 1980s.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story says pRF is \u201cfar cheaper\u201d than steroid injections, but there\u2019s no data on its cost.\nWe found one web site, MD Save, offering procedures for $2,500, but it\u2019s unclear whether that\u2019s representative.\nThe story could have helped readers by comparing the cost of CT-guided pRF, CT-guided steroid injections, and lumbar disk surgery.", "answer": 0}, {"article": "Qi Sun of the Harvard School of Public Health and his colleagues analyzed data collected from 13.984 female nurses participating in the Nurses\u2019 Health Study, an ongoing study examining a variety of health issues.\nNow, the researchers stressed that wasn\u2019t the case for women who consumed more than two drinks a day or four drinks or more at a time.\nFor women who like a nice glass of wine at the end of the day, there\u2019s more good news: Even middle-aged women can have about a drink a day of any kind of alcoholic beverage as part of what they do to try to stay healthy as they age, according to new research.\nThat was after accounting for other factors, such as smoking.\n\u201cThese data suggest that regular, moderate consumption of alcohol at midlife may be related to a modest increase in overall health status among women who survive to older ages,\u201d the researchers wrote.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The cost of alcoholic beverages isn\u2019t in question.", "answer": 2}, {"article": "Ancient Greek and Chinese medical practitioners used a patient\u2019s scent to make diagnoses.\nBut not every physician\u2019s nose is a precision instrument, and dogs, while adept at sniffing out cancer, get distracted.\nThese molecules offer a whiff of who we are, revealing age, genetics, lifestyle, hometown \u2014 even metabolic processes that underlie our health.\nEach of us has a unique \u201codorprint\u201d made up of thousands of organic compounds.\nBlindfolded, would you know the smell of your mom, a lover or a co-worker?\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Given that all the sources here have a vested interest in seeing these products come to market, clearly there\u2019s investor excitement\u2013aka \u201cprofit potential.\u201d When that\u2019s the case, it\u2019s a good idea to spend some time discussing what these products might cost, especially if they\u2019re not any more precise than current methods, which remains unknown. Healthcare costs in the U.S. are staggering\u2013will these products magnify this problem, or alleviate it?", "answer": 0}, {"article": "In addition to He and Dibaba, other contributors included Pengcheng Xun, a faculty member in IU's Department of Epidemiology and Biostatistics; Kuninobu Yokota of The Jikei University School of Medicine in Tokyo, Japan; and Emily White of the University of Washington in Seattle.\nThe study found that every 100-milligrams-per-day decrease in magnesium intake was associated with a 24 percent increase in the occurrence of pancreatic cancer.\n\"While more study is needed, the general population should strive to get the daily recommendations of magnesium through diet, such as dark, leafy greens or nuts, to prevent any risk of pancreatic cancer.\"\n\"The five-year survival rate is really low, so that makes prevention and identifying risk factors or predictors associated with pancreatic cancer very important.\"\nThe study also found that the effects of magnesium on pancreatic cancer did not appear to be modified by age, gender, body mass index or non-steroidal anti-inflammatory drug use, but was limited to those taking magnesium supplements either from a multivitamin or individual supplement.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "No cost information is provided but there are cost implications to following the recommendations. The release concludes that everyone \u201cshould strive to get the daily recommendations of magnesium through diet\u201d and \u201cadding a magnesium supplement to their diet may prove beneficial in preventing this disease.\u201d", "answer": 0}, {"article": "The American Diabetes Association has more about diabetes-related eye complications.\nThe American Academy of Ophthalmology will review the study findings and make recommendations on whether Lucentis plus laser treatment should be the preferred treatment for a large number of patients with DME.\nThis is a \"seminal\" study,\" added Dr. George A. Williams, a board member of the American Academy of Ophthalmology and chair of the ophthalmology department at Oakland University William Beaumont School of Medicine.\nThe study, published online in the journal Ophthalmology, was conducted by the Diabetic Retinopathy Clinical Research (DRCR) Network.\nBut researchers say it can also improve vision in people with DME, a common form of diabetic retinopathy.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Cost isn\u2019t mentioned and in that oversight is perhaps the biggest flaw of the story \u2013 that it did not explain \u2013 as the New York Times story did \u2013 that there are questions about Lucentis vs. a cheaper alternative. From the NYT: ", "answer": 0}, {"article": "They include people like Danielle Denlein, who, to her total shock, developed a serious heart problem.On October 20, 2008, at 1:50 p.m., Ms. Denlein was driving to a drug store to buy formula for her 5-day-old baby girl.\n\u201cIt\u2019s just a phenomenal tool.\u201d\n\nThere is a downside, though: \u201cInformation overload is a very serious problem\u201d for the doctors, said Dr. Lynne Warner Stevenson, director of the Heart Failure Program at Brigham and Women\u2019s Hospital in Boston and a professor at Harvard Medical School, who counts herself as a proponent of smart devices.\nOne solution, being tested by St. Jude Medical, a medical device company in St. Paul, is to let patients deal with important data.\nThe hope is that the devices, now being tested in clinical trials, will save lives, reduce medical expenses and nudge heart patients toward managing their symptoms much the way people with diabetes manage theirs.\nBut it can be even harder for primary care doctors, who have less expertise in heart failure yet care for most of the six million patients in the country with the condition.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "\u00a0Mixed bag. The story explained that the devices \"can cost as much as $30,000.\"\u00a0 And there was one data point from one study on one device that users\u2019 hospital costs were $1,600 less per admission.\u00a0 But the device costs are variable and device performance will be variable.\u00a0 We\u2019ll give the story the benefit of the doubt but it painted the cost picture with really broad strokes. ", "answer": 1}, {"article": "The Mediterranean diet can vary from country to country but the foods consumed from Greece to Spain tend to be high in fruits, vegetables, fish, legumes, nuts, bread, pasta, cereals, potatoes and unsaturated fats like olive oil.\nThey are the first studies to examine the association between the Mediterranean Diet and neurological diseases \u2013 specifically Alzheimer's.\n\"The next step would obviously be to do an intervention trial where one group eats the diet, the other eats a traditional American diet and then look at the outcome.\n\"Those who moderately adhered to the diet had a 53 percent reduction in risk of developing Alzheimer's disease,\" The Early Show medical contributor Dr. Emily Senay.\nThis study, as well as another published earlier this year, were both conducted by Columbia University Medical Center and sponsored by the National Institution of Health (NIH).\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story advocates a diet of fresh fruits and vegetables, beans, nuts, fish and moderate consumption of wine. Fresh foods may cost more than pre-packaged fast food and may not be readily available to poorer people living in urban areas. These people are at even greater risk of developing health problems from a traditional American diet of processed, high-fat foods. This is not addressed in the news story.", "answer": 0}, {"article": "The panel suggests that heart patients be screened by first asking two standard questions: In the past two weeks, have you had little interest or pleasure in doing things?\nPsychiatrist Michelle Riba said the statement\u2019s emphasis on frequent screening is important.\n\u201cA lot of patients with depression don\u2019t follow up on it,\u201d said Dr. Mary Whooley, a professor of medicine at the University of California, San Francisco, who was not on the panel.\nOne doctor said screening isn\u2019t enough; patients need close monitoring to make sure they get help.\n\u201cI know we can do more.\u201d\n\nAlthough there\u2019s no direct evidence that heart patients who are screened fare better, depression can result in poorer outcomes and a poorer quality of life, the panel said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story didn\u2019t describe the costs of depression screening nor did it mention reimbursement issues as a barrier to providing the screening.", "answer": 0}, {"article": "When it reaches the area of the heart that causes abnormal rhythms, the tissue is ablated, or destroyed.\nPatients in the Medtronic-sponsored trial who underwent the cryoablation procedure \u2014 which involves using a catheter to freeze away the heart tissue where the problem originates \u2014 was just as safe as drugs used to treat the condition and far more effective, meeting the study\u2019s primary goal of eliminating atrial fibrillation one year after the procedure.\nA small pilot study funded by St. Jude Medical Inc STJ.N compared the two therapies in a sicker population of patients and also found that the procedure worked better than drugs.\nLess than 1 percent of patients treated with cryoablation were hospitalized for a recurrence of the disease, compared with 6 percent in the drug group.\nDubbed Stop-af, the Medtronic trial showed that almost 70 percent of patients who had cryoablation remained free of the condition after one year, compared with just 7 percent of patients who received drug therapy, according to data presented at the American College of Cardiology meeting in Atlanta.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "\u00a0There was no discussion of costs.", "answer": 0}, {"article": "Calcineurin is an enzyme that regulates communication between brain cells and memory formation.\nHowever, the question of whether such a strategy would prevent the onset and progression of Alzheimer's in people is challenging because treatment with a calcineurin-blocking agent suppresses the immune system.\nA new study from The University of Texas Medical Branch at Galveston has revealed that a treatment taken daily by people who have had organ transplants to prevent organ rejection protects against Alzheimer's disease.\nTo bypass this issue, the UTMB team analyzed data from the medical records of 2,644 patients who received organ transplants and must take calcineurin inhibitor-based medications, such as Tacrolimus or cyclosporine, for the rest of their lives to prevent rejection of the transplanted organ.\nAn early online version of this paper detailing the findings has been published and is scheduled for publication in the July 7 issue of the Journal of Alzheimer's Disease.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The economic and clinical toll taken by Alzheimer\u2019s and other forms of dementia is staggering, so a treatment that could reduce the likelihood of developing the disease would have large consequences. \u00a0Identifying who should receive the treatment is important since not everyone will develop dementia. \u00a0That makes the cost of the intervention an issue from the economic perspective. These are difficult issues to explore in a new release, but the release could have at least signaled the importance of the discussion by mentioning the cost of these drugs. The medications are currently available for use by transplant patients \u2014 so pricing should not be hard to find.", "answer": 0}, {"article": "Some critics say Medicare would not be doing a review of a drug already approved by the F.D.A.\nHowever, the panel gave very low scores to evidence that the drug would help prostate cancer patients other than the type who participated in the clinical trial, which were men with advanced cancer, but no or minimal symptoms.\nDr. Jacques said he ordered the review after being contacted by federal lawmakers questioning why their constituents could not get the drug.\nHowever, Dr. Smith said he doubted that was the case because there were signs the drug also controlled tumors outside the bones.\nA late-stage trial could begin as early as next year, he said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story provided the costs for the FDA approved Provenge ($93,000/patient); as XL184 is under study and not available for sale, there was no information about what its costs might be.", "answer": 1}, {"article": "A surgically implanted electrical device that stimulates the sacral nerve can calm an overactive bladder, according to a company that sells it. Physicians say sacral neural stimulation works well for many patients, but a test period with an external device is recommended first.\n\nMillions of Americans suffer from \"urge incontinence,\" accidents caused by a strong, sudden need to get to the bathroom, or overly frequent urination, defined as eight or more times a day. Quality of life is affected, as sufferers must...", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story mentions the cost of the device.", "answer": 1}, {"article": "Cabozantinib, also known as XL184, is an oral drug designed to limit blood supply to tumors and to block two segments of a pathway used by cancer cells to grow and spread.\nThe drug reduced by 87 percent the risk of disease progression or death.\nThe study results were reported on Monday at the American Society of Clinical Oncology\u2019s annual meeting.\nOther Phase 2 data presented over the weekend showed that treatment with cabozantinib led to significant tumor shrinkage in 24 percent of patients with metastatic ovarian cancer.\nThe disease remained stable in 23 other patients, or 21 percent, and worsened in three.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No discussion of projected costs \u2013 not even a statement that the company has not yet projected costs.\u00a0 We look for cost information in every single story.", "answer": 0}, {"article": "\u201cNow we know that electrical impulses to the olfactory bulb can provide a sense of smell \u2014 and that\u2019s encouraging.\u201d\n\nIn addition to Dr. Holbrook, authors on the International Forum of Allergy & Rhinology study include co-first author Sidharth V. Puram, MD, PhD, of Washington University School of Medicine, Reiner B.\nReporting online today in International Forum of Allergy & Rhinology, the research team describes their results, which provide a proof of concept for efforts to develop implant technology to return the sense of smell to those who have lost it.\nThis breakthrough in human patients opens the door for a \u201ccochlear implant for the nose\u201d to be developed \u2014 though the study authors caution that the concept of an olfactory stimulator is more challenging than existing technologies.\nThere are currently no proven therapies for these cases.\nThe findings described in the International Forum of Allergy & Rhinology report demonstrate this feasibility.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Cost isn\u2019t addressed, but we wouldn\u2019t expect much here in regard to cost. The work is far too preliminary to attach a price tag, and the release highlights just how far off any relevant technology is from becoming a reality. Ideally, some discussion of cost, even in the most general terms (even if, for example, it were simply to say that it is far too early to estimate cost) would have been desirable.", "answer": 2}, {"article": "The closed loop insulin delivery system, for example, computes insulin doses and administers them according to glucose levels detected by a sensor.\nWithout replacement insulin, people with type 1 diabetes couldn't survive.\nHovorka's team is one of several working to produce an effective artificial pancreas, also known as a closed loop system or closed loop delivery.\nSeveral weeks later, the participants came back for another meal and switched overnight regimens.\nBut, replacing insulin isn't easy.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story makes no mention of costs, even though the costs of statins are easy to find, and, in Canada, because of the universal health care system, the costs of statins to the government should be an easy number to quantify.", "answer": 0}, {"article": "Scientists have used a form of stem-cell therapy to improve survival rates for the most severely sick lupus patients, a group that usually has no remaining treatment options.\n\nLupus is an autoimmune disease that attacks an individual's own organs, causing symptoms that range from swollen joints and skin rashes to severe damage to kidneys, lungs and other parts of the body.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The costs for HSCT was not mentioned.", "answer": 0}, {"article": "Ten years ago, scientists started looking at the hormones made in the pituitary gland to see how they act on certain targets.\nBut it could also be a unique drug because it lowers body fat and makes bones stronger.\nTheir next step is to \u201chumanize\u201d the antibody, so it can be tested without triggering an immune response.\nThat would then lead\u2014if all goes well\u2014to the first human trials in three to four years.\u201d\n\nAt present, the researchers are focusing on the adiposity, rather than bone loss, for drug development: \u201cI think obesity is a more prevalent disease\u2014but osteoporosis at the tail end can be tagged on.\nThey found some of these hormones had an effect on bone mass.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Cost is not discussed. The Nature article notes that \u201cIcahn School of Medicine at Mount Sinai has filed a provisional patent application that covers the application of FSH inhibition to decrease body fat,\u201d so clearly the researchers have considered the possibility of commercializing the relevant antibody. And while it is likely far too early for one to say what a related medical treatment might cost, the story needs to make clear that there will be a cost. Is it easy to produce antibodies like this one? Does it involve esoteric technologies or components that could contribute to cost? Is it something that could be made using existing manufacturing processes? If nothing else, the story could at least say that researchers aren\u2019t sure what any resulting treatments might cost (assuming someone asked the researchers about this).", "answer": 0}, {"article": "Older people tend to get less slow-wave sleep and are at greater risk for memory impairment.\nBut first, says Zee, larger and longer studies are needed to confirm the findings and show that there are benefits to long-term use, rather than on just one night.\nThe researchers hope to develop an affordable device that people can use at home.\nOn one of those nights, headphone-clad participants were played a series of short bursts of pink noise during deep sleep, spaced out enough to prevent the brain from getting used to and ignoring them.\n\u201cIt\u2019s just noticeable enough that the brain realizes it\u2019s there, but not enough to disturb sleep.\u201d The sounds were timed to match their slow-wave oscillations.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The article makes clear that commercial development of a pink noise generator is in the future, so it\u2019s too early to say what such a technology would cost. Indeed, we\u2019re told that the researchers hope to develop an affordable device. Affordable is too vague to be helpful here. We encourage reporters to at least dig up some numbers on existing alternatives. For instance, there are 99-cent apps to generate white noise and presumably higher quality speaker devices that run up to $120. But the pink noise study relied on timing the noise to sleep waves \u2014 so would a commercial product need to include an electroencephalogram device as well? That seems a different price category altogether.", "answer": 0}, {"article": "As technologies and processes continue improve this is likely to be reduced,\" she continues.\nThese vaccines are not necessarily the future of personalized cancer treatment.\n\u201cIt is still unknown whether these vaccines will extend the survival of cancer patients, or whether they are more effective than other recently developed immunotherapies.\nCornelius Melief, from the Leiden University Medical Center, Netherlands, said in an accompanying News & Views article that controlled, randomized Phase II clinical trials will be needed to work out if the vaccines are effective.\nHe added, however, that the studies confirm the potential of cancer vaccines.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "This story doesn\u2019t discuss how much the vaccines cost. Therefore, readers can\u2019t compare the affordability of these vaccines to existing treatment options.", "answer": 0}, {"article": "All rights reserved.\nIn a recent nationwide survey of gastroenterologists, IBgard\u00ae was the number one recommended peppermint oil for IBS.\nAn international scientific and medical review team reported that there are a range of agents available to treat IBS and physicians should be knowledgeable about the efficacy and risk profile of any option they are about to prescribe.\nAmong the thirteen IBS options that Dr. Enck and the authors reviewed, only peppermint oil had the lowest NNT (number needed to treat) of 2-3 patients needed for one patient to benefit from the therapy.\nIn the section of the article discussing management options for IBS, Dr. Enck and the accompanying panel of researchers stated \"peppermint oil\u2026is beneficial in reducing IBS symptoms.\"\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The news release by the maker of IBgard notes that its product is available at \u201cCVS/pharmacy, Walgreens and Rite Aid\u201d and other stores, but it neglected to tell readers that the recommended doses would cost up to four times as much as generic peppermint oil capsules, with a monthly cost that could exceed $100 (6 capsules/day). (CVS lists IBgard at $22.99 for 48 capsules, or 63 cents each vs. 15 cents each for generic capsules.)", "answer": 0}, {"article": "New research is helping Pfizer Inc. build a case for getting an important drug in its portfolio approved to treat a mysterious pain condition that could offer a big additional source of sales.\n\nThe New York drug maker said Tuesday that Lyrica, already on the market to treat certain types of pain, reduced painful symptoms among sufferers of fibromyalgia, a chronic and controversial condition that may affect as many as six million Americans. And today, it will unveil results from another study that it says shows Lyrica has a lasting...", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There is no information about the costs of this medication.", "answer": 0}, {"article": "Neuroblastomas are cancers that start in early nerve cells and commonly form in the tissue of the adrenal glands, near the kidneys.\nOverall, the nano-therapeutic treatments showed a more pronounced effect in MYCN-amplified cells, which are traditionally more resistant to drug therapies.\nThis research is an excellent example of the collaboration between Nemours Children's Hospital and the University of Central Florida.\n\"High-risk neuroblastoma can be resistant to traditional therapy, and survival can be poor.\nThe study, conducted in partnership by researchers at Nemours Children's Hospital and the University of Central Florida, demonstrates a potentially novel treatment for neuroblastoma, the most common cancer in infants.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "This news release is about a pre-clinical study that looked at the effects of cerium oxide nanoparticles and curcumin in cell culture. It will be a while before this type of technology is studied in living patients.\nWe rate this one Not Applicable.\nWe caution news release writers that if it\u2019s not too early to talk glowingly about the potential life-saving benefits of an intervention in a news release, it\u2019s not too early to give some attention to the costs. However, this research is clearly far too preliminary to make such projections.", "answer": 2}, {"article": "A capsule of Probiotic Immunity from New Chapter Inc., based in Brattleboro, Vt., contains 1 billion each of 10 different organisms, including Streptococcus salivarius subsp. thermophilus and Lactobacillus acidophilus, two species of bacteria often found in yogurt. Other ingredients include herbs such as cumin, ginger and spinach. Users are instructed to take two capsules each day, preferably one in the morning and one in the evening, on an empty stomach. You can buy a bottle of 90 capsules for about $20 at many health food stores.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story includes the cost of several of the products mentioned.", "answer": 1}, {"article": "So patients are caught in the middle.\"\nAnd the study's authors note that the ImPAT approach has the potential to be easily and inexpensively adopted by addiction treatment centers and groups worldwide, through team members trained in standard psychological techniques.\nIn an editorial accompanying the new paper, another addiction and pain specialist, William C. Becker, Ph.D. of Yale University and the Connecticut VA, notes that the new results are even more impressive because ImPAT was compared with another psychosocial approach.\nIn the meantime, he notes, people struggling with addiction who want to seek relief from pain should explore the full range of treatment options that have been shown to work in non-addicted patients, including physical therapy, exercise and psychotherapy as well as antidepressant medications.\nThe larger ongoing study, based in an abstinence-based treatment facility in Michigan and funded by the National Institute on Drug Abuse, has largely avoided that issue by decreasing the delay between study recruitment and the start of the treatment groups, Ilgen says.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Costs aren\u2019t addressed. How much might one ImPAT session cost\u2013given that patients may need as many as 10 sessions (or more) to see benefits? Is it possible that these sessions would be covered by insurance? It\u2019s not clear. However, to the release\u2019s credit, it does note that this treatment \u201chas the potential to be easily and inexpensively adopted by addiction treatment centers and groups worldwide, through team members trained in standard psychological techniques.\u201d That\u2019s a positive point. But it doesn\u2019t get at what the costs might be for patients. For example, does\u00a0\u00a0inexpensive adoption by treatment centers guarantee inexpensive treatment sessions?", "answer": 0}, {"article": "According to the American Cancer Society, melanoma accounted for more than 68,000 cases of skin cancer in 2009, and 8,650 deaths.\nResults of a late-stage study of the drug in melanoma patients will be detailed in a \u201clate-breaker\u201d session at ASCO\u2019s annual meeting in June.\nThe study is the first to test ipilimumab in patients whose skin cancer had spread to the brain, and the findings, released in an abstract or brief summary, support its potential use in these patients, the researchers said.\nIn the phase 2 trial, researchers said four out of 51 patients with at least one brain lesion had a partial response to the drug, and in 5 out of 51 patients, both brain and other tumors in the body stabilized after 12 weeks of treatment.\n\u201cThese findings may have implications for the use of ipilimumab therapy in the long-term management of advanced melanoma,\u201d the researchers reported in the abstract.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "1clip_filelist.xml\" rel=\"File-List\"/>\n\n\n\nAlthough the cost of this experimental therapy may not be known, it would have been useful to point out whether this drug is similar to other drugs that carry extremely high price tags (some are thousands of dollars per dose) or might be something that might be offered at a lower cost. \u00a0", "answer": 2}, {"article": "\u201cDr.\n\u201cThis variation of a standard technique used during breast reconstruction will revolutionize the post-operative recovery in patients who meet certain criteria for the procedure,\u201d notes Dr. Small.\nValley was the first hospital in northern New Jersey where an innovative technique \u2013 called pre-pectoral placement of a tissue expander -- was utilized during breast reconstruction surgery following a mastectomy.\n\u201cHere at Valley, we are proud to offer this option for our patients and are excited about its potential for vastly improving patient care for women with breast cancer.\u201d The technique involves placing tissue expanders (interim implants) under the skin on top of a woman\u2019s pectoralis muscles after her breast tissue has been removed.\n\u201cOver the past decade there have been dramatic improvements in breast reconstruction that utilize various types of surgical innovations, implants, and biologic tissue,\u201d notes Dr. Small.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "No dollar signs here. However, not including a mastectomy (anywhere from $15,000 to $55,000 or more), tissue-expander breast surgeries typically cost about $40,000 per breast. But if there are any complications, those costs can skyrocket due to additional surgeries and other medical costs.", "answer": 0}, {"article": "Miner continued.\nIn this study, the serum presence of a mesothelioma-specific form of the ENOX2 protein (a recently identified marker of malignancy) was found within the serum of asbestos-exposed individuals an average of 6.2 years in advance of clinical symptoms by using the ONCOblot tissue of origin cancer detection test.\nMorNuCo Laboratories is elated to share these results with the public, as early detection is widely considered the corner stone of an effective strategy to reduce cancer-related deaths.\nA 510(k) application is being prepared for submission to the FDA to register the ONCOblot test as a medical device.\nThe ONCOblot Test is CLIA registered and meets all current FDA regulations as an LDT.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "It is notable that the company that sells the ONCOblot test (which can be used for early detection of 26 different cancers) doesn\u2019t discuss its price. Some clinics list their test cost at $850 or $1000. It is not known how often testing would need to be repeated, if it is found to be useful for people exposed to asbestos.", "answer": 0}, {"article": "The found the chronic poor sleepers became sick more often: those who slept for five hours or less each night were 4.5 times more likely to catch the cold than people who slept seven hours or more.\nIn fact, sleep was more important than any other factor, including age, stress or income level, in predicting who would get sick after being exposure to the cold virus, the researchers say.\nThe study provides more evidence of the link between healthy sleeping habits \u2014 which experts say means at least seven hours of sleep each night \u2014 and overall good health.\nThe study is unique because it used objective measures to show that poor sleep habits make people more vulnerable to a cold virus, says Badr, who was not involved in the research.\nThe actigraphy measured sleep in a much more accurate way than information researchers get from self-reports, he says.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story makes no mention of costs, but there is no obvious commercial product involvement here, so we\u2019ll rate it Not Applicable. Although in theory there may be a cost to more sleep \u2014 \u00a0people often give up sleep for work or other activities.", "answer": 2}, {"article": "\u201cAll it does is allow us to choose the best embryos to transfer so that we can get the patients pregnant faster,\u201d he said.\nSpecialists now have a way to test the parents-to-be that may not only increase their chances of getting pregnant but also reduce the risk of them passing on certain genetic diseases.\nExperts say the couples are not the only people who benefit from these tests.\nA diagnosis before pregnancy may sound like a designer baby, but doctors say that\u2019s not the case.\nFor 6.7 million American women of child-bearing age, getting pregnant is not an easy task.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story doesn\u2019t address cost at all, which is a huge oversight in a story about preimplantation genetic screening. First of all, preimplantation genetic screening is only an option for people who are using IVF \u2014 which is expensive and often not covered by insurance. Second, the screenings themselves often cost thousands of dollars.", "answer": 0}, {"article": "Close to 800,000 people in the U.S. suffer a stroke each year, mostly older adults.\nHe said that larger studies at multiple treatment sites are needed to determine how helpful magnetic stimulation can be in stroke recovery.\nThe ideal option might end up being a combination treatment that involves stimulation in certain patients and other therapies that address a range of skills important for regaining function, Barrett added.\nBut researchers said it\u2019s still unclear what types of patients might benefit from the treatment and by how much.\n\u201cThey\u2019re less likely to become completely independent.\u201d\n\nMost of those patients can improve with therapy and exercises, she said, but the process is often slow, and keeping people in the hospital during it is costly.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story states that the transcranial magnetic stimulation\u00a0(TMS) machine costs about $50,000, but it could also have noted \u2014 as WebMD did \u2014 that there are\u00a0costs associated with training clinicians to use\u00a0the machine. In addition, neither story tried to estimate what a course of\u00a0treatment might\u00a0cost patients or their insurers \u2014 information which probably could be gleaned by looking at the costs of TMS treatment for depression. Although there was room for improvement here, we think the story does enough to\u00a0merit a satisfactory.", "answer": 1}, {"article": "New guidelines\u2026 (Photo illustration by Gary\u2026)\n\n\u201cMigraine is a condition that involves recurring headaches.\nThese medications \u201care effective for migraine prevention and should be offered to patients with migraine to reduce migraine attack frequency and severity,\u201d Silberstein and colleagues wrote in the new guidelines, which were based on a review of 284 publications.\nThe authors also noted that frovatriptan (Frova), which is used to treat migraine symptoms, can also help prevent menstrual migraines.\nNeurologists say that only about one-third of those who could benefit by migraine-preventing medication actually use it.\nMany migraines can be prevented by taking medication every day.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The cost of migraine prevention drugs was not mentioned and cost is an important consideration.\u00a0 The costs range from pennies a day for beta blockers to over $300 for a monthly regimen of Trova. Even the guideline authors mentioned cost as a potential barrier.\n\u00a0", "answer": 0}, {"article": "Related links:Department of PsychologyCentre de recherche interdisciplinaire en r\u00e9adaptation du Montr\u00e9al m\u00e9tropolitain\u00c9cole d'optom\u00e9trie at the Universit\u00e9 de Montr\u00e9alMAB-Mackay Rehabilitation Centre\nA study recently described in Good Times Magazine provides the first experimental evidence that the Apple iPad is as good as technology traditionally used in reading rehabilitation for individuals with visual impairment.\n\u201cWhen we took previous experience into account, we found that participants who had used iPads before read on average 30 words per minute faster than those who were using the iPad for the first time.\n\u201cWhat\u2019s more, compared to the devices currently used by those with low vision, iPads are multi-functional, allowing the user to go online, check email, make video calls \u2014 and they cost less than the traditional devices,\u201d he says.\nThe study's third co-author is Julie-Andr\u00e9e Marinier, from the Centre de recherche interdisciplinaire en r\u00e9adaptation du Montr\u00e9al m\u00e9tropolitain and \u00c9cole d'optom\u00e9trie at the Universit\u00e9 de Montr\u00e9al.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "We are glad to learn, as the release points out, that there may be a less expensive option for seniors needing vision aids, but we were disappointed that the release did not give any actual costs. The newest iPad models range in cost from about $260 to more than $400, depending on the features. However, people can buy used ones for far less money. Some of popular iPad competitors cost around $100 on Amazon.\nThe release states only this as far as cost: \u201cEnter the iPad: a technological device that\u2019s relatively cheap.\u201d We would have rather seen the release give us the actual cost of one of the \u201cexpensive\u201d devices and then compare it to the typical cost of an iPad. We also think the release could have mentioned other tablet devices, rather than focusing on one brand. For some people, expensive devices may be covered by an insurance provider, while less expensive ones are not. This complicates the cost to an individual. It was good to see a brief mention to reimbursement issues in the release.", "answer": 0}, {"article": "Software engineer Ben Wallace underwent subchondroplasty in November to help shore up a damaged hip.\nThe best candidates for the procedure are patients who still have some cartilage protecting their joint, but have somehow \"overloaded\" and injured the bone, causing swelling and pain, Hepinstall said.\nIt is much less invasive than a knee or hip replacement, and typically is performed on an outpatient basis, Vasileff said.\nThose with full-blown bone-on-bone arthritis or joint pain caused by damage to the cartilage and ligaments will get little to no relief from the procedure, Vasileff said.\nThe procedure involves a smaller incision than joint replacement surgery, so there's less risk of infection, and a quicker recovery time that means fewer of the side effects associated with being bedridden, Vasileff said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story did not mention any cost-related concerns. The story posits that this procedure is less invasive than the standard joint replacement surgery, which suggests there would be cost savings associated with pursuing a \u201cbone cement\u201d or \u201csubchondroplasty\u201d procedure, but this is not explicitly stated in the story. Also, like any new medical treatment, the cost might be much higher than expected.", "answer": 0}, {"article": "March 29, 2011 -- A minimally invasive procedure that cuts off the blood supply to an enlarged prostate may help when medications fail, and it appears to provide good symptom control without sexual dysfunction, a new study shows.\nThe authors report that the dead tissue required surgical removal.\nThe study was presented at the Society of Interventional Radiology annual meeting in Chicago.\nDespite the promising results of this small trial, experts said it was far too early to recommend PAE to patients.\n\u201cIt was my inspiration -- uterine fibroids.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There was no discussion of costs.", "answer": 0}, {"article": "The iron in the blood increases infants' iron storage, and iron is essential for healthy brain development.\nMuch of the research has focused on preterm infants, who appear to benefit most from delayed cord clamping, Rabe said.\nUntil recently, clinicians believed early clamping reduced the risk of hemorrhaging in the mother, but research hasn't borne that out.\nBut Rabe said these infants may actually benefit most from the practice.\nDelayed cord clamping has garnered more attention in the past few years for its potential benefits to the newborn.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The difference of slowing down the clamping of the newborn\u2019s umbilical cord does not seem to add any cost to care for a delivery. The story might have talked about potential \u201csavings\u201d if widespread use of this new technique made iron-deficiency for babies less common in US. But any benefit would be difficult to quantify. We\u2019ll rate it Not Applicable.", "answer": 2}, {"article": "The University of Pennsylvania Health System's patient care facilities include: The Hospital of the University of Pennsylvania and Penn Presbyterian Medical Center -- which are recognized as one of the nation's top \"Honor Roll\" hospitals by U.S. News & World Report -- Chester County Hospital; Lancaster General Health; Penn Medicine Princeton Health; Penn Wissahickon Hospice; and Pennsylvania Hospital -- the nation's first hospital, founded in 1751.\nIn addition to the benefits for antibiotic stewardship, Barbieri pointed to several studies showing long-term oral antibiotic use may be associated with antibiotic resistance, lupus, inflammatory bowel disease, and even colon and breast cancer.\nHowever, those same anti-hormonal effects can help prevent acne outbreaks in women.\nThe prescription change is a proxy for ineffectiveness, since switching is often the result of treatment failure due to lack of efficacy, side effects, cost, or other factors.\n\"This indicates spironolactone may have a better safety profile than oral antibiotics, which is another factor that makes it such an appealing option,\" Barbieri said.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The news release doesn\u2019t provide the cost for either antibiotics or spirinolactone. It only suggests that using spirinolactone could be \u201cless expensive\u201d than the antibiotic course.", "answer": 0}, {"article": "In addition, some people have implanted defibrillators or pacemakers.\n\"These findings need to be replicated in larger trials, and you have to be able to predict whether improved heart function from cimaglermin will help people live longer and feel better,\" she noted.\nCimaglermin, however, may be such a drug, she said.\nPeople with heart failure often take a combination of drugs, Lenihan said.\nEvery drug currently used to treat heart failure has to be given daily or several times a day to get it to work, Bishopric said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There is no mention of the cost for the tested drug, cimaglermin, in this story.\u00a0 The costs for regularly prescribed drugs for the medical condition that\u2019s the focus of the study \u2014 weakened left ventricular function \u2014 are well known and although cimaglermin is an experimental drug, it should be possible to predict whether the new drug would be comparatively priced, cheaper or more expensive.\u00a0 Readers would benefit from that knowledge.", "answer": 0}, {"article": "Bleier said the device, which consists of a lead wire and a neurostimulator the size of a stopwatch, is implanted on top of a buttock muscle. Patients don't feel it when they sit down and you can't see its imprint under a tight pair of pants. Patients can try the stimulation for two weeks with the pacemaker outside the body before deciding whether to have it implanted, an outpatient procedure. Medicare pays about $21,500 for the device and treatment.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story mentions what Medicare pays for the pacemaker InterStim device and treatment.\nBut no cost estimate was given for Solesta.\u00a0 One site states: \u201cThe average wholesale price of Solesta\u00ae is $1,107 per 1 ml injection or $4,428 per treatment session.\u201d\nIn order to give readers a more complete sense of the cost of alternative options, we think cost estimates should have been given for both of the newer options mentioned.\nSome of the other treatment options mentioned in the story can be both effective and less expensive in appropriate patients.\u00a0 Cost is an important issue in this arena.", "answer": 0}, {"article": "Guyuron, chair of plastic surgery at University Hospitals Case Medical Center in Cleveland, went on to identify four common \"trigger sites\" and publish studies showing that, in selected patients, surgical decompression of nerves in one or more of these sites provides lasting migraine relief. He has also taught 250 plastic surgeons around the world (none in the Philadelphia area) to perform the outpatient operation, which costs an average of $10,000 and is not covered by many insurers.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does talk about costs and the fact that the procedure is not covered by many insurers. We would like to find any insurer that would cover a cosmetic procedure like this that has no scientific support. The story says, \u201cHe has also taught 250 plastic surgeons around the world (none in the Philadelphia area) to perform the outpatient operation, which costs an average of $10,000 and is not covered by many insurers.\u201d", "answer": 1}, {"article": "Iowa Democrats may have saved the caucuses\n\nIf the proposed Democratic plan is adopted, the Iowa Democratic caucuses will be both familiar and new and may well endure as first in the nation.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No mention of costs. The author should have mentioned that the cost of installing a digital system is substantial and the cost-effectiveness of digital mammography as a screening program has not yet been evaluated.", "answer": 0}, {"article": "\"Anything we can do to get those rates up has the potential to save lives.\nDetection rates for the first doctor were about 67 percent while listening to music and 30 percent with no music.\nBetter detection of these so-called adenomatous polyps could save lives, the study authors noted, as survival rates for colorectal cancer are better than 90 percent if the disease is detected early.\nThe study authors suggested that the findings could help reduce the number of people affected by invasive colorectal cancer -- the third most common cancer diagnosed in men and women in the United States, according to background information in the news release.\nThis was up from a baseline detection rate of 21 percent before the study began.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There are no extensive costs associated with listening to Mozart\u2019s music.", "answer": 2}, {"article": "6 Kowdley KV, et al.\n\"This study is a breakthrough for the management of children aged six to 11 years old with Hepatitis C, demonstrating that the new DAA regimen is highly efficacious and, more importantly, safe in this group of HCV-infected children\", said Prof Frank Tacke, University Hospital Aachen, Germany, and EASL Governing Board Member.\nThis ongoing, open-label study enrolled 90 children aged between six and 11 years with chronic HCV, mostly genotype 1 (n=86).\nThe study, presented at The International Liver Congress\u2122 2017 in Amsterdam, The Netherlands, also showed that the fixed-dose combination of LDV/SOF was well-tolerated, and no patients experienced a serious adverse event considered related to the study drug.\n\"These data establish the use of the oral direct-acting antivirals as an important treatment option in HCV-infected children aged six to 11 years old.\"\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There\u2019s no mention of costs. The manufacturer, Gilead Sciences, has been charging $94,500 for a 12-week regimen of this combination therapy, marketed to adults as Harvoni. While government and private payers have balked at the cost, the company says the price tag is justified by its effectiveness in eradicating the virus, which will save the cost of treating serious liver disease down the road.", "answer": 0}, {"article": "Prostate cancer begins when cells in a man\u2019s prostate gland mutate and start to grow uncontrollably.\nThis procedure is the first in the world that is precise enough to potentially avoid negative ramifications like urinary incontinence or sexual impotency.\nThe fusion of MRI and ultrasound imaging technology that we use to accurately identify and diagnose the cancer, combined with the extreme precision of the gold nanoshells in targeting the diseased cells, allows us to be incredibly accurate at obliterating them.\n\u201cThe side effects of traditional treatment were not worth it to me, and I wasn\u2019t afraid to try the most cutting-edge technology.\n\u201cThe side effects of current prostate cancer treatments can be extremely traumatic.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "No discussion of cost, but one could imagine that a treatment made from gold is not likely to be inexpensive.", "answer": 0}, {"article": "; Eur Uro 2016 \n\niii Loeb et al.\nSince the introduction of the SelectMDx test in mid-2016, over 23,000 patients have been tested and 15 commercial contracts have been signed with US based insurance companies.\nThe researchers found that incorporating SelectMDx resulted in an average gain of 0.045 life years, or approximately 16 days, in full health gained at a cost-savings of $1,694 for each patient undergoing biopsy.\nThis press release contains forward-looking statements and estimates with respect to the anticipated future performance of MDxHealth and the market in which it operates.\nThe test helps to reduce the need for MRI procedures and invasive prostate biopsies by up to 50%, thereby improving quality of life and lowering healthcare costs per patient.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Although a major aim of the study was to examine societal costs of employing this test, the actual cost of the test to an individual patient is nowhere to be found.\u00a0 It appears to be in the hundreds of dollars, and there is no sign that Medicare is covering it as of yet.\u00a0 The release notes that a number of US-based insurance companies have contracted to use the test.", "answer": 0}, {"article": "Oral immunotherapy, swallowing small amounts of the allergen, has shown to be more effective than sublingual therapy, which involves putting even tinier quantities of milk under the person's tongue.\nSome participants have shown they can safely eat milk products up to a year after stopping the therapies, Wood said.\nThis is the first time the sublingual therapy has been studied in terms of its benefit as a precursor to the oral immunotherapy, Wood said.\nIt's not known yet whether children respond better to this kind of treatment than adults, since there have been so few participants in this research.\nIt's still in the early stages, but Dr. Robert Wood of Johns Hopkins, who has been on the forefront of food allergy research, estimates the treatment could be brought to the public within six to eight years.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There wasn\u2019t any estimate given of the cost of oral immunotherapy, nor of the drug mentioned at the end of the article that is being studied for use against food allergies.", "answer": 0}, {"article": "\"This is pretty exciting,\" said Alycia Halladay, senior director for environmental and clinical sciences for Autism Speaks, an autism advocacy group.\nThe Norwegian study is the largest to date on the benefits of folic acid for autism prevention, and marks one of the first tangible things a woman can do to reduce her risk of giving birth to a child with the disorder.\nBut some experts aren't quite ready to tout the benefits of folic acid too loudly, particularly for autism prevention.\nDespite the fact that a link between taking folic acid and reducing autism risk isn't fully proven, Halladay says there's no harm in taking the supplement, and women should be taking it anyway to prevent birth defects.\nThe same dose appears to provide some benefit in preventing autism, according to the research.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The cost of folic acid supplements is not in question.", "answer": 2}, {"article": "The findings \"are pretty much in line with what all the other studies have shown comparing Atkins and low-fat diets,\" said Bonnie Brehm, assistant professor of nutrition at the University of Cincinnati College of Nursing and co-author of two, independent studies of the Atkins diet.\nBoth the authors and other weight-loss experts were quick to note that the new findings did not answer the question of what is the best way for most people to shed weight.\nBut as researchers noted, if participants ate as little as they said, all the groups would have lost much more weight.\nAll the participants reported eating about 2,000 calories a day when the study began.\nAll also reported having cut their intake -- some by as much as 500 calories per day at two to six months -- but then gradually adding back many of those calories.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story did not mention the relative costs for following any of the particular diets mentioned.\u00a0 It did not mention the cost of the books nor the costs associated with dietician visits.", "answer": 0}, {"article": "Aggression scores declined to 3.8 from 7.1 in the dextromethorphan-quinidine group and to 5.3 from 7.0 in those who took a placebo.\nNow researchers report that a combination drug already in use for treating certain neurological problems may be a better remedy.\nThere are no currently approved treatments for agitation, and we\u2019re very enthusiastic about this finding.\u201d\n\nCorrection: October 8, 2015 \n\nA report in the In Brief column on Sept. 29 about a combination drug that could ease the agitation of Alzheimer\u2019s disease described incorrectly a disorder treated with the combination drug, dextromethorphan and quinidine.\nResearchers then rated them using a well-validated scale that measures aggression and agitation.\nIn combination, they are used to treat pseudobulbar affect, a neurological disorder involving involuntary crying or other emotional displays.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Cost is always an important factor that should be considered in a story about a potential new use for an existing prescription drug. \u00a0This is a glaring drawback of this piece, since the drug, Nuedextra, is already marketed and currently approved for \u00a0\u201cpseudo-bulbar affect\u201d \u2014 an unrelated neuralgic condition. (Pseudo-bulbar affect refers to uncontrollable laughing or crying, even though the person doesn\u2019t necessarily feel the emotions of happiness or sadness) . A look at Costco, considered one of the least expensive places to buy drugs, came up with a price of $2,222 for 180 capsules. At 2 capsules daily, this would last 3 months. Citalopram, also helpful for agitation in randomized trials as the authors noted, is one of those $4 prescriptions available at Costco, Target.", "answer": 0}, {"article": ".\n\"However, further research is needed to assess the benefits of using statins before surgical repair of other types of aneurysms.\"\nThe bottom line is that patients who used statins were more likely to survive during and after an elective endovascular procedure.\"\nPatients who took statins and had traditional open procedures also did better, but the difference was not nearly as significant as with endovascular repair.\nNow, University of Missouri researchers have found that patients who took cholesterol-lowering medications before endovascular surgery experienced fewer complications and better outcomes.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There is no discussion of costs in the release, not costs of statins or costs of the surgeries and procedures referenced. If the researchers truly believe that statin medication before, during, and after the procedure are a significant factor in reducing mortality, talking about the medication costs would help make their point as statins are a relatively cheap therapy.", "answer": 0}, {"article": "It\u2019s this type of innovation that sets MPTC apart from other proton treatment centers.\u201d\n\nAbout the University of Maryland School of Medicine\n\nCommemorating its 210th Anniversary, the University of Maryland School of Medicine was chartered in 1807 as the first public medical school in the United States.\nMPTC offers a robust clinical trial program to all its patients to further evidence-based medicine.\nMPTC is the only center in the world to offer these two treatments at the same facility, an advantage to patients because these therapies are typically given within an hour of each other.\nRadiation oncologists at UMGCCC already use external thermal therapy to treat a range of cancers, but do not currently use it for cancers that are deeper in the body.\nMPTC \u2013 which is affiliated with the University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center (UMGCCC) at the University of Maryland Medical Center \u2013 is the only proton treatment center in Maryland.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The news release doesn\u2019t mention the cost of either of the treatments, or whether or not insurance will cover these procedures. We\u2019ve discussed before that proton beam therapy can cost between $30,000 and $120,000. But it is hard to find cost information on the more experimental hyperthermia treatment, and the University of Maryland website doesn\u2019t list any information.", "answer": 0}, {"article": "Attention, memory, and language improved.\nThey envision that the utilization of a dietary pattern, such as the MedDiet, will be an essential tool to maintain quality of life and reduce the potential social and economic burdens of manifested cognitive declines like dementia.\nMoreover, the benefits to cognition afforded by the MedDiet were not exclusive to older individuals.\nThe researchers stress that research in this area is important due to the expected extensive population aging over the next 20-30 years.\nThe Mediterranean diet can improve your mind, as well your heart, shows a study published in the open-access journal Frontiers in Nutrition.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Although the text clearly identifies the components of the Mediterranean diet, it does not attempt to \u201ccost\u201d them out for the typical American. The costs of adhering to a Mediterranean diet could be prohibitive, especially for older adults living on fixed incomes. While it would be some work to estimate the annual cost of eating this way for a person or family, the cost consideration could at least be acknowledged.", "answer": 0}, {"article": "Alexander who had troubles with chronic laryngitis whenever he performed.\nAfter a year, those who had massage were no better off.\nThose who had six Alexander lessons showed some improvement.\nBut finding a remedy for back pain can be a lot like a guessing game.\nBut there is evidence it can ease chronic low back pain over the long run.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The article did not discuss the costs of Alexander Therapy. The clinical trial mentioned in the article involved up to 24 sessions with an Alexander therapist, so this treatment can be expensive. \nA systematic review conducted for the British National Health Service found instruction in the Alexander Technique to be significantly less cost-effective than a simple exercise program (See Nice, 2009; p. 97). So costs are an issue with this therapy and they should have been discussed in the article.\n", "answer": 0}, {"article": "The etonogestrel implant is a small plastic rod resembling a matchstick that is inserted under the skin in the upper arm.\nOf course, some couples fail to use any contraception, but others rely on contraceptive methods that have significant failure rates even when properly used.\nThe risk of an unwanted pregnancy with these other methods was especially high among women under 21, whose rate of unintended pregnancy was nearly double that among older women.\nIn real-world use, these methods are associated with a one-year pregnancy rate of less than one per 100 women.\nOnce inserted, these long-acting methods remove the risk of patient error when a sexually active woman wishes to avoid pregnancy.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "We applaud the way this story examines what may be the \u201cunder use\u201d of devices and clearly explains some of the nuance about up-front costs versus the long-term cost of contraception. Bravo for pointing out that the Affordable Care Act now covers these devices, which at one time may have seemed \u201ctoo expensive\u201d for some patients.\nWe think it would have been even better if the story had a few actual figures in it \u2013 to demonstrate this. For example, one website from Planned Parenthood explains the cost for the copper IUD this way:\n\u201cThe cost for the medical exam, the IUD, the insertion of the IUD and follow-up visits to your health care provider can range from $500 to $900. That cost pays for protection that can last more than a decade.\u201d\nAs the story points out \u2013 that cost will not fall to an individual patient who is covered under the ACA. But the old prejudices about cost may be part of the reason for the gap in popularity.", "answer": 1}, {"article": "\"I'm single, I'm bouncing around, and I'd like the opportunity to have a family, so I just figured, 'Why not?'\nAnd yet, even Widra agrees that egg freezing has appeal if it can help avoid the anguish of infertility.\nNow, technology is dangling the possibility that women can stop that clock, at least for a while.\nStill, he says, freezing eggs offers many women the biggest game changer since the birth control pill 50 years ago.\nThe bigger challenge, Sher and others say, is reaching out to younger women \u2014 getting them to take action before it's too late.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story includes the high price tag for freezing eggs and the possibility that a family may need more than a single \u201cfreezing.\u201d\u00a0The story quotes about $40,000 for a safe number of eggs in storage and seems to imply that price includes the in- vitro fertilization required. But we wish they had done a better itemizing more ofl the costs of a high-tech pregnancy, including the possible higher risk of twins and pre-term delivery.", "answer": 1}, {"article": "Instead, they recruited 20 volunteers who were overweight or obese and assigned them to a week of either egg breakfasts or ready-to-eat cereal breakfasts.\nBoth types of breakfasts had the same number of calories, but the egg breakfasts contained \u201chigher protein quality,\u201d according to an abstract for the study, posted online here.\nThat\u2019s right \u2013 the folks who sell eggs paid for a study that comes to the shocking conclusion that eggs are an ideal breakfast food.\nThe folks who carried out this egg industry-funded research were from the Pennington Biomedical Research Center in Baton Rouge, La.\nAfter a two-week gap, the groups were switched.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The cost of eggs and cereal are not in question.", "answer": 2}, {"article": "An infarct, a kind of stroke, happens when the passage of blood is slowed or completely blocked by clotting.\nIt is possible that the diet protects the brain vessels themselves, irrespective of other problems such as high blood pressure, Scarmeas said.\nThe next step would be to have controlled experiments concerning food and dementia in which participants are randomly assigned to follow a diet, Cole said.\nThe bottom line for dementia is that fish oil may help in the very early stages, but more research must be done to confirm this, he said.\nIn general, dietary patterns are consistent for at least seven or eight years, Scarmeas said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Another not applicable criterion for this story.\u00a0 Costs not mentioned, but also hard to pin down costs of this diet. ", "answer": 2}, {"article": "In 2012, the Food and Drug Administration updated labeling on statins to include warnings about confusion and memory loss, elevated blood sugar leading to Type 2 diabetes, and muscle weakness.\nAnd if even more people were given statins -- if they were given to people with a 3 percent risk of developing heart disease over 10 years -\u2013 another 160,000 heart attacks and strokes would be prevented, they estimated.\nLimiting factors should be a patient's own preference about taking a daily pill, price and the risk of diabetes, they said.\nOne of the recommendations was that statins should be prescribed to anyone with a 7.5 percent risk or higher of developing heart disease over the next 10 years.\nExperts estimate that another 8 million to 13 million Americans would get statins if everyone used the new criteria -\u2013 with just under half of all adults aged 40 to 75 eligible.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "While the New York Times skipped the cost question, NBC gave readers the numbers they needed to know. It said that \u201cStatins, which include Lipitor, Mevacor, Crestor and Zocor, are extremely popular. They\u2019re prescribed to about 15 percent of U.S. adults, at a cost ranging from about $4 a month for the cheapest generic version to $600 for a pricey name-brand.\u201d That\u2019s a huge cost range and, multiplied out for the millions more Americans who are being encouraged to take statins, represents a significant potential increase in health care spending. To inform readers even more fully, the story could have looked at what those global costs would add up to for the entire country. It also could have explained what researchers mean when they say that the drugs are \u201cworth it\u201d and how the value of treatment was calculated in the study.", "answer": 1}, {"article": "Dr. David E. Neal, a professor of surgical oncology at the University of Cambridge in the U.K. and author of an accompanying editorial, believes that, \"PSA testing detects prostate cancer early in its natural history when it causes no symptoms.\nThis study adds to previous evidence that PSA testing and screening for prostate cancer saves lives, he said.\nStill, the PSA test remains \"a blunt instrument,\" when it comes to determining the aggressiveness of a particular tumor, Neal said.\nOf the men in the screened group diagnosed with prostate cancer, nearly 79 percent were diagnosed because they took part in the study, the researchers noted.\nFor men at high risk for the disease -- blacks and men who have a father, brother or son found to have prostate cancer at an early age (before 65) -- that discussion should start at age 45.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "\u00a0While mentioning that PSA testing is rather routine practice in the US, there was no indication of its cost. Now, while the cost of PSA testing itself is relatively minimal, this was a study not just about screening but treatment.\u00a0 As Dr. Otis Brawley of the American Cancer Society wrote on the ACS blog: \nSo we think the story should have included at least a nod in the direction of WHAT\u00a0IT\u00a0COST to achieve the result trumpeted in the headline \u2013 especially given the proliferation of expensive robotic surgical systems and newer radiation therapy techniques. \u00a0\nThis is a classic example of how cost gets left out of the discussion. ", "answer": 0}, {"article": "During the DaTscan test, an imaging drug is injected into a patient's bloodstream and the patient undergoes a single-photon emission computed tomography, or SPECT, scan.\nIn cases where a diagnosis isn't necessarily clear-cut, the DaTscan offers important advances in patient care and treatment, said Dr. Michael Rezak, director of the Movement Disorders Center at Central DuPage Hospital, where the scan is offered.\nSince June, 25 men and women of all ages have been tested with DaTscan at Central DuPage, Rezak said.\n\"DaTscan is used in difficult-to-diagnose cases and must be used in conjunction with a clinical evaluation and a patient's response to medications,\" Rezak said.\nIt is the first \"radiopharmaceutical adjunct imaging agent\" approved by the Food and Drug Administration that helps physicians better evaluate patients who are thought to have Parkinson's disease or other parkinsonian syndromes.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "\n\n\nYes, the story reports that a DaTscan costs about $1500. Oddly, instead of reporting what the hospitals featured in the story charge for a scan, the story attributes the price estimate to a quote taken from an article by Medscape Medical News. But there is a much higher price listed on the web site of the Michael J. Fox Foundation for Parkinson\u2019s Research, which estimates a DaTscan costs almost $3000. Still, because the story does address cost we will give it credit on this criterion.\n\nMichael J. Fox Foundation for Parkinson\u2019s Research page on DaTscan:\nhttp://www.michaeljfox.org/newsEvents_parkinsonsInTheNews_article.cfm?ID=694", "answer": 1}, {"article": "In addition, BCG alters metabolism so cells consume higher levels of glucose, drawing more of it out of the blood, in a process called aerobic glycolysis.\nWhile the results, from only nine patients, must be replicated in a larger study, said Dr. Joseph Bellanti of Georgetown University Medical Center, \u201cif what they found is true, they really have something here.\u201d Bellanti, who was not involved in the research, said the study\u2019s eight-year follow-up and use of a placebo control arm made him \u201ccautiously optimistic\u201d that two doses of the BCG vaccine \u201ccan decrease levels of A1c,\u201d a measure of blood glucose that predicts the likelihood of serious complications such as stroke and kidney failure.\nAfter the vaccine showed signs of effectiveness, an additional six patients were vaccinated five years ago, and 111 more recently.\nThe new paper describes how the BCG vaccine, which has been used for nearly 100 years against tuberculosis and is considered extremely safe, might affect diabetes.\nAn experimental therapy for type 1 diabetes, widely derided by mainstream diabetes researchers, lowered blood sugar levels to near normal, a small, ongoing trial found.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story notes that the BCG vaccine costs less than $1 per dose, though it remains to be seen if the cost will remain the same if it\u2019s approved for diabetes. The story does acknowledge\u00a0that treatment with the BCG vaccine did not eliminate the study patients\u2019 need for insulin.", "answer": 1}, {"article": "\"It is not inconceivable that in the near future you will see the I-Portal goggle used on every sideline in America,\" Hoffer said.\nThe results of the trial met the expectations of Hoffer and his team of researchers.\nWith these findings, it appears the I-Portal goggle may be a solution.\nThe research findings published by PLOS ONE help support their objective.\nAnother benefit for this research was that \"this next generation test has the considerable advantage of not requiring baseline testing,\" said study co-author Carey Balaban, Ph.D., of the University of Pittsburgh.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The news release mentions that researchers made diagnoses by running tests with the I-Portal goggle, which gauges eye movement through video cameras and computers. But there is no discussion on what the costs for a session with the I-Portal goggle may be.\nThis sounds like a new technology, and it would have been helpful to know the ballpark range of what it may cost for consumers.\nFor this reason, we give the news release a Not Satisfactory rating here.", "answer": 0}, {"article": "\"We definitely need a whole menu of treatment options,\" he said.\nBlack said the benefits of mindfulness training were on par with what's been found in studies of sleep medications and cognitive behavioral therapy -- a form of \"talk therapy\" that is often helpful for insomnia, for example.\nIn fact, they did better than their counterparts who were given conventional lessons on good sleep habits, the study authors said.\nThe program, Black said, did not specifically address sleep -- a topic that might only stir anxiety in people who are already worried about a lack of sleep.\nOn top of that, poor sleep itself can lead to psychological \"distress,\" such as depression symptoms, Black said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There is no mention of costs. There were a few good opportunities to introduce costs here. For one, the meditation therapy requires a certified instructor. Find out how much it costs in terms of money and time to join a group like that. It mentions online courses, books, and CDs, and could have mentioned costs for each. And if the results were comparable to sleep medication, make note of how much some of those drugs cost in comparison.\u00a0The class that was studied is offered by UCLA, which has classes for $165 and free drop-in classes.", "answer": 0}, {"article": "Learn more at: www.DecipherTest.com and follow Decipher on Twitter @DecipherTest and on Facebook.\nThe study was designed to evaluate how the Decipher Prostate Cancer Classifier, which predicts the risk of metastasis after prostatectomy, would impact adjuvant treatment recommendations made by urologists and radiation oncologists.\nAdding truly unique information to the treatment decision-making process, Decipher generates a risk result that is completely independent and distinct from PSA, Gleason score and other clinical risk factors.\nThe test provided a more accurate and precise estimate of a patient's risk of recurrence.\nDecipher was developed in partnership with the Mayo Clinic.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There isn\u2019t a dollar sign in this release, and we could find no reliable figure for how much each Decipher test costs. (A New York Times article suggests similar genomic tests for prostate cancer cost roughly $3,000, if not more.) We\u2019ve reached out to the company\u2019s PR agency for an average per-test cost, but haven\u2019t received a response in time for the publication of this review.", "answer": 0}, {"article": "In contrast to photon radiotherapy, in which a dose of radiation is delivered all along the x-ray beam as it passes through a patient's body, in proton therapy the dose is precisely focused on the target area with little or no dose delivered to normal tissues in front of or behind the tumor.\n\"At experienced centers, proton therapy has a proven track record of treatment success and safety.\"\n\"Proton radiotherapy is still not widely available in the U.S. or around the world, but it is increasingly recognized for its potential to reduce the side effects of treatment, particularly in the pediatric population,\" says Torunn Yock, MD, MCh, MGH Department of Radiation Oncology, lead and corresponding author of the report.\nAll had previous surgery to remove as much of the tumor as possible, and all received chemotherapy before, during or after proton therapy.\nThe use of proton radiotherapy to treat the most common malignant brain tumor in children is as effective as standard photon (x-ray) radiation therapy while causing fewer long-term side effects such as hearing loss and cognitive disorders, according to a study receiving online publication in Lancet Oncology.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release does not address the costs of the therapy. This is especially important to include in any discussion of proton therapy because its costs are astronomically high \u2014 often twice as much as standard therapy.\nWe\u2019ve previously described some of the issues with costs in other reviews and blog posts\u00a0focusing on proton therapy. You can search the HealthNewsReview.org site for many others.", "answer": 0}, {"article": "\"Patients with acute coronary syndrome have options to prevent recurrent events,\" study lead author Dr. Kenneth W. Mahaffey, co-director of cardiovascular research at the Duke Clinical Research Institute, and associate professor of medicine at Duke University Medical Center, said in an AHA news release.\nA study author agreed that for most patients, using the drug with a lower dose of aspirin is usually warranted.\n\"A higher aspirin dose (325 mg versus 81 mg) increases the risk of bleeding without increasing the efficacy of the drug.\"\n\"Physicians choosing to use ticagrelor in countries where it is approved and available should consider using a low-dose of maintenance aspirin with the drug.\"\nBrilinta has already been approved for use in many other countries.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No discussion of costs. Ticagrelor isn\u2019t available in the US. But its cost \u2013 where available elsewhere \u2013 could have been cited. Cost will certainly be an issue if it\u2019s approved because its competitor, clopidogrel, will soon be available in the US as a generic drug.", "answer": 0}, {"article": "A new study raised questions about the benefits of a relatively common procedure for heart patients\u2014implanting tiny devices that prop open clogged arteries to relieve chest pain.\n\nThe 200-patient study conducted by U.K. researchers found that patients with stable chest pain, or angina, who received stent devices experienced no significant improvement in exercise time on a treadmill, compared with similar patients who received no stents during sham procedures.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not mention the cost of stent insertion, which can run into the tens of thousands of dollars.", "answer": 0}, {"article": "Mitochondria are the organelles within the body\u2019s cells that generate energy.\nDr. Ronald M. Evans, a leading expert on the hormonal control of metabolism at the Salk Institute, said that the report by Dr. Auwerx\u2019s team had \u201cshown very convincingly that resveratrol improves mitochondrial function\u201d and fends off metabolic disease.\nBut even Longevinex\u2019s capsules, which at present contain 40 milligrams of resveratrol each, would have to be gulped in almost impossible quantities for a human to obtain doses equivalent to those used in mice.\nTheir rationale for testing resveratrol was evidence obtained three years ago that it could activate a genetic mechanism known to protect mice against the degenerative diseases of aging and to prolong their lifespan by 30 percent.\nWhether much lower doses would benefit athletic performance is not clear, Dr. Evans said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There was no\u00a0estimate of costs for any reservatrol product \u2013 real or imagined.\u00a0 However, the web site of the company mentioned as selling reservatrol, states that a 30 day supply (which is actually much less reservatrol than was fed to the mice in the study) is $34.95.", "answer": 0}, {"article": "Immunotherapy moves to the front lines in fight against lung cancer\n\nThe cancer death rate has dropped again.\nExperts said it was especially significant that the study showed that patients benefited from the Keytruda-chemo combination regardless of the levels of a protein, called PD-L1, found on their cancer cells.\nDrew Pardoll, director of Hopkins\u2019 Bloomberg-Kimmel Institute for Cancer Immunotherapy, said that it is too early to know whether the findings will translate into longer survival.\nBut the disease is so lethal that many patients don\u2019t survive long enough to try second- or third-line treatments, so researchers are trying to develop and use more effective approaches earlier.\nAnd he said the trial showed that \u201ctumor mutational burden\u201d is a reliable way to predict who will benefit from the medications.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Costs of these drugs weren\u2019t given. Checkpoint inhibitors run about $150,000 a year, according to some published news reports. With 140,000 people in the U.S. diagnosed annually with non-squamous non-small cell lung cancer \u2014 the type in the Keytruda trial \u2014 the cost of treating people with this drug could easily run into the billions.\nIt\u2019s also worth noting it isn\u2019t clear how long treatment with these drugs should continue, which significantly affects costs.", "answer": 0}, {"article": "Women who took hormones had an average of 24 fewer hot flashes per month, while those who took soy had 12 per month fewer.\nAnd not every woman needs treatment, notes Bachmann, who was not involved in the study.\nThat means that if women do take hormones, Bachmann told Reuters Health, it should be the lowest dose and for the shortest possible period of time.\nWomen with severe or frequent hot flashes or whose hot flashes keep them up at night, should consider treatment, she said.\nThe study did not look at whether eating soy in food has the same effect on hot flashes as supplements, Bolanos-Diaz said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "We were pleased to see that the story included cost estimates of both soy supplements and of hormone replacement therapy pills.", "answer": 1}, {"article": "GLYX-13 targets parts of the brain linked to learning and memory.\nAn advantage is that the drug doesn't have the side effects of other drugs that target these same areas, such as hallucinations and schizophrenia-like symptoms, the researchers noted.\nMoskal, however, said he is confident that this drug will be a breakthrough in treating depression.\nFor his part, Bruno cautioned that the long-term effects of the drug need to be studied before it can be used regularly in clinical practice.\nA new trial that makes use of the drug in pill form is slated to get under way next year, Moskal noted.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There is no discussion of costs in this story, either for the new drug GLYX-13 or for existing drugs, such as Prozac, Paxil, Zoloft and Lexapro.", "answer": 0}, {"article": "Inflammation strips the myelin coating from nerve cell extensions, called axons, and connections at the ends of nerves, called synapses, are lost, together disrupting signaling and eventually causing permanent disability depending on where this occurs.\nWorking with a mouse model of MS, the research team assessed astrocytes in various regions of the brain and spinal cord known to be involved in walking, vision or cognition.\nThe team focused on astrocytes, a type of brain cell that becomes activated in MS and plays several important roles in disease, examining gene expression in astrocytes in different regions.\nGene expression in specific cells and in specific regions can provide a more precise, neuroprotective approach than traditional treatments for neurological diseases.\nThe work was supported with funding from the Conrad N. Hilton Foundation, the National Institutes of Health, the California Community Foundation, the Tom Sherak MS Hope Foundation, the Rhoda Goetz Foundation for Multiple Sclerosis, and other partners of the UCLA Multiple Sclerosis Program.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The news release does not discuss potential costs.", "answer": 0}, {"article": "\"You've got to have a teacher right there in front of you teaching according to experience,\" he said.\nAn outside expert, however, said the study is too limited in size and scope to allow conclusions as to whether meditation really reduces risk of death or disease.\nBut a cardiology expert said that although the study adds to evidence supporting meditation, it doesn't prove a cause-and-effect relationship between the practice and better health outcomes.\nHe added, however, that meditation would work as well among whites and other populations.\nEven though the findings in this study were statistically significant, the new study was too small to be conclusive, Fonarow said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "According to the story, \u201cAn initial 10-hour course runs about $1,500 when taught by nonprofit groups, and there is continued lifetime follow-up.\u201d And it\u2019s generally not covered by insurance.", "answer": 1}, {"article": "The biopharma company Amarin is making some heart-medicine history Monday with its proprietary, prescription formulation of fish oil, called Vascepa.\n\nIn a stunning clinical trial result that upends years of skepticism about the long-term heart benefit of products containing omega-3 fatty acids, Amarin\u2019s Vascepa significantly reduced the risk of deaths, heart attacks, strokes, and other serious cardiovascular events compared to a placebo.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story reports that Vascepa costs about $2,400 per year. However, that price is much lower than indicated by online searches (here and here) that show prices around $3,400 per year at the 4 gram per day dose used in this study.", "answer": 1}, {"article": "George E. Jordan may be reached at gjordan@starledger.com or (973) 392-1801.\nThe study said there were still many unanswered questions about Pfizer's pill, torcetrapib, the first in a new class of heart medicines known as a CETP inhibitors, which raise HDL, or good cholesterol, and lower LDL, or bad cholesterol.\nIt was unclear what the mixed bag of data presented at the American Heart Association's Scientific Session in Orlando would mean for CETP drugs under development by Merck and Roche, and another candidate in early-stage development by Pfizer.\nPfizer suspended development of the tablet, its most important experimental drug, after it caused an increase in deaths and heart problems in clinical trial volunteers.\nCardiologists had hoped it would reduce the buildup of plaque in blood vessels that can cause heart attacks.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not mention costs, or potential costs of the new drug. At least a general statement could have been made about costs of combination drugs. ", "answer": 0}, {"article": "AMG145, along with other PCSK9 inhibitors being developed by companies like Pfizer, Regeneron Pharmaceuticals Inc in partnership with Sanofi and Roche, is a man-made antibody.\nThe new drug, given by injection every four weeks, is part of a promising new class of biotech medicines known as PCSK9 inhibitors designed to target a protein that prevents the body from removing artery blocking LDL cholesterol from the bloodstream.\nThe trial, presented here at the annual scientific meeting of the American Heart Association, included 168 patients with heterozygous familial hypercholesterolemia, in which a defective gene inherited from one parent impairs the ability to properly metabolize LDL.\nThe most common side effects seen in the trial were injection-site reactions, cold-like symptoms and headache.\nThe Phase II trial found that after 12 weeks, patients treated with a low dose of AMG145 had a 43 percent reduction in LDL, while those given a higher dose had a drop of 55 percent.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Although this drug is still experimental, the story should have told readers that some analysts predict that this sort of drug, known as a biologic, will cost at least $10,000 a year, compared to less $200 a year for a generic statin. Many observers predict that the extremely high cost of this new type of cholesterol-lowering treatment is likely to mean it would be used only when statins don\u2019t do the job, which means this line of research may never be relevant to most people.", "answer": 0}, {"article": "They had 68 percent fewer spine fractures and 40 percent fewer hip fractures than the study participants who got dummy shots.\nDenosumab, an injection just under the skin, would have to compete against eight major types of pills and injected medicines, including estrogen and generic and brand-name Fosamax pills, long the market leader.\nThose drugs' annual retail cost can range from $385 for generic Fosamax, to roughly $1,250 for most brand-name pills, to $11,100 for injected Forteo, which must be injected daily.\nBut with many cheaper, heavily advertised treatments, doctors view its expected high cost as a drawback.\nA first-of-its-kind osteoporosis drug lowers the risk of bone fractures better than some existing treatments, two studies suggest, and could soon add a more expensive but easier to manage treatment option to the booming market.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Pricing for this drug is not yet available; however, the story suggests that it could be expensive, with similarly engineered drugs costing more than $10,000 a year.\u00a0 In addition, the costs of currently prescribed osteoporosis medications are provided.\u00a0 \u00a0\u00a0\u00a0", "answer": 1}, {"article": "Caucasian men more commonly reported circumcision (69%) than African American men (43%).\nIt's important to note, right off the bat, that this study is not purporting to establish a cause and effect relationship.\nA few potential caveats to note include the reliance on self-reporting when it comes to a man's history of STIs, as well as his sexual partners.\nThe bottom line from the American Cancer Society: While this is an interesting finding, it's not likely to spur any change in recommendations or medical practice.\nThe good news, we're told, is that there are many things we can do \u2013 or not do \u2013 in our adult lives to lower our risk of developing different types of cancer.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Although the story didn\u2019t discuss costs, we don\u2019t think the cost of circumcisions is really in question.", "answer": 2}, {"article": ".\nThe drug also proved to be highly selective, meaning it hit the intended targets inside the body and did not cause troubling side effects.\nIf approved, lorcaserin would be Arena's first marketable product.\nThe drug was pulled from the market in 1997, costing Wyeth millions of dollars.\nArena has conducted safety studies on the drug, and no heart valve problems have been reported.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "If it\u2019s not too early to project that the drug may be submitted to the FDA for approval within a year, then it\u2019s not too early to get some estimate of cost or at least to give some context about the cost of other obesity drugs on the market.\u00a0 ", "answer": 0}, {"article": "A type of sleeping pill that several major pharmaceutical companies are racing to develop received good news yesterday when Swiss biotech company Actelion Ltd. reported positive clinical data.\n\nSleep experts say the drug class needs further study but could potentially offer some benefits beyond Ambien, the top-selling drug in the $3.8 billion global market for sleeping pills. While Ambien and similar drugs, called nonbenzodiazepine drugs, are effective and easily tolerated by most people, some insomniacs don't respond to the...", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Costs were not discussed but this drug is still in development. ", "answer": 2}, {"article": "Current methods for determining if a prostate has become cancerous include a physical examination of the prostate (known as a digital rectal examination or DRE), MRI scans, a biopsy or tests to determine levels of the chemical prostate-specific antigen (PSA) in the blood.\nThe Dundee University-based team say they have used an ultrasound process called shear wave elastography (SWE) to detect prostate tumours.\nWe can now see with much greater accuracy what tissue is cancerous, where it is and what level of treatment it needs.\nOne in eight men will develop the condition at some point in their lives with more than 47,000 new cases being diagnosed every year.\n\u201cThe technique now needs to be tested in a much larger number of men to confirm just how well it can detect the aggressive cancers, while also ruling out those who do not have prostate cancer,\u201d said Simon Grieveson, head of research funding at Prostate Cancer UK, which funded the Dundee project (with support from the Movember Foundation).\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The only mention of costs in this Guardian story is the following sentence, \u201cThe method is non-invasive and cheaper than current detection techniques.\u201d\u00a0 But the story offers no information to back up that statement. There\u2019s no mention of the current costs for the available screening approaches and there\u2019s no estimate of\u00a0what this new technique might cost patients.", "answer": 0}, {"article": "\"The truth is that quit smoking programs, like other programs that treat addictions, often have fairly low success rates. But that doesn't mean they're not worthwhile or that you should be discouraged. Your own success in quitting and staying that way is what really counts, and you have some control over that. Even if you don't succeed the first few times, keep trying. You can learn from your mistakes so that you'll be ready for those pitfalls next time.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Both groups in this study used smoking cessation products, and so it would have been helpful to know how much they cost, even if it was just a quick approximation or discussion of affordability. At the same time, these aren\u2019t high-dollar items, so cost isn\u2019t as important to discuss as say, when reporting\u00a0findings about a new cancer drug or surgery.", "answer": 0}, {"article": "Happiness won\u2019t help you live longer (but unhappiness won\u2019t kill you either)\n\nGuinea is finally declared Ebola-free, but that does not mean the crisis is over\n\nMost popular Washington Post health stories of 2015: A mother tells her story of how she lost her darling daughter a few weeks short of her 29th birthday when she stepped in front of a train in Baltimore.\nThe other piece of good news regarding the medications is that ACE inhibitors, as well as many ARBs, are now generic -- meaning that the cost difference is minimal.\nBut some doctors and researchers were puzzled by the fact that in head-to-head comparisons between the two classes of drugs they appeared to equally safe and effective.\nNow a large new analysis involving 250,000 patients shows that these medications may be as effective and safe as their older cousins, the angiotensin converting enzyme, or ACE inhibitors.\nThat led many doctors and standards groups to conclude that ACE inhibitors were more effective than ARBs.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "While the story could have been a bit more specific, it gets points for stating that most ACE inhibitor drugs, and many ARB drugs, are now available in generic form, which means the cost for the medications would usually be considerably less than their comparative name-brand compounds. We\u2019ll rate this Satisfactory, but we\u2019d add that though more ARBs are generically available, this class of medications continues to be more expensive than ACEIs. For patients struggling to meet the cost of their medications, this is a major consideration, and important information for any news story.", "answer": 1}, {"article": "During colonoscopy, the doctor inserts a slim, flexible tube into the rectum.\nAs a result, he said, it is hard to know whether removing polyps in younger people would in turn lower their risk of getting cancer.\nLeFevre, a member of the U.S. Preventive Services Task Force, a federally appointed expert panel, said the chances that a polyp turns into cancer is currently a matter of debate.\nAllen, of Minnesota Gastroenterology PA, said this risk factor might be taken into consideration when deciding when to screen, but that so far more studies were needed before recommending colonoscopy at younger ages.\n\u201cThis paper substantiates what we suspected, that people who are obese have higher risk of colon cancer,\u201d Dr. John Allen, a colon cancer expert and a community practice counselor with the American Gastroenterological Association, told Reuters Health.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not mention costs of screening colonoscopy. Costs of screening a younger population is especially important given that more people would need to be screened to find one case of cancer.", "answer": 0}, {"article": "The images of the children in the study -- MRIs of the brain -- were taken at 12 to 29 months while their language was assessed one to two years later at 30 to 48 months.\nNow scientists believe that they have a way to distinguish between those paths, at least in terms of language ability, in the toddler years using brain imaging.\nFiguring out a child's trajectory once he or she is diagnosed is just as challenging.\nSuch research has become critically important as the number of children diagnosed with autism has soared in recent decades to 1 in 68.\nScientists have looked at numerous possible causes, from genetics to environmental exposure, but no definitive answers.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There was no discussion of costs. It would have been worth mentioning in the story that the out-of-pocket cost of a brain MRI ranges from $1,000 to several thousand dollars depending on the type of test and where it is done. However, most insurance policies do cover some or all of the cost of imaging tests if they\u2019re considered medically necessary.", "answer": 0}, {"article": "One patient with ovarian cancer had a complete response that lasted 89 weeks, one patient with gastroesophageal cancer had a partial response that lasted 16 weeks, and four patients (two with colon cancer, one with prostate cancer, and one with ovarian cancer) had stable disease.\nAccording to Berzofsky, the main scientific limitation of the study is that it is a relatively small, phase I clinical trial with no placebo control.\nAmong the six patients who received the lowest dose of the vaccine, 5 million dendritic cells per injection, no clinical benefit was seen.\nThe patients' vaccines are individually customized by Berzofsky and colleagues using their own immune cells isolated from their blood.\nPreclinical studies, which were previously published in the AACR journal Cancer Research, showed that this type of vaccine could eradicate large, established tumors as well as lung metastases in mice.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release noted that the vaccines were individually customized using each person\u2019s immune cells. That technology does not sound cheap yet there was no discussion of cost.", "answer": 0}, {"article": "This measure of metabolic health is called \u201cinsulin sensitivity,\u201d and it is one of many metabolic functions that goes awry in people with obesity. In those who develop type 2 diabetes, sensitivity to insulin becomes so impaired that the body is tricked into believing less insulin is needed, and it pares back its production. The insulin-producing cells in the pancreas will often atrophy and die in response. As a person\u2019s insulin production declines, an external supply of insulin is needed to control blood sugar and deliver fuel to muscles and organs.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Even though deep brain stimulation (DBS) is not close to being recommended for diabetes, it is a current therapy for Parkinson\u2019s disease and other movement and psychiatric disorders. Thus, cost information\u00a0could have been included \u2014 we found estimates ranging from $35,000 \u2013 $50,000.\nOf course, the costs associated with the use of this technology for diabetes might differ from the costs with Parkinson\u2019s disease. However, our rule of thumb in these situations is, If it\u2019s not too early to claim this approach \u201cmay offer treatment,\u201d it\u2019s not too early to discuss what that treatment may eventually cost.", "answer": 0}, {"article": "After adjusting for age, diabetes, hypertension and other factors, men who took a daily aspirin or another Nsaid reduced their risk of moderate or severe urinary symptoms by 27 percent, and their risk of an enlarged prostate by 49 percent.\nThe study, published online by The American Journal of Epidemiology, had limited data on dosage, but scientists believe that even low doses of anti-inflammatory drugs reduce the risk of urological problems.\nDr. Lieber acknowledged that the study was observational and not a placebo-controlled trial.\nTaking aspirin every day may lower the risk for prostate enlargement, a new study has found.\n\u201cAt least half the patients I see are taking a daily aspirin for other health reasons,\u201d said Dr. Michael M. Lieber, an author of the study and a Mayo Clinic urologist.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The article does not mention any costs of these medications if taken on a daily basis or per dose. ", "answer": 0}, {"article": "For men, the difference came out to 103 fewer cancer deaths a year per 100,000 people; for women, the number was 42.\nOne of the problems with the new study as well as with previous aspirin trials, he said, is something called detection bias.\nDr. Kausik Ray of St. George\u2019s University of London, who has studied aspirin, said the new study did not look at overall death rates or side effects such as serious stomach bleeds.\nIt discourages the use of aspirin to stave off colorectal cancer in people at average risk for the disease.\nEarlier this year, Ray\u2019s team published an analysis of previous aspirin trials showing the medication did not prevent deaths from heart disease or cancer, and was likely to cause more harm than good.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The cost of aspirin is not in question.", "answer": 2}, {"article": "A biopsy involves the removal of tissue or fluids to test for disease.\nIn addition, image-guided biopsies are more accurate, Quencer said.\nFor these areas, open biopsies are easier to do and need less imaging guidance, Kwan's team noted.\nQuencer thinks the use of image-guided biopsies will continue to increase over time, even for lymph nodes and soft tissues.\nThat's an annual growth of 3 percent in number of biopsies, the researchers noted.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No discussion of costs \u2013 which is curious in a story describing the growth in use of less invasive biopsies, supposedly allowing for shorter hospital stays. ", "answer": 0}, {"article": "And then there's the lengthy recovery ahead, a less than ideal situation to find yourself in.\"\nThe researchers are continuing to investigate the use of this drug to treat Dupuytren's disease in a phase 2b trial called the RIDD trial, which is currently running in Oxford and Edinburgh.\nThe team found that adalimumab (at a dose of 40mg formulated in 0.4ml) reduces expression of the fibrotic markers, -smooth muscle actin (-SMA) and type I procollagen, at 2 weeks post injection, suggesting this drug could be used to stop the growth of disease causing myofibroblast cells.\nIn conjunction with Professor Sir Ravinder Maini, Sir Marc identified TNF as a therapeutic target in patients with rheumatoid arthritis.\nThis randomised trial (phase 2a) recruited 28 patients with Dupuytren's disease who were scheduled to have surgery in Edinburgh to remove diseased tissue in their hand.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The cost of a single 40 mg injection of the the anti-TNF (tumor necrosis factor) drug, adalimumab (brand name, Humira) isn\u2019t mentioned.\u00a0Given the level of the research at the moment, the durability of what can best be described as a change in a surrogate marker is unknown. \u00a0Although the cost of 40mg of Humira is around $5,000 for two 40mg/0.8ml pens, according to GoodRx, the true cost of this potential treatment is unknown but likely to be costly.", "answer": 0}, {"article": "\"We try to time the pattern to stimulation so that it's integrated with their ability.\nNathan Makowski, an investigator at the Cleveland FES Center, created by Case Western Reserve and the Cleveland VA, said that FES technology has been used primarily for therapy in stroke patients in the past.\nDue to his improvements, the research team is developing a system that McGlynn can use at home and outside.\nThe researchers hope these studies will lay the foundation for implanted systems that restore some independence to people with MS or who have suffered a stroke.\n\"I went in there and I could barely take two steps,\" said Bush, 42, who researchers believe is the world's first MS patient to \"test-drive\" an implanted FES system.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There\u2019s no discussion of costs. While it may not be possible to put an exact price tag on a treatment that is so preliminary, we think some estimate of the costs involved is warranted. One study put the indirect costs of multiple sclerosis at more than $30,000 per person per year, due mainly to impaired mobility. The news release hints at the high cost by mentioning that the researchers are seeking funding to fit one of the patients with a permanent device in a clinical trial.", "answer": 0}, {"article": "Sept. 28, 2010 -- Intrauterine devices (IUDs) -- used to prevent pregnancy -- may also be an effective treatment for some patients with early-stage uterine cancer who want to preserve their fertility.\n\nIn a small, early study, carefully selected patients with cancer that had not spread beyond the inner lining of the uterus were treated with IUDs that released the hormone progesterone.\n\nThe treatment was found to be as effective as oral hormone therapy, which is the most widely used nonsurgical, fertility-sparing treatment for the cancer.\n\n\u201cOur results show promise for the treatment of younger endometrial cancer patients with early disease who desire pregnancy in the future,\u201d gynecologic oncologist Lucas Minig tells WebMD. \u201cBut patients must be screened very carefully to make sure their disease has not spread.\u201d", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not mention the costs of the IUD or implantation.", "answer": 0}, {"article": "Consumers can wake up with Red Bull and then wind down with Slow Cow.\nThe back of the Snooz'n bottle says the beverage will \"combat stress, energy drinks and sleeplessness\" and takes about 30 minutes to take effect.\nNow, the field includes a slew of new drinks promising a better night's sleep using such ingredients as melatonin, valerian root and - think turkey - tryptophan.\nWhen it launches nationally in March, Snooz'n will be available in grocery and convenience stores and pharmacies, like most of these drinks.\nThey have apt names such as Unwind, iChill and Dream Water, and offer such flavors as Berry-Berry Tired, Snoozeberry and Lullaby Lemon.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "These beverages don\u2019t come cheap, but you wouldn\u2019t know it\u00a0from reading the story, which had no information on costs.\u00a0According to the blog for iChill, one of the drinks mentioned in the story, a 2 oz \u201cshot\u201d\u00a0retails for $2.99 at 7-Eleven.", "answer": 0}, {"article": "Side effects of dopamine agonists can include euphoria, hallucinations, weight loss, nausea, insomnia, tiredness or weakness, dizziness and drowsiness.\nNonetheless, for people with moderate to severe restless legs syndrome symptoms, these medications provided important benefits, at least in the short term, Wilt said.\nThe harms of medications may outweigh benefits for these individuals, Wilt said.\n\"Up to 25 to 50 percent with even moderate to severe and longstanding symptoms stop taking these medications after more than a year due to either side effects or lack of benefit,\" he noted.\n\"These are the only treatments approved by the [U.S. Food and Drug Administration],\" he added.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story provides monthly cost information for the drugs discussed, and notes that out of pocket expenses will\u00a0vary depending upon insurance coverage. One note is that neurontin is available generically and is less costly than the brand name described.", "answer": 1}, {"article": "She exercised.\n\u201cSomething like this could potentially flatten that curve and change the epidemiology of pancreatic cancer.\u201d\n\nStill, Donahue said, the method needs to be \u201cheavily vetted and validated.\nAnd even if it passes muster, it will take some time before a test could be developed to screen for the disease.\nIt is a good example of how this disease sneaks up on people and gives no warning.\u201d\n\nA test for pancreatic cancer could save lives, perhaps even Flippo-Morton\u2019s, Raghavan said.\nFurther, levels dropped when patients had surgery to remove their tumors, so the marker could also be used to follow the progression of the disease, Kalluri said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There is no mention of costs in this story. No costs for the test. No costs for the downstream treatments and surgeries. If a researcher is going to be quoted as saying a clinical test could be on the market in a year, there should be some mention of costs.", "answer": 0}, {"article": "The item you've requested, /cgi-bin/article.cgi?f=/n/a/2006/02/09/national/a005536S75.DTL&type=health, was not found.\n\u2022 the item no longer exists, or\n\u2022 there has been an error on the site.\n\nIf you feel the address you entered is correct you can contact us, mentioning the error message received and the item you were trying to reach.\n\nWe apologize for any inconvenience. From here, you can:\n\u2022 use the menu bar above\n\u2022 select an item from our site index below", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No mention of the cost of this drug, though it is labeled \u201cinexpensive\u201d. Inexpensive is relative and may not be viable for health centers w/out funding from clinical trials. However, there is explicit consideration of cost for resource-limited countries.", "answer": 1}, {"article": "Parkinson's is not considered an inflammatory disease, he said, adding: \"We might be missing something.\nStudy author Dr. Xiang Gao, an instructor and epidemiologist at Harvard Medical School and Brigham and Women's Hospital in Boston, said the findings are important for anyone at increased risk for Parkinson's because most people with the disease eventually become severely disabled.\n\"So it narrows the focus to a subgroup of [anti-inflammatory drugs].\"\nDr. Michele Tagliati, an associate professor of neurology and director of the Parkinson's Disease Center at the Mount Sinai School of Medicine in New York City, described the results as somewhat surprising and said they emphasized the need for further study.\n\"It's intriguing [that the finding applied to] just ibuprofen and not aspirin or acetaminophen or other commonly prescribed medications for inflammation because it implies something more specific to ibuprofen that should be investigated,\" Tagliati said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Not applicable.\u00a0 Costs not discussed but most people know that ibuprofen products are inexpensive. ", "answer": 2}, {"article": "Dr. Stehling is a German Professor of Radiology, a former Associate Professor at Boston University and served as Research Assistant to Sir Peter Mansfield, Prof of Physics and Nobel Prize winner in Medicine in 2003 (for discoveries concerning magnetic resonance imaging).\nThe study which was conducted at the Prostata Center of Offenbach, Germany (www.prostate-center.org) will be presented today at the annual meeting of the Radiological Society of North America (RSNA).\nDr. Stehling has treated the most prostate cancer patients in the world using this image guided treatment, while generating the best therapeutic results.\nThe IRE treatment also had very low toxicity on the rectum and bladder, even in cases of advanced cancer infiltrating these structures in patients who were not candidates for surgery or radiation therapy anymore.\nData found that the most common side effects are either eliminated or greatly reduced using image guided treatment.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release does not discuss costs.", "answer": 0}, {"article": "\"They are a gateway out of smoking,\" says Etter.\nBut some critics argue these electronic nicotine delivery systems (ENDS) are fueling a new addiction to nicotine -- particularly among young people experimenting with them.\nThat's backed up by Etter's research as well as a recent study by researchers at Penn State College of Medicine, in which e-cigarettes were found to be less addictive than tobacco cigarettes.\n\"[They may] expand their market to other customers who didn't use cigarettes but might consider nicotine use.\"\nBauld's research hasn't identified a dependence on nicotine with e-cigarettes in the same way as the addiction resulting from regular cigarettes.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "We are disappointed that the story did not give any direct costs for tobacco cigarettes, e-cigarettes, or smoking cessation aids such as nicotine gums and patches.\nThe story does bring cost into the discussion when it quotes a researcher noting that increasing tobacco prices has an effect on consumption. \u201cFor every 10% increase in tax you have 4% reduction in tobacco consumption.\u201d\nBut it would have been easy to attach some real numbers to the claim: A pack per day smoker of tobacco spends roughly $2,500 per year, according to a reference we found at NerdWallet\nConsumption of a similar number of e-cigarettes from a rechargeable device would cost about $600, the same story said.", "answer": 0}, {"article": "\u201cI don\u2019t want to throw cold water on an interesting thing, but that\u2019s what it is \u2014 an interesting thing,\u201d Gallo said.\nIt requires destruction of a patient\u2019s own bone marrow \u2014 itself a harrowing process \u2014 and then a transplant from a donor who has a near-exact blood and immune system type.\n\u201cOur results strongly suggest that cure of HIV has been achieved in this patient,\u201d they wrote in the journal Blood.\nSchneider\u2019s team has been following the patient, taking samples from his colon, liver, spinal fluid and brain as he developed various conditions that justified the tests.\nThe patient, who had both HIV infection and leukemia, received the bone marrow transplant in 2007 from a donor who had a genetic mutation known to give patients a natural immunity to the virus.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story makes no mention of costs.\u00a0With an estimated cost of $150,000 to 200,000, the cost of a allogenic bone marrow transplant is significant enough to be mentioned.", "answer": 0}, {"article": "MRI highlights angiogenesis, the formation of new blood vessels, especially those that feed cancerous tissues.\nWith the MRI screen, \"we found cancer in just over 3 percent of women [with a personal history], which was double [that found in those with a genetic or family history],\" she said.\nHowever, still more research is needed to clarify the role of MRI in this population, she said.\n\"Women in the personal history group [who had MRI] were also less likely to be recalled for additional testing, and less likely to have a biopsy for a false positive finding,\" she said.\nOverall, the MRI detected 25 of 27 cancers, DeMartini said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "\n\n\n\nAlthough the story acknowledges that women may need to pay for such imaging out of their own pockets, it does not provide any estimate of the cost\u2026 which may run more than $1000 per MRI scan. And since such testing is rarely a one-time event\u2026 women who choose to have MRI scans that are not covered by their health care insurance may spend thousands of dollars. \nOne estimate of the cost of MRI for women at an extremely high (50%) risk of developing breast cancer concluded that more than $50,000 was spent for each cancer found. \nAccording to the abstract of this study, cancers were found in 3 percent of the women with a history of breast cancer, which means that about 33 women were scanned for each cancer found, so the scanning cost would be somewhat more than $30,000 for each cancer found. And since conventional mammography was not part of this study, the researchers cannot claim that MRI found any tumors that would not have been found by conventional mammography, so there is no way to conclude from this data that there was any incremental advantage to adding MRI.\n", "answer": 0}, {"article": "The results are published in the journal PLOS ONE.\nThis is the first clinical study to suggest that neoadjuvant chemotherapy (treatment prior to surgery) may improve breast cancer recurrence rates and patterns in African-Americans.\nThe researchers studied rates and patterns of tumor recurrence after hormone, radiation and chemotherapy among African-American and European-American breast cancer patients.\nThe researchers also found that among early stage patients (noninvasive or minimally invasive breast cancer), African-Americans displayed higher tumor recurrence than European-American patients.\nAmong patients who received neoadjuvant chemotherapy, African-Americans exhibited trends of lower regional and distant tumor recurrence than European-Americans, but higher local recurrence, which is easier to manage clinically and is associated with a relatively better prognosis.\"\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The news release did not discuss costs, but presumably receiving chemo before surgery\u2013instead of after\u2013does not considerably increase costs.", "answer": 2}, {"article": "Antioxidants are found in different levels in fruits and vegetables, such as blueberries or broccoli.\n\u201cWho the heck knows what the active ingredients are?\u201d\n\nMarion Nestle, a nutrition expert at New York University, said the effects might not be unique to pomegranate juice.\nBrosius was skeptical of the benefits, although he said the juice was unlikely to cause harm.\n\u201cThis study does not demonstrate anything special about pomegranate juice,\u201d she told Reuters Health in an e-mail.\nThey found that such patients who gulped a few cups of the tart liquid every week lowered their chances of infections, the second-leading killer of the more than 350,000 Americans on dialysis.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story included a price estimate for one brand of pomegranate juice \u2013 about $4 for a 16 oz. bottle.", "answer": 1}, {"article": "Adding small amounts of powdered ginger to food may help take the edge off seasonal allergy symptoms, according to an animal study published online in the Journal of Nutritional Biochemistry. Daily intake of dried ginger significantly reduced sneezing and other signs of allergy in rodents with induced allergic rhinitis, or hay fever.\n\nA major component in ginger, 6-gingerol, suppresses the activation of T lymphocytes, or T cells, a type of white blood cell that plays an important role in sensitizing people to specific allergens,...", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story did not talk about the cost of adding a daily dose of ginger to one\u2019s diet. But since that cost can\u2019t be very significant, we\u2019ll rate this Not Applicable.", "answer": 2}, {"article": "The 54-year-old said: \"I knew straight away that I had been given the drug.\n\"This new drug could be a game changer for future treatment of asthma\" - Professor Chris Brightling, NIHR Senior Research Fellow at the University of Leicester\n\nThe first new asthma pill for nearly 20 years has the power to significantly reduce the severity of the condition, a study led by the University of Leicester has found.\nThe research was funded by Novartis Pharmaceuticals, National Institute for Health Research (NIHR) and the EU (AirPROM), and is described by the lead researcher as \"a game changer for future treatment of asthma.\"\nProfessor Christopher Brightling, who is a NIHR Senior Research Fellow and Clinical Professor in Respiratory Medicine at the University of Leicester, led the study at the NIHR Respiratory Biomedical Research Unit, which is based at the Glenfield Hospital in Leicester.\nThe study was designed primarily to examine the effects on inflammation in the airway by measuring the sputum eosinophil count.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release does not mention the cost of the potential new drug, nor is there any estimate of what the cost might be in comparison to other asthma treatments currently in use including inhalers and corticosteroids. The release would have been more helpful to people with asthma if it had included some cost estimates since new medications tend to be very expensive.\nIf it\u2019s not too early to promote a treatment to a patient audience, it\u2019s not too early to provide a ballpark cost.", "answer": 0}, {"article": "47(5) pp.\nThe Agency for Healthcare Research and Quality (AHRQ) reported significant improvements in the safety of metabolic/bariatric surgery due in large part to improved laparoscopic techniques.\nThe device is manufactured by Obalon Therapeutics, Inc., based in San Diego, CA.\nAll patients at the 15 study sites also underwent 25 minutes of lifestyle therapy administered by a blinded registered dietitian every three weeks.\nResults of the study were based on a double-blinded randomized, sham-controlled trial of 387 patients, about half of whom received treatment with the Obalon balloon and the other half with a sugar-filled sham capsule designed to look like the device.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release does not discuss costs. Although the manufacturer has not revealed the price it plans to charge in the U.S., the Obalon device is on the market in Europe and Mexico, where prices, including office procedures, range from $2,500 to $4,000. It should be noted that prices for medical devices in the US are generally higher than those charged in other countries.", "answer": 0}, {"article": "While some people are helped by over-the-counter medications like ibuprofen, others need prescription medications that may cause side effects, such as dizziness.\nFor 63-year-old Lynn Kaufman, the battle against migraines consumed her life.\nThe aim of the medication is to stop a migraine before it even starts.\nAnother advantage: it could lead to a decrease in the amount of medications used by patients to handle headaches acutely.\nHowever, the price tag could be as much as $10,000 a year.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story tells us the drug, if approved, may cost $10,000 a year. This is very useful context.", "answer": 1}, {"article": "April 28, 2010 -- Federal researchers say a new treatment can reverse vision loss in many patients with diabetic macular edema, a leading cause of blindness in people with diabetes.\n\nIn a news conference yesterday, researchers announced findings from a government study comparing treatments for swelling of the retina caused by leaking blood vessels in the eye.\n\nNearly 50% of patients given eye injections of the drug Lucentis along with laser treatments showed improvement in vision after a year of treatment, compared to just over a fourth of patients treated with laser alone.\n\nFor several decades, laser has been the standard treatment for diabetic macular edema, or DME, in which fluid builds up near the center of the retina.\n\n\u201cFor the first time in 25 years we have definitive proof that a new treatment can lead to better results for the eye health of people with diabetes,\u201d said Neil M. Bressler, MD, who oversaw the study as chairman of the Diabetic Retinopathy Clinical Research Network.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story covers cost in the very last two lines. ", "answer": 1}, {"article": "U.S.\nUSRM has been a part of more than 10,000 stem cell procedures in the past 19 years for a variety of indications including orthopedic, autoimmune, degenerative and neurological diseases.\nThe paper outlines the case study of a 56-year-old male with a chronic meniscus injury.\nThe arthroscopic images showing resolution were also consistent with quality of life improvements for the patient, including a reduction in pain and resumption of normal activities.\nTo management's knowledge, USRM has completed more clinical treatments than any other stem cell company in the world.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There is no mention of the cost of this proposed procedure to the patient, nor is there any indication that such a procedure might be covered by medical insurance, since this is a very early experimental approach. The procedure involves outpatient liposuction to obtain a small quantity of the patient\u2019s fat tissue, and various complicated separation procedures to obtain the cell mixture ultimately used in the treatment. The cost for each of those procedures should be well-known and the release could have offered a comparison with the typical cost of the current approach to treating meniscus injuries.", "answer": 0}, {"article": "For decades, researchers have searched unsuccessfully for ways to automatically coordinate insulin delivery with real-time changes in blood sugar to essentially create an artificial pancreas that maintains target blood sugar levels with minimal effort.\nNow new technology is making this possible, and new research shows that an experimental system can improve nighttime blood sugar control.\nAaron J. Kowalski, PhD, of the Juvenile Diabetes Research Foundation, which was involved in funding the research, says the study represents an important step forward in the search for a clinically feasible artificial pancreas to improve outcomes and quality of life among insulin-dependent diabetes patients.\nThe system proved better than a conventional insulin pump for maintaining optimal blood sugar levels during the night in a study from the U.K.'s University of Cambridge.\nFeb. 4, 2010 - It has been called the Holy Grail of treatment for insulin-dependent diabetes, and it may be close to reality.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "If this technology\u00a0is as close to reality as this story suggests, then it\u2019s\u00a0appropriate to discuss costs. This\u00a0story didn\u2019t.\u00a0 The story could have at least nodded in the direction of financial impact of new technologies.\u00a0\u00a0 Many patients with type 1 diabetes are not using currently available pumps and sensors because of the high cost of these devices.\u00a0It seems likely that this new treatment, if it ever becomes widely available, will be as expensive or more so than the current pump and sensor technology.", "answer": 0}, {"article": "Lauren Gravitz is a science writer and editor in Hershey, Penn.\nRight now, the longest patients have been on one of these new therapies is one to two years.\nAt their best, the headaches are an annoyance.\nYet, despite decades of research, there isn't a drug on the market today that prevents them by targeting the underlying cause.\nHe has good reason to be: Each of the therapies decreases migraine frequency by at least one to two days per month.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story says these treatments could cost \u201canywhere from $8,000 to $18,000 a year.\u201d", "answer": 1}, {"article": "\"Shireen had the idea, 'Why can't I just test my food and figure out what's in it?'\nThe company plans to deliver the product by the middle of next year after they've tested it more thoroughly, Sundvor.\nNima is not FDA-approved and it's not intended for medical use, but the company intends it as a \"consumer\" tool to use when dining out, Sundvor said.\n\"Certainly an FDA-approved device that could help people determine if they were accidentally ingesting gluten could go a long way to helping people and would be useful.\"\nMarilyn Grunzweig Geller, chief executive officer of the Celiac Disease Foundation, said she is not familiar with the new gluten-sensing device and was unable to comment on it directly.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story clearly states the cost of the \u201cpre-order\u201d version of Nima and the cost of \u201ctest pods.\u201d", "answer": 1}, {"article": "Dr.\nThe specificity of the Exact Sciences test is 88 percent, meaning that 12 percent of the time the patient will be given a false alarm.\nThe practical value of the tests depends critically on details like their sensitivity, meaning the proportion of tumors that are detected, and their specificity, meaning how many of the positive results are in fact false alarms.\nBoth tests would be less expensive than colonoscopy, and potentially more effective.\nBut the blood-based test may have a similar problem, since a positive signal could come from cancers anywhere in the body.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story says, \u201cBoth tests would be less expensive than colonoscopy, and potentially more effective.\u201d\u00a0 No specific cost estimate is given.\u00a0 The Philadelphia Inquirer said \u201cThough the cost has not been set, it could be as low as $300 per test.\u201d Reuters reported that the company said earlier that it would aim for $300-400 per test.\nThe story also states that \u201cCompliance with colonoscopy is low, since people don\u2019t want to have one, and the overall cost per detection is high\u201d \u2013 implying that the new test might be more cost-effective.\u00a0 But it\u2019s unclear at this point if that would be true. For example,\u00a0previous stool DNA tests have performed much worse (higher costs, lower efficacy) than colonoscopy in modeling studies.", "answer": 0}, {"article": "HER2+ breast cancer is more likely to affect younger women and also more likely than other breast cancers to metastasize specifically to the brain.\n'There are women who are alive today because of this drug,' says University of Colorado Cancer center researcher\n\nPhase 1 clinical trial data published this week in the journal Clinical Cancer Research show early promise of the investigational anti-cancer agent tucatinib (formerly ONT-380) against HER2+ breast cancer.\nBorges has been a major driver of the drug's development from its invention at Array Biopharm in Boulder, CO and now through clinical trials of the drug, which is licensed to Cascadian Therapeutics of Seattle, WA.\nBecause the drug is taken in pill form and has a very favorable side effect profile, Borges points out that it is relatively patient-friendly, allowing women to avoid treatments in infusion centers and also many of the side-effects associated with chemotherapies.\nThese data led to two subsequent Phase Ib studies, resulting in tucatinib earning FDA fast-track status and the expansion of this study once meant only to demonstrate drug safety into the \"pivotal\" trial that will determine approval.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The news release provides no information about how much tucatinib treatment might cost. If it\u2019s not too soon to promote the potential benefits of a drug it\u2019s not too soon to provide cost estimates.\n[Editor\u2019s note: We had originally rated this criteria Not Applicable since it is an investigational drug in very early trials and it\u2019s plausible costs are unknown. However, the rating has been revised to be consistent with past reviews and to reflect our general position that costs (or cost estimates based on similar drugs or treatments) should be presented.]", "answer": 0}, {"article": "Melanoma is one of the most common forms of cancer and the most serious type of skin cancer.\nFor the study, a former associate professor of Dermatology and Pathology at Yale University, Rossitza Lazova, M.D., collaborated with a national and international team of researchers to determine whether atypical moles could be more accurately diagnosed as either benign or cancerous (melanoma) using imaging mass spectrometry (IMS) \u2014 a technology that enables pathologists to focus in on individual proteins within sampled skin cells.\nThe researchers found that in nearly all cases, the IMS analysis was a more accurate predictor, both of benign lesions and melanomas, than standard microscopic examination.\n\u200b\u200b\u200b\u200bCalifornia Skin Institute \u2014 A recently developed test for assessing suspicious moles for melanoma is more accurate than standard analyses, according to Dr. Rossitza Lazova, a former Yale investigator.\nThe test, which analyzes proteins in cells, could provide more reliable results for clinicians with patients who might be at risk for this deadly cancer.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The news release does not say how much IMS costs or how it compares with using a microscope. According to an article posted by the American Association for Clinical Chemistry, most mass spectrometry methods \u201crequire labor-intensive\u2014and hence costly\u2014sample preparation. Other factors include limited sample counts over which to amortize fixed expenses, and the fact that expertise for maintenance and assay development may be in short supply.\u201d", "answer": 0}, {"article": "\"Compared to childhood vaccines, people would [probably] think 55% is not too impressive, because many childhood vaccines are in the range of 80% to 90% [effective],\" says researcher Hung Fu Tseng, PhD, MPH, a research scientist at Kaiser Permanente Southern California.\nAnother new study, published in the American Journal of Preventive Medicine, finds that by 2008, less than 7% of U.S. adults aged 60 and older had gotten the vaccine, which has been available just since 2006.\nHowever, he tells WebMD, the 55% risk reduction ''is pretty high compared to other adult vaccines.\"\nCalled Zostavax, the shingles vaccine is made by Merck.\nAbout a million episodes of shingles, sometimes debilitating, occur in the U.S. annually, Tseng says.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "\n\n\nThis story includes a comment that \u201cvaccine expense is another barrier for some\u201d and that not all insurance plans cover the cost of this vaccine, but readers are not told that it can cost about $200. Nonetheless, we\u2019ll give it the benefit of the doubt on this criterion since cost and insurance are at least addressed.\n", "answer": 1}, {"article": "In recent years, emergency service dispatchers have been coaching callers in hands-only CPR rather than telling them how to alternate breaths and compressions.\nBut less than a third of victims get this essential help.\nThe CPR guidelines had been inching toward compression-only.\nThis action should be taken only for adults who unexpectedly collapse, stop breathing and are unresponsive.\nNow the heart association has given equal standing to hands-only CPR.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Cost is not associated with this treatment. ", "answer": 2}, {"article": "The requested URL /usnews/health/articles/061008/16organ.htm was not found on this server.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The article does not mention any costs, including who pays for travel, hospital, physician, or immunosuppresant medication expenses. Also, the kidney swap program entails huge logistical hurdles/challenges, as not every medical center can afford/provide 4 transplant teams working simultaneously; the swap entails 4 hospital rooms, 4 surgical teams, etc.", "answer": 0}, {"article": "\"Are [aromatase inhibitors] better than tamoxifen?\nThe paper, issued by the American Society of Clinical Oncologists (ASCO) and published July 12 in the Journal of Clinical Oncology essentially brings guidelines in alignment with today's practice.\n\"In general, for postmenopausal women, we are offering them aromatase inhibitors based on the single studies that have been referenced [in these guidelines] and what has already been reported in national meetings.\"\nOn the other hand, Burstein pointed out, the aromatase inhibitor anastrozole recently became available as a generic, which should lower the cost significantly.\nThey also concluded that women could use them as long as five years after tamoxifen therapy to lower their risk that the cancer will reoccur.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story specifically points out that generic tamoxifen costs $21.90 a month and the aromatase inhibitor, Arimidex\u00ae, costs $379.80 a month. The story was also quick to note that a generic form of Arimidex\u00ae is now available and costs much less. Going one step further, the story included a discussion of\u00a0how the cost of treatment can factor into the decision-making process. ", "answer": 1}, {"article": "The U.S. Centers for Disease Control and Prevention has more on flu.\nThe disinfecting success of initial experiments still need to be confirmed, said lead research David Brenner.\nHowever, Brenner and his colleagues wondered if a much narrower spectrum of ultraviolet light, far-UVC, might be a safer option.\nLamps with this type of UV light currently cost less than $1,000, Brenner said, but that price would likely fall if the lamps were mass-produced.\nAs the researchers explained, broad-spectrum UVC light kills viruses and bacteria, and it is currently used to decontaminate surgical equipment.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "It\u2019s mentioned \u201clamps with this type of UV light currently cost less than $1,000 \u2026 but (according to the study author) that price would likely fall if the lamps were mass-produced.\u201d The article gets credit for addressing this issue, but the tone seemed a bit speculative.", "answer": 1}, {"article": "Compared to 52 women who only received an American Cancer Society pamphlet on chemotherapy, the 48 women in the texting group reported an overall lower level of distress and a higher quality of life during their therapy.\nSurprisingly, the older the patient, the greater the likelihood that she would text back, seeking more information.\nOne of the patients texted the program 1,217 times.\nThey also felt they had better communication with their doctors.\nThe feasibility study was designed to see if texting could relieve some of the anxiety that comes with the fatigue, hair loss and other body changes that can accompany anticancer drugs.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "How much would a texting system cost? Who would pay for it? Would it require extra staffing at the doctor\u2019s office? This story left us wondering.", "answer": 0}, {"article": "\u201cBut I wasn\u2019t really doing well,\u201d said Ms. Schomaker, 73.\nFriends thought Anne Schomaker was coping well with her loss, she recalled.\nI was missing my husband so badly.\u201d\n\nEven after seeing a therapist, which helped, she suffered from nightmares and couldn\u2019t bear to hear arias from their favorite operas.\n\u201cI had many interests.\u201d She traveled and even tried dating again.\n\u201cI had terrible pangs of sadness and despondency.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not tell us what it costs to get 16 weeks of complicated grief therapy. The insurance issues for medical care are thorny enough, but mental health coverage often lags behind other categories. The story would have been more useful had it mentioned that most therapy costs upwards of $150 an hour, and that a 16-week set might be more than $2,400 and might not be covered.", "answer": 0}, {"article": "Dr. Heather Hayes, Director of Food Innovation with Devenish, said:\n\n\"Offering birds a natural and sustainable source of omega-3 PUFA is good for the bird and good for the consumer.\n\"We worked closely with Moy Park, Waitrose and the Royal College of Surgeons in Ireland, to deliver an innovative, nutrient-rich food, that increases omega-3 levels in consumers, naturally.\n\"This science has demonstrated the importance of food nutrients to promote good health and prevent ill health.\n\"Therefore, in this project we studied the recently developed alternatives to oily fish or supplementation, namely chicken meat and eggs, naturally enriched with sustainable algae-based omega-3 PUFA.\nThe chicken meat and eggs used in the study came from birds offered OmegaPro, a sustainable and algae-based source of omega-3 PUFA, developed by Devenish.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There is no mention of the costs that might be\u00a0incurred by consumers interested in choosing chicken and eggs that ate this new feed.\u00a0 Will the new feed cost more than conventional feed, which is likely to be passed along to customers?\nThe only mentions of cost are a vague assertion that chicken and eggs are \u201cvery affordable sources of quality protein.\u201d But that doesn\u2019t tell us what the cost will be of chickens that consume the enhanced feed.\nThe release also makes an unsubstantiated claim that nutrient-rich foods such as this feed will help reduce the UK\u2019s and the whole world\u2019s cardiovascular disease burden. It says:\n\u201cThe cost to the health service of treating cardiovascular related illness in the UK is \u00a310billion/year. Having access to sustainably produced nutrient-rich food, with a scientifically proven health claim, offers huge potential to turn this around globally.\u201d\nThere wasn\u2019t any evidence provided to support that claim.", "answer": 0}, {"article": "\"It's human nature.\"\nA multisite study that appeared Thursday in the New England Journal of Medicine reinforces recommendations by the American College of Obstetricians and Gynecologists that discourage scheduling C-sections before 39 weeks of pregnancy unless there is documentation of lung maturity or it is medically necessary.\nThe findings from the study sponsored by the National Institute of Child Health and Human Development's Maternal Fetal Medicine Units Network also underscore the importance of a woman seeking medical care as early into her pregnancy as possible, so that doctors can accurately gauge the gestational age with an ultrasound, Mercer said.\nThe tests the doctors perform to determine the extent of the fetus's development are often not sophisticated enough to determine subtle milestones for breathing and processing food independently, said Dr. John Thorp, a University of North Carolina-Chapel Hill obstetrician and one of the authors of the study.\nThe findings offer important guidance to the growing number of women who face planned C-sections -- one in three babies in the United States, estimates the National Center for Health Statistics.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No data comparing costs of c-section vs. vaginal birth is provided. \nThis is surprising, given the fact that one reason experts discourage elective c-sections is high cost. ", "answer": 0}, {"article": "; Menno V. Huisman, M.D., Ph.D.; Pieter W. Kamphuisen, M.D., Ph.D.; J\u00f6rg Kreuzer, M.D.\nThe association has strict policies to prevent these relationships from influencing the science content.\nVideo clips with researchers/authors of the studies will be added to the release link as available.\nThe association makes no representation or warranty as to their accuracy or reliability.\nThe new results are part of a large on-going phase III study testing idarucizumab in a range of patients who take dabigatran and have dangerous bleeding or need urgent surgery or other procedures that carry serious bleeding risks.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release doesn\u2019t mention cost at all. According to NEJM Journal Watch, the cost is reported to be in the ballpark of $3,500 per use, which we consider to be a very conservative amount.", "answer": 0}, {"article": "So does cardiologist Roger Blumenthal, who heads the Ciccarone Center for the Prevention of Heart Disease at Johns Hopkins.\nAnd it is only useful as a screening test for people who haven't had heart disease.\nIt's important to note that statin drugs are generally safe, and harms are uncommon.\nAnywhere from 50 to 200 healthy people need to take a statin daily to prevent a single heart attack for five years, so even small harms may outweigh the potential benefits, the Swiss scientists say.\nBut that test, which Grundy says is available for about $100, is controversial among some physicians.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There\u2019s no discussion of cost, even to mention that statins are relatively inexpensive these days and are mostly generically available. To its credit, the article does mention the cost of a calcium scan.", "answer": 0}, {"article": "\"These are very basic facts, concerning simply who lived and died,\" he noted.\nRemote monitoring via telephone lines and online physician access is available for all ICD and CRT-D devices, the authors noted, and enrollment in such programs is typically free with a cardiologist's recommendation.\nThe same is true for 88 percent of CRT-D patients, they noted.\nThe study team also found that patients whose implants were monitored remotely, on a continual basis, by a health facility network were about half as likely to die as patients who only had intermittent in-person assessments.\nBut at our facility we think it makes caring for a patient much easier.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There is no mention of the costs of the devices, which is a shame for two reasons. First, these devices are costly, and the procedures to put them in are costly. Costs can run as high as\u00a0$50,000 for the device along with hospital and physician charges. The costs of the remote monitoring program would have been a welcomed addition to the information as well. Given the national discussion on health care cost, some attention to the price of the treatments and monitoring should have been included.\u00a0Secondly, we\u2019re talking about comparing devices, and there should have been some discussion of cost effectiveness. If we are claiming that there is a significant benefit to choosing one device over another or to subscribing to a remote monitoring plan, which the story does say \u201cis typically free with a cardiologist\u2019s recommendation,\u201d we should know how much each approach costs.\n", "answer": 0}, {"article": "A healthy cholesterol level is less than 200 mg/dL, according to the American Heart Association, while 200 to 239 mg/dL is considered \u201cborderline high.\u201d\n\nIn the groups taking 100 and 200 micrograms of selenium daily, total cholesterol dropped an average of 8.5 mg/dL and 9.7 mg/dL, respectively, compared to the group taking a placebo pill.\nStill, the finding is \u201creassuring\u201d because previous research had linked high selenium with higher cholesterol levels, said study author Dr. Eliseo Guallar, from the Johns Hopkins Bloomberg School of Public Health in Baltimore.\nThey recruited about 500 older adults in the UK to take one of three different doses of selenium daily \u2014 100, 200, or 300 micrograms \u2014 or a placebo pill with no selenium.\nThe picture of selenium\u2019s health benefits \u2014 or possible health risks \u2014 has been anything but clear.\nWhile Guallar said the results are \u201cgood news\u201d in showing that high selenium intake is probably not a risk for high cholesterol, he wanted to add a note of caution.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story says a month\u2019s supply of selenium costs about $2. But many people may be getting selenium in\u00a0their daily multivitamin,\u00a0and may not\u00a0need to buy\u00a0more.", "answer": 1}, {"article": "His \"tactile imaging system\" capitalizes on the fact that cancerous lumps tend to feel harder and less movable than harmless abnormalities such as fluid-filled cysts or fibrous nodules. The fist-sized, $1,000 machine \u2014 with an elastomer probe, a light, and a camera \u2014 acts like ultrasensitive fingertips. It measures the size, elasticity, and mobility of a breast lump, then a computer program converts the data into a score from 1 to 5, with scores under 2 likely to be benign.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The prototype device is said to cost $1000.\u00a0 At this stage of development, the exact cost of the device and of screening is difficult to predict.\u00a0 We\u2019ll give the story the benefit of the doubt given the early stage of development of the device", "answer": 1}, {"article": "We keep them at that temperature for the first 24 hours, at which time we re-warm them,\" Likosky explains.\nWhen 57-year-old Dean Cowles suddenly suffered a heart attack, he was lucky that he worked at a company that made defibrillators,reports.\nIt requires training and a lot of coordination.\nIt's called induced hypothermia.\nBut what helped save his brain \u2014 and left him remarkably undamaged \u2014 was a simple procedure in the ER: chilling his body.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Although one of the physicians commenting on the treatment contrasted this treatment with the situation in medicine where there are expensive treatments that may make little difference \u2013 and explained this procedure as being just \"ice\"\u00a0 \u2013 the video showed some specialized equipment for controlled lowering of body temperature. The story gave no estimate for the cost of the treatment.", "answer": 0}, {"article": "Surgeons sometimes fly blind when operating on hard-to-reach anatomical parts or hard-to-see conditions. For visual references inside the brain or body, they often rely on images and scans taken before an operation.\n\nA growing number of hospitals are equipping operating suites with magnetic resonance imaging, CT scanners and other technology that enables surgeons to scan a patient in real time, without having to move them from the operating table.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story notes that the technology needed to implement these real-time imaging techniques is costly for hospitals, and lists examples of technologies that range in price from $1.5 million to $7 million. The story could have done even better if it had placed those numbers in context. How much does it normally cost to outfit a surgical suite? And what do these costs mean for patients? It would have been hugely helpful to compare costs for the same surgery with or without the new technology. On a related note: are insurers covering the costs of these real-time imaging procedures?", "answer": 1}, {"article": "Drs.\nThis study and others are providing evidence for changes in obstetric practice that could help safely reduce c-section rates.\nThis study suggests that IV fluids could help women maintain hydration at appropriate levels, reduce the likelihood of c-section, and decrease length of labor,\" says Dr. Berghella.\n\"The results are compelling and strongly argue for a change in practice,\" says Vincenzo Berghella, M.D., the Director of Maternal Fetal Medicine and Professor in the Department of Obstetrics and Gynecology at the Sidney Kimmel Medical College at Thomas Jefferson University.\nWith the data pooled, the researchers could see a clear difference in outcomes for women in the two groups.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Cost does not make an appearance in this release. The concept may seem trivial when considering the cheap ingredients in saline\u00a0fluid, but little about American medical care is cheap.\nAnother important consideration is the cost of cesarean section compared with that of vaginal delivery, which is not addressed in the release.", "answer": 0}, {"article": "The women who ate more berries also tended to eat healthier overall, consuming more vegetables and fruits than those who didn\u2019t eat as many berries; but when the scientists broke down the women\u2019s diets, they found that the highest consumers of berries even had a lower risk of heart attack compared with women who still ate plenty of fruits and vegetables but fewer berries.\nThe benefits for the heart of eating strawberries and blueberries can build up over a lifetime, according to the latest research.\nThat means that regular consumption of berries might be a relatively easy way to lower a woman\u2019s risk of having a heart attack later in life, possibly even insulating her from heart problems.\nThe researchers focused on blueberries and strawberries because these are the most widely consumed varieties in the U.S.\n\u201cAlthough we know about the effects of antioxidants and flavonoids, and their effects in wine and chocolate, it is interesting to look at their effects in such a large group of women over a long period of time,\u201d says Dr. Suzanne Steinbaum, director of women and heart disease at Lenox Hill Hospital in New York City, who was not involved in the study.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Not applicable.\u00a0 Cost of berries not discussed, but we can assume most readers know the ballpark costs.", "answer": 2}, {"article": "Soon after Zane relapsed, he and his father bumped into friends in a local doughnut shop who told them about a TV segment on CAR T-cell therapy.\nIt seemed an equally promising target that could broaden the therapy\u2019s impact, researchers thought.\nThat\u2019s a major achievement in a group whose cancer is emboldened by every treatment failure.\nAs it happened, Fry, head of the blood-cancer section in NCI\u2019s pediatric oncology branch, had already launched the world\u2019s first trial using CAR T-cell therapy to focus on CD22.\n\u201cWe\u2019re kind of up against the edge.\u201d\n\nFry thinks she might be able to undergo a second round of her latest immunotherapy, as long as her cancer is still producing CD22 proteins.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The CAR T-cell therapy is currently available only in clinical trials, where costs presumably aren\u2019t an issue (a point the story might have made for readers who aren\u2019t familiar with clinical trials).\nThat leaves the question of how much this therapy may cost if it becomes more widely available. And this is where the story offers some valuable insight: \u201cIt is also far from clear that such a personalized approach \u2014 possibly costing hundreds of thousands of dollars \u2014 is economically viable on a large scale.\u201d In other words, to quote the story again: \u201cbig questions surround the therapy.\u201d", "answer": 1}, {"article": "\u201cBut we do expect the patients to have significant improvements in mobility.\u201d\n\nNearly 30,000 Asterias\u2019s shares were traded by 12:30 p.m.\nThe therapy, AST OPC-1, is the first product derived from human embryos to be tested on humans.\nThe early study tested the benefits of a smaller dose of 2 million stem cells that are tuned to develop into nerves.\nMenlo Park, California-based Asterias expects to release complete safety data from the first half of the study later in the year.\nData showed that the severity of the spinal injury was reduced in the first patient and two other patients were able to resume their rehabilitation programs soon after being injected with the stem cells.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The therapy, AST OPC-1, is in its early developmental stages \u2013 making it difficult to estimate costs in this case.\nSince the story is clear about the early state of the research, we rate this one Not Applicable.", "answer": 2}, {"article": "If a robot is to be enlisted, he recommends asking how the procedure would be performed if the robot is not available or if it doesn\u2019t work.\nThe robotic equipment provides better three-dimensional vision, increased range of motion and intuitive, downscaled movements, while adding a few thousand more dollars to the procedure\u2019s price tag, the authors note.\n\u201cHowever, if the surgeon is skilled enough to do the hysterectomy without the robot by laparoscopy then the outcomes will be similar.\u201d\n\nNezhat further noted that while robotic assistance can be a good \u201cenabler\u201d for a minimally invasive approach, surgeons should have at least the basic knowledge of regular laparoscopy too, as there may be times when the robotic equipment doesn\u2019t work.\nThe researchers found that the two advanced minimally invasive techniques led to similar results, and both appeared to be generally superior to the traditional open procedure.\nMore research is needed to be able to compare long-term outcomes, wrote the researchers.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story only cites the researchers\u2019 statement that the robotic approach adds \u201ca few thousand more dollars to the procedure\u2019s price tag.\u201d\u00a0 But why not give an estimate of actual costs?\u00a0 One surgeon\u2019s definition of a \u201cfew thousand\u201d may differ greatly from a patient\u2019s definition. There was also no discusison of whether insurers pay for robotic procedures \u2013 another key consideration for readers/consumers.", "answer": 0}, {"article": "By the time most lung cancers are diagnosed -- which usually involves an invasive examination of the lungs -- patients already have advanced malignancies.\nCurrently, there is no good way to detect lung cancer -- the number one cancer killer -- in its early stages when it's most treatable.\nMaybe one day, screening could be done using an even simpler nasal or sputum test, the researchers said.\nThe minimally invasive procedure involves using a small brush to collect a smattering of cells from the windpipe (a bronchoscopy), explained study co-author Andrea Bild, an assistant professor of pharmacology and toxicology at the University of Utah in Salt Lake City.\nThe study findings were published in the April 7 issue of the journal Science Translational Medicine.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Not applicable because of the early stage of research. ", "answer": 2}, {"article": "To resolve that possibility, a new trial is under way at 20 cancer centers, including M.D.\nAlmost all the patients mounted an immune response.\nThe trial's big surprise was that the chemotherapy didn't stop the vaccine from prompting a strong immune response and instead enhanced it.\nHe noted the impressive results could be the result of cherry-picking patients, accepting only those whose tumors had been excised by surgery and radiation.\nAfter surgery and follow-up radiation, he and his doctors decided to combine Temodar, the now-standard chemotherapy, and the vaccine, until then only used alone.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There was no mention of costs associated with the two additions to current glioblastoma treatment strategies.\u00a0 How much does Temodar cost?\u00a0 How much does Avastin cost?\u00a0 Would insurance cover it?\u00a0 And why didn\u2019t the story at least include a projection of how much the vaccine would cost?\u00a0 These are increasingly important issues in cancer treatment. ", "answer": 0}, {"article": "Fish like salmon, herring and sardine are a common source of EPA-DHA, while ALA is found in vegetables including soybeans, flax seeds and walnuts.\nDaan Kromhout of Wageningen University, who led the study, told the European Society of Cardiology the lack of efficacy might reflect the good background drug treatment patients were receiving, with 85 percent on cholesterol-lowering statins, as well as blood pressure and blood-thinning tablets.\nUnilever, whose margarine brands that contain omega-3 include Flora and I Can\u2019t Believe It\u2019s Not Butter, said the lack of benefit seen with EPA and DHA was surprising, considering the weight of evidence published to date.\n\u201cThe results indicate that more investigation is required into the efficacy of vegetable omega 3, but do not question the current authoritative dietary recommendations and advices for omega 3 intakes on which our products are based,\u201d the company said in a statement.\nDiabetes patients also showed a possible benefit.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Not applicable; the product in question is not commercially available. But why didn\u2019t the story give us some range for comparison by giving us the price of Unilever\u2019s existing omega-3 margarine brands? ", "answer": 2}, {"article": "Patients with Type-1 diabetes typically compensate by monitoring their blood sugar levels every few hours and injecting themselves with insulin as many as five times a day.\nThe experimental therapy eliminated the need for insulin injections for months or even years in 14 of 15 patients who were recently diagnosed with the disease.\nBut other doctors said that even if the benefits of the therapy are temporary, the research provides valuable insight into the mechanism behind the disease.\nThe study suggests a new avenue for treating the intractable disease, in which the immune system destroys insulin-producing beta cells in the pancreas.\nEven if patients continue to require insulin shots, the treatment should be considered a success if it halts the destruction of beta cells, said Dr. Jay Skyler, with the Diabetes Research Institute at the University of Miami Miller School of Medicine, who wrote an editorial accompanying the study.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not mention any costs of the experimental procedure.\u00a0 ", "answer": 0}, {"article": "\u201cThis is great news,\u201d says Kay Dickersin, PhD, an epidemiologist with the Johns Hopkins School of Public Health and director of the U.S. Cochrane Center.\nIt updates a 1999 Cochrane review that found no strong evidence to recommend zinc as a help for colds.\n\u201cThe evidence from the recent trials does support the use of zinc lozenges in treatment of common cold,\u201d says study researcher Meenu Singh, MD, a pediatric pulmonologist at the Post Graduate Institute of Medical Research in Chandigarh, India.\nIt also appeared to prevent colds in people who used it over the course of about five months.\n\u201cWe really don\u2019t have interventions for colds that work.\u201d\n\nThe review of 15 studies with 1,360 participants was published by the Cochrane group, an international collaboration of researchers that reviews evidence behind therapeutic interventions.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There was no mention of costs in this story. What the Reuters Health story did was mention the actual costs for the lozenges and also the cost in lost productivity of people calling in sick from colds. Both would have been nice to see in this story.", "answer": 0}, {"article": "\u2022 The percentage of days with full asthma control were virtually the same for acetaminophen and ibuprofen: 85.8 and 86.8 percent, respectively.\n(The asthma therapies were given in varying order as part of a concurrent randomized trial, making this, in effect, a \"trial within a trial.\")\nWhile the study was modest in size, it was powered to detect any clinically significant differences, more so than past retrospective studies, Phipatanakul notes.\nThe study enrolled 300 children 1 to 5 years old with mild persistent asthma.\nThe 18-site study should settle a debate that originated when several retrospective studies seemed to indicate that children had exacerbations of their asthma when receiving Tylenol for pain and/or fever.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Costs are not addressed in the Boston Children\u2019s Hospital news release. The acetaminophen medication used in the study, Little Remedies, costs about 50 percent more than Children\u2019s Advil \u2013 $8.86 versus $4.96, respectively \u2013 at Walmart. It would have been helpful to readers to include the less costly generic versions of these drugs.\nSince costs are not mentioned in the news release, we give it an Unsatisfactory rating here.", "answer": 0}, {"article": "It needs to be tested in large trials,\" he said.\nAnother trial in 2013, however, suggested that removing clots was not beneficial, he added.\nIn this latest trial, researchers found that routinely removing clots was not beneficial, Jolly said.\nHowever, preliminary results from small trials of mechanical clot removal have not been promising, Jolly noted.\nJolly said the lesson from his team's trial is that clot removal should be used only as a rescue treatment when an angioplasty fails to clear an artery.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not discuss the cost of angioplasty, or whether that cost would be affected if routine practice regarding clot removal is changed. While there are many ways that costs might change that would be difficult or impossible to predict (for example, the impact of differing stroke rates and the related follow-up care), it should have been possible to estimate the direct costs of the procedure with or without clot removal.", "answer": 0}, {"article": "''It's been known anecdotally,\" says researcher Mark Ware, MD, assistant professor of anesthesia and family medicine at McGill University in Montreal.\nThe new study ''adds to the trickle of evidence that cannabis may help some of the patients who are struggling [with pain] at present,\" Henry McQuay, DM, an emeritus fellow at Balliol College, Oxford University, England, writes in a commentary accompanying the study.\nBut Ware's study is more scientific -- a clinical trial in which his team compared placebo with three different doses of cannabis.\n\"About 10% to 15% of patients attending a chronic pain clinic use cannabis as part of their pain [control] strategy,\" he tells WebMD.\nThe research is published in CMAJ, the Canadian Medical Association Journal.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "", "answer": 0}, {"article": "Using the Clinformatics Data Mart, a database of one of the largest commercially insured populations in the U.S., Baillargeon and colleagues examined data of 450 men aged 40 to 63 with COPD who began testosterone replacement therapy between 2005 and 2014.\n\"The findings suggest that testosterone replacement therapy may slow the progression of disease in men with COPD.\"\nThe goal of the study was to find out whether testosterone replacement therapy reduced the risk of respiratory hospitalizations in middle-aged and older men with COPD.\nThe paper is currently available in Chronic Respiratory Disease.\n\"However, we are the first to conduct a large scale nationally representative study on this association.\"\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There was no discussion of costs.", "answer": 0}, {"article": "The Kennedy Institute's Professor Kim Midwood said: 'What is particularly exciting is that when we looked at samples taken from people before their arthritis began, we could see these antibodies to cTNC up to 16 years before the disease occurred - on average the antibodies could be found seven years before the disease appeared.\nWhile tests for individual proteins usually have a relatively low diagnostic sensitivity, a more general test called CCP, that detects synthetic citrullinated peptides, identifies a lot more RA cases.\nThis latest research provides the basis of tests that could improve diagnosis and, importantly, detect disease at a very early stage, with the promise even that people at risk of developing rheumatoid arthritis can be followed before the disease begins.\nFor that reason, tests that spot antibodies to citrullinated proteins are already used to diagnose the disease.\nA team from the Kennedy Institute of Rheumatology at Oxford University found that a blood test that looks for antibodies that recognize the protein tenascin-C could reliably show those who will contract the condition.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release doesn\u2019t provide discussion of what the cost of the blood test might be. If the test is promising enough to issue a news release about it, readers should be given some idea of the cost. A related test called the CCP assay, which detects certain peptides that also predict future RA, is already in use and would make a good comparison. Moreover, there would not only be the cost for this test, but also the downstream costs of earlier treatment (and potential benefits). In general, the potential benefits in terms of cost savings are usually offset by higher costs associated with treatment for a longer duration of time (earlier diagnosis = earlier \u201clonger\u201d treatment).", "answer": 0}, {"article": "Inflammation can make urination difficult.\nThose with the highest levels of inflammation benefited the most from the periodontal treatment.\nSymptom scores on the IPSS test also showed improvement.\nThe dental school has previously found a link between gum disease and fetal deaths, rheumatoid arthritis and heart disease.\nDuring the periodontal care, the men received no treatment for their prostate conditions.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release and the study both suggest that treating periodontal disease might be a \u201crequired approach\u201d to reducing prostate inflammation and possibly prostate cancer.\u201d So the release probably should have said something about the social and financial costs of untreated gum disease and prostatitis, and the costs of providing dental care to what is likely a substantial percentage of the population. It\u2019s likely that if further studies do in fact demonstrate the value of dental treatment that money might be saved in terms of downstream treatment of prostatitis, prostate cancer, and dental disability. Dental care is not cheap in the United States, and insurance coverage, even where it exists, usually pays for only a fraction of the care.\nAlso, not mentioned anywhere is that PSA testing as a routine cancer screen is not recommended anymore. Unnecessary testing is costly.", "answer": 0}, {"article": "LONDON (Reuters) - An \u201celectronic nose\u201d could be used as a simple breath test to detect lung, breast, bowel and prostate cancers, Israeli scientists said Wednesday.\nKuten and his colleagues studied the breath of 177 people \u2014 some healthy and some with various types of cancer \u2014 to detect the different chemicals emitted from the surface of cancer cells as they grow.\nTheir findings, published in the British Journal of Cancer, build on earlier research published by scientists at the same institute last year showing that a sensor made with gold nanoparticles could detect lung cancer in breath.\nUsing the sensor to pinpoint chemical variations, the team found they could not only distinguish between healthy and malignant breath but also identify the four different common tumor types.\n\u201cIf we can confirm these initial results in large-scale studies, this new technology could become a simple tool for early diagnosis of cancer along with imaging,\u201d said Abraham Kuten of Technion Israel Institute of Technology.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "But for precisely those reasons, the story gets a strike for passing on the unchallenged speculations that the hypothetical tool could be cheap.\u00a0 Unsound journalistic practice. ", "answer": 0}, {"article": "A systematic review of C.B.T.\nImprovements like mine and those reported in the study bring sleep statistics for those with insomnia quite close to those without it.\nIt demonstrated progress \u2014 the nights in which I got only four or five hours of sleep became less common, and, on average, my nights of sleep lengthened by 30 minutes.\nThis further emphasizes the point that many insomniacs aren\u2019t that different from normal sleepers.\nMy experience is consistent with these averages.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "We wish this story comparing effectiveness of different therapies for insomnia had compared costs as well. How often is cognitive behavioral therapy for insomnia covered by insurance? Is there a co-pay per visit? What is a typical number of treatments, and what might it cost? How does that compare to taking some of the common drugs?", "answer": 0}, {"article": "Feb. 6, 2012 -- You may have heard about brown fat -- a unique type of fat that acts like a furnace in the body to burn calories instead of storing them as excess weight.\nIf studies show the same thing in humans, the heart hormone may hold the key to an effective weight loss treatment, says researcher Sheila Collins, PhD, of Sanford-Burnham Medical Research Institute in Orlando, Fla.\n\u201cThese hormones are involved in fluid regulation, but we showed in this study that they also play a role in breaking down fat,\u201d she says.\nAdults don\u2019t have much brown fat, but a new study suggests that hormones produced by the heart just might help them make more.\nResearchers found that the hormones, known as cardiac natriuretic peptides, caused regular energy-storing white fat cells to turn into energy-burning brown fat in mice.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Not applicable. There are no established ways to increase brown fat.", "answer": 2}, {"article": "Then President Richard Nixon declared drugs \u201cpublic enemy No.\nIn the past 20 years or so, a small amount of research has once again begun to focus on these chemicals, showing that they have promise for treating a range of conditions, from addiction to depression and anxiety, says Evan Wood, a psychiatric researcher at the University of British Columbia.\nThat said, when studied under controlled and supervised conditions, these chemicals have not been found to cause lasting negative health consequences, the Canadian Medical Association Journal review noted.\nAll of which adds up to a compelling argument that psychedelics \u201cshould be the focus of intensive study for treating mental illness,\u201d Wood says.\nBut at the same time, many of these substances were taken in uncontrolled settings by large numbers of people, and certain proselytizers (like Timothy Leary) advocated their widespread use.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Not discussed at all. Presumably without patentable drugs derived from these substances, they could be very economical, yet we have no idea if the substances used in these experiments underwent substantial processing or packaging which, of course, would all affect cost.", "answer": 0}, {"article": "The requested URL /usnews/health/articles/070715/23knee.htm was not found on this server.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The article does not mention cost. In knee replacement there is more to cost than the price of the implant and the hospital and surgeon\u2019s fees. After surgery, patients must plan for time away from work, intensive rehabilitation, and perhaps the cost of an inpatient rehab facility or visiting nurse.", "answer": 0}, {"article": "For more on breast cancer, visit Breastcancer.org.\nSimilar drugs have already been used to treat advanced, BRCA-mutated ovarian cancer, according to the agency.\nThis targeted form of treatment takes advantage of a weakness in the BRCA gene to further cripple the cancer cell's ability to repair itself, grow and spread, said Weiss, who was not involved with the study.\nIn addition, several ongoing studies are looking at combinations with PARP inhibitors \"to try to expand who may benefit or lengthen how long they may work,\" Litton said.\nIn January, the FDA approved the first PARP inhibitor, Lynparza, to treat BRCA-mutated breast cancer.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not mention costs.\nWhen a drug has not been approved, and thus is not on the market, it can be hard to estimate cost. In this case, however, there is a similar drug on the market: The PARP inhibitor olaparib (Lynparza) is $13,440 per month, without insurance, according to a 2015 report.", "answer": 0}, {"article": "\u201cThere is a lot more to be done to fill in the research on the biological mechanism,\u2019\u2019 Dr. Horne said.\nBecause about 90 percent of the patients were Mormons, a faith that encourages its members to fast for one day a month, the doctors expected to find a relatively high rate of regular fasting among the study participants.\nThat\u2019s the finding of a new study from doctors in Utah who looked at the relationship between periodic fasting and cardiovascular disease.\nHe said the group was planning additional research into the potential health effects of regular fasting.\n\u201cBut what it does suggest is that fasting is not a marker for other healthy lifestyle behaviors.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Not applicable.\u00a0 Cost of fasting not an issue.", "answer": 2}, {"article": "Such screening is increasingly used in research.\nThe findings also confirm that amyloid screening, by PET scan or cerebral spinal fluid test, can help identify people for clinical trials of drugs to prevent Alzheimer\u2019s.\nExperts say previous trials of anti-amyloid drugs on people with dementia failed because their brains were already too damaged or because some patients, not screened for amyloid, may not have had Alzheimer\u2019s.\n\u201cThe papers indicate that amyloid imaging is important to be sure that the drugs are being tested on people who have amyloid,\u201d said Dr. Roger Rosenberg, the director of the Alzheimer\u2019s Disease Center at the University of Texas Southwestern Medical Center at Dallas, who wrote an editorial about the studies.\nThe largest analysis to date of amyloid plaques in people\u2019s brains confirms that the presence of the substance can help predict who will develop Alzheimer\u2019s and determine who has the disease.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "One of the quoted researchers noted that the scans are expensive and not covered by insurance. The latter means they are not ready for clinical use to any large degree, so we\u2019ll give the story a pass. We\u2019d add\u00a0that if either of these amyloid screening methods \u2014 PET scans or cerebral spinal fluid testing \u2014 becomes adopted as a preventative practice, it could involve many millions of people and be very costly to an already overburdened public health system.", "answer": 1}, {"article": "Pulses become more intense when arteries near the heart are worn down -- usually by lifestyle factors such as poor diet and drug use -- and can no longer \"cushion\" the blood flow coming from the heart.\nIf the findings are confirmed by larger studies, they could vastly improve the ability to detect dementia in middle age.\nThe test, which analyzes the pulse of blood vessels in the neck, could become part of routine testing for cognitive decline, according to the study by scientists at University College London (UCL), who presented their work Sunday at the American Heart Association's annual scientific conference.\nA group of almost 3,200 patients, aged 58-74, had ultrasounds on their necks in 2002, before having their cognitive functions monitored for up to 14 years, from 2002 to 2016.\nThere is currently no cure for dementia, though medication can be used to temporarily treat its symptoms.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Cost isn\u2019t discussed. Various online estimates for carotid ultrasounds put them at $200-$800.", "answer": 0}, {"article": "Dr. Farah, who serves as the Chief Medical Officer for the Phoenix Health Center in Hagerstown, prior NE Regional Medical Director for United Healthcare Clinical Services and Director ASAM explains, \"Based on ASAM's definition of addiction, about half of substance abuse is due to genetic factors.\nStudy author, Gregory A. Smith, M.D, former Director of Pain Management at Harbor UCLA, explains, \"Having used this technology for 6 years, this data provides further evidence that clinicians can use Proove Opioid Risk\u00ae for ruling out patients unlikely to exhibit aberrant behaviors, and identifying high-risk patients for alternative therapies.\"\nProove\u00ae's medical advisory board is led by those NIH-funded researchers and the company has licensed some of its technology from leading academic centers, such as the University of North Carolina at Chapel Hill, the University of Utah, and other institutions.\nThis study shows that analyzing genetics with lifestyle and behavioral variables in a predictive algorithm can accurately stratify patient risk.\"\nPeer-reviewed clinical studies show that the Proove Opioid Risk\u00ae profile accurately identifies patient risk for opioid abuse.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The news release provides no information about how much the Proove Opioid Risk (POR) system costs. Presumably, this system would be used by health care providers to determine whether it was safe to prescribe opioids to specific patients. However, such providers would have no way of knowing, based on this news release, how much of an investment this would require.", "answer": 0}, {"article": "Among 46 chronic pain sufferers, those who spent time each day in a sauna for four weeks enjoyed a 54% improvement in sleep quality and were 27% more likely to return to work compared to a no-sauna group.\nBeever\u2019s review also looked at some of the other purported health benefits of infrared saunas\u2014including pain management.\nHe says there\u2019s evidence to support the use of infrared saunas for high blood pressure, congestive heart failure and chronic pain.\nThe heart health benefits were even greater for men who sweated it out in a sauna more frequently.\nWhile there\u2019s not a ton of published research looking specifically at infrared saunas, Beever has published a review of all the existing studies he could turn up on the subject.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not mention costs. Standard saunas are generally available at fitness gyms, but it\u2019s unclear where a person finds an \u201cinfrared\u201d sauna, and if they cost more to install and/or use.", "answer": 0}, {"article": "He contended that kratom does not act on the brain's opioid receptors the way prescription painkillers and heroin do. But back in 2016, the Journal of the American Chemical Society reported that kratom indeed works this way. Last month, an FDA study found that 22 of the 25 of the most prevalent compounds in kratom do bind to opioid receptors, and so should be considered an opioid. The study also said most deaths did occur in people who used kratom in addition to other drugs, though in one case, only kratom was detected.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story states, \u201cTen one-gram capsules of kratom cost $20, while 30 grams of powder is $34.99.\u201d\n(However, it\u2019s not clear how much a person might use per day.)", "answer": 1}, {"article": "Tim Barham, the vice president of HBB, the maker of Lazy Cakes, said, \u201cWe look at the brownie as a supplement.\u201d\n\nNews reports have classified Lazy Cakes as dietary supplements, but last month, Douglas Karas, an F.D.A.\nBut she added, \u201cI don\u2019t want to go on the record saying this drug \u2018can\u2019 cause respiratory issues, that should be a \u2018may.\u2019 \u201d\n\nLazy Cakes appear harmless, even amusing, with swirly purple packaging; Kush Cakes have a tie-dye-printed wrapper.\nOf melatonin, Dr. Seres warned, \u201cIf you take it while you\u2019re driving a car, you will find yourself in a ditch.\u201d\n\nMaybe.\nFor me, it\u2019s to get a good night\u2019s sleep.\u201d\n\nYet the products, intended for adults only, are being marketed as a novel way to relax in a stressed-out, wired world.\nThat said, he would not advise eating Lazy Cakes, partly because he was not sure that their other purportedly sleep-inducing ingredients like valerian root work and partly because food delays rather than hastens the absorption of melatonin.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story includes some pricing estimates for these products.", "answer": 1}, {"article": "Joslin has one of the largest diabetes training programs in the world, educating 150 M.D.\nAt the start of the trial, 660 adults with DME were enrolled: their average age was 61 years and 90 percent had type 2 diabetes.\n\u201cThe results clearly remove any doubts about anti-VEGF drugs\u2019 efficacy in treating DME.\nOne year after starting treatment, all participants had improved vision.\nPhysicians now have robust data to help them counsel patients and make informed decisions regarding treatment options,\u201d says study co-author Lloyd P. Aiello, M.D., Ph.D., Professor of Ophthalmology at Harvard Medical School, Director of Joslin\u2019s Beetham Eye Institute, co-head of Joslin's Section of Vascular Cell Biology, and founding chair of the DRCR Network.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The costs of the three anti-VEGF drugs evaluated in the study were listed as about $1960 for aflibercept (Eylea), $1200 for ranibizumab (Lucentis) and $70 for bevacizumab (Avastin), per injection. This is\u00a0satisfactory, although since a treatment course involves multiple injections, we\u2019d like to have seen the total cost of treatment compared without having to do the math ourselves.", "answer": 1}, {"article": "Bushra Imtiaz, Heidi Taipale, Antti Tanskanen, Miia Tiihonen, Miia Kivipelto, Anna-Mari Heikkinen, Jari Tiihonen, Hilkka Soininen, Sirpa Hartikainen, Anna-Maija Tolppanen.\nThe study also showed that the postmenopausal removal of ovaries, uterus or both was not significantly linked to the risk of Alzheimer's disease, irrespective of the indication of surgery or hormone therapy use.\n\"In the light of these findings, hormonal replacement therapy may have a beneficial effect on cognition if started early, around the time of menopause.\nThe newest results were published recently in Neurology and Maturitas and the earlier results in the Journal of Alzheimer's disease.\nHormonal therapy may protect cognition if started at the onset of menopause\n\nIn the present study, long-term use of hormonal replacement therapy was associated with a better performance in certain cognitive domains - global cognition and episodic memory - and a lower risk of Alzheimer's disease.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There is no discussion of costs in the release. Hormone replacement therapies have been on the market for decades, and their well-known costs should have been included. The cost to an individual may not be very high, but the cost to society of unnecessary, and potentially harmful, hormone prescriptions could be very high.", "answer": 0}, {"article": "As a result, sticky mucus builds up in a patient's lungs, causing infections and making it hard to breathe.\nAt the time, scientists predicted that a genetic test for CF was just around the corner.\nBut for people who do have that mutation, the drug works remarkably well.\nBut they also thought a drug to treat the disease was in reach.\nOne of those chemicals ultimately became a successful drug, but it had to be modified so patients could take it by mouth, and so it would last the right length of time in a patient's body.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "It doesn\u2019t come until the last sentence in the story, but it also leaves listeners and readers with a pretty sobering reality: \u201cThe time from gene discovery to successful drug may be shortening, but there are only a handful of successful drugs so far, and for a while at least, the appearance of new ones will be slow.\u00a0They\u2019re also likely to be expensive. Kalydeco costs in the neighborhood of $300,000 per year.\u201d", "answer": 1}, {"article": "But researchers controlled for these and many other factors, and found that compared with women who ate no walnuts, those who consumed 8 ounces of walnuts or more a month reduced their risk for Type 2 diabetes by 24 percent.\nWalnuts may have some unique benefits.\u201d\n\nThe study was supported with grants from the National Institutes of Health and the California Walnut Commission.\n\u201cThere\u2019s been a lot of research on nuts in general in relation to cardiovascular health,\u201d said the senior author, Dr. Frank B. Hu, a professor of medicine at Harvard.\nEating walnuts may reduce the risk for Type 2 diabetes in women, a large new study concludes.\nThe scientists, writing in the April issue of The Journal of Nutrition, used dietary and health data on 138,000 women participating in a large continuing study of women\u2019s health.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The cost of walnuts is not addressed.\u00a0 When we checked the comments left on the New York Times blog appended to this story, cost was mentioned in 4 of the first 10 comments left.\u00a0 So you may think our criterion is too strict, but apparently some readers don\u2019t think so \u2013 one writing, \u201cWalnuts are an EXPENSIVE luxury.\u201d", "answer": 0}, {"article": "When I began training last year for my first marathon, my running partner Dave Freedholm, an experienced amateur distance runner, impressed on me the need to vigilantly avoid dehydration. His drink of choice was Accelerade. Like Gatorade, the original sports drink, it's packed with sugars and sodium to provide energy and replace the electrolytes depleted in sweat. But it also contains protein, which he said would help my muscles repair themselves more quickly after the punishing training runs he took me on.\n\nSure enough, I never felt much pain until after the marathon itself, and even then I recovered within a couple of days...", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Although the story states that the protein-containing drink is more expensive than the traditional sports drink, this is insufficient information on costs. How much more expensive? What is the actual price? ", "answer": 0}, {"article": "Drs.\nAsher and Burri, along with their co-investigators, now recommend that patients with one to three brain metastases should no longer receive routine whole brain radiation therapy, and should be treated with focused therapy alone to better preserve cognitive function and quality of life.\nThis is a very relevant finding, as over 200,000 patients still receive whole brain radiation in the United States each year, and the majority of patients with brain metastases have a limited number (typically three or less) of brain lesions.\nThe study, released on July 26, 2016, shows that patients with the most common form of brain tumor can be treated in an effective and substantially less toxic way by omitting a widely used portion of radiation therapy.\nThese results will allow tens of thousands of patients with brain tumors to experience a better quality of life while maintaining the same length of life.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Since both the focused radiation and whole brain radiation are common treatments for brain tumors, an estimate of typical costs should have been included in the release.\nThere is likely to be a range of costs because of issues with the specific tumor\u00a0target. However, the release could have made note of that.", "answer": 0}, {"article": "Minimally invasive procedures increased to 31 percent of all radical prostatectomies in 2005 from 12.2 percent in 2003.\nBut the surgery increases the chance for longer term problems that require further therapy, the research says.\nThe widely advertised procedure is becoming more popular, said Dr. Jim C. Hu, the lead author of the study and an instructor in surgery at Harvard.\n\u201cThis paper,\u201d Dr. Hu said, \u201cdemonstrates that there are hidden risks for patients who opt for laparoscopic or robotic surgery.\u201d\n\nIn laparoscopy, a surgeon inserts instruments through small cuts in the skin instead of making large incisions to expose the organs.\nLaparoscopic operations for prostate cancer, a minimally invasive surgery that is in rising demand, result in fewer immediate complications and quicker recovery than the more common open procedure, a new study reports.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not report how much the laparoscopic surgery costs, either directly or over time due to fewer complications or more treatments. \nOne assumes that robot-assisted surgeries are more expensive, though again the story should have specified. Given the possibility of economic self-interest by proponents of laparoscopic surgery, this information would have been very useful. \nA daVinci machine reportedly costs over a million dollars, with signficant annual maintenance costs in addition.\u00a0", "answer": 0}, {"article": "In a study published last month in Nature, 80 percent of infants diagnosed with autism as toddlers had an increased rate of growth in the surface area of their brains in their first year, compared to toddlers who were not diagnosed with autism.\nExcess brain fluid may be more than an early marker for autism, Di Martino said.\nCompletely different mechanisms may be at work for kids without an older sibling with autism, said Shen and Dimartino.\nIt may also be a mechanism in the development of autism, and it opens up new possibilities for research, she said.\nBut if the fluid is not flowing properly, these byproducts hang around and cause inflammation, which could \u201champer brain development\u201d and lead to autism, said Shen.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Although this article made it clear that parents of children with autism should not rush out and get MRIs of infant siblings, it did not mention the costs of MRIs, which may be prohibitive for parents without good insurance coverage.", "answer": 0}, {"article": "Chemotherapy deals heavy damage to tumors \u2014 but often, the cancer cells are able to regroup and repair themselves.\nIts results built upon exciting data it released in June \u2014 showing that its drug can increase the window of time in which a woman\u2019s cancer doesn\u2019t get worse.\nIt showed that patients with recurrent ovarian cancer treated with the drug got an extra 15 months without their disease getting worse, compared to a control group.\nOther groups of patients treated with the drug also had significantly better outcomes than control groups.\nBut the data it presented at the European conference showed that the drug may not actually be more effective than Lynparza, the PARP inhibitor that\u2019s been marketed by AstraZeneca since 2014.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story didn\u2019t include costs. While the cost to consumers of the three new drugs may still be a question, the cost of the established drug \u2014 Lynparza by AstraZenaca \u2014 is well known and can run around $3,000 or more for a bottle of 112 capsules.\u00a0 And readers would benefit if only by knowing if the new drugs would be cheaper or more expensive than current medications.", "answer": 0}, {"article": "U.S. alone, seventy-five percent of teens and adults are vitamin D deficient.\nThe research shows that RayVio's UV LEDs could be used for treating patients that are vitamin D deficient.\nTyler Kalajian and his research team, led by Dr. Michael F. Holick, Ph.D., M.D., and supported by Boston University School of Medicine and a Boston University Ignition Award, found that skin samples exposed to RayVio's UV LED for just 0.52 minutes produced more than twice as much vitamin D3 as samples exposed to 32.5 minutes of sunlight.\n\"This study will lead to a new generation of technology that can be labeled as photopharmacology in which the use of LEDs with targeted wavelengths can cause specific biologic effects in human skin to help treat and prevent chronic illnesses.\"\nThis device for making vitamin D is ideally suited for patients with fat malabsorption syndromes including inflammatory bowel disease and gastric bypass surgery.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Our philosophy: if not too early to talk about a device\u2019s effectiveness, then it\u2019s not too early to start discussing its potential price on the market. And the release claims there \u201cwill be\u201d a new generation of marketable products based on this research.\nThe news release states RayVio\u2019s 293nm UV LED was the most effective out of all the UV LEDs tested in this study. The California-based manufacturer sells its UV LED products online, with unit prices ranging between $6.93 to $68.06 for a single device.\nSince costs are not discussed in the news release, we give it a Not Satisfactory rating here.", "answer": 0}, {"article": "Bipolar disorder carries one of the highest rates of suicide of any mental illness, alongside schizophrenia and alcohol and drug addiction.\nThe lead author behind the research told the Guardian that widespread \u201clithium stigma\u201d among patients is leading to them receiving the wrong treatment and ending up admitted to hospital unnecessarily because their condition is not as well controlled as it could be.\nThe researchers\u2019 analysis bore out one of the two main criticisms of lithium, but found the other to be baseless.\nIt is seen by patients, and some psychiatrists, as a dangerous drug.\nResearchers claim that although the drug does carry some health risks, its overall effectiveness, especially its ability to reduce self-harm and suicide, mean it should be much more widely used.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story did not address costs. Because this ran in the U.S. edition of The Guardian, this is important and useful information for readers stateside, who often have substantial out-of-pocket drug costs.", "answer": 0}, {"article": "\"We've got a lot of repeat customers, unfortunately,\" Shah said.\nShe and others say they know of no other physician in the Washington area who favors the radial approach.\nRaybuck, who learned to perform the procedure in Quebec 12 years ago, estimates he uses it fewer than two dozen times annually, and only when circumstances require it.\n\"I think there is a reluctance among physicians who are used to doing procedures a certain way\" to change, said Mazhari, who learned to do the procedure last year and uses it about 80 percent of the time.\nSome senior interventional cardiologists say they worry that the method may be hyped.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story mentions that using the wrist may better enable patients to avoid an \"expensive overnight hospital stay\" and that Medicare reimbursement was the same even though this route for catheterization may involve more physician time. But the story didn\u2019t include any specific cost information about this new approach.\u00a0 Shouldn\u2019t the physicians interviewed know whether their charge to patients depends on the vessel used? Nonetheless, we\u2019ll give the story the benefit of the doubt on this criterion.  ", "answer": 1}, {"article": "Another person said of their pet birds: \"If I didn't have my pets I think I would be on my own.\nThe pets provided more than just emotional support and companionship, participants said.\nBrooks says, \"Many felt deep emotional connections with their pet that weren't available from friends and family.\"\nSixty percent of the people who considered pets to be a part of their social networks placed them in the central, most important circle \u2014 the same place many people put close family and social workers.\nHe feels this study is important because, although there's a lot of work looking at the benefits of trained therapy animals, they can be expensive and out of the reach of many patients.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Costs aren\u2019t addressed.\u00a0There is the hint that it might be out of reach for some people with this quote in the story:\n\u201cHe feels this study is important because, although there\u2019s a lot of work looking at the benefits of trained therapy animals, they can be expensive and out of the reach of many patients.\u201d", "answer": 0}, {"article": "Concussion is a major public health concern, often resulting in significant acute symptoms and in some individuals, long-term neurological dysfunction.\nThis new method, fully funded by the Children's Health Foundation and conducted by the Western Concussion Study Group, is unique in that previous attempts have looked unsuccessfully for a single highly accurate protein biomarker that can distinguish concussed from non-concussed adolescent patients.\nIn the new study, researchers have demonstrated that a blood test can now accurately diagnose a concussion using a form of blood profiling known as metabolomics.\n\"With further research, we anticipate that our blood test will also aid clinicians in predicting concussion outcome, as well as aid rehabilitation after concussion.\"\nLONDON, ON - Scientists from Children's Health Research Institute, a program of Lawson Health Research Institute, and Western University have developed a new blood test that identifies with greater than 90 per cent certainty whether or not an adolescent athlete has suffered a concussion.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "We are told the test is \u201crelatively inexpensive\u201d as would be the drawing of blood, but we\u2019re not given a hint at what the cost is for measuring more than a dozen metabolites. The release might have better addressed the unknowns about this preliminary test by letting readers know that a commercial test is not yet available and its cost remains unclear.", "answer": 0}, {"article": "Chronic insomnia is defined by the Diagnostic and Statistical Manual of Mental Disorders as sleeping poorly at least three nights a week for a month or longer, despite adequate opportunity for a full night's sleep.\nAdditional training in the therapy for behavioral health providers in all branches of the military is needed, he said.\nA third control group of participants was contacted by the researchers every other week during the six weeks, but did not receive cognitive behavioral therapy.\nIt is \"a significant problem in the military,\" said Taylor, who noted that military personnel often develop insomnia because of rapidly changing schedules and deployments that keep them constantly on alert.\nHe noted that that cognitive behavioral therapy is \"a multifaceted intervention that can be difficult to administer without the benefit of a therapist.\"\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Obviously there are likely major differences in costs associated with in-person CBTi versus internet-delivered CBTi so it is unfortunate these were not discussed in this release.\nThe only mention of cost was that of the $1.16 million grant the University received for the 6-week study.", "answer": 0}, {"article": ".\nHowever, this security system is so effective at protecting the brain that it prevents many life-saving drugs -- all but some small molecules -- from being able to treat cancer and other diseases of the brain.\n\"Clinical trials revealed that PPF can cross the blood-brain barrier, and has minimal side effects,\" Dr. Tran said.\n\"PPF could be easily translated to the clinic as an adjuvant therapy in combination with standard of care treatment for GBM patients.\"\nAs a result, there has been little progress in recent decades in finding new effective treatments for GBM.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Even though propentofylline, the drug being studied, is not FDA approved for use in people, the release could have easily included some basic price information since the drug is currently sold for use in elderly dogs in many countries. One online pharmacy quotes a price of $67 for sixty 100 mg tablets tablets. Of course, the price would likely be higher for a drug that meets FDA standards for human use.", "answer": 0}, {"article": "The study was published online Oct. 1 in The Lancet.\n\"This analysis provides further support for the benefit of apixaban, but given the very low risk of bleeding with apixaban, it also suggests that the current stroke and bleeding risk scores may not be sensitive enough to tease out those patients with the very lowest risk of stroke who might benefit from apixaban therapy,\" said Ansell, who is chairman of the department of medicine at Lenox Hill Hospital in New York City and a consultant to Bristol-Myers Squibb and Pfizer, the companies that are marketing the drug as Eliquis.\nAspirin is less effective than warfarin, but carries a lower risk of bleeding for patients with atrial fibrillation and one risk factor for stroke.\nThe findings suggest that the current risk scoring systems for tailoring anti-clotting (anticoagulant) treatment to individual patients may be less relevant when using apixaban for patients with atrial fibrillation who have at least one risk factor for stroke, according to the Duke University Medical Center researchers.\nData from more than 18,000 patients also found that apixaban was safer overall than warfarin, and tended to cause less bleeding in the skull in patients who faced the highest risk of bleeding.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There is no mention of costs in this story, even though apixaban has been found to be quite costly. A study in Nature Cardiology, for example, found that apixaban cost $3,545 per patient compared to $1,805 for patients treated with aspirin.", "answer": 0}, {"article": "The first figure is systolic pressure, generated when the heart is pumping, and the second figure is diastolic pressure, created when the heart is relaxing and filling with blood.\nThe trial was double-blind, which means neither the administering clinicians nor the patients knew whether the beetroot juice they were given was the placebo or the active supplement.\nThis is the first study that shows evidence of dietary nitrate supplementation's long-lasting benefit in a group of patients with high blood pressure.\nThe authors note that the reduction achieved in the active supplement group is close to that achieved by medication.\nAs for the next step in confirming the relationship between beetroot juice and blood pressure, she says this was a small trial.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story fails to mention costs. The cost of typical hypertension drugs is relatively well-known and the cost of beets\u00a0from the neighborhood grocer, from which beetroot juice can be derived, is equally available. A well known online supplement supplier sells beet root juice for about $6 a bottle, suggesting a potential cost for the daily regimen studied here of about $3 a day, or possibly $90 a month.", "answer": 0}, {"article": "The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices.\nThe safety and efficacy of Dupixent have not been established in the treatment of asthma.\nThe safety and efficacy of Dupixent were established in three placebo-controlled clinical trials with a total of 2,119 adult participants with moderate-to-severe atopic dermatitis not adequately controlled by topical medication(s).\nThe FDA granted the application for Dupixent Priority Review and Breakthrough Therapy designation.\nThe U.S. Food and Drug Administration today approved Dupixent (dupilumab) injection to treat adults with moderate-to-severe eczema (atopic dermatitis).\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The FDA evaluates drugs without considering costs, which is why they are not discussed in this news release. We rate this one Not Applicable. We hope the FDA will also begin commenting on the projected cost of a drug and its cost-effectiveness.\nIn this case, costs are very steep. An NBC.com story on the approval which we also reviewed, predicts the drug will cost $37,000 annually. It\u2019s unknown if Dupixent will be covered by health insurance.", "answer": 2}, {"article": "\"People were saying, 'I had absolutely zero symptoms.\nHe says the benefits of the worms definitely didn't outweigh the bad side effects.\nIt could be that the whipworm larvae weren't prepared correctly.\nHe talked to many people who were using an unlikely tool to treat their problems: parasitic worms that live in your gut \u2014 permanently.\nAnd he would never try treating his alopecia or hay fever with them again.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Costs aren\u2019t mentioned. Parasites can costs thousands of dollars for a year\u2019s supply, and worms must be replenished because they tend to die off. Since this is a non-approved and non-proven therapy, all costs would likely be\u00a0out of pocket.", "answer": 0}, {"article": "I weigh 160 pounds, and when I do this I put about half my weight into it,\" he said.\nHe said the latest research on CPR supports the notion that in the critical minutes before an ambulance or defibrillation device arrives, it is very important to provide uninterrupted, deep chest compressions.\nThe Heart Association also stressed that three-quarters of sudden cardiac arrest cases outside the hospital occur in the home.\nThat's a risk well worth taking when the odds of survival without CPR are so slim.\nOnly about 6 percent of victims whose hearts stop outside of a hospital survive.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The news story does not mention costs, but a discussion of cost is relatively unimportant in the context of this story.", "answer": 2}, {"article": "In a statement, Dr. Lesley Russell, Cephalon's chief medical officer, said:\n\nThe most common side effects for Nuvigil, include diarrhea, headache, insomnia and nausea, according to Cephalon.\nThe regulators just gave a second thumbs down to drugmaker Cephalon's application to sell Nuvigil as a remedy for jet lag.\nBut the regulators weren't buying the evidence put forward by the company to prove the medicine's benefits in treating travelers' \"excessive sleepiness\" outweighed its risks.\nFinally, it should be said that the Drug Enforcement Administration has made Nuvigil a federally controlled substance because it has the potential for abuse and dependence.\nCephalon soldiered on, giving FDA more data.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No discussion of cost, which we wish had been included.", "answer": 0}, {"article": "\u201cThat\u2019s a simple enough statement, and people are not put off by that,\u201d she said.\n\u201cWe are now trying to see if people can learn, perform and have continuing confidence without the physician reinforcement,\u201d said Robinson.\nEach person in the study was trained on how to find melanoma and attended booster sessions every four months.\nThe researchers previously found that skin cancer survivors and their partners could be trained to spot potentially cancerous moles by doing skin exams.\nAmong people who received the skin exam training, the researchers found a steep increase in their confidence at performing skin exams between the start of the study and four months later.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Although presumably there is\u00a0a cost associated with training people to\u00a0recognize melanomas, having a partner help check for suspicious moles can be assumed to be cost-free.", "answer": 2}, {"article": "Most Australian adults have been infected with the herpes zoster virus and are at risk of shingles, even if they do not remember having chicken pox.\nThis is 12 times higher than other less effective shingles vaccines.\nIt is the first shingles vaccine to combine a non-live antigen with a specifically designed adjuvant.\nThe vaccine also contains an adjuvant--a substance that helps your body fight off the virus.\nA new study has shown how the body's immune system responds to the new shingles vaccine, Shingrix, making it more than 90% effective at protecting against the virus.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "No cost information is provided. According to GoodRx, Shingrix costs about $300 out-of-pocket for a course of two injections.", "answer": 0}, {"article": "Sharon Samuels was a teenager when she was first diagnosed with essential tremor.\nHe added that since these patients were only followed for a year, there isn\u2019t enough data available yet to determine the long-term efficacy of the treatment.\nBut the procedure brings lasting side effects in some patients, and its long-term usefulness is still being studied.\nThe doctors at Brigham will follow up with Samuels \u2014 and others who undergo the treatment \u2014 for up to five years and run more MRI scans and neurological exams to find out for how long the lesion lasts and keeps the tremor suppressed.\nFor now, the treatment has had an immense impact on patients\u2019 lives.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not say how much this new procedure costs or compare it with existing treatments for patients who don\u2019t respond to medication. Deep brain stimulation, the current treatment standard, can run anywhere from $30,000 to $70,000, according to various online cost estimates.\u00a0There also may be additional costs incurred by those patients who have adverse effects.", "answer": 0}, {"article": "For the really Type A personality, here's a chance to measure how well you are relaxing. Makers of home biofeedback devices that monitor your heart rhythms say the devices teach you to combat emotional stress. Psychologists and psychiatrists say the gadgets appear to help their stressed-out patients but warn that there isn't yet strong scientific evidence that they work.\n\nBiofeedback has long been used to treat stress in psychologists' offices -- with an expert who leads the patient in relaxing breathing exercises and...", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Although the story mentions costs, the story does not meet this criteria because it fails to provide cost estimates of the alternative treatments.", "answer": 0}, {"article": "He is president and chair of the department of public health sciences at the University of Li\u00e8ge in Belgium.\nNearly one in 100 people have evidence of knee osteoarthritis on an X-ray.\nStudy head Jean-Yves Reginster, MD, PhD, presented the findings today at the American College of Rheumatology (ACR) Annual Meeting in Washington, D.C.\nNov. 12, 2012 -- A drug used outside the U.S. to treat osteoporosis may not only lessen the everyday pain associated with knee osteoarthritis, but may even slow down the progression of osteoarthritis, researchers say.\nThe wearing away of cartilage leads to pain and other symptoms.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story did not discuss costs. Presumably, since this drug is already sold\u00a0outside of the U.S., the story could have provided at least a ballpark estimate.", "answer": 0}, {"article": "March 15, 2010 -- A common pain reliever may help people with type 2 diabetes control their blood sugar levels.\nHowever, it also has been shown to increase protein in the urine and its long-term safety will need further investigation.\nOther markers of glycemic control and heart disease risk also improved in the three salsalate groups compared with the placebo group.\nThat prompted researchers to take another look at salsalate in reducing blood sugar levels.\nDue to the small size of the study and short follow-up time, researchers say it's too soon to recommend use of salsalate for the treatment of type 2 diabetes.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Costs are not discussed explicitly.", "answer": 0}, {"article": "\"Oral morphine versus ibuprofen administered at home for postoperative orthopedic pain in children: a randomized controlled trial\" is published October 10, 2017.\nThey note that as neither treatment completely relieved pain, more research is needed into effective pain relief, especially for more severe pain.\nIn the first 24 hours, more than 80% of the children in the study needed pain relief at home.\nWidely available ibuprofen is a better choice for pain relief in children who have undergone minor orthopedic outpatient surgery, as it has fewer adverse effects compared with oral morphine, according to results from a clinical trial published in CMAJ (Canadian Medical Association Journal).\n\"Morphine did not provide superior analgesia, but was associated with significantly more adverse effects, making ibuprofen a better analgesic option,\" write the authors.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Readers are likely aware that non-prescription strength ibuprofen is readily available at a low price. The release doesn\u2019t mention how much oral morphine costs, however. Thus, readers can\u2019t tell whether ibuprofen might not only save children some unpleasant side effects, but save their parents money as well.", "answer": 0}, {"article": "\"Blueberries are one of the more potent foods in terms of protecting the brain,\" Morris said.\nThe MIND diet recommends limiting yourself to no more than five of these treats per week.\nNow here are the five food groups it says you should avoid to reduce your risk of developing dementia...\n\nYou already know they're not so good for your waistline, and it turns out pastries and other sweets could have a negative effect on brain health as well.\nThe MIND diet recommends eating berries at least twice a week.\nBerries are the only fruit specifically recommended in the MIND diet.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There is no discussion of the costs of the diets in this story.\u00a0 Some parts of the diets, including berries out of season and greens year round, can become expensive.\u00a0 The types of foods included in this diet are not necessarily readily available in economically depressed areas of the US. A quick nod to either of those facts would have earned the story a satisfactory rating.", "answer": 0}, {"article": "Followers of the popular regime eat during an eight-hour window, in this case between 10 a.m. and 6 p.m. And for the 16 hours in between, they consume only calorie-free drinks, such as water.\nWe observed that fewer participants dropped out of this study when compared to studies on other fasting diets,\u201d said Varady.\nCommenting broadly on fast-style diets, James Catterson of the Institute of Healthy Ageing at University College London, who was not involved in the study, previously told Newsweek the jury is still out on fasting diets.\nKrista Varady, one of the study's authors and associate professor of kinesiology and nutrition at the University of Illinois at Chicago's School of Applied Health Sciences, said in a statement that the take-home message from the study is that cutting out certain foods or counting calories aren\u2019t the only effective methods for losing weight.\nThe authors noted that the results mirror those from previous studies of other forms of intermittent fasting, including alternate day fasting, where an individual eats normally every other day.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There\u2019s no cost associated with following this diet.", "answer": 2}, {"article": "This, too, is suggested by sense and common experience, as it is affirmed by the science reported here,\" Katz said.\nLower stress by itself predicted more weight loss during the first phase of the trial, they added.\nThose in the second phase of the trial continued their diet and exercise program.\nThis study shows that people are more likely to lose weight when not impeded by sleep deprivation, stress or depression, he said.\nThe important message is that weight loss should not be looked at with tunnel vision, Katz said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Not applicable.", "answer": 2}, {"article": "Joslin has one of the largest diabetes training programs in the world, educating 150 M.D.\nThe results, published by the Journal of the American Medical Association, demonstrate the first major therapy advance for the condition in nearly 40 years.\nSlightly more than half (53 percent) of eyes in the laser group received Lucentis injections to treat DME.\nThe DRCR.net enrolled 305 participants (394 eyes) with PDR in one or both eyes at 55 clinical sites across the country.\nAbout 6 percent of eyes in the Lucentis group received laser therapy, mostly for issues other than DME.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The story doesn\u2019t mention cost at all. Since Lucentis can cost $2,000 per injection, that\u2019s a significant oversight. It would also be useful to tell readers how Lucentis injections compare with the cost of laser treatment.", "answer": 0}, {"article": "Atrial fibrillation also increases the risk for dementia.\nHowever, the findings show that people with atrial fibrillation should start taking blood thinners as soon as possible after their diagnosis and continue to take the drugs, Friberg noted.\nDuring the study, more than 26,000 of the 440,000 participants, all with atrial fibrillation, were diagnosed with dementia.\nThe findings strongly suggest that blood thinners reduce the risk for dementia in people with atrial fibrillation, but proving that would not be possible, the Swedish researchers said.\nWhen the researchers focused on people who continued to take the drugs, they found an even larger reduction (48 percent) in the risk for dementia.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No mention of costs, which is unfortunate because there can be substantial costs associated with anticoagulation, especially with the newer anticoagulants.", "answer": 0}, {"article": "\"We do not want to give anyone false hopes that this is ready for the clinic yet.\nCarissa Cascio, an assistant professor of psychiatry from Vanderbilt University School of Medicine, who specializes in autism and neuro-imaging, believes these study results are important.\nThe images of the brains helped researchers correctly identify those with autism with 94 percent accuracy, says Nicholas Lange, an associate professor of psychiatry at Harvard Medical School and one of the study authors.\nLange believes this brain scans can be done on younger children, as long as they can go to sleep in the scanner \u2013 on their own, without sedation (because you can't move during the test).\nStill he believes this is new study can help pinpoint the earliest markers of concern in developing brains.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Just as Reuters did, CNN ignored costs. MRI scans are a major driver of healthcare costs and the use of this technology as a routine screening instrument could have a significant direct financial impact. The cost of a routine MRI could have been provided.", "answer": 0}, {"article": "\"'Promising' is the perfect way to describe our findings,\" said study lead author Dr. David Woodrum, an interventional radiologist at the Mayo Clinic in Rochester, Minn. \"But whether or not this minimally invasive approach would ultimately become a primary method of treatment in the future will depend on the long-term results of this trial, which is still under way.\nFor his part, Dr. David Carbone, a professor and director of the James Thoracic Center at the Ohio State University Wexner Medical Center, said that the findings regarding cryoablation are \"not incredibly novel,\" given that the procedure has been around for years.\nThe procedure is performed by an interventional radiologist on patients coping with metastasized lung tumors, the researchers noted.\nAt least in the short-run -- meaning three months after the procedure -- the intervention known as \"cryoablation\" appeared to kill all targeted tumors that had spread to the lung from elsewhere, preliminary results suggest.\nThe authors noted that side effects were minimal, typically involving air or fluid around the lungs after the procedure, and in all cases were resolved quickly.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There was no discussion of cost of cryoablation nor of cost for stereotactic radiosurgery which was mentioned as an alternative.", "answer": 0}, {"article": "Trans fats raise bad cholesterol, lower good cholesterol and ultimately increase the risk of heart attacks and strokes.\n\u201cHere we find on a population level when we restrict them, it benefits society by reducing heart attacks and strokes.\u201d\n\nThe findings suggest the FDA\u2019s action will lead to health benefits across the country, he added.\nAfter three years or more, the combined rate of hospitalizations for heart attacks or strokes was about 6 percent lower in the counties with trans fat regulations.\n(Reuters Health) - - People were less likely to go to the hospital with heart attacks or strokes after several counties in New York State restricted the use of trans fats, according to a new study.\nStill, the study can\u2019t say the trans fat restrictions caused fewer admissions in those counties.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "While there might be an aggregate, societal cost to this change in food ingredients, it is not clear that individuals will incur monetary costs as a result of this change.", "answer": 2}, {"article": "A common heart drug called a beta blocker was associated with a striking increase in survival for women with ovarian cancer in a study that suggests a possible new strategy for treating a variety of tumors.\n\nResearchers analyzing a database of 1,425 women with the tough-to-treat cancer found those who had taken a certain type of beta blocker lived more than four years longer on average than those who hadn\u2019t been prescribed the drug. The women were taking the medicine to treat high blood pressure or another heart problem, not...", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story mentions that beta-blockers are available as generics but doesn\u2019t specifically mention costs. As a class, beta blockers drugs are low cost ($10 to $200 a month according to some estimates).", "answer": 0}, {"article": "The F.D.A.\nAnd the drug failed to do that by a statistically significant measure.\ninstead said it wanted more proof that the drug worked and would await results from a trial that was then under way.\nDr. Gold said there were about 100,000 men who get such a diagnosis each year.\nJudy Leon, a spokeswoman for the F.D.A., said the agency sympathized with patients but that it was necessary for drugs to meet agency standards for safety and efficacy.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "While the story anticipates approval and comments on the drug maker\u2019s stock price, it fails to anticipate the drug\u2019s cost or comment on the expense required to extend life by several months. ", "answer": 0}, {"article": "GeneSight's test is covered by Medicare for patients under the care of psychiatrists and who have failed to achieve satisfactory results with at least one antidepressant. The company has coverage with some commercial payers and is working to widen that coverage, said Myriad Genetics spokesman Ron Rogers. The Genomind Genecept Assay is partly covered by Medicare and Medicaid. If the out-of-pocket cost for people with commercial plans is more than $300, Genomind will contact the client before processing the test. The company also has a financial assistance program for uninsured patients.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The article notes that the GeneSight test is covered by Medicare if a patient is being treated by a psychiatrist and that some insurance plans also cover the test. It also tells us that the\u00a0Genomind Genecept Assay is covered by Medicare and Medicaid.\nWe aren\u2019t provided out-of-pocket costs for the GeneSight test, though. Nor could we find the full price of Genomind\u2019s \u2018Genecept Assay\u2019 on its website or elsewhere.", "answer": 1}, {"article": "\"The next questions are, 'how do we increase the number of patients who respond?'\nPublished online by the New England Journal of Medicine and being presented this week at a Presidential session of the European Cancer Congress (ECC), the findings of CheckMate-025 provide definitive evidence that an immune checkpoint inhibitor is a valid treatment strategy for patients with advanced RCC, and supports a paradigm change in the standard of care treatment, according to the authors.\n\"The overall survival benefit shown in this study sets a new benchmark for therapeutic strategies for advanced RCC patients in need of a second-line therapy.\"\nIn the randomized phase III clinical trial, patients whose disease progressed on antiangiogenic therapies were treated with either nivolumab or everolimus.\nIn addition to demonstrating increased overall survival, the researchers showed a higher objective response rate - the number of patients who respond to the treatment - with nivolumab.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Cancer treatments are very (some would same ridiculously) expensive and the two treatments highlighted in this release are no exception.\u00a0 To put it into perspective, we calculate the monthly cost of nivolumab to be in the vicinity of $12,600 (not including administration fees) and of everolimus at $11,500 month.\ncalculation\nnivolumab = 3mg/kg x 70kg = 210mg @$30/mg=$6,300 x 2 = $12,600 everolimus = $11,500 for 30 tablets", "answer": 0}, {"article": "After five years, 74 percent of the angioplasty group and 72 percent of the medication group were free of chest pain \u2014 \"no significant difference,\" Boden said.\nAlso, the clogs treated with angioplasty are not the really dangerous kind.\nNeither treatment proved better for any subgroups like smokers, diabetics, or older or sicker people.\nAbout 40 percent had a prior heart attack.\nHe led the study and gave results Monday at a meeting of the American College of Cardiology.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "This story did not include a comparison of the costs for the two treatments.\u00a0 This was not a part of the journal article describing the study but was contained within the presentation given at the recent meeting of the American College of Cardiology. (Note: both the journal article and the meeting were mentioned in the story.)", "answer": 0}, {"article": "\u2022 Gaziano TA, Fonarow GC, et al.\n\"In addition to survival benefits, the study also recognizes other treatment effects of Entresto, particularly in reducing HF hospitalizations.1 Coupled with the recent Class I recommendation, the strongest endorsement, in the focused update to the US HF Guideline,2 these findings underscore the potential of Entresto as a standard therapy for chronic HFrEF patients.\"\n2016;1(6):1-4. doi:10.1001/jamacardio.2016.1724\n\u2022 Yancy CW, Jessup M, Bozkurt B, Butler J, Casey Jr DE, Colvin MM, Drazner, MH, Filippatos G, Fonarow GC, Givertz MM, Hollenberg SM, Lindenfeld J, Masoudi FA, McBride, PE, Peterson PN, Stevenson LW, Westlake C, 2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure, Journal of the American College of Cardiology (2016), doi: 10.1016/j.jacc.2016.05.011.\n2013 ACCF/AHA guideline for the management of heart failure: A report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines.\nThe target treatment dose of Entresto is 97/103 mg twice daily.11\n\nNovartis is committed to providing patients with affordable access and resources through Entresto Central.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release mentions cost-effectiveness several times but does not give any indication of what the price of therapy with Entresto would be, nor the comparative cost between Entresto and other medications. Nor does it quantify what it means when it says the drug is \u201ccost-effective.\u201d The Institute for Clinical and Economic Review, ICER, warned in a draft report that the drug\u2019s current price was too high and that widespread use could overwhelm the health system. The drug cost was estimated at about $4,600 per year for a typical patient. According to the report:\n\u201cAt the list price of $4,560 per year, Entresto does not save money over the long term but its added costs are well-aligned with the degree of benefit it brings to patients, meaning that Entresto can be judged \u201ccost-effective\u201d in the long-term according to commonly accepted cost-effectiveness thresholds.\u201d\n\u201cHowever, ICER\u2019s analysis predicts that nearly 2 million patients could be prescribed Entresto over the first five years, creating a total budget impact so high that excessive cost burdens would be placed on the overall health care system. In order to keep health care cost growth in line with growth in the national economy, ICER\u2019s value-based price benchmark for Entresto is $3,779 annually, a 17% discount off the list price.\u00a0 Private insurers and Medicaid programs are frequently able to achieve discounts at this level.\u201d\nThe published study did address cost in terms of quality-adjusted life-years (QALYs). It would have been helpful for the release to add at least some costs which would add context.", "answer": 0}, {"article": "The first placebo-controlled study of two vaccines against the Ebola virus found they both successfully created a powerful antibody response for a year, suggesting they both could be tools to save lives in a future epidemic of the deadly disease.\n\nThe research, by doctors from the U.S. and Liberian governments and elsewhere, was published Wednesday in the New England Journal of Medicine. The study looked at 1,500 patients in Liberia, and took place amid and after the outbreak of Ebola in Liberia from 2014 into 2015.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Vaccine pricing is complicated and prices are unknown at this point in development (pre-clinical). The story could have addressed cost as a potential limitation even if price is unknown at this time.", "answer": 0}, {"article": "Even today, in much of the developing world, people exercise through activities such as farming and fetching water that are necessary for survival.\nWhat is a bit surprising about this chart is that running faster or farther doesn\u2019t seem to reduce death rates any more than running slowly and, in fact, in both cases is slightly worse.\nWe may tend to attribute the health of this group to their running habits.\nEven if we dismiss the possibility that running harder is worse, it is probably useful to note that running harder or farther doesn\u2019t seem to be better.\nHowever, I\u2019d argue that the comparisons the studies make among runners are still valid.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not go into the costs associated with running or moderate jogging, but there are few costs that are explicitly associated with it. While runners often spend significant amounts of money for high-end running shoes, lightweight shorts and tops, or to enter races, none of those things are absolutely necessary. Once could jog for 25 minutes, three times a week, in any old clothes, wearing inexpensive shoes (or no shoes at all). In short, the amount of money that people can choose to spend on running is so widely variable as to make a discussion of costs effectively meaningless. For that reason, we\u2019ll call this n/a.", "answer": 2}, {"article": "[3] Yokell et al.\nEVZIO was the first naloxone product specifically designed, FDA approved and labeled for the emergency treatment of opioid overdose by individuals without medical training.\nRICHMOND, Va., March 29, 2016 /PRNewswire/ -- kal\u00e9o, a privately-held pharmaceutical company, today announced that EVZIO\u00ae (naloxone HCl injection) Auto-injectors have been reported to help save more than 1000 lives.\nEach kal\u00e9o product combines an established drug with an innovative delivery platform with the goal of achieving superiority and cost effectiveness.\n\"People at an overdose scene may be very emotional, so it really helps that EVZIO has audio instructions on how to administer this potentially life-saving medication,\" said Laurie Fugitt, RN, BSN, co-founder of Georgia Overdose Prevention.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The news release makes no mention of cost. That\u2019s an important omission since the cost of even generic naloxone is undergoing steep price increases. According to a report from the American Society of Health-System Pharmacists last year, \u201cWhen Kaleo Inc. launched its Evzio 1-mg/mL naloxone hydrochloride autoinjector in July 2014, the company priced each carton at about four times the invoice price of a box of same-strength 2-mL naloxone syringes, said Matthew Rosenberg, an analyst at FDA.\u201d\nAn online search revealed that Evzio\u2019s retail price was about $700 per kit, according to a MedPage Today article. Prices for standard naloxone kits ranged from around $40 to $60 per kit, with on-going price hikes.\nThere\u2019s a very limited supply of money for drug abuse treatment and a naloxone injection is only the start. Is having an extremely expensive one the\u00a0best use of funds? The release needed to address the cost disparity between this device and less expensive ones on the market.", "answer": 0}, {"article": "We've found a way to block CatK only in bone tissue that we think will prevent these other negative effects.\"\nThe study builds on previous research by Br\u00f6mme and his team that looked at the effectiveness of red sage, known as Danshen in Chinese and used to treat bone ailments, in stopping the activity of CatK in limited ways.\nAn herb widely used in traditional Chinese medicine might hold the key to a new osteoporosis therapy that could prevent bone loss without causing side effects.\n\"All clinical trials to date have failed due to side effects ranging from stroke, skin fibrosis and cardiovascular issues.\nThey found that it prevented bone loss and increased the bone mineral density of the mice treated with the compound by 35 per cent, when compared with the control group.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There\u2019s no mention of cost. HealthNewsReview.org found a bottle of 60 capsules of 500-mg red sage online for $19.95. Of course, that could be far from the cost of an actual treatment should one be developed, since we don\u2019t know the cost of processing, marketing, and quality assurance.", "answer": 0}, {"article": "Olive oil users may, for example, have higher incomes, eat better overall or exercise more often than people who never use the oil.\nAnd after they did, olive oil was still linked to a lower stroke risk.\nThe findings, according to Scarmeas, argue for more research into olive oil\u2019s potential benefits against not only heart disease, but stroke and other neurological diseases as well.\nWhat\u2019s needed, he said, are clinical trials where people are randomly assigned to use olive oil or not, then followed over time to see who suffers a stroke.\nPeople who said they used olive oil for both cooking and as a dressing were considered \u201cintensive users.\u201d\n\nOver the next five to six years, those intensive users suffered strokes at a rate of 0.3 percent per year.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Not applicable.\u00a0 The cost of olive oil is not in question.", "answer": 2}, {"article": "Barley reduced both low-density lipoprotein, or LDL, and non-high-density lipoprotein, or non-HDL, by seven per cent.\nDespite its benefits Dr. Vuksan said barley is not as well-established as some other health-recommended foods -- such as oats.\nThe research review, published today in The European Journal of Clinical Nutrition, included 14 studies on clinical trials conducted in seven countries, including Canada.\nIt is the first study to look at the effects of barley and barley products on both LDL and non-HDL cholesterol in addition to apolipoprotein B, or apoB, a lipoprotein that carries bad cholesterol through the blood.\n\"Barley has a lowering effect on the total bad cholesterol in these high-risk individuals, but can also benefit people without high cholesterol.\"\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Barley, like oats or other grains are cheap and plentiful. Mentioning their cost in the story is unlikely to be an important factor.", "answer": 2}, {"article": "\"Pecans are naturally high in monounsaturated and polyunsaturated fats, so replacing a portion of the saturated fat in the diet with these healthier fats can explain some of the cardio-protective effects we observed,\" said lead researcher, Diane McKay, Ph.D. \"But pecans also contain a number of bioactive plant compounds as well as vitamins and essential minerals that all likely contributed to this benefit.\nIn this placebo-controlled crossover study of 26 men and women (average age 59 years), all meals were provided to carefully control their food intake.\nWhile a growing body of evidence has linked tree nuts such as pecans to reduced risk of CVD, this is the first study to look at the effects of pecan consumption on factors other than blood lipid levels and specifically those related to T2D.\nBoth the control diet and the pecan-rich diet were low in fruits, vegetables and fiber.\nA new study published in Nutrients shows that eating just 1.5 ounces of pecans - one small handful - every day may protect adults at risk for developing cardiovascular disease (CVD) and type 2 diabetes (T2D).\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release does not mention the cost of pecans. More expensive than some other tree nuts, the ballpark price of pecans should be known to the average reader.", "answer": 0}, {"article": "Schizophrenia is a long-term mental health condition that causes a range of psychological symptoms, ranging from changes in behavior through to hallucinations and delusions.\nThe researchers said this was important, since lack of motivation is a common feature of schizophrenia.\n\u201cThis proof-of-concept study...demonstrates that the memory game can help where drugs have so far failed.\nScientists at Cambridge University said tests on a small number of patients who played the game over four weeks found they had improvements in memory and learning.\nThe game, \u201cWizard\u201d, is designed to help so-called episodic memory \u2014 the type of memory needed to remember where you left your keys several hours ago, or to remember a few hours later where you parked your car in a multi-storey car park.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story doesn\u2019t discuss cost at all. The relevant iPad game is, presumably, not free. And even if it were, a patient would need to own or have access to an iPad (definitely not free). While these things may be presumed, it\u2019s still worth mentioning. For example, it would be good to know if the game were free, or if it could be accessed on a PC \u2014 in which case patients may have more low-cost options for accessing the game.\nEven if \u2013 or especially if \u2013 it were a low-cost intervention, that would be worth a one-line mention.", "answer": 0}, {"article": "Mihai G. Netea, PhD, professor in the Department of Internal Medicine at Radboud University Medical Center in the Netherlands, says of this study, \"The clinical effects and the proposed mechanism demonstrated are exciting and add to the emerging consensus that the BCG vaccine can have a lasting and valuable impact on the immune system.\nThe MGH team's findings set the stage for further testing of BCG administration, including the FDA-approved phase 2 study currently underway, testing multiple BCG doses in a large group of participants with longstanding type 1 diabetes.\nLong-term follow-up of participants in clinical trials of a generic vaccine to reverse advanced type 1 diabetes finds significant clinical benefits, including restoration of near-normal blood sugar levels.\n\"In addition to the clinical outcomes, we now have a clear understanding of the mechanisms through which limited BCG vaccine doses can make permanent, beneficial changes to the immune system and lower blood sugars in type 1 diabetes.\"\nThe researchers also found that BCG could reduce blood sugar elevations in mice that were caused by means other than autoimmune attack, raising the possibility that BCG vaccines could also be beneficial against type 2 diabetes.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The cost of the bacillus Calmette-Gu\u00e9rin (BCG) vaccine is not mentioned.\nAlthough the wholesale price is usually less than $1 US dollar, the cost in the United States usually runs between $100 to $200.", "answer": 0}, {"article": "It took a year for the company to get clearance for the trial from the F.D.A.\nDr. Peter J. Francis, an associate professor at the Oregon Health and Science University, which will be a site for the trial, says the eye is a good place to test stem cell therapy because it is accessible.\nStill, even starting the trial could be a boost to Advanced Cell, which often makes headlines but has struggled to raise money.\nIt is likely to be several years before such a treatment can reach the market, if it works.\nAlso, he said, there is less chance of rejection of the implanted cells because the eye is shielded somewhat from the body\u2019s immune system.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does\u00a0mention the cost per dose of two competing drugs, Lucentis and Avastin (which are\u00a0actually two\u00a0different\u00a0formulations of the same drug that are made by the same company, Genentech).\u00a0Lucentis is the version of the drug meant for the eye, whereas Avastin is approved and sold as a cancer treatment.\u00a0However, doctors can use Avastin off-label in the eye\u00a0with much smaller doses than cancer patients need.\u00a0The result is that the cost per dose is vastly lower for Avastin than it is for Lucentis. A head-to-head trial of Avastin and Lucentis is now underway that will probably have important implications for pricing and prescribing of these drugs. (If Avastin works just as well as Lucentis, more doctors will presumably switch to it at much lower cost to patients.)\u00a0Moreover, allegations have surfaced recently that Genentech is providing questionable\u00a0financial inducements for doctors to use the more costly Lucentis instead of Avastin. Given the significance of these developments for anyone who needs or may need treatment for AMD,\u00a0we feel the\u00a0story could have and probably should have gone into\u00a0a bit more detail about why these two drugs have\u00a0such wildly different costs.\nWe also think that if the story is interviewing a company about its plans to seek marketing approval in just a few months, they certainly could get some kind of pricing estimate from them. Nevertheless, by at least mentioning costs, the story accomplishes\u00a0more than most other\u00a0health articles that we review\u00a0and does enough to satisfy the\u00a0minimum for this criterion. We\u2019ll award a satisfactory.", "answer": 1}, {"article": "New medtech apps put specialist knowledge in patients' pockets\n\nDeep-learning networks have already been applied to produce algorithms capable of diagnosing diseases like melanoma and blindness caused by diabetes.\nThe method\u2014detailed in a paper published on Monday in the Nature journal Biomedical Engineering\u2014involves analyzing blood vessels in an area of the eye called the retinal fundus.\n\u201cMost cardiovascular risk calculators use some combination of these parameters to identify patients at risk of experiencing either a major cardiovascular event or cardiac-related mortality within a pre-specified time period, such as 10 years,\u201d the paper states.\nThe researchers from Verily, formerly known as Google Life Sciences, developed the algorithm in the hope of making accurate assessments of patients\u2019 cardiovascular health more quickly and easily than current methods.\nThe researchers concluded: \u201cThe opportunity to one day readily understand the health of a patient\u2019s blood vessels, key to cardiovascular health, with a simple retinal image could lower the barrier to engage in critical conversations on preventive measures to protect against a cardiovascular event.\u201d\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "This Newsweek story offers no information on what the cost of such retinal scan might be, nor does it mention whether health insurance would cover such screening, if it is proven to eventually work.\u00a0 There are a number of free cardiovascular risk assessment tools available online.", "answer": 0}, {"article": "\u201cFor antidepressants in adolescents, this equation will rarely favor prescribing; in younger children, almost never.\u201d\n\nTo be clear, Jureidini believes there is almost never a justification for prescribing antidepressants to children or adolescents.\nThat\u2019s because the FDA has deemed that Prozac has demonstrated benefits that outweigh one of the suspected downsides of antidepressants in kids and teens: disrupting brain development.\nAnd there\u2019s another major problem with the use of many antidepressants in children: They may increase suicidal thoughts and behavior.\nIt\u2019s notoriously hard to treat depression in kids\u2014the antidepressants we rely on to treat adults seem to be less effective and more dangerous when used on younger minds.\nDr. Andrea Cipriani, psychiatrist and lead author on the study, says these are concerns that practicing psychiatrists confront daily.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not discuss the cost of antidepressants, though does mention that the alternative, cognitive behavioral therapy, \u201cis a high-cost intervention in terms of both dollars and time invested.\u201d A cost comparison would have been useful since the study encourages a shift away from drugs and toward therapy.\u00a0Seeing a therapist for psychotherapy may not be so high a cost if the patient learns some lifetime skills and insights that help lessen and prevent depression, which tends to be recurrent.", "answer": 0}, {"article": "For example, a normal-weight woman should gain between 25 and 35 pounds, while an overweight woman should gain between 15 and 25 pounds.\nThere was no clear benefit among the women in the diet and exercise groups when the researchers looked at other complications, such as cesarean delivery, but it did look like there may be some benefit, they write.\nAfter including the new studies, the new review found \u201chigh-quality evidence\u201d to show diet, exercise or both can reduce the risk of excessive weight gain during pregnancy, write the researchers in The Cochrane Library.\nWhile the new study generally did not show fewer complications in the diet and exercise group, Dr. Loralei Thornburg told Reuters Health that it\u2019s good that there was no increase in complications.\nThe review incorporates dozens of new studies to update a previous review that did not find enough evidence to support the use of diet and exercise during pregnancy.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story doesn\u2019t address costs. But the interventions are so broadly defined that it would be difficult or impossible to address cost in a meaningful way. We\u2019ll rate this not applicable.", "answer": 2}, {"article": "Excessive drinking alone is linked to 88,000 deaths each year.\nThe good news is that the research suggests the spiritual aspect doesn\u2019t fully explain why the 12 steps are effective for some people.\nWhile alternatives like SMART or LifeRing do exist, they\u2019re not nearly as available as AA \u2014 and they certainly aren\u2019t built into professional treatment programs in the same way as the 12 steps.\nThere\u2019s good research into how AA works, but it\u2019d be good to figure out if SMART, LifeRing, and Women for Sobriety work in a similar way.\nThere\u2019s a good explanation for that: While the research shows that 12-step treatment can be as effective as professional treatment modalities like cognitive behavioral therapy, the research also shows that the 12 steps don\u2019t work for everyone.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not discuss costs associated with either AA or the alternative addiction treatment groups. That would be useful information for people who may not understand how these groups work. However, since these groups generally don\u2019t charge members for participation (although they may solicit donations or require the purchase of recovery literature), we\u2019ll rate this Not Applicable.", "answer": 2}, {"article": "When the researchers used the longer Tao brush, they were able to detect endometrial cancer in all but 7% of the women who had the disease, and close to half of the ovarian cancers. Combined with the fact that these tests were performed with a mere swipe of the uterine wall, these measures of \u201csensitivity\u201d \u2014 the ability to detect cancers that are actually there \u2014 represent a major improvement over the screening tests currently available.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No costs are discussed, though the US National Library of Medicine says individual genetic tests \u201ccan range from under $100 to more than $2,000\u201d \u2014 and PapSeek appears to use three genetic tests (on Pap smear, Tao brush, and blood tissues).", "answer": 0}, {"article": "of fat lost over 30 days.\n\"Capsimax is supported by multiple studies with findings showing safety, increased lipolysis and satiety and improved healthy body composition.\nThe company develops IP-protected, science-backed branded ingredients from natural sources using cutting edge technologies.\n\"Since Capsimax is made using a proprietary beadleting technology, OmniBead, which coats the capsicum extract, releasing it only when it reaches the intestines where it is absorbed without discomfort, we were able to deliver beneficial levels of capsaicinoids to our subjects, which made the MR Study possible.\"\nThe company's centers of excellence are located in North America and India, whereas its cGMP and HACCP system-compliant manufacturing operations are located at multiple FDA inspected sites in India.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The cost of Capsimax (or products containing the Capsimax proprietary supplement) is not mentioned.", "answer": 0}, {"article": "Cervical cancer is the fourth most common cancer in women, with more than 500,000 new cases occurring annually worldwide.\nThe device also includes a channel through which contrast agents used for the cervical cancer screening procedure can be applied.\nHealth providers -- or even women themselves -- are able to capture images of the cervix using the rounded tip of the device to manipulate its position if necessary.\nAsiedu is also working to automate the screening process.\nRamanujam and Asiedu are now working on clinical trials to see how their design stacks up against the traditional colposcopy used with a speculum.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The news release\u00a0indicates that the pocket colposcope will be much less expensive than current equipment, although no specific numbers are provided. The omission is unfortunate, since the study it\u2019s based on does provide cost estimates, citing a cost of $54 for the camera and $1 for the inserter. This device also requires the availability of a cell phone or laptop, and, at least for the present,\u00a0images must still be read by a trained technician. We don\u2019t know how much savings the device will generate, and it\u2019s difficult to estimate how feasible\u00a0it will be for low-resource clinics domestically or internationally. It\u2019s true the device is at an early stage of testing, but more information would have been helpful.", "answer": 0}, {"article": "The women were then followed for an average of three years.\nActivities like these account for more than 55% of older adults\u2019 daily activity, says LaCroix, so the fact that they were protective in this study is very good news.\nLaCroix says her new study refutes that research and shows that older adults can still benefit at levels below the moderate-to-vigorous guidelines.\n\u201cBut what we have here is solid evidence that light physical activity reduces a woman\u2019s risk of dying over the next three to four years\u2014and we see the benefits are substantial and independent of moderate-to-vigorous physical activity.\u201d\n\nThe study could not show a cause-and-effect relationship between activity level and risk of death, only an association.\nQuestionnaires used in self-reported studies don\u2019t do a good job of encompassing all the ways people get physical activity throughout the day, she says, which may have skewed previous study results.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Cost wasn\u2019t mentioned, but given that this is light activity, we\u2019ll rate this N//A. Still, the story could have explicitly said that the activities that are highlighted in this study probably have no cost associated with them.", "answer": 2}, {"article": "Co-authors with Sharma, who presented the data at ASCO, are Petri Bono, Helsinki University Hospital, Helsinki, Finland; Joseph Kim, Yale Cancer Center; Pavlina Spiliopoulou, Beatson, West of Scotland Cancer Centre, Glasgow; Emiliano Calvo, Centro Integral Oncol\u00f3gico Clara Campal, Madrid,Spain; Rathi Pillai, Emory Winship Cancer Institute, Atlanta; Patrick Ott, Dana Farber Cancer Institute, Boston; Filippo DeBraud, Istituto Nazionale dei Tumori, Milan, Italy; Michael Morse, Duke University Medical Center, Durham, N.C.; Dung Le, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore; Dirk Jaeger, Heidelberg University Hospital, Heidelberg, Germany; Emily Chan, Vanderbilt University, Nashville, Tenn.; Chris Harbison, Chen-Sheng Lin, Marina Tschaika, Alex Azrilevich, of Bristol-Myers Squibb, and Jonathan Rosenberg of Memorial Sloan Kettering Cancer Center.\nOverall survival will be analyzed in conjunction with the Phase II portion of this clinical trial, which provides nivolumab or a combination of nivolumab plus the immune checkpoint inhibitor ipilimumab.\nLong-term follow up shows 22 percent of those treated with the drug survive 10 years or longer.\nThe U.S. FDA approved atezolizumab, which blocks PD-L1, for these patients.\nThe immune checkpoint blockade drug nivolumab reduced tumor burden in 24.4 percent of patients with metastatic bladder cancer, regardless of whether their tumors had a biomarker related to the drug's target, according to clinical trial results from The University of Texas MD Anderson Cancer Center.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release doesn\u2019t address costs at all, which is particularly problematic given that Opdivo is already on the market for use in treating other forms of cancer. In an NEJM piece published last year, one doctor that, when used for treating metastatic renal-cell cancer, nivolumab costs, \u201cby my estimate, around $65,000 for Medicare beneficiaries and up to twice that for commercially insured patients.\u201d Other estimates are that nivolumab treatment \u2014 again, for cancers other than bladder cancer \u2014 could cost more than $100,000 per patient. That is a huge factor in making treatment decisions, and needs to be addressed.", "answer": 0}, {"article": "\"Nobody has the answer at this time,\" Perle said.\nThe analyses indicated that SMT -- which involves manual manipulation of the spine and surrounding muscles -- has only a short-term impact on pain relief, although it eases pain faster than other treatments.\nBut which treatment is right for any patient depends not only on their specific pain, but their doctor's recommendations and their own comfort level with various options, said Stephen Perle, a spokesman for the American Chiropractic Association.\n\"In short, no single therapy is better than another, although some individuals are likely to have more success with one therapy than another,\" said study author Sidney Rubinstein, a research fellow at VU University Medical Center in Amsterdam.\nIn all evaluations, patients were randomly assigned to SMT or another comparison treatment, including active treatments such as exercise or inactive placebo treatments.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The article did attempt to offer information on the costs of manipulation by consulting a spokesman for the American Chiropractic Association. However, the article only offered the unsatisfactory observation that costs vary. The journalist could have dug deeper and documented the range of costs per manipulation treatment\u2014and the typical number of visits per back pain episode.\n\nThe costs and cost-effectiveness of manipulation are important issues. If multiple treatments for chronic back pain provide similar benefit, then the value of the treatment modality is really dependent on the cost.\n", "answer": 0}, {"article": "Needle-phobia, or trypanophobia, is a recognized medical condition that causes sufferers to avoid medical care.\nThe patch, which is lined with microscopic needles that dissolve into the skin, could provide a painless alternative to hypodermic needles and make visits to the doctor's office or clinic for a traditional flu shot a thing of the past.\nThe microneedle technology may also be used for other vaccinations, such as polio and measles, said Prausnitz.\nIn a mouse study reported Sunday in the online edition of Nature Medicine, Prausnitz's team found the patch improved the immune system's antibody memory and was more efficient at clearing the lungs of the flu virus, compared to a placebo and hypodermic needle-delivered vaccine.\nThe muscle into which needles deliver vaccine is not nearly as active immunologically.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story relays a researcher\u2019s guess that the patch technology will be no more expensive than the standard flu vaccine once it is mass-produced. That\u2019s enough for a satisfactory given the early stage of development. At least it\u2019s more than the competing AP story did. ", "answer": 1}, {"article": "medical personnel.\nThe upshot, Dr. Galetta believes, is that parents and coaches \u201cshould absolutely consider\u201d familiarizing themselves with the King-Devick test and administering it to young athletes before the season starts, then having those baseline numbers and the test itself handy on the sidelines.\nIt is still too early to say, however, whether the King-Devick test can replace other, more conventional concussion evaluations for young athletes, including the standardized assessment, despite its shortcomings in this study, Dr. Galetta cautioned.\nThe test is so simple and inexpensive that any coach or parent potentially could administer it, the study\u2019s authors believe, and any league afford to provide it as a way to help evaluate and safeguard players.\nInterestingly, uninjured athletes are almost always faster at reading the numbers during games or practices, because physical exertion sharpens the kind of visual performance being tested.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story notes several times that the cost per player is minimal, but does not offer details. A check at the King-Devick test website revealed that the tests are sold in packages under an annual license for testing from 5 to 1,000 athletes at a cost of $50 to $1,000. With 100,000 public schools in the United States, the test could be a major revenue stream for the test owners if widely adopted. In addition, while the article talks about this being done by volunteer coaches and parents, one could imagine that this could be required for high school athletes. Performing a baseline test in all athletes could fall to teachers and coaches who are paid and may be a significant burden in terms of time required to administer the baseline tests. It is also unclear how often this in-depth baseline testing would need to be repeated.", "answer": 0}, {"article": "Imaging equipment makers such as GE Healthcare, Siemens, Philips and Toshiba Medical Systems are working to develop low-dose CT scanners.\nThe findings, published in the Archives of Internal Medicine, add to mounting evidence that Americans are overexposed to radiation from diagnostic tests, especially from a specialized kind of X-ray called a computed tomography, or CT, scan.\nRedberg, who wrote a commentary on the studies, said U.S. doctors\u2019 enthusiasm for the tests has led to an explosion in their use that is putting patients at risk.\nThe researchers said efforts need to be taken to minimize CT radiation exposure, including reducing the number of unnecessary tests, cutting the dose per study, and standardizing the doses across facilities.\n\u201cIt\u2019s estimated that just from the CT scans done in one year, just in 2007, there will be 15,000 excess deaths,\u201d Redberg said in a telephone interview.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not\u00a0describe the costs of CT scanning, which are substantial and increasing.", "answer": 0}, {"article": "This study received funding from the Divers Alert Network and U.S.\nHe also said research is ongoing to further illuminate the causes of SIPE and potential ways of diagnosing it early.\nMoon and colleagues studied these responses in 10 athletes who had experienced the condition while exercising or competing in triathlons.\nIn addition to Moon, study authors include Stefanie D. Martina, Dionne F. Peacher, Jennifer F. Potter, Tracy E. Wester, Anne D. Cherry, Michael J. Natoli, Claire E. Otteni, Dawn N. Kernagis, William D. White, and John J. Freiberger.\nMoon said larger studies are needed to replicate the results and learn more about possible adverse side effects of the drug.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Cost is not mentioned in the release.", "answer": 0}, {"article": "Doctors usually try to start people off with lifestyle treatment, such as weight loss, drinking less caffeine and alcohol, and avoiding lifting heavy objects.\nIt\u2019s good news for women with severe urge incontinence, who can choose between treatments based on preference, said Dr. Cindy Amundsen of Duke University, who led the study.\nOn average, both treatments cut the number of \u201caccidents\u201d \u2013 Botox by almost four times a day and the nerve stimulator by about three times a day.\nThe Botox injections freed 20 percent of the women in the study of incontinence, compared to 4 percent who had a nerve stimulator implant, Amundesen and colleagues reported in the Journal of the American Medical Association.\nThe women in the study had to suffer at least six episodes of incontinence over three days.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "We hear a lot about costs throughout this story, but see no specific numbers or meaningful discussion. And this is a major oversight, since\u2014at least according to a 2015 study that focused on the UK National Health Service\u2014Botox combined with quality supportive care \u201cappears to be a cost-effective use of resources.\u201d\nA neurostimulator for bladder issues costs between $20,000 and $30,000. Meanwhile, one unit (or \u201cU\u201d) of Botox costs roughly\u00a0$10-$28, with a typical cost hovering between $10-$12 per U.\u00a0Since the treatment uses 200 U of Botox, its price is likely about $2,000-$2,500 per 6-month treatment course, but that doesn\u2019t include the cost of administering it, which is likely to be considerable.", "answer": 0}, {"article": "Hospice care is intensive palliative care including home nursing, but insurers and Medicare usually cover it only if the patient abandons medical treatment and two doctors certify that death is less than six months away.\nIn practice, Medicare and private insurers do pay for some palliative care, said Dr. Gail Austin Cooney, a former president of the palliative medicine academy.\nThis trial was paid for by the American Society of Clinical Oncology and private philanthropy.\nBut the National Institutes of Health is under budget pressure, and the other major source of money for medical research, the pharmaceutical industry, has little incentive to study palliative care.\n\u201cBut I couldn\u2019t have completed the program without the psychosocial support.\u201d\n\nPalliative care experts now want to study patients with other cancers, heart disease, stroke, dementia and emphysema.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Although it touches on reimbursement, this story never addresses the key issues that most readers will be interested in \u2014 how much do palliative care consultations typically cost, does insurance cover it,\u00a0and does this approach\u00a0stand to increase or decrease the overall cost burden on our health care system?", "answer": 0}, {"article": "More than 20 percent of Americans have significant symptoms of depression or anxiety each year, but only around 20 percent of people with a mental health problem get adequate treatment.\nBut Northwestern researchers hope participants will provide confidential feedback, via four weekly questions, that will be used to further develop the system.\nThe data will help the system make even better recommendations and provide more personalized treatment.\nThe IntelliCare algorithm recommends new apps each week to keep the experience fresh, provide new opportunities for learning skills and avoid user boredom.\nSome also will have access to an IntelliCare coach via text messaging and phone calls, who are available to support them in using the apps.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release notes that there is no cost associated with downloading the Intellicare apps. But because Intellicare is part of \u201ca national research study\u201d the researchers request that users provide \u201cconfidential feedback\u201d weekly to help them further develop the system. Some people may not be comfortable sharing personal data over the internet, with good reason.", "answer": 1}, {"article": "\"What we wanted to find out was: 'Would cooling the surface of the brain of insomnia patients result in lower metabolism and improved sleep?\nBecause this study was extremely small and presented at a medical meeting, the data and conclusions should be viewed as preliminary until published in a peer-reviewed journal and confirmed in larger studies.\nThe cap is not yet available to consumers, although the lead researcher, Dr. Eric Nofzinger, has plans to bring it to market, Buysse said.\nDr. William Kohler, medical director of the Florida Sleep Institute, said the concept was exciting and worth further research in larger studies that include body temperature measurements and brain imaging tests.\nThe cooling cap was, however, associated with an increased amount of slow-wave sleep -- or the deepest, restorative portion of sleep, the researchers reported.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Not applicable.\u00a0 No discussion of costs but that\u2019s understandable at this early stage of development.", "answer": 2}, {"article": "Men who only father daughters appear to be at greater risk of developing prostate cancer, according to a study published last week in the Journal of the National Cancer Institute.\nIn the first controlled study that compared a group of hypochondriacs given the drug with a group that got psychological talk therapy and another group that received sugar pills, the medication significantly reduced people's fears about imaginary illnesses.\nThe study was published this month in the American Journal of Psychiatry by researchers at Leiden University in the Netherlands and other Dutch centers.\nThe study found that hypochondriacs who got cognitive behavior therapy, which encourages people to challenge the validity of their disabling beliefs, also improved -- as much as those given the drug.\nResearchers suggested that a combination of this talk therapy and medication might be especially effective.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There was no mention of costs.", "answer": 0}, {"article": "\u201cIf out of 10 years the patients have left to live we can keep them at home in a relatively mild state of the disease for three, four, five years, it\u2019s a lot.\u201d\n\nAccording to Alvaro Pascual-Leone, director of the hospital\u2019s Berenson-Allen Centre for Non-invasive Brain Stimulation, brain stimulation - or transcranial magnetic stimulation - involves a very low current applied to a specific part of the brain and is approved by the FDA for treatment of a variety of ailments and diagnostic applications.\nThe system is in trials at Harvard Medical School/Beth Israel Deaconess Medical Centre.\nThe device, which combines electromagnetic stimulation with computer-based cognitive training, is already approved for use in Europe, Israel and several Asian countries such as Singapore.\n\u201cWe see improvement lasting for 9-12 months and the good thing is that patients can return and undergo treatment again,\u201d Baror said.\nThe device, which consists of a chair containing an electronic system and software in the back and a coil placed at the head, has been tested on mild to moderate Alzheimer\u2019s patients who suffer from dementia but are not totally dependent.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The approach is not yet approved in the US, so it\u2019s understandable that costs here were not included.\u00a0 The story did note that \u201cIn Israel, the treatment costs $6.000.\u201d\nBut we aren\u2019t certain what exactly is the definition of \u201ctreatment.\u201d\u00a0 Is that in total or for each session?\u00a0 According to the company\u2019s website, patients receive daily treatments, five days a week for 6 weeks to start.\u00a0 At $6,000 per session (in Israel) that is $180,000.\u00a0 The published proof of concept study (http://www.springerlink.com/content/27622j8188653442/ ) suggested the need for twice a week treatments for an additional 3 months.\u00a0 That is another $144,000 if the cost is as described.\u00a0 So, is the cost $6,000 or $324,000?", "answer": 0}, {"article": "Spinal cord stimulation works by implanting an electrode near the spinal cord, inserted through the same place where epidural pain relief is injected for women in labor.\nDoctors say simple adjustments to the device may solve that problem.\nAnother concern is that patients who require high doses of stimulation drain the battery quickly, requiring surgery to replace the device.\nBut spinal cord stimulators offer significant relief to only about half the patients who try them.\n\u201cIt quickly becomes clear that \u2018weird\u2019 is going to be just fine if it replaces the pain.\u201d\n\nChronic pain is a particularly difficult problem to understand and solve.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The article notes the cost of the device alone ($20,000), the cost inclusive of hospital and other charges ($40,000), and the cost in comparison to other operations (\"cheaper\"). But let\u2019s not forget that the alternatives include non-invasive treatment.\u00a0 ", "answer": 1}, {"article": "This level is equivalent to two to three 8-oz cups of coffee per day, five to six 8-oz cups of black tea, or seven to eight 12-ounce cans of cola.\nIntake was estimated from questions about coffee, tea, and cola beverage intake, including frequency and serving size.\nThe findings come from participants in the Women's Health Initiative Memory Study, which is funded by the National Heart, Lung, and Blood Institute.\nDriscoll and her research colleagues used data from 6,467 community-dwelling, postmenopausal women aged 65 and older who reported some level of caffeine consumption.\nIn 10 years or less of follow-up with annual assessments of cognitive function, 388 of these women received a diagnosis of probable dementia or some form of global cognitive impairment.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Caffeine is already ubiquitous and people consume it daily in coffee, tea, sodas and supplements. A discussion of costs isn\u2019t necessary. ", "answer": 2}, {"article": "Melanoma is the most serious, and often deadly, form of skin cancer.\nThe phase 1 and 2 study was sponsored by GlaxoSmithKline, which developed both drugs.\nBy targeting different points in the same growth-factor pathway, the kinase inhibitor drugs dabrafenib and trametinib postponed the development of drug resistance in patients with BRAF-positive metastatic melanoma, the study authors said.\nThe drug combination is now being tested in a larger phase 3 study, which is required for U.S. Food and Drug Administration approval.\n\"We investigated this (drug) combination because of research we and others have conducted into the molecular underpinnings of resistance to BRAF inhibitor therapy,\" study lead author Dr. Keith Flaherty, of the Massachusetts General Hospital Cancer Center, said in a hospital news release.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Costs were not discussed. Neither of these drugs is approved for\u00a0sale, so it may be hard to offer a concrete figure. But\u00a0new drugs targeting melanoma via similar pathways are very expensive \u2014 in the neighborhood of $9,000/month, or $56,000 for a course of treatment.\u00a0The story should have mentioned this, even if the drug combo is only available under a research protocol.", "answer": 0}, {"article": "The page you are looking for has moved. Please go to the main EurekAlert! homepage to locate the section you are interested in and reset your bookmarks.\n\nFor further assistance, please contact webmaster@eurekalert.org.", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "This news release mentions both a treatment and a screening test. The treatment is ibuprofen, an over-the-counter, nonsteroidal anti-inflammatory drug that is probably widely known to be quite affordable.\nThe screening test is measuring levels of amyloid beta protein 42 (Abeta42) in the saliva. The cost of that test is not included in the news release.", "answer": 0}, {"article": "Those with the BRCA1 mutation also have a 36 to 63 percent higher risk of ovarian cancer and those with the BRCA2 mutation have a 10 to 27 percent higher risk of ovarian cancer.\n\u201cThis is the first study to prove women survive longer with these preventive surgeries and shows the importance of genetic testing when there is a family history of early breast or ovarian cancer,\u201d Dr. Virginia Kaklamani of Northwestern University in Chicago wrote in a commentary about the study published in the Journal of the American Medical Association.\n\u201cOur results confirm that risk-reducing mastectomy is associated with a significant reduction in breast cancer risk,\u201d Domchek and colleagues wrote.\nThe study shows the benefits of genetic tests that give women with a family history of cancer the chance to take steps to increase their chances of survival, they said.\n\u201cIt\u2019s not cookie-cutter medicine,\u201d Pruthi, who was not involved in the study, said in a telephone interview.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "1clip_filelist.xml\"/>\n\n\n\nThe story does not mention the costs of testing, surveillance or treatment.", "answer": 0}, {"article": "Toshiaki Higashihara, President & COO of Hitachi, Ltd. stated that, \u201cWe are greatly honored that Johns Hopkins selected Hitachi as their proton partner.\nThe next-generation system \u201cPROBEAT\u201d, which comes with IMPT (Intensity Modulated Proton Therapy) and cone-beam CT, will have improved spot scanning capability in all 3 gantry-type treatment rooms, along with a fixed irradiation room dedicated to cancer research.\nHitachi has delivered the first hospital based spot scanning system in May 2008 and has treated over 1,500 patients to date.\nHitachi will continue to globally expand the healthcare business where proton therapy is its flagship solution, and contribute to cancer treatment around the world.\nIn fiscal year 2015 (ending March 2016), one of Hitachi's new PBT site is planning to start treatment of patients.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There is no discussion of costs. PBT typically costs twice as much as traditional radiotherapy so it\u2019s definitely relevant to any announcement of a new facility. Several large insurance companies have ruled out coverage of PBT for prostate cancers. Any reliable reporter covering the business, healthcare or technology beats who writes a story based on this news release would be expected to ask about the costs so why not include at least some ballpark figures in the release?", "answer": 0}, {"article": "A study of more than 20,000 patients with traumatic injuries and at risk of bleeding to death found those who were treated with tranexamic acid were significantly less likely to die than those who got a placebo.\nAlso, there was no difference in deaths from clots blocking blood vessels in either group, a potential safety concern for the medicine.\nThat improvement may not seem so dramatic, but drug is pretty easy to give -- an initial 10-minute infusion within 8 hours of injury, followed by a second infusion over 8 hours.\nThat means 66 people would have to get tranexamic acid to prevent one death.\nSome 14.5 percent of patients who got the drug were dead within a month of being injured compared with 16 percent of those who got the dummy medicine.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "TXA costs $10 per treatment, according to the story. Although this cost is characterized as low, the story could have noted that the price may be prohibitively expensive\u00a0in many poor countries.\u00a0", "answer": 1}, {"article": "A new, detailed mammography exam catches more cancers while causing fewer false alarms, according to the company that sells it. The downside, some physicians say, is that it costs more and delivers twice as much radiation as traditional mammograms.\n\nTomosynthesis, or three-dimensional mammography, has been available in the U.S. since February from Hologic Inc., Bedford, Mass. In just a few months, radiologists say they are finding cancers they would have missed with the standard exam.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story stated, \u201cInsurance often doesn\u2019t cover the 3-D portion so doctors say you often need to pay about $50 out of pocket.\u201d However, would have preferred a quote from an insurance company instead of doctors to be sure that this cost is reflective of true out-of-pocket expenses.", "answer": 1}, {"article": "\"It's like 'Star Trek.'\nAnd while some patients like Campbell do well with the implant, there are some who struggle.\nAnd just recently, during a vision test, Campbell was able to correctly identify a sequence of letters for the first time in decades.\nThen earlier this year, she went from coping with blindness to hoping she might see again.\nToday, the artificial retina is primarily for sufferers of retinitis pigmentosa, but it could expand to other diseases, like dry age-related macular degeneration, Mech said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story fails to mention the cost of the technology being used in the research, a figure that is certainly available. \nFor example, the New York Times \u2013 when it reported on this work 3 months ago \u2013 simply asked the manufacturer, who said the device \"would cost up to $100,000.\"\u00a0 \nAt a time of debates about controlling the costs of health care, reporters can play an important role by reminding the public that every breakthrough has a price tag.", "answer": 0}, {"article": "\"There were times when I would yell at myself: 'I can't do this.\nIf made widely available, this kind of brain scan could be an important complement to the assessments -- based on reading and behavior -- already available for diagnosing dyslexia, Hoeft said.\nIt is hard to know who will be able to improve reading skills over time, and how much extra help is necessary.\nAnd those kinds of skills should be taken advantage of in school, said Wendy Weiner, principal of the arts-focused Conservatory Prep in Davie, Florida, and mother of a dyslexic child.\nBecause of this, Weiner said, three-dimensional letters and numbers, perhaps made out of plastic or clay, help a dyslexic child grasp the shapes better.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "\n\n\nNone of the stories we reviewed gave readers sufficient information on the cost of the research scans used in the study. This story includes a comment from a researcher saying that increased use of this type of brain scan would bring the \u201chigh cost\u201d down, but it doesn\u2019t provide an estimate of the current cost or any comparison to alternative methods of assessing reading ability or other features of dyslexia.", "answer": 0}, {"article": "\u201cWe\u2019ve seen individuals who have lost significant amounts of weight in the six-month period.\nZafgen has not identified the patients who died or said at which of 14 US trial sites they were taking the drug.\nSome analysts have suggested the FDA might approve the drug, despite the adverse events, if Zafgen can prove its benefits outweigh its risks to some patients.\nWhile the FDA\u2019s clinical hold prevented Zafgen from completing its trial, Dennis D. Kim, the company\u2019s chief medical officer, said it was largely finished.\nThomas E. Hughes, chief executive of Zafgen, said the Boston company will use the data to prepare a \u201crisk-mitigation\u201d plan to help persuade the Food and Drug Administration to lift its so-called clinical hold on the late-stage trial, allowing it to resume.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "As the drug is still pending approval from the FDA, the exact cost of the drug is unknown. However, it seems close enough to approval that some cost estimate should have been attempted \u2014 perhaps via a market analyst or company officials. Should it be approved, the drug will most likely be quite expensive.", "answer": 0}, {"article": "In its statement, the panel said that \"for some adults ages 76 to 85, the benefits of screening are smaller, and the potential for harm greater.\nPeople with disorders or medical histories that raise their odds for colon cancer may need more rigorous screening, the USPSTF said.\nHowever, the U.S. Preventive Services Task Force stopped short of saying any one screening method was better than another.\nAll of the recommendations are specific to symptom-free people 50 years of age or older with an average risk colorectal cancer, the panel stressed.\nThe USPSTF notes that only one-third of eligible adults in the United States are screened for colon cancer, and more need to take advantage of this effective method of prevention.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The costs of screening vary dramatically, not only by test but also by the terms of a person\u2019s health care insurance coverage. Insurance may completely cover the cost of screening, but depending on their insurance, people who get follow-up tests to check a suspicious screening test result may get hit with thousands of dollars in medical bills. Especially since the task force highlighted the importance of individuals deciding on the right type of colon cancer screening for themselves, which certainly includes their insurance coverage, the story should have mentioned costs. Also, though not directly addressed in these guidelines, it is worth noting that colon cancer screening is covered under the Affordable Care Act, but that workup of an abnormal screening test may not be.", "answer": 0}, {"article": "Aug. 10, 2011 -- Two of three patients dying of chronic lymphocytic leukemia (CLL) appear cured and a third is in partial remission after infusions of genetically engineered T cells.\nBut the therapy worked vastly better than University of Pennsylvania researchers David L. Porter, MD, Carl H. June, MD, and colleagues had dared to hope.\nWhat's new about the current treatment is the addition of a special signaling molecule called 4-1BB.\nThis may be why relatively small infusions of the CAR T cells had such a profound effect.\nThe treatment success came in a pilot study that was only meant to find out whether the treatment was safe, and to determine the right dose to use in later studies.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Unlike the Reuters story, this story did not discuss costs.", "answer": 0}, {"article": "LONDON -- Sanofi-Aventis SA's obesity drug Acomplia can improve blood-sugar levels and weight loss in diabetic patients, according to a study presented at the World Diabetes Congress in South Africa.\n\nThe findings from the clinical trial have shown newly diagnosed patients with type-two diabetes who weren't taking antidiabetic drugs had significantly improved blood-sugar levels and lost more weight with Acomplia, compared with a dummy pill over a period of six months. In addition, Acomplia -- also known as rimonabant -- helped...", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story didn't discuss the cost of the drug. ", "answer": 0}, {"article": "Nothing worked.\nShe stood ramrod-straight, head held high, to make the bulge less apparent.\nBy middle age, Ms. Gallagher, 51, the owner of a pet-sitting business in Torrance, Calif., was avoiding mirrors and considering liposuction, but she worried about the effects of anesthesia and the recovery time.\nThen she discovered another option: a series of fat-reducing injections intended to slim down a double chin.\nEven as a pigtailed child, Ashley Gallagher was self-conscious about a certain fullness in her face.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story notes that the price has not yet been set, which we\u2019ll call good enough for a Satisfactory rating. It could have noted whether insurers are likely to pay for the treatment.", "answer": 1}, {"article": "The U.S. National Cancer Institute has more on prostate cancer.\n\"This benefit was seen whether these patients were treated with surgery or radiotherapy,\" Choe added.\nAn initial review at six years suggested that those taking the combination therapy had a 43 percent reduced risk of dying from prostate cancer, while side effects were not \"major,\" Mason said.\n\"But we may expect to see this benefit in those who are taking aspirin for other [usually cardiovascular] reasons.\"\nOf the almost 2,000 patients on anticoagulants in the study, 1,649 were taking aspirin, 428 warfarin, 287 clopidogrel (Plavix), 26 enoxaparin, and 408 a combination of blood thinners.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "\n\n\nA story that says that aspirin seemed to account for more benefit than far more expensive drugs certainly should address the cost differential between the inexpensive \"ubiquitous\u2026pedestrian\" drug and others. Cost was never mentioned. ", "answer": 0}, {"article": ".\nThe association has strict policies to prevent these relationships from influencing the science content.\nThe current results demonstrate the importance of prompt imaging and treatment of patients with clot-caused stroke, even in those who wake up having experienced a stroke or who for other reasons are not identified in the first few hours after the onset of symptoms.\n\u2022 Available downloadable B-roll, animation and images to this news tip are on the right column of the tip link https:/\n\u2022 For more news at AHA International Stroke Conference 2018, follow us on Twitter @HeartNews #ISC18.\nThe association makes no representation or warranty as to their accuracy or reliability.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The cost of a thrombectomy procedure isn\u2019t addressed. Even through the study is comparing the procedure within 6 hours vs. within 24 hours, it would help readers if they knew how much this procedure runs.\nFrom a health policy standpoint, expanding the treatment window for more people would certainly cost more, but just what those costs might be is hard to extrapolate.", "answer": 0}, {"article": "So, indeed, there has been a strong interest in giving the best additional therapy possible,\" Choti added.\nAfter nearly three years of treatment, the researchers found almost no difference between survival rates in the two groups.\nThe study authors noted that, currently, the prognosis for pancreatic cancer is very poor, with a five-year survival rate of less than 5 percent.\nDr. Michael Choti, a professor of surgery and oncology at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University in Baltimore, described the study as \"important,\" but he does not believe it will alter the current approach to post-surgical chemotherapy.\nAt the three-year mark, patients on the gemcitabine regimen achieved an average survival rate of 23.6 months.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Costs of these chemotherapy agents are not discussed. The study compared a drug available only as a brand name to a regimen consisting of two drugs available generically.", "answer": 0}, {"article": "A 6-month supply of vitamin D supplements can be bought for less than $10, and many multivitamins contain the recommended daily dose of vitamin D.\n\nAs for calcium, the NIH advises 1,000 mg per day for men ages19-70, and then 1,200 mg per day for men older than 70.\nDespite the findings, people still need to get enough calcium and vitamin D to reduce the risk of osteoporosis, or bone thinning, said Dr. Mone Zaidi, an osteoporosis researcher at the Mount Sinai School of Medicine in New York, who was not involved in the study.\nHowever, there isn\u2019t enough data to say if vitamin D can help treat or prevent these diseases, Zaidi said.\nAdding the supplements to the exercise program provided no extra benefit, hinting that the men already had enough vitamin D and calcium in their diets to be able to boost their bone strength through exercise alone.\nHowever, exercise did boost bone mineral density, a proxy for bone strength, their report shows.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "It is rare to see a story include costs of what might be viewed as inexpensive supplements, but this story included the costs \u2013 at least \u2013 of vitamin D supplements.", "answer": 1}, {"article": "In 2012, a federally funded panel of experts on preventive care concluded there are more risks than benefits to screening American men for prostate cancer with the PSA test. And in April 2017, the U.S. Preventive Services Task Force dumped the decision squarely into the laps of patients and their doctors. Some men between 55 and 69 years of age might well decide to get their PSA checked, the task force said. After hearing the ledger of pros and cons, however, others in that age bracket might just as reasonably skip the screening test, the panel concluded.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not address the cost of the PSA test itself or of follow-up testing or treatment.", "answer": 0}, {"article": "\u201cBut it is definitely a breakthrough.\nThe study\u2019s authors noted that patients would need to stay on the drug in order to receive protection against the allergy.\n\u201cReactions from the oral challenges at the end of the study were much milder than prior to treatment,\u201d Tilles said, according to EurekAlert.\nIn addition, the symptoms caused by the 100-fold higher dose at the end of the study were milder than the symptoms on the lower dose at the beginning of the study.\u201d\n\nEXPERTS: CHILDREN AT RISK OF LEAD POISONING IN CHATTANOOGA\n\nWith FDA approval this drug would mark the first treatment available by prescription for peanut allergies.\nWhile the drug is not being hailed as a cure for peanut allergy, it has proven successful in building up patients\u2019 tolerance to peanuts over time, lessening the potential for life-threatening complications.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not mention costs \u2014 particularly important since the treatment might have to be taken for life. Also, it\u2019s expected to be marketed next year.", "answer": 0}, {"article": "\u201cBut I point out that we don\u2019t yet have randomized, controlled-trials data to back it up.\nThe one thing the research leaders are certain of is that the public\u2019s faith in vitamin D as a modern panacea has far outpaced what the scientific evidence proves.\nIn fact, the physician has wagered a few good bottles of champagne that none of three large randomized trials now underway will find proof of positive effects.\nThat\u2019s why there are no official recommendations yet from any medical organizations.\nUnfortunately, the lessons of history have shown repeatedly that many of these supplements that appeared to be very promising did not pan out in more rigorous testing.\u201d\n\nManson should know.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "A brief mention of cost would have improved an already strong article.\u00a0While it can be argued that most people have a rough idea of the price of vitamin D supplements, a quick word on the monthly cost of supplements, or the potential cost-effectiveness of supplementation as a prevention strategy, would have been welcome.", "answer": 0}, {"article": "The average daily dose of insulin dropped almost 39 percent after 12 weeks for the group with some beta cell function and 25 percent in those with no beta cell function, suggesting that the group with no beta cell function now produced insulin.\nThis was an initial clinical trial designed to test for safety.\nBoth experts said the treatment appears safe, with no risk of rejection.\n\"In the absence of complete remission, there are very sizable advantages to having some beta cell function,\" Inverardi noted.\nAlthough the treatment didn't wean anyone off insulin completely, average blood sugar levels dropped significantly, which would reduce the risk of long-term complications.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "We\u2019ll rule this Not Applicable. The research into this potential treatment is so preliminary that it is difficult to estimate cost figures in the story. That said, the story gives readers the impression that the research is much farther along, at a point where we would normally expect some discussion of costs. The error here is the over-stretch on the effectiveness not the omission of cost data.", "answer": 2}, {"article": "\"This is outside the box. I've never used it this far out,\" Metz said. \"My radar is up if I see [such an injury] again. As we get more follow-up from David, it will be important to publish this case so people will be aware.\"", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The article discussed that Medicare covers the treatment at $450 for a two-hour session. There wasn\u2019t a discussion about whether other insurance programs covered the treatment. It would have been helpful to know how much the entire treatment plan for the profiled patient cost and whether it was covered by his insurance.", "answer": 1}, {"article": "Newswise \u2014 RESEARCH TRIANGLE PARK, NC\u2014 Major depressive disorder affects more than 32 million Americans, and their first stop for treatment is often their primary care provider.\nHowever, the evidence shows that cognitive behavioral therapy can be just as effective, providing important information for patients and their physicians to consider when choosing among available treatment options.\"\nThe authors focused specifically on comparing second generation antidepressants, such as Wellbutrin, Lexapro and Prozac with cognitive behavioral therapy, which includes several in-person or phone sessions with a therapist to examine how actions and thoughts can impact depression.\nThe research from the RTI International-University of Chapel Hill Evidence-based Practice Center was published today in the British Medical Journal.\n\"Our findings indicate that both options should be considered effective initial treatment strategies.\"\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release gives a slight nod to costs without saying very much. It states, \u201cHowever, psychotherapy can be time-consuming and may be substantially more expensive, depending on the patient\u2019s insurance benefits.\u201d Medications and CBT both have costs so it would have been nice to compare them.", "answer": 0}, {"article": "It is also not available for pregnant women, people with heart conditions or very high blood pressure, patients with kidney disease or clotting disorders, patients on blood thinners, patients with a history of strokes or brain tumors and people with substance abuse issues.\nThe site includes a list of frequently asked questions and will be updated as UVA prepares to make the treatment available.\nThe essential tremor research has been supported by InSightec, the Focused Ultrasound Foundation and the BIRD (US-Israel Binational Industry Research and Development) Foundation.\nThe procedure is not for everyone with essential tremor.\nThe FDA approval means UVA can make the procedure available to eligible patients.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release mentions cost, saying, \u201cBecause the approach is so new, insurance plans will not yet cover the procedure, though that may change in the coming months. The cost at UVA has not yet been determined.\u201d\u00a0 But the procedure is still neurosurgery which is inherently expensive.\u00a0 Readers might benefit from knowing the cost of the current alternative surgical approach to treating this condition, deep-brain stimulation. The fact that other language in the release does come close to marketing this procedure for the medical center is also troubling.", "answer": 1}, {"article": "Professor Peter Sadler, a medicinal chemist at the University of Warwick commented:\n\n\"Platinum compounds are the most widely used drugs for cancer chemotherapy, but we urgently need to respond to the challenges of circumventing resistance and side-effects.\nChemo-catalysts, especially those with immunogenic properties, might provide a breakthrough.\nManipulating and applying well-established chemistry in a biological context provides a highly selective strategy for killing cancer cells.\nSince this new research functions in a totally new and unique way, it may overcome this acquired resistance and widen the spectrum of anticancer activity.\nUniquely, this chemo-catalyst treatment can be recycled and reused within a cancer cell to attack it repeatedly.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Given how early this research is in the development process, it would be impossible to place a specific cost on the potential treatment \u2014 or even a range of costs. However, the release could tell readers whether the process used to make JPC11 is expensive, time-consuming, relies on novel technologies, or has the potential to be easily scaled up \u2014 all of which can affect ultimate cost. For example, if it\u2019s a relatively straight-forward process that does not rely on specialized equipment or high-cost components, that\u2019s worth mentioning. If it\u2019s a complex, multi-step process that relies on highly-processed (and expensive) ingredients or technologies, that\u2019s worth mentioning too. The release doesn\u2019t address potential issues related to cost.", "answer": 0}, {"article": "Compared with the 16% of people who didn't drink coffee at all, those who downed two or more cups each day were about 18% less likely to have died during the study period. In addition, those who drank just one to six cups of coffee per week were 12% less likely to die. Both of these figures were calculated after taking into account known risk factors for early death, such as smoking (which is often paired with coffee drinking), diet and body mass index.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There\u2019s little need to discuss costs of a substance as well known as coffee.", "answer": 2}, {"article": "\"We are not going to reverse any of the chronic diseases in this country by changing the composition of the diet,\" Dr. Howard said.\nSome medical specialists emphasized that the study did not mean people should abandon low-fat diets.\n\"The studies were well designed,\" Dr. Freedman said, \"and the investigators tried to confirm popular hypotheses about the protective effect of diet against three major diseases in women.\"\nThe women in the study reduced all kinds of fat.\nThat could mean that fat in the diet may have a small effect, Dr. Rossouw said, perhaps in some subgroups of women or over a longer period of time.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "", "answer": 2}, {"article": "He reviewed the findings for WebMD.\nAlthough approved by the FDA, the femtosecond laser procedure is not widely used in the U.S., according to the American Academy of Ophthalmology.\n\"If you have a technique to soften the cataract, there appears to be less chance of damage [to the eye ],\" Salz says.\nThe surgery is performed to remove the natural lens of the eye after it has become clouded over time.\nThe new studies looked at using the so-called femtosecond laser to deliver near-infrared light to fragment the cataract into tiny segments prior to removal.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story notes that cost is an important barrier\u00a0to wider use of the\u00a0laser procedure, since the\u00a0equipment\u00a0carries a price tag of\u00a0$400,000 and insurers currently won\u2019t cover the extra cost. We\u2019ll call this satisfactory, but to make the information\u00a0more meaningful to\u00a0readers, the story should have broken down how the cost of an individual laser procedure compares with that of the\u00a0standard procedure.", "answer": 1}, {"article": "The requested URL /usnews/health/articles/070225/5laser.htm was not found on this server.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story provides the variation in cost for different laser eye surgeries. The story also mentions that the surgery may not be covered by insurance. ", "answer": 1}, {"article": "\"Surprising thing was it didn't really matter what type of probiotic was used or in which setting,\" Allen says.\nAllen says that since the original review, there's been increasing interest in probiotics and, therefore, more research.\nEven so, Allen says more research is needed to determine the specific strains of bacteria that are most effective.\nAuthors of the review note that probiotics can work in several ways, including robbing the offending bacteria, viruses or parasites of nutrients.\nThe review confirms the findings of another review in 2004, which also showed that probiotics had some effect against diarrhea.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There was no discussion of costs. Because we always think cost is important \u2013 even if it doesn\u2019t amount to much \u2013 we wish the story had included some cost estimates for probiotics-containing products. Does it add much to the cost of yogurt and other products?", "answer": 0}, {"article": "The risk of lung cancer death was 30 percent lower, the risk of colorectal cancer death was 40 percent lower and the risk of esophageal cancer death was 60 percent lower, the study reported.\nThe specific dose of aspirin taken did not seem to matter \u2014 most trials gave out low doses of 75 to 100 milligrams \u2014 but the participants in the longest lasting trials had the most drastic reductions in cancer death years later.\n\u201cThis is important as a proof of principle that a single simple compound like aspirin can reduce the risk of cancer substantially,\u201d said the study\u2019s lead author, Dr. Peter M. Rothwell, professor of neurology at the University of Oxford.\nAs part of the new study, published online Monday in the journal Lancet, researchers examined the cancer death rates of 25,570 patients who had participated in eight different randomized controlled trials of aspirin that ended up to 20 years earlier.\nParticipants who had been assigned to the aspirin arms of the studies were 20 percent less likely after 20 years to have died of solid tumor cancers than those who had been in the comparison group taking dummy pills during the clinical trials, and their risk of gastrointestinal cancer death was 35 percent lower.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "This story does not discuss the cost of daily aspirin intake. Because the cost to individuals is low and well-known, we won\u2019t insist on this point. Nevertheless, were a recommendation made for everyone to begin taking aspirin daily starting at age 45 the national price tag would be substantial. Readers would also benefit from an acknowledgement that such a recommendation would lead to higher spending on treatment of bleeding ulcers and other adverse events that would offset some of the potential cancer-related savings.", "answer": 2}, {"article": "Breast MRI currently is used to screen women at high risk of breast cancer and as a diagnostic adjunct to mammography.\nThe new approach is not intended to replace current contrast-enhanced breast MRI protocols in general, Dr. Bickelhaupt emphasized, but to expand the spectrum of options available for answering specific clinical questions.\nShould the results hold in larger trials, the model has potential advantages in the clinic beyond its ability to reduce unnecessary biopsies in women with BI-RADS 4 lesions.\nThe software algorithm makes the assessment reader-independent, ensuring that its accuracy is maintained across different imaging facilities.\nThe examination relies on gadolinium-based contrast agents that need to be injected intravenously.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Although it seems self-evident that reducing the number of unnecessary biopsies could save on medical costs, the release doesn\u2019t elaborate on the role of MRIs as an adjunct to mammography. In what proportion of cases are MRIs ordered prior to tissue biopsy? Does diffusion kurtosis imaging add to the cost? Cost of this procedure simply isn\u2019t addressed.", "answer": 0}, {"article": "All rights reserved.\nAdding the gene test put 100 men into that category, said another study leader, Dr. Matthew Cooperberg of UCSF.\nHe said a gene test may have made him more comfortable with that decision.\nGenomic Health has not published any results on the prostate test, another thing that makes doctors wary.\nThe gene test shifted about half of the men into either a lower or a higher risk category.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The cost of the new test \u2013 and of one that recently came on the market \u2013 were listed (> $3,000 each). And the story explained it\u2019s not known if insurers will pay for the tests.", "answer": 1}, {"article": "Professor Elwood said: \"Our review, based on the available evidence, suggests that low-dose aspirin taken by patients with bowel, breast or prostate cancer, in addition to other treatments, is associated with a reduction in deaths of about 15-20%, together with a reduction in the spread of the cancer.\nThis is not the only significant study Professor Elwood led research examining ways to improve peoples' health.\nIn no study was serious or life-threatening bleeding reported.\"\nThe study was the longest of its kind to probe the influence of environmental factors in chronic disease.\nProfessor Elwood also led a major study which monitored the health habits of 2,235 men over a 35-year period and found that exercise significantly reduces the risk of dementia.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release doesn\u2019t touch on cost but because aspirin is so widely available, and its cost so minimal, we\u2019ll mark this one \u201cnot applicable.\u201d", "answer": 2}, {"article": "If a pill could prevent teenagers from taking dangerous risks, would you consider it for your children?\n\nI\u2019d be tempted. My skateboard- and bicycle-riding son was hit by a car\u2014twice\u2014when he was a teenager. I would have welcomed anything that could have averted those dreadful phone calls from the emergency room.\n\nWhile some bumps and scares...", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Costs of the drugs are not discussed, nor is\u00a0whether they are generally covered by insurance, or how long kids would have to take them (for a few years? into adolescence? into adulthood?).", "answer": 0}, {"article": "NEW YORK -- Scientists acknowledged that an HIV vaccine recently tested in Thailand may be less effective than they originally suggested, but said it still provided valuable leads for further research.\n\nWhen first publicly disclosing the outcome of the vaccine trial in September, researchers said the vaccine had lowered the risk of infection by about 31%. That result was modest but statistically significant. Coming after two decades of failed HIV-vaccine trials, the announcement was welcomed by researchers around the world.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Since the vaccine is not available, a discussion of costs is not warranted. ", "answer": 2}, {"article": "Autism is a complex brain disorder characterized by difficulties in social interaction and communication, ranging from mild to profound impairment.\nThe accuracy of the scan in predicting autism was so high that the results were strongly significant, despite the small number of patients involved.\nExperts not involved in the research applauded the research but cautioned further study was still needed.\nThe new scanning method \u2014 which picks up on structural changes in the brain\u2019s grey matter \u2014 could be ready for general use in a couple of years.\n\u201cAlthough this method is not ready for normal diagnostic situations, any step to easier diagnosis is welcome,\u201d said Terry Brugha, professor of psychiatry at the University of Leicester.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "", "answer": 0}, {"article": "The requested URL /usnews/health/articles/070513/21sunscreen.htm was not found on this server.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Although the story suggests that competition in the marketplace for new sunscreen formulations is vigorous, it makes no mention of costs.", "answer": 0}, {"article": "African-American women are more likely than white women to report hot flashes.\nAlthough the benefit was modest, it appeared to be significant enough that women might consider trying it, the researchers said.\nIn the new study, Ellen Freeman of the University of Pennsylvania School of Medicine in Philadelphia and colleagues gave 205 women who were either starting to go through menopause who had already gone through menopause either Lexapro or a placebo for eight weeks.\nAn antidepressant can help alleviate hot flashes that plague many menopausal women, according to new federally funded research.\nThe study is the first to examine whether there are any racial differences in how well an antidepressant works in alleviating hot flashes.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "This story did not mention costs. Lexapro costs about $110/month and is not available as a generic. Because of this, insurance companies will probably relegate it to 2nd or 3rd\u00a0tier status with higher copays\u00a0for those who wish to use it.", "answer": 0}, {"article": "\u201cRemember this day.\nKeytruda, as a sole agent, was targeted only at patients with high PD-L1, making them more receptive to immunotherapy.\nAs a monotherapy, Keytruda halved the risk of disease progression and cut overall deaths by 40 percent compared to chemotherapy alone in pre-selected patients whose tumors had been tested using a biomarker.\nAn editorial in the New England Journal of Medicine, where the Merck monotherapy results were published, said Keytruda could become \u201ca new standard of care\u201d.\nAnother similar drug from Roche also demonstrated broad efficacy as a so-called second-line option in patients who had received prior treatment.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Cost is not discussed, even though the FDA approved Keytruda for advanced, non-small cell lung cancer treatment in 2015.", "answer": 0}, {"article": "Overall, this is very exciting.\u201d\nThere, engineers have partnered with Nanovision Biosciences Inc. to create a retinal implant that uses silicon nanowires smaller than the width of a cell to sense light entering the eye and stimulate retinal neurons.\nBut Dr. Grazia Pertile, director of ophthalmology at the Sacred Heart Don Calabria in Negrar, Italy and one of the Italian researchers, said in a written statement that her team's device could be \u201ca turning point in the treatment of extremely debilitating retinal diseases.\u201d\n\nShe\u2019s not alone in that assessment.\nRelated: This Revolutionary Gene-Editing Tool Could Change the World\n\nWhen the prosthesis was tested in rats, the animals' pupils constricted in response to exposure to light.\nThe new prosthesis is designed to be implanted onto the back wall of the eye, where it absorbs light and transforms it into an electrical signal that stimulates the still-active retinal cells to restore vision.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Both artificial retinas are in the earliest stages of development, still to be tested in humans. Even if there\u2019s no product yet, we\u2019d like to see\u00a0stories make mention of costs. For instance, the cost of implanting the current FDA-approved artificial retina (mentioned in the article) might serve as a benchmark for estimating future cost of the new devices.", "answer": 0}, {"article": "\"What they do is give you a really small dose, like a crumb, basically,\" explains Jula.\nLanser says it can be tricky to diagnose food allergies.\nShe says the results aren't that surprising, since allergists had classified these patients as low-risk for reacting to the foods they were being tested for.\nA new study published in the Annals of Allergy, Asthma & Immunology illuminates just how many people come to find out they can eat foods they've long avoided.\nAs we've reported, people sometimes misinterpret the symptoms of a condition such as lactose intolerance for a food allergy.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not mention the cost of oral food challenges. That\u2019s too bad because the economics of food challenges are part of the overall newsworthiness of the procedure, although it was not a focus of this particular study. Considering that oral food challenges take three to six hours and require multiple staff to provide adequate supervision, families with inadequate or no insurance may not consider looking into the time-consuming procedure. However, families of patients on special diets spend thousands of extra dollars per year on groceries. Prior research suggests that in the end, having a food challenge earlier rather than later could save money for children assessed as low risk.", "answer": 0}, {"article": "USUALLY NOT THE FIRST STEP\n\n\u201cI have a long list of chronic pain patients coming to seek acupuncture,\u201d said Jongbae Park, head of Asian Medicine & Acupuncture Research at the University of North Carolina at Chapel Hill School of Medicine.\nIt\u2019s usually \u201cnot their first approach to address the condition,\u201d he said - rather people seek acupuncture when traditional care fails to stop their pain.\nBut patients treated with fake or \u201csham\u201d acupuncture - using retracting needles that don\u2019t stick in the skin, for example - estimated their pain at somewhere in between the other two groups, suggesting that they also got some benefit from the procedure.\nIn those cases, he said, acupuncture is very safe - and the main downsides are costs and the inconvenience of getting to a clinic.\n\u201cA doctor who has a patient in pain has a lot of options,\u201d such as medications and physical or talk therapy, said lead author Andrew Vickers, from Memorial Sloan-Kettering Cancer Center in New York.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "\u201cA typical acupuncture session runs for about $100 and is often not covered by health insurance,\u201d according to the story.", "answer": 1}, {"article": "High blood pressure, or hypertension, is a major risk factor for cardiovascular diseases \u2014 the leading causes of death worldwide.\nThe Cochrane review attracted sharp criticism from nutrition experts.\nWhile previous trials have found there is a blood pressure benefit from cutting salt, research has yet to show if that translates into better overall heart health in the wider population.\nSimon Capewell, a professor of Clinical Epidemiology at Liverpool University, said the review was \u201cdisappointing and inconclusive\u201d and did not change public health consensus that dietary salt raises blood pressure.\nIn a systematic review published by The Cochrane Library, British scientists found that while cutting salt consumption did appear to lead to slight reductions in blood pressure, that was not translated into lower death or heart disease risk.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Not applicable.\u00a0 Costs not in question in this context.", "answer": 2}, {"article": "Rosie Dow, Head of Sing with Us at Tenovus Cancer Care and co-author of the research, added: \"This research is so exciting, as it echoes everything all our choir members tell us about how singing has helped them.\nThe research raises the possibility that singing in choir rehearsals could help to put people in the best possible position to receive treatment, maintain remission and support cancer patients.\nWe have been building a body of evidence over the past six years to show that singing in a choir can have a range of social, emotional and psychological benefits, and now we can see it has biological effects too.\nFollowing on from this research, Tenovus Cancer Care is launching a two year study looking in more depth at the longitudinal effect of choir singing over several months.\n\u2022 At Tenovus Cancer Care our aims are simple: to help prevent, treat and find a cure for cancer.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release does not mention any costs. While the non-profit Tenovus makes choir singing available to people for free that doesn\u2019t mean such an activity would be free to people everywhere if they wished to access it. If a cancer treatment center needed to establish a new choir program, with a director, that would require resources \u2014 financial and otherwise.", "answer": 0}, {"article": "The main campus also includes University Hospitals Rainbow Babies & Children's Hospital, ranked among the top children's hospitals in the nation; University Hospitals MacDonald Women's Hospital, Ohio's only hospital for women; and University Hospitals Seidman Cancer Center, part of the NCI-designated Case Comprehensive Cancer Center.\nPrevious survey research completed by Dr. Kingsberg and others has shown that while 32 million women may be experiencing symptomatic VVA and suffering from related impacts on sexual function, interpersonal relationships, self-esteem and overall quality of life, only 7 percent are currently using a prescription therapy to alleviate symptoms.\n\"We still have to find better ways to educate the millions of women suffering with VVA about the symptoms, however, so that more of them know it is common, decide to discuss treatment with their healthcare professional, and seek symptom relief with appropriate treatment.\"\nThe survey, which included 731 respondents with a 96 percent response rate, sought to quantify participants' satisfaction with the application method and overall treatment delivery system.\nThe majority of women taking either TX004HR or placebo (85.4 - 92.1 percent) found the product easy to use.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The news release provides no information about how much the softgels might cost.", "answer": 0}, {"article": "Viagra is one of three licensed drugs to treat erectile dysfunction, Davies explained. The other two are Cialis and Levitra. They can take from half an hour to several hours to work, and they're not for everyone: Men who've had a stroke or heart attack are told to use the drugs with caution, reports the Daily Mail. Even those without medical issues simply don't like the wait.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "It\u2019s understandable that a story might not be able to discuss the costs of something that\u2019s 10 years away from availability. What is not so understandable, however, is why they did the story now. ", "answer": 2}, {"article": "WASHINGTON\u2014People with mild Alzheimer\u2019s disease who started taking an experimental Eli Lilly & Co. drug earlier in the course of their disease fared better than patients who started later in a clinical trial.\n\nThe outcome may bolster the company\u2019s case that the drug, solanezumab, can slow the decline of memory and function in mild Alzheimer\u2019s patients, despite prior studies with negative results. But the new data aren\u2019t final proof of the drug\u2019s benefit\u2014a separate, continuing study due to end in late 2016 is designed to...", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "While the story tells readers that solanezumab and aducanumab could generate annual sales of $3 billion and $10 billion respectively, it says nothing about the potential cost of the drugs to consumers or insurance companies. Those billions would likely come largely from Medicare. These drugs are still far removed from the marketplace, but presumably the experts they spoke to were basing their annual sales estimates on more than guesswork. That makes it particularly problematic that the story doesn\u2019t touch on cost at all.", "answer": 0}, {"article": "She is 5-foot-7, and her starting weight was 165 to 170; after two months she had lost about 28 pounds.\nPart of the reason for the study, Dr. Ravussin said, was to find out whether people could stand calorie restriction.\nHe wound up in the group assigned to cut calories by 25 percent.\nThey had to take time off work for metabolism tests and also ate many meals at the clinic.\nAnother group ate 75 percent of what members needed to keep their weight steady.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Everything has a cost. Yet the story gave no cost estimate for the costs associated with consumption of foods \u2018high in nutrients but low in calories.\u2019 ", "answer": 0}, {"article": "The Ache: Nearly 5,000 people a year die from choking in the U.S., according to the nonprofit National Safety Council.\n\nThe Claim: Two new easy-to-use devices work like plungers to suck out obstructions in the airway, providing another option if standard treatment\u2014such as abdominal thrusts developed in 1974 by Henry Heimlich\u2014fail to clear the airway, say the companies who sell them.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The article provides prices on both devices:\nBoth the Dechoker, $89.95, and the LifeVac, $69.95, have a plastic mask that provides a seal over the mouth and nose while suction is provided.", "answer": 1}, {"article": "For men with advanced prostate cancer, the news for decades has been mostly bleak. Until recently, only two treatments had been shown to prolong survival.\n\nResearchers reported Monday that the drug abiraterone, being developed by Johnson & Johnson, extended survival by an average of 3.9 months among men with cancer that has spread beyond the prostate and for whom other treatments have failed. Among men, prostate cancer is the second-leading cancer killer, behind only lung cancer.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "\n\n\n\n\n\nThe story does not include any estimate of the cost of the drug, but the treatment is still experimental, so it is not surprising that there is no firm estimate of the drug\u2019s price. The story does note the high costs of other recently approved drugs to treat advanced prostate cancer\u2026 and that cost may be an issue for this product as well.", "answer": 1}, {"article": "About 35 million Americans have migraines, according to the American Headache Society, and about 20% to 30% of these patients have headaches that are preceded by visual or other sensory warning signs.\nDrugs commonly used in the treatment of severe headaches are generally not considered effective in the aura phase of migraine attacks, and many patients want to treat their migraines without using drugs, neurologist and headache specialist Richard B. Lipton, MD, tells WebMD.\nCompared to patients who got sham treatments, more patients treated with the experimental device, known as single-pulse transcranial magnetic stimulation (sTMS), were pain-free two hours later.\n\"Some people don't tolerate the drug treatments very well and others just want to avoid them.\"\nMarch 3, 2010 -- A handheld device that magnetically zaps pain may be a promising new treatment for patients with a common type of migraine.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No mention of cost was made in the report about this device.\u00a0 As medications exist for treatment of migraine during aura, the comparative cost is important. Speculation as to whether this device would be covered by insurance would have also been helpful. \u00a0\u00a0 ", "answer": 0}, {"article": "NEW YORK (Reuters Health) - In a new study of middle-aged New Jersey men, taking cholesterol-lowering drugs was linked to a lower chance of dying from prostate cancer.\nThe findings don\u2019t prove that the drugs, called statins, ward off aggressive cancer.\nBut they jibe with previous studies suggesting that getting cholesterol levels under control might help reduce the risk of life-threatening disease, researchers said.\nThe researchers also couldn\u2019t tell whether men started using statins before or after they were diagnosed with aggressive cancer.\nBut Freedland said that other strategies for lowering cholesterol \u2014 such as eating better and exercising regularly \u2014 are ways almost everyone can lower their disease risks in the meantime.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Cost range estimates for statins are given in the story.", "answer": 1}, {"article": "Tissue plasminogen activator, known as tPA, can dramatically reverse stroke symptoms in those whose strokes are caused by blood clots and blockages, which account for an estimated 85 percent of all strokes.\nThe study, reported online Nov. 2 and in the December issue of the journal Radiology, reinforces results from similar research, Oppenheim said.\nDr. Wally Ghurabi, emergency department director at Santa Monica-UCLA Medical Center, said a group of ongoing studies there include a similar focus on MRIs and stroke.\n\"These results will be useful for centers that offer 24-hour access to acute stroke patients.\nOppenheim said the next step would be clinical trials to validate whether MRIs serve as a \"surrogate clock\" for stroke onset.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There was no discussion of costs \u2013 not for the individual and not for health planners and society. As we discussed in the \u201cavailability\u201d criterion above, this is an important question.", "answer": 0}, {"article": "Anthony Cunningham, Executive Director of the Westmead Institute for Medical Research in Australia and Principal Investigator of the ZOE-70 study said: \"These data show that this investigational vaccine maintains high efficacy against herpes zoster in people over 70 and 80 years of age, the age groups who are most affected by the disease.\nThe primary objective of this study is the overall vaccine efficacy against shingles in people aged 50 years or older, compared to placebo.\nThe co-primary objectives of the pooled analysis over both studies are the assessment of overall vaccine efficacy in reducing the risk of developing shingles and PHN in people aged 70 years and over, using pooled data from both ZOE-70 and ZOE-50 studies.\nAbout the phase III study programme\n\nInvolving more than 37,000 subjects globally, the phase III programme for GSK's candidate shingles vaccine evaluates its efficacy, safety and immunogenicity.\nThe candidate vaccine was shown to be 89% (95% confidence interval: 68-97%) efficacious in preventing PHN in people aged 70 years and older and 91% efficacious (95% confidence interval: 75-98%) in people aged 50 years and over1.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The vaccine in question has not yet been submitted to the FDA for approval, so we wouldn\u2019t expect to have a specific price for the vaccine. The price GSK will charge for the vaccine will vary by country. Still, GSK ought to have some idea of how much this vaccine would cost in one of the largest global markets. The release never mentions cost at all.", "answer": 0}, {"article": "In more than 22% of cases, implantable defibrillators are given to heart patients who don\u2019t meet the guidelines for receiving the pricey devices, according to a study just published in JAMA.\n\nThe research, based on 111,707 cases submitted to a national registry over a three-and-a-half-year period, also finds that those patients who didn\u2019t meet the guidelines had a higher risk of dying in the hospital and of complications from the implantation.\n\nICDs, which can cost north of $30,000, monitor the rhythm of the \u2026", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story deserves high marks for bringing costs into the discussion right in the lead. \u201cIn more than 22% of cases, implantable defibrillators are given to heart patients who don\u2019t meet the guidelines for receiving the pricey devices, according to a study just published in JAMA.\u201d The story also says, \u201cICDs, which can cost north of $30,000, monitor the rhythm of the heart and produce a shock to bring irregular beating back to normal.\u201d But just as with the Times story, the cost of the device and hospitalizations is only a piece of the economic picture. Additional costs of maintaining the device and battery replacement drive the costs higher. In reality however the overall economic impact of the devices is just about the same as treatment of high blood pressure and elevated cholesterol when life years (a commonly applied economic marker) is considered.", "answer": 1}, {"article": "If an AAA is found, doctors sometimes use a stent to repair the aorta, but it doesn't always work since the aneurysms are often in places where a stent can\u2019t fit.\nWe can anticipate challenges by practicing the procedure beforehand.\u201d\n\nSo far doctors at Mayo Clinic have done this personalized procedure on more than 450 patients.\nUsing a minimally invasive endoscopic vascular surgical technique, patient recovery times are quicker.\nThe cardiology community now prefers the endovascular approach.\n\u201cAn aneurysm in no way means that you're going to die.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There\u2019s no discussion of how much this procedure costs or whether it\u2019s covered by insurance, and no comparison with stent procedures that don\u2019t include the 3D printing and customized fit.", "answer": 0}, {"article": "There's no definitive answer to that just yet, Wang said.\nWhile larger studies are needed to confirm the findings, tai chi looks promising as an alternative treatment, Yeh said.\n\"This could represent an ideal exercise for fibromyalgia sufferers.\nPrior research has shown exercise can improve mood, Wang added.\nThe improvements were still evident at 24 weeks, according to the research reported in the Aug. 19 issue of the New England Journal of Medicine.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "\u00a0The story does not mention costs.\u00a0", "answer": 0}, {"article": "Lauren Dunn is a medical producer for NBC News; Linda Carroll is a contributor for NBCNews.com\n\"You need to be monitored by your surgeon during that period of time.\u201d\n\nOne downside: the implants aren\u2019t covered by insurance or Medicare, says Hamilton, adding \u201cthe cost is around $4,000 to $5,000.\u201d\n\nThere are other risks with the procedure, but they are rare, according to clinical trials.\nIt\u2019s functioning in your day-to-day life.\u201d\n\nEkstadt has the privilege of being the first person in the nation to get the Raindrop outside of a clinical trial.\nBoth of the new implants, Raindrop and KAMRA, go into only one eye.\nAlso, Hamilton notes, the implants aren\u2019t a \u201cbe all end all.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story gives us the price of $4-5,000 for surgery, which is not likely to be covered by insurance or Medicare.", "answer": 1}, {"article": "For more information on breast cancer, visit the American Cancer Society.\nEating bitter melon could also have a beneficial effect, Ray said.\n\"We didn't see any death in the normal cells,\" she said.\nThe next step is to see if the team can repeat these findings in animals, Ray said.\n\"Many supplements have biologic activity, but before I recommend that people take isolated supplements they need to be tested in humans.\"\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Costs weren\u2019t mentioned.\u00a0 It took us only a few seconds to find out how much this stuff is sold for online. ", "answer": 0}, {"article": "In addition, Drs.\nThe pump is reusable; the balloon, microchip, and lab test together cost around $20, all supporting the increasing acceptance of breath tests as a cost-effective, easy-to-perform, non-invasive, and rapid option for the diagnosis of lung cancer.\n\u201cWe hope that the breath analysis can serve as the primary screening tool for cancer recurrence and a CT scan ordered only if the breath test suggests that there has been a change,\u201d said Dr. van Berkel.\nNow the test is being used to monitor for disease recurrence.\nNewswise \u2014 Chicago \u2014 A single breath may be all it takes to identify the return of lung cancer after surgery, according to a study posted online today by The Annals of Thoracic Surgery.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release does mention that the cost of materials to conduct the test is \u201caround $20\u201d which is considerably less than the cost of CT scan imaging which is now being used. It is unclear, however, how much patients would be actually charged.\u00a0The release should\u2019ve been clearer about the actual cost to patients.\u00a0", "answer": 1}, {"article": "Cystic fibrosis (CF) is a genetic disorder that causes persistent lung infections.\nWhat's most exciting, they said, is that the triple-drug approach could open up new options to nearly all cystic fibrosis patients.\nThe trials were short-term, finding that the drug combinations improved adult patients' lung function over four weeks.\nBut experts said they were optimistic the results will hold up in the larger, longer-term trials already underway.\nBoth new trials focused on those two groups of patients.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story brought up the \u201creal-world issue of price\u201d if the drugs are approved. It reported that the company that makes them \u2014 Vertex Pharmaceuticals \u2014 markets the combination of two other CFTR modulators \u2014 tezacaftor and ivacaftor \u2014 for a list price of $292,000 a year.\nAdditional cost comes from the continued need for hospitalization on a regular basis, at least for some patients. Treating these patients may well cost millions over the course of a decade.", "answer": 1}, {"article": "LONDON (Reuters) - First results from a human trial of an Ebola vaccine from GlaxoSmithKline show it is safe and generates an immune response, scientists said on Wednesday, but larger trials are needed to see if it protects and if a booster is needed.\nThe early-stage Phase I trial of GSK\u2019s vaccine was primarily designed to test safety, but Adrian Hill, who led the work at Oxford\u2019s Jenner Institute, said it was \u201cencouraging\u201d that the shot also prompted responses from the immune system.\nJeremy Farrar, director of the Wellcome Trust charity which helped fund the trial, said it provided \u201cgood initial evidence that the GSK vaccine will be safe to use in people\u201d.\nThe vaccine is being developed by the U.S. National Institutes of Health (NIH) and GSK against the Zaire strain of Ebola \u2014 the one circulating in West Africa \u2014 and the first doses for a larger trial arrived in Liberia last week.\nThe data, published in the New England Journal of Medicine, were from 60 healthy volunteers given the vaccine in Britain between Sept. 17 and Nov. 18 last year.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Although accurate cost information is unlikely to be available at this point, cost will undoubtedly become an issue for successful deployment of any vaccine in one of the lowest-resource geographical areas in the world. We think that could have been mentioned, even at this early stage of development.", "answer": 0}, {"article": "\"If someone really feels they need to take this and they need to try it, well go ahead and do it.\n\"Further, the subjects in the study were not monitored for certain cognitive parameters until several years after the trial began, creating difficulty in determining accurately whether they experienced a decline in cognition or not.\nEarlier results from the same study found that ginkgo did not prevent or slow the development of Alzheimer's or other dementias, DeKosky said.\nNo measurable effect from ginkgo is seen on cognition, Schneider said.\nThis age group is not typical of the age of both healthy people and those with mild cognitive impairment who use ginkgo for improving mental performance.\"\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There was no mention of how much ginkgo biloba products cost.\u00a0 Even an NBC story, with limited broadcast time, mentioned that Americans spend more than $100 million on a year on these products. A USA Today story said US sales were $99 million in 2008.\u00a0 But what does it cost the individual?\u00a0 ", "answer": 0}, {"article": "Metabolic syndrome is characterized by obesity, hypertension and other cardiac risk factors.\nFunding for the study was provided by Wakunaga of America Co., Ltd., the producer of Kyolic Aged Garlic Extract.\nOther LA BioMed researchers who participated in the study were: Suguru Matsumoto, Rine Nakanishi, Dong Li, Anas Alani, Panteha Rezaeian, Jeby Abraham, Michael A. Fahmy, Christopher Dailing, Ferdinand Flores and Sajad Hamal.\n\"This study is another demonstration of the benefits of this supplement in reducing the accumulation of soft plaque and preventing the formation of new plaque in the arteries, which can cause heart disease,\" said Matthew J. Budoff, MD, an LA BioMed lead researcher.\nFollowing evaluation, the participants were given either a placebo or a dose of 2,400 milligrams of Aged Garlic Extract every day.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "This release makes no mention of the cost of this supplement in its discussion, although the supplement and its cost are easily available via the web. It would be nice to know what a year\u2019s worth at the prescribed dose would cost.", "answer": 0}, {"article": "\u201cLow levels of vitamin B12 are surprisingly common in the elderly.\"\nDuring the study, published in Neurology, 17 people developed Alzheimer\u2019s disease.\nBlood levels of folate, another nutrient believed to lower homocysteine levels, were not linked to Alzheimer's disease risk.\nIn addition, each micromolar increase in blood homocysteine level raised the risk of Alzheimer's disease by 16%.\nResearchers found that each picomolar increase in blood vitamin B12 level was associated with a 2% reduction in the risk of Alzheimer's disease among the elderly.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story mentions B12 supplements, but does not discuss their cost. Even if inexpensive, we think cost is important. ", "answer": 0}, {"article": "\"Emergency departments are going to have to think twice about a test like that,\" says Michael Shannon, senior physician in emergency medicine at Children's Hospital Boston.\nA new cold and flu test can precisely diagnose a dozen winter ailments and reduce unneeded use of antibiotics, says the company that sells it.\nPhysicians say the test is accurate and the most comprehensive available, but some say its long processing time limits usefulness in emergency rooms.\nThe downside is that the test is expensive, about $300 to $400, but is covered by most insurers.\nThe test is expected to be used mainly in hospitals and emergency rooms, but doctors can send the swab to a local lab.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "This story does a good job of providing\u00a0the cost of the\u00a0XTag respiratory panel, $300-400,\u00a0and cost-related information.\u00a0 The test\u00a0is relatively expensive but is also covered by insurance.", "answer": 1}, {"article": "Learn more about Mayo Clinic.\nHowever, it was unclear whether these drugs could be used safely in cancer patients until now.\nDr. McBane noted that cancer and cancer treatment can be associated with kidney injury, which can limit the drug's use further.\nDr. McBane says quality of life surveys, which were taken monthly throughout the six-month trial, showed that patients markedly preferred oral apixaban over injectable dalteparin.\nHe says these qualities make this class of drug much easier to use than the traditional blood thinners.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The news release did not discuss the costs of apixaban or how it compares to the cost of the injectable medication heparin. According to GoodRx, the average cost of apixaban is $424, while the average cost of heparin is $189 (these costs do not reflect insurance coverage). There is also no generic version of apixaban (sold under the brand name Eliquis) available yet. The release did quote the study author saying that a downside to heparin injections is that they \u201care expensive at nearly $100 per day,\u201d however no information was provided about how apixaban costs compare.\u00a0", "answer": 0}, {"article": "\"Like many things, the evidence changes over time,\" says Hensrud.\nBut he says that newer studies suggest that drinking coffee may actually be good for you.\nHowever, coffee alone may not be the answer according to some experts.\nBut he is concerned that the side effects of coffee are not addressed in this study.\nCoffee did not decrease the risk of a third type of oral cancer \u2013 laryngeal cancer.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Not applicable \u2013 the cost of coffee is not in question.", "answer": 2}, {"article": "(Fellow parents, let's do the math.\nIf sleep extension could have a salutary effect on helping people lose weight,\" he says, we'd have another tool in the fight against obesity.\nThat means turning off all electronics, including the TV, and creating as quiet a sleep space as you can.\nIf your teen has to get up at, say, 6:30 to be at school by 7:30, that means bedtime's at 9:15 or 9:30 p.m.)\n\nVorona says he'd like to delve deeper into the sleep-obesity question.\nInstead, choose whole-wheat crackers, which can control insulin.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Costs are not directly relevant to the dynamics of sleep and weight, nor to the interventions described in the story.", "answer": 2}, {"article": "It is known as BMS-790052.\nIn fact, no fewer than 90 studies are currently underway examining different HCV-targeting drugs.\nBut the study provides the first clinical evidence that targeting the HCV protein NS5A may be an effective strategy for curing patients who are chronically infected with the HCV virus, says Nicholas A. Meanwell, PhD, who is executive director of chemistry with Bristol-Myers Squibb.\nA unique thing about the NS5A-targeting drug, according to Meanwell, is that laboratory studies show it to be effective against all HCV genotypes.\nThe current treatment for chronic HCV -- intravenously administered peg-interferon and ribavirin -- cures about half of people with genotype 1 who take it.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "SInce the test drug is in the very early stages of development, this criterion is technically not applicable.\u00a0However, the present treatment regimen of an interferon and ribavirin costs thousands of dollars monthly for 6-12 months and it is likely that any newer antivirals will be additive and not replacements.\u00a0A comment on the potential for significant additional costs would have been desirable.\u00a0", "answer": 2}, {"article": "The study was supported by the Andrew Sabin Family Fellowship Program; the American Association for Cancer Research \u2013 Stand Up to Cancer; the National Institutes of Health (CA219896-01A1, HL124112); the Cancer Prevention & Research Institute of Texas; and the Melanoma Moon Shot\u2122, part of MD Anderson\u2019s Moon Shots Program\u2122, a collaborative effort to accelerate the development of scientific discoveries into clinical advances that save patients\u2019 lives\n\nIn addition to Wang, other MD Anderson authors include: Diana Wiesnoski, Christopher Sanchez, and Chia-Chi Chang, Ph.D., all of Genomic Medicine; Beth Helmink, M.D., Ph.D., and Vancheswaran Gopalakrishnan, Ph.D., both of Surgical Oncology; Hamzah Abu-Sbeih, M.D., Gottumukkala Raju, M.D., and John Stroehlein, M.D., all of Gastroenterology, Hepatology & Nutrition; Edwin Parra, M.D., Ph.D., and Alejandro Francisco-Cruz, Ph.D., both of Translational Molecular Pathology; Matthew Campbell, M.D., Jianjun Gao, M.D., Ph.D., and Sumit Subudhi, M.D., Ph.D., all of Genitourinary Medical Oncology; Dipen Maru, M.D., of Pathology; Jorge Blando, DVM, and James Allison, Ph.D., both of Immunology; Padmanee Sharma, M.D., Ph.D., of Genitourinary Medical Oncology and Immunology; Michael Tetzlaff, M.D., Ph.D., of Translational Molecular Pathology and Pathology; Jennifer Wargo, M.D., of Genomic Medicine and Surgical Oncology; and Robert Jenq, M.D., of Genomic Medicine and Stem Cell Transplantation.\nThe study from The University of Texas MD Anderson Cancer Center, which includes two patients, suggests fecal microbiota transplantation (FMT) is worth investigating in clinical trials as a therapy for this common side effect of immunotherapy.\n\u201cBased on these results, this should be evaluated even as a first-line therapy for ICI-associated colitis because it\u2019s safe, quick, and the effect is durable - from one treatment.\u201d\n\nImmune checkpoint inhibitors, which release a block on the immune system to attack cancer, have been successful in providing durable responses for patients with several cancer types.\nHowever, these treatments are often associated with significant immune-related toxicities.\nStill, post-treatment gut bacteria remained distinct from their own pre-treatment microbiome.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Although the use of fecal transplants to soothe severe colitis in cancer patients (caused, in this case, by immunotherapy) has yet to be tested clinically, the treatment itself is increasingly popular for other gastrointestinal issues and typically costs in the $1000 to $2000 range.\u00a0 Alas, we learn nothing about that cost in this release.", "answer": 0}, {"article": "Alcohol is known to activate some of the same receptors in the brain that opioids do, and studies find that by tempering the pleasure from alcohol, naltrexone can help people drink less.\nNaltrexone is certainly not a cure-all, researchers say.\nAnd it won't help everyone who has a drinking problem \u2014 especially if the disorder is severe.\nIt's now been about five months since he started taking the medication.\nMany physicians are \"unaware that there are medications to treat alcohol use disorders,\" says Koob.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "This was a close call. The story mentions that an analysis found the drug \u201ccost effective\u201d for treating alcohol use disorders. But it doesn\u2019t mention any specific numbers, nor if insurance covers it.", "answer": 0}, {"article": "The results of the Women's Health Initiative (WHI)--the largest, most scientifically rigorous study of older women's medical issues ever conducted--continue to startle researchers, confuse the public and frustrate headline writers. Case in point: last week's report that taking estrogen for seven years does not increase the risk of breast cancer for many women. There is a lot of good news in that finding, as well as some important caveats.\n\nIn many ways, the story began four years ago when researchers halted a different part of the WHI--one that looked at the long-term health effects of taking the hormone combination estrogen and progestin...", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The article does not mention costs of estrogen.", "answer": 0}, {"article": ": Link will be live at the embargo time http://jamanetwork.\nStudy Limitations: The results apply only to pain after two hours.\nBottom Line: For adults coming to the emergency department for arm or leg pain due to sprain, strain, or fracture, there was no difference in pain reduction after 2 hours with ibuprofen-acetaminophen vs three comparison opioid-acetaminophen (paracetamol) combinations.\nAuthors: Andrew K. Chang, M.D., M.S., of Albany Medical College, Albany, New York, and coauthors\n\nResults: After 2 hours pain was less in all participants, without any important difference in effect between the four groups.\nThe findings suggest that ibuprofen-acetaminophen is a reasonable alternative to opioid management of acute extremity pain due to sprain, strain, or fracture, but further research to assess longer-term effect, adverse events and dosing is warranted.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Costs are not discussed. The costs of ibuprofen and acetaminophen are fairly low \u2014 but the relevant opioids are also relatively inexpensive. For the relevant dosages, the costs would be more or less comparable, with the hydrocodone/acetaminophen combination likely being the most expensive.", "answer": 0}, {"article": "When Marin Mejia was pregnant with her son Owen, one such blood test that picks up DNA from mother and baby came back showing abnormal results.\nMore testing showed she had anal cancer.\nBut doctors told Mejia they needed to investigate what caused the irregular finding.\nFurther testing showed the baby was healthy.\nThe findings are published in the Journal of the American Medical Association.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "In such a short piece, discussions of cost are almost always missing, but they were missing as well in the competing WSJ article.", "answer": 0}, {"article": "However, Owens said, \u201cit\u2019s hard to do all of that in your head.\nThe problem with the old-fashioned way, he told Reuters Health in an email, is that there are many pieces of information about a patient to consider.\nBut the new study looked at a more sophisticated way of estimating individual patients\u2019 needs.\nEddy said that the calculator, or others like it, could be integrated into electronic health records.\nA researcher not involved in the work said it was a \u201cnice study\u201d that is a first step toward showing that tailored guidelines could have benefits.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Couldn\u2019t Dr. Eddy have commented on the projected cost of implementing his idea?\u00a0 And certainly the projected cost saving impact of his Archimedes system has been the focus of past news coverage. So even a line about cost impact would have been appreciated.", "answer": 0}, {"article": "Try to eat a pound of vegetables each day, half of which are cooked and the other half eaten raw, as well as half a pound of raw fruit.\nBut while certain common foods \u2014 like raw onions, garlic, citrus juices, coffee and chocolate \u2014 are likely to cause reflux in most people with the condition, Dr. Aviv and other experts emphasize that everyone is different, and trial and error is the most effective way to determine an individual\u2019s trigger foods and drinks.\nLosing weight is one of the best ways to find relief without having to rely on medication.\nA food does not have to be obviously acidic to be troublesome.\nHe said they should be taken 30 to 60 minutes before eating breakfast or dinner (or both), but not used as an \u201cantidote\u201d to consuming acidic foods.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not mention cost, but given that the treatment option the story focuses on broad, non-specific recommendations for lifestyle changes, we\u2019ll give it a pass.\nEating less fatty food and more produce is not a viable option for everyone, particularly those who live in so-called \u201cfood deserts\u201d that have limited access to healthy foods they can afford, but that is a broader discussion \u2014 and not one that we would expect to be addressed in a story like this one. Taking all of that into account, we\u2019ll rate the cost criterion as not applicable here.", "answer": 2}, {"article": "Feb. 22, 2012 -- When women in their 40s get breast cancer , their tumors need less intense treatment and recur less often if they were first detected during routine mammogram screening.\nEven the USPSTF accepts the fact that beginning breast cancer screening at age 40 saves lives.\nBut the vast majority of women will never develop breast cancer during their 40s.\nThese women will suffer the harms of early screening.\nFor women in their 50s and 60s, the benefits of getting regular mammograms clearly outweigh the risks.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No discussion of costs of mammograms.\u00a0 Stories should not assume that all insurance companies will cover costs of mammograms for women in their 40s.\u00a0 Cost is an issue and can be addressed in just one additional line in a story.", "answer": 0}, {"article": "Smokers who count on nicotine patches or gum to help them quit may want to reconsider: A new study finds that these and other nicotine replacement products aren't effective at preventing former smokers from relapsing in real-world conditions.\nThose who had used nicotine patches, gum, inhalers or nasal sprays were just as likely to relapse as those who had quit without them, researchers from Harvard University and the University of Massachusetts found.\nIn those trials, volunteers using such products were up to three times more likely to kick the smoking habit.\nIn some cases, studies have found that people who use products like nicotine patches and gums are more likely to relapse than their counterparts who go cold turkey.\nBut the latest results are in line with other studies that have found little \u2014 if any \u2014 benefit from the products when used by smokers in real life.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story addresses the broad scope of costs: \u201cAmerican smokers spend more than $1.5 billion on nicotine gum, patches and related products each year, according to the study. Much of that comes from public health programs, which are facing further rounds of budget cuts.\u201d\nWe would have liked to see actual costs for some of these products and a comparison to cigarettes. People might be more likely to continue buying nicotine products if they are cheaper than the cigarettes themselves.", "answer": 1}, {"article": "Bladder cancer is the fourth most common cancer in men, but it is less common in women.\nResearchers wrote that the findings \"underscore the need for further high-quality trials to assess surgical innovation before this surgical technique is widely adopted in clinical practice.\"\nThree Loyola Medicine urologists, Marcus Quek, MD, Gopal Gupta, MD, and Alex Gorbonos, MD, are co-authors of the study.\nMAYWOOD, IL - Robotic surgery is as effective as traditional open surgery in treating bladder cancer, according to a landmark study published in the journal Lancet.\nLoyola is among 15 centers that participated in the nationwide trial of 350 patients, who were randomly assigned to undergo robotic surgery or open surgery to remove cancerous bladders.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There is no discussion of cost in this release. The journal article says several institutions refused to provide their prices. Nevertheless, the high cost of robotic surgery is an important issue. The researchers wrote they were unable to say whether those high costs might be offset [or not] by certain potential benefits (such as shorter hospital stays), but the release should have at least acknowledged the cost issues.", "answer": 0}, {"article": "Tobias Hartmann, the project's coordinator, said, \"We have known for a while that diet can reduce the risk of developing dementia.\nThe clinical trial, headed by Professor Hilkka Soininen is part of a large EC project (LipiDiDiet) to explore the therapeutic and preventative impact of nutrition on neuronal and cognitive performance in ageing, AD and vascular dementia.\nThe primary outcome parameter was selected to assess the effect on cognitive function (a broad measure of thinking) during 24 months intake of Fortasyn Connect compared with a control product.\nThe LipiDiDiet study illustrates that this nutritional intervention can help to conserve brain tissue and also memory and patients' ability to perform everyday tasks - possibly the most troubling aspects of the disease.\nAs part of the LipiDiDiet project, the first randomised clinical trial to investigate the effects of a medical food Fortasyn Connect (Souvenaid), in patients with very early AD (pre-dementia), has just been completed.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Presumably, the aim here is to make an over-the-counter nutritional drink along the lines of Ensure for people to take as they age to stave off memory loss. If that\u2019s the case, the release should explain what something like this costs to make and what it might cost on the shelf.", "answer": 0}, {"article": "But in leg arteries, the active flexing can cause a stent to break.\nThe study is the largest to look at the effectiveness of atherectomy, Covidien said, and enrolled 800 patients at 47 centers in the U.S. and Europe.\nThomas Gunderson, a senior analyst for Piper Jaffray & Co., said the Covidien study could lead to greater use of atherectomy and a bigger market.\nAlso of note, Garcia said, is that the procedure proved as effective at improving blood flow for patients with diabetes as those without diabetes.\nThe company says this is a major step forward in treating PAD because, unlike stents, atherectomy \"leaves no metal behind.\"\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No mention of costs of atherectomy nor of the tool in question.", "answer": 0}, {"article": "Developed in the laboratory of UHN transplant surgeon Dr. Markus Selzner, with the help of UHN transplant surgeons Drs.\n\u201cThis technique will change the landscape of organ donation by improving organ preservation, allowing us to better assess and regenerate the donor organ on the device before we transplant it into a patient.\nThe new warm preservation technique avoids the damage of cold storage and instead allows the donor organ to improve and repair itself, potentially leading to better outcomes for patients.\nSince the kidney did not \u201cstruggle\u201d after transplant, there is a greater likelihood that its long-term outcome will be better, he adds.\n\u201cThis new technology can help us answer the critical question, \u2018What\u2019s the best way to improve function and recover and repair the kidney before transplantation to get the best results for our patients?\u2019\u201d\n\nDr. Grant, who is also Professor of Surgery at the University of Toronto, emphasized that high-impact research projects such as this require strong collaborative teams \u2013 including researchers, surgical residents, nurses, Canadian Blood Services, perfusionists, colleagues at SickKids - working together on experimental and clinical trials.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Cost is not addressed. Does the technology used to keep the kidney viable in ex vivo organ perfusion increase costs? Is this something that would be passed on to patients?\nThe economics of improving the viability of kidneys for transplant is an important consideration that isn\u2019t mentioned, either. The estimated first-year cost of a kidney transplant is in the $270,000 range and that of renal dialysis about $70,000 annually, so despite its costs, transplantation is economically as well as clinically preferred over the long run. The techniques described likely will add costs over cold storage but knowing how much would have been an important aspect of the story.", "answer": 0}, {"article": "\"In many of those cases we decide, 'OK, this lesion is too small to be treated with a filling.'\nThe treatment, called Icon, is one of several new cavity treatments that avoid drilling.\nWolff says that while the no-drill approach to treating this type of tooth decay has promise, fluoride treatments and other patient-applied methods are still more inexpensive, less invasive and have a much longer track record of success.\nA new procedure used by Phark and other doctors claims to stop the progress of cavities without drills or Novocain.\nParis says the key to getting the treatment to work was finding a filling material that wasn't thick and goopy so the porous enamel would immediately suck it up like a sponge.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "\n\n\nOddly, while the story says this product is cheaper than drilling and filling a cavity\u2026 and it includes a comment from an expert saying this product is more expensive than other approaches to preventing cavities, it does not say how much this product costs.", "answer": 0}, {"article": "She\u2019s healed, basically,\u201d she said.\n\u201cEven the marks where it was climbing up my neck are all gone.\u201dFurther study needed\n\nWhat Diamond is hoping for now is funding for a full clinical trial so that he can test the combination in advanced triple-negative breast cancer patients who test positive for p53.\nDiamond developed the vaccine and has been studying its effectiveness in clinical trials at COH since 2010.\nReferred to City of Hope by her physician at Davis, she began responding to the experimental treatment right away, Yuan said, her skin tumors disappearing and the latest biopsies showing no cancer.\nIn a subsequent laboratory study, the COH researchers showed that these patients\u2019 immune cells could be reactivated by treatment with a PD1 inhibitor that is a biosimilar to the clinical drug called pembrolizumab.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release referred to a combination of a new vaccine targeting the p53 gene and a pembrolizumab biosimilar. Pembrolizumab is currently used as a chemotherapy drug but no mention of costs were given for this drug or the combination treatment of the vaccine\u00a0with pembrolizumab. According to GoodRX, four vials of 50 mg Keytruda cost around $9,000.", "answer": 0}, {"article": "We've had a lot of migrants from European nations, so they're fair-skinned ... and we do have a very intense sun here,\" Ziman said.\nZiman said current methods of melanoma detection are expensive and invasive, involving a trip to a clinician, who must biopsy the lesion to discover whether it is cancerous.\nFor potential sufferers in remote areas, away from skin specialists, diagnosis can be especially tricky, he said, making a simple blood test an easy alternative to identify those at risk.\nPatients who returned a positive result would still need a biopsy to confirm the blood test and determine how far the cancer had developed, Ziman said.\nOver three years, the research team identified a combination of 10 types of antibodies that best signal the presence of a melanoma.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "This test, since it involves ten separate autoantibody antigens is likely to be expensive. \u00a0A test to determine breast cancer recurrence risk, Oncotype DX cost approximately $3,000. \u00a0It is unclear how often a blood test for melanoma would need to be repeated, so the cost will be an important consideration, and should have at least been acknowledged.", "answer": 0}, {"article": "Some insurance plans cover EMDR.\n\u201cEMDR processing is untangling the knot.\u201d\n\nOnce the memories are processed, therapists say, they are less vivid \u2014 less like the film reel Henn would see in her mind.\nEMDR, Henn said, allowed her to have a do-over \u2014 to be able to grieve properly and then to move beyond grief.\nTalk therapy helped her manage those attacks, but it didn\u2019t address the root cause.\nThis distraction had a positive effect on her, she said, allowing her to dive deeply into the therapy without freezing in the face of fear.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Cost of treatment surfaces only in the context of whether individuals\u2019 health insurance plans will pay for the treatment. Some will and some won\u2019t; regardless, we have no idea what that cost is.", "answer": 0}, {"article": "\"Nobody wants to sedate a healthy infant,\" says Dawson.\nWiznitzer \u2013 a pediatric neurologist at Rainbow Babies & Children's Hospital in Cleveland, Ohio \u2013 notes that what the study can't tell us is what the differences in brain activity between the two groups of babies actually mean.\nHe said that, judging by the differences in brain activity, he and his colleagues could detect which babies were in the high-risk group.\nThe EEG technique is much easier to use because the baby can be awake and moving and wiggling around, says Dr. Geraldine Dawson, chief science officer for the advocacy group Autism Speaks, which partially funded this research.\nDoctors and scientists not connected to the study are intrigued by the results but caution that this is very early research and not something concerned parents can be looking for as a screening tool for their babies any time soon.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story did not address costs. To see why this is such a serious omission, look no further than this comment that was posted below the story online on the CNN website:\n\u201cThis is great, but if your insurance won\u2019t cover any Autism treatments, what\u2019s the point? I have a 3.5 yr old and two year old boys, both on the Autism spectrum. Our insurance covers nothing for them with regard to any treatment. It\u2019s left to us to absorb. Both require intensive speech and behavioral therapy at a cost of roughly $5,000 per month. I barely make $5,000 a month for a family of 4. \u2026I wholeheartedly approve of the advances they are making, but if insurance won\u2019t cover anything, why bother?\u201d", "answer": 0}, {"article": "Cortisol levels fluctuate during the day meaning results were not always accurate, and only revealed cortisol levels at a single point in time.\nBut it did reveal it was important to further study hormones and the body\u2019s endocrine system, and how they relate to mental illnesses like anxiety and depression, he said.\nThe greater number of traumatic events a child had experienced, such as divorce, injury, moving house, severe illness or the death of a family member, the higher the hair cortisol concentrations were, the researchers found.\n\u201cWhat\u2019s less commonly understood is that beyond poor mental health, it can also be associated with the development of other illnesses such as diabetes, obesity and cholesterol issues, because cortisol is also central to glucose availability, blood pressure and immune function, so identifying these children is important.\u201d\n\nWhile blood or saliva tests could be used to detect cortisol levels, these methods were sometimes problematic, especially in children, Simmons said.\n\u201cHowever, hair samples are not only easier to obtain, but provide us with a picture of total cortisol throughout the system across many months rather than just at a point in time,\u201d Simmons said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Although the hair test is far from ready for any practical, clinical use, the story speculates that it could be a tool to identify children at risk. If it\u2019s not too soon to make such predictions, it\u2019s not too soon to give readers an idea of what the test might cost.", "answer": 0}, {"article": "And general practice physicians missed cancers 60 percent more often than gastroenterologists.\n\u201cThis is very different from a population undergoing screening.\u201d\n\nColonoscopy would probably miss a smaller percentage of cancers in such a large population, Lieberman said, because the rate would be lower.\nGiven the wide variation in colonoscopy training, the researchers call for standardizing it, including credentialing and re-credentialing.\nCanadian researchers note that their finding should be a heads-up to clinicians performing the exam, as well as to patients preparing for it.\nDr. Charles Kahi of the Indiana University School of Medicine, in Indianapolis, noted that the rate found in the new study was a bit higher than previously reported.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not discuss costs and should have. If colonscopy is not providing that value that people once thought, it should be examined from a cost basis as well.\u00a0 Since fecal occult blood stool slide testing is so much cheaper (something referenced in the story but without cost estimates given), this is an even more important issue. ", "answer": 0}, {"article": "We have to really ask the question: 'How low do you go?'\nAlthough the reason for the increased risk remains a mystery, Nabel and other experts stressed that the benefits of blood sugar control have been well established for diabetics and said patients should not make any changes in their care without consulting their doctors.\nBut the findings cast doubt on a major hope about diabetes treatment -- that pushing levels below current targets would be beneficial -- and would force experts to rethink how to treat one of the nation's leading health problems.\nOfficials defended the study, saying previous research had suggested that intensive blood sugar lowering would be beneficial.\nMany earlier studies had shown that tightly controlling blood sugar significantly reduced the risk of many complications.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There was no cost information provided; it is both relevant and available. \u00a0The medications used to more tightly control sugar levels are expensive.", "answer": 0}, {"article": "The researchers from Harvard's T.H.\n\"The results of this study emphasize the role of an early life high-fiber diet on prevention of breast cancer in later life.\nIn an accompanying editorial, Duke University Medical Center's Dr. Kimberly Blackwell said there's longstanding evidence that dietary fiber may cut down on circulating estrogen levels through changes in the gut microbiome.\nShe said that recently more evidence has come to light suggesting a relationship between dietary fiber and breast cancer risk, and that eating more fiber would be a simple way to reduce risk.\n\u2022 Lesser-known signs of breast cancer women should watch out for\n\nDr. Deanna Attai, assistant clinical professor of surgery at the David Geffen School of Medicine at the University of California Los Angeles, said that while it's an observational study, not a clinical intervention, its larger point about diet and health is important.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There are a lot of foods you can eat to increase your dietary intake of fiber, and the story lists\u00a0apples, pears, raspberries, artichokes, green peas, broccoli, split peas, lentils, beans, whole wheat pasta, whole grain bread, brown rice, bran flakes, and oatmeal. We\u2019ll rate the story Not Applicable since most people are aware of the cost of the foods mentioned. However, we wish the story had discussed the fact that many of these healthy sources of dietary fiber are either unaffordable or unavailable to many young women, particularly those from low-income backgrounds who live in food deserts. As we noted with the NPR story, we recognize that this is a story about breast cancer risk, not about food availability. However, if a story focuses on the importance of a healthy diet, there should ideally be at least a brief acknowledgment that many people do not have access to the foods that make up a healthy diet.", "answer": 2}, {"article": "So the jelly may ooze a little bit, but it will not run out like an oil,\" says Schulman.\nMoreover, that data are limited to just the last two or three years \u2014 not enough, Wolf says, to make any real claims about the long-term safety of the implants.\nStill, there are plenty of satisfied customers among the nearly 400,000 women who receive breast implants each year.\nStill, he warns his patients that no procedure is without risks \u2014 and additional surgeries are a very real possibility.\nBut now the Food and Drug Administration has evaluated the safety of the second generation of silicone implants and the results are mixed.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The article sidesteps any issues related to costs of breast implants or the remedies for failures, a glaring omission in light of frequent complications and adverse outcomes.\n", "answer": 0}, {"article": "LONDON -- GlaxoSmithKline PLC said it has produced an effective bird-flu vaccine for humans and could begin producing the shots at year's end, leaving it to governments to decide whether to begin ordering the shots.\n\nGlaxo, the world's second-biggest drug maker by sales behind Pfizer Inc., called the findings a breakthrough but said it needs to gather additional data before it can answer several important questions, including how much of the vaccine it will be able to manufacture.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does mention that the shot would cost between 4 and 7 euros. The story should have commented on the greater societal costs of implementing such a vaccination program.", "answer": 1}, {"article": "When researchers compared patients who had gastric bypass surgery to those who lost the same amount of weight by dieting, they found that the surgery patients had lower levels of amino acids that have been linked to insulin resistance.\nBut researchers say the preliminary findings could one day lead to diabetes treatments.\nThe study was small, including just 10 patients who had the surgery and 11 patients who followed severely calorie-restricted diets.\nAnd the patients in both groups had lost just a fraction of the weight they needed to lose at the time of the analysis.\nNow a new study from Duke University Medical Center and Columbia University may help explain why.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Although there was an acknowledgment that it simply wasn\u2019t possible to offer gastric bypass surgery to everyone with type II diabetes, there was no discussion about the costs of gastric bypass surgery.", "answer": 0}, {"article": "The new research provides more evidence of the need for new regional centers of care, in order to minimize the time it takes to transport a patient to hospital capable of providing stent therapy, according to Dr. William J.\nRelated: New Recommendations Say More Americans Should Take Aspirin\n\nFor Reisch, the impact was almost immediate: he began to regain feeling while undergoing the procedure.\n\u201cThey are destined to be in a nursing home or to be dead and when we re-establish blood flow \u2014 often times right there on the table \u2014 they get better.\u201d\n\nStent retriever therapy is a new procedure experts call the most major advance in stroke treatment in two decades.\nFirst responders asked Reisch to smile and immediately recognized his drooping mouth as a sign of a stroke.\nAt the hospital, the first-line therapy, a powerful blood-thinning medication called tissue plasminogen activator or tPA could not dissolve the blood clots in Reisch\u2019s brain.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "We found multiple studies that discuss the cost of these types of clot retrieval procedures, including this one. It would have been helpful for the reporter to have asked how much the procedures cost, on average, in the cases studied for the journal article.", "answer": 0}, {"article": "Omega-3 fatty acids are unsaturated fats found in most fish, but especially in fatty fish that live in cold seawater, such as salmon and herring.\nCAVEATS Most participants were white.\nTesting and measurements were done once, providing no data for comparison over time or to determine any link to dementia.\nThe research described in Quick Study comes from credible, peer-reviewed journals.\nWHO MAY BE AFFECTED?\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The cost of fish is not in question.", "answer": 2}, {"article": "\u201cWe are not hopeful here.\u201d\nCanakinumab had stirred considerable scientific interest because it appears to finally deliver proof that fighting inflammation offers a promising new way to counter heart disease in patients who already get cholesterol-lowering treatment.\nIlaris now costs about $200,000 per patient annually for treating rare immune conditions and brings in some $400 million in yearly sales for the Swiss company, though its price is likely to be slashed should it win approval in the heart setting.\nWhile Narasimhan said it was too early to discuss pricing, he argued so-called PCSK9 cholesterol drugs that cost about $14,000 annually should not be relied on as a yardstick.\n\u201cI don\u2019t think you can necessarily just make comparisons to existing benchmarks, such as the PCSK9s.\u201d\n\nEven so, Tim Anderson, a Bernstein analyst, said the \u201cmarginal\u201d data are not compelling enough to dispel what for Novartis will remain a pricing conundrum, should canakinumab\u2019s approval be expanded for heart patients.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "This article does a great job of noting the cost and pricing issues inherent in the drug company\u2019s efforts to develop, test and market novel biologicals. The headlong rush to \u201cpersonalized\u201d medicine, pharmacogenetic approaches to treatment, limited resources even in wealthy nations with gold-plated insurance policies, and the opacity of drug industry research costs make it imperative to explain to the public the realities of medicine\u2019s pricing system.", "answer": 1}, {"article": "An experimental spray improved sex for some men who regularly experience premature ejaculation, according to the results of two studies set to be presented Tuesday at a urology conference.\n\nMen who applied the aerosol spray, a mixture of the anesthetics lidocaine and prilocaine, reached orgasm a mean of 3 minutes 18 seconds after beginning sex, compared with about 56 seconds for those who got a placebo spray. The 539 men completing the two studies, who were randomly assigned to the real drug or the fake version, had an average...", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The company behind the product undoubtedly has done market research about\u00a0how much of this product it might sell and at what price. At a minimum, that information should have been included here.", "answer": 0}, {"article": "\"I hear a lot of moms say, 'I'm disappointed I had to have a C-section.'\nBut for many women, being told they need a C-section is unpleasant news.\nHospitals aren't charging more for it \u2014 so cost doesn't seem to be a major factor.\nAnd there were a bunch of little adjustments, such as moving the EKG monitors from their usual location on top of the mother's chest to her side.\nBy late evening she was told she'd need a C-section to deliver her son, Avery.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story said hospitals aren\u2019t charging more for the family-centered cesarean. We\u2019ll judge this nod in the direction of costs to be sufficient for a satisfactory rating, but ideally we\u2019d like to see a dollar estimate for what a traditional cesarean costs. In addition, we\u2019d note that the family-centered cesarean does involve some additional resource costs \u2014 for example,\u00a0extra nursing staff and the logistics of getting the neonatal team into the operating room \u2014 that should be considered, even if these are not currently reflected in typical hospital charges.", "answer": 1}, {"article": "Moffitt is the No.\nThe researchers previously developed a vaccine that helps the immune system recognize the HER2 protein on breast cancer cells.\nImportantly, the immune responses among the patients were similar, regardless of the route of vaccine administration.\nThe researchers report that the dendritic cell vaccines were well-tolerated and patients only experienced low-grade toxicities.\nThey also show that the vaccine was able to stimulate an immune response in the majority of the patients.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There\u2019s no mention of how much this treatment costs.", "answer": 0}, {"article": "Vasopressin, an anti-diuretic, reduces urine production.\nIn the United States there's no approved drug to treat the problem, the study authors said.\nThis suggests that the anti-inflammatory impact of routine exercise may minimize nocturia, he said.\nThe new drug, while promising, is of concern because of its potential to lower blood sodium levels in the elderly, one doctor said.\nBut help could soon be at hand in the form of a nasal spray, new research suggests.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The price or potential price of this drug is not discussed. Since there is mention of the drug already being \u201ccommonly\u201d used in children, we assume there\u2019s some idea of how much it costs\u2013though it\u2019s not made clear.", "answer": 0}, {"article": "This didn't stop MS.\"\n\n\"But, this is extremely hopeful research,\" he added.\nIf the experimental medication is eventually approved for use, it would be only the second oral MS drug available to patients, alongside a number of long-standing injectable options.\n\"And with the one oral option we have today, there has been a lot of concern over a possible risk for immune suppression and also an increased risk for cancer,\" added Zamvil, who was not a part of the current study team.\nAnd it's also important to note that this is not a cure.\nThe study found that to date, the new drug appears to be both safe and well-tolerated.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Multiple sclerosis is a chronic illness requiring ongoing treatment. So, cost of treatment is an important consideration. This story did not include cost information,in part because the drug in question is not on the market. Acccording to this Bloomberg story, it costs $4,000 a month, and searches on Drugstore.com and other sites back this up.\nTip:\u00a0 we\u2019ve added a new resource for journalists to help them track down costs of medical interventions.", "answer": 0}, {"article": "Foods to avoid\n\n Dairy: Milk, ice cream, yogurt, cottage and ricotta cheeses (except for lactose-free versions)\n\n Fruits: Apples, peaches, pears, watermelon, cherries, figs\n\n Vegetables: Garlic, onions, leeks, asparagus, cauliflower or large servings (more than \u00bd cup) of broccoli and Brussels sprouts\n\n Grains: Wheat (except in sourdough bread), rye, barley\n\n Legumes and nuts: Cashews, kidney beans, soy beans and soy milk\n\n Sweeteners: Honey, fructose, xylitol, agave syrup\n\nFoods to include \n\n Dairy and dairy substitutes: Kefir, almond milk, coconut milk\n\n Fruits: Bananas, blueberries, grapes, oranges, strawberries\n\n Vegetables: Carrots, green beans, bell peppers, potatoes, tomatoes\n\n Grains: Rice, oats, gluten-free bread (but check labels for high-FODMAP ingredients)\n\n Legumes and nuts: Peanuts, pecans, walnuts\n\n Sweeteners: Cane sugar, aspartame, stevia\nIt\u2019s not known if the diet leads to any nutritional deficiencies or keeps working in the long run \u2014 especially for patients who get little support from doctors or dietitians.\nWhen patients do make their way to Kate Scarlata, a Boston area registered dietitian who specializes in the diet, the first thing she tells them is that it \u201cis a dietary experiment.\nBut few dietitians are trained in the diet, and insurers typically do not cover the visits, Lacy notes.\n\u201cPhysicians are largely administering the diet by giving patients sheets of paper with foods to exclude,\u201d Chey says.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story notes that health insurance is unlikely to cover the costs of a clinic visit with a dietitian to discuss the proper implementation of the diet, but it fails to offer an estimate of what that out-of-pocket cost might be. The story could have offered an estimate on how other approaches to IBS treatment, such as medications or probiotics, might stack up. And since food manufacturers are apparently already offering low-FODMAP products, the story would have helped readers by indicating whether those products are more costly than their \u201cregular\u201d counterparts.", "answer": 0}, {"article": "A minimally invasive procedure designed to shrink prostate tissue with a series of nine-second blasts of steam offers men a new treatment for urinary symptoms commonly associated with enlarged prostates.\n\nThe procedure, called Rez\u016bm (pronounced \u201cresume\u201d) and developed by NxThera Inc. of Maple Grove, Minn., became widely available in the U.S. in the second half of 2016. Thermal energy in the form of steam is applied to the prostate with a needle. As it cools it releases heat energy into the tissue, killing cells and shrinking...", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does a good job here, noting that a treatment with Rez\u016bm costs around $2,000, and that it is often (but not always) covered by health insurance. In addition, the story notes that patients may need multiple treatments.\nAs a side note, we would like to know how this compares with costs of surgery and with costs of other minimally invasive procedures.", "answer": 1}, {"article": "Pneumonitis was more frequent among patients who were not actively using ace-inhibitors (Odds Ratio (OR) = 3.49, p = 0.02) and less frequent in smaller tumors (OR = 0.03, p < 0.01).\nThe advanced form of radiation therapy (RT) was well tolerated among this relatively understudied elderly population, indicating that SBRT is a viable option for patients who may otherwise be offered no curative treatment.\nRecursive partitioning analysis (RPA) was conducted to determine which patients were most likely to benefit from therapy.\n\u201cElderly patients, who are otherwise doing well, should not have treatment withheld based solely on concerns about side effects and age.\u201d\n\nThe abstract, \u201cStereotactic body radiotherapy for early stage non-small cell lung cancer in patients 80 years and older: A multi-center analysis,\u201d will be presented in detail during the poster session at the 2017 Multidisciplinary Thoracic Cancers Symposium in San Francisco (full details below).\nAbstract and Presentation Details\n\u2022 Stereotactic Body Radiotherapy for Early Stage Non-Small Cell Lung Cancer in Patients 80 Years and Older: A Multi-Center Analysis\n\u2022 News Briefing: Friday, March 17, 1:00 \u2013 1:45 p.m. Pacific time, Foothill F, http://bit.do/thoracic2\n\u2022 Poster Session, Thursday, March 16, and Friday, March 17, Yerba Buena Salons 7 and 8\n\u2022 This news release contains additional and/or updated information from the study author(s).\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release does not report the cost of stereotactic body radiation therapy (SBRT) or any alternatives a patient could consider.", "answer": 0}, {"article": "Besides M.D.\nBut she added that an ongoing study in the United Kingdom involving 200,000 women should more definitively determine the test's value.\nBut none proved as accurate as CA-125 after a Harvard scientist developed a mathematical model combining trends in test results and a patient's age.\nOne expert said the study is an important step but definitely needs follow-up work.\nAmong the study participants was Liz Stegall, who enrolled at the request of the family of Linda Nelson Taylor, a friend who died of ovarian cancer that wasn't diagnosed until it was advanced.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does mention how much the blood test and ultrasound cost. The story could have raised the question of whether this might be too expensive given that thousands of women must be tested in order to find one case of ovarian cancer.", "answer": 1}, {"article": "For more information on the field of anesthesiology, visit the American Society of Anesthesiologists online at asahq.org.\nNewswise \u2014 CHICAGO \u2013 Epidural anesthesia may do more than relieve pain during labor; in some women it may decrease the likelihood of postpartum depression, suggests a preliminary study presented at the ANESTHESIOLOGY\u00ae 2016 annual meeting.\nAdditional research is needed to identify which women are more likely to experience severe labor pain and who would benefit the most from effective labor pain-control strategies to help reduce the risk and affect of pain on postpartum recovery.\n\u201cPostpartum depression can develop from a number of things including hormonal changes, psychological adjustment to motherhood, social support, and a history of psychiatric disorders.\u201d\n\nLabor pain may be more problematic for some women than others, the authors note.\nAnd, therefore, alleviating this pain might help reduce the risk for postpartum depression.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The cost of a birth with an epidural isn\u2019t mentioned. While it depends on the insurance carrier \u2014 some pass all or part of the costs of anesthesiology during birth onto consumers \u2014 the average epidural in the US\u00a0adds about $1,200\u00a0to a birth bill, with some anesthesiologist practices charging\u00a0more than $2,700\u00a0per epidural.", "answer": 0}, {"article": "Dr. Claudia Henschke of New York Presbyterian/Weill Cornell Hospital says CT scans offer hope to many people who are at-risk for the disease, including current smokers, former smokers, and in some cases people were never smokers but exposed to second-hand smoke.\nThat's because standard chest X-rays too often can't spot it until it's too late, reports.\nIf Lazarus hadn't had any studies, says Dr. Harvey Pass of the NYU Medical Center in New York, the tumor would have grown causing pain, cough bleeding and maybe not have been able to be surgically removed.\nIt turned out to be cancer.\nBut doctors decided to use a more sophisticated test \u2014 a CT scan that can detect tumors as small as a kernel of rice.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does mention that the cost of the scan is about $300 and is generally not covered by insurance.", "answer": 1}, {"article": "Asthma patients suffer fewer attacks and need fewer hospital visits.\nThe one-time cost of $20,000, they say, is dwarfed by the tens of thousands of dollars in hospital bills and medication costs that a severe asthmatic can easily accumulate in a single year.\nBut several five-year studies showed no long-term safety issues.\nBut the procedure is expensive, costing around $20,000, and insurers have been reluctant to cover it.\nDr. McEvoy argued that it made economic sense, and earlier this year Health Partners agreed.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story discusses the high price of the procedure and the unwillingness of most insurers to cover it. One could argue that the story is off base when it suggests that the procedure would be highly cost effective, without citing any supporting evidence or allowing a rejoinder from the opposing camp. However, we\u2019ll give the benefit of the doubt here.", "answer": 1}, {"article": "Where did this Ron DeSantis come from? Florida\u0092s governor surprises everyone but himself.\n\nA month into his term, Gov. Ron DeSantis has shattered assumptions that he would govern exclusively from the right. He has drawn unexpected praise from Republicans and Democrats.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The costs associated with liver transplantation were not provided beyond the sense that they were out of reach for a family of modest means without medical insurance.\nThe costs associated with the recommendation that pediatricians include liver testing as a routine part of patient care was also not discussed.\u00a0\nLastly \u2013 there was no discussion of the costs for behavioral treatment programs designed to better enable children and their families lose weight.\u00a0\nAll of these approaches have costs; no such costs were explained. \u00a0", "answer": 0}, {"article": "Involuntary muscle spasms (spasticity) are common symptoms of MS.\n\"Considering the distress and limitations spasticity brings to individuals with MS, it is important to carefully weigh the potential for side effects with the potential for symptom relief, they say in the news release.\nThe researchers say that many existing therapies for this condition are difficult to obtain, ineffective, or associated with intolerable side effects.\nBut subjective assessment of relief of spasticity suggested significant improvement after treatment, they write.\nSide effects varied greatly and depended on the amount needed to limit spasticity, the researchers write.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "If the marijuana extracts are experimental, we could understand why costs might not be mentioned \u2013 which they weren\u2019t.\u00a0 But since the story never explained whether these are available products or not, we have no idea of availability nor of cost.\u00a0 ", "answer": 0}, {"article": "No serious adverse events were reported.\nLarger and longer studies are now needed to prove that the twice-daily pill can also reduce severe asthma attacks, known as exacerbations.\nPills for asthma used to be standard treatment 40 or 50 years ago, but those older products were often associated with worrying side effects.\nAt the same time, many drugmakers are developing improved asthma inhalers, including \u201csmart\u201d devices with sensors that monitor use.\nThey have since been replaced by inhalers that deliver small amounts of drugs directly into the lungs.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not address how much fevipiprant might cost and how it might compete with currently available treatments. A 2013 story in the New York Times reported that asthma inhalers ranged from $50 per month for one of the oldest drugs to as much as $350, with prices being buoyed in recent years by patent extensions.", "answer": 0}, {"article": "A vicious cycle ensues: The heart enlarges, so the mitral valve leaks.\nBut that research included many patients with less severe valve problems, the procedure was not performed as adeptly, and the patients\u2019 medications were not as well optimized as in the new study.\nUntil today, researchers were not sure that fixing the mitral valve would do much to help these patients.\nThe result was to convert a valve that barely functioned into one able to regulate blood flow in and out of the heart.\nA smaller study in France with similar patients failed to find a benefit for the MitraClip.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story reported that \u201cthe device itself costs about $30,000, not counting the cost of the hospital and doctors: a surgeon, an interventional cardiologist and an echocardiologist, among others, all in the operating room.\u201d An idea of the total cost would have been useful, since it\u2019s likely to be far higher than $30k.", "answer": 1}, {"article": "Angioplasty, which uses a balloon to open blocked arteries, has been a popular alternative to bypass surgery in part because it brings less trauma to the patient.\n\"The exactness of bypass surgery is so high that many people are reluctant to do it without tactile as well as visual feedback.\"\nUsing robotics to bypass major blocked arteries and putting stents in other blocked arteries is gaining some currency, Rabbitt said, although few surgeons have come close to Srivastava's familiarity with the robot.\nSrivastava said it is true that the normal sense of touch is missing from robotic work, and that is a shortcoming, but it can be overcome with practice.\nThe maker of the robotic systems, Intuitive Surgical Inc. of Sunnyvale, Calif., is an enthusiastic backer of the University of Chicago's initiative.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The reporter fails to indicate how costs of robot-assisted bypass compare to costs of conventional bypass operations.\u00a0The article\u00a0does not report whether insurance companies pay the additional costs, if any. And since the\u00a0device maker offers a comparison between bypass surgery and stents, the report should\u00a0compare prices\u00a0of stent insertion\u00a0to robot-assisted bypass surgery. ", "answer": 0}, {"article": "Chinese herbal medicine increased IELT by about two minutes, Ayurvedic herbal medicine increased IELT by nearly a minute and topical cream increased IELT by more than eight minutes.\nWhen they were reported, the adverse effects were generally mild, the study team writes.\n\u201cThis is a common condition that has serious psychological effects on relationships,\u201d said Patrick, who wasn\u2019t involved in the study.\nBias was unclear in most of the studies, and only five used stopwatches to measure IELT, which is the \u201cgold standard\u201d for premature ejaculation studies, Patrick said.\nThe improvements were small, and the studies were of varying quality, but preliminary evidence suggests that acupuncture, Chinese herbal medicine, Ayurvedic herbal medicine and a Korean topical cream may all have desirable effects, researchers conclude in the journal Sexual Medicine.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There were no discussions of cost here, apart from the fact that the products in question would likely be available without a prescription and hence, the costs pertaining to a doctor\u2019s visit would not\u00a0be relevant here.", "answer": 0}, {"article": "In skin testing, a practitioner makes rows of pricks on a patient\u2019s back or forearm so allergen-containing extracts can seep into the skin.\nWhile most allergy patients are seen by these generalists, he says, many allergies are not adequately diagnosed.\nDr. Roberts says that if primary-care physicians used the blood test, many more patients would be treated appropriately.\nBecause they were not considered very sensitive, physicians were left with a lasting impression that blood testing was inferior to skin testing.\nBecause the test comes with a small risk of a serious reaction, it should not be performed in very young children and pregnant women, among others.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not mention the cost of the blood test compared to the skin prick test. While it does refer to the contention by some that \"allergists resist blood testing in part to protect their revenue,\" the story does not describe the actual fees surrounding either the blood tests or the skin-prick tests. ", "answer": 0}, {"article": "These studies have been done with people, but other promising research has only been done with lab animals so far. In one 2009 study in the Journal of Medicinal Food, tart cherries helped fat rats. Not our favorite role models perhaps, but the obese beasties' risk of Type 2 diabetes and heart disease were reduced significantly, and parallel studies are now in the works with members of our own species, says lead author E. Mitchell Seymour: \"There are some interesting and potentially exciting results on the horizon. Stay tuned.\"", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The cost of cherries is not in question (although one of our reviewers recently got a spouse-scolding for NOT checking price and coming home with $18 worth of cherries!)", "answer": 2}, {"article": "The U.S. National Institute on Deafness and Other Communication Disorders has more about ear infections in children.\nThe study included 520 youngsters with ear infections.\n\"The results of this study clearly show that for treating ear infections in children between 9 and 23 months of age, a five-day course of antibiotic offers no benefit in terms of adverse events or antibiotic resistance,\" Hoberman said.\nThese infections are the most common reason why children are given antibiotics, the University of Pittsburgh researchers noted.\nThe study was published Dec. 21 in the New England Journal of Medicine.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No mention of costs was included in the news story.", "answer": 0}, {"article": "Bisphosphonates include such common drugs as Fosamax (alendronate), Boniva (ibandronate), Actonel (risedronate) and Reclast (zoledronic acid).\nA randomized trial is need to prove that bisphosphonates are protective against colorectal cancer, Rennert said.\n\"Results from the only other study of bisphosphonate use and colorectal cancer, a recent large study from the United Kingdom, do not support an important protective effect,\" Jacobs noted.\n\"The adverse effects profile is of major importance if bisphosphonates are going to be recommended for cancer prevention in healthy people,\" the study authors cautioned.\n\"The magnitude of the reduced risk is less important because this is an association study; however, it is very significant after controlling for a dozen other known risk factors,\" Rennert said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Unlike the Reuters Health story, this story did not discuss costs. This is a shame because if the monthly cost is $10, as Reuters Health notes, that may be cheap on an individual level. As a public health policy, though, $120 a year across a huge population could add significantly to an already overspent health care system.", "answer": 0}, {"article": "\u201cPatients readmitted after surgery almost always have a postoperative complication, either medical or surgical,\u201d Drs.\nIt might be harder for patients to get appropriate care at the other hospitals, where they don\u2019t have a pre-existing relationship with a surgeon, and so treatment might be delayed, Dimick and Miller wrote.\nDoctors who did not perform the surgery won\u2019t have that context, which may explain part of the survival benefit of returning to the original hospital, he said.\n\u201cA lot of big Fortune 500 companies contract with bigger hospitals for patients undergoing major surgery,\u201d Brooke said, noting the Wal-Mart has contracted with the Cleveland Clinic.\nPatients should try to stay in the immediate vicinity of their surgical hospital for at least a week, Brooke said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Alas, though the story contains some interesting information, it does not explore or speculate as to what the cost would be of returning most patients to an index hospital. It\u2019s possible there would be downstream savings.\nInterestingly, in the U.S. hospitals may face a penalty from Medicare if they have high readmission rates. In that sense, they could have an incentive to discourage patients from coming back to the same institution.", "answer": 0}, {"article": "DURHAM, N.C. - Most high-risk lung cancer patients might not need annual low-dose computed tomography (LDCT) screenings if they are cleared of disease in their initial test, according to a study led by a Duke Cancer Institute researcher.\nThe researchers determined that eliminating the first annual screening after the initial negative test might have resulted in, at most, an additional 28 lung cancer deaths in the LDCT group (186 vs. 212 deaths per 100,000 per years) over the course of the study.\nOf the initial 19,066 participants with a negative initial LDCT scan, 444 (2 percent) were diagnosed with lung cancer at the time of the last available follow-up.\nAn additional 75 patients (0.4 percent of the initial negative group) were diagnosed with lung cancer between the first and second annual screening.\nHe added that improving the accuracy of LDCT screening for lung cancer would also significantly reduce the number of annual screens.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release appropriately mentioned that a changed frequency of screening could save millions of dollars in subsequent screenings and \u201creduced downstream\u201d effects of false positive tests.", "answer": 1}, {"article": "Strawberries have the potential to prevent esophageal cancer, according to a preliminary study released Wednesday.\n\nResearchers, led by Ohio State University, were able to show that freeze-dried strawberries slowed the growth of dysplastic, or precancerous, lesions in about 30 people who consumed the fruit for six months.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Not applicable because the cost of strawberries is not in question.", "answer": 2}, {"article": "In a study suggesting that red wine might be the next big thing in breast cancer prevention, a study has found that women who drank just under two servings of red wine daily experienced hormonal changes that mimic the effects of a drug used to prevent malignant breast tumors from coming back.\n\nThe study, published Friday in the Journal of Women's Health, found that consuming the same amount of white wine did not have the same effect in premenopausal women participating in the study.\n\nWomen intent on warding off breast cancer have been warned about alcohol consumption: as recently as November, a study found that women who consumed as few as three servings of alcohol a week increased their risk of developing the disease, which strikes one in eight American women at some point in life.\n\nWhite wine and other alcoholic beverages are believed to promote the conversion of androgens--\"male hormones\" such as testosterone, which circulate in all women's blood--into estrogen. And the greater a woman's lifetime exposure to estrogen--whether her own or estrogen that comes from medication or environmental sources--the higher her risk of developing breast cancer.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Not applicable.\u00a0 The cost of red wine is not in question.", "answer": 2}, {"article": "A complex and expensive pacemaker-defibrillator can significantly improve the chance for survival among the tens of thousands of heart-failure patients with only mild symptoms, according to a major, multiyear clinical study.\n\nThe research, regarded as likely to change medical practice, showed that the device to \"resynchronize\" the hearts of such patients lowered the death rate by 29% in such patients over 40 months, compared to those who had a standard defibrillator implanted.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "This story was more precise on costs than the LA Times, saying, \u201cThe devices cost up to $35,000, versus the roughly $25,000 cost of a standard defibrillator. Hospital and doctor fees can raise the total cost over $50,000.\u201d Both stories said, vaguely, that \u201cthe cost\u201d of the disease every year is $40 billion. This is confusing to readers for two reasons. One, there is no single payer shelling out $40 billion every year to treat heart failure, and so that number is likely not much more than a very good guess. Two, it leads people to believe that the device, at $50,000 per person, may be a bargain if heart failure right now costs $40 billion to treat. We applaud the Journal for at least raising this issue high in the story. The story cites\u00a0Eric J. Topol, cardiologist and chief academic officer at Scripps Health, saying, the reduced rate of hospitalizations in the study \u201cmay actually present a net reduction in costs from a societal standpoint.\u201d That\u2019s a big what if.", "answer": 1}, {"article": "It also includes UCSF Health, which comprises top-ranked hospitals, UCSF Medical Center and UCSF Benioff Children's Hospitals in San Francisco and Oakland -- and other partner and affiliated hospitals and healthcare providers throughout the Bay Area.\nIn their new study, published online January 13, 2017 in the Journal of Neurotrauma, the researchers used a technique called functional MRI (fMRI), coupled with sophisticated statistical analysis, to track activity in the brain networks of 75 patients, aged 18 to 55, within the first two weeks of their having experienced concussions.\nThe fMRI method and analysis developed for the study highlighted abnormal patterns of brain activity that pointed to a higher risk for long-term, post-concussive symptoms, even among the 44 study participants who had no evidence of bleeding or bruising in the brain in the immediate aftermath of brain trauma on computed tomography (CT) or ordinary MRI scans.\n\"This is an exploratory, proof-of-concept study showing that we can identify patients soon after mild brain trauma who may have more persistent symptoms, despite no other evidence of injury within the brain,\" said Pratik Mukherjee, MD, PhD, professor of radiology and biomedical imaging at UCSF and the senior author of the study.\nFor concussion sufferers, even those who never lost consciousness, physicians may now be able to predict early on who is more likely to continue experiencing symptoms months or years after the head-jarring event, using a new non-invasive magnetic resonance imaging (MRI) method devised by a consortium of researchers led by UC San Francisco scientists.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Medical imaging studies are known to be expensive, and MRIs are no exception.\u00a0Functional magnetic resonance imaging (fMRI) is a relatively new procedure that uses MRI techniques to measure metabolic changes in an active part of the brain. MRIs focus on a body part\u2019s anatomical structure, while fMRIs mainly concentrate on its metabolic processes.\nConsumer websites estimate an MRI to cost between $400 and $3,500, depending on the type of procedure, body part\u00a0and center location. According to the Healthcare Bluebook, a brain MRI (with or without contrast) should cost around $1,212.\nSince the news release doesn\u2019t discuss these costs, we give it a Not Satisfactory rating here.", "answer": 0}, {"article": "The study, conducted at the University of Texas M.D.\nPrevious research into diet and breast cancer has shown mixed results, but the authors of this study said the earlier ones were not rigorous.\nThe findings, published in today's Journal of the American Medical Association, are a setback to the hope that better diets can prevent breast cancer recurrence.\nAnderson say a healthy diet, exercise help ward off its recurrence\n\nA healthy diet and exercise help prevent the return of breast cancer, but meals loaded with fruits and vegetables provide no extra benefit, according to a new study.\nAn earlier analysis of the study concluded that women who ate five servings of fruit and vegetables and exercised 30 minutes a day had significantly improved cancer-free survival.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There was no discussion about the costs associated with including fruits and vegetables in the diet, although it\u2019s reasonable to assume that the reader could figure out the costs.", "answer": 2}, {"article": "This type of drug development program, which enrolled patients with different tumors but a common gene mutation, wouldn\u2019t have been possible a decade ago because we knew a lot less about such cancer mutations,\" said Dr. Gottlieb.\nIts approval reflects advances in the use of biomarkers to guide drug development and the more targeted delivery of medicine.\"\n\"This new site-agnostic oncology therapy isn\u2019t specific to a cancer arising in a particular body organ, such as breast or colon cancer.\n\"Using our breakthrough therapy designation and accelerated approval processes, we support innovation in precision oncology drug development and the evolution of more targeted and effective treatments for cancer patients,\" the FDA stated.\nFor the second time, the U.S. Food and Drug Administration has approved a drug that, instead of targeting tumors by location\u2014breast cancer, prostate cancer, lung cancer\u2014attacks cancers according to specific genetic structures, known as biomarkers.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Surprise \u2014 or at least it will be to readers of this Newsweek story: The list price of the drug is nearly $400,000 a year, as a more complete story in Forbes reported. The company marketing the drug said it will help patients pay their share of the cost.", "answer": 0}, {"article": "Brown rice is a whole grain \u2014 white rice before it has been refined and polished and stripped of the bran covering, which is high in fiber and nutrients.\nBut, Dr. Sun said, there were many possible explanations for why brown rice eaters are at lower risk for Type 2 diabetes.\nBut the Harvard study is one of the first to distinguish between brown rice and white rice consumption in the United States, where rice is not a staple food and relatively little is eaten overall, said Dr. Qi Sun, an instructor in medicine at Brigham and Women\u2019s Hospital, which is affiliated with Harvard Medical School.\nJust replacing a third of a serving of white rice with brown each day could reduce one\u2019s risk of Type 2 diabetes by 16 percent, a statistical analysis showed.\nSuch food studies can be unreliable, since they rely on self-reported surveys.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "We\u2019ll rule this not applicable, because, while there was no discussion of how the cost of white rice and brown rice compare, most people probably have a sense of the price ballpark.\u00a0 However, we have seen Chinese restaurants that charge extra for brown rice. ", "answer": 2}, {"article": "NEW YORK (Reuters) - The U.S. Food and Drug Administration approved on Tuesday the sale of Amgen Inc\u2019s osteoporosis drug Prolia to help prevent fractures in post-menopausal women just days after the medicine received European approval.\nAmgen said the drug will be available within the next two weeks and cost $825 per 60 milligram injection based on wholesale acquisition cost.\nThe approval comes with a risk evaluation and mitigation strategy (REMS) that includes a medication guide for patients and information for healthcare providers that explains the risks and benefits of the drug, the FDA said.\nAn analysis of data combined over multiple U.S. health plans showed approximately 50 percent of patients discontinue oral bisphosphonate therapy within the first year, Amgen said.\nAmgen last month applied for U.S. approval to market the drug for reduction of fractures and other skeletal-related problems in patients with advanced cancer.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "According to the story, each injection is estimated to cost $825 and people will require two injections\u00a0per year. There is no mention of whether insurance companies will cover the cost, particularly since cheaper drugs for osteoporosis are available.\u00a0", "answer": 1}, {"article": "It will also help remove the uncertainty surrounding which sub type of the disease an individual has and therefore be a catalyst for better outcomes for all people with MS.\"\n\nMultiple Sclerosis (MS) is a chronic inflammatory demyelinating disease of the central nervous system (CNS).\nPublished today in Scientific Reports, the discovery identifies tiny 'dysregulated' micro-RNA molecules that correctly diagnose MS and discriminate between patients at different disease stages - all in a simple blood test.\nMS is a chronic disease, so current diagnostic and monitoring tests are costly and still have limited utility to discriminate between different stages of the disease.\nThe research team assessed the utility of microRNAs (miRNA) in serum (blood) exosomes as biomarkers of MS disease.\nA breakthrough study led by the University of Sydney's Brain and Mind Centre and Royal Prince Alfred Hospital has revealed unique molecules in the blood of people with Multiple Sclerosis (MS) that could become definitive diagnostic biomarkers of the world's most common neurologic disability in young adults.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Although this research is basic stuff, a source in the release is already talking about its diagnostic value. Claims of that sort should be accompanied by at least cursory information about possible cost.\nIn reality, this test is so far from clinical use that estimating cost would be difficult.", "answer": 0}, {"article": "Newswise \u2014 Columbus, OH.\nEarly results, which were presented at the Wound Healing Society\u2019s Annual Meeting in April 2016 indicate that infected wounds covered by the experimental bioelectric dressing healed better and more quickly than those covered with a plain dressing that is commonly used in the care of wounds today.\nThe patch\u2019s design significantly advances existing FDA-approved wireless electroceutical dressing (WED) that harnesses the body\u2019s innate response to injury to help wounds heal.\nA team of researchers at The Ohio State University has brought a potentially transformative solution to the problem by creating a portable adhesive patch that drives a continuous, small electrical current to stimulate healing and reduce the risk of infection.\nThe team\u2019s next move is to focus on the bioelectric bandage as a treatment for chronic wounds in a patient population; however, the technology could also be used to treat acute injuries.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "In general, if a product is\u00a0far from deployment, an\u00a0estimate of its cost\u00a0could seem\u00a0premature. However, this release contains the following statement:\n\u201cThe patch\u2019s design significantly advances existing FDA-approved wireless electroceutical dressing (WED) that harnesses the body\u2019s innate response to injury to help wounds heal.\u201d\u00a0\nAnd if it\u2019s not too soon to make a declaration like that, it\u2019s not too soon to estimate what the cost might be. The release might have looked to the cost of existing FDA-approved WEDs to suggest an estimate. For example, this 2015 article on WED in Advances in Wound Care journal by Ohio State University researchers suggests a cost-savings over other wound care methods by reducing the number of dressing changes required per week.", "answer": 0}, {"article": "If necessary, he suggests finding an indoor place to move, whether it's the gym, a staircase or a shopping mall.\n\"Just 30 minutes a day of walking, riding a bike, doing yoga -- anything active, really -- can result in significant reduction of asthma symptoms.\"\nFortunately, new research shows there is a simple antidote: 30 minutes of exercise a day, year-round.\n\"It would be great to see physicians recommending physical activity to patients with asthma, alongside traditional pharmacological treatments,\" he says.\nIt's something to keep in mind during winter months, when fitness levels tend to drop along with the temperature, and cold air provides another trigger for asthma symptoms.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Physical activity was broadly defined in the study and included activities such as walking, dancing and swimming. We rate this Not Applicable, since cost is not a major factor here. But we need to keep in mind that this piece was recommending 30 min per day of activity. That\u2019s 3.5 hours per week. This is time that could be spent doing other things (including paying work) and there may be a cost \u2013 either positive or negative \u2013 associated with it. In theory, if exercise does in fact reduce asthma symptoms, one could argue that patients with asthma who exercised would have lower costs of care for things such as emergency visits. But this, of course, is unproven.", "answer": 2}, {"article": "The F.D.A.\nThe review for Medicare said there was insufficient evidence to judge whether Provenge would work if used off-label.\nBut the analysis for Medicare said that there were issues in how the trials were designed that made it difficult to assess how effective Provenge really was.\nThe analysis is part of a controversial review by the Centers for Medicare and Medicaid Services to determine whether to pay for Provenge, which costs $93,000 per patient and extended lives by about four months in clinical trials.\nThere is only \u201cmoderate\u2019\u2019 evidence that the newly approved prostate cancer drug Provenge helps patients, according to an analysis done for Medicare that was made public on Wednesday.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story appropriately reports that Provenge treatment costs $93,000 per patient and is satisfactory based on the criterion. However, the costs should ideally be put into context and compared to alternative treatments. An editorial published along with the Provenge trial in the New England Journal of Medicine noted the costs of alternative treatment is $1,800 per patient.", "answer": 1}, {"article": "Newswise \u2014 Bethesda, Md.\nThe article is published ahead of print in the American Journal of Physiology\u2014Gastrointestinal and Liver Physiology.\nIn some studies, the research team found that statins reduced inflammatory molecules that are typically elevated with liver disease and improved inflammation in the endothelium (cells that line the blood vessels).\nNOTE TO JOURNALISTS: To schedule an interview with a member of the research team, please contact the APS Communications Office or 301-634-7209.\nThe Society represents more than 10,500 members and publishes 15 peer-reviewed journals with a worldwide readership.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There is no information about the cost of statin therapy. This class of medicines includes a number of generic formulations that are relatively inexpensive. The release refers to statins as cost-effective. This reference to cost probably refers to their use for preventing heart disease. Whether these agents are cost-effective for treating liver disease is unknown.", "answer": 0}, {"article": "Some doctors are raising concerns about a new cancer-treatment device that uses electrical jolts to zap tumors but that hasn't been through a large clinical trial to prove it's safe and effective in people.\n\nThe device, called NanoKnife, is currently being used in about 13 U.S. hospitals including Baptist Health Medical Center in Little Rock, Ark., University of Louisville, and Shands Hospital/University of Florida in Gainesville, Fla. Each machine costs as much as $300,000. Some of the hospitals are aggressively promoting...", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story says that each machine \"costs as much as $300,000.\" It does not provide a per-treatment cost, which would have been nice. It does say, though, that \"Medicare doesn\u2019t specifically pay for use of the NanoKnife, though hospitals and doctors get reimbursement under more general medical-treatment billing codes. Some private insurers, including Arkansas BlueCross BlueShield, decline to cover its use because of the lack of \"scientific evidence of effectiveness in improving health outcomes.\"\"", "answer": 1}, {"article": "A study of a proposed diabetes drug, Januvia, from Merck & Co. showed it lowered a key measure of blood sugar when taken in combination with another common diabetes drug.\n\nThe study, due to be presented Thursday at the European Association for the Study of Diabetes in Copenhagen, involved 1,056 patients diagnosed with Type 2 diabetes who hadn't previously been treated with diabetes medications.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not mention projected costs for the new drug. The story could have provided some insight into the costs of available drugs to treat Type 2 diabetes. The likelihood of this new drug in combination with metformin being less exepnsive than available drugs is very low. ", "answer": 0}, {"article": "April 18, 2011 -- The FDA has approved a new noninvasive portable device for the treatment of a deadly type of brain tumor. The device uses electrical fields to slow and possibly reverse tumor growth.\n\nThe device, manufactured by Novocure, is called the NovoTTF-100A System and is meant for adults with glioblastoma multiforme that recurs or progresses after chemotherapy and radiation treatment.\n\nGlioblastoma multiforme is a common type of brain cancer, and the tumor is highly resistant to standard treatments, such as surgery, radiation, and chemotherapy, the FDA says in a statement.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "NO discussion of costs \u2013 even though the story allowed a company spokesman (from a news release) promote the potential for the device.\u00a0 Why not ask that company directly for the cost?", "answer": 0}, {"article": "Inflammation occurs when the body is exposed to pathogens, such as bacteria or viruses, which puts the immune system in overdrive until the \"attack\" ceases and the inflammatory response abates.\nWhile IL-6 has normal functions in the body, elevated levels are associated with an increased risk of developing certain cancers and diabetes and may be implicated as a cause of depression, Duggan said.\nHalf of the study participants were randomly selected to receive 2,000 IU of vitamin D daily for the duration of the year-long trial, and the other half received an identical-appearing placebo, or dummy vitamin.\nBiomarkers of inflammation were measured at the beginning and end of the study.\n\"We were quite surprised to see that vitamin D had an effect on an inflammation biomarker only among women who lost at least 5 percent of their baseline weight,\" Duggan said.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There was no mention\u00a0of the potential costs of screening women for vitamin D levels (as encouraged in the release in a statement from the principal investigator) or the cost of supplementation.", "answer": 0}, {"article": "During such a surge, healthy vessels dilate, or relax, but unhealthy ones stiffen and narrow, impairing blood flow and indicating possible incipient heart disease.\nSuch fatty, low-carbohydrate Atkins-type diets are well established as a means of successful weight reduction, Dr. Stewart said.\nStill, the early results are thought-provoking.\nThe volunteers, all of whom exercised, generally became more physically fit during the study, Dr. Stewart said.\n\u201cThose on the high-fat diets showed no harmful impacts\u201d after 45 days or so, she said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There was no information about costs but a motivated reader reader could calculate this.\u00a0 However, it\u2019s worth noting that long-term costs of following a restrictive diet are not inconsequential.", "answer": 2}, {"article": "To make sure it works, though, the Centers for Disease Control and Prevention says doctors need to do a number of things:\n\u2022 Prescribe Truvada only for men at high risk of getting infected \u2013 that is, only for men who have sex with men, those who have multiple sex partners, and those who live in areas where there's a lot of HIV circulating.\n\u2022 Above all, tell patients they must take the drug every day \u2013 not just when they've had risky sex.\nThe pill, called Truvada, is already on the market for treating HIV infections.\nNow health officials are warning doctors that preventing the disease will take more than just writing a prescription.\nBut those who said they took the drug at least 9 out of every 10 day had a 73 percent lower risk.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Strong point.\u00a0 The story said, \u201cThere\u2019s one other thing, the CDC says. Make sure patients understand that warding off HIV isn\u2019t cheap. Each pill currently costs around $36, which adds up to more than $13,000 a year. Some insurers might pay, but some might balk\u201d", "answer": 1}, {"article": "\u2022 4.9 million babies are born with a serious birth defect worldwide every year\n\u2022 3.3 million children under five die from serious birth defects annually\n\u2022 Congenital heart disease is the most common form of birth defect, affecting 1 in 100 babies\n\u2022 42 babies are born with a heart defect in Australia every week\n\u2022 30 babies will undergo heart surgery in Australia every week\n\u2022 Heart defects account for 30% of deaths in children under five\n\n[1] Baker H, DeAngelis B, Holland B, Gittens-Williams L, Barrett T Jr. Vitamin Profile of 563 Gravidas during Trimesters of Pregnancy.\nThis discovery is akin to the revolutionary breakthrough made last century that confirmed folic acid supplementation can prevent spina bifida and other neural tube defects in babies.\nAt the heart of the paramount discovery is the dietary supplement vitamin B3, also known as niacin.\n\u201cJust like we now use folate to prevent spina bifida, Professor Dunwoodie\u2019s research suggests that it is probably best for women to start taking vitamin B3 very early on, even before they become pregnant.\nhttp://www.nejm.org/\n\nThis study would not have been possible without the generous support of the Chain Reaction Foundation, the Key Foundation and the National Health and Medical Research Council.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The cost of the supplement (vitamin B3, also known as niacin) is not mentioned. A quick Google search shows that you can buy it online for less than $10. ", "answer": 0}, {"article": "An enzyme is a protein that performs a chemical reaction.\nSome experts identified limitations to the research.\nA new study, however, offers some potential for hope.\nBut this could take a few years to develop.\nThe re-engineered enzyme, named KumaMax, appears to be highly effective, at least in a test tube.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "We\u2019ll rate this not applicable since the concept is obviously still in the very early stages of development.", "answer": 2}, {"article": "For example, blood pressure (BP), not only tends to increase but as well become more irregular.\nNone of these effects was found in 34 placebo treated seniors, thus ruling out the possibility that rhythms could be improved just because of regular schedule and presence of medical personal who took measurements.\nThe present study was aimed to investigate whether such changes can be reversed by daily melatonin ingestion.\nThe hypotensive effect was dependent on time.\nIn conclusion, melatonin can be of great value for aged people suffering from hypertension as an adjuvant substance complementing basic medication as it is able to stabilize circadian BP, heart rate profiles and their phase relationships.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release doesn\u2019t mention cost. Melatonin is widely available over-the-counter and a range of costs should be reported. According to GoodRX, a bottle of 100 1mg melatonin tablets cost around $7.\n(We acknowledge that the study was conducted in a country that has a different health system including different price supports. But since the news release is aimed at a U.S. audience, the cost criteria \u2014 as well as availability and alternatives that apply in the US but not elsewhere \u2014 are fair game.)", "answer": 0}, {"article": "More: The hidden side of dementia: Families fight over care, end-of-life decisions, finances, estates\n\nDementia is a term used to broadly describe symptoms of cognitive decline; Alzheimer's disease is the most common cause of dementia.\nIf the vaccine proves safe and effective in humans, it could slice the number of dementia diagnoses in half, the study's senior author told USA TODAY.\nDoris Lambracht-Washington, a professor of neurology and neurotherapeutics at the University of Texas Southwestern Medical Center, said researchers believe the vaccine could extend lives by preventing the disease from developing.\nAn experimental vaccine that could hold off Alzheimer's disease showed promising results in animal testing, according to researchers at the University of Texas Southwestern Medical Center.\nPrevious attempts to find an Alzheimer's vaccine either caused harmful side effects, such as brain inflammation, or used less effective approaches, she said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There\u2019s no discussion of costs.\nIt might be difficult to estimate the cost of a vaccine that hasn\u2019t yet been tested in humans. However, the story could have pointed out that at least some researchers have begun to consider the financial impact of treatments that are in development to slow or delay Alzheimer\u2019s.\nFor example, British study released in March estimated that a hypothetical vaccine given to everyone over 50 that delayed the onset of Alzheimer\u2019s by five years would yield a savings of about $9,000 in health, social care, and unpaid care costs over a person\u2019s life. It estimated that the justified cost of such a vaccine, if it had to be given every two years, would be $1,175 per dose. However, those figures would drop to a lifetime savings of $2,200 and a justified cost of $293 per dose if the vaccine delayed onset of disease by just one year.", "answer": 0}, {"article": "\u201cPeople who smoke a pack of cigarettes a day are chronically inflaming their lungs,\u201d he says.\nWhen it comes to heart disease, however, it\u2019s clear that inflammation-fighting medications like canakinumb may represent the next generation of treatment.\nBut whether anti-inflammatory agents, like canakinumab, or even over-the-counter drugs like aspirin, should be part of standard cancer treatment isn\u2019t clear yet.\n\u201cThis all makes sense to me.\u201d Studies have already shown, for example, that inflammation may be a factor in prostate cancer and colon cancer.\nThe inexpensive CRP test could identify those with higher inflammation, who might be candidates for taking a drug like canakinumab.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story makes clear enough that far more must be done at the bench and bedside to bring this drug into first line use, even for subsets of people who already have had heart attacks or who have cancer. One reason is the $200,000 per year price tag already in place for the drug\u2019s use in some rare autoimmune disorders tied to its anti-inflammatory effects. The pricing challenges are a substantial and enlightening part of the Reuters treatment of the study, which we also reviewed, but nowhere to be found in this TIME article.", "answer": 0}, {"article": "Pancreatic cancer is the fourth leading cause of death from cancer in the United States.\nPart of the group was given gemcitabine, the most favored treatment according to oncologists.\nOnly about 6 percent of those with the diagnosis live longer than five years.\nThe other patients were given a combination of four chemotherapy drugs, (oxaliplatin, irinotecan, fluorouracil and leucovorin) known as FOLFIRINOX.\nInvestigators concluded that although the FOLFIRINOX did improve survival rates over gemcitabine, the toxicity of the drug combination caused numerous negative side effects.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No discussion of costs.\nOne of the online commenters on the CNN website wrote:\n\u201cWhat is the cost for these treatments? How long would the person live with no chemotherapy, just drugs for pain management? If a person wants to pay for these treatments on their own dime that\u2019s one thing. But as a society that shares limited resources for health care can we really afford to spend inordinate amounts to prolong a person\u2019s life a couple months? Not heartless, just pragmatic.\u201d\nAnother wrote, in response:\n\u201cI was one who was fortunate enough to be on Gemcitabine (at $2,000 per prescription for 6 weeks) after a whipple and radiation. That was almost 7 years ago. I have been able to further my education, re-marry, and watch my young son grow into a young adult.\u201d\nYet the story itself was silent on costs.", "answer": 0}, {"article": "The amygdala processes incoming emotionally salient stimuli, whereas the prefrontal cortex, as the executive center of the brain, decides whether the incoming stimuli are noteworthy.\nThe initial results demonstrate that the efficacy of this digital therapeutic is comparable to drug therapy, with a highly favorable safety profile.\nThis treatment was developed at the Icahn School of Medicine at Mount Sinai by Brian Iacoviello, PhD, an Assistant Professor of Psychiatry who is Director of Scientific Affairs for Click Therapeutics, and Dennis S. Charney, MD, Anne and Joel Ehrenkranz Dean and Professor of Psychiatry, Neuroscience, and Pharmacological Sciences.\nThe Clickometrics\u00ae adaptive data science platform continuously personalizes user experience to drive cognitive and behavioral outcomes.\nMSIP is responsible for the full spectrum of commercialization activities required to bring the Icahn School of Medicine's inventions to life.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There is no mention of costs. The release would have been stronger if it allowed readers to see the economic context of this new therapy.", "answer": 0}, {"article": "The disease causes patches of thick, red, inflamed skin that have silvery scales.\nThe current study included 317 people with moderate to severe psoriasis.\nFor people living with psoriasis, Bebo said the message from this study is that \"dramatic progress has been made from where we were just five years ago.\"\nAt the time, Abbott withdrew its application for approval from the U.S. Food and Drug Administration pending further research.\nOf the increased infections and cancers, Reich said, \"Although these differences were not statistically significant, they lead to questions regarding a favorable risk-benefit profile of the drug.\"\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "We also would have liked to have seen some comment on the costs of biologic drugs in the treatment of psoriasis. These drugs can cost $1,500-2,000/month. We think that any discussion about a new drug should include some comment about costs", "answer": 0}, {"article": "The I.V.\nThe author, Dr. Alan Gaby, has long promoted the use of intravenous vitamins for a wide range of clinical conditions.\nBut as for whether they\u2019ll help a client prepare for an important presentation?\nOne didn\u2019t turn up any significant improvement in patients who received the infusions.\nA longitudinal study would be needed to back those claims with evidence, she added.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story provides the retail price for the supplements described in the story.\u00a0 (Between $325 and $875 for an infusion.)\u00a0That\u2019s great, but it would have been even better to know the mark-up. How much the ingredients cost vs. how much is charged to the patient? And does insurance cover this, ever?", "answer": 1}, {"article": "Moderate-fat diet with one avocado a day lowered 'bad' cholesterol by 13.5 mg/dL\n\nThe researchers found that participants' levels of low-density lipoprotein (LDL) - referred to as the \"bad\" cholesterol - were an average of 8.3 milligrams per deciliter (mg/dL) lower after following the lower-fat diet without an avocado and 7.4 mg/dL lower after following the moderate-fat diet without an avocado, compared with their baseline average.\nStill, the team believes their findings indicate that people should consider replacing saturated fatty acids in their diet with healthier fats from avocados and other sources.\nAlthough these findings demonstrate that an avocado a day alongside a moderate-fat diet has the potential to reduce bad cholesterol, the team notes that their research was a controlled feeding study.\nOur Knowledge Center article on the health benefits of avocado reveals some of the other ways the food may be good for us, as well as the potential risks of avocado consumption.\nWhat is more, the team found that a number of additional blood measurements - such as total cholesterol, small dense LDL, triglycerides and non-HDL (high-density lipoprotein) - were better after participants followed the moderate-fat diet with one avocado a day, compared with the other two diets.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The article does not mention a direct price for avocados, but it does mention that avocados tend to be expensive in many parts of the country at certain times of the year.", "answer": 1}, {"article": "A popular new type of prenatal test intended to find genetic flaws in a fetus can in rare cases also reveal previously undiagnosed cancer in the mother.\n\nThe unexpected finding emerged in a study involving eight women who initially had abnormal results from the prenatal blood test, but for whom a subsequent assessment showed their babies were normal. When the mothers\u2019 DNA was reanalyzed, researchers said, the anomalies were linked to cancer in each of the women.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Although the story does not explicitly note the cost of the two commercially available tests, it does provide substantial context about the rising popularity of the tests among clinicians and pregnant women, as well as cautionary notes about their use from both those involved in the study and an expert who wrote an accompanying editorial to the JAMA article.", "answer": 0}, {"article": "Neurostimulation works by sending low-intensity electrical impulses to targeted portions of the spinal cord.\nThere is considerable data showing connections between the brain, nervous system and heart, said Torre, but until now, no one has attempted to take advantage of the relationship therapeutically.\nTorre said though patients may feel some euphoria in the early days, it likely will take about a month before doctors have a good idea whether the therapy is working.\nIf the experiment proves successful, it would provide an entirely different approach to heart failure, a chronic, progressive disease that affects nearly 6 million Americans.\nBecause new drugs can only be tested on top of existing therapy, introducing potentially better drugs is difficult.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There was no discussion of costs. With an approach that is this early in its development, we probably can\u2019t expect an accurate price tag on this particular device. Nevertheless, to provide some context, the story could have easily offered information about the cost of\u00a0similar neurostimulation devices used to treat pain\u00a0and urinary incontinence.\u00a0", "answer": 0}, {"article": "SAMe may influence the expression of genes involved in depression or alter the function of different receptors and structures that transport neurotransmitters in the brain.\nDr. Nelson, who was not involved in the Harvard study, said the results need to be replicated in a larger study, and that more information is needed on dosing, side effects and long-term treatment with SAMe, among other things.\nThat\u2019s probably the best hypothesis.\u201d\n\nOther studies have suggested that SAMe can relieve symptoms of depression.\nThe research offers hope to patients who haven\u2019t been helped by traditional antidepressant treatment.\nDr. Papkostas, Dr. Nelson and other researchers involved in the study all disclosed several financial relationships with makers of prescription antidepressants.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There\u2019s a nice summary of costs and lack of insurance coverage, citing the editorial.\n However, we were surprised to see in this summary that \u201cthe cost is relatively low\u201d when the cited editorial states \u201cSAMe is relatively expensive.\u201d This mistake may have been unintentional, and while it\u2019s the exact opposite conclusion of the one in the source, we are inclined not to dock the article a point because the rest of the summary provides balance about copays and, most importantly, tells its readers the absolute monthly cost of the supplement.", "answer": 1}, {"article": "The findings, presented on Sunday at a meeting of the American Academy of Allergy, Asthma and Immunology in Washington, suggest that a treatment for peanut allergy may be developed in two or three years, said Dr. Wesley Burks, the chief of the division of pediatric allergy and immunology at Duke University Medical Center, who helped conduct the research.\nWhile drugs can be used to treat an allergic reaction, there are no approved treatments for food allergies.\nA medically supervised daily dose of peanuts may help children with peanut allergies greatly increase their tolerance to the food, according to two new studies that raise the possibility of a cure for this potentially life-threatening condition.\nNearly half of the 150 deaths attributed to food allergies each year in the United States are caused by peanut allergies, according to Duke University.\nAn estimated 12 million Americans suffer from food allergies, including about 2.2 million children.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Discussing costs isn\u2019t particulary relevant with this approach and at this early stage of research. ", "answer": 2}, {"article": "The results were striking.\n\u201cThere is a body of literature that argues that the whole approach to studying acupuncture doesn\u2019t lend itself to the Western reductionist scientific method.\u201d\n\nBut the study\u2019s lead author, Dr. Maria E. Suarez-Almazor, notes that the sham treatment was developed with the help of trained acupuncturists.\nRather than proving that acupuncture does not work, in other words, the study may suggest that it works even when administered poorly.\nThe researchers, who published their findings in Archives of Internal Medicine, speculated that inserting needles in or around an area of pain may have caused a \u201csuper placebo\u201d effect, touching off a series of reactions that changed the way the body experienced pain.\nThis year, researchers at Henry Ford Hospital in Detroit solved the problem of creating a sham acupuncture treatment: they didn\u2019t have one.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "      \n\n\n \n\n \nThe article didn\u2019t address costs or reimbursement issues.\n If acupuncture could be shown to be efficacious for common health conditions, its relatively low cost could be viewed as a major selling point in a world of spiraling treatment expenditures.\n ", "answer": 0}, {"article": "Toxins produced by bacteria, such as salmonella, can severely harm the digestive system by damaging nerves critical to healthy gut function.\nThe tests, created by Mark Pimentel, MD, director of the GI Motility Program and Laboratory, confirm when a patient has developed IBS because of food poisoning, a major cause of the disorder.\nThe new blood tests identify the presence and amount of specific antibodies reacting to the toxins.\nFor more information on IBS and the new blood test for the disorder, watch this video:\n\nFirst Ever Blood Test for IBS\n\nCedars-Sinai has entered into an exclusive license agreement with Commonwealth Laboratories for several patent applications covering the blood tests, developed by Pimentel to detect both anti-CdtB and anti-vinculin antibodies in the diagnosis of irritable bowel syndrome and inflammatory bowel disease.\n\"The fact that we can now confirm the disease through their blood, not their head, is going to end a lot of the emotional suffering I have seen these patients endure.\"\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The story does not address the cost of the IBS diagnostic tests at all. A consumer website for the tests, which are sold by Commonwealth Laboratories Inc., also did not include information about the cost of the tests.", "answer": 0}, {"article": "New York Eye and Ear Infirmary of Mount Sinai is ranked No.\nThis is the first study to demonstrate that among advanced cancer patients admitted to an inpatient oncology service, standardized use of triggers for palliative care consultation is associated with substantial improvement on multiple quality measures.\nPublished today in the Journal of Oncology Practice, the study also determined that a systemized process of referrals resulted in significant improvements in 30-day readmission rates, hospice referral, and receipt of chemotherapy after discharge in patients with advanced cancers.\nConsultation with the palliative care team included establishment of goals of care, advance care plans using standardized communication protocols, transition planning and symptom assessment and treatment using the Edmonton Symptom Assessment Scale (ESAS).\n\u201cPalliative care involvement helps patients understand their prognosis, establish goals of care, and formulate discharge plans in line with those goals, and this study is the first to confirm the impact of using standardized criteria and automatic palliative care consultation on quality of cancer care.\u201d\n\nCo-authors of the study include Kerin Adelson, MD, Division of Hematology/Oncology at Yale University School of Medicine.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The news release makes several general statements about the costs of not referring patients early to palliative care.\nIt\u2019s not clear whether the cost savings at a large hospital like Mount Sinai would carry over to smaller hospitals across the country that might not have the requisite staff already in place. Additionally, a\u00a0statement about the implications of costs incurred by patients for early palliative care would improve the release.", "answer": 1}, {"article": "\"This is the first study looking at women who have failed so many other treatments,\" Krop tells WebMD.\nThe new drug, called T-DM1, combines Herceptin with a potent chemotherapy drug.\nIt's a Trojan horse approach, where Herceptin homes in on cancer cells and delivers the cancer-killing agent directly to its target.\nThe findings were presented at the San Antonio Breast Cancer Symposium.\nThey had been treated with an average of seven different therapies, including Herceptin, Tykerb, and Xeloda, and each had failed.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Costs are not mentioned in the article. As the expense of Herceptin (trastuzumab) alone has come up in public discourse, such as in this Atlantic\u00a0article, it stands to reason that a novel compound including trastuzumab would have economic considerations.", "answer": 0}, {"article": "One found improvement in infants given fennel extract compared to infants given a placebo; another found that infants given a tea containing chamomile, vervain, licorice, fennel and balm-mint seemed to work; while a third found infants given a tea containing fennel, lemon balm and chamomile cried less than infants given a placebo.\nAll of the trials reviewed had \"major limitations,\" such as having too few patients, relying on parental reports of symptoms, or the study design (such as not being double-blinded).\n\"This is pertinent given that simethicone is considered the best available and most commonly prescribed treatment for colic, although it previously has been shown to be no more effective than the placebo,\" according to the authors.\nBecause pediatricians can't offer parents much help with it -- for the most part, babies grow out of colic in time -- desperate parents often turn to alternative or complementary treatments, according to the study.\n\"The notion that any form of complementary and alternative medicine is effective for infantile colic currently is not supported from the evidence from the included randomized clinical trials,\" the researchers from the United Kingdom wrote.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story did not discuss costs. Some of the products described could end up being quite costly, and chiropractic treatment would definitely be an expensive option. At a minimum, we would have liked to have seen some description of the range of costs, from the minimal cost of a few cents a day using a sugar-water mixture to the large cost of chiropractic treatment.", "answer": 0}, {"article": "on Sept. 2.\nMr. Schimmer\u2019s note was entitled \u201cFolotyn Prices High, Reiterate Outperform.\u201d He estimated annual sales of the drug in the United States reaching about $300 million by 2014.\n\u201cA peripheral T-cell lymphoma patient,\u201d he said, \u201cat first blush will see this therapy as a very good thing.\u201d\n\nAllos, which is still unprofitable, has lost $350 million since its founding in 1992 and failed to win approval of a previous drug.\nIn a note to clients in October, Joshua Schimmer, an analyst at Leerink Swann, estimated that a typical treatment would last 3.5 months and cost $126,000, or about $36,000 a month.\nAbout $60,000 of the cost would be incurred in the first eight weeks, when the drug is given more frequently.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story goes into some detail about the cost of Folotyn, which is extraordinarily high. The story also does a great job of comparing the cost of the drug to other expensive cancer drugs. Costs were the main focus of the story.", "answer": 1}, {"article": "\"It's clear that these medications are beneficial,\" said Wadden, who has been a paid consultant to pharmaceutical companies as well as Weight Watchers. \"Unfortunately, there's a sense that they must not work if you have to take them indefinitely. But I think obesity medications should be used on a long-term basis for chronic weight management, just as I take a [cholesterol-lowering] statin and a blood-pressure medication for the long term.\"", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No costs were discussed, but the counseling component indeed carries a price tag. It\u2019s critical for readers to understand what that would cost, in general terms.", "answer": 0}, {"article": "\"They do research online, are more informed and sometimes go to the doctor demanding, 'I think I need an MRI.'\nShe has far fewer headaches and when she does have them, they're far less severe.\nIt's estimated that every year 12 million Americans go to the doctor seeking help for headaches.\nBernstein says she sees lots of desperate patients like Bradford.\nFor Terri Bradford, the years of searching for effective treatment proved futile.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Costs are not discussed in any way, either for the treatments that the woman at the heart of this story ostensibly underwent or the handful of alternatives tossed in at the end of the story.", "answer": 0}, {"article": "Another approach to assessing the meaning of a PSA reading is to analyze how much antigen is traveling free in the blood and how much is bound to a companion protein, Dr. Scardino suggested.\nFor them, if other factors like prostate infection are not the cause of the high level, a biopsy is in order.\nThey will also suggest that testing start at 40 to obtain a baseline measurement, with the test repeated at 45 and 50, after which it should be given annually until 70.\nThis rate, known as PSA velocity, will be part of the new guidelines, which will suggest that in men with low readings, doctors consider the changes in levels over the course of three measurements.\nThe revised guidelines are expected to reduce the cost of screening, the cost per life saved and overall deaths from prostate cancer.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No costs are mentioned.\u00a0 ", "answer": 0}, {"article": "Traumatic injuries to the head, often from car accidents, tend to sever brain cell connections and leave many neurons intact.\nWithout this context, Dr. Fins said, the imaging tests could create some confusion, because like any medical tests they may occasionally go wrong, misidentifying patients as exhibiting consciousness or lacking it.\n\u201cIf you put her scans together with the other 12 volunteers tested, you cannot tell which is the patient\u2019s,\u201d Dr. Owen said in an interview.\nThis means by definition that the young woman has transitioned from an unresponsive, vegetative state to a sometimes responsive condition known as a minimally conscious state, Dr. Laureys said in an interview.\nThe imaging technique, called functional M.R.I., reveals changes in activity in specific brain regions.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not mention the costs of the imaging test.", "answer": 0}, {"article": "The Department of Nutrition, Exercise and Sports conducts research, education, innovation, and dissemination of information in nutrition, human physiology and sports at the highest international level, and incorporates the humanities as well as health and social sciences.\nThe research analyzed data from three diet clinical trials which collectively looked at more than 1,200 individuals - Diet, Obesity, and Genes (DiOGenes); the OPUS Supermarket intervention (SHOPUS); and the Nutrient-gene interactions in human obesity (NUGENOB).\nThe latest findings, as published in AJCN, concluded that a personalized nutritional approach based on an individual's biomarkers will lead to improved weight loss and maintenance success.\nThe latest findings, as reported in AJCN, have garnered international support with further analysis conducted by researchers from the University of Colorado, Tufts University, and Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Fisiopatolog\u00eda de la Obesidad y Nutrici\u00f3n (CIBER OBN).\nThe different studies (six in total) employed a variety of nutrition strategies, including caloric restriction and ad libitum diets, varying the contributions of carbohydrate and fat, and increasing fiber intake.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release gives no indication of how expensive it would be for the average person to use these markers for customizing their weight loss program. There is no mention of how much the testing would cost, (and of importance to US audiences, whether insurance would cover the expense), how often patients would need to be tested in order to ensure efficient weight loss, and what fees would be charged by doctors and dietitians to interpret the results and guide the weight loss effort.", "answer": 0}, {"article": "I couldn't get anything done,\" Ham said.\nIt would also be wrong to portray marijuana as completely safe, they say, because it can also be addictive.\nCannabis could have limited benefits as a treatment alternative, said Harvard Medical School's Dr. Kevin Hill, who last year authored the JAMA study that found benefits in using medical marijuana to treat chronic pain, neuropathic pain and spasticity related to multiple sclerosis.\nAdvocates argue a growing body of scientific literature supports the idea, pointing to a study in the Journal of Pain this year that found that chronic pain sufferers significantly reduced their opioid use when taking medical cannabis.\nGetting on that list is crucial and has resulted in a tug of war in many states, including several in which veterans have been unsuccessful in getting post-traumatic stress disorder approved for marijuana treatment.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The article does a disservice by not mentioning the costs of medical marijuana, even if it is hard to estimate it. If cannabis becomes a major substitute for opioids, the economic implications of this could be huge both for individuals and society.", "answer": 0}, {"article": "Your cells might be aging faster than you are, and new tests purport to help you find out.\n\nA few companies are offering mail-order testing to measure the length of people\u2019s telomeres, the protective caps of DNA on the ends of chromosomes that have been likened to the plastic tips that prevent shoelaces from fraying. Telomeres gradually shorten as people age and eventually may disappear, leaving cells vulnerable to disease and death.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story mentions these tests are available for $89, and that a company also charges\u00a0$395 to get the panel of all 92 telomeres.", "answer": 1}, {"article": "The studies suggest that fewer physicians are recommending annual mammograms for women in their 40s, fewer patients in that age group are getting screened and that tumors found through routine mammography are more likely to be detected in early stages of cancer.\nThese cancers were more treatable because they were caught in earlier stages, Plecha said.\n\"I would still recommend screening mammograms starting at age of 40,\" because cancers caught earlier would be more curable.\nThe studies examined the impact of the controversial guidelines issued by the U.S. Preventive Services Task Force, a federal advisory board.\n\"The benefit in 40- to 49-year-old women is pretty small,\" said Dr. Virginia Moyer, chair of the task force, about annual mammograms.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "At some point, costs must enter into this discussion.\u00a0 But this story never got there.", "answer": 0}, {"article": "People with poorly controlled diabetes, for example, may have breath that smells fruity due to an overproduction of chemicals called ketones; people with kidney or liver failure can have fishy breath.\nCleveland Clinic pulmonologist Peter Mazzone, MD, who is conducting lung cancer studies, says a breath test for cancer may be a reality in as little as five years if all goes well.\nIn a new study from Italy, researchers were able to identify patients with colorectal cancer with an accuracy of over 75% by analyzing samples of their breath.\nSimilar research is under way to develop breathalyzer-like devices to detect lung, breast, prostate, and other cancers.\nThe lung cancer device Mazzone is testing, called an \"electronic nose\" sensor, changes color based on the chemicals in the breath.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Costs were not mentioned, but since this test is in an early stage of development, it would be difficult to provide an accurate cost figure. That figure would have to include both the cost of the test and any unnecessary follow-up tests and procedures due to false-positive results.\u00a0 We\u2019ll rule it not applicable.", "answer": 2}, {"article": "\u201cI couldn\u2019t wear a brassiere for three months,\u201d she recalled.\nBut it is worth remembering that however effective it is, screening can\u2019t ward off disease.\nIn fact, if screening finds cancer, some seniors won\u2019t withstand the surgery, usually a lobectomy, that may cure it.\nResearchers call it \u201ccompeting mortality.\u201d Finding lung cancer is a hollow victory if patients endure testing and treatment, then die of another illness before the cancer would have killed them.\nNationally, deaths from this operation run two to four times higher, and they increase with the patient\u2019s age.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story describes the case of one patient who paid $95 out of pocket for a lung cancer screen in 2013. But while the story does\u00a0attempt to at least provide some cost perspective with the coverage,\u00a0we\u2019d note that under the Affordable Care Act, approved preventive tests do not carry copayments, so the cost of the initial scan is not really an issue for eligible patients. And in any case, the real costs to individuals and society are not really addressed by the cost of one scan. The story notes high up that the number of Americans who would be eligible for Medicare-funded scans would be in the millions. So the cost to Medicare and private insurers to fund this program will be, well, gargantuan at that scale. There is the cost of the initial test, annual testing if negative, and potentially more testing if an abnormality is found. This is not going to be a cheap program.", "answer": 0}, {"article": "For example, she says, someone might say, \" 'I find that I'm staying in my room, not answering the phone, not answering texts, not answering emails.'\nThe next step is for the patient \u2014 with help from the clinician \u2014 to come up with a set of coping strategies to help get through moments of intense suicidal ideation.\nThe intervention involves creating a safety plan for each patient and following up with phone calls after discharge.\nThat follow-up is key, says Julie Goldstein Grumet, a psychologist at the Zero Suicide Institute at the Education Development Center, a Washington, D.C.-based nonprofit.\nIn other words, the intervention had nearly halved the risk of suicide in the six months after discharge.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "We\u2019re told the intervention takes a few minutes up to two hours for nurses or social workers to administer when a patient comes to the emergency room after a suicide attempt. We assume this counseling is provided at no additional cost, but we\u2019d like to know for certain. One possible additional cost is having a delegated staff person in the ED at all times to\u00a0accommodate these patients. Also, there may be cost savings in not having these patients wait for a full psychiatric evaluation by a psychiatrist or a psychiatric social worker or nurse.", "answer": 0}, {"article": "Some years ago, Italy instituted a countrywide rule requiring competitive athletes to undergo an electrocardiogram, a test that records the electrical activity of the heart.\nCurrently, an EKG and echocardiogram would cost parents a minimum of $2,500, Anderson says.\nIf an ongoing program of testing happens, the hospital would try to tap into third-party funding, donations and grants, Towbin says.\nSince the study began about a year ago, 500 local teens have been screened and 26 diagnosed with heart abnormalities.\nBut the Children's Hospital study is showing more than twice that rate and a higher rate for more minor abnormalities as well, perhaps because of better technology, Grenier says.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story reports that this sort of screening would typically cost $2500 and that the cost is a challenge. The story might have made the challenge more obvious by noting that screening all high school athletes would cost $20 billion.", "answer": 1}, {"article": ".\nDr. Brennan cautions that while this study uses a larger sample than most, further studies are warranted.\nHowever, \"this study suggests dry needling as an effective alternative to cortisone injection.\"\nThe study is titled \"Dry Needling Versus Cortisone Injection in the Treatment of Greater Trochanteric Pain Syndrome: A Noninferiority Randomized Clinical Trial.\"\nDr. Brennan adds that, \"The potential detrimental side effects of steroid injection, particularly repeated injections, are of concern for patients and providers alike.\"\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There\u2019s no discussion of costs for either steroid injections or dry needling. According to costhelper.com, the cost of a steroid injection runs $100 to $300, not including the cost of a doctor\u2019s office visit. Dry needling is considerably less expensive but typically requires more frequent treatments. We found one Kansas physical therapy practice that charges $25 for the first treatment and $20 for additional visits. Both may be covered by insurance.", "answer": 0}, {"article": "\"Further studies are needed to address these questions.\"\nThe study serves to point out the need for further, rigorous, study designed to answer the many questions that remain about ketamine for TRD, such as optimal dosing and route of administration, dosing interval and treatment length, and long-term effects\u2014just to name a few.\"\nJames Stone, a clinical senior lecturer from the Institute of Psychiatry, Psychology and Neuroscience at King's College London, who was not involved in the study, told Newsweek that there is \"a lot of potential for the use of ketamine as a second or third line antidepressant where other treatments have failed.\"\n\"Although ketamine is potentially a huge breakthrough in the treatment of depression, we still don\u2019t know about the long-term safety, or about how to keep people well from depression without requiring regular ketamine dosing,\" Stone added.\nThe latest study involved 13 young people ages 12 to 18 who had failed two previous trials of antidepressants.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There was no mention of the costs of ketamine infusions, which can be expensive.\u00a0 A quick internet search yields costs of between $400 to $800 per infusion. Therefore, the six infusions used in this study would cost\u00a0 a family $2,400 to $4,800.\u00a0 And since ketamine is not FDA-approved for treating depression, insurance companies probably wouldn\u2019t cover it.\u00a0 Given the heightened concern that parents feel for their adolescents suffering from depression that doesn\u2019t respond to conventional drug treatments, information on the costs presented by this new approach is warranted.", "answer": 0}, {"article": "Further,Dr.\nCrucially, this woman was in good health, suggesting that therapies aimed at blocking PCSK9 would not only be effective, but also safe.\nMr. Brown had been part of a clinical trial testing the safety and effectiveness of one of the new PCSK9 inhibitors and, when the drugs were approved, Dr. Khera began working to get Mr. Brown approved by his insurance to be on the new regimen.\nWe\u2019d exhausted the other options in trying to control his cholesterol.\u201d\n\nTwo months after he started his biweekly injections of the new drug, Mr. Brown\u2019s LDL cholesterol level was down to 111 \u2013 not quite normal, which is 100 or less \u2013 but an almost 50 percent reduction from the level it had been for years.\nTwo of these drugs, in a category known as PCSK9 inhibitors, were approved by the Food and Drug Administration last summer for use by some individuals with extremely high cholesterol levels.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release does not address cost at all. While the release does not tell us which of the two new drugs the patient took, it does tell us that he took either evolocumab (sold under the trade name Repatha) or alirocumab (sold under the trade name Praluent). Both drugs are given via injection either once or twice a month. According to press materials issued when Repatha was approved by the FDA in August 2015, \u201cThe U.S. Wholesale Acquisition Cost (WAC) price of Repatha is $542.31 for one 140 mg single-use prefilled SureClick autoinjector or prefilled syringe, or $14,100 annually for the every two weeks administration.\u201d That\u2019s not chump change. According to press materials issued when the FDA approved Praluent last July, \u201cThe U.S. WAC price of Praluent is $40 per day ($1,120 every 28 days) for both the 75 mg and 150 mg doses.\u201d Again, that\u2019s not an insignificant expense. The cost to consumers may vary, depending on each patient\u2019s insurance, etc., but failure to address cost is a significant oversight.", "answer": 0}, {"article": "University of Eastern Finland, Institute of Public Health and Clinical Nutrition, tel.\nThe new study provides further evidence on the health benefits that fermented dairy products may have over non-fermented ones.\nLower consumption levels were not associated with the risk.\nThe findings were published in the British Journal of Nutrition.\nApproximately 2,000 men participated in the study.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Costs are not mentioned but we\u2019ll let this pass since it\u2019s reasonable to assume the approximate pricing of most of the dairy products tested are widely known.", "answer": 2}, {"article": "\"It's odd and it's tough and people say, 'I'm sorry.'\nBut it's hard to know what would have happened without them.\nAnd for one patient, it is promising.\nAnd after six months, he was noticing changes then, too.\nThat really hit hard.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not address the cost of this procedure.", "answer": 0}, {"article": "All rights reserved.\nAmerica's favorite dietary supplements, multivitamins, modestly lowered the risk for cancer in healthy male doctors who took them for more than a decade, the first large study to test these pills has found.\nThat is less effective than a good diet, exercise and not smoking, each of which can lower cancer risk by 20% to 30%, cancer experts say.\nThe result is a surprise because many studies of individual vitamins have found they don't help prevent chronic diseases and some have even caused problems.\nAbout one-third of U.S. adults and as many as half of those over 50 take them.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Not applicable.\u00a0 Most people know that multivitamins are inexpensive.", "answer": 2}, {"article": "The liquid is called silver diamine fluoride, or S.D.F.\nBut studies show it can halt the progression of cavities and prevent them, and dentists are increasingly using it off-label for those purposes.\nIt\u2019s been used for decades in Japan, but it\u2019s been available in the United States, under the brand name Advantage Arrest, for just about a year.\nNow there\u2019s an alternative: an antimicrobial liquid that can be brushed on cavities to stop tooth decay \u2014 painlessly.\nThe Food and Drug Administration cleared silver diamine fluoride for use as a tooth desensitizer for adults 21 and older.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story addresses cost in multiple places. One dentist notes that using SDF \u201ccomes out to pennies per tooth.\u201d Elsewhere, the story refers to the overall treatment as costing $25 \u2014 and notes that getting a cavity filled at the same dentist\u2019s office costs $151. We were glad to see the cost of a traditional filling included, since it gives readers useful context. The story also notes that Oregon is, so far, the only state to reimburse Medicaid providers for treating cavities with SDF.\nOne factor not noted is that some cavities may need to be repeatedly treated, raising the cost.", "answer": 1}, {"article": "Finally, in 2000, a group of researchers including Dr. Segal in Toronto, J.\nOthers, like Dr. Linehan, insist that patients in severe mental distress are the best candidates for mindfulness.\nYet so far, the evidence that mindfulness meditation helps relieve psychiatric symptoms is thin, and in some cases, it may make people worse, some studies suggest.\nThe question, said Linda Barnes, an associate professor of family medicine and pediatrics at the Boston University School of Medicine, is not whether mindfulness meditation will become a sophisticated therapeutic technique or lapse into self-help clich\u00e9.\nDr. Kabat-Zinn taught the practice to people suffering from chronic pain at the University of Massachusetts medical school.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Cost of treatment is not mentioned, but the story includes an excellent sidebar noting additional (free or low-cost) forms of mindfullness therapies and their demonstrated benefit\u00a0 to date. The story also adequately describes the practice and provides resources for personal practice. It would still have been helpful to hear a range of costs for therapy (and typical number of sessions for the patient to master the technique) for a common problem, such as anxiety disorder. ", "answer": 1}, {"article": "\u201cA 5 percent loss of weight is associated with a 50 percent lower risk of diabetes and a 10 percent loss is associated with an 80 percent lower risk.\u201d\n\nPatients in Bohula\u2019s study did see improvements in hypertension and blood sugar levels with weight loss.\nPeople need to realize that in obesity treatment, just as in hypertension therapy, one drug won\u2019t fit all, Aronne said.\nThat\u2019s how we need to start looking at drugs for obesity.\u201d\n\nWhat many don\u2019t understand is that weight gain leads to changes in the brain that may not be reversible, Aronne said.\nThe media attention that followed would scare patients off diet pills for years \u2014 a fear that continues today.\nThey won\u2019t make a morbidly obese patient model-thin, but they\u2019ll shave off enough excess fat to improve heart disease risk factors such as hypertension, high blood sugar and high cholesterol, experts say.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story mentioned cost and lack of insurance coverage as factors in the low uptake of weight loss drugs, but it doesn\u2019t give data. The drug highlighted in the story, lorcaserin, marketed in the U.S. as Belviq, costs $285 for a 30-day supply if you pay out of pocket, according to web sources. It wasn\u2019t made clear how long people must stay on these drugs, which also affects cost.", "answer": 0}, {"article": "Men and women with mildly high blood pressure who ate three kiwi fruits a day for eight weeks had systolic blood pressure levels that were 3.6 millimeters of mercury lower than those of volunteers who ate an apple a day.\nDon't start popping lutein in supplement form based on these results, he noted.\nModeration is the key with kiwis or any food, he said.\nBecause this study was presented at a medical meeting, the data and conclusions should be viewed as preliminary until published in a peer-reviewed journal.\nA blood pressure reading that is less than 120/80 is considered ideal.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Not applicable.\u00a0 No discussion of costs.\u00a0 Shoppers probably have a ballpark idea.", "answer": 2}, {"article": "L-Nutra, to sell products that serve this purpose, which may be seen as a conflict of interest.\n(CNN) How much -- or how little -- you eat could influence how long you live.\nThis activation, or reduction, of pathways is why the components of the diet, such a proteins, must also be controlled.\nFasting has been performed by communities and cultures for millennia and Longo's team are curious about the advantages.\nTo him, diet underpins longevity.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Fasting to improve your health sounds like a great way to spend less money on food, and it\u2019s tempting to assume this diet would be cheap to follow. But that doesn\u2019t seem to be the case:\u00a0The story indicates study participants were fed a custom-designed meal program that would have to be replicated in the general population to achieve the same benefits. This will presumably cost money\u2013but we\u2019re not given any idea of how much that might cost.", "answer": 0}, {"article": "In addition, we saw that several smaller brain areas actually started to grow in response to training,\" says Ulrik Dalgas.\nThe researchers behind the study are still unable to explain why training has a positive effect on the brain in people with multiple sclerosis.\nThe study shows that resistance training has a number of positive effects on the brain, which go beyond what can be achieved through effective disease specific medication.\nOn the other hand, the study indicates that systematic physical training can be a far more important supplement during treatment than has so far been assumed.\nDrugs can counter this development, but we saw a tendency that training further minimises brain shrinkage in patients already receiving medication.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Patients in the intervention group underwent resistance training twice a week for 6 months. The news release does not specify what types of exercises were included. It\u2019s unclear whether the exercise program would require supervision by a physical therapist or whether it could be adapted to be done at home, perhaps with friend or family help. In any case, there are cost implications that should have been addressed.", "answer": 0}, {"article": "Traditional knee surgery cuts through muscles and tendons.\nO'Brien spent just a few hours in the hospital after surgery before she was well enough to go home.\nO'Brien successfully charted the course and headed out of the hospital to a smooth recovery.\n\"I'll be chipping and putting in three weeks \u2014 maybe four,\" joked O'Brien from the operating table.\nFor Linda O'Brien, a grandmother and scratch golfer, chronic knee pain was making life unbearable.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There was no mention of the costs associated with this type of knee replacement nor the expected lifespan for this device.", "answer": 0}, {"article": "You\u2019re shepherding a fixed amount of resources across a large population and trying to do it according to some sort of evidence-based system.\u201d\n\nKaiser Health News is an editorially independent program of the Henry J. Kaiser Family Foundation, a nonprofit, nonpartisan health policy research and communication organization not affiliated with Kaiser Permanente.\nWhile rTMS has ardent supporters, its effectiveness is still debated, and there is little evidence showing how long the results last.\nThat 19-member panel voted 10 to 5 last year that studies of the treatment showed it to be as good as or better than usual care for depression.\nMagnetic stimulation is aimed at patients with such \u201ctreatment-resistant depression.\u201d\n\nSupporters say rTMS is worth the cost \u2014 between $6,000 and $12,000 for the four-to-six-week treatment \u2014 because it enables people such as Curtis to resume productive lives.\nThe treatment, which has been approved by the Food and Drug Administration, is covered by Medicare in five states, but few private insurers pay for it routinely.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The costs of rTMS, and the market forces that work to encourage or restrain use of this technology, are well described.", "answer": 1}, {"article": "Sonata uses a probe that is inserted through the cervix into the uterus. The probe not only allows the doctor to see the fibroid using ultrasound, but it also has a radio-frequency device at the tip. The doctor hits a foot pedal to send energy through the probe to heat the fibroid, shrinking it over time. The body absorbs the dead tissue, so it does not have to be surgically removed.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story pulls off a difficult trick: addressing cost in a meaningful way when it\u2019s not clear what the price tag will be. The story tells readers \u201cSonata\u2019s manufacturer declined to say what the procedure might cost once the trials are complete and it is approved.\u201d The story also explains that \u201cbecause it\u2019s still under investigation in the U.S., it\u2019s not covered by insurance.\u201d And the story also quotes an independent expert as saying that \u201cIf insurance doesn\u2019t pay for Sonata, no one is going to get it.\u201d The story also notes that a comparable procedure cost tens of thousands of dollars.", "answer": 1}, {"article": "Hair changes about as fast as grass grows, which is to say it\u2019s extraordinarily slow and not visible to anyone checking impatiently in the mirror every day.\nFor now, Maryanne Senna, a dermatologist and the director of the Hair Academic Innovative Research Unit at Massachusetts General Hospital in Boston, said the best she can tell patients who ask \u2014 and a lot of them do \u2014 is that Harklinikken won\u2019t do any harm.\nClients must also use the company\u2019s shampoo, conditioner and styling products, forsaking all others \u2014 a psychological as well as a financial buy-in, Dr. Senna said.\nOne is how much emphasis the company places on compliance, the major stumbling block in the efficacy of any treatment, said Dr. Senna, an author of studies on the subject.\n(Mr. Skjoth, who has a master\u2019s degree in nutrition and chemistry but is not a doctor, said this is because other products may clog the scalp, causing hair loss.)\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story barely rates satisfactory by calling this an \u201c$88-a-month serum.\u201d It would have better served readers by giving the total cost treatment, which well exceeds $1,000 annually and isn\u2019t covered by insurance.\nWhile patients are described seeing results after three or four months, there\u2019s no mention of the fact that the company\u2019s web site recommends \u201ccontinuing application\u201d to maintain results. And while the story says patients \u201cmust also use the company\u2019s shampoo, conditioner and styling products,\u201d it doesn\u2019t say what they cost.\nFurther, when HealthNewsReview.org requested an online consultation via the company\u2019s web site, we were notified of a $49 \u201cstart-up cost\u201d if we qualified for treatment along with $29 for each \u201cfollow-up\u201d consultation. Those costs aren\u2019t mentioned in this article. There\u2019s also no cost comparison with other hair loss treatments. We found a year\u2019s supply of minoxidil on Amazon for as little as $54 for an annual supply.", "answer": 1}, {"article": "\u201cIt\u2019s a tricky thing to get your mind around,\u201d Whitlock said.\nAnd no one knows yet whether HPV testing actually catches cervical cancer at an earlier stage, or reduces deaths from the disease, compared with Pap tests.\nThe report, in the Annals of Internal Medicine, sums up a research review done for the U.S. Preventive Services Task Force (USPSTF), an expert medical panel supported by the federal government.\nYou\u2019re trying to make a tradeoff between sensitivity and specificity.\u201d\n\nSince cervical cancer screening is repeated over time, what\u2019s needed is evidence of the longer-term effects of different tests, according to Whitlock.\nIn an interview, she noted that the decision of whether to do a conventional or liquid-based Pap test is not the patient\u2019s.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "This story does not mention the cost of any procedure, nor does it tackle the societal cost of changes in screening frequency or method.", "answer": 0}, {"article": "The requested URL /usnews/health/articles/061210/18vitamin.htm was not found on this server.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There was no discussion of costs of vitamin D rich foods, vitamin D supplemented foods, or vitamin D containing supplements.\u00a0 Though the story starts with a quip that \"it's free\", this only applies to sunlight.\u00a0 A brief discussion even of the costs of supplements at the doses recommended would have strengthened the story.", "answer": 0}, {"article": "So, for example, a person who is actively using opioids and can't manage the withdrawals may be better suited for buprenorphine, while someone coming from a facility where he or she has detoxed and who doesn't want to use opioids may be better suited for naltrexone.\nWhat was important, Lee said, was for opioid addicts as well as treatment providers to understand that addiction isn't one-size-fits-all.\nWithout the opioids, people can go into withdrawal, all contributing to a cycle of dependency.\nOnce on either of the medications, people fared equally well.\nPublic health experts consider medicated-assisted treatment the gold standard of opioid addiction treatment.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Cost does not make an appearance. This is a problem for a comparative story, as the prices for these two drugs seem quite different, with Vivitrol looking by far the more expensive.", "answer": 0}, {"article": "Labor may be induced by breaking the amniotic sac or by using hormones called prostaglandins or medication such as oxytocin, which can set off contractions.\n\u201cThere are anywhere between 25,000 to 30,000 stillbirths a year in the United States.\u201d\n\nLockwood and Norwitz\u2019s support for induction at 39 weeks not only surprised many of the doctors at the session, it also upset those who believe less intervention is the safest route for mother and baby.\nFor Dekker, the major benefit of spontaneous labor is avoiding the risks of a medical induction.\nDekker said there were flaws in the research showing that women who received elective induction had lower rates of Caesarean delivery.\n\u201cIt\u2019s obvious that a blanket policy of 39-week inductions would not affect all of the stillbirths that happen before 39 weeks,\u201d Dekker said, adding that the CDC report concludes, \u201cDespite intensive investigations, for a substantial number of fetal deaths a specific cause of death cannot be determined.\u201d\n\nAnd, Dekker said, the public has the misconception that inductions are simple, noninvasive procedures.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There is no discussion of the cost of elective induction of labor or how it compares to waiting longer for labor to begin on its own.", "answer": 0}, {"article": "The requested URL /usnews/health/articles/070520/28healthwatch.lede.htm was not found on this server.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Not applicable.\u00a0 The story didn\u2019t discuss the costs of multivitamins, but this is common knowledge.", "answer": 2}, {"article": "Corticosteroids are involved in a wide range of physiological processes in the body, including regulating metabolism, blood pressure and helping the body to cope with physical stress.\nThe researchers say that, with further research, these findings may one-day lead to improved therapies for other conditions that respond to steroid treatment, including asthma and rheumatoid arthritis.\nThe new treatment - expected to have fewer side effects than existing therapies - could help people with disorders of the adrenal gland whose bodies are unable to produce a class of steroids called corticosteroids.\nThe researchers tested the therapy in a small group of patients with Addison's disease.\nThe therapy could help people with conditions such as Addison's disease and congenital adrenal hyperplasia, who need steroid treatment to avoid the risk of potentially fatal illness during physical stress.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Although this is basic research at the moment, the study does compare health outcomes between corticosterone\u00a0and an existing treatment.\u00a0 It could well have also offered a preliminary cost assessment.", "answer": 0}, {"article": "If a woman's doctor tells her she does not need radiation after a mastectomy, the woman should be told why and she should ask if the radiation oncologist weighed in on the decision.\nThe guidelines don't offer a single formula for which patients need radiation therapy, Edge noted.\nAndrews said that one take-home message for patients is to expect the surgeon to have consulted with the radiation oncologist and others on her team.\nEdge was a panel representative from the American Society of Clinical Oncology, which created the guidelines along with the American Society for Radiation Oncology and the Society of Surgical Oncology.\nDoctors need to weigh the risks and benefits, Edge added.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Cost is not addressed in the story. That\u2019s problematic because, as the American Cancer Society notes, \u201ctreating cancer with radiation can cost a lot.\u201d According to an August 2015 paper in the Journal of Oncology Practice, radiation therapy for breast cancer can cost anywhere from $7,300 to $10,300. That\u2019s a lot of money, and worth noting.", "answer": 0}, {"article": "That wouldn\u2019t be surprising.\nThere are other reasons not to take calcium supplements.\nTeen girls, who are in crucial bone-building years, often have diets that fall short of their needs, 1,300 mg a day, Wallace says.\nAnd supplements come with extra risks: increases in kidney stones and, for some people, constipation and bloating.\nCalcium intake from food has been rising, he says, with recent surveys finding averages around 1,000 mg a day \u2014 close to or meeting the 1,000 mg. to 1,200 mg recommended for adults (the higher level is advised for women over 50 and men over 70).\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Cost is not\u00a0mentioned. While calcium supplements are not prohibitively expensive for most patients (prices vary, but tend to cost less than $10 for several months\u2019 worth of pills), they are not free \u2014 and expense can be an important consideration for many patients. Also, given that most people can get enough calcium through foods and beverages, and yet more than one-third of Americans take calcium in supplement form, it would be informative for the reader to understand how much is spent annually on supplements that may not provide additional benefit.", "answer": 0}, {"article": "This condition occurs when the cushions, or discs, that serve as shock absorbers for the spine become inflamed and bulge or break open.\nNone of the people in this study had been helped by other nonsurgical therapies, and supporters say the new therapy could become a standard treatment for such patients.\nStill, ozone therapy could even help many patients with unrelenting back pain to avoid surgery, Lehnert tells WebMD.\nBut a back pain specialist who spoke to WebMD says that further research is needed.\nLehnert presented the findings here at the annual meeting of the Radiological Society of North America.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Though this is still an experimental approach, it would have been appropriate to discuss the costs in terms of the closest similar treatment \u2013 an epidural steroid injection. Since the story claims the experimental approach has been used thousands of times in Europe, some cost frame of reference was possible.", "answer": 0}, {"article": "A variation of a drug commonly given to cancer patients with bone damage appears to be an effective tool for preventing repeat hip fractures in elderly patients, according to a study in the New England Journal of Medicine.\n\nThe study results, which were to be presented yesterday in Hawaii, have potentially big implications because hip fractures are a common and debilitating injury for older people. Most of the 300,000 hip fractures each year in the U.S. are related to osteoporosis in older people, as well as falls, according...", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There was no information about the cost to the consumer for this product.\u00a0 \nThe story did, however, provide an estimate about projected annual sales.", "answer": 0}, {"article": "(H\u00f6gqvist Tabor says it's tricky because it depends on the individual, and can range from a few beats per minute to 10 beats per minute.)\nScientists put Fitbits on five employees and found that the devices could track their resting heart rate patterns during their menstrual cycles.\nIf you\u2019re curious exactly what kind of increase in resting heart rate you should look out for, Clue hasn\u2019t revealed that information yet, but says it will publish that and other data in a paper later.\nBy monitoring these multiple biomarkers while a woman is asleep, Ava\u2019s wearable and app can notify her during the five days she\u2019s most fertile, ending in ovulation, according to von Bidder, who says Ava has conducted studies on about 60 people.\nVon Bidder said it was promising to see that Fitbit might be able to provide heart rate data to women trying to conceive.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story quotes a company official calling this a \u201ccheaper\u201d method for those who want to get pregnant. But no numbers are provided to back this up. Fitbits can cost anywhere from 60 to more than 100 dollars. They also require users to have smartphones or tablets to interact with the fitbit \u2014 and with the (free) app discussed in the bulk of the article. Other technologies are also discussed in the article, with no mention of related costs.", "answer": 0}, {"article": "A new study shows that computer technology known as machine learning is up to 93 percent accurate in correctly classifying a suicidal person and 85 percent accurate in identifying a person who is suicidal, has a mental illness but is not suicidal, or neither.\nThose enrolled included patients who were suicidal, were diagnosed as mentally ill and not suicidal, or neither - serving as a control group.\nThey then used machine learning algorithms to classify the patients into one of the three groups.\nThe results showed that machine learning algorithms can tell the differences between the groups with up to 93 percent accuracy.\nDr. Pestian and his colleagues enrolled 379 patients in the study between Oct. 2013 and March 2015 from emergency departments and inpatient and outpatient centers at three sites.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "No\u00a0costs\u00a0are presented.", "answer": 0}, {"article": "\u201cIt\u2019s time for her to be a kid again and get her childhood back,\u201d Mr. Whitehead said.\nDespite the mixed results, cancer experts not involved with the research say it has tremendous promise, because even in this early phase of testing it has worked in seemingly hopeless cases.\nHerv\u00e9 Hoppenot, the president of Novartis Oncology, called the research \u201cfantastic\u201d and said it had the potential \u2014 if the early results held up \u2014 to revolutionize the treatment of leukemia and related blood cancers.\nIn two adults, the treatment did not work at all.\nSome patients have had the cells for years.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The study addresses costs nicely,\u00a0noting that any commercial treatment resulting from this research will probably be very expensive. It notes that other targeted\u00a0cancer treatments cost more than $5,000 a month. And it provides the estimate of experimental cost ($20K per patient).", "answer": 1}, {"article": "\u201cIt\u2019s a bit like with mobile phones.\n\u201cThese devices could transform the management of type 1 diabetes, but it is likely to be a gradual process,\u201d Roman Hovorka of Cambridge, who led the research, said in a telephone interview.\nThe new system, which involves patients wearing a matchbox-sized monitor and a similar-sized pump with a tube to deliver insulin into the body, also halved the amount of time blood sugar dropped to worrying or dangerous levels, they said.\nThe ultimate goal is to create a device that can check patients blood day and night, during and between meals, and deliver insulin as required.\nThe Cambridge study found their device performed better than a conventional pump, which delivers insulin at pre-set rates and which kept blood sugar levels around normal for 40 percent of the time compared with 60 percent for the artificial pancreas.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "If we\u2019re far enough along to determine that that the \"artificial pancreas\" was better than conventional techniques at managing glucose,\u00a0we\u2019re far enough along to\u00a0start talking about what this approach may cost.\u00a0 \nMany patients with type 1 diabetes are not using currently available pumps and sensors because of the high cost of these devices.\u00a0It seems likely that this new treatment, if it ever becomes widely available, will be as expensive or more so than the current pump and sensor technology. \n\u00a0", "answer": 0}, {"article": "Details of the cases are documented in the paper \"Artemisia annua dried leaf tablets treated malaria resistant to ACT and i.v.\nGrowing Artemisia annua and producing and testing the tablets, Weathers noted, are ideal local business that can provide jobs in impoverished areas and greatly expand access to antimalarial therapy.\nAnother advantage of DLA over conventional malaria treatments is its low cost and the relative simplicity of its manufacture, Weathers said.\nIn effect, the dried leaves constitute a robust natural combination therapy, one whose benefits far surpass those of ACT and other combination drugs.\n\"To our knowledge, this is the first report of dried-leaf Artemisia annua controlling ACT-resistant malaria in humans,\" the authors of the Phytomedicine paper note, adding that more comprehensive clinical trials on patients with drug-resistant malaria are warranted.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release mentions this would be an \u201cinexpensive treatment option\u201d and goes into some detail about the economics of the region where the drug was tested and the advantage of a low cost therapy.\n\u201cAnother advantage of DLA over conventional malaria treatments is its low cost and the relative simplicity of its manufacture, Weathers said. While the processes for manufacturing ACT is costlier and requires a higher degree of expertise, producing DLA tablets can be accomplished with simpler equipment and a modest amount of training. Growing Artemisia annua and producing and testing the tablets, Weathers noted, are ideal local business that can provide jobs in impoverished areas and greatly expand access to antimalarial therapy.\u201d\nNormally we like to see specific costs but in this case, an attempt is made to discuss the challenges and opportunities of developing a low cost therapy which seems appropriate here.", "answer": 1}, {"article": "Instead of shrinking as expected, as part of the normal aging process, the memory center in the brains of seniors maintained their size and, in men, grew modestly after two years in a program that engaged them in meaningful and social activities, new Johns Hopkins Bloomberg School of Public Health-led research suggests.\nThe researchers were particularly interested in the results, considering that people with less education and who live in poverty are at greater risk for cognitive decline.\nShe says the program increases involvement in so many different kinds of activities that retired people may not have engaged in otherwise.\nThe control arm of the study, those not involved in Experience Corps, exhibited age-related shrinkage in brain volumes.\nExperience Corps is a national program, however it can be costly and isn't available everywhere.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The program under study welcomes study participants as volunteers, so there is no \u201ccost\u201d to them.\u00a0 It is not a drug or device, but we still might encourage the next release to quantify the costs a bit better. Bare minimum Satisfactory for this mention: \u201cExperience Corps is a national program, however it can be costly and isn\u2019t available everywhere.\u201d", "answer": 1}, {"article": "Digital rectal exams can tell a specialist that the prostate is getting bigger, but that happens with normal aging as well as with cancer.\nThe test had a sensitivity of 49 percent, meaning it correctly identified 49 percent of cancers.\nThe test was approved for use in Europe in 2006 but is not yet approved in the United States.\nThe Progensa test looks for a genetic material called PCA3.\n\u201cIf the PCA3 is abnormal, above about 35, you have got an 80 percent chance of having cancer,\u201d Crawford said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "\u00a0Although this product is used elsewhere in the world, there was no estimate of its cost.", "answer": 0}, {"article": "Hepatitis C is a viral disease that causes inflammation of the liver that can lead to diminished liver function or liver failure.\nEpclusa also carries a warning not to use with certain drugs that may reduce the amount of Epclusa in the blood which could lead to reduced efficacy of Epclusa.\nThe safety and efficacy of Epclusa was also evaluated in a clinical trial of 267 subjects with decompensated cirrhosis (moderate to severe cirrhosis), of whom 87 subjects received Epclusa in combination with ribavirin for 12 weeks, and 94 percent of these patients had no virus detected in the blood 12 weeks after finishing treatment.\nKnowing the genotype helps inform treatment recommendations and the duration of treatment.\nThe U.S. Food and Drug Administration approved Epclusa to treat adult patients with chronic hepatitis C virus (HCV) both with and without cirrhosis (advanced liver disease).\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release does not discuss cost. The FDA evaluates drugs without consideration of cost, so it\u2019s understandable that they wouldn\u2019t comment on it \u2014 and that\u2019s why we\u2019re rating this Not Applicable.\nWe look forward to the day when any news release about a new drug \u2014 even one from the FDA \u2014 includes some mention of cost in its message. After all, the value of a new drug is a function not just of how well it works, but its cost-effectiveness.", "answer": 2}, {"article": "Moffitt is the No.\nThe researchers found that delaying surgery due to neoadjuvant radiation therapy was not a detriment to survival.\nThe study was supported by funds received from the American Cancer Society and the DeBartolo Family Personalized Medicine Institute Pilot Research Awards in Personalized Medicine.\nCurrently, there are no studies that have analyzed the long-term effects of neoadjuvant radiation therapy on breast cancer patients.\nThese data are promising, but randomized clinical trials are needed to confirm the benefit of neoadjuvant radiation therapy.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The costs of neoadjuvant radiotherapy vs. postoperative-adjuvant radiotherapy were not discussed.", "answer": 0}, {"article": "\"And in that case, I see this as just a waste of money.\"\n\"[But] this work adds an important piece of information to the autism puzzle,\" she said.\nThe study was limited to high-functioning males and so did not allow researchers to generalize the findings to females, younger children, or \"lower functioning\" individuals with autism, the researchers wrote.\n\"It adds evidence of functional impairment in brain connectivity in autism and brings us a step closer to a better understanding of this disorder.\n\"I would say that if this is geared to, or opens up, any specific avenue to targeted therapy that can help left and right brain communication among certain children for whom that's the pathway to autism, then it should certainly be explored,\" Bono said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "It takes until the very end of the story for there to be a comment on costs. An autism activist mentions,\"So if there\u2019s no targeted treatment to follow up on the results of this kind of scan, then it\u2019s just another expensive test for parents who are already barraged with so many tests at diagnosis,\" she said. \"And in that case, I see this as just a waste of money.\" We don\u2019t know enough about the benefits or the harms so it\u2019s hard to say if it\u2019s a waste of money. The cost information about MRIs would not have been hard to find.", "answer": 0}, {"article": "\u201cWe do not know for sure, and we do not know which particular aspect of olive oil is the most relevant to stroke,\u201d he says.\nShe calls the findings \u201cintriguing\u201d but says they \u201cdo not equate a randomized clinical trial and should be used with appropriate caution in making broad recommendations.\u201d\n\nSuzanne Steinbaum, MD, director of women and heart disease at Lenox Hill Hospital in New York, says moderate use of olive oil in cooking and on bread may help protect against stroke in people older than 65.\n\u201cMaybe olive oil improves vascular risk factors such as hypertension, dyslipidemia, diabetes, heart disease, obesity, which may in turn reduce stroke risk, or it may be that olive oil is anti-inflammatory or an antioxidant.\u201d Scarmeas writes an accompanying editorial.\n\u201cOlive oil is a healthy fat and it can reduce cholesterol and inflammation, and has been shown to help reduce the incidence of heart disease,\u201d she says.\nShe agrees with the study authors and editorialist that it is too early to make any recommendations about olive oil intake and stroke risk.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Not applicable.\u00a0 The cost of olive oil is not in question.", "answer": 2}, {"article": "McIntyre points out that the bowel communicates with the brain through other pathways as well, including the metabolic and nervous systems.\nThose changes in brain activity \u201csupport the notion that this probiotic has anti-depressive properties,\u201d the authors wrote in their paper.\nFor the new research, scientists from McMaster University in Canada recruited 44 adults with IBS as well as mild to moderate anxiety or depression.\nStudies have looked at various types of probiotics for IBS patients, the authors wrote, and a recent review found that seemed to work better for gastrointestinal symptoms than another common probiotic, .\nNow, a small study published in the journal suggests that taking a probiotic supplement may provide relief from both conditions.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Readers aren\u2019t given information about\u00a0how much the probiotic might cost.", "answer": 0}, {"article": "But are they receiving it?\nThis fear, however, is not based on actual evidence and cannot be used to suppress or otherwise keep the public uninformed of what is clearly known about the lower risks of these products,\u201d adds Kozlowski, PhD, one of the world\u2019s leading researchers on smoking behavior.\n\u201cYet, such facts are being kept from adult consumers of legal tobacco/nicotine products, either by not informing or actively misinforming consumers.\nThis \"information quarantine\" in turn helps explain the woeful lack of public knowledge about relative risks, violating basic consumer rights as well as the public health principles of individual rights and health literacy, the researchers say.\nTo illustrate their point, Kozlowski and Sweanor use the example that if one type of alcoholic beverage caused 3 in 5 regular users to die prematurely \u2014 as is the case with smoking traditional cigarettes \u2014 while another caused massively fewer deaths, consumers would want to know which product was the safer alternative.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "No mention is made of the costs of either cigarettes (whose cost has skyrocketed in recent years in some areas) or of smokeless tobacco products. One can argue that that is immaterial when comparing lives saved versus lives lost, but that argument may not carry weight with people who are addicted to nicotine, and trying to figure out how to feed their addiction while limiting their risk.", "answer": 0}, {"article": "The requested URL /usnews/health/articles/070225/5disease.htm was not found on this server.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not mention the cost of Lucentis, which is substantial, up to $2000 per injection. Since the injections need to be\u00a0given monthly for an indefinite amount of time, cost is a huge issue and has the potential to be a signficant barrier to obtaining the drug. The story does mention that Avastin is a much cheaper alternative, but this is not enough information on the cost of treatment.", "answer": 0}, {"article": "\"It's an outpatient procedure, and no physical therapy is required before or after this procedure,\" he said.\n\"This therapy is very well-targeted to that particular mechanism, and certainly it should be investigated further,\" said Vedantham, who wasn't involved with the study.\nDr. Suresh Vedantham, president of the Society of Interventional Radiology, called the new procedure \"very promising,\" given that it focuses on the inflamed knee lining that causes the pain.\n\"Patients overall were able to improve their physical function in the knee after the procedure, and there were no adverse events related to this treatment,\" said lead researcher Dr. Sandeep Bagla.\nThe microparticles are inserted using a catheter run through a pinhole-sized incision, in a procedure that lasts between 45 and 90 minutes, Bagla said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Although it may be too early to nail down an exact price, the topic of how much this might cost wasn\u2019t broached at all, nor were the costs of currently available treatments.", "answer": 0}, {"article": "But in the U.S., most prostate cancers are identified by PSA screening, and less than half have palpable tumors.\nSo there's reason to think men followed with active surveillance and treated when necessary would fare better than the \"watchful waiting\" group in the newly published study.\nBy the way, 9 out of 10 prostate cancers in the U.S. these days is considered low risk.\nAlmost 90 percent had tumors their doctors could feel on digital rectal exams.\nSo \"low risk\" in the Swedish study means higher-risk than the current \"low risk\" men diagnosed in the United States.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There was no discussion of costs. Costs would include treating the double digit rates of incontinence and erectile dysfunction in these younger men who do have surgery. The surgery may help them live longer, but many, especially since younger at time of surgery, live decades with these potential harms and folllowup costs of the surgical choice.\u00a0 This should get at least a line in such stories.", "answer": 0}, {"article": "These days, most patients have a generally low risk of blood clots after knee replacement for a number of reasons.\nAlthough warfarin costs a few dollars for a 30-day supply, its cost approaches that of the other anticoagulants when doctor visits for monitoring are factored in, Hallstrom says.\nThe study suggests most patients can have just aspirin without increasing the risk for venous thromboembolism, but doctors need to consider factors such as a patient's history of clots, obesity and ability to mobilize after surgery when determining the best measure for clot prevention, Hallstrom adds.\nThose reasons include shorter surgical times, less invasive procedures and use of regional anesthesia that allows early mobilization after surgery, Hallstrom says.\nBased on the experience of 41,537 Michigan patients undergoing knee replacement, the study may further the debate about the routine use of aspirin for clot prevention.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The cost differences between aspirin and anticoagulant drugs are listed and the potential savings by using aspirin are highlighted.", "answer": 1}, {"article": "Unlike a heart attack, which happens when blood flow to a portion of the heart is blocked, cardiac arrest occurs when the heart\u2019s electrical system malfunctions, often due to irregular heart rhythms.\nThe study is observational and doesn\u2019t prove bystander CPR increases survival odds, the authors note in Circulation.\nAfter 13 minutes, patients who got CPR at the scene continued to have better survival odds but the difference was no longer statistically meaningful.\nIf the ambulance took more than 13 minutes, the survival rate was 3.7 percent in the CPR group and 1.5 percent for the others - a difference that wasn\u2019t statistically meaningful.\n\u201cEarly CPR saves lives, and the lack of CPR efforts from bystanders could result in significantly decreased chances of survival,\u201d said lead study author Dr. Shahzleen Rajan of Copenhagen University Hospital in Denmark.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There is no direct cost to bystander CPR, so this category is not applicable.", "answer": 2}, {"article": "About 23 percent of the women reported taking a low-dose aspirin (81 milligrams), 18 percent took ibuprofen, 11 percent took full-strength aspirin (325 mg) and about 10 percent took a COX-2 inhibitor or another nonsteroidal anti-inflammatory drug (NSAID).\n[Certain adults should take a daily baby aspirin, expert panel says]\n\nWho may be affected?\nMillions of people take a low-dose aspirin daily in hopes of reducing their chances of having a heart attack.\nAbout 1 of every 8 women in the United States will develop breast cancer at some point.\nData on aspirin and other NSAID usage came from the women\u2019s responses on questionnaires.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Cost isn\u2019t mentioned. This may be because the story assumes the public knows that low-dose aspirin is inexpensive (a year\u2019s supply would likely be less than $20). It\u2019s good to make that clear, but because of the minimal cost will rate it N/A.", "answer": 2}, {"article": "Both groups went to their V.A.\nBased on the study results, it could be that patients need to renew their regimen with the cream every year.\nThe study did show a significant decrease in the risk of needing Mohs surgery to treat a BCC in the first year.\nThe dose is the same as dermatologists currently employ to treat actinic keratosis.\nIn his clinical work, Weinstock said that for particularly high-risk patients, he has recommended 5-FU treatment.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release does mention costs twice, by saying that treating these cancers surgically is more costly, and that the use of the cream \u201ccan reduce the resources needed to treat these carcinomas.\u201d\u00a0 But it doesn\u2019t mention that the fluoroucil cream is fairly expensive. According to GoodRx, one 40g tube of 5% fluorouracil cream ranges from $73 to $136 a different pharmacy retailers. The cost may be considerably reduced by insurance plans, but the release does not address that either.\nAlso of note, according to results in the published study, at least 11\u00a0patients must be treated with the cream in order to possibly prevent one\u00a0additional cancer, leading to a drug cost of over $14,000 to prevent that one cancer. That may exceed the cost of surgery.\u00a0  ", "answer": 0}, {"article": "These plaques, which are caused by blood cholesterol, build up over time and cause arteries to narrow, leading to heart disease as the heart works harder to pump blood through the body.\nPeople with many calcium deposits can improve their long-term prospects by eating right, exercising, and taking medication to treat heart risk factors such as high blood pressure, elevated blood cholesterol and type 2 diabetes, Shaw said.\nUp to now, however, there's been little evidence showing that a calcium scan can provide a solid assessment of a person's long-term health risk, the study authors said in background information.\n\"The best use is in patients who have no symptoms, but the value of the test is not well known.\"\nThe test, called a coronary calcium scan, uses a regular CT scan to look for calcium deposits in the three major arteries that carry blood away from the heart, said lead author Leslee Shaw, a professor of cardiology at Emory University in Atlanta.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story helpfully notes that the CAC test costs about $100, which matches price quotes from other sources, though the price may be higher in some parts of the country. The story would have been even more useful had it noted that the cost of the test may not be covered by insurance.", "answer": 1}, {"article": "A study believed to be the largest of its kind suggests that the physical aspects of yoga are effective at relieving low back pain, but it didn't find any evidence that yoga provided broader mental benefits.\n\nThe study, funded by the National Institutes of Health's National Center for Complementary and Alternative Medicine, was published online Monday in the Archives of Internal Medicine. It was lead by researchers at Seattle's Group Health Research Institute.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The Wall St. Journal article did not discuss the costs or cost-effectiveness of any of the interventions.\n", "answer": 0}, {"article": "One 2016 study compared Coolief to popular cortisone injections, with patients reporting greater, longer-lasting pain relief with the new treatment than injections.\nCoolief can be repeated if necessary, but it's not a permanent solution.\nSome of the reported risks from the procedure include bleeding and infection.\nBecause it was just approved by the FDA in April, the treatment is not widely available yet, but pain centers across the country are beginning to offer it.\nThe cost of the treatment is between $2,000 and $4,000.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Costs are indeed addressed.", "answer": 1}, {"article": "It takes an hour or less,\" he said.\n\"That risk is much higher than we initially thought,\" said study co-author Dr. Andrew Krahn of the London Health Sciences Center in Ontario.\nAll the patients had devices that were recalled by manufacturers, Canada's national health system or the FDA.\nA new Canadian study provides the first estimate of the risk of major complications from replacement surgery, important information for patients facing the choice.\nKrahn said the rate of complications from surgical removal will surprise doctors, because replacing a defibrillator is considered a minor procedure.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The article notes that surgery to replace devices that are the subject of safety advisories can cost thousands of dollars. ", "answer": 1}, {"article": "For example, insulin resistance, where the body does not use insulin effectively, occurs long before blood sugars reach the level seen in type 2 diabetes.\nResearchers found that blood tests that screened for these amino acids accurately predicted risk of type 2 diabetes in otherwise healthy adults as well as in those with traditional risk factors such as obesity.\n\"These findings could provide insight into metabolic pathways that are altered very early in the process leading to diabetes,\" says researcher Thomas Wang, MD, of Massachusetts General Hospital's Cardiovascular Research Center, in a news release.\n\"They also raise the possibility that, in selected individuals, these measurements could identify those at highest risk of developing diabetes so that early preventive measures could be instituted.\"\nResearchers say metabolic abnormalities that eventually lead to type 2 diabetes can be present years before diabetes is diagnosed.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "It\u2019s a bit early for costs, since no clinical test has been devised. When we get there we can start asking how expensive\u00a0this type of\u00a0metabolite profiling is and the costs and cost-effectiveness of screening people, especially\u00a0the asymptomatic high-risk folks with normal blood sugar\u00a0identified in\u00a0this study.", "answer": 2}, {"article": "Diabetes, high cholesterol, high blood pressure, stroke and being overweight jeopardize vascular health.\nWhile the cause of Alzheimer's remains elusive, it is clear that maintaining a healthy blood-brain barrier is a critical preventative measure.\nBy detecting Alzheimer's disease long before symptoms emerge, Dr. Nagele hopes those with disease-related autoantibody biomarkers will be encouraged to make beneficial lifestyle changes that may help to slow development of the disease.\n\"I can't think of a single patient who wouldn't take steps to prevent the progression of Alzheimer's if they could directly affect their prognosis.\"\nDr. Nagele's work focuses on utilizing autoantibodies as blood-based biomarkers to accurately detect the presence of myriad diseases and pinpoint the stage to which a disease has progressed.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Our longstanding policy is that if it\u2019s not too early to use such phrases as \u201cnearing development of a blood test\u201d or \u201cclosing in on a blood test\u201d \u2013 as this story does \u2013 then it\u2019s not to early to give at least a ballpark estimate of what this supposedly imminent test would cost. \u00a0There is no discussion of cost in this story,", "answer": 0}, {"article": "increases at age 4, although no cognitive benefit was seen in infants or 7-year-olds.\nThe lead researcher, Dr. Maria Makrides of the University of Adelaide in Australia, said this suggested that full-term babies already get enough DHA in the womb, and that \u201cthere\u2019s no extra boost\u201d from getting more.\nHe said more research was needed, but for now, \u201cI think the market is running way out in front of the science.\u201d\n\nScientists agree that DHA, naturally transmitted to a fetus through the placenta in the last half of pregnancy, is important, probably to visual and brain development.\nShe said babies in her study might have received more DHA than those in this study.\nThat study\u2019s lead author, Dr. Ingrid Helland of Oslo University Hospital, said that perhaps the benefit shown at age 4 existed at 7 but was difficult to identify amid other developmental factors.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No discussion of cost and we always think there should be. ", "answer": 0}, {"article": "Fluctuating levels of levodopa result in erratic periods of muscular control and involuntary movements throughout the day, disrupting activity at least half a dozen times a day.\nAn estimated 90 percent of levodopa-treated patients, about 200,000 people in the United States, suffer from LID, the company said.\nAdamas is also testing the drug to treat walking impairment in patients with multiple sclerosis.\nThe long-acting therapy is taken once-daily at bedtime.\nThese patients have little recourse, other than opting for deep brain stimulation, a surgical procedure that involves blocking electrical signals from targeted areas in the brain.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "While raising hopes of patients, it is irresponsible to be mentioning this \u201cnew\u201d drug, as well as its basic, generically-available ingredient, amantadine, without discussing costs to patients. The new drug is likely to be much more expensive than generic amantadine, as this STAT article reports.", "answer": 0}, {"article": "The study, conducted in conjunction with the University of Washington, involved 56 men who were assigned to receive one of three types of gels: one gel containing both testosterone plus a gel containing one of two doses of the synthetic progestin; or a gel containing testosterone on its own plus a \"placebo\" gel with no progestin.\nBecause the new study was presented at a medical meeting, the data and conclusions should be viewed as preliminary until published in a peer-reviewed journal.\nAnother question is how reversible this would be in terms of restoring sperm counts, Alukal said.\nOne important and unanswered question is what the long-term side effects of this regimen might be.\nA new formulation currently being developed that contains half the amount of testosterone might decrease or eliminate that problem, Wang speculated.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "It\u2019s probably too early to know what this treatment would cost were it commercially available, so we\u2019ll rate this not applicable.", "answer": 2}, {"article": "\"There is a tremendous lack of kidneys for transplant,\" he explained.\nBut the cost effectiveness of using these kidneys versus remaining on dialysis would be significant, he noted.\nAbout 15 percent of dialysis patients have HCV, the researchers said.\nThough some patients might not want to take the risk associated with an infected kidney, others might consider it a good option, given the high death rates for dialysis patients awaiting transplants, the researchers suggested.\nUsing hepatitis C-infected kidneys would expand the organ pool and save lives, said lead researcher Dr. Peter Reese.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story quoted the lead researcher saying the \u201cpotential cost savings could be significant,\u201d and the alternative \u2014 dialysis \u2014 \u201ccan cost more than $88,000 a year, according to the U.S. National Institute of Diabetes and Digestive and Kidney Diseases.\u201d\nBut there was no data on the cost of a transplant or of HCV treatment\u2013which is the intervention being studied.\nAccording to various online sources, kidney transplants in the U.S. average just over $400,000, with the cost of anti-rejection drugs at several hundred dollars a month. Anti-rejection drugs must be taken for life.\nThe HCV treatment used in this study, Zepatier, has a list price of $54,600 for a 12-week treatment course and $72,800 for a 16-week course. Harvoni, which was listed as the best-selling HPV treatment in 2017, cost $63,000 for an eight-week course and $189,000 for a 24-week course.\nThis means that in reality, the cost comparisons are complex, which the story didn\u2019t convey.", "answer": 0}, {"article": "Mammography with ultrasound spotted 78 percent.\nAnd it's an important story, because about half of women under the age of 50 are found to have dense breast tissue when they get their mammograms.\nA mammogram had missed her cancer, CBS News medical correspondent Dr. Jon LaPook reports.\nFortunately, her doctor had an extra tool to screen her for breast cancer - an ultrasound.\nDoes it cross her mind what would have happened if she didn't have the ultrasound?\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The broadcast mentioned that a breast ultrasound is less expensive than MRI, but it does not list the cost. Medicare reimbursement for breast ultrasound is $85, \"which does not fully cover the costs of perfoming and interpreting the examination.\" [ref Berg].\u00a0 This highlights the common cost problem of insurance payments not being sufficient to cover costs.\u00a0 The same situation applies for mammography \u2013 hospitals lose money on every mammogram they do.\u00a0 The source article contains information on issues related to increased resources anticipated with additional screening. Discussion could have easily been included.", "answer": 0}, {"article": "From a crusty baguette to a big thick steak, some foods may be hard to digest, particularly as we age. Enzyme capsules taken before a meal can relieve discomfort by helping the body to break down problem foods, say companies that sell the pills. Doctors say some enzyme supplements work well, but others need more human studies.\n\nDigestive enzymes are proteins that work like scissors to break down foods. The pancreas, where many of these enzymes are made, can slow down as we age, which can result in bloating and other gastrointestinal...", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The study does not discuss the costs of any of the products mentioned.\u00a0 You could say, \u201cwell it doesn\u2019t amount to very much,\u201d we suppose.\u00a0 But 70% of the nearly 1,900 stories we\u2019ve reviewed fail to adequately discuss cost.\u00a0 It all adds up.\u00a0 We think it\u2019s an important item to include in any story about claims for health care interventions.", "answer": 0}, {"article": "A total of 117 clusters (or \"rings\") were identified, each made up of an average of 80 people.\nMerck has also submitted the vaccine to WHO's Emergency Use and Assessment Listing procedure, a mechanism through which experimental vaccines, medicines and diagnostics can be made available for use prior to formal licensure.\nThe vaccine is the first to prevent infection from one of the most lethal known pathogens, and the findings add weight to early trial results published last year.\nTo assess safety, people who received the vaccine were observed for 30 minutes after vaccination, and at repeated home visits up to 12 weeks later.\n[1]\n\nThe vaccine, called rVSV-ZEBOV [2], was studied in a trial involving 11,841 people in Guinea during 2015.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The news release provides no information about how much the vaccine is likely to cost.\u00a0Cost is especially important in the developing world where it is most likely to be used and in large quantities.", "answer": 0}, {"article": "The potential use of psilocybin in patients diagnosed with life-threatening diseases comes at a moment when medical care at the end of life is a subject of growing concern among patients and physicians. Research finds it's still common for dying patients to get painful and futile procedures. Palliative and hospice care, both aimed at easing the discomfort of the seriously ill, are growing specialties in American hospitals. An increasing number of patients, meanwhile, are demanding the right to die with a physician's help.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Given that this is an illegal substance banned by the U.S. Drug Enforcement Agency, cost as a therapeutic would be difficult to ascertain. We liked that the story took pains to explain that approval of this drug faces many hurdles.", "answer": 2}, {"article": "Switching to AstraZeneca PLC's breast-cancer drug Arimidex after treatment with older drug tamoxifen not only helps women live longer, but also increases their chances of staying cancer-free after initial therapy for breast cancer, according to a study in the online edition of the Lancet Oncology medical journal.\n\nThe data, which come from more than 4,000 patients in three clinical trials, have shown that switching treatment from tamoxifen to Arimidex reduces the risk of dying by 29%.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not provide the cost of either anastrozole or tamoxifen.\u00a0Hormone therapy is a\u00a0regimen of daily medication for 5 years, so whether switching\u00a0medications or continuing with tamoxifen has major cost implications is debatable.\u00a0 Instead of just giving sales figures for Astra-Zeneca, the story should have explained how much these drugs cost consumers. \n\u00a0\n", "answer": 0}, {"article": "The decrease we saw was larger than is seen with the currently used medications,\" Lanctot said.\nMarinol is now being tested for its usefulness in treating Alzheimer's symptoms, Lanctot said.\nHowever, many study patients suffered from sedation due to the drug, noted Keith Fargo, director of scientific programs and outreach at the Alzheimer's Association.\n\"It's a milder form of TCH\" compared to whole-leaf marijuana, Lanctot said.\nFor example, only one person out of five to 14 treated with antipsychotics actually experiences a decrease in agitation, Lanctot said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The cost of nabilone is not mentioned.\nAccording to drugs.com:\nThe cost for Cesamet (nabilone) 1 mg capsules is around $2,054 for a supply of 50 capsules, depending on the pharmacy you visit.\nGoodRx.com quotes a similar price point with a 60-count bottle of 1 mg capsules costing $2,300-2,400.\nCost per tablet, therefore, would be roughly $40. Of note, the dosage used in this study wasn\u2019t mentioned.", "answer": 0}, {"article": "Foods with fiber, such as fruits, vegetables and whole grains, can reduce cholesterol levels, while carbohydrates that are low in fiber tend to raise triglyceride levels and lower \"good\" HDL cholesterol levels.\nWhat effects, if any, the prunes had on cholesterol levels were not mentioned in the study abstract.\nDespite the addition of several hundred calories a day to their diet, the apple-eating women didn't gain weight over the course of the study.\nThe daily serving of dried apples contained about 240 calories, according to the study.\nDaily apple consumption also significantly lowered levels of C-reactive protein and lipid hydroperoxide, two substances that may indicate an increased risk of heart disease.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Not applicable.\u00a0 The cost of apples is not in question.", "answer": 2}, {"article": "Bateman suggests her patients pace themselves, and try to do only as many activities as they can manage.\nShe's skeptical about the Lancet study, pointing out that patients improved only moderately, and not much more than those who were counseled about pacing themselves.\nWe still don't know what exactly causes the syndrome.\nAll of them received medical care for symptoms like pain, insomnia or anxiety.\nIn the study, over 600 patients with chronic fatigue syndrome were assigned to different treatments.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "This was a significant hole in the story. Any sort of behavioral therapy usually requires multiple visits that can add up to thousands of dollars per month. If you add an exercise program that could require a gym membership or even a personal trainer, this could prove to be far too expensive for the typical chronic fatigue patient.", "answer": 0}, {"article": "But what about Alzheimer\u2019s?\nOne recent analysis of previous studies found that people who took a low dose of aspirin every day for several years reduced their risk of developing Alzheimer\u2019s by 13 percent.\nIt\u2019s believed that aspirin, and possibly other nonsteroidal anti-inflammatory drugs, may reduce or head off that process.\nDoctors have long said that an aspirin a day can help ward off heart attacks.\nThe claim that aspirin can prevent the disease stems from the notion that Alzheimer\u2019s is caused by inflammation that disrupts proteins in the brain.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There was no information about the cost of treatment, though, again, knowledge about this product, including its cost, is widespread.", "answer": 2}, {"article": "Fibromayalgia is a condition marked by fatigue, disturbed sleep, and pain.\nCyclobenzaprine, marketed in higher doses by others as Amrix, Fexmid, and Flexeril, is already widely used ''off-label'' for patients with fibromyalgia, Lederman says.\n\"Bedtime treatment of fibromyalgia patients with low-dose cyclobenzaprine was safe and appears to be effective,\" says Seth Lederman, MD, president of TONIX Pharmaceuticals, which funded the study.\nTONIX is developing a lower-dose version and improving the formula, Lederman says.\nHowever, a rheumatologist not connected to the study does not expect the new drug to be a ''game-changer.\"\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The reporter did ask about cost, and since the research is at such an early stage, it may be reasonable to accept the company president\u2019s reply that he cannot estimate the cost. Since the drug is available for other uses, it would have been informative to include a range of prices for the pills already on the market for other conditions. For example, 5 mg tablets of generic cyclobenzaprine are listed as costing just $4 for 30 tablets at walmart.com. However, a new brand name formulation with a new FDA approved use may be sold at a different price than the available generics. We think that this easily identified information should have been included to provide readers with a benchmark.", "answer": 0}, {"article": "The General Director of the Danish section of MSF Jesper H. Brix notes:\n\n\"Acute malnutrition is still a major global health problem.\nThe results of the study can be used directly both in the treatment and prevention of acute malnutrition.\nThe main Treatfood results are presented in the paper: Effectiveness of food supplements in increasing fat-free tissue accretion in children with moderate acute malnutrition: A randomised 2 \u00d7 2 \u00d7 3 factorial trial in Burkina Faso, published in the open access medical journal PLOS Medicine.\nResearchers from the University of Copenhagen and humanitarian organizations have conducted a large study in Burkina Faso in West Africa treating more than 1600 children with acute malnutrition.\nThe study, published Monday 11 September in the open access medical journal PLOS Medicine, showed that corn-soy porridge should be replaced with a lipid-based nutrient supplement (LNS), a fortified peanut butter.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "No comparison is made in the news release between the cost of the current corn-soy blend (CSB) nutrient supplement and the alternative lipid-based supplement. This is strange considering that the original study devotes some space to addressing the issue of cost-effectiveness. The researchers conclude that although LNS is about twice as expensive as CSB, the possibility that it could require a shorter treatment regimen, is easier to prepare, and has a longer shelf life could make it more cost-effective in the long run. They call for detailed cost-effectiveness studies to inform policy decisions, a point that goes unmentioned in the release.", "answer": 0}, {"article": "\u25a0 A woman who freezes eggs rather than embryos avoids potential custody problems if she and her partner split up.\nFreezing eggs now is no guarantee of a baby later.\nCheck out more than one clinic and make sure you know what it defines as a \u201csuccess\u2019\u2019 \u2014 a viable transferring of an egg leading to a baby, or just a safely thawed egg.\n\u25a0 The \u201csuccess\u2019\u2019 rates of egg freezing may vary widely from one fertility center to another.\nThings to consider before freezing your eggs\n\n\u25a0 Beware of a false sense of security.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Excellent.\u00a0 Estimate of $10,000 or more per procedure and states that insurance usually doesn\u2019t cover it. ", "answer": 1}, {"article": "Dr. Gaetan Michel, Chief Executive Officer of Volition's wholly-owned subsidiary, Belgian Volition SPRL, commented, \"We would like to thank the Walloon Region for their continued support of the company.\nVolition's actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties.\nBased on this data, we believe that this test could assist clinicians in more accurate patient selection for prostate biopsy and treatment and substantially reduce the amount of unnecessary procedures in men with low-grade tumors or no tumor.\nIf these results are validated in larger trials, they will present a potentially significant new market opportunity.\nThese forward-looking statements relate to the effectiveness of Volition's bodily-fluid-based diagnostic tests as well as Volition's ability to develop and successfully commercialize such test platforms for early detection of cancer and/or other disease applications.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Although this blood test is still experimental, the company must have some idea about how much it thinks it will charge if it ever gets into clinical use. Another way the release could have addressed cost, absent an estimated cost for this test, would be to comment on the cost of a PSA, other similar blood tests this company has developed for other conditions, or even the cost of a biopsy that in theory could be avoided.", "answer": 0}, {"article": "Dana Greene, a nutritionist in Boston, regularly tells her patients to consume more fruits and vegetables, including berries.\nAlthough more research is needed to confirm these benefits, \"these data are important from a public health perspective because these fruits can be readily incorporated into the habitual diet,\" the study concluded.\nThis held true even among women who ate a diet rich in other fruits and vegetables.\nMen are likely to benefit from eating berries as well, although this study included only women, said Cassidy, who is head of the department of nutrition at Norwich Medical School at the University of East Anglia, in England.\nDuring the study period, 405 participants had heart attacks.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Not applicable.\u00a0 Costs not mentioned but we think most readers know the ballpark costs of berries.", "answer": 2}, {"article": "About the American College of Surgeons\n\nThe American College of Surgeons is a scientific and educational organization of surgeons that was founded in 1913 to raise the standards of surgical practice and improve the quality of care for surgical patients.\nAlong with discovering that the use of laparoscopy for the surgical treatment of GERD has increased significantly in the last decade, the researchers also found that, on average, the minimally invasive approach reduced length of hospital stay by approximately two days, and open operations were more than $9,000 more expensive than minimally invasive procedures.\n\"We found that laparoscopic surgery is associated with significantly lower costs.\nThe study showed that the rate of laparoscopic procedures increased from 24.8 percent in 2000 to 84.3 percent in 2013.\nPaula D Strassle, MSPH Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC also participated in this study.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The story focused on costs, including information about the relative cost comparison between what are called \u201copen\u201d surgeries and those done laparoscopically (with a thin flexible tube.)", "answer": 1}, {"article": "For more information about Hebrew SeniorLife, visit http://www.\nBOSTON -- Researchers from Hebrew SeniorLife's Institute for Aging Research, University of Western Australia, University of Sydney, and Edith Cowan University have discovered that bone density scans, typically used to determine fracture risk, could also be an aid in identifying cardiovascular disease.\nResearchers analyzed the bone density scans of over 1000 older women from Australia for the presence of calcium deposits in the large artery in the abdomen called the aorta.\nThe Musculoskeletal Center within IFAR studies conditions affecting bone, muscle, and joint health with aging.\n\"Our study highlights the fact that having a bone density test not only tells women about their risk of fracture, but also their long term risk for cardiovascular disease.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The cost of a bone density scan is not mentioned and this is an important omission. Cardiovascular risk is currently assessed based on the epidemiological data from the Framingham Heart Study. The Framingham Cardiovascular Risk Calculator is based on these data and provides an easily obtained validated 10-year risk assessment. The only tests required are a blood test for total and HDL cholesterol (at a cost of $30-$40).\nThe US Preventive Services Task Force recommends screening for the presence of osteoporosis in women over age 65 years based on a cost-benefit assessment for that disorder. That means the cost of the screening is offset by the clinical benefits obtained. The use of a bone density scan to identify cardiovascular disease, especially in women under the age of 65 specifically for the diagnosis of osteoporosis and cardiovascular disease is a separate issue. While the cost of a bone densit scan is roughly $150-250 and still relatively low compared to other type of scans, it exceeds the cost of a total cholesterol and HDL cholesterol blood test. Unless and until the use of a bone density scan has been shown to provide more precise information, the cost could be viewed as excessive.", "answer": 0}, {"article": "\"This represents their average intake of fatty acids, not just a snapshot,\" Tan said.\nA clinical trial comparing high and low intake of omega-3s in relation to brain imaging would help answer those questions, he said.\nBut questions remain over whether fatty-acid levels really influence changes in brain size, Scarmeas added.\nTan added, however, that it remains possible that factors they did not control for, such as fruit and vegetable consumption, are really responsible for the brain benefits.\nThe study, published in the Feb. 28 issue of the journal Neurology, did not prove that omega-3 fatty acids prevent mental decline, merely that there may be an association between consumption of fatty acids and brain health.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The cost of fish is not in question, although a word about the cost of fish oil supplements would not have been inappropriate.", "answer": 2}, {"article": "[Who should take statins?\nThe report greatly expands the universe of people who should be screened to see if they need the medication to everyone over age 40 regardless of whether they have a history of cardiovascular disease.\nLast month, National Institutes of Health Director Francis Collins wrote in the journal Lancet that \u201cit\u2019s a force for good.\u201d But Rita Redberg, a cardiologist at the University of California at San Francisco and editor of JAMA Internal Medicine, and others have been vocal about their belief that the drugs are overprescribed and that the side effects \u2014 which range from muscle pain and cataracts to possibly an increased risk for diabetes in women \u2014 should be taken more seriously.\nThe task force and AHA groups carry tremendous influence in medical practice and in what insurance companies will cover.\nThe recommendations also support the position of the American College of Cardiology and the American Heart Association, which in 2013 radically shifted their advice from suggesting that doctors focus on the level of a patient\u2019s low-density lipoproteins (LDL) or \u201cbad cholesterol\u201d to looking at a more comprehensive picture of risk based on things such as weight and blood pressure, as well as lifestyle factors.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Costs of the drugs are not included. Recently, total costs for statin therapy in the U.S. were estimated at approximately $17 billion. It would also be useful to know that there is a wide variety in prices over the many statins currently on the market.", "answer": 0}, {"article": "Former NASA astronaut Mark Kelly announced that he is running for John McCain's Senate seat in Arizona in the 2020 election.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The frequent emergency room visits described in this story represent a big cost burden that this treatment might help alleviate. But the treatment itself is also likely to be expensive and might counteract these benefits. Regardless, the story doesn\u2019t mention costs.", "answer": 0}, {"article": "Although the company selling Xiaflex will be Auxilium Pharmaceuticals of Malvern, Pa., the F.D.A.\nWith Dr. Korn\u2019s help, BioSpecifics licensed the drug to Auxilium in a matter of weeks, receiving $5 million initially.\napproval was a belated triumph for the drug\u2019s original developer, BioSpecifics Technologies of Lynbrook, N.Y., on Long Island.\nAuxilium and BioSpecifics hope that the half-century-old collagenase might eventually become as versatile as Botox, another bacterial product.\nIt now has only five employees and a business of collecting a roughly 11 to 12 percent royalty on sales of Xiaflex.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The main story estimates a course of treatment will cost\u00a0about $5400,\u00a0and the sidebar helpfully compared this amount to some of the other treatment options including surgery and\u00a0needle aponeurotomy.", "answer": 1}, {"article": "In Manhattan some raw-milk drinkers hire a mule to bring the white stuff to an agreed-upon location in...\nNow that's trickier.\nAnd they consider themselves lucky.\nNo?\nGot milk?\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Although the story did not contain specific price details, it did mention that the farmers can sell raw-milk and raw-milk products at a \u2018thick premium\u2019 from which the reader could gather that the costs would be more than milk which has been pasteurized.\n\u00a0", "answer": 2}, {"article": "Radiology is edited by Herbert Y. Kressel, M.D., Harvard Medical School, Boston, Mass., and owned and published by the Radiological Society of North America, Inc.\n\nRSNA is an association of more than 54,000 radiologists, radiation oncologists, medical physicists and related scientists promoting excellence in patient care and health care delivery through education, research and technologic innovation.\nResearchers said that in some cases MRI findings of additional cancers not seen on mammography may necessitate a change in treatment.\nOf the 2,021 patients, 285, or 14 percent, had additional cancer detected on MRI that was hidden from view on mammography.\nIn addition, the MRI-detected multicentric cancers were greater than 1 centimeter in size in 25 percent of the 73 patients.\n\"The results show that multicentric cancer detected on breast MRI after mammography appears to represent a larger tumor burden in approximately a quarter of patients and can result in potential changes to cancer grade and treatment,\" Dr. Iacconi said.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release does not discuss the cost of breast MRI or the cost of altering treatment based on the results of the imaging. In addition, we\u2019d note that MRI\u00a0may not be covered depending on insurance, and given the way some of the plans are currently structured, the cost may be prohibitive.", "answer": 0}, {"article": "Currently, almost all concussions in children are diagnosed only by symptoms, which are either observed, like vomiting or balance problems, or symptoms that are reported by the child, like headaches, blurred vision or feeling groggy.\nResearchers plan to do more studies with the blood test, but they hope it will be commercially available within the next 5 years.\nAs expected, the high definition imagery from the CT scans was able to identify which patients had suffered visible traumatic brain injuries.\nEven more impressive, the blood test also gave doctors an indication of how severe the brain injury was.\nCT scans can provide a more definitive profile of the injury, \"however, they are expensive and are associated with radiation exposure,\" said Papa.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release doesn\u2019t address cost at all. The release makes clear that the blood test is not ready for clinical use, stating that researchers \u201chope it will be commercially available within the next five years.\u201d However, if the release is going to discuss what such a diagnostic tool would look like (e.g., \u201cmobile devices that could diagnose concussions on the spot\u201d), it should also provide a ballpark figure on what such a diagnostic tool might cost.", "answer": 0}, {"article": "\u2018\u2018I\u2019ve had chemotherapy.\nMary Lou Smith, a breast cancer survivor and advocate who helped design the trial for ECOG, the Eastern Cooperative Oncology Group, which ran it, said she thought women \u2018\u2018would be thrilled\u2019\u2019 to skip chemo.\n\u2018\u2018These patients who had low risk scores by Oncotype did extraordinarily well at five years,\u2019\u2019 said Dr. Hope Rugo, a breast cancer specialist at the University of California, San Francisco, with no role in the study.\nBut independent monitors recommended the results on the low-risk group be released, because it was clear that adding chemo would not improve their fate.\nThe study was sponsored by the National Cancer Institute.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story states the Oncotype gene test costs $4,175 and adds that many insurers, as well as Medicare, cover it.", "answer": 1}, {"article": "People getting the combination of immunotherapy and chemotherapy were 51% less likely to die after 10.5 months than people receiving chemotherapy alone.\nDoctors can also determine if a person\u2019s lung cancer is genetically vulnerable to the checkpoint inhibitor drugs tested in the current study.\nNearly 300 people were randomly assigned to receive either the combination of the immune-based drugs or the traditional chemotherapy treatment.\nThe results are even more encouraging for people with early stage lung cancer.\nThe studies involve a group of immune-based cancer drugs called checkpoint inhibitors, which are designed to rip away the molecular cloak behind which cancer cells hide from the immune system.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The $150,000-plus annual cost of these drugs isn\u2019t mentioned.", "answer": 0}, {"article": "Overweight people on low-carbohydrate and Mediterranean diets lost more weight and got greater cardiovascular benefits than people on a conventional low-fat diet, according to a study that endorses alternative diets published in a major medical journal.\n\nThe study, which tracked 322 Israelis for two years, surprisingly found that a low-carb diet, often associated in the U.S. with high levels of meat consumption -- was better than a low-fat diet in boosting blood levels of \"good\" cholesterol, or high-density lipoproteins...", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "We wish the story would have at least mentioned whether there were any cost differences among the three diets.\u00a0 Was there a cost to the workplace cafeterias to offer these diets in the specialized manner in which they delivered them?\u00a0 We also wish the story had mentioned whether the study subjects had to pay, or were paid, to participate (a criticism of another diet study).\u00a0 ", "answer": 0}, {"article": ".\nPublished early online in CANCER, a peer-reviewed journal of the American Cancer Society, the findings may help resolve controversies over soy's potential link to breast cancer outcomes.\n\"Because of this disparity, it remains unknown whether isoflavone consumption should be encouraged or avoided for breast cancer patients.\"\nOur findings suggest that survival may be better in patients with a higher consumption of isoflavones,\" said senior author Esther John, PhD, of the Cancer Prevention Institute of California.\nA free abstract of this article will be available via the Cancer News Room upon online publication.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Although a report on this\u00a0study did not necessarily require observations involving the $ sign, the release would have been more helpful had it noted that soy products are relatively inexpensive compared to other sources of protein and might also have mentioned the financial and social costs of breast cancer.", "answer": 2}, {"article": "Most clinics just draw the cells from bone marrow or fat and inject them back into the patient without checking for stem cells, hoping that patients get better,\u201d he says.\nThe researchers say such testing is needed because there are at least 600 stem cell clinics in the U.S. offering one form of stem cell therapy or another to an estimated 100,000-plus patients, who pay thousands of dollars, out of pocket, for the treatment, which has not undergone demanding clinical study.\nHe adds that these findings are important because while use of a patient\u2019s own stem cells for regenerative therapy is extraordinarily popular, the treatments may be untested and are often poorly regulated.\nFunding for this study was from Mayo Clinic\u2019s Center for Regenerative Medicine.\nThe study was conducted in Mayo\u2019s Human Cell Therapy Lab.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release notes that patients may pay \u201cthousands\u201d out of pocket. It could have offered some information on the cost of alternative therapies, which would have put the cost burden in context.", "answer": 1}, {"article": "Atrial fibrillation is a common heart abnormality that affects nearly 3 million American adults.\nThe researchers said that the key is to start blood thinners, such as warfarin, soon after atrial fibrillation is diagnosed.\nThe longer the delay in giving blood thinners, the more the risk for dementia, the researchers said.\nIn patients with atrial fibrillation, the risk of stroke is usually measured using the so-called CHADS score, the researchers said.\nAlthough the study looked at patients taking warfarin (Coumadin), newer drugs -- including rivaroxaban (Xarelto) and apixaban (Eliquis) -- should reduce the risk of dementia even more, Bunch said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Although the lead author of the study makes a strong recommendation on behalf of prescribing blood thinners after an atrial fibrillation diagnosis, the text offers no information about what that ongoing treatment would cost. \u00a0While warfarin, the blood thinner identified in the story, remains relatively cheap, other drugs can cost hundreds of dollars per month.", "answer": 0}, {"article": "BioZorb has received 510(k) clearance from the U.S. Food and Drug Administration.\nThe study also noted that the device provides a helpful guide for post-treatment mammograms and other long-term follow-up to check for any cancer recurrence in these patients.\nThe article reports that the device provides clear visualization of the surgical site where the tumor was removed, thereby improving communication between the surgeon and radiation oncologist.\nBy providing better targeting, they said, the marker could also play a role in facilitating the use of external beam partial breast irradiation.\nThey concluded that the tissue marker could significantly reduce radiation of healthy breast tissue (an average of 65% reduction), as well as avoid irradiating inadvertent seromas that are more common with oncoplastic procedures.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The news release declares\u00a0the cost of treatment will be cut \u201cby approximately 25%\u201d without indicating a starting cost for treatment without the implant.\nBut the release does go in to some detail on how cost savings were estimated: During the three-year span of the study, the marker facilitated many physicians to shift from traditional external beam radiation to the shorter course hypo-fractionated radiation therapy, which results in a cost savings. The patient outcomes remain similar, however.", "answer": 1}, {"article": "Each year, almost 800,000 Americans suffer a stroke, and more than 140,000 die.\nDr. Walter J. Koroshetz, deputy director of the institute that sponsored the North American trial, said the Crest trial was the first in which the results of stenting and surgery had been found to be equivalent \u2014 suggesting that the stent procedure had improved with time.\nThe death rate in the trial was very low, but risks varied depending on the procedure.\nAmong the possible explanations offered for the disparities are that the European study included only symptomatic patients, who may have had more advanced disease, and that the North American trial carefully screened the doctors doing the stenting procedure, including only highly skilled physicians with a lot of experience.\nThe trial included patients who had suffered a stroke or a ministroke and those who were asymptomatic.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Although it hints at potential implications of expanded Medicare coverage for stents, this story doesn\u2019t make any explicit reference to costs.", "answer": 0}, {"article": "In patients with age-related macular degeneration - or AMD - the center of the retina responsible for vision deteriorates over time.\nThree months ago, he noticed his vision was distorted.\nShe's had two doses of Lucentis.\nHe was diagnosed with wet macular degeneration, the most acute form, affecting 1.7 million Americans.\nIt's not a cure, but it's a blessing for Rochelle Faller.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does states that the cost of the drug is about $2000 a month. However, the story should have provided more context by comparing this cost to the cost of other treatments for AMD.", "answer": 1}, {"article": "\"The issue is, can you detect these in patients that don't have advanced cancer?\" Venook said. \"The answer is, we don't know.\" The numbers tested by the MD Anderson researchers -- 251 patients with pancreatic cancer (five of whom had very early lesions), 32 with chronic pancreatitis and 120 healthy controls -- aren't nearly large enough to draw such conclusions. And getting a clear answer, Venook said, would probably require lengthy and expensive studies on very large populations.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story doesn\u2019t mention costs of the screening tool, should one be developed. Costs for screening tests vary widely.", "answer": 0}, {"article": "For example, psoriatic arthritis manifests most often in the lower extremities and is associated with the autoimmune skin condition called psoriasis, in which raised red, scaly patches appear on the skin.\nLilly has filed for approval of the drug by the U.S. Food and Drug Administration.\nThe drug, an injectable monoclonal antibody, is already commercially available for the treatment of psoriasis, for which it has been remarkably effective, said Genovese.\nAlthough the ultimate cause of the disease remains unknown, there was a good clinical rationale for hoping it might be responsive to ixekizumab.\nFor the last decade or so, Genovese said, another pro-inflammatory substance called IL-17 has been drawing the attention of immunologists focusing on psoriasis and psoriatic arthritis.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "No cost information was provided, even though the drug is already on the market for another condition. According to GoodRx, one 80 mg auto-injector of the drug costs around $4,700.", "answer": 0}, {"article": "\u201cThe difference is, the length of stay is cut in half,\u201d he said.\nUnlike other surgeries, there are no minimally invasive alternatives for valve repairs, he said.\nLiao said the robotic surgery was the right choice for Holmes, the bypass patient.\nThose limitations haven\u2019t deterred hospital executives, though, who see the robotic systems as crucial for attracting and retaining surgeons and patients.\nThe learning curve for cardiac surgeons was too steep, though, and the system\u2019s tools weren\u2019t as useful for heart surgeries as they were for other procedures, said Dr. Goya Raikar, a cardiothoracic surgeon at Regions Hospital in St. Paul.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The article says the daVinci devices have \"a million dollar price tag.\" But it does not say whether any of this cost is passed along to insurers and patients in the form of higher costs. \nThe story also mentions the possibility that hospital costs will be reduced but does not provide any data to back it up.\u00a0 \u00a0\nNonetheless, at least it nodded in the direction of costs. \u00a0", "answer": 1}, {"article": "Knee surgery for a torn meniscus is done about half a million times each year in the U.S.\nSurgery costs about $5,000, compared with $1,000 to $2,000 for a typical course of physical therapy, Katz said.\nThe therapy was nine sessions on average plus exercises to do at home, which experts say is key to success.\nThirty percent of patients assigned to physical therapy wound up having surgery before the six months was up, often because they felt therapy wasn't helping them.\nOne study participant \u2014 Bob O'Keefe, 68, of suburban Boston \u2014 was glad to avoid surgery for his meniscus injury three years ago.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story included researcher estimates: \u201cSurgery costs about $5,000, compared with $1,000 to $2,000 for a typical course of physical therapy.\u201d", "answer": 1}, {"article": "The Society works closely with many other sports medicine specialists, including athletic trainers, physical therapists, family physicians, and others to improve the identification, prevention, treatment, and rehabilitation of sports injuries.\n\u201cWhile young athletes and parents may be wary of surgery, our study shows the advantages of this treatment approach,\u201d commented Marshall.\nThe study examined 121 patients at an average of 51 months post-surgery.\n\u201cHowever, this study shows a substantial benefit for athletes undergoing surgery to prevent recurrent instability down the road.\u201d\n\nThe research data was collected between 2003 and 2013 from eight fellowship trained surgical practices, with patient ages ranging from 16 to 30 years old.\nThe average age of patients was 19 years old.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The news release does not mention costs.", "answer": 0}, {"article": "For that reason, UV devices are often used for sterilization \u2014 for medical equipment in hospitals, for example, or drinking water for backcountry campers.\n\u201cIf you have a lamp over the surgical site that can sterilize the air, you can prevent the bacteria from floating down and contaminating the wound.\u201d\n\nBrenner can\u2019t predict how long it might take for these lamps to be commercially available, but he says he\u2019s \u201cextremely optimistic\u201d about the technology.\n\u201cThink about doctor\u2019s waiting rooms, schools, airports and airplanes\u2014any place where there\u2019s a likelihood for airborne viruses.\u201d And unlike the flu vaccine, he says, far-UVC light is likely to be effective against all airborne microbes, including newly emerging virus strains.\n\u201cWe don\u2019t see cost as being a limiting factor here.\u201d\n\nUVC lamps could also have potential implications in clinical settings, as well \u2014 in the operating room during surgeries, for example.\nBut conventional germicidal lamps aren\u2019t safe for humans to be around.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The lead author of the study is quoted as saying \u201cThe lamp we\u2019re using at the moment costs less than $1,000, and you can imagine that if it were put into general circulation, the price would drop dramatically \u2026 we don\u2019t see cost as being a limited factor here.\u201d\nThe first part of the quote gives a frame of reference, though \u201cless than $1,000\u201d is somewhat ambiguous. The second part also is speculative, so this is a barely passing satisfactory.", "answer": 1}, {"article": "Bathing-suit season is here and with it, anxiety over cellulite. A new laser device that burrows under the skin is getting praise from some doctors who say it gives more dramatic and longer-lasting results than previous treatments, but others caution that more research is needed.\n\nCellulite is a dimpled, uneven appearance of skin caused by fat underneath. It affects some 85% of women and about 5% of men. Until recently, the main treatments to battle cellulite have been external treatments such as creams and radio-frequency and...", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Costs were discussed. But the story didn\u2019t discuss insurance coverage.\u00a0 One online reader did, though, writing:\n\u201cInteresting how while plastic surgery isn\u2019t covered by health insurance, the follow-up care and complications often are. The side effects of this procedure sound horrific, and we all get to pay for it.\u201d", "answer": 1}, {"article": "Her mother, aunt and grandmother died of cancer.\n\u201cProphylactic removal of ovaries and fallopian tubes is strongly recommended in women before age 40 in BRCA1 and BRCA2 mutation carriers,\u201d said Dr. Susan Domchek, executive director of the University of Pennsylvania\u2019s Basser Research Center, which specializes in BRCA mutations.\n\u201cThere is no effective screening for ovarian cancer and too many women with advanced stage ovarian cancer die of their disease.\u201d\n\nWriting for The New York Times\u2019s Op-Ed page, Ms. Jolie Pitt, 39, said she had expected to have her ovaries and fallopian tubes removed, a procedure called a laparoscopic bilateral salpingo-oophorectomy, but that a cancer scare made her decide to undergo the procedure sooner.\nCancer experts said Tuesday that the actress and filmmaker Angelina Jolie Pitt was wise to have had her ovaries and fallopian tubes removed last week because she carries a genetic mutation, BRCA1, that significantly increases the risk of ovarian cancer, a disease so difficult to detect that it is often found only at an advanced, untreatable stage.\nIt is unclear how common the mutations are in other racial and ethnic groups.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Since the story focuses on the story of Ms. Jolie Pitt, a woman with financial resources beyond those of most women, we think discussion of costs is particularly relevant. First, there are costs of genetic testing to find out if you carry the BRCA mutation. Those tests may cost hundreds or several thousand dollars, and insurance coverage for the tests varies with different carriers.\u00a0[As noted by a commenter, the costs of BRCA testing are covered under the Affordable Care Act for women at high risk of breast cancer. Here\u2019s a post from the KevinMD blog with more information] As far as the surgery goes, commercial and government insurers consider elective removal of ovaries and bilateral mastectomy to be standard of care for this condition, and provide coverage under a specific set of criteria.", "answer": 0}, {"article": "Patients lie in a CT scanner, which takes a series of pictures from a variety of different angles, and a computer compiles the snapshots in two different ways.\nThat\u2019s a bit of a surprise, given that not all medical experts agree on whether the virtual screen is as reliable as a traditional colonoscopy, in which doctors insert a scope with a small camera into the colon.\nAnd given the relatively low cost of investing in the software and other equipment required to run a virtual scan, more hospitals may be adding the option to their patient services.\nThe prep for both the virtual and actual colonoscopy is the same \u2014 the dreaded \u201ccolon cleanse\u201d that many patients find is the worst part of the procedure.\nBut according to Dr. Marc Gollub, director of CT and gastrointestinal radiology at Memorial Sloan-Kettering Cancer Center, \u201cthe radiation is much lower than a regular CT scan and has not been proven to be of any risk.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No discussion of cost except a vague line about \u201cthe relatively low cost of investing in the software and other equipment.\u201d But nothing on the patient charges.\u00a0 For a story headlined, \u201cIs It Right For You?\u201d this would seem to be important.\nAnd the discussion of Medicare coverage is wrong when it says that the US Preventive Services Task Force concluded the evidence \u201cwasn\u2019t strong enough to justify Medicare coverage.\u201d\u00a0 The USPSTF concluded\u00a0 that the evidence is insufficient to assess the benefits and harms of computed tomographic colonography and fecal DNA testing as screening modalities for colorectal cancer.\u201d What Medicare chooses to do is its decision \u2013 not that of the USPSTF.", "answer": 0}, {"article": "But an electrolyte imbalance caused by dehydration, influenza or other health problems that deplete the system of potassium, magnesium and other minerals also can cause cardiac arrest.\nBut putting the therapy into practice in many hospitals has been slow.\nThat's most likely what happened to Mr. Beck, whose heart arteries were clear.\nMr. Beck said he didn't regain full consciousness for nine days.\nAlthough the cases are few, AGH's success rate points to the value of the therapy.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not include any information about the expense of this treatment; it also does not indicate whether hospitals need to purchase special equipment in order to provide this treatment.", "answer": 0}, {"article": "\u201cIf you can give [someone like Robison] an idea of what emotions may be hidden behind a voice or face, then it enables his brain, without TMS, to change the way he approaches life and people.\u201d\n\nNevertheless, Pascual-Leone acknowledges that these changes can be challenging as well as beneficial, as Robison describes.\nStill, for all the positive changes described in \u201cSwitched On,\u201d Robison\u2019s fourth book, there were negatives he was forced to deal with.\nYet it is more than a linear account of a life transformed by cutting-edge medical technology.\nIt didn\u2019t occur to me that most of the news out there, most of the emotion, is, if not bad, at least not all good.\n\u201cThe experience was richer and deeper, with an added layer of feeling,\u201d he writes.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There is no discussion of costs. The exact number of sessions necessary, the duration of treatment and the repeat treatments through time are not discussed, either. But, an idea of cost is important\u2013this treatment is unlikely to be covered by insurance, and readers given hope by this story will want to know how much it may cost.", "answer": 0}, {"article": "(Reporting by Susan Kelly, editing by Dave Zimmerman)\nBergenstal said patients who are not achieving their goals with multiple daily injections should consider using a pump and sensor.\n\u201cWhat we\u2019ve been able to show is that by combining this technology, you can lower the A1C, which reduces your risk of complications, and you can do it safely without increasing your rate of hypoglycemia,\u201d said study author Dr. Richard Bergenstal, executive director of the International Diabetes Center at Park Nicollet Health Services in Minneapolis.\nAdult and pediatric patients using the pump and continuous glucose monitoring device saw reductions in levels of A1C, a commonly used measure of blood sugar, that were four times greater than those who received regular insulin injections in the study of 485 patients ranging from age 7 to 70.\nIn the study, patients on pump therapy saw a reduction in average A1C levels of 0.8 percent, compared with a 0.2 percent average reduction for those who received multiple injections.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "1clip_filelist.xml\" rel=\"File-List\"/>\n\n\n\nThe story does not mention that the devices cost thousands of dollars and their use requires ongoing purchases of supplies and services. These costs may or may not be covered by health care insurance.", "answer": 0}, {"article": "Related: New Test Detects Heart Disease Risk, Especially for Black Women\n\nIt\u2019s not just the fat cells that lead to heart disease, the No.\nRelated: Why Young Women are Having Heart Attacks\n\nThe team studied more than 450 people having heart bypass surgery, removing some of the fat clogging their arteries.\n\u201cTreatments that are known to reduce the risk of heart attacks, such as statin drugs, reduce inflammation much more than any detectable reduction in coronary artery narrowing,\u201d said Oxford\u2019s Keith Channon, who also worked on the study.\nResearchers say they\u2019ve developed a better way of scanning someone\u2019s heart to predict who is most at risk of a heart attack or stroke \u2014 long before conventional imaging methods can do it.\n\u201cBut until now, there's been no way to detect inflammation in the coronary arteries.\u201d\n\nRelated: Half of People Who Have Heart Attacks Don\u2019t Even Know It\n\nDoctors run many different tests to assess someone\u2019s risk of heart disease.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The article doesn\u2019t discuss what the study authors new \u201cway\u201d of assessment might add in the way of costs.", "answer": 0}, {"article": "Cirrhosis - the most severe stage, occurring after years of inflammation, where the liver shrinks and becomes scarred and lumpy; this damage is permanent and can lead to liver failure (where the liver stops working properly) and liver cancer\n\nIt can take years for fibrosis or cirrhosis to develop and the presence of this scarring predicts those people with the worse prognosis.\nWe currently have to rely on liver biopsy to measure fibrosis at its early stages - by examining a piece of the liver under the microscope.\nIt's important to make lifestyle changes to prevent the disease from getting worse.\nThis research was supported by the National Institute for Health Research (NIHR) Biomedical Research Centre.\nIt is the first time an epigenetic signature in blood has been discovered which is diagnostic of the severity of fibrosis for people with Non-alcoholic Fatty Liver Disease (NAFLD).\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The technique is likely not at the stage of commercial availability so costs would be uncertain. Still, cost isn\u2019t mentioned at all, even in an abstract way. Could this be comparable to the cost of existing diagnostic tools? Cheaper? More expensive? There\u2019s still much work to do to demonstrate the value of this test.", "answer": 0}, {"article": "A health claim, in the language of the FDA, characterizes the relationship between a substance and a reduction in the risk of contracting a particular disease.\nThe Food and Drug Administration said it reviewed 105 articles and other publications submitted as part of the petition but could find no evidence to support claims of the beverage's health benefits.\n\"There is no credible evidence to support qualified health claims for green tea or green tea extract and a reduction of a number of risk factors associated with (cardiovascular disease),\" the FDA said on its Web site last week.\nNonetheless, the belief that drinking green tea confers health benefits has driven its popularity over the past decade, the Tea Association of the United States has said.\nIto En Ltd., a Japanese company that bills itself as the world's largest green tea company, and its U.S. subsidiary, Ito En (North America) Inc., petitioned the FDA in June, seeking to make the claim that drinking at least five ounces of green tea a day may reduce the risk of heart disease.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The article did not contain any reference to the cost of green tea.", "answer": 0}, {"article": "Dr. Gheorghe Doros has received payment for statistical analysis from Bayer Pharma.\nAccording to the researchers, long-term TTh in men with hypogonadism appears to be an effective approach to achieve sustained improvements in cardiometabolic function and reduces the risk of CV events.\nThese findings appear online in the Journal of Cardiovascular Pharmacology and Therapeutics.\n\"The low CV events observed in the T-group compared to the untreated (control) group strongly suggest that TTh is protective.\nIn the non-treated control group, there were 21 deaths, 19 of which were related to CV events.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Cost estimates for long-term testosterone therapy are missing from this release. This matters because, although health insurance often covers testosterone treatments if a physician deems them warranted, a month\u2019s worth of medication can cost hundreds of dollars.", "answer": 0}, {"article": "Brain waste includes amyloid \u03b2 (amyloid) and tau proteins, chemicals that negatively affect brain processes if they build up.\nDr. Benveniste cautioned that while the research team speculates that the human glymphatic pathway will clear brain waste most efficiency when sleeping in the lateral position as compared to other positions, testing with MRI or other imaging methods in humans are a necessary first step.\n\u201cThe study therefore adds further support to the concept that sleep subserves a distinct biological function of sleep and that is to \u2018clean up\u2019 the mess that accumulates while we are awake.\nThe method enables researchers to identify and define the glymphatic pathway, where cerebrospinal fluid (CSF) filters through the brain and exchanges with interstitial fluid (ISF) to clear waste, similar to the way the body\u2019s lymphatic system clears waste from organs.\nTheir finding is published in the Journal of Neuroscience.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Cost is not an applicable criteria since there\u2019s no cost associated with sleeping (unless one goes to a sleep clinic).", "answer": 2}, {"article": "But, that's an entirely different problem, compared with atrial fibrillation,\" he said.\nWith apixaban, patients can use a standard dose that doesn't need monitoring and adjusting, Ansell said.\nAs to apixaban's expected higher price tag, Ansell said that since the drug does not require monitoring and the incidence of stroke and major bleeding are less, savings in doctors' visits and stroke treatment should more than compensate.\nAlso, unlike warfarin, apixaban has few interactions with other drugs or foods, he added.\nIn that trial, published in July in the New England Journal of Medicine, apixaban's use was associated with raised odds for bleeding -- without providing patients with any reduction in heart attack risk.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story mentioned that apixabane would cost more than warafarin, and included a quote from a company spokesperson to indicate that the exact price is uncertain as the medication has not yet been approved. \u00a0The story also presented a reasoned examination of total costs for the use of warafin that accounted not just for per pill costs but also the expenses associated with the routine blood draws to examine warafarin levels.", "answer": 1}, {"article": "Uterine fibroids are benign tumors that grow in and around the uterus.\nPatients with the condition say it\u2019s time for better treatments.\nIf a woman has no symptoms, treatment of fibroids isn\u2019t necessary, experts say.\nWomen often must take it with hormone replacement therapy.\nThe drug has been available in Europe and Canada for several years.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The article does not offer any cost information.", "answer": 0}, {"article": "Milo A. Puhan, MD, is director of the Epidemiology, Biostatistics and Prevention Institute and professor of epidemiology and public health at the University of Zurich.\nThis information is essential for making rational guidelines for aspirin in primary prevention.\nHere\u2019s the problem: The lower an individual\u2019s risk of a future heart attack or ischemic stroke, the less he or she will benefit from taking daily low-dose aspirin.\nThat means for some low-risk individuals, taking daily aspirin could do more harm than good.\nThat\u2019s ironic because aspirin is ubiquitous and most patients perceive it to be safe and harmless.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "It is universally known that aspirin is cheap, sold widely and in a manner where its cost will not be a barrier to consumption, so the cost information is not necessary to reiterate in this report.", "answer": 2}, {"article": "Radiologists and urologists have been frustrated for decades by the inability of conventional imaging tests, such as CT and MRI, to distinguish benign from malignant kidney tumors.\nThe research team reports that the potential improvement in diagnostic accuracy will spare thousands of patients each year in the United States alone from having to undergo unnecessary surgery.\nThe addition of sestamibi SPECT/CT increased the reviewers\u2019 diagnostic certainty in 14 of the 48 patients, or in nearly 30 percent of all cases.\n\u201cSestamibi SPECT/CT offers an inexpensive and widely available means of better characterizing kidney tumors, and the identical test is now being performed as part of a large trial in Sweden, for which the first results have just recently been published and appear to confirm our conclusions.\u201d\n\nAlthough further study is needed to validate the accuracy of sestamibi SPECT/CT, this test appears to be a less expensive, faster, noninvasive alternative to surgery, says Michael A. Gorin, M.D., the other resident involved in developing this approach and now chief resident with The James Buchanan Brady Urological Institute of the Johns Hopkins University School of Medicine.\nFollowing surgery, similarly \u2018blinded\u2019 pathologists analyzed the tumors without knowing the radiologists\u2019 imaging results.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "This release notes several times that sestamibi SPECT/CT is inexpensive and widely available. It would have been good to include some cost estimates, particularly since reducing unneeded surgeries by the \u201cthousands\u201d presumably would be a huge cost savings.", "answer": 0}, {"article": "\"We're trying to make it simpler, but we don't want to lose the efficacy,\" he said.\nBredesen said that to simplify the program, they are connecting patients with health coaches.\nJames E. Galvin, M.D., M.P.H., a professor of clinical biomedical science at FAU's Charles E. Schmidt College of Medicine and a professor in the Christine E. Lynn College of Nursing, who was not involved in the study, agreed that personalized approaches such as the MEND protocol are the types of approaches needed for this disease going forward.\nBredesen noted, too, that the MEND protocol was suitable for patients in the early stages of Alzheimer's.\nBredesen said that his team has a couple of larger trials planned to confirm or refute the results in the current study and to address key questions about how long results can be maintained and how late in the course of cognitive decline reversal is possible.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story doesn\u2019t discuss costs. Although the MEND protocol appears to involve many inexpensive interventions, such as reducing processed carbohydrates, practicing yoga, and taking over-the-counter supplements such as melatonin, those expenses aren\u2019t within the reach of millions of Americans. Moreover, the costs of hormones and supplements as well as health coaches to guide patients through the individualized program would be significant.\u00a0The story also does not mention that the researchers recommend widespread genetic testing to determine risk for Alzheimer\u2019s, which comes at a cost, too.", "answer": 0}, {"article": "Researchers at Brigham and Women's Hospital and Harvard Medical School set out to test melatonin's effects...\nWhat was lacking was clear evidence that taking melatonin in supplement form had the same sleep-inducing effect.\nThat's why there's so much interest in a study in the current issue of the journal Sleep.\nDo melatonin supplements really help people sleep?\nBut the scientific evidence has been slim.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Though melatonin is readily available, no estimates for the cost of treatment were provided.", "answer": 0}, {"article": "The study, published in the December 26 issue of the Journal of Clinical Oncology, showed that patients treated with reduced radiation had less difficulty swallowing solids (40 percent versus 89 percent of patients treated with standard doses of radiation) or impaired nutrition (10 percent versus 44 percent of patients treated with regular doses of radiation).\n\u201cAnd while traditional chemoradiation has demonstrated good tumor control and survival rates for patients, too often they encounter unpleasant outcomes that can include difficulty swallowing solid foods, impaired nutrition, aspiration and feeding tube dependence,\u201d said Dr. Burtness.\n\u201cToday, many younger patients are presenting with HPV-associated squamous cell carcinoma of the oropharynx,\u201d said Dr. Burtness.\n\u201cYounger patients may have to deal with these side effects for decades after cancer treatment.\nPatients with good clinical response then received reduced radiation.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release does not mention costs. We would have liked some context. What kind of rehabilitation costs are associated with the severe lifelong swallowing side effects that are mitigated by the reduction in dose discussed in the study?", "answer": 0}, {"article": "We can't find the page you're looking for. Try one of these options.\n\nAre you sure this is the right web address? Let us know.", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The cost of therapy is not mentioned in the news release. Media reports have said prices will depend on how often the cap is used during chemotherapy, but it\u2019s likely a course of treatment will cost between $1,500 and $3,000.\nAccording to DigniCap\u2019s website, the company is working toward getting the treatment covered by health insurance. It also states, \u201cDignitana is in the process of setting up a Patient Assistance Program to help subsidize DigniCap\u00ae treatment costs for patients with financial need.\u201d Since there is no discussion of costs in the FDA news release, we give it a Not Satisfactory rating here.", "answer": 0}, {"article": "Esler's team found that more than 83 percent of those who had denervation treatment before had a drop in systolic blood pressure of at least 10 mmHg after six months and almost 79 percent maintained the reduction at 12 months.\nThe procedure is safe as well as effective, the study authors said.\nIf it is applicable, it could mean patients need not take blood-pressure drugs, Esler suggested.\nThe study was funded by medical device maker Medtronic.\nEven with this technique, people will most likely still have to take blood-pressure medications, Singh said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No discussion of costs.\u00a0 This approach is not going to be cheap.", "answer": 0}, {"article": "\"The idea is when you get the treatment and it is successful and the pain gets better then you can start cutting down the on the medication, and see how low you can go\" said Dr. Richard Cruciani.\nThis therapy is being tested at several centers around the world and more study is needed, but this new variation on an ancient concept is promising -- using electricity to try to zap the perception of pain.\n\"Whatever the cause, it dials down the pain on the brain center.\nIt's called TDCS, Transcranial Direct Current Stimulation.\nThis new approach places them right on the scalp.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The reporter says \"That\u2019s the hope\u2026whatever the cost.\"\u00a0 No cost was discussed.\u00a0 Granted, this is early research on an experimental approach.\u00a0 But it was given network news time.\u00a0 Our rule of thumb is:\u00a0 if it\u2019s not too early to project possible benefits, it\u2019s not too early to project possible costs. If the story can use words like \"breakthrough, promising, hope\" to describe this very early research and project those words onto an unsubstantiated potential market of 1 in 4 Americans suffering from chronic pain or 1 in 10 having it for over a year, then we suggest it\u2019s time to talk costs. \u00a0 \n\u00a0\n ", "answer": 0}, {"article": "Though randomized controlled clinical trials of bright light are difficult to do properly \u2014 one expert is fond of saying that it is difficult to \u201cblind\u201d studies of bright light \u2014 the American Psychiatric Association considers bright-light therapy an effective low-risk treatment for both S.A.D.\n\u201cIf you can fix the drift, you can fix the depression.\u201d\n\nLight therapy may even help with major nonseasonal depression, experts say, and with sleep disorders.\n\u201cStudies have also shown that light influences serotonin and epinephrine pathways in the brain, the same neurotransmitter systems known to be affected in people with general depression.\u201d\n\nBut while part of the appeal of light therapy is that it can be self-prescribed, using a light box is not as simple as it may appear.\nAnd because it has few side effects, researchers are studying whether light therapy can help with depression during pregnancy and be used to treat elderly people with dementia.\nSome say their patients don\u2019t have the patience to sit in front of a light for 30 to 45 minutes every morning.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Light sources for therapy cost about $200, the story explains. But it gives an incomplete picture by not factoring in follow up visits to a health provider when getting light therapy vs. receiving medication or psychotherapy. The story raises a very big issue, but does not provide evidence. Do patients need the same level of followup from a physician when getting light therapy as those treated with medication or psychotherapy?\u00a0 Does avoidance of drug side effects lead to additional overall cost savings to the health care system?\nThe story states \u201cthere is little profit to be made from it and no commercial incentive to promote the treatment.\u201d At $200 per box online \u2013 and with \u201cmillions\u201d using \u201cbright-light therapy as the treatment of choice\u201d \u2013 as the story claims \u2013 is there not some commercial incentive in those kinds of numbers?", "answer": 0}, {"article": "Without strong evidence for its efficacy, the American Congress of Obstetricians and Gynecologists does not include the treatment in its Practice Bulletin for Urinary Incontinence in Women. L. Elaine Waetjen, professor of obstetrics and gynecology at the University of California, Davis Medical Center, who has spent more than 15 years treating women for this problem, said that there is \"no scientific evidence that the O-Shot works for incontinence and there is also no clear biological mechanism for why it should treat this condition.\"", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does a good job of not only giving the price of the O-shots, but leaving the reader with the clear understanding that they may be spending money on a therapy for which there is no scientific evidence of benefit. The story could have been strengthened by noting the costs of alternatives to the O-shot.", "answer": 1}, {"article": "Dr. Scolnick has not seen the results of the Novartis trial, but was told of them and concluded that if the drugs work in fragile X, \u201cthere\u2019s nothing to say that they won\u2019t work in some cases of broader autism-spectrum disorders.\u201d\n\nThe roots for the Novartis results began in 1982 when Stephen T. Warren, then a graduate student in genetics at Michigan State University, was looking for a job and something to research.\nSure enough, mice, fish and fruit flies that through genetic engineering were made to have fragile X seemed to become normal when given Dr. Bear\u2019s compound.\nThey found that if Dr. Bear reverse-engineered his compounds, they seemed to slow brain transmissions.\nAnd despite going to some of the best hospitals in the country, four years would pass before Andy\u2019s condition was properly diagnosed.\nThe results of the trial were something of a jumble until Novartis scientists noticed that patients who had a particular, undisclosed biological trait improved far more than others.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Since the drug is in such an early stage of development,\u00a0we\u2019ll call this one not applicable.", "answer": 2}, {"article": "The home self-collection test indicated that 12.4 percent of women were infected with high-risk HPV, the self-collection tests used in the clinic found 15.5 of the women had high-risk HPV infection, and the clinician-collected test identified 11.4 percent of the women had high-risk HPV infection.\nEarlier this year, the U.S. Preventive Services Task Force gave an \"A\" rating to HPV primary screening alone for women aged 30 to 65.\nOffering HPV testing using self-collection by mail has a lot of potential to reach women who are the highest risk of being screened: those who don't access regular medical care.\"\nSmith said there is more work to be done, such as identifying ways to make the self-collection process more efficient and cost-effective, and getting FDA approval for the clinical use of self-collection for cervical cancer screening.\nResearchers provided study participants with self-collection brushes along with instructions for how to take a sample from inside the vagina.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release does not place a pricetag on HPV screening \u2014 which would include the test kit, analysis and follow-up clinical visit. However, the release does explicitly say that \u201cthere is more work to be done, such as identifying ways to make the self-collection process more efficient and cost-effective.\u201d That acknowledgment is enough to earn it a satisfactory rating here.", "answer": 1}, {"article": "Co-authors are: Leslie Donato, Ph.D.; Sandra Bryant; Grant Spears; Peter Berger, M.D.\nThe present study is also the first to test its clinical utility in a U.S. population.\nPatients were grouped into four risk categories according to their ceramide levels: low (0\u20132), intermediate (3\u20136), moderate (7\u20139) and high (10\u201312).\nResearchers measured four different types of ceramides in the blood at baseline and combined the values into a 12-point scale.\nOverall, 5.1 percent of patients had a major cardiovascular event each year.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The news release provides no information about how much the blood ceramide test costs.", "answer": 0}, {"article": "Learn more about both types of diabetes and treatments from the National Institute of Diabetes and Digestive and Kidney Diseases.\nThe new drug, Afrezza, which is awaiting approval from the U.S. Food and Drug Administration, works faster, keeps blood sugar levels at a closer to normal level and has less risk of causing low blood sugar levels (hypoglycemia) than currently available injectable insulins, researchers say.\nWhile Afrezza looks promising, it can't replace all injections for people with diabetes.\nAfrezza may have an impact on lung function, but Leone-Bay said once people stopped taking Afrezza, this effect went away.\nThis finding came after Exubera had been pulled from the market, and the sample size wasn't large enough to draw a definitive link between the drug and the increased risk of lung cancer.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Costs are not mentioned. It\u2019s relevant because one of the problems Exubera faced was that\u00a0it cost about twice as much\u00a0per day as standard insulin, according to a NY Times article. The overall economic burden of Exubera was influenced by (see page 105 of this\u00a0journal article) its enormous development costs and the needs for\u00a0much higher doses than standard insulin,\u00a0thorough training for patients prior to using the inhaler, and multiple lung function tests.", "answer": 0}, {"article": "The armpits, palms, and soles are often affected.\nAll had hyperhidrosis, a condition where a person sweats much more than the body needs to cool itself.\nHe presented the findings here at the annual meeting of the American Academy of Dermatology.\nThe study was small and the findings are preliminary.\nIt works, he says, by heating and destroying the sweat glands under the arm.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story seems to excuse itself from this issue by saying the researcher \u201cdid not estimate costs.\u201d\u00a0 Well, that\u2019s not good enough.\nThe story explains that the technology is already approved for eyelid lifts.\u00a0 Even though that\u2019s a totally different ballgame, what does that cost?\u00a0 Use of new technologies is not free \u2013 and stories promoting efficacy claims shouldn\u2019t give researchers a free ride on the cost issue.\nIt took us just seconds to find cost estimates online.\u00a0 One plastic surgeon wrote: \u201d rough pricing guidelines: Axillary treatment: Botox (~6 months): $600-995; Ultrasonic therapy (permanent): $3800 Hands OR Feet: Botox (~6 months): $400-895.\u201d", "answer": 0}, {"article": "Metastatic SCCA, a cancer often associated with human papillomavirus (HPV) infection, is normally treated with chemotherapy, although no trials have established a standard of care.\nThe phase II study, for which findings are being presented at this week's American Association for Cancer Research's annual meeting in New Orleans, was designed and led by researchers at The University of Texas MD Anderson Cancer Center's Human Papillomavirus-Related (HPV) Cancers Moon Shot Program.\nThe study revealed encouraging correlations between immunologic biomarkers and responses to treatment.\nStudy results showed a decrease in frequency of CD8 T-cells in post-treatment tumor samples among responder-patients.\nThe study employed the monoclonal antibody nivolumab, one of the drugs represented among the growing arsenal of immunotherapy therapies.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There is no discussion of the sky-high cost of nivolumab, the drug tested in this study. It\u2019s disappointing because it\u2019s at least the second time MD Anderson has failed to mention the cost of this drug in a news release. In a separate review last fall, HealthNewsReview.org calculated the monthly cost of nivolumab to be in the vicinity of $12,600, excluding administration. Nor does this review address whether a patient\u2019s health insurance is likely to cover the cost.", "answer": 0}, {"article": "Prostate cancer patients had a 28 percent higher relative chance of having a fatal heart attack and a 21 percent increased chance of dying from heart disease.\nStill, these risks were low in absolute terms: researchers estimated the hormone therapies would cause an extra 10 heart problems \u2013 like chest pain or a heart attack \u2013 a year for every 1,000 prostate cancer patients.\nHelen Rippon, head of research management at Britain's Prostate Cancer Charity, said the benefits of hormone therapy ultimately outweighed the increased risk of heart problems.\n\"What patients should do is talk about this with their doctor,\" said Michael Thun, a vice president emeritus at the American Cancer Society, who was not connected to the research.\nThus, hormones that interfere with testosterone could be deadly.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "\n\n\nCosts are not mentioned in the story.", "answer": 0}, {"article": "They form when the skin is rapidly stretched, such as during puberty, pregnancy, and rapid weight gain, says Joshua Zeichner, MD, director of cosmetic and clinical research at Mt.\nThe study, funded by Merz Pharmaceuticals, which makes the cream, was presented at the annual meeting of the American Academy of Dermatology.\nThe new product also contains pennywort, a plant found in Asia, Africa, and the Americas that has anti-inflammatory properties and is widely used in Indian naturopathic medicine for ulcer healing, she says.\nAnd it has sulfur, which fights bacteria and infection, and a moisturizing cream to help rehydrate the skin, Draelos says.\nOnions contain flavonoids, a type of antioxidant, that have anti-inflammatory properties, Draelos says.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story notes that a 5.29-ounce tube of the product retails for $39.99 at drugstores.", "answer": 1}, {"article": "He says:\n\n\"When I was diagnosed with early prostate cancer, I had the option of active surveillance but I didn't want to wait until it got worse so when I was offered a place on the trial I signed up straight away.\nThe chances of cancer progressing to a more dangerous stage were three times lower for patients on VTP, and the treatment doubled the average time to progression from 14 months to 28 months.\nWith such an approach we should be able to achieve a significantly higher remission rate than in the trial and send nearly all low-risk localised prostate cancers into remission.\nThe VTP treatment is currently being reviewed by the European Medicines Agency (EMA), so it is likely to be a number of years before it can be offered to patients more widely.\nThe new treatment, 'vascular-targeted photodynamic therapy' (VTP), involves injecting a light-sensitive drug into the bloodstream and then activating it with a laser to destroy tumour tissue in the prostate.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There\u2019s no discussion of the costs of either VTP or of active surveillance, the current standard of care for low-risk prostate cancers. Given that VTP is a new commercialized therapy involving both a drug and a device, it\u2019s likely to be considerably more expensive than monitoring.\nFurthermore, the study indicates that 75 of the 197 patients who started the therapy were retreated within 2 years. \u00a0Because cancer was still being detected during follow up, this implies that these patients will need the same monitoring as those undergoing active surveillance.", "answer": 0}, {"article": "\"Weight loss was similar but substantial in both groups we studied, but blood pressure improved more in the low-carb dieters,\" said study author Dr. William Yancy Jr., an associate professor of medicine at Duke University Medical Center and a staff physician at the Department of Veterans Affairs Medical Center in Durham, N.C.\n\n\"There are options out there.\nThe more intensive intervention was more successful with 31 percent losing more than 5 percent of their body weight, compared to just 9 percent of the Internet group.\nTheir study, published in the Jan. 25 issue of the Archives of Internal Medicine, found that both diets helped participants lose almost 10 percent of their body weight.\nThe group taking orlistat received a 120-milligram dose of the drug three times daily and got less than 30 percent of their calories from fat.\nAnd, she said, these studies show that you don't necessarily need to get to your \"ideal body weight\" to make substantial improvements to your health.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not mention the costs of the medication used in the low-fat diet group.\u00a0Including this information would have helped readers make\u00a0a more\u00a0informed comparison of the two approaches. \u00a0", "answer": 0}, {"article": "Obstructive sleep apnea (OSA) is marked by interruptions in breathing while asleep; it is common among children with enlarged tonsils or adenoids.\nHowever, half of the 417 children in this latest study who had sleep apnea and were bedwetters stopped wetting the bed after they had their tonsils or adenoids removed.\nThose who did not stop wetting the bed after the surgery were more likely to be born prematurely, be male, be obese or have a family history of bedwetting, the investigators noted.\nThere are many other causes of bedwetting, Lakshmanan said.\nPremature birth was the greatest predictor of continued bedwetting after surgery.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not discuss costs. Tonsillectomies are not cheap, and the cost definitely should have been factored in here. Also, there is a question about whether insurance would cover a tonsillectomy that was done primarily to resolve a bedwetting problem.", "answer": 0}, {"article": "You've probably heard about it \u2014 maybe you even remember seeing it once \u2014 but you're not really sure what it is or even where to find it.\n\nThe female condom (FC2), or internal condom, is a non-hormonal barrier method of birth control. But instead of going on a penis, it goes in a vagina, which is why it's also sometimes referred to as an internal condom. For more information, BuzzFeed Health spoke with two experts who could demystify this lesser-known contraceptive:\n\n* Dr. Harry Fisch, clinical professor of urology and reproductive medicine at Weill Cornell Medical College, and chief corporate officer of Veru Healthcare, which distributes FC2\n\n* Dr. Lauren Streicher, associate clinical professor of obstetrics and gynecology at Northwestern University\u2019s Feinberg School of Medicine", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Hooray for details on cost, including nuances about \u201cfree\u201d but only with prescription. We also believe the details on availability and position on shelves is very important.\nHere\u2019s what story says:\n\u201cUp until the past few months, the female condom lived on store shelves, usually right next to the male condoms. But it was difficult to get shelf space and secure the product in every outlet, Fisch tells BuzzFeed Health. Plus, the female condoms came in three-packs, making them more expensive than a big box of male condoms.\nRecently, Veru Healthcare moved FC2 behind the counter, where it\u2019s available in packs of 12 with a prescription from your provider. Under the Affordable Care Act, insurance plans must cover at least one form of contraception from each FDA-approved method at no cost. And since FC2 is the only FDA-approved female condom, it will be free with a prescription from your doctor.\u201d", "answer": 1}, {"article": "The requested URL /usnews/health/articles/070107/15downs.htm was not found on this server.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Although the story does mention the cost of amniocentesis and chorionic villus sampling, the story does not mention the cost of the new twofold screening protocol. This is important information for consumers given that insurance may not cover the screening yet.", "answer": 0}, {"article": "The longer the comet tail, the more DNA damage is present, which correlates with the presence of cancer.\nThe research team believes that the test could be the first screening tool to 'rule in, or rule out' cancer in patients under suspicion of the disease, alongside other traditional diagnostics methods.\nIMSTAR's vice-president for medical applications, Dr Michel Soussaline, confirmed that the company will be working to automate the full test workflow further to take it to market.\nScoring a minimum of 2,000 cells per slide, the IMSTAR Pathfinder\u2122 system was able to separate all individuals of the cancer group from the healthy control group with confirmed statistical significance.\nThe Bradford team had scored 100 cells per slide, but the Pathfinder\u2122 system is able to analyse up to 10,000 cells per slide, and uses Artificial Intelligence concepts in its proprietary software.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Although the release\u2019s lead emphasizes efforts to bring this blood test to market, there are no cost estimates in the text. A source affiliated with the company that licensed the test is quoted as valuing the maintenance of \u201caffordable cost,\u201d but we have no idea what that might mean.", "answer": 0}, {"article": "\"We don't yet have a full understanding--nobody does--of how the bile acid actually does what it does in heart cells,\" explains Michalak.\nThe study discovered the specific triggers activating the development of fibrosis which accelerates heart failure.\nThe team is now pushing forward with additional studies to see if the same therapeutic effect can be achieved in humans.\nThey also aim to gain a better understanding of exactly how bile acids can prevent cardiac fibrosis from occurring.\nCurrently patients with heart failure have poor quality of life and a dismal prognosis.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "At this stage of the research, cost is not of major concern. Having said that, tauroursodeoxycholic acid or TUDCA (the bile salt used in the experiments) is readily available from health food stores (for better or worse) and is relatively inexpensive.", "answer": 2}, {"article": "That exercise doesn\u2019t have to be intense, either, they say.\nIf their hypothesis is right, they say, 12% of depression cases could be prevented if everyone got just one hour of exercise a week.\n\u201cGiven that the intensity of exercise does not appear to be important,\u201d the authors wrote in their paper, \u201cit may be that the most effective public health measures are those that encourage and facilitate increased levels of everyday activities, such as walking or cycling.\u201d\n\nOf course, there are other benefits to more frequent and more intense bouts of exercise.\nThe study could not prove a cause-and-effect relationship between exercise and the risk of depression, but the authors say it strongly suggests one\u2014especially because they controlled for other potential factors, including age, gender, social support, smoking, drinking and body mass index.\nIt\u2019s also possible, they add, that exercise may trigger changes in self-esteem, the release of mood-boosting endorphins and the production of certain proteins.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Costs aren\u2019t a factor in this story given that the researchers are suggesting that even minimal exercise, such as walking and cycling, can lead to the decrease in depression they say that they have found. It costs nothing to walk and, aside from the cost of a bicycle, cycling is also free. Perhaps the biggest cost is a time cost\u2013people who work long hours at sedentary jobs may have a hard time fitting this into their schedules.", "answer": 2}, {"article": "He uses an electric mobility scooter for long distances, but he can still walk.\nMany of the clinical trials failed to satisfy the statistical requirement to prove a drug works\u2014at least not for the main outcome the company was looking at.\nIf they do say no, the Vertins could lose access to the drug that has stabilized their condition.\nTo Betty, the benefits are clear, even if they aren\u2019t easily quantified.\nThe Vertin brothers are not among them; the drug shouldn\u2019t help them at all.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Cost plays an important role in this story, as the drug (should it come to market) would be expensive and there is considerable uncertainty about whether insurance would pay for it.", "answer": 1}, {"article": "\"To address inconsistencies in prior studies on vitamin D and to investigate associations in population subgroups, we analyzed participant-level data, collected before colorectal cancer diagnosis, from 17 prospective cohorts and used standardized criteria across the studies,\" said Stephanie Smith-Warner, PhD, an epidemiologist at the Harvard T.H.\n\"This study adds new information that agencies can use when reviewing evidence for vitamin D guidance and suggests that the concentrations recommended for bone health may be lower than would be optimal for colorectal cancer prevention.\"\nOptimal vitamin D concentrations for colorectal cancer prevention may be higher than the current National Academy of Medicine recommendations, which are based only on bone health.\nThese associations persisted even after adjusting for known colorectal cancer risk factors.\nThe study appears online in the Journal of the National Cancer Institute.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "This release is not reporting on vitamin D supplementation but about circulating levels of vitamin D in the body. Although some readers may not make this distinction, cost is not strictly applicable here and we won\u2019t penalize the release for not mentioning it.", "answer": 2}, {"article": "\"That time frame is not anything to write home about,\" Gulley says.\nOverall, however, the limited success in some patients and the complete success in one is good news, he says.\nAs exciting as that is, he says, \"a lot of work needs to be done to prove whether this can be effective [for more patients].\"\nOne woman who got the investigational vaccine now has no X-ray evidence of cancer, says study researcher James Gulley, MD, PhD.\nThe study, funded by the National Cancer Institute, is published in Clinical Cancer Research.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does discuss costs, but the framing is problematic. The story, based on a conversation with one source, the study\u2019s lead investigator, says, \u201cIt\u2019s difficult at this point to predict costs. However, he expects costs will not approach those for Provenge, the pricey treatment vaccine for prostate cancer approved by the FDA in 2010. Provenge costs $93,000 for the one-month, three-dose treatment. Medicare covers it.\u201d This tells readers that, no matter what the drug costs, Medicare likely will cover it. We appreciate the effort to bring cost information into the story, but this type of information is misleading.", "answer": 1}, {"article": "Researchers at Italy's Institute of Neuroscience injected rats and mice with botulinum neurotoxin A in doses comparable to those used in people.\nYes, there was some evidence the toxin slipped into the bloodstream or the lymph system, but Botox in the bloodstream cannot enter the brain, says its manufacturer.\nA big reason Botox and its cousins, such as Myobloc, were OK'd was that preclinical testing showed that after being injected, they did not travel along the body's highways\u2014nerve cells\u2014to the brain and spinal cord.\nWith the new evidence that Botox can spread to the brain in ways that preclinical tests failed to turn up, it's enough to bring back those Botox-erased frown lines.\nThose unapproved uses are another concern of the agency.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No costs of treatment were mentioned but that\u2019s understandable in the context of this story about potential harms. ", "answer": 2}, {"article": "March 7, 2011 -- Traditional Chinese acupuncture may be useful in reducing the severity of hot flashes and other symptoms of menopause, a new study suggests.\nThose in the comparison group were treated with shams needles at the same acupuncture points.\nThe rest were treated with \u201csham\u201d acupuncture needles that were blunted and did not penetrate the skin.\nA five-point scale was used to measure the severity of hot flashes, vaginal dryness, urinary symptoms, mood swings, and other symptoms in the postmenopausal women.\nTwenty-seven women received traditional Chinese acupuncture twice a week for 10 sessions from an experienced and licensed acupuncturist.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No discussion of cost.\u00a0 10 weeks of acupuncture treatment \u2013 the course given in the study \u2013 ain\u2019t chump change.", "answer": 0}, {"article": "1 Yiou et al.\nPHOENIX, Oct. 19, 2017 /PRNewswire/ -- Creative Medical Technology Holdings (OTCQB \u2013 CELZ) announced today completion of the safety data analysis on 20 patients with pharmacologically-resistant erectile dysfunction treated with the Company's patented CaverStem\u2122 procedure.\nThe trial, sponsored by Creative Medical Technology Holdings, was conducted at the University of California Los Angeles Harbor Hospital/LA Biomed under Institutional Review Board (IRB) approval.\n\"Having published the first peer-reviewed paper on this procedure back in 2013 together with internationally renowned urologists and stem cell experts3, it is very exciting for me to watch this translate from bench to bedside.\"\n\"Based on establishment of safety of the CaverStem\u2122 procedure in a formal university-based clinical trial, and independent confirmation of efficacy in an European clinical trial1, we have launched commercialization for the CaverStem\u2122 procedure,\" said Timothy Warbington, President and Chief Executive Officer of Creative Medical Technology Holdings.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The news release does not mention anything about the cost of the CaverStem procedure. A look on the company\u2019s website FAQ section shows only that it is not covered by insurance, but there is still no mention of actual cost. Given that the piece claims commercialization is imminent, information about the cost of a procedure that is unlikely to be covered by insurance is warranted.", "answer": 0}, {"article": "According to the Skin Cancer Foundation, metastatic melanoma accounts for only about 1 percent of skin cancer cases but causes the majority of skin cancer deaths.\nOne cancer surgeon who reviewed the findings was impressed.\n\"Based on this study, it appears that patients with advanced melanoma who have their disease completely removed by surgery should go on to receive additional therapy with Opdivo,\" said Dr. Gary Deutsch.\nAll underwent surgery for their cancer before they began treatment with either Opdivo (nivolumab) or Yervoy (ipilimumab), the drug that's the current standard of care.\nThe international study was funded by Opdivo's maker, Bristol-Myers Squibb, and included more than 900 patients with stage III and stage IV melanoma.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Cost is not addressed. That\u2019s a significant oversight given that treatment with Opdivo can reach well into the tens of thousands of dollars\u2013or more.", "answer": 0}, {"article": "Dr. Roger Fielding (Tufts University) is partially supported by the U.S. Department of Agriculture, under agreement No.\nThe researchers acknowledge limitations of this study, including examining the different quantities of exercise participation achieved in the LIFE study participants and not specifically prescribing different amounts of exercise to different study groups.\nWe wanted the physical activity sessions to include exercise that participants could do outside of the study, and we hope that learning of these results might motivate others to try to make safe, incremental changes to their activity levels.\nParticipants were evaluated at baseline, six, 12, and 24 months.\nWhile the researchers saw improvements in all participants who added some physical activity to their routine, those who got more exercise saw greater changes.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Although there could be modest costs to those who participate in the kinds of exercise used in this study (e.g. a good pair of walking shoes, a set of ankle weights), it\u2019s clear to the reader that walking at a fairly modest clip, and performing some stretches and balance exercises, can be done at home, in malls, in hallways, in public parks and at very little, if any, cost beyond one\u2019s time.\nHowever, the exercise intervention described here included a twice-weekly supervised program. Although many senior centers offer similar programs for free, there may well be costs associated with participation outside the research program.", "answer": 2}, {"article": ".\nThe researchers will continue clinical studies with the OCT device, looking at other types of solid-state tumors.\nDiagnostic Photonics, a start-up company Boppart co-founded that also collaborated on the study, is commercializing the OCT probe technology for broader use.\n\"For the first time, this study demonstrates the use of OCT for imaging tumor margins within the tumor cavity, in the patient, during surgery,\" Boppart said.\nThe interdisciplinary research team led by Stephen Boppart, a University of Illinois professor of electrical and computer engineering and of bioengineering, performed the study on 35 patients with breast cancers at the Carle Foundation Hospital in Urbana, Illinois.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Although the study was not designed to assess relative costs of gold standard histology and OCT. the release would have helped both the news value of the study and the reader\u2019s understanding of technological innovation if it had included some estimate of costs associated with use of the device.\u00a0Operating room time is incredibly expensive, and any procedure that adds significant time will also add significant cost. In addition, prolonging any surgical procedure will extend the amount of time that the patient is under general anesthesia. We suspect (based on experience with the Dune Medical device, which is similar) that the procedure doesn\u2019t take more than about 5-10 minutes, but the release could have made this clear. Another issue could be the cost of the device to the facility. There is no CPT (billing) code for this procedure, so when commercially available, the cost likely cannot be passed along to the patient. Hospitals may not be interested in purchasing this equipment as they may not be able to get reimbursed for the cost of the device.", "answer": 0}, {"article": "In addition, people can obtain folic acid from breads, cereals and other grain products enriched with folic acid, as well as folic acid supplements.\nHowever, there is no scientific evidence that taking folate supplements will be beneficial, Armstrong noted.\nIn fact, folate deficiencies may be involved in the development of autism, he added.\nNone of the other factors they examined accounted for their finding, Nilsson's team noted.\n\"We know that, in young children, folate deficiencies are associated with poorer neurocognitive function and neurocognitive development,\" he noted.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Not applicable.\u00a0 No discussion of costs but we don\u2019t think that\u2019s a big issue in this case.", "answer": 2}, {"article": "Surgeons may also perform what\u2019s known as angioplasty, which uses a catheter to insert a tiny balloon and inflate it to open the valve; sometimes surgeons will also insert a stent, or tiny wire mesh cage, to keep the artery propped open.\nResults of the current study reaffirm that a minimally-invasive procedure can be a viable option, even for elderly people who are high-risk surgical patients, said Dr. Samir Kapadia, a cardiovascular medicine researcher at the Cleveland Clinic in Ohio.\nPatients in the study had minimally-invasive surgery that fixes the problem by inserting a replacement valve to send blood around the damaged valve while leaving it in place.\nOverall, the current analysis included 2,775 patients from a total of 20 previously published studies on outcomes for this type of surgery.\nThe analysis focused on people with what\u2019s known as aortic stenosis, which occurs when the large blood vessels leading away from the heart narrow, forcing it to work much harder to pump blood.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There\u2019s no mention of the cost. TAVR procedures averaged $55,136 in 2013, 8.4% higher than open-heart surgery, according to research covered by MedPage Today. TAVr procedures are more expensive due to the high cost of the device.", "answer": 0}, {"article": "\"There is a fairly active and vocal group of families in Colorado who are using cannabidiol oils that are made artisanally,\" she said.\nIf CBD proves effective in controlled trials, it could be two to five years before the drug is approved by the U.S. Food and Drug Administration, Devinsky noted.\nBut, researchers believe it may interact with a brain receptor that plays a role in the development of seizures, Devinsky said.\nPrevious studies have shown some benefit in adults, and word has spread.\nAll participants in these studies knew they were taking the oil, which could have affected reports of its effectiveness.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Cost is not mentioned.", "answer": 0}, {"article": "TUHS neither provides nor controls the provision of health care.\nThe study, published online in the journal Molecular Neurobiology, raises new hope for human patients affected by dementia.\nOther researchers contributing to the study include Phillip F. Giannopoulos and Jian Chiu at the Alzheimer's Center at Temple, LKSOM.\nThe study is especially exciting because zileuton is already approved by the Food and Drug Administration for the treatment of asthma.\nTheir superior performance suggested a successful reversal of memory deficiency.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "At this level of research, speaking to costs would seem to be unnecessary but since the drug used in the study is commercially available, the cost is relevant and should have been mentioned in the release. The drug is expensive \u2014 at $500 to $3,000 a month for asthma patients depending on insurance and co-pays \u2014 even though it\u2019s impossible to know at this stage what \u00a0the costs or dosing would be if it is ever proven to be useful in patients with Alzheimer\u2019s disease. Noting the cost could have been done in the context of the costs to care for someone with Alzheimer\u2019s for years or decades.", "answer": 0}, {"article": "\u201cBut now, we\u2019re seeing this whole new spectrum of treatments.\nIt\u2019s a risky proposition to give patients the foods they\u2019re deathly allergic to \u2014 inducing anaphylactic reactions simply to test drugs in clinical trials.\n\u201cThat hypothetically decreases the risk for adverse events.\u201d\n\nFor all the research on allergies, none of the drugs in the pipeline is a sure thing.\nThe potential market is huge: It\u2019s estimated that 50 million Americans have allergies.\n\u201cThere\u2019s really no doubt that there have been cold feet in the industry about this issue.\u201d\n\nBut investigators around the world have shown they can carry out these \u201cfood challenge\u201d trials safely \u2014 which could help hasten the development of new drugs.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Although the\u00a0story\u00a0cites the hundreds of millions of dollars of investment made by drug companies and research institutions, it doesn\u2019t address the potential costs of some newly developed commercial products, including one in stage 3 clinical trials that (literally) encapsulates bits of peanut protein designed to offer desensitization to peanut allergy. The approach has long depended on what the article calls the \u201chome brews\u201d of food allergy \u201cconcoctions\u201d and injections that have been compounded and prescribed by allergists for decades. Nor does it mention the cost of a biologic made by Genentech that already is on the market for a form of asthma and is likely much more expensive than antihistamines and even the notorious Epi-Pens that would compete for an expanded market.\u00a0The story also mentions Xolair, but does not mention the cost of this drug, which is quite prohibitive.", "answer": 0}, {"article": "\"That's about what you see with standard drug therapy,\" says researcher J. David Prologo, MD, assistant professor of interventional radiology at Case Western Reserve University\u2019s School of Medicine in Cleveland.\nBut other experts tell WebMD that questions about the long-term consequences remain.\nResearchers tested the technique on 24 men who hadn't been helped by standard treatments.\nIts supporters say the technique, or a similar one involving heat therapy, could someday become a standard treatment for the condition.\nA time to ejaculation of more than two minutes is normal, he tells WebMD.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The company estimates that this procedure costs about $3500 \u2014 a cost which obviously would rise if the procedure has to be repeated in order to maintain efficacy as suggested in the story. But we wish the story had more explicitly addressed this:\u00a0 costs that could reach $14,000 a year if effects wear off within 3 months.\u00a0 It also would have been interesting to see some comparison of\u00a0this cost with that of drug therapy and/or psychological counseling.", "answer": 0}, {"article": "\u201cIt\u2019s like you\u2019re possessed,\u201d said Lorie Novak, who has suffered from chronic migraines since childhood.\nBut the companies\u2019 fortunes are intertwined, he said, and \u201cthe class only wins if headache care in America improves.\u201d\n\nAiming to prevent migraines before they start\n\nThere\u2019s plenty of room for improvement.\nThat medication, Topamax, has been dubbed dubbed \u201cSleepomax\u201d by doctors and patients because it\u2019s also a heavy sedative.\nTargeting CGRP is not a particularly new idea.\nMerck got all the way into late-stage trials with an anti-CGRP tablet, spending more than $1 billion only to find in 2011 that the drug had toxic effects on the liver and thus no future.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Cost or an expected cost range for these drugs in development is not mentioned in the story, although one drug company source notes that the \u201chypercompetition\u201d among the four companies may well influence price.", "answer": 0}, {"article": "\"(But) we used aspirin long before we knew how it worked.\nThose who got the therapy also had significantly more improvement in other measures of symptoms, according to the study that will appear today in the Journal of the American Medical Association.\n\"That's huge,\" said lead author Fran Weaver, a researcher with the Hines VA Hospital in Hines, Ill.\n\nShe said the best drugs provide only one to two hours of added improvement, or \"on time.\"\nBeyond that, doctors need to do a better job of optimizing drug therapy, he said, noting that there are thousands of potential combinations of drugs that can be used to control symptoms.\nIn a sense it's a field of science that works backward: Stimulation is applied to the brain, some people get better, and doctors try to figure out why.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story reports that the procedure costs about $120,000. \nBut we wish it had given the price of the many drugs and treatments used in conventional therapy for Parkinson\u2019s disease. As a consequence, the reader is led to believe the cost comparision is $120,000 vs. $0. In fact it\u2019s $120,000 vs. some other number, perhaps a higher one. Some comparison would have been useful.\u00a0 ", "answer": 1}, {"article": "Systolic blood pressure (the upper number in blood pressure readings) indicates how much pressure your blood is exerting against your artery walls when the heart beats.\nThe researchers conclude that mangos may be a heart-healthy fruit that may help play a role in reducing the risk of cardiovascular disease.\n\"Our results build on previous animal and cell studies that point to the potential benefits of mangos to promote health.\"\nAdditionally, some of the participants showed favorable changes in the production of breath methane, an indication of the potential influence on gut fermentation.\nThe research was supported in part by funds from the National Mango Board and USDA.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Cost is not addressed. That said, if one has access to mangoes, their cost is likely comparable to many other fruits in some parts of the country and higher in others. This raises the question of cost and access to fresh fruits and vegetables \u2014 which is a significant problem in many parts of the U.S. \u2014 but which is beyond the scope of what we can expect to be addressed in a news release. Taking all of this into account, we\u2019ll mark this as \u201cnot applicable.\u201d", "answer": 2}, {"article": "According to the National Cancer Institute, about 32,050 men died from prostate cancer in 2010 and 217,000 new cases were diagnosed.\nMen who took acetaminophen for less than five years saw no protective benefit.\nThe findings are in line with previous research suggesting that physical activity may help reduce the risk of disease-related death in certain cases of prostate cancer.\nAnother potential source of the associated reduction was reduced inflammation due to a lower circulation of interleukin-6, high levels of which \u201cpredicted a 73% increased risk of dying from prostate cancer among normal-weight men,\u201d the researchers wrote.\nThe patients\u2019 average age at diagnosis was 65.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Not applicable.\u00a0 Cost is not much of an issue here.", "answer": 2}, {"article": "Prostate cancer killed an estimated 258,000 men around the world in 2008 and is the second most common cause of cancer death in men in the United States.\n\u201cThe protein is easy to detect because it is found in urine and would potentially be a very simple test to carry out on men to identify those most at risk of developing the disease,\u201d said Hayley Whitaker of the Cambridge institute, who led the study.\nWhitaker said that while it could be around five years before the results of this study are translated into a test for doctors to use in clinics, she hoped it would then also help them to determine which patients have aggressive tumors.\n\u201cAt the moment, PSA testing is the best method we have to detect prostate cancer but it has significant limitations, so there is an urgent need to find new biomarkers such as MSMB that could be used in screening and diagnosis,\u201d said Rosalind Eeles of the ICR and The Royal Marsden Hospital, who also worked on the study.\nCommenting on the study, Kate Holmes of the UK\u2019s Prostate Cancer Charity, said they could prove very valuable in future.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "\u00a0Not applicable. There was no discussion of cost but since this test is investigational, information about pricing is not expected at this time.", "answer": 2}, {"article": "A lot changed in between the births of my second and third daughters. For one thing, this time around I really am getting no sleep; for another, the pediatrician recommended something for our 1-month-old that is different from what had been suggested for our other children. She said we needed to pick up a liquid multivitamin that contains 400 international units (IUs) of vitamin D. It was a little confusing, because with our first daughter, now almost 4, the doctor told us to simply get her out in the sun from time to time to let her body produce vitamin D,...", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There was no indication of whether the levels of vitamin D in multivitamin preparation had any impact on its price.\u00a0 Not only was the cost of the supplement ignored, so was the cost of monitoring treatment, costs of complications of overdosage, and \u2013 at the other end of the spectrum \u2013 potential savings from improved health.\u00a0\u00a0 Cost is a factor in such stories. ", "answer": 0}, {"article": "Up to 30% of men suffer some degree of premature ejaculation, defined as ejaculation that occurs within one minute of vaginal penetration.\nNonetheless, doctors like Irwin Goldstein, MD, director of San Diego Sexual Medicine at Alvarado Hospital in San Diego, tell WebMD they're excited because this is the first time a drug is being rigorously tested for men with really serious premature ejaculation problems.\nPremature ejaculation can be devastating for both a man and his partner, triggering anxiety, depression, and relationship problems, says Goldstein, who heard the results presented at the annual meeting of the American Urological Association.\nJune 2, 2010 (San Francisco) -- A quick spray of a new drug may help men who suffer from premature ejaculation last nearly six times longer, new research suggests.\nAll used the product for three months, for a total of 23,000 doses.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story explains that \"No price has been set.\"\u00a0 We give it credit for thinking about cost and addressing it \u2013 even if the answer is uncertain at this point.\u00a0 70 percent of the stories we review fail to adequately address costs. ", "answer": 1}, {"article": "With relaxation of the muscles, the distance between the vertebrae returns,\" Dr. Napoli explained.\nNinety percent of the patients were able to avoid surgical treatment.\nSix patients required a second pulsed radiofrequency session.\nThe patients underwent a minimally invasive interventional radiology procedure in which, with the help of CT imaging, a needle is guided to the location of the bulging disc and nerve root.\nDr. Napoli said no patients experienced side effects after receiving the minimally invasive outpatient treatment.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There is no mention of costs in the release.", "answer": 0}, {"article": "Fat tissue has been linked to higher levels of damaging metabolic stress compounds, so losing weight and becoming more fit may create more hospitable conditions for sperm and improve its quality and volume.\nThey wanted to see what effect different types of exercise, and different intensity activity, had on sperm quality and count.\nIn the current study, the men in the moderate intensity, continuous activity program showed the most improvements compared to men in the other two more intense groups.\nNow, researchers publishing in the journal have found that another lifestyle change\u2014exercise\u2014may also help improve sperm quality.\n\u201cBut this is a much better done study than almost anything that\u2019s been done before on the subject.\u201d He notes that most previous studies did not randomly assign people to exercise groups and compare the outcome on sperm quality, but rather recorded sperm measures among men who reported their exercise habits after the fact.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There was no mention of the cost of the methodology used in this study. Yes, in general exercise is free via walking or jogging, so we\u2019ll rate this N/A. But, it\u2019s worth pointing out that one of the studied exercise methods here\u2013known as high-intensity interval training\u2013was done on a treadmill, and may require paid expertise to learn how to do it safely and correctly.", "answer": 2}, {"article": "Two new devices\u2014one that deflates fat cells, one that destroys them\u2014have just been cleared for \"body contouring\" in doctors' offices by the Food and Drug Administration.\n\nZeltiq grabs onto love handles and belly pouches and freezes the fat cells inside, causing them to self-destruct over several months. Zerona...", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "\u00a0There was no mention of costs for any of the\u00a0treatments mentioned, which is especially troubling given that most cosmetic procedures are not covered by insurance. \u00a0", "answer": 0}, {"article": "Philadelphia, PA, August 14, 2017 - Stanford University scientists have described a new type of test that can detect genetic mutations in minute amounts of DNA released from cancer cells into the blood.\nAccording to the report in The Journal of Molecular Diagnostics, this highly sensitive test has the potential to be personalized to recognize mutations unique to any individual cancer.\nIn contrast, molecular tests like the one we have developed will enable patients to be monitored at every visit, and thus have the potential for quickly tracking cancer growth and spread.\nAfter generation of customized mutation detection assays, the researchers were able to identify tumor-derived circulating DNA from three out of six patients.\n\"For monitoring patient tumors, only a handful of blood tests are available which are limited to only several types of cancers.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "We like that the cost issue is addressed. But the terms are vague. It says that the test is \u201crelatively low cost.\u201d Relative to what? To traditional \u201cwhole body imaging,\u201d as the release notes above? Then provide some of those costs. It also says, \u201cespecially compared to next-generation DNA sequencing,\u201d which costs how much?", "answer": 0}, {"article": "Visit the U.S. Centers for Disease Control and Prevention for more on obesity.\nSix months after the balloons were removed, nearly 90 percent maintained the weight loss they achieved during treatment, Pryor said.\nAfter six months, patients with the Obalon balloons had them removed.\n\"The long-term results are dependent on patients keeping their motivation to stay with their diet and exercise programs.\"\nThe balloon treatment will be available starting in January, but the cost hasn't been announced, Pryor said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "While the story notes that the U.S. price of the Obalon intragastric balloon has yet to be announced, the story could have reported that the device and related care typically cost $2,500 to $4,000 in Europe, where it has been available for almost three years. Costs are also likely markedly higher than working with a behavioral team.", "answer": 0}, {"article": "\u201cSometimes serious addiction needs to be coaxed down the stairs one at a time, not thrown off the top floor,\u201d said Dr. Abrams, who was not involved in the study.\nStill, some researchers not involved in the study said the topic required more work.\nThe study was funded by Pfizer, the drug company that makes Chantix, a treatment that costs about $250 a month.\nThe practice is common for smoking cessation therapies, said Robert West, director of tobacco studies at University College London, who was among the study\u2019s authors.\nIf such studies were funded by the government, which sustains a lot of academic research, taxpayers would bear the burden for what the company would eventually profit from, he said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story makes clear that Chantix costs approximately $250 per month. The story also notes that some insurance companies would not cover the cost of smoking cessation drugs if an individual has not set a quit date. However, it\u2019s not clear how many insurance companies will pay for smoking cessation drugs at all, or how many would pay for the drugs without a quit date.", "answer": 1}, {"article": "For example, robots that provide sensory feedback could eventually help a disabled person cook a meal or clean up things at home.\nOf course, mind-controlled robots are still years away from consumer applications, McLoughlin says.\nThat makes it very challenging to perform simple tasks like grasping a foam coffee cup without crushing it, McLoughlin says.\nIt's a mind-controlled robotic arm that has pressure sensors in each fingertip that send signals directly to Copeland's brain.\nStill, the ability to receive touch sensation from a robotic arm has the potential to help not only thousands of people who are paralyzed, but also people with a wide range of physical disabilities, McLoughlin says.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story states:\u00a0\u201cAt the moment, they [robotic arms\u00a0with touch sensitivity] are still too expensive, too bulky and too finicky to be used outside a laboratory setting.\u201d\nWhile the story\u00a0could have helped provide more\u00a0context by explaining the cost of the experimental surgery on the patient\u2013even without speculating on the cost of the robotic arm\u00a0itself\u2013this is enough to merit a satisfactory rating.", "answer": 1}, {"article": "Please consult your doctor or other qualified health care provider if you have any questions about a medical condition, or before taking any drug, changing your diet or commencing or discontinuing any course of treatment.\nThe findings appear in an upcoming issue of the Clinical Journal of the American Society of Nephrology (CJASN).\nThe article, entitled \u201cHealthy Dietary Patterns, Mortality and End-Stage Kidney Disease in CKD: A Meta-Analysis of Cohort Studies,\u201d will appear online at http://cjasn.asnjournals.org/ on December 8, 2016, doi: 10.2215/CJN.\nHighlight\n\u2022 A healthy diet high in fruits, vegetables, fish, legumes, cereals, whole grains, and fiber, and low in red meat, salt, and refined sugars was linked with a reduced risk of early death in an analysis of 7 studies.\nTo investigate, a tem led by Giovanni Strippoli, MD, PhD (University of Bari, in Italy and Diaverum, in Sweden), and Jaimon Kelly (Bond University, in Australia) analyzed the medical literature, finding 7 relevant studies that included a total of 15,285 participants.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release could have explored two aspects of costs: the costs on a per-patient or per-month basis of treating chronic kidney disease and also the costs of eating healthy the way the people in this study did, but we suspect there is little data available on the latter.", "answer": 0}, {"article": "Philadelphia, PA, April 18, 2017 - In the past, all forms of metastatic prostate cancer have been considered incurable.\nWhile the study is only a first step, one-fifth of the patients treated had no detectable disease, with an undetectable prostate-specific-androgen (PSA) and normal blood testosterone, after 20 months.\nLonger follow-up is needed to determine whether these patients were in fact cured.\nOf the five patients with extra-pelvic lymph node involvement, four achieved an undetectable PSA after ADT and surgery, while the fifth needed radiation to reach this milestone.\nThe results suggest that some men who have previously been considered incurable can possibly be cured; investigators also establish a new paradigm for testing various drug combinations in conjunction with local treatment of the prostate to determine which is the best approach (ie, has the highest undetectable disease rate).\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Costs are not discussed at all. Given the scope of the treatments, we think it\u2019s important for a release like this to at least give some cost estimates. It\u2019s also unclear from the release whether insurance would cover these treatment plans. The study\u00a0noted that one patient could not complete the protocol\u00a0due to lack of insurance coverage.", "answer": 0}, {"article": "\"Doctors are already doing these [glucose and HbA1c] tests together -- if a patient is obese, for example, and has other risk factors for diabetes, the physician is likely to order tests for both glucose and HbA1c from a single blood sample.\nBut taking the test twice takes up time and money and could still result in missed diagnoses, said a team from the Johns Hopkins Bloomberg School of Public Health in Baltimore.\n\"The CDC reports that greater than 52 percent of the U.S. population has either clinical diabetes or prediabetes,\" Bernstein noted.\n\"Given these numbers, any abnormality of glucose should be regarded as sufficient reason to start preventative treatment with an education program, lifestyle change and first-line medication such as metformin.\"\nAccording to Bernstein, if only one diagnostic test were needed, \"this would mean that a follow-up visit would be a look at the treatment benefits -- rather than a confirmation of an abnormal glucose.\"\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story provided no information on how much these tests cost. A check online found CVS drug store offered these tests for $59 apiece.", "answer": 0}, {"article": "Dec. 20, 2010 -- Scientists using brain scanning technologies say they have been able to predict with 90% accuracy which children with dyslexia will be able to improve reading skills over a period of a few years.\n\nResearchers say their findings reveal activity in specific brain regions during reading that could eventually lead to new treatments for people with dyslexia.\n\n\u201cAt this time, we cannot say which treatment type will each child benefit from,\u201d study researcher Fumiko Hoeft, MD, PhD, an imaging expert at Stanford University, tells WebMD in an email. \u201cBut with more research, and if researchers combine it with intervention studies, then we should be able to identify brain patterns that are predictive of responding to one type of intervention or another.\u201d\n\nShe says in a news release that the study \u201cgives us hope that we can identify which children might get better over time\u201d and that the findings represent \u201ca huge step forward.\u201d\n\nThe discovery of brain regions involved in the learning disorder \u201cmay provide a mechanism for enduring improvement that promotes relatively successful reading development,\u201d according to the study, published in the Dec. 20 issue of the Proceedings of the National Academy of Sciences.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "\n\n\n\nSophisticated imaging of the brain and its function is an expensive diagnostic tool.\u00a0 Applying these sophisticated tests to all children would be a huge expense.\u00a0 While other stories at least mentioned cost (for example the CNN report quoted the author of the study as saying, \u201c\u2026as the usage of fMRI becomes more useful and commonplace, the high cost per scan would go down\u201d) this story fails to do so.", "answer": 0}, {"article": "At the moment, testing often requires costly and complex equipment that can take a couple of days to produce a result,\u201d said Graham Cooke, who co-led the research from the Imperial\u2019s department of medicine.\nIt could be particularly useful in remote settings to help HIV patients manage their treatment more effectively, since current tests to detect virus levels take at least three days and involve sending a blood sample to a laboratory.\nBut in some cases the drugs stop working - sometimes because virus has developed resistance to them - and the first sign of that would be a rise in a patient\u2019s so-called \u201cviral load\u201d.\nCurrent AIDS drugs, called anti-retrovirals, reduce virus levels in a patients blood to near zero.\nAny HIV in the sample triggers an acidity change, which the chip transforms into an electrical signal.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The\u00a0cost of\u00a0either test in the study isn\u2019t shared, and it\u2019s a simple question to ask for a ballpark figure on what a mass-produced\u00a0lab-on-a-chip might cost. Absent that number, a comprehensive HIV viral load test with traditional (and bulky) equipment is about $24.90 to $44.07. Such tests are recommended by the World Health Organization (WHO) 6 months after the start of anti-retroviral treatment, at 1 year, then every year after that. \u00a0\u00a0", "answer": 0}, {"article": "Worse, these same people tend to promote abstinence-only education, which has been shown conclusively to be the worst possible sex education; kids taught his way tend to have more pregnancies and more STIs than ones who are taught progressive, healthy sex ed.\nThis, sadly, is expected; more than 178 million doses of Gardasil have been given worldwide, and given that huge number it\u2019s a statistical certainty that some young people will die not long after getting them.\nThe vaccines are not to blame here.\nIt\u2019s very frustrating; mounds of data show these vaccinations are incredibly low-risk, but it only takes a little bit of doubt and fear to make vaccine rates drop.\nAnd, just like essentially every claim made by the anti-vaccination movement, these arguments are wrong.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No mention was made of the cost of the vaccine.", "answer": 0}, {"article": "According to the U.S. Centers for Disease Control and Prevention, high blood pressure affects 30 percent of American adults.\nIn the case study, a 55-year-old man was implanted with a deep brain stimulator to treat severe pain stemming from a stroke.\nAbout 10 percent of high blood pressure cases either can't be controlled with medication or patients cannot tolerate them, study author Dr. Nikunj K. Patel, a neurosurgeon at Frenchay Hospital in Bristol, England, said in a journal news release.\nThe finding introduces the possibility that deep brain stimulation -- a surgical implant that delivers electrical pulses to the brain -- might one day become a treatment for drug-resistant hypertension or lead to clues about the brain's role in regulating blood pressure.\nThe study adds to other recent research focused on neuromodulation, which harnesses the power of electrical impulses in the body for therapeutic benefit.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story speculates that DBS might become a treatment for hard-to-control high blood pressure. But it didn\u2019t offer any estimates as to what it might cost to treat patients with this technology. At the very least, the story could have pressed the authors of the case report\u00a0to discuss the cost of the device and\u00a0the price tag for a typical implantation procedure.\u00a0In this 2008 Chicago Tribune blog post, the cost of\u00a0DBS was estimated at $150,000 or more per patient.\u00a0There would also be additional costs for ongoing monitoring and follow-up once the device\u00a0was\u00a0implanted.", "answer": 0}, {"article": "Prostate cancer becomes more common as men age \u2014 autopsies of elderly men find that most had prostate cancer, whether they knew it or not.\nStill, he said the new test could help patients if it was used with caution.\nBut some said that if the test leads to more screening, it is not necessarily a good thing.\nThe next step was to ask whether those variants really could predict who had prostate cancer.\n\u201cWe are just feeding off of this cancer phobia.\u201d\n\nWhat is needed, and what the new test does not provide, is a way to decide which cancers are dangerous and which are not, Dr. Isaacs said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story included a cost for the test.", "answer": 1}, {"article": "To learn more about breast cancer surgery, visit the American Cancer Society.\nThe expected cost of the MarginProbe in the United States, if approved, is not yet known, said Michael Graffeo, a spokesman for its maker, Dune Medical Devices.\nIn June, the radiation-free device won the blessing of a U.S. Food and Drug Administration advisory panel.\nLooking at the volume of tissue excised, the researchers said not much more tissue was removed when the device was used compared to tissue removed in the initial and subsequent surgeries among the control-group patients, Boolbol said.\nIn Europe, where the device is available, each probe (one per patient) sells for about 600 euros or $760, he said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "While the\u00a0cost of the device in the United States is\u00a0not known, the story quotes a spokesperson from the manufacturer who points out that the device sells in Europe for 600 euros, or $760.\u00a0 A new device is needed for each surgery.", "answer": 1}, {"article": "When skin is exposed to sun, it makes vitamin D.\n\nStill, the doctor wanted to run a blood test to see if Rebecca Rosen had adequate vitamin D.\n\n\"So my wife said, 'Well, why do I need to have a vitamin D [test]?'\nThe evidence is strongest for colorectal cancer, she says.\nAn Institute of Medicine panel is working on a vitamin D update, which may come out this summer.\nNeither study subjects nor investigators will know until the end which regimen they are on.\nManson and her colleagues are launching such a trial.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The cost of testing for vitamin D levels was provided.\u00a0 No information about the costs of vitamin D supplements, but we\u2019ll give the story the benefit of the doubt on this one. ", "answer": 1}, {"article": "In 2015, he was ranked the No.\nThe researchers selected 69 as the lower age limit because Medicare coverage of the general population begins at age 65, and the exposure of interest was regular mammography screening in the four years immediately preceding breast cancer diagnosis.\nAlthough many guidelines rely on self-reports, Hennekens and his collaborators from Baylor College of Medicine and Meharry Medical College, used the Surveillance, Epidemiology, and End Results (SEER) program file linked to the Medicare administrative claims file, which allowed them to identify screening mammography use from 1995 to 2009 from 64,384 non-Hispanic women (4,886 black and 59,498 white).\nAmong elder women, the American Cancer Society and the United States Preventive Services Task Force recommend regular mammography for ages 65 to 74.\nHennekens notes that further research is needed, but that in the future, the use of regular claims-based surveillance for mammography as a source of data may offer some unique advantages over self-reports.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Does not mention any costs \u2014 either direct or societal. And because patients over 74 are typically covered by Medicare, the financial costs to society would be substantial. \u00a0In addition to covering the cost of screening mammography, Medicare also covers the use of computer-aided diagnosis (CAD) which multiple studies have found to increase the number of false positives.", "answer": 0}, {"article": "Cigarette smoke causes 90 percent of all cases of lung cancer, which kills 1.2 million people a year globally.\nFewer than half of all lung cancer patients who do well after a first course of chemotherapy get more treatment, but the Italian group said their study shows this is worth doing.\n\u201cOral iloprost showed promise for preventing lung cancer in former, but not current, smokers in a phase II clinical trial,\u201d they wrote in a summary presented to a meeting of the American Thoracic Society in New Orleans.\nSeparately, Italian researchers reported that advanced lung cancer patients given the targeted therapy drug Tarceva as so-called maintenance treatment \u2014 after they finished a course of standard chemotherapy \u2014 lived a little bit longer.\nSix months later, \u201cformer smokers showed significant improvements on all measures, indicating that treatment with iloprost may reduce the risk of developing lung cancer among former smokers,\u201d the researchers said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No price tags. A New York Times article from 2005 discussed the expense of drugs like Tarceva. According to drugstore.com, the regimen used in the study costs $4700 a month. Iloprost isn\u2019t cheap, either.", "answer": 0}, {"article": "And is the outcome the same for everyone?\u201d\n\nPuigserver, who runs a cancer biology lab at Dana-Farber Cancer Institute, noted that addressing health and aging through metabolism involves a complex web of pathways and mechanisms.\nIf Elysium Health were developing Basis as a drug, it would have to conduct clinical trials with humans to prove that it works, and the Food and Drug Administration would have to sign off on its scientific evidence before it could be sold as medicine.\n\u201cWe are filling a space by combining natural compounds with scientific validation.\u201d\n\nThe active ingredients in Basis are nicotinamide riboside, a substance that makes NAD and is found in traces in many foods such as milk, and pterostilbene, an antioxidant found in blueberries.\nBut as a supplement, Basis and similar products only have to be shown to be safe for humans to take, with labels that are not misleading.\nIndeed, one scientist not involved with Elysium questions the company\u2019s marketing pitch, saying there is too little information to know what Basis can do.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story tells us early on in the story that a month\u2019s supply of the pill, called Basis, costs $50-60. So consumers will pay up to $700 a year for the privilege of helping the company test its pills.", "answer": 1}, {"article": "Instead, they pass through to the large intestine, where they draw water into the gut and start to ferment.\nIf your gut can handle FODMAPs, foods that contain a lot of them can be very good choices \u2014 partly because the fermentation helps your gut biome and partly because the way FODMAPs are digested means you\u2019re absorbing fewer calories than indicated on a FODMAP-rich product\u2019s label.\nBut there\u2019s a problem with a low-FODMAP diet.\nEven some people who don\u2019t have celiac disease feel better when they don\u2019t eat wheat.\nThe fermentation that is painful to that 10 percent is good for your gut because it stimulates growth of the kind of bacteria associated with digestive health.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Cost is really not a consideration in this story. The foods listed are found in the average grocery store and are not esoteric.", "answer": 2}, {"article": "\"That's where the money is,\" Malmgren said.\nMalmgren, a breast cancer survivor, says more focus should be placed on the benefit of early diagnosis, because it often means less treatment is needed.\nHowever, she said, the study does not provide support for all women aged 40 to 49 to have routine mammograms.\n\"The data from randomized trials and modeling show there is a very modest improvement in mortality with mammograms from 40 to 49,\" she said.\nIn 2009, the U.S. Preventive Services Task Force issued mammogram recommendations.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No discussion of costs regarding mammograms. \u00a0Stories should not assume that every woman in the 40s who chooses to get a mammogram will have this covered by their insurance.", "answer": 0}, {"article": "An experimental Johnson & Johnson drug substantially reduced the severity of the inflammatory skin disorder psoriasis, according to a new study.\n\nJ&J is developing ustekinumab as part of a new category of drugs that targets proteins known as interleukins. In addition to psoriasis, J&J is studying the compound's potential to treat Crohn's disease, a gastrointestinal ailment.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story didn\u2019t project any ballpark of costs for the drug, yet it was able to project the company\u2019s plans to file for approval within the next two months.\u00a0 You can be sure if they\u2019re ready for that, they have a ballpark idea of how much they will charge for the drug. ", "answer": 0}, {"article": "Merck & Co. and Schering-Plough Corp. said a long-awaited trial showed their cholesterol drug Vytorin failed to slow progression of heart disease better than a cheaper drug, threatening the companies' $5 billion-a-year cholesterol-fighting franchise.\n\nSchering-Plough's shares fell 8% to $25.52 and Merck declined 1.3% to $59.78 at 4 p.m. in New York Stock Exchange composite trading.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The cost of this treatment (two medications in one pill) was provided as well as the costs for other cholesterol lowering medication.", "answer": 1}, {"article": "PepsiCo's product portfolio includes a wide range of enjoyable foods and beverages, including 22 brands that generate more than $1 billion each in estimated annual retail sales.\nNewly published research in the Journal of the American College of Nutrition showed that a hearty bowl of instant oatmeal helped curb food intake at lunch better than a leading oat-based, cold cereal -- even when each bowl provided the same number of calories.\n\"The fact that choosing instant oatmeal over a cold cereal may also help Americans curb their intake at lunch is especially encouraging.\"\nThe Quaker Oats Center of Excellence is focused on elevating the relevance and benefits of oats through science, agriculture and innovation.\n\"The recent 2015 Dietary Guidelines for Americans Committee Report emphasized the importance of eating breakfast for all Americans - and we know that instant oatmeal is a popular and convenient choice,\" comments Marianne O'Shea, PhD, Director of the Quaker Oats Center of Excellence.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "While the cost per serving of Quaker instant oatmeal versus Honey Nut Cheerios (the brands studied) might be similar, it still would be worth noting as the news release is attempting to make the case that an instant oatmeal breakfast will lead to less caloric intake at lunch. Nevertheless, we\u2019ll rate this Not Applicable since most readers have at least a rough idea of what these products cost.", "answer": 2}, {"article": "In a twist in the debate about the safety of menopause hormones, new research suggests the real problem may not be the hormone itself, but the fact that it's typically swallowed as a pill.\n\nThis week, the medical journal Circulation offers some of the strongest evidence yet that the risks of hormones are dramatically reduced when the drugs are absorbed through the skin in patches and gels rather than taken as pills. The study by French researchers showed that one of the most serious risks associated with hormone use -- blood...", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not mention costs of any of the types of hormone therapy, an important piece of information since they are often not covered well by insurance.", "answer": 0}, {"article": "Individuals with panic chronically hyperventilate, even when not experiencing a panic attack.\nThe peer-reviewed published multi-center Freespira clinical trial, presented by Dr. Tolin, demonstrated that 71% of patients were panic attack free immediately after treatment and 79% of patients were panic attack free 12 months post-treatment.\nThis latest study, conducted as part of the VITAL Program at Allegheny Health Network in Pennsylvania, also demonstrated a 50% reduction in healthcare costs in patients with panic symptoms 12 months after being treated with Freespira.\nTwo studies reported nearly 80% of Freespira-treated patients were panic attack free at 12 months post-treatment.\nDANVILLE, Calif., April 11, 2018 /PRNewswire/ -- Palo Alto Health Sciences, Inc. (PAHS), developer of the drug-free Freespira\u00ae treatment for panic attacks and other symptoms of panic disorder, today announced that another study has demonstrated clinically significant symptom improvement, with 80% of patients panic attack free one year after treatment.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The news release does not give us the cost of the Freespira treatment. This is especially troubling since the release claims that the treatment reduces overall costs \u201cby 50%\u201d after a year of treatment.\nWhen we reviewed a news story about Freespira in 2015, the monthly cost was reported as $500.", "answer": 0}, {"article": "S. Bagla; R. Piechowiak; T. Hartman; J. Orlando; A. Isaacson; Vascular Institute of Virginia, Woodbridge, VA; UNC Chapel Hill, Chapel Hill, NC; University of North Carolina, Chapel Hill.\nThis prospective, multicenter clinical trial evaluated 13 patients with severe osteoarthritis pain.\nThis study builds on the growing international research around GAE and osteoarthritis.\nTogether the scales represent an 80 percent improvement in function compared with pre-procedure conditions.\nAs an outpatient treatment, GAE does not require open surgery or physical therapy, and takes 45-90 minutes to perform.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "This release doesn\u2019t mention anything about the cost of this new procedure although interventional radiography procedures are normally complex and expensive. The release is remiss in not pointing out that GAE is likely to be more costly than other standard treatments for knee OA such as corticosteroid injections, exercise regimens and weight loss.", "answer": 0}, {"article": ".\nThe article is available free on the Journal of Child and Adolescent Psychopharmacology website.\nThe article entitled \"Efficacy and Safety of HLD200, Delayed-Release and Extended-Release Methylphenidate, in Children with Attention-Deficit/Hyperactivity Disorder\" is coauthored by Steven Pliszka, MD, from The University of Texas Health Science Center at San Antonio and colleagues from Massachusetts General Hospital (Boston, MA), Westside Medical Family Practice (Clinton, UT), University of Tennessee Health Science Center (Memphis, TN), Meridien Research (Maitland and Bradenton, FL), Children's Development Center (Winter Park, FL), Ironshore Pharmaceuticals & Development (Grand Cayman, Cayman Islands), and Mount Sinai Medical Center (New York, NY), on behalf of the HLD200-108 Study Group.\nThe Journal is dedicated to child and adolescent psychiatry and behavioral pediatrics, covering clinical and biological aspects of child and adolescent psychopharmacology and developmental neurobiology.\nChildren taking the delayed-release stimulant did not have to wait for a morning dose to take effect and also benefited from improved symptoms later in the afternoon and evening, according to the study results published in Journal of Child and Adolescent Psychopharmacology, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There is no mention of the cost of methylphenidate in this release. While the price of the existing forms of this drug\u00a0are readily obtainable, this research touts a new extended/delayed release form of the medicine and therefore, it is conceivable that the price will be different, and more than likely higher.", "answer": 0}, {"article": "Dennis Halmi, a member of the Bluepoint Surgical Group in Woodbridge, says that in 2002 \"we did a handful\" of second operations on obesity patients, \"maybe five, six.\nOf course, a second obesity surgery comes with increased risk.\nThe second time around, many, like Thayer, are opting for the adjustable band, which works differently from the bypass.\nIf the patient doesn't go in for adjustments, the whole thing won't work.\nNot enough time has elapsed since the advent of second operations to get a long-term assessment.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story provided no information about the cost of gastric banding or how the increased time that may be needed for the procedure when conducted after gastric bypass affected the costs.", "answer": 0}, {"article": "\"I feel like I can accomplish what I want to accomplish.\nWhile the results are striking, this technology is not a guarantee of complete resolution of depressive symptoms or medication side effects.\nFinally, her psychiatrist, suspicious that her body might process medication differently than most, recommended a genetic test to see why Ellis wasn\u2019t responding to the prescriptions.\n\u201cOnce the genetic testing became available it provided Sarah with more than just physical relief,\" says Dr. Matthew B. Stanley of the Avera Medical Group in Sioux Falls, South Dakota.\nIt's unclear how many patients have had to stop or chosen to stop treatment for depression due to side effects.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story notes that the genetic test touted costs $179 and says it is often covered by insurance.", "answer": 1}, {"article": "Researchers told the American Diabetes Association\u2019s (ADA) annual meeting that 13.0 percent of patients on Victoza died from cardiovascular causes or suffered non-fatal heart attacks or strokes, against 14.9 percent of those on placebo.\nThere was also concern that Victoza did not appear to lower heart risks in American patients monitored in the study, despite doing so in other parts of the world and producing a solid result globally.\nThe Victoza trial, known as Leader, had been designed to show Novo\u2019s drug did not increase heart risk, so its superiority is welcome news for the company, especially as Sanofi\u2019s (SASY.PA) rival Lyxumia failed to show heart benefits in an earlier test.\nMads Krogsgaard Thomsen, Novo\u2019s chief science officer, said the results should encourage doctors to use Victoza earlier, since they could now see it offered \u201clife-expanding\u201d treatment.\nJefferies analyst Jeffrey Holford said market expectations had been for a mid-to-high teens percent reduction in complications.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There is no mention of the costs of Victoza.\u00a0This would have been easy to include\u00a0given\u00a0the drug is widely prescribed and pricing information is freely available on the internet. The article compares the performance of Victoza against rival diabetes drugs, so it would have been informative to have a comparison of costs as well.", "answer": 0}, {"article": "But on Oct. 23, the F.D.A.\nOf the 32 patients who received the drug that way, 29 were still alive, BioCryst said in late October.\nHe said the drug should be distributed so that hospitals could have it in stock.\nMr. Stonehouse defended the price of the drug, saying it would save the health system money by getting patients out of intensive care earlier.\nAnecdotes like Ms. Gurno\u2019s aside, the efficacy of peramivir is still in question, according to the government.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "\n\n\nThe story says the federal government is paying about $2,250 per patient for a standard 5-day treatment course. It also notes that the approved alternative treatments are less expensive.", "answer": 1}, {"article": "\u201cThe baby will grow and the biodegradable material will disappear,\u201d he said.\nHe said bioresorbable materials have great potential for other uses, particularly for stents to repair the pulmonary arteries and aortas of babies.\nSerruys said current stents are essentially \u201ccages\u201d that hamper the flexibility of arteries and make them more prone to reclogging as they develop scar tissue and plaque builds up.\n\u201cThe trial\u2019s results would be equivalent to an excellent metallic stent - that type of performance,\u201d said Dr. Patrick Serruys, a cardiologist from Erasmus University Hospital in Rotterdam, who led the study.\nThe findings, which follow similarly promising 6-month and 9-month data on the plastic device, were described at the annual scientific sessions of the American College of Cardiology in New Orleans.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No discussion of costs.\nThe Wall Street Journal, by comparison, at least reported:\u00a0\u201cAbbott expects to charge more for the Absorb device than the permanent, medicated stents currently available, which cost around $1,500 to $2,000.\u201d", "answer": 0}, {"article": "Makers include General Electric Co\u2019s GE Healthcare Siemens AG, Toshiba Corp, Hitachi and Philips.\nThe researchers waited until an independent panel could document a 20 percent reduction in cancer deaths, or could determine that there was no significant benefit.\nThe study sponsored by the U.S. National Cancer Institute is the first to show that people can be screened for lung cancer, akin to mammograms for breast cancer and tests for colon and prostate cancer.\nIt is not clear when or how guidelines for lung cancer screening could be drawn up, and until they are, insurers including government programs such as Medicare are unlikely to pay the average $300 cost of a scan.\nIt is also possible the scans will turn up tumors that would never have killed the patients, and that some people will undergo unnecessary surgery if they are screened.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The cost of diagnostic testing and the return on that investment in both clinical and financial terms should be routinely included in any story. Like many others, this story fails in this regard. Simply describing the cost of the diagnostic test does not provide the reader with an appreciation of the true cost of the testing. The number of people you need to scan to find one with an early stage lung cancer is 304. There are 33 million Americans who smoke daily. At $300 to $1,000 per scan, scanning everyone would cost $9.9 to $33 Billion annually. Any discussion on cost should also include comments on the false positive rate. In this case, 25% to 60% of subjects had a lesion that needed further workup. The financial costs of these false results should have been noted", "answer": 0}, {"article": "Millions of Americans suffer from pet allergies that prevent them from enjoying the benefits of owning a dog or a cat.\nShe consulted an allergist at Weill Cornell Medicine/New York-Presbyterian Hospital, where a clinical trial involving immunotherapy toothpaste was taking place.\nJoyce, who lives in the Bronx, New York, signed on for the year-long study that required six of the 12 volunteers to brush their teeth for two minutes using two pumps of the toothpaste in either the morning or night, and the other six to use drops under their tongue.\nVolunteers using the toothpaste were also required to log their usage in a journal.\nI was really uncomfortable and miserable.\u201d\n\nJoyce tried over-the-counter medications but couldn\u2019t find relief.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story earns a Satisfactory rating because it says that the toothpaste mentioned in the story costs $400 every three months (or $1,600 per year), and that it isn\u2019t covered by health insurance.\u00a0 But we would have liked it better had the writer offered comparative costs for a year\u2019s worth of the current allergy treatment of choice.", "answer": 1}, {"article": "New Jersey and Ohio were the first to participate statewide in the program.\nShe said the program was eye-opening for how much information she learned about how to prevent sudden unexpected infant death.\nThe boxes aren\u2019t the only option for safe sleeping, of course, but health officials say they\u2019re a useful part of a broader safe-sleep education program.\nThe boxes are a new idea for many Americans.\nThe boxes provide a clutter-free sleep space that has been shown to reduce accidental and unexpected deaths, she said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does say that these boxes are being distributed for free, but by a for-profit company that requires parents to \u201cregister\u201d at a website in order to receive one.\nWe think the collection of information on new parents may benefit the for-profit company. The story would have been stronger if it faced that issue squarely. See more on this under the funding and conflicts of interest criteria section below.", "answer": 1}, {"article": "Functional MRI scans generate a dynamic map of the outer surface of the brain, showing changing hot spots of activity over time.\nIt's exciting to think that these individual differences may be related to personality, cognitive ability, or psychiatric or neurological disease.\nAlthough the technique's potential to identify brain disorders and diseases was noted years ago, fcMRI-based diagnostic tests have yet to make their way into doctors' offices.\nAll of the scanned brains belonged to young, healthy scientists and doctors.\nWe show here that it's not measuring what you're thinking, but how your brain is organized.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "No mention is made of the cost of functional MRIs, or how likely it is that insurance companies might cover that cost.", "answer": 0}, {"article": "Currently many women with a gene mutation choose surgical removal of their breast tissue and ovaries to reduce their chance of developing breast and ovarian cancer.\nProfessor Lindeman, who is also a medical oncologist at The Royal Melbourne Hospital, said the discovery of RANK as a marker of cancer precursors was an important breakthrough, because inhibitors of the RANK signalling pathway were already in clinical use.\nIf confirmed in clinical studies, this would provide a non-surgical option to prevent breast cancer in women with elevated genetic risk.\nProfessor Visvader said the discovery had its basis in more than a decade of investigations of breast stem cell function.\nAustralian researchers have discovered that an existing medication could have promise in preventing breast cancer in women carrying a faulty BRCA1 gene.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release doesn\u2019t address costs at all. Given that denosumab is already on the market to treat other conditions, under the trade names XGEVA and Prolia, this is a significant oversight. Costs are listed in various public outlets as ranging from $990 for a six-month course to $1,650 per year (neither estimate includes the cost of clinical care to administer the drug).", "answer": 0}, {"article": "You've seen high-definition televisions. Now some medical centers are marketing their high-definitioncolonoscopes, which they say will detect more pre-cancerous polyps. Several recent studies have found a small benefit to high-definition colonoscopy over the standard variety, but gastroenterologists say physician technique is more important in detecting polyps than equipment.\n\nColonoscopy, a screening test doctors recommend for most people starting at age 50, allows doctors to remove pre-cancerous growths before they become...", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story devotes a few sentences to costs, without actually providing dollar figures. Still, the effort is far stronger than in most stories about colonoscopies or other procedures. This sentence was especially nice to see: \"An alternative to colonoscopy is flexible sigmoidoscopy, a shorter, less expensive exam which looks only at the bottom portion of the colon, combined with a fecal occult blood test, which looks for blood in the stool.\"", "answer": 1}, {"article": "Malignant pleural mesothelioma is a rare and aggressive cancer that represents about 90 percent of all malignant mesothelioma cases.\nThere are multiple studies going on right now to confirm these findings, which the authors note is a necessary step before the drug can become a standard second-line therapy.\nThe study, published this month in The Lancet Oncology, is the first to show a positive impact from checkpoint inhibitor immunotherapy drugs on this disease.\nThis poor prognosis is partially due to the fact that most patients are not diagnosed until they are already at a late stage of the disease.\nPHILADELPHIA - Pembrolizumab, an antibody drug already used to treat other forms of cancer, can be effective in the treatment of the most common form of mesothelioma, according to a new study led by investigators from the Perelman School of Medicine at the University of Pennsylvania.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "No mention of costs here. Describing cost information in new cancer therapies is essential as it will have a significant impact on future patient access.", "answer": 0}, {"article": "\"It is a question of what specific question you are looking to answer,\" he said.\nIndeed, CT appears to be better for assessment of coronary artery disease, matched against not only MRI but other methods, such as echocardiography, he said.\nCT is the preferred noninvasive technology for assessing the condition of heart arteries, whether there is narrowing that might end with the total blockage that causes a heart attack, Schoepf said.\nIndeed, CT and MRI are not contenders in clinical practice but are used for different reasons to make different assessments, Schoepf said.\nThat difference helps explain why there are so few studies doing head-to-head comparison of CT versus MRI, he said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The significant costs of both MRI and CT angiography are not discussed. Their adoption as screening tests could have a substantial impact on overall health care costs, and the omission of a discussion of costs is a major oversight. See this\u00a0New York Times article\u00a0for why\u00a0the costs of CT angiography are relevant.", "answer": 0}, {"article": "In 2008, Medicare paid for 480,000 injections of Avastin to treat macular degeneration and 337,000 injections of Lucentis, according to a study led by Dr. Philip Rosenfeld of the University of Miami.\nA far less expensive alternative proved roughly as effective as Genentech\u2019s costly drug Lucentis in preserving or improving vision in elderly people with a common eye disease, according to two people familiar with the results of a closely watched clinical trial.\nBut there has never been a definitive trial to compare the two drugs.\nYet Medicare paid only $20 million for the Avastin compared to $537 million for the smaller number of Lucentis injections.\nSales of the drug for each company were about $1.5 billion last year.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Costs are the heart of this story.\n", "answer": 1}, {"article": "The item you've requested, /cgi-bin/article.cgi?f=/n/a/2006/03/29/national/w155455S59.DTL&type=health, was not found.\n\u2022 the item no longer exists, or\n\u2022 there has been an error on the site.\n\nIf you feel the address you entered is correct you can contact us, mentioning the error message received and the item you were trying to reach.\n\nWe apologize for any inconvenience. From here, you can:\n\u2022 use the menu bar above\n\u2022 select an item from our site index below", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Costs were not mentioned, but since the story is about an early vaccine trial (one that showed the vaccine to have less than desirable effectiveness), we think cost is not applicable in this case. ", "answer": 2}, {"article": "The brain\u2019s synapses control how much of these chemicals are released, and drugs like Zoloft effectively prevent the little serotonin being produced from reabsorbing back into the nerve cells from which they were released, resulting in a higher concentration of serotonin.\nThe biggest drawback to TMS, according to advocates, is the limitations on just who can undergo the treatment.\nEven those who are approved to undergo the treatment face another barrier as TMS is not widely covered by health insurance.\nMore studies will be needed to determine whether this method can be used as a widespread treatment for other brain-related disorders, but if today\u2019s research is any indication, TMS could be a key to improving the lives of Americans suffering from a multitude of disorders.\nAt this point, specific symptoms can be targeted depending on the patient\u2019s needs.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Cost is mentioned in the photo caption. And, the reader will find a cautionary comment lower in the story warning that \u201cTMS is not widely covered by health insurance,\u201d although other TMS stories indicate that insurance companies are slowly coming to the table.", "answer": 1}, {"article": "Shingles is a viral disease produced by the chicken pox virus, a common childhood disease, and is characterized by pain and a blistering rash along the nerves that have housed the dormant virus.\nDespite the FDA\u2019s approval, the vaccine has not caught on as much as some had hoped.\nBut researchers cautioned that because they did not follow patients over the longer term, they didn\u2019t know how effective the vaccine is years later.\nEveryone in the study, published in the Journal of the American Medical Association, was at least 60 years old, and the researchers didn\u2019t include anybody for whom the live vaccine is not recommended.\n\u201cThe human cost of shingles is enormous,\u201d said Michael Oxman, who studies infectious diseases at the University of California, San Diego, and was involved in a previous study of the vaccine.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "\n\n\nThe story reports that the vaccine can cost $200.", "answer": 1}, {"article": "Commenting on the next stage of the research, she said: \u201cIn the larger phase II trial we\u2019ve recruited 140 women with relapsed ovarian cancer across the U.K. to standard chemotherapy (paclitaxel) or paclitaxel in combination with vistusertib.\nDr. Dean A. Fennell, professor and consultant in thoracic medical oncology at the University of Leicester, who was not involved in the study, told Newsweek the study presents an \u201cexciting result.\u201d\n\nHe was particularly surprised by the magnitude of the response triggered by vistusertib combined with paclitaxel, which is closely related to standard chemotherapy.\nThe U.K.-based researchers used a new drug along with chemotherapy medication known as paclitaxel on 25 women with high-grade, serous ovarian cancer, and 40 participants with squamous non-small cell lung cancer.\nThe cocktail also stopped the cancer growing for almost six months, which is unexpected for patients with advanced-stage cancers who were unresponsive to currently available treatments, including chemotherapy, the authors said.\nCombined with paclitaxel chemotherapy, the scientists were able to block cancer cells from harnessing p-S6K.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There\u2019s no discussion of the potential cost of this drug, which is likely to be significant due to the high cost of new cancer therapies. As a comparison, a recently approved new cancer drug also made by Astra Zeneca, Imfinzi, costs $180,000 a year.", "answer": 0}, {"article": "A diet that includes tomatoes could lower the chance of having a stroke.\n\nA new study shows that men who had the highest levels of lycopene\u2014an antioxidant found in tomatoes\u2014had fewer strokes than men who had the lowest level of lycopene in their blood. Overall, the risk of strokes was reduced by 55%.\n\nThe study, based in Finland, will be published...", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The cost of tomatoes, or other sources of lycopene, is not in question.", "answer": 2}, {"article": "\u201cWe are looking for corporate partners as we head into Phase II trials,\u201d Kalos said.\nThe results provide \u201ca tumor-attack roadmap for the treatment of other cancers,\u201d including those of the lung and ovaries as well as myeloma and melanoma, researchers said.\nFurther study will show whether the latest results \u201creflect an authentic advance toward a clinically applicable and effective therapy or yet another promising lead that runs into a barrier that cannot be easily overcome,\u201d Urba said in an NEJM editorial.\nThe engineered T-cells were detected in patients\u2019 blood for several months afterward, and a portion of them turned into \u201cmemory T-cells,\u201d which could provide ongoing protection against cancer recurrence, researchers surmised.\nThe research group plans to treat four more patients with CLL before moving into a larger Phase II trial.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "While WebMD missed the cost component, Reuters smartly raised this issue and discussed how future research will be funded. \u201cAll of the funding for the University of Pennsylvania\u2019s gene therapy work has come from the academic community, but the work is expensive. \u2018We are looking for corporate partners as we head into Phase II trials,\u2019 Kalos said.\u201d", "answer": 1}, {"article": "Troponin I is a protein that is released into the bloodstream when the heart muscle has been damaged such as during a heart attack.\nThe troponin tests were more predictive than other biomarkers used to make the diagnosis, the study showed.\nThe findings appear in the Dec. 28 issue of the Journal of the American Medical Association.\nThe new test yields sensitive results in three hours.\nAnother measure, specificity, rules in disease with a high degree of confidence.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There is no discussion of cost \u2013 not of the new troponin I test nor of any existing test.", "answer": 0}, {"article": "\"I would say that hearing better kind of completes your personality, and I think Ethan became a complete personality once his hearing came online.\u201d\n\nAfter witnessing Priddy's miraculous results, Naberhaus was inspired to shrug off his image as the hard-of-hearing teacher and get a cochlear implant.\nEventually, he decided to get another cochlear implant in his left ear.\nBerryhill said the cost of the implant and surgery is in excess of $60,000, but it is covered by most insurance companies as well as Medicare and Medicaid.\nBut Priddy adapted quickly to his second implant and can now talk on the telephone all he wants.\nHe was nervous about this because, being left-handed, he favors his left ear and was worried that he wouldn't be able to do one of his favorite pastimes: talking on the telephone.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story cites a physician who says the cost of the device and surgery is about $60,000, and that it is covered by most insurance companies, Medicare, and Medicaid.", "answer": 1}, {"article": "Lisinopril is a member of a drug family called ACE (angiotensin-converting enzyme) inhibitors.\nBut there have been a number of observational studies implicating various molecules, including estrogens, in dementia, he said.\nThe risk was nearly halved for those taking both angiotensin-targeting drugs.\nWolozin said that it's not clear why the drugs would have a beneficial effect on the brain, but improved blood flow probably plays a role.\nBut the evidence is not sufficient to support routine use of angiotensin receptor blockers to prevent Alzheimer's disease, Wolozin said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The cost of the drugs was not mentioned.\u00a0 And the possible cost-effectiveness ramifications of the research were not mentioned.\u00a0 As is often the case with 70% of the stories we review, cost just doesn\u2019t seem to matter.\u00a0 But we all know it does. ", "answer": 0}, {"article": "Ultraviolet light can alter chromophores so they no longer absorb color, but UV light can damage the retina.\nThe laser treatment reduces the light absorption and also helps restore the lens proteins to their proper structure.\nTo make cataract treatment available to more people around the world, a less-invasive, less-expensive technique is needed.\nIn their approach, described in the open-access journal PLoS ONE, they \u201cbleach\u201d the lens with a laser.\nMuch more research and development work remains, Dr. Kessel said, but the goal is a relatively simple procedure that would last half an hour at most and use largely automated equipment in mobile clinics.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Not applicable. Costs not discussed, which is understandable at this early stage of research.\u00a0 ", "answer": 2}, {"article": "GHRH, a hormone produced by the hypothalamus in the brain, is linked to the insulin system, but also has a host of other effects.\n\u201cThey wanted to know where they could get (the hormone) after the study was over.\u201d\n\nBut that\u2019s jumping the gun, she warned, because the treatment is still experimental and GHRH is not approved to treat mental decline.\n\u201cOn self-report, many of the folks in the active group reported they felt better,\u201d Baker, who led the study, told Reuters Health.\n\u201cWe recommend commonly that people start exercising when they are having mild cognitive impairment,\u201d Baker said.\nAt the end, those who got the drug did better on psychological tests of executive function - whether or not they had mild cognitive impairment.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Not only did the story estimate cost \u2013 $700 for a single shot \u2013 but it put it up high in the 5th paragraph along with caveats about \u201cjumping the gun.\u201d", "answer": 1}, {"article": "Nov. 5, 2012 (Los Angeles) -- An IV infusion of \"good\" HDL cholesterol seems to rapidly remove cholesterol out of plaque-clogged arteries following a heart attack, a small, early study suggests.\nThe goal of the new treatment is to reduce the high risk of a second heart attack in people who have had a heart attack.\nHDL removes cholesterol from artery walls, but current HDL-boosting drugs, such as niacin and fibrates, take years to work, according to Gille.\nStandard heart attack medications, such as aspirin and anti-clotting drugs, prevent clotting but don\u2019t eliminate an underlying factor: cholesterol that has built up on artery walls, he says.\nGille is head of clinical and translational science strategy at CSL Limited (which funded the study) in Parkville, Australia.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No discussion of cost.\u00a0 Can\u2019t you give us some ballpark of what it costs to offer \u201cIV infusion of \u2018good\u2019 cholesterol\u201d?\nWe appreciate the fact that CSL 112 is in an early stage of development and that costs are not known at the moment.\u00a0 But shouldn\u2019t some attention be given to the potential impact of a drug that requires IV infusions?", "answer": 0}, {"article": "\"They got it completely wrong,\" he said.\nLike other mass screening tests including mammography, the overarching question is whether the benefits of virtual colonoscopy outweigh the risks.\nAt issue is whether virtual colonoscopy will enhance quality or whether it is, in the words of one physician blogger, \"a proxy for high-tech excesses.\"\nInitially regarded as a high-tech novelty, the new procedure has in recent months received key endorsements as a first-line screening test from influential medical groups, notably the American Cancer Society, after several large studies found it to be effective at finding large polyps.\nIts supporters, many of them radiologists who read CT scans, tout virtual colonoscopy as a more palatable alternative that has the potential to boost low rates of screening.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story describes the cost of virtual colonoscopy compared to standard colonoscopy, although it isn\u2019t clear that $1500 versus $800 is accurate in all settings and also does not include the fact that 20% will require a follow-up colonoscopy. The story also mentions the crucial issue of insurance coverage. While more insurance companies are starting to cover the procedure, many do not. The recent CMS decision not to cover it has been highly influential.", "answer": 1}, {"article": "\"The results and especially the rapidity of the effects observed in the gantenerumab trial went beyond our expectations,\" Luca Santarelli, MD, study co-author and Roche senior vice president of neuroscience, writes in an email.\nTherefore, it's not known if reducing the amount of them will slow or stop the disease.\nThe experimental compound, known as gantenerumab, is being developed by Roche, the Swiss pharmaceutical company.\nWhat is not entirely known at this point, though, is if these plaques cause Alzheimer's or are by-products of the disease.\nThe study is published in the online edition of Archives of Neurology.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Not applicable.\u00a0 It\u2019s understandable that costs wouldn\u2019t be discussed at this early stage of research.", "answer": 2}, {"article": "In the United States, about 10 percent of people say they have chronic insomnia, according to the U.S. Centers for Disease Control and Prevention.\nStandard sleep medications work more widely throughout the brain, Bazil explained, which is why they can have a host of side effects.\nFor most people, he said, medication should be a temporary treatment; behavior change is the long-term fix.\nThe effect was essentially comparable to what has been seen with other sleep medications, said Bazil, who was not involved in the research.\nA drug, ideally used for a short time, may help encourage sleep and get people on the right track, Bazil said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No discussion of costs.\u00a0 If the drug has been submitted to the FDA for marketing approval, as the story states, you know that the company has price estimates. It\u2019s the job of journalism to give more cost context.", "answer": 0}, {"article": "The Lancet.\n\"Our data has the potential to influence national policies around prevention of hip fractures, which is particularly relevant in our ageing society.\nCommunity screening for osteoporosis could prevent more than a quarter of hip fractures in older women, according to new research.\nThe randomised controlled trial 'SCreening for Osteoporosis in Older women for the Prevention of fracture' (SCOOP) was funded by the Medical Research Council and Arthritis Research UK.\nGiven that the number of costly and debilitating hip fractures are expected to increase with an ageing population, the results of this study potentially have important public health implications.\"\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "This release was very thorough in most areas. However, we\u2019re only told that the proposed screening program is \u201clow cost.\u201d But the FRAX screening is just a questionnaire, so there is minimal cost to using it.\nThe costs of screening, of course, arise from those women who go on to get bone density scans and get treated for osteoporosis. We think the additional costs of scans and treatment deserved a mention.", "answer": 0}, {"article": "Professor Francesca Cordeiro at UCL Institute of Ophthalmology, who led the research, said: \"Detecting glaucoma early is vital as symptoms are not always obvious.\nFurther studies will now be carried out to into DARC and how it can be used not only to diagnose and treat glaucoma patients but also for other neurodegenerative conditions.\nIt uses a specially developed fluorescent marker which attaches to cell proteins when injected into patients.\nThe initial clinical trials established the safety of the test for patients.\nThe examination uses equipment used during routine hospital eye examinations.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There is no discussion of the costs of the test and the potential costs or cost savings of identifying patients earlier than they otherwise would be identified.", "answer": 0}, {"article": "Impaired insulin sensitivity is one risk factor for type 2 diabetes, which is associated with age and obesity and happens when the body can\u2019t properly convert blood sugar into energy.\nAnd it doesn\u2019t prove that catching up on sleep will prevent diabetes.\n\u201cBy catching up on sleep on the weekends, people are reducing average extent and severity of the effects of sleep deprivation,\u201d Gangwisch added by email.\n\u201cIt gives us some hope that if there is no way to extend sleep during the week, people should try very hard to protect their sleep when they do get an opportunity to sleep in and sleep as much as possible to pay back the sleep debt,\u201d said lead study author Josaine Broussard of the University of Colorado Boulder.\nBut then, when they let the men get extra sleep for the next two nights, their blood tests returned to normal, countering the effect of the short-term sleep deprivation.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The cost of the \u2018intervention\u2019 (catching up on sleep) is what is at issue here, and that is \u2018free\u2019. So we\u2019ll rule this Not Applicable.", "answer": 2}, {"article": "The stool was more solid, the diarrhea goes away, and the bloating is much less.\"\nThat can translate to big changes in the lives of those with IBS, estimated to affect about 15% of adult Americans.\nWith the drug treatment, Pimentel says, those with the IBS ''can enjoy social outings without the worry of having to run to the bathroom and having diarrhea.\"\nThe study looked only at those IBS patients with the non-constipation form, he tells WebMD.\n''The major finding was that all IBS symptoms improved,\" says Mark Pimentel, MD, director of the GI Motility Program at Cedars-Sinai Medical Center, Los Angeles, who led the clinical trial of the drug at Cedars.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "This story made no mention of costs. This is a shame in a story that is essentially promoting off label use for a costly drug that is only approved for a very narrow range of treatments. The Associated Press story that we also reviewed estimated that the pills cost $21 a pop, resulting in a $910 price tag for a two week supply. Given that IBS sufferers may require long term treatment, this bill could grow exponentially.", "answer": 0}, {"article": "And unfortunately there is no cure.\n\u201cThis is the only methodically rigorous clinical trial to show that diet-based therapy can not only improve symptoms, but also quality of life in patients with IBS,\u201d says U-M assistant clinical professor and gastroenterologist Shanti Eswaran, M.D., who researches the role of diet and food in functional bowel diseases such as IBS.\nBecause of the many unknowns about the chemical causes and triggers of IBS, the list of \u201cbad\u201d foods is exhaustive and elusive, and help from a dietician is highly recommended.\nThe results were impressive: More than 50 percent of the patients on the low FODMAP diet had major improvement of their abdominal pain, compared with 20 percent of the control group.\nThat\u2019s the result of research by the University of Michigan Health System, presented at Digestive DiseaseWeek, that studied for the first time in the United States the result of following a carefully controlled diet to improve the symptoms and quality of life for those with irritable bowel syndrome.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "A low FODMAP diet might raise grocery bills, since it requires specialty products that eliminate wheat, lactose, fructose, and other common ingredients. It\u2019s understandable that the news release doesn\u2019t address a potential modest increase in food expenses. However, the cost of working with a registered dietitian over several months to adopt a low FODMAP diet and tailor it to a patient\u2019s individual food tolerances is significant. That should have been addressed in the news release, along with how that cost might be offset by eliminating less effective pharmaceutical therapies and increasing the productivity of patients who regularly miss work because they are debilitated by IBS symptoms.", "answer": 0}, {"article": "\u2022 Swelling or thickening in part of the breast.\nAnd there are some lifestyle-related risk factors that can be controlled, such as hormone therapy after menopause, obesity, alcohol intake and physical inactivity, Evers said.\nOlder age is a leading risk factor for breast cancer.\nThere are three tests often used to look for breast cancer, Evers said.\nIn some cases, women never develop any of these symptoms, Evers noted.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The article lacked information on costs. Insurance does not always cover screening.", "answer": 0}, {"article": "But in this case, if anything, we're taking money out of our own pockets.\"\nThe American Cancer Society, which has led the opposition to the mammography guidelines issued by the U.S. Preventive Services Task Force, was involved in the discussions leading up to the Pap test guidelines and will consider them in reevaluating its own recommendations, an official said.\n\"We are persuaded that the guidelines are really consistent with the evidence,\" said Robert Smith, the society's director of cancer screening.\nThe change comes amid sharp controversy over new recommendations from a federal task force that women wait until age 50 before they begin having routine mammograms and that women age 50 to 74 scale back to getting the exams routinely every two years.\nWhite House aides said the political team leading the fight to pass health-care reform first heard about the upcoming report -- which the panel approved in March -- in the past two weeks, and viewed it as one of many potential headaches that opponents could use to attack the reform efforts.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story quotes two sources who dispute the notion that the guidelines are motivated by a desire to save money. \nUnfortunately, it never says how much money the test costs\u2013or whether applying the new guidelines would cost or save money. ", "answer": 0}, {"article": "Visit the U.S. National Cancer Institute for more on aspirin and cancer risk.\nMoreover, the benefit of aspirin in reducing overall cancer risk appeared to depend on how much one took.\nThe benefit was no longer seen within four years of stopping it, the researchers found.\n\"The results of ongoing research to develop more tailored treatment based upon a personalized assessment of risks and benefits is critical before recommending aspirin for preventing cancer,\" she said.\nAmounts ranged from less than one aspirin a week to 15 or more, the researchers said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There was no mention of cost, but there did not need to be. Aspirin is widely known to be cheap. The story could have mentioned the savings we\u2019d collectively reap (in terms of treatment costs) if aspirin truly does prevent colorectal cancer, and/or the cost of treating downstream complications such as bleeding. But we\u2019ll rate this Not Applicable.", "answer": 2}, {"article": "While other studies have found a link between eating chocolate and reduced stroke risk, this research found a slight difference in protection, depending on type of stroke.\nThose who ate the most chocolate were protected a bit more from strokes caused by hemorrhage than strokes caused by obstruction such as blood clots.\nThe new Swedish study echoes previous research in men and women.\n\"The protection started at more than 45 grams [about 1.5 ounces] a week,\" says researcher Susanna C. Larsson, PhD, of the Karolinska Institutet in Stockholm, Sweden.\nIn this group, the median intake (half ate more, half less) was about 2.3 ounces a week.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does a good job of emphasizing that health benefits are more likely with chocolate that has a higher concentration of cocoa solids. However, these premium chocolates\u00a0come with\u00a0a corresponding increase in\u00a0price compared with your average Hershey Bar\u2013 something the story could have explained.\u00a0 Nonetheless, we\u2019ll rule this not applicable as most people probably have a general idea about the cost of chocolate.", "answer": 2}, {"article": "Bochner and his colleagues Drs.\nIf the results are favorable, the next step would be to get funding to actually test whether taking a BTK inhibitor will improve the ability of food-allergic adults to eat foods they're allergic to.\nWhile the study was small - only two patients qualified out of about 35 that were screened for allergies - the implications are much larger for later phases of this study.\nA rather unlikely pairing - cancer and allergies - Bochner thought to test if a cancer drug could prevent allergic reactions by collaborating with Feinberg's oncology department.\nThe promising data from this pilot study could have greater implications for adults with food allergies.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Although this line of research is in the earliest stage of human tests, the release should have noted that the drug, as it was used in the study, cost more than $100 a day. Obviously, cost is an issue that would have to be dealt with before declaring that this treatment could be used routinely by allergy sufferers.", "answer": 0}, {"article": "We're sorry, but Newspapers.com doesn't work properly without JavaScript enabled. You will need to enable Javascript by changing your browser settings. Learn how to enable it.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story didn\u2019t discuss the cost of what it called the current \"standard of treatment,\" Biaxin, nor the cost of the new drug, cethromycin. If a drugmaker says it is ready to file for new drug approval within a few months, as the story states, you can be assured they have some ballpark estimate of what they expect to charge.\u00a0 The story should have probed for that information. ", "answer": 0}, {"article": "Others mixed them with applesauce and cinnamon in a blender or chopped them up and added them to meatloaf, hamburger, and spaghetti sauce.\nHalf the men were randomly assigned to eat 2.5 ounces of walnuts a day, along with their usual diet.\nEating 2.5 ounces of walnuts a day -- a little more than half a cup -- for 12 weeks improved sperm quality in healthy young men, researchers report.\nTheir study is part of a growing body of evidence that men\u2019s dietary and lifestyle choices might affect their fertility.\nThe researcher looked at sperm concentration, vitality, ability to move, shape and size, and chromosome abnormalities, all thought to be related to fertility.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Costs aren\u2019t mentioned, but the price of walnuts\u00a0isn\u2019t\u00a0a major concern.", "answer": 2}, {"article": "reflect problems that cause squeaking, which it contends occurs in less than 1 percent of implants.\nAlready, dozens of patients have elected to endure subsequent surgeries to replace the noisy hips.\nNow, tens of thousands of ceramic hips later \u2014 from Stryker and other makers that entered the field \u2014 many patients say their squeaking hips are interfering with daily life.\nNow that the squeaking has raised caution flags, researchers are weighing the noted durability of ceramic-on-ceramic hip joints like Stryker\u2019s Trident model against products with other combinations of materials.\nWhatever the actual frequency, some investigators who have looked at the problem say the squeaking seems to be associated with extreme flexing of the ceramic implants, but exactly how is unclear.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The article states that the costs are \u201cgenerally \u2026 close to $45,000.\u201d", "answer": 1}, {"article": "The page may no longer exist or may have moved to another web address. Try again to locate what you want by choosing a section from the navigation menu at left, viewing our Site Map or using the search box below.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not detail the costs of the weekly sessions of therapeutic hypnosis, which are likely to be high. But if the woman can learn the technique and use it herself over several years, it may be more cost effective than medication. This is what makes the cost consideration worth mentioning.", "answer": 0}, {"article": "\u201cEveryone was hoping vitamin D would be kind of a panacea,\u201d Dr. Black said.\nBut, the committee concluded, a level of 20 to 30 nanograms is all that is needed for bone health, and nearly everyone is in that range.\nAnd there is evidence that excess calcium can increase the risk of heart disease, the group wrote.\nMost people need to take supplements to reach levels above 30 nanograms per milliliter, he added.\nIt is not clear how or why the claims for high vitamin D levels started, medical experts say.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Most people know roughly what a bottle of vitamin D supplements might cost them, so the lack of information on cost is not a significant gap. We appreciate that the story provided\u00a0data showing the large and growing amount our society is spending on vitamin D\u00a0supplements ($430 million in 2009), with apparently little health benefit to show for it.", "answer": 1}, {"article": "I was absolutely terrified because I saw my mom go through it, and I saw how much pain she was in,\" Barletta says.\nLaPook notes that it will be a few more years before this procedure is widely available.\nThat's still the standard procedure for the 50,000 Americans who are operated on each year for this problem.\nDr. Saibal Kar performed the innovative procedure on Barletta at Cedars Sinai Hospital in Los Angeles.\nWhen Barletta's valve problem got worse two years ago, she faced the same operation.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There was no cost estimate provided for this medical device.\u00a0 \n\u00a0", "answer": 0}, {"article": "Many researchers have found that statin drugs, which include Pfizer Inc\u2019s Lipitor and AstraZeneca Plc\u2019s Crestor, have effects far beyond lowering cholesterol and reducing the risk of heart disease.\nAnd U.S. health officials have been watching data that suggests some statins such as Merck & Co\u2019s blockbuster drug Vytorin may actually raise the risk of cancer, although they have saidf this is unlikely.\n\u201cOur findings suggest that randomized controlled trials designed to test the hypothesis that statins reduce the risk of colorectal cancer are warranted,\u201d Samadder added in a statement.\nThe longer people took the highly popular cholesterol-lowering pills, the lower their risk of later developing colon cancer, the researchers told a meeting of the American College of Gastroenterology.\nSamadder\u2019s team did what is known as a meta-analysis, combining the findings of 22 scientific studies with more than 2.5 million volunteers.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "\u00a0Although statin medications have been on the market for a long time and information about the costs of both name brand and generic versions of these drugs is readily available, the story included no information about costs. ", "answer": 0}, {"article": "And if you wake up in the middle of night and don\u2019t fall back asleep easily, get out of bed.\u201d\n\n\u201cYou don\u2019t want to have any linkage between the experience of lying in bed and being awake,\u201d he said.\nWhen the researchers looked at information from a different, more in-depth sleep monitoring system, however, they failed to find significantly better outcomes with the behavioral therapy.\nBuysse and his colleagues wondered if the pill-free treatment could be shortened and simplified, providing more rapid results at a lower cost.\nThese improvements were sustained for at least 6 months, and were backed up by data from a sleep monitor worn on the wrist or ankle.\nThe new results were similar to those previously published on the more intense cognitive behavioral therapy.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "\n\n\nAlthough this trial was a preliminary experiment, the proposed intervention is clearly defined as two office visits and two telephone calls with a nurse, so it should have been possible to estimate the cost. Since one purpose of testing this sort of brief intervention is to offer lower-cost alternatives to established behavioral treatment for insomnia, readers should have been given some estimate of the relative costs of the interventions.", "answer": 0}, {"article": "The National Cancer Institute has more on prostate cancer.\nA final study of almost 4,000 patients found that surgeons needed to perform 1,600 procedures known as robotic-assisted laparoscopic radical prostatectomies (RALP) to become adept at the procedure.\n\"A low PSA, particularly those in men who have less than 1.0, and probably those less than 2.0, certainly could be considered for substantially longer intervals of PSA screening... Personalization of PSA screening is clearly underway.\"\nA second study also being presented at the symposium found that a drug already used to treat enlarged prostate gland may delay the progression of low-risk, early prostate cancer among men who choose a wait-and-see approach to treatment.\nOne caution, though, is that the study only looked at three surgeons performing RALP.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There was no discussion about how costs might be affected by any of the three aspects of prostate cancer testing and treatment described in this story. And all three had significant cost implications.", "answer": 0}, {"article": "\"The disc is made up of mostly water, and it get tears in it.\nHe says his intent was not to put some orthopedic surgeons out of business.\nBut no matter where you live, surgery is not necessarily the best or only option.\nWhether you have surgery often depends on where you live and what doctor you see.\n\"However what was really interesting is that patients who decided not to have surgery who could wait also did very well.\"\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not mention costs of surgery or any of the non-operative options.", "answer": 0}, {"article": "People who have chronic inflammation because of chronic infection, autoimmune disease or conditions such as obesity have a higher cancer risk because of damage to normal cells.\nThis is a neat solution: blocking the uptake of a nutrient needed by prostate cancer cells with nutrients that are commonly in the human diet.\nThese compounds minimize one of the risk factors for cancer, inflammation within the body.\n\"These nutrients have potential anti-cancer properties and are readily available,\" says Tiziani.\nThe researchers first tested 142 natural compounds on mouse and human cell lines to see which inhibited prostate cancer cell growth when administered alone or in combination with another nutrient.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The cost of adding these foods to your diet would be negligible for most people, although taking supplements over long periods could pose a significant cost.", "answer": 2}, {"article": "The Lancet.\nThe clinical efficacy results reported today are from the JET8 Phase-III clinical study (3107) (the JET8 study).\nThis clinical design allowed for the study of HETLIOZ\u00ae without the confounding effects of sleep deprivation and variable light conditions.\nHETLIOZ\u00ae will be potentially useful under circumstances of rapid eastward transmeridian travel experienced by frequent travelers, the rapid deployment of military troops and any circumstances that will necessitate the abrupt phase advance of the sleep wake cycle.\nBased on animal data, HETLIOZ\u00ae may cause fetal harm.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Hetlioz currently costs an estimated $280 per capsule or $102,000 a year for the blind and a relatively few non-blind who use it to treat a rare circadian rhythm disturbance. Cost is a significant data point in any story promoting a drug\u2019s benefits, especially if the benefits are relatively modest.", "answer": 0}, {"article": "Type 2 diabetes, which is often tied to obesity, affects about 8 percent of the U.S. population, according to the U.S. National Institute of Diabetes and Digestive and Kidney Diseases.\nIt\u2019s also not possible to say from the current evidence that heavy coffee drinkers (and tea and decaf drinkers) don\u2019t have other characteristics that might protect them against developing diabetes, they add, such as eating a healthier diet.\nIn the years since then, they add, the amount of research on coffee and diabetes risk \u201chas more than doubled,\u201d while other studies have suggested that tea and decaf coffee may also be preventive.\nThe current analysis could have overestimated the effect of these beverages on diabetes risk due to statistical issues with the smaller studies, Huxley and her colleagues note.\nFor every additional cup of coffee a person consumed each day, the study\u2019s authors found, a person\u2019s risk of diabetes was reduced by 7 percent.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "\u00a0There was no discussion of costs, but most people know what coffee and tea costs.", "answer": 2}, {"article": "But it also lowered women's risk of dying from breast cancer by 11% and men's risk of dying from prostate cancer by 23%.\n\"This study found strong evidence that aspirin use may reduce cancer death.\nNot everyone can take aspirin, particularly if you are at high risk for ulcers and gastrointestinal bleeding.\nStudies have also found that aspirin can help patients who have had (or are at high risk for) a heart attack or stroke, and of course it is a good drug to relieve pain.\nIt may also reduce your chances of dying from cancer, according to a study on long-term regular aspirin use and different kinds of cancer.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There are no costs discussed in this story, however, aspirin is ubiquitous and very inexpensive.", "answer": 2}, {"article": "Researchers have long known that people who are very thin tend to have a shorter life expectancy, often because they're dealing with cancer or other serious illnesses.\nAnd all of the people in this study are white, so that's a limitation.\nSo being fatter, at least a bit, may be healthier.\nThe most relevant was the decline in smoking since the 1970s.\nBut this does raise the prospect of whether it may soon be time to tweak the official definition of normal, healthy weight.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "", "answer": 2}, {"article": "Nov. 18, 2012 -- Researchers say they've been able to use nanoparticles to stop multiple sclerosis (MS) in mice that are bred to have the disease.\n\u201cThis technology could be very effective,\u201d says Timothy Coetzee, PhD, chief research officer for the National Multiple Sclerosis Society.\nWhat remains to be seen is whether the researchers have picked the right proteins that might turn off the disease in humans, he says.\n\u201cWill these peptides actually induce tolerance in people?\nThe particles are about 200 times smaller than the thickness of a human hair.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story could have done what the competing MSNBC story reported:\nMSNBC quoted a researcher saying that one stage of the research\u2026\u201dwas hideously expensive.\u201d \u2026 \u201cIt cost probably about a million dollars to treat 10 patients using live cells,\u201d he said.", "answer": 0}, {"article": "The use in spine surgery of bone-growth proteins like Medtronic Inc.\u2019s product Infuse has led to widespread nationwide increases in hospital charges ranging from 11% to 41% above conventional surgical costs, researchers found.\n\nThe researchers studied the results of a broad U.S. sample of 328,000 spine surgeries from 2002 through 2006. They report their findings this week in JAMA, the Journal of the American Medical Association.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story fails spectacularly with the issue of costs. \nFirst, it\u2019s not clear why the story focuses primarily on the 11- to 41-percent higher in-hospital costs of BMP\u2013the study\u2019s findings on prevalence and complication rates are at least as significant.\u00a0 \nYet despite the story\u2019s focus on costs, the story lacks basic reporting on them. The story fails to say how much the surgery costs, how big that 11 to 41 percent premium really is, and who pays for it. And in whose pocket that extra spending winds up in.\u00a0\u00a0 \nAs it happens, the journal study itself includes these details: The BMP product costs about $4,000. For anterior cervical fusion, the surgery without BMP cost about $31,000. With BMP, about $46,000.\u00a0 \nBut it gets worse. \nAs the story itself explains, the issue of total BMP costs has been controversial since the technology\u2019s inception because [as BMP makers suggest] patients who get BMP surgery may require less treatment over the course of their lives than their peers. Despite the interested source, it\u2019s a legitimate argument worth exploring.\u00a0\nAnd yet: As the authors of the journal article themselves explain, this study did not follow patients over time and therefore lacked the power to speak to the question of total costs at all. Its findings about in-hospital costs are useful but not in any way conclusive. \nIn other words: the story focuses on the findings of higher costs of BMP despite the fact that the study cannot resolve the question of total costs\u2013which, from a public health perspective, is the only one that counts. ", "answer": 0}, {"article": "Men with low-risk prostate cancer are currently put under active surveillance, where the disease is monitored and only treated when it becomes more severe.\nResults of a trial in 413 patients showed that the drug, which is activated with a laser to destroy tumor tissue in the prostate, was so effective that half the patients went into remission, compared with 13.5 percent in a control group.\nThe trial involved 47 treatment sites in 10 European countries, most of which were performing VTP for the first time.\nThe VTP treatment is now being reviewed by the European Medicines Agency (EMA) for possible license, but it likely to be several years before it can be offered to patients more widely.\n\u201cThese results are excellent news for men with early localized prostate cancer, offering a treatment that can kill cancer without removing or destroying the prostate,\u201d said Mark Emberton, a University College London consultant urologist who led the trial.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not discuss the potential costs of this therapy.", "answer": 0}, {"article": "They might be more health conscious or conscientious, or have other traits associated with longevity.\nThe analysis, published Monday in Annals of Internal Medicine, drew wildly different reactions, as is often the case with research on PSA screenings.\nThis is a screening test that saves lives.\u201d\n\nThose gains come at some cost to health, though: For every life saved, she estimated, five men will be told they have cancer when in fact their abnormal cells would never grow, spread, or harm them.\nIf the new analysis is correct, one of the influential PSA studies, called PLCO, reduced deaths from prostate cancer by 27 percent to 32 percent, not the zero percent that PLCO researchers themselves found.\n\u201cNo matter how sophisticated, they shouldn\u2019t trump data from real people who participated in the randomized trials\u201d \u2014 which in PLCO found zero lives saved from PSA screening.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The lack of any cost information is one flaw to this article. Reminding the readers of the costs of PSA screening programs\u2013in terms of the huge volume of medical services that it can catalyze (including the costs of the test itself, the drugs, surgeries, urology consultations, hospital and operating time, as well as the lost income for men who are recovering from treatment)\u2013is a necessary part of the story.", "answer": 0}, {"article": "T. Kondo, R. Goto, K. Ono, S. Kitano, M. A. Suico, M. Sato, M. Igata, J. Kawashima, H. Motoshima, T. Matsumura, H. Kai, and E. Araki, \"Activation of heat shock response to treat obese subjects with type 2 diabetes: a prospective, frequency-escalating, randomized, open-label, triple-arm trial,\" Scientific Reports, vol.\nIn the researcher's next clinical trial, 60 obese patients with type 2 diabetes from both genders were given a 12-week treatment with the belt-shaped MES+HS medical device.\nThe current study reports clinical trial results for optimal use frequency.\nThis determined the most effective treatment frequency.\nFurthermore, adding the MES+HS treatment to a DPP-4 inhibitor, which is the most often used therapeutic drug for diabetes in Japan, showed an even stronger blood glucose improvement.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The news release\u00a0makes no mention of the potential cost of the device. A potential source of comparison is Ab toner and waist trimmer electronic belts of various brands sold at Walmart. They vary from the $21.25 Healthmate Forever AB Muscle Stimulation Multi Belt, to the $149 Ab Transform Pro Abdominal, Arm and Leg Training System.", "answer": 0}, {"article": "Doctors in Seattle cured a late-stage cancer patient after tinkering with his body's defenses against infection, leading to cautious optimism about treating late-stage melanoma, a deadly skin cancer.\n\nThe surprising result, published in this week's issue of the New England Journal of Medicine, is the latest hopeful finding from the 30-year-old field of \"adoptive immunotherapy,\" which theorizes that the body can be taught to fight off its own cancers.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "\nThe story says the cost is roughly $30,000 to $50,000.\n", "answer": 1}, {"article": "\"As soon as you stop the chemo, you feel stripped, and you think, 'Wow, what do I do now?'\n\"\n\nServan-Schreiber did what he knew best -- he hit the books, and was surprised to find studies on how nutrition and exercise might help the body fight cancer -- information doctors never told him.\nIn addition, LaPook spoke with several other cancer patients who told him they're left in the dark, too, about how exercise and eating the right foods might help them in their battles against the disease:\nThen, he discovered in one of his own brain scanner experiments that he -- had brain cancer.\nHe says vegetables and fruits such as brussel sprouts, asparagus and raspberries can target specific cancers, at least in test tubes.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "It\u00a0is not necessary for the story to discuss the costs of such common items, however it would have been nice if the story had mentioned that eating a diet high in fruits and vegetables could be more expensive than the traditional Western diet.", "answer": 2}, {"article": "Menopause is a normal part of a woman's aging process but pre-menopausal women treated with chemotherapy can also develop premature menopause, and consequently, severe menopausal symptoms including sleep disorders, vulvovaginal atrophy (VVA), vasomotor symptoms (VMS), mood changes, depressive symptoms, cardiovascular disease, osteopenia, and osteoporosis.\n\u2022 Smoking cessation, weight loss (if indicated), limiting or avoiding alcohol, maintaining adequate levels of vitamin D and calcium, eating a healthy diet, and regular physical activity are suggested for all women with prior breast cancer\n\u2022 Non-pharmacologic therapies for VMS such as cognitive behavioral therapy, hypnosis, and acupuncture may be helpful as are vaginal lubricants and moisturizers\n\u2022 Several emerging approaches such as selective estrogen receptor modulators (SERMs), Tissue selective estrogen complex (TSECs), estetrol, and neurokinin B inhibitors show promise as useful agents to expand options for symptom relief with less breast cancer risk but have not yet been tested to confirm safety in women with prior breast cancer\n\nOther authors of the study include: Cynthia A. Stuenkel of the University of California, San Diego in La Jolla, Calif.; Susan R. Davis of the School of Public Health and Preventative Medicine, Monash University in Australia; JoAnn V. Pinkerton of the University of Virginia in Charlottesville, Va.; Ann Gompel of Paris Descartes University in France; and Mary Ann Lumsden of the University of Glasgow School of Medicine, Dentistry, and Nursing in Scotland.\nThe study, \"Managing Menopausal Symptoms and Associated Clinical Issues in Breast Cancer Survivors\" is published online at https:/ , ahead of print.\nA comprehensive review published in the Endocrine Society's Journal of Clinical Endocrinology & Metabolism focuses on current and future approaches to management of menopausal symptoms after breast cancer.\nSanten and colleagues reviewed controlled clinical trials, observational studies, evidence-based guidelines, and expert opinion from professional societies to address the gap in treatment recommendations for management of menopausal symptoms after breast cancer.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The report lists a variety of methods for reducing menopausal symptoms, but no costs associated with any of the methods are mentioned.\nMany of the recommended methods \u2014 like cognitive behavioral therapy, hypnosis and acupuncture \u2014 may not be covered by insurance or even available to many women depending on their location. ", "answer": 0}, {"article": "\"It's been a miracle to me,\" Wolfe said.\nThe Topamax group cut back to six drinks a day, on average, assuming everyone who dropped out of the study relapsed into heavy drinking.\nThe drug costs at least $350 a month, plus the price of doctor's visits.\nThe study, published in today's Journal of the American Medical Association, was funded by the maker of the drug, Johnson & Johnson Inc.'s Ortho-McNeil Neurologics.\nAll volunteers were encouraged \u2014 but not required \u2014 to stop drinking.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story provided an estimate for the cost of the treatment as well as the reminder that the costs for the doctor\u2019s visit also needed to be factored in.", "answer": 1}, {"article": "Learn more about intrauterine devices from the Association of Reproductive Healthcare Professionals.\nThe researchers randomly assigned nearly 600 women with heavy menstrual bleeding to receive either the IUD or standard medical care.\nBritish researchers found that the treated IUD was more effective at reducing the effects of heavy menstrual bleeding (also called menorrhagia) on quality of life compared to other treatments.\nResults of the study, which was funded by the United Kingdom's National Institute of Health Research, appear in the Jan. 10 issue of the New England Journal of Medicine.\nAnother expert said the findings show promise for women bothered by heavy bleeding.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There was no mention of costs even though the Mirena\u2019s website has it at about $800 (a significant number of insurers will pay for it).", "answer": 0}, {"article": "Among those 40 to 49 who had regular screening, for every 1,000 women tested, 121.2 had a false positive.\nFor every 10,000 women screened repeatedly over 10 years, four lives are saved in women 40 to 49; eight in women 50 to 59; 21 in women 60 to 69; and 13 in women 70 to 74, the task force found.\nThe guidelines relied in part on a study of records from 405,191 women who had digital mammograms from 2003 to 2011, which found that false positives were common, especially in younger women.\nDr. Constance Lehman, a professor of radiology at Harvard Medical School and director of breast imaging at Massachusetts General Hospital, who is not on the task force, said she was pleased to see that although its advice had not changed, the group had placed more of an emphasis than before on the importance of women\u2019s having the freedom to decide how often to be screened and when to start.\n\u201cThe science supports mammography as an important tool in the fight against breast cancer,\u201d said Dr. Michael LeFevre, a former chairman of the task force and a professor of medicine at the University of Missouri.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does a good job of explaining how the USPSTF recommendations may affect insurance coverage of mammography screening \u2014 which is laudable, given the complexity of the issue. However, the story does not tell readers the bottom line: how much would a mammogram cost if it were not covered by insurance? While we found varying estimates, a 2011 paper stated that the overall cost of a mammogram was $266 \u2014 a considerable sum, and likely out of reach for many women. This was a shortcoming of both the New York Times and Washington Post stories.", "answer": 0}, {"article": "DOI: 10.1001/jamacardio.2016.4828\n\nCONTACT: For more information or to schedule an interview, please contact the NHLBI Office of Science Policy, Engagement, Education, and Communications at 301-496-5449 or nhlbi_news@nhlbi.nih.gov (link sends e-mail)\n\nPart of the National Institutes of Health, the National Heart, Lung, and Blood Institute (NHLBI) plans, conducts, and supports research related to the causes, prevention, diagnosis, and treatment of heart, blood vessel, lung, and blood diseases; and sleep disorders.\nWHAT: A new study shows that the drug fenofibrate might reduce the risk of cardiovascular events in patients with type 2 diabetes who have high levels of triglycerides and low levels of \"good\" cholesterol, despite being treated with statins.\nThe study, funded by the National Heart, Lung, and Blood Institute (NHLBI), appears in the December 28 issue of JAMA Cardiology.\nHowever, a randomized study is needed to confirm these findings, according to the authors.\nThe findings suggest that fenofibrate therapy may be beneficial in the way the researchers hoped: by reducing cardiovascular events in patients with type 2 diabetes who take statins but still have especially high triglycerides levels and low HDL cholesterol levels.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The drug being studied,\u00a0fenofibrate, goes by the brand name Tricor. Its costs are well known \u2014 about $100 for 90 pills \u2014 and could easily have been dropped into the release, making it clear how much it would cost for a typical person to replicate the regimen necessary to see any of the benefits seen in the study.", "answer": 0}, {"article": "\u201cYou don\u2019t need any fancy equipment.\nAnd, he said, they might also lead to better management and treatment of people with autism, a complex and mysterious brain disorder usually first diagnosed in early childhood.\nThey found that the brain circuitry is significantly different in those with autism compared to people with normal brain function, specifically in areas of the brain that are engaged in language and social and emotional functioning.\nBy measuring six aspects of the brain\u2019s circuitry, the test was able to correctly pick out people who had been diagnosed with autism with 94 percent accuracy.\nHe said the findings, published in the journal Autism Research, were very preliminary, but if confirmed in several more and larger studies, they might replace current subjective tests now used to diagnose the disorder.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The cost of the specialized MRI scan and its interpretation is not provided. MRI scans are a major driver of healthcare costs and the use of this technology as a routine screening instrument could have a significant direct financial impact. The cost of a routine MRI could have been provided", "answer": 0}, {"article": "Worse, Anderson says, \"I could feel the tumors getting bigger.\nStill, the study stands as \"a major landmark in cancer immunotherapy,\" says Dr. Bernard Fox, president of the International Society for Biological Therapy of Cancer.\nAfter one year, the once palpable tumors were no longer detectable in diagnostic scans.\nTwo years ago, she gained access to an experimental immune-enhancing treatment in clinical trials at Providence Cancer Center in Portland.\nResearchers linked 14 deaths to the study drugs, half caused by immune-system reactions.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No discussion of costs.\u00a0 Is this OK because this is still experimental?\u00a0 We don\u2019t think so, not when the drug company is allowed to project possible approval within a year.\u00a0 Much better to say, as a Wall Street Journal story did, that the company said it was too early to set pricing.\u00a0 But to ignore costs entirely is a mistake in our view. ", "answer": 0}, {"article": "Myo-inositol is also found in fruits, beans, grains and nuts, although Bild said the finding does not necessarily explain why people who eat more of these foods have a lower risk of cancer in general.\nAnd, they said, a natural supplement derived from food that is being tested to prevent lung cancer appears to halt the precancerous changes.\nThe researchers have patented their findings through the universities but Bild said myo-inositol supplements are cheap and freely available.\nAnd the second group was taking the natural supplement, myo-inositol, to try to prevent lung cancer.\n\u201cEven in normal cells or premalignant cells prior to cancer development we see this pathway being turned on,\u201d said Andrea Bild of the University of Utah, who worked on the study published in the journal Science Translational Medicine.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "     \n This test is not yet available, so a discussion of its cost is perhaps not warranted. The story states that myo-inositol is \u201ccheap,\u201d but that\u2019s a relative term.\u00a0 Nonetheless, because of the early stage of the research, we\u2019ll rule this not applicable. ", "answer": 2}, {"article": "1Wiseman JT, Guzman AM, Fernandes-Taylor S, et al.\nThe study results appear as an \"article in press\" on the website of the Journal of the American College of Surgeons ahead of print.\nDr. Gunter said they were very successful in giving patients knowledge and access to technology so they could participate in the study.\nThis protocol also has a cost-savings component, in addition to the patient safety and satisfaction aspects.\nSupport for this study came from the Agency for Healthcare Research and Quality: AHRQ R21 HS023395.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The news release addresses the overall cost of post-surgical infections and the potential for cost savings using the monitoring app. The lead author of the study is quoted saying that preventing readmissions due to infection could lead to \u201csignificant savings to the health system,\u201d and the release notes that \u201ccapturing specific numbers related to cost-savings was not part of this study.\u201d\nThe news release helpfully states that providers have to pay for training and in some cases smartphones for patients, and pay staff to monitor the data in a \u201cdedicated transitional care program.\u201d\nThe the app itself is free for patients to download, which isn\u2019t explicitly mentioned. There\u2019s no mention of whether hospitals have to pay to use it.", "answer": 1}, {"article": "Not since 1998, when the FDA approved the PSA test for early detection of prostate cancer, had new technology been created in early cancer detection until the stool DNA test.\n\"Clearly by itself, it is not reaching other people,\" said Markowitz, who sits on the medical advisory board of the National Colorectal Cancer Research Alliance.\nUp until June 1, LabCorp of America had a product on the market.\nAnd you've probably heard about how early screening means early detection and removal of polyps before they turn into cancer.\nThat's why the American Cancer Society, which estimates there will be about 108,000 new cases of colon cancer and 40,700 new cases of rectal cancer this year, added the stool DNA test to its screening guidelines this spring.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story notes that one test that was available through June 1 costs about $800. It also mentioned that some insurance and health plans covered the cost partially or in full.", "answer": 1}, {"article": "Their average dose of mealtime insulin decreased by seven units (30%) and their need for all-day insulin dropped by eight units (32%).\nThose who continued treatment for a full year continued these improvements and felt much better overall, says study leader Paresh Dandona, MD, of the State University of New York, Buffalo.\nAnd during Victoza treatment, patients needed less and less insulin.\nAdding Victoza to insulin therapy quickly eliminated these peaks and dips in blood sugar.\nYet all patients' blood sugar peaked and dipped at unpredictable intervals.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not discuss costs. Adding Victoza to a diabetic\u2019s treatment regimen would cost an additional\u00a0$350 per month, according to coverage of the study by MedPageToday. This is not a trivial sum.", "answer": 0}, {"article": "Flu season has already begun, and last year\u2019s was one of the most lethal in decades; about 80,000 Americans died of flu or its consequences, the Centers for Disease Control and Prevention said earlier this month .\nThe pill will cost $150, according to a spokeswoman for Genentech, which will sell Xofluza in this country.\nThe first new flu drug in 20 years won approval Wednesday from the Food and Drug Administration.\nstill strongly recommends that every American over the age of six months get a flu shot as soon as possible.\nGenentech will offer coupons that lower the price to $30 for patients with health insurance and to about $90 for the uninsured.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story devotes its second paragraph to cost, including how that cost may differ depending on whether patients have insurance. Well done.", "answer": 1}, {"article": "As with each of our next generation OTC drug products, we intend to license HSRx 2121 to a leading marketing entity that has the resources and expertise to maximize sales, here and abroad,\" Parise said.\nThe HSRx product demonstrated superior treatment performance throughout the entire clinical study.\nEach product is subjected to independently conducted clinical trials against a current market-leading product to demonstrate its ability to deliver superior treatment outcomes with reduced side effects.\nHSRx Group has developed a portfolio of next generation OTC drug products for many categories of common health conditions.\nAcne treatment represents a vast global market estimated at $3-4 billion annually, with significant expansion expected among surging middle class populations in China and India.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There is no mention of cost in the release, not even a mention of where this new product will be on the spectrum of OTC products via-a-vis price. For a product whose manufacturer boasts in the release that it will come out of the gate to become a global competitor, one would expect they\u2019d have a price point to offer.", "answer": 0}, {"article": "Coronary angioplasty is a procedure in which arteries are opened to increase blood flow to the heart.\nOf the study\u2019s patient population receiving PCI, 9 percent received the procedure in which doctors used wrist access.\nThe researchers estimated that shifting standard practice by 30 percent to the wrist approach, along with same-day discharge, could save the United States $300 million per year.\nAccording to Amin, improved technology has allowed wrist access to become a viable route to the coronary arteries, even for complex cases, and should be considered for more patients.\nThe research, published Feb. 20 in JACC: Cardiovascular Interventions, suggests that the lower costs of the wrist approach largely are due to the fact that patients experience fewer complications and can be discharged earlier, compared with procedures that access the heart through the larger, deeper artery in the groin.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Cost comparison across angioplasty strategies is the raison d\u2019etre of this study and its accompanying news release.\u00a0 The release reflects on costs for both the individual procedure and for the country in great detail.", "answer": 1}, {"article": "The women were followed for an average of about 3.5 years.\n\"These findings really emphasize how important it is for all women with a family history of early breast or ovarian cancer to undergo genetic testing,\" said Dr. Virginia Kaklamani, co-author of an editorial that accompanied the study.\nTUESDAY, Aug. 31, 2010 (HealthDay News) -- Women who carry genetic mutations that boost their odds of breast and ovarian cancer can live longer and reduce their cancer risk by having preventive surgery, a new study suggests.\nKaklamani added that she hoped the findings would encourage more women to ask their primary care physicians whether they are candidates for genetic counseling.\nSilver added that women who are found to carry one of these genetic mutations face \"a very complex set of considerations, so the more hard facts you can give them, the better.\"\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "1clip_filelist.xml\" rel=\"File-List\"/>\n\n\n\nThe story does not mention the costs of genetic testing, increased cancer surveillance or surgery.", "answer": 0}, {"article": "\"Once injected into a patient's artery, many stem cells are lost due to the combination of tissue blood flow, which can wash out stem cells, and cardiac contraction, which can squeeze out stem cells.\n\"Stem cell therapies show great promise as a treatment for heart injuries, but 24 hours after infusion, we found that less than 10 percent of the stem cells remain in the injured area,\" Dr. Eduardo Marban, director of the Cedars-Sinai Heart Institute in Los Angeles, said in a news release from the institute.\n\"This remarkably simple method could easily be coupled with current stem cell treatments to enhance their effectiveness.\"\nMarban and colleagues developed a technique in which they loaded cardiac stem cells with microscopic bits of iron.\n\"Tissue viability is enhanced and heart function is greater with magnetic targeting,\" Marban said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Not applicable due to very early stage of research. ", "answer": 2}, {"article": "One of the top research universities in the world, MSU focuses its vast resources on creating solutions to some of the world\u2019s most pressing challenges, while providing life-changing opportunities to a diverse and inclusive academic community through more than 200 programs of study in 17 degree-granting colleges.\n\u201cIt\u2019s believed that cognitive function decreases in many of those with HIV partly due to chronic inflammation that occurs in the brain,\u201d said Norbert Kaminski, lead author of the study, now published in the journal AIDS.\n\u201cWhat we learn from this could also have implications to other brain-related diseases like Alzheimer\u2019s and Parkinson\u2019s since the same inflammatory cells have been found to be involved.\u201d\n\nKnowing more about this interaction could ultimately lead to new therapeutic agents that could help HIV patients specifically maintain their mental function.\n\u201cThis happens because the immune system is constantly being stimulated to fight off disease.\u201d\n\nKaminski and his co-author, Mike Rizzo, a graduate student in toxicology, discovered that the compounds in marijuana were able to act as anti-inflammatory agents, reducing the number of inflammatory white blood cells, called monocytes, and decreasing the proteins they release in the body.\n\u201cIn fact, those who used marijuana had levels pretty close to a healthy person not infected with HIV.\u201d\n\nKaminski, director of MSU\u2019s Institute for Integrative Toxicology, has studied the effects of marijuana on the immune system since 1990.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There is nothing in this release about costs. And there\u2019s really nothing about dosing, either. So a reader and an HIV patient would have no idea what a true marijuana therapy would cost to see any \u2014 assuming there are any \u2014 benefits.\nThe release notes that the study relies on self-reporting of marijuana use by the blood donors and then correlation with THC levels in the blood. We are at least a couple steps away from knowing how much THC is needed for an actual clinical outcome (which is not addressed in the study) and as a consequence would not be able to estimate cost.", "answer": 0}, {"article": "Army veteran Vivian Cooke has long struggled with debilitating depression.\nFinzi notes previous studies show between 50 to 60 percent of patients may benefit from the treatment.\n\u201cSo Botox basically inhibits the muscle and calms it down, so it becomes more difficult to feel those negative emotions.\u201d\n\nThe makers of Botox recently announced plans for the final phase of testing it as a treatment for depression.\n\u201cI had less problems with depression.\u201d\n\nEven though the study she took part in is now over, she said she will continue to get Botox injections.\n\u201cOur hope is eventually it will form a place as one of the tools to treat depression,\u201d he said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Citing the American Society for Aesthetic Plastic Surgery, the article says that the average cost for a botox treatment\u00a0 was $376 in 2016. We also learn from the article that a typical treatment should confer benefits for about three months. This is important information considering that botox is not currently FDA approved for treatment of depression. Unless a patient is enrolled in a clinical trial, he or she will have to pay the approximately $1300 per year\u00a0out of pocket.", "answer": 1}, {"article": "All rights reserved.\nThe study hints at the potential for widespread health benefits from an upcoming nationwide ban, the authors and other experts say.\nDr. Mark Creager, former American Heart Association president, said the results echo previous studies \u201cand are consistent with the thinking of most scientists\u201d on potential benefits of these bans.\nThe results translate to 43 fewer heart attacks and strokes per 100,000 people, said lead author Dr. Eric Brandt, a Yale University cardiology fellow.\nHospital admissions for heart attacks and strokes in those areas declined 6 percent starting three years after the bans, compared with counties without bans.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "While there may be costs associated with different food ingredients (i.e., different types of fats), that does not seem relevant here.", "answer": 2}, {"article": "And the warriors had a 40 percent lower risk of cardiovascular death and an 18 percent lower risk for cancer-related death.\nThis could be something as simple as a brisk walk or other low-impact options for vigorous exercise about 20 minutes a day.\nHowever, there are also some limitations to this study, the researchers say.\n\u201cI think that the weekend warrior physical activity pattern is beneficial because they are actually doing a large proportion of vigorous intensity activity.\nThe information about physical activity was reported by the participants, and it\u2019s likely that many were too generous in their estimates of how much time they spent at the gym.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Given the nature of the study we don\u2019t think that this issue is relevant.", "answer": 2}, {"article": "\u201cI\u2019ve been doing clinical trials for 30 years in C.F.\nBut since there are only about 1,200 Americans who are candidates for the drug, the price is likely to be tens of thousands of dollars a year.\nStill, the news is expected to be greeted favorably by doctors and patients and by Wall Street.\nThe long time needed to develop a drug for cystic fibrosis is a lesson for those expecting a quick payout from the sequencing of the human genome, which was completed a decade ago.\nDr. Ramsey, a professor of pediatrics at the University of Washington, was briefed on the results by Vertex.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "It discusses the drug\u2019s costs, which are expected to be substantial.\u00a0Given the relatively small population that the drug might be of benefit to, price considerations are important. The story briefly notes both aspects.", "answer": 1}, {"article": "A flu drug \u2014 shown to reduce the duration of symptoms \u2014 could upend treatment in U.S.\n\nNext winter, there may be a new drug for people who contract influenza \u2014 one that appears to be able to shut down infection quickly and, unlike anything else on the market, can be taken as a single dose.\n\nThe Food and Drug Administration on Tuesday said that it would give the drug, baloxavir marboxil, a priority review, and approval has the potential to upend the way influenza is treated.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story makes clear the \u201cbig unknown\u201d remains the price and \u201chow much people are willing to spend to cut a day or so off of a bout of flu.\u201d The story reports that Genentech, the drug\u2019s manufacturer, said it\u2019s too early to comment on the drug\u2019s U.S. price. The story also notes that in Japan, where the drug was invented, it \u201csells for the equivalent of about $43.50.\u201d", "answer": 1}, {"article": "The average age of children in the study was 7.\n\"This raises the hope that these findings could form the base for development of a diagnostic tool that can be applied very early on, such as in toddlers only a few months old.\nIt wasn't clear if this impairment would show up in a test of the sniff response, however.\nThe findings suggest that a sniff test could be quite useful in the clinic, although the researchers emphasize that their test is in no way ready for that yet.\nThe findings suggest that non-verbal tests related to smell might serve as useful early indicators of ASD, the researchers say.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release doesn\u2019t address cost at all. And while the release notes that a so-called \u201csniff test\u201d is still far from ready for clinical use, it does expressly discuss the possibility of using such a test as a diagnostic tool. We feel that if it is worth discussing a finding\u2019s clinical application, it\u2019s worth discussing the potential cost. We understand that it may be difficult or impossible to place a dollar value on such a diagnostic tool, but the release likely could have discussed the cost in general terms. For example, does it rely on expensive technologies or specialist skills? Or is it something that could be done by a trained general practitioner with inexpensive items? Or do we simply not know yet? Regardless, a quick sentence or two could have shed some light on the matter.", "answer": 0}, {"article": "The Biggest Loser diet and the DASH diet came in second and third, respectively, in the diabetes category.\nThe MIND diet ranked first in the \"Easiest Diet to Follow\" category in a three-way tie with Weight Watchers and the Fertility diet, which asserts that certain dietary changes can boost fertility.\nThe Raw Food diet was also considered the most difficult diet to follow, though it was one of the top ranked weight-loss diets, the panel found.\nThe DASH (Dietary Approaches to Stop Hypertension) diet was designed to lower blood pressure and cholesterol levels by limiting fats, red meat and sugar in favor of healthy grains, poultry, low-fat dairy and nuts, the U.S. National Heart, Lung, and Blood Institute says.\nThe Weight Watchers diet ranked highest out of all weight-loss diets but tied with the Mayo Clinic diet as the \"Best Commercial Diet.\"\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The article doesn\u2019t address costs associated with maintaining a DASH diet or other diets. According to an analysis published study in JAMA Internal Medicine in 2013, adoption of the diet has been low, despite its favorable recommendations by nutritionists. The authors noted, \u201cIts limited uptake might be explained by economic constraints, since food prices influence food choices and constitute a major barrier to dietary change. Nutrient-dense foods, central to DASH, tend to be more costly compared to calorie dense alternatives.\u201c", "answer": 0}, {"article": "Dr. Reisa A. Sperling, an Alzheimer\u2019s expert at Brigham and Women\u2019s Hospital in Boston and co-chairwoman of the session where the results were presented, said, \u201cPersonally, I found the data quite convincing.\u201d\n\nDr. Sperling, an investigator on a different AVID study but who is not paid by the company, said the challenge now will be to see whether the scans can accurately predict whether people are developing Alzheimer\u2019s before they have symptoms.\nAlthough the scans looked promising, the companies needed to show that what they revealed was the same as what a pathologist would see on autopsy.\nNeither the radiologists nor the pathologists knew whether the patients had dementia.\nAnd the data showed that the scans were completely accurate in ruling out Alzheimer\u2019s pathology: unlike doctors, they never said people had Alzheimer\u2019s pathology when they did not.\nThat was what Avid demonstrated with its study, presented Sunday by its medical director, Dr. Christopher M. Clark.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "\u00a0There was no discussion about the potential costs of this test.\u00a0 This at least could have been estimated.\u00a0 PET scans are extraordinarily expensive.\u00a0 ", "answer": 0}, {"article": "The higher a person's insulin levels are, the more likely they are to have or develop insulin resistance, which can increase blood sugar levels and diabetes risk.\nIn fact, the majority of the participants \u2014 83 percent \u2014 had only one or no risk factors three years after their surgeries.\nBefore surgery, only 3 percent of the teens had no cardiac risk factors at all, but three years later, just over half of them (52 percent) had no risk factors.\nThe findings are important because many of the participants in this study likely already had some level of cardiac damage, such as thickened arteries or heart walls, says Geetha Raghuveer, a pediatric cardiologist at Children's Mercy Kansas City in Missouri who was not involved in the study.\nThe risk factors measured in the study included elevated blood pressure (above 120/80 mg/Hg), high cholesterol, high insulin levels in the blood and abnormally high levels of C-reactive protein, an indicator of inflammation in the body.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There\u2019s no mention of the cost of these procedures or whether they are covered by insurance. The average cost of gastric bypass surgery is $23,000, the average cost of lap band is $14,500, and the average cost of sleeve gastrectomy surgery $14,900, according to the web site ObesityCoverage.", "answer": 0}, {"article": ".\nThe rate of fractures in the treated women who had osteoporosis declined by 50 percent during the 10-year-long study.\nThe study, \"Effect of Growth Hormone Treatment on Fractures and Quality of Life in Osteoporosis - A 10-year Follow-up,\" was published online at http://press.\nAfter 18 months, the women who received the placebo halted the injections.\nMore than 10 million American adults have osteoporosis, and 80 percent of the people being treated for the condition nationwide are women, according to the Society's Endocrine Facts and Figures Report.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release does not mention cost at all, possibly because the study was conducted in Sweden, which has a taxpayer-funded public health system. However, in the U.S., growth hormone treatments can cost hundreds of dollars per month \u2014 and it\u2019s not clear if that would be covered by insurance for treating osteoporosis. This high cost is certainly worth mentioning.", "answer": 0}, {"article": "The question then becomes whether ACH-3422 plus ACH-3102 - a weaker nuke and a stronger NS5A inhibitor - could be a good enough doublet as Harvoni, William Blair\u2019s Katherine Xu said.\nMonday\u2019s data shows Achillion\u2019s NS5A inhibitor, ACH-3102, looks best-in-class, which could make up for its nuke, ACH-3422, being perhaps less effective than Sovaldi, analysts said.\nThe all-Achillion regimen could hit the U.S. market by 2020 in a conservative scenario, Deutsche Bank\u2019s Alethia Young estimated.\nAchillion, one of the few companies developing hepatitis C therapies independently, plans to begin a mid-stage study this year to evaluate its proprietary doublet.\nShe expects the treatment to cost about $35,000 per patient per year, assuming a 55 percent discount.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "This is a business story, and the early post of this story included a lot of financial information, such as company share prices, the size of the market for hepatitis C drugs, and the total sales for the drugs being studied. But it didn\u2019t include costs.\n[Later in the day, the story was updated to include a price for the drug combination being reported on and other available treatments. It estimated a cost for the new drug combination of about $35,000 per patient per year, assuming a 55 percent discount. Other drug combinations were said to cost $83,000 to $93,000. We applaud the addition of extra information, but that wasn\u2019t the story we reviewed.]\nIt\u2019s also possible \u2014 but not discussed \u2014 that these drugs could end up paying for themselves in the long run if they reduce the need for liver transplants. Such benefits haven\u2019t been established.", "answer": 0}, {"article": "\"Here, fertility is very important to many young women,\" he said.\nAnd no cancer developed in the transplanted tissue, Jensen said.\nDr. Avner Hershlag, chief of the Center for Human Reproduction at North Shore University Hospital in Manhasset, N.Y., called the new research \"innovative and exciting.\"\nAnd for 15 of the women, transplantation had taken place more than five years earlier, the researchers said.\nThe women's average age when the tissue was removed and frozen was nearly 30.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Surgery to remove a healthy ovary,\u00a0storage of that tissue for as long as a decade,\u00a0and surgical reimplantation all involve\u00a0substantial cost. The story doesn\u2019t help the reader begin to put this in context. If the patient requires IVF, in-vitro fertilization, when she hopes to conceive again, the costs will go much higher. Almost half of the pregnancies in the study required IVF, according to the story. The story let the readers down here. (Here\u2019s more about the high costs of infertility treatment from an advocacy group.)", "answer": 0}, {"article": "Estrogen stimulates the growth of ER+ tumors.\nThe most common form of breast cancer, ER+ accounts for about three-quarters of all breast cancer cases in the United States, the authors noted.\nAfter the four months of estrogen-lowering therapy, the research team found that 82 percent of those women in the marginal group were, in fact, able to undergo successful breast-conservation surgery.\nIt focused on postmenopausal women who had been diagnosed with estrogen receptor-positive (ER+) breast cancer that was either at stage II or stage III -- that is, tumors that were around an inch or greater in size and might have spread to the lymph nodes under the arm.\nThe investigation was funded by the American College of Surgeons Oncology Group and led by Dr. Julie A. Margenthaler, an assistant professor of surgery and a breast surgeon at the Siteman Cancer Center at Washington University in St. Louis.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No discussion of costs in this story. It could have pointed out that two of the estrogen-lowering drugs tested in this study are off patent and relatively cheap, whereas the third drug, exemestane,\u00a0is a brand name drug that remains quite costly.", "answer": 0}, {"article": "More than 25 million people in the United States and about 2.5 million Canadians suffer from chronic rhinosinusitis, or sinus infection, and experience compromised quality of life.\nPatients who were instructed to use nasal irrigation showed improvement at 3 and 6 months, as measured by the Rhinosinusitis Disability Index.\nSince the impact was less than in previous studies that had used more intensive coaching about nasal irrigation, the authors suggest that further research is needed to understand how much coaching of patients is required.\nResearchers from the United Kingdom conducted a randomized controlled trial on the effectiveness of advice from primary care physicians to use nasal irrigation and/or steam inhalation for chronic sinusitis.\nThe study involved 871 patients from 72 primary care practices in England who were randomly assigned to 1 of 4 advice strategies: usual care, daily nasal and saline irrigation supported by a demonstration video, daily steam inhalation, or combined treatment with both interventions.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release does not mention cost. Normal saline can easily be made at home or purchased from a local pharmacy. The cost is low in both cases and it should have been mentioned in the story especially in contrast to the cost of antibiotics.", "answer": 0}, {"article": "A colonoscopy isn\u2019t something you get just for giggles. Beyond the obvious unpleasantness, there\u2019s the small but real risk of complications that in rare cases can lead to hospitalization or even death.\n\nThat\u2019s why the American Cancer Society and other groups recommend that people screened for colorectal cancer using a colonoscopy wait a decade in between tests if no polyps or other signs of potential cancer are found. Polyps are slow-growing, and the benefits of being screened more frequently than that don\u2019t seem to outweigh the risks \u2026", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story didn\u2019t discuss costs.\u00a0 And cost is a significant issue here.\u00a0 The AP story, by comparison, reported that \u201ccolonoscopy costs vary widely but typically exceed $1,000.\u201d", "answer": 0}, {"article": "\"You're going through all this suffering and stuff and you want to know, am I going to survive?\nAs a practical matter, the goal of researchers is to convince federal regulators to cover the procedure under Medicare and Medicaid, which would open the door to routine use.\nThe hope is that, over time, FLT PET would prove reliable for giving a faster answer on whether an experimental treatment is working.\nThis experimental imaging relies on a familiar hospital workhorse: PET scans, typically used for things like detecting cancer or revealing the effects of a heart attack.\nThe new research tests both standard PET scans and a newer approach that involves injecting a different tracer substance.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not mention costs of PET scans under the proposed use. In this case in particular\u2013where the costs and benefits of PET scans are in hot dispute\u2013this is inexplicable. \nConventional PET scan cost is estimated at $3,000 to $5,000. ", "answer": 0}, {"article": "If green coffee extract were a medication seeking approval from the Food and Drug Administration, these results would make it a viable candidate \u2014 more than 35% of subjects lost more than 5% of their body weight, and weight loss appeared to be greater while subjects were taking the pills than when they were on the placebo.\nThe pilot study drew strong cautions from several scientists who weren't involved in the research.\nDr. Arthur Grollman, a pharmacologist at the State University of New York at Stony Brook, said coffee beans contain about 250 different chemicals \u2014 some with positive and others with negative effects on human health.\nThe trial was conducted in India and paid for by Applied Food Sciences Inc. of Austin, Tex., a manufacturer of green coffee bean extract.\nOf the 16 volunteers, six wound up with a body mass index in the healthful range.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story states that green coffee extract is available at roughly $20 per month.", "answer": 1}, {"article": "For more information, visit https://www.nichd.nih.gov.\nSimilarly, research is needed to determine whether lowering HbA1c with lifestyle changes, either in early pregnancy or before pregnancy, could reduce the risk for the condition.\nThe authors noted that further studies are needed to confirm whether measuring HbA1c levels in early pregnancy could determine a woman\u2019s later risk for gestational diabetes.\nAccording to the authors, comparatively few studies have examined whether the HbA1c test could help identify the risk for gestational diabetes, and these studies have been limited to women already at high risk for the condition.\nIn the current study, researchers evaluated whether the HbA1c test (also called the A1C test), commonly used to diagnose type 2 diabetes, could identify signs of gestational diabetes in the first trimester of pregnancy.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The absence of cost information is unfortunate in this release. \u00a0In general, the public has little experience of or understanding of the overall costs of routine, widespread screening. Sources put the cost of A1C screening at anywhere from $12 to $65. There are nearly 4 million live births in the U.S. each year, and many more pregnancies. Even if we use a $35 midpoint price, that\u2019s $140 million just to screen for gestational diabetes. Worth it? Maybe. Particularly given that the glucose tolerance test given later in pregnancy has an average cost of $60 to $85, according to some sources. And the savings to be realized in potentially preventing gestational diabetes could be substantial. In any case, cost considerations are important in the overall scheme of health care delivery and limited health care dollars.", "answer": 0}, {"article": "But all I need to do is add 5 and 5.\u201d\n\nEspecially in a time of concern over rising medical costs, \u201cwe should not simply use the highly sophisticated technology just because it\u2019s there,\u201d Falcone said.\n\u201cWe were surprised that (surgery with the robot) did not have better outcomes than (the surgeon alone), as we have always believed if you can see more and see better you can do more and do better,\u201d the authors write.\nDr. Tommaso Falcone, chair of obstetrics and gynecology at Cleveland Clinic, said this study shows that more technology is not always better.\nIn this case, the robot could turn what would have to be an open surgery into a simpler one.\nUsing a robot for basic surgery, like the kind studied here, would be like using a computer to do addition, he told Reuters Health.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The reporter notes that the robots cost $1.5 million apiece, a cost that has to be asorbed at some point by the insurer or the patients. The story also includes some great context from Dr. Tommaso Falcone at Cleveland Clinic saying spending a lot of money on robots might not be money well spent.\nBut we\u2019re not given any per-patient per-treatment cost estimates and we\u2019re not told that the robots may drive up cost with longer operating room time and added costs for facility, anesthesia and surgeon \u2013 huge cost drivers.", "answer": 0}, {"article": "Please use our search feature and update your bookmarks. Thank you!", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release could have used some explicit indication of the potential cost of adding estriol to treatment with injectable glatiramer acetate. The text suggests that the hormone is widely available and thus likely to be simpler and less costly to take.\nIn the United States estriol is available only as a vaginal cream, not in tablet form. It is mostly used in \u201cbioidentical\u201d hormone replacement products obtained from compounding pharmacies.", "answer": 0}, {"article": "Pacemakers zap the heart with low levels of electricity when the heartbeat becomes too fast, too slow or too irregular.\nStill, he said, the new device will probably be more expensive than other pacemakers, and may pose special risks of its own.\nAnd the existing version of the device won't work for most pacemaker patients because it lacks some key features.\nStill, a new company-funded study shows that \"this is now a possibility\" that could reduce infections and the severity of pacemaker surgery, said study author Dr. Vivek Reddy, director of the Cardiac Arrhythmia Service at Mount Sinai Hospital in New York City.\nHe expects the pacemaker \"will likely be utilized for some select patients\" after more testing.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story explains that this is in the \u201cearly testing\u201d phase, so it\u2019s understandable that a cost estimate might not be given.\nIn the second paragraph, the story states that the cost is unknown.\nAnd an independent expert postulated that \u201cthe new device will probably be more expensive than other pacemakers.\u201d", "answer": 1}, {"article": "According to traditional medicine, specific acupuncture points on the skin are connected to internal pathways that conduct energy, or qi (\u201cchee\u201d), and stimulating these points with a fine needle promotes the healthy flow of qi.\nIt is unclear, Manber said, why acupuncture might help lessen the severity of depression.\nThe study, which followed 150 pregnant women with major depression, tested \u201cdepression-specific\u201d acupuncture against massage and acupuncture sessions that, according to traditional Chinese medicine, does not specifically target depression.\nAll completed a standard measure of depression severity at the outset and again after four and eight weeks of treatment.\nAfter eight weeks, patients in the depression-specific acupuncture group had a higher rate of response to treatment.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No mention of the cost of acupuncture, which is relevant, especially since acupuncture is not always covered by insurance", "answer": 0}, {"article": "It may also improve vision in those with mild myopia (nearsightedness).\nIt should be acknowledged that some researchers involved in many of these studies have financial ties to GlassesOff.\nReading at our normal pace, the brain has only about 250 milliseconds to do this work until the eyes automatically move onto the next letter or word.\nAfter training, the older adults\u2019 ability to see low-contrast images improved to the level that the college-age ones had before training.\nFor example, a study tested the approach in 23 young adults, around age 24.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The column provides\u00a0clear\u00a0information about the cost of the app tried by the writer. It would have been strengthened by information about the cost of bifocals and, in particular, over-the-counter drugstore \u201creaders.\u201d", "answer": 1}, {"article": "\"If you are an Asian kid, you've had these placed on you since time immemorial,\" he said.\nPain patches have a number of benefits, Rosenquist and Dombrowski said, not the least of which is convenience.\nThe main downside to pain patches, however, apparently comes from their effect on the skin.\nOn the other hand, people have to be sure to carefully follow instructions for using the patches, to avoid overdose.\nThe patches also deliver their medicine directly to the site of a person's pain.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There is no mention of costs. At CVS.com, a box of five patches costs $7.99. This isn\u2019t high for short-term use, but if you are a chronic pain sufferer (a category not addressed in this story) you might run through a box or two per day. Regardless, costs should have been mentioned.", "answer": 0}, {"article": "UCLA's Bhat noted another limitation in the study: \"These are all genetic cataracts.\nHe's said it's unclear if the results will be mirrored in older cataract patients, the same concern expressed by others in the field.\nDr. Kathryn Hatch, an ophthalmologist at Massachusetts Eye and Ear in Boston, told CBS News the procedure \"seems very exciting,\" but more research is needed.\nShe said, even without answers to the question of whether it will work in aging eyes, it creates hope for children with congenital issues.\nHe hopes the surgery will be available to the general population within four to five years.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story doesn\u2019t discuss\u00a0costs for this new approach. One web source points to an average cost of $3,400 per eye for conventional\u00a0cataract surgery, although the costs can be considerably less under some insurance plans. The story does not make clear if this\u00a0procedure would be similarly priced.", "answer": 0}, {"article": "They are packed full of growth factors, of healing factors, and when given into a specific area, you get a hyper-healing response,\" Gearhart says.\nHe is one of the few patients to get it so far \u2014 clinical trials are now testing PRP's safety and effectiveness.\nIt's called Platelet Rich Plasma therapy \u2014 or PRP.\nSide effects reportedly have been minor; it seems like the biggest problem so far: The needles hurt.\nA leading sports medicine expert, he believes we can speed up the body's ability to heal itself with a remarkably simple technique.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No mention of costs, nor any projection of possible future clinical costs.\u00a0 If such a preliminary experimental approach is ready for primetime TV, then it should be ready for even a preliminary discussion of what this approach will cost. ", "answer": 0}, {"article": "Shares of Vanda, which has a market of about $116 million, closed at $4.12 on Tuesday on the Nasdaq.\nThe drug is being tested for \u2018non-24-hour disorder\u2019 that has no approved treatment.\nTasimelteon received orphan drug status \u2014 which offers several years of marketing exclusivity for drugs developed for rare conditions \u2014 from the FDA in 2010 and from the European Commission in 2011.\nVanda on December 18 said the drug performed better than a placebo in the first of the four planned late-stage trials on the drug.\nThe study, named Reset, was a 20-patient trial designed to test the maintenance effect of a 20 mg dose of the drug, tasimelteon.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Not applicable.\u00a0 No cost estimate given but this is still an experimental approach.", "answer": 2}, {"article": "For dementia, which people with Type 2 diabetes have double the risk of developing compared with non-diabetics, metformin has been found in a number of studies to cut that risk substantially.\nMoreover, the drug was being studied in clinical trials as a way to lower the risk of cancer, heart disease and dementia \u2014 not just for diabetics, but for everyone.\nThe question is whether the rate-of-living theory is operational in mammals.\u201d\n\nPollak says that none of the most exciting possible benefits for the drug have yet been proved in randomized clinical trials of non-diabetics.\n\u201cIf we can even slightly lower their average blood sugar with metformin,\u201d Wilkin said, \u201cI believe we can have a big benefit on their risk of developing Type 1.\u201d\n\nDespite all these potential benefits of metformin \u2014 and despite a recommendation from the American Diabetes Association that it be tried before any other drug for newly diagnosed Type 2 diabetics \u2014 a recent study found that only about half of all such people get metformin as their first prescribed medication.\nThe one goal the study did not achieve was better blood-sugar control.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Part of why this topic is exciting is that metformin is relatively cheap, but the story doesn\u2019t put a price tag on the drug. The story calls the drug \u201ccheap\u201d in the first sentence, and one\u00a0could argue that cost lurks\u00a0beneath the surface of one brief mention of a study that found only about half of newly diagnosed type 2 diabetics were prescribed metformin right off the bat. Other patients, experts speculate in the story, may be taking newer drugs being touted in advertising. One can infer that these newer drugs are\u00a0more costly than metformin, but we think it would have been easy enough to provide some actual numbers that would have illustrated the meaningful difference.", "answer": 0}, {"article": "Almost everyone suffering from back pain says something like, \"I want to feel better, I want to play golf again, or I want to be able to play baseball with my grandkids,\" anesthesiologist and lead author Steve P. Cohen tells Shots.\nThe study's suggestion on how to manage back pain also runs counter to current guidelines from major medical groups.\nSkipping the diagnostic nerve blocks can save $10,000 in medical costs.\nDr. Nikolai Bogdu at the Newcastle Bone & Joint Institute in Australia told Reuters that further cost analysis is needed to account for millions of patients who might not get pain relief from the radiofrequency treatment.\nOf about 150 patients, the group that got radiofrequency treatment immediately had more people who felt better.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story said that \"skipping diagnostic nerve blocks can save $10,000 in medical costs.\" ", "answer": 1}, {"article": "More than one million athletes experience a concussion each year in the United States.\nEach of the concussed athletes had their brain blood flow measured with the advanced ultrasound headset within an average of six days after the injury.\n\"This research suggests that this advanced form of ultrasound may provide a more accurate diagnosis of concussion,\" said Hamilton.\nTesting of the TCD technique at the sideline at the time of injury will be an important next step to determine its ultimate utility,\" said Randolph S. Marshall, MD, MS, with Columbia Presbyterian Medical Center in New York and a member of the American Academy of Neurology's Science Committee.\n\"This important work provides insight into a tool that may yet prove useful in the recognition and management of concussion,\" said Jeffrey Kutcher, MD, FAAN, with the The Sports Neurology Clinic in Brighton, Michigan.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "While the study\u2019s principle investigator notes that the device may be \u201cless expensive\u201d than MRI, costs are not broached in the text. To have one of these devices at all sport events, say, starting at high school and beyond, would be quite expensive. Plus, staff would need to be trained to use the device and interpret the results. Dopplers are not used and interpreted by the lay public. The practicality of this was not mentioned.", "answer": 0}, {"article": "\"Nothing happens,\" he told Stahl.\nBut Kanzius wasn't happy with all the time it would take Curley to get through the usual human clinical trials and approval by the FDA.\nWhat he did have was a deadly form of leukemia and a determination to use whatever time he had left to come up with a better way to treat the disease.\nHe managed to intrigue Dr. Steven Curley, a liver cancer surgeon at MD Anderson Cancer Center in Houston.\nAll that chemo had been keeping him alive, barely.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "\n\n\nThe device is at a very early stage of experimentation, so it\u2019s understandable that costs wouldn\u2019t be discussed.", "answer": 2}, {"article": "Too much insulin can cause low blood sugar (hypoglycemia), which can be life-threatening, while too little causes the serious damage of diabetes such as kidney, vision and circulation problems.\nUsing this technology is still seen as a stopgap, however, while a biological solution to diabetes is sought.\nHowever, teenagers did not see a benefit, probably because they were less likely to wear the device, Tamborlane said.\nAll patients felt self-conscious wearing the device, Ritholz noted.\nIn the first report, Dr. Roman Hovorka, a principal research associate in the department of pediatrics at the University of Cambridge, reported that the technology can significantly improve overnight blood sugar control in adults without the fear of developing hypoglycemia.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Costs of the new approach or the currently available components, continuous glucose monitors and insulin pumps, are not described.\u00a0The two components are not cheap and many insurance companies aren\u2019t covering them except in special circumstances.", "answer": 0}, {"article": "For example, before adjusting for these kinds of differences between the groups, the researchers found that light drinking was connected with 33% lower rates of overall behavior problems in boys \u2014 after the adjustment, that effect fell to 23%.\nThis data is notoriously hard to interpret, however, in part because it is based on women\u2019s self-reports: the public health message against drinking during pregnancy has been so widely adopted that women who do drink may significantly underreport their consumption to researchers.\nA glass of wine or two a week \u2014 and not more than one large glass on any occasion \u2014 may be safe during pregnancy, according to a large study just published in the Journal of Epidemiology and Community Health.\n(More on Time.com: If I\u2019m Drunk, Then You Stepped On My Toes On Purpose)\n\nInterestingly, the new study parallels the effects of alcohol on health more generally; lighter drinkers tend to do better than teetotalers while the heaviest drinkers do worse.\nBut for those women who drink before finding out they\u2019re pregnant or who have an occasional glass of wine afterward, this study can provide reassurance that very low levels of alcohol consumption during pregnancy are unlikely to cause serious problems.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "This does not seem to apply.", "answer": 2}, {"article": "Although total sleep deprivation or partial sleep deprivation can produce clinical improvement in depression symptoms within 24 hours, antidepressants are the most common treatment for depression.\nAlso, future studies are needed to include a more comprehensive assessment of potential predictors of treatment outcome to identify those patients most likely to benefit from sleep deprivation.\nThe authors note that further research is needed to identify precisely how sleep deprivation causes rapid and significant reductions in depression severity.\nReviewing more than 2,000 studies, the team pulled data from a final group of 66 studies executed over a 36 year period to determine how response may be affected by the type and timing of sleep deprivation performed (total vs early or late partial sleep deprivation), the clinical sample (having depressive or manic episodes, or a combination of both), medication status, and age and gender of the sample.\n\"More than 30 years since the discovery of the antidepressant effects of sleep deprivation, we still do not have an effective grasp on precisely how effective the treatment is and how to achieve the best clinical results,\" said study senior author Philip Gehrman, PhD, an associate professor of Psychiatry and member of the Penn Sleep Center, who also treats patients at the Cpl.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release does not mention costs. One may assume there is no cost to sleep deprivation but the release notes that the deprivation in the studies was mostly monitored in inpatient facilities. That has a cost. However, if the intervention is not done in an inpatient facility there would not be a directly attributable cost so we\u2019ll rate this Not Applicable.", "answer": 2}, {"article": "Load up on berries.\nAnd if they're out of season, like now, studies show frozen berries have similar levels of beneficial compounds.\nAnd when you eat a steady diet of them, they seem to have a number of positive health effects.\nBut he says it's important to point out that the women in this study weren't prime candidates for heart attacks anyway.\nIt's certainly not a perfect way to detect how certain foods may influence health, but it identifies important associations.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Not applicable.\u00a0 Costs not mentioned but we think most people know the ballpark cost of berries.", "answer": 2}, {"article": "Abbott Laboratories is betting heart patients will benefit from a new type of arterial stent that dissolves away when it is no longer needed.\n\nStents are scaffold-like devices used to prop open clogged heart arteries. Most stents are made of metal. But Abbott's new device, called Absorb, is made from a plastic-like material called polylactide that is commonly used in surgical sutures. The Absorb scaffold\u2014Abbott doesn't call it a stent\u2014is designed to completely fade away in two years and to cease supporting arteries at six...", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "We were happy to see some attention to the potential cost of the stent and in comparison to the existing drug eluting stents.\u00a0In addition, the story provided information on the market size at the present time.", "answer": 1}, {"article": "This page either does not exist or is currently unavailable.\n\nFrom here you can either hit the \"back\" button on your browser to return to the previous page, or visit the ABCNews.com Home Page. You can also search for something on our site below.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Did not mention cost of treatment", "answer": 0}, {"article": "In a similar study published in the journal Pediatrics in 2004, researchers recruited 100 children with upper respiratory tract infections who had been coughing for an average of over three days.\nUltimately, the honey produced the greatest improvements when it came to better sleep and reduced cough frequency and severity.\nAlthough children in all three groups experienced a reduction in coughing, those who received the flavored water fared the best.\nIn this occasional series, the New York Times \u201cReally?\u201d columnist, Anahad O\u2019Connor, explores the claims and the science behind alternative remedies that you may want to consider for your family medicine cabinet.\nThe thinking is that sweet substances of any kind help soothe the back of the throat and break up mucus in the airways.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story makes no mention of costs. We also would have liked to have seen some explanation of whether it mattered if a parent used the cheapest honey or the pricey organic stuff.", "answer": 0}, {"article": "However, antibiotics do come with significant side effects including diarrhea, rashes, yeast infections and vomiting.\nRosenfeld says it's never wrong to prescribe an antibiotic for a well-diagnosed ear infection.\nIn treatment outcomes for pain, there was no difference, he notes.\nOne of the strengths of both studies, Rosenfeld said, is that the researchers took the time to make a solid diagnosis.\nThe foundation for the \"watchful waiting\" treatment recommendation instead of taking drugs is based on this and previous studies that did not have very many children under age 2 in the clinical trials.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "This story did not discuss the costs of antibiotic prescriptions to the individual or costs of policies on our health care system and society. We think it should have.", "answer": 0}, {"article": "\"Take some individual responsibility to stay healthy during the flu season,\" said Health and Human Services Secretary Kathleen Sebelius, who scheduled her own seasonal shot for Friday.\nAnd a standard 15-microgram dose \u2013 not the double dose that also was tested \u2013 was enough.\nBut scientists had feared that people of all ages would need two shots about a month apart because the new H1N1 strain is so genetically different from normally circulating flu strains that most of the population has little if any immunity.\nAustralian and U.S. researchers said Thursday that one dose of the new swine flu vaccine looks strong enough to protect adults \u2013 and can begin protection within 10 days of the shot.\nHad it taken twice that dosage, or two shots apiece, half as many people could have received the vaccine.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "\n\n\nThe story should have mentioned the typical range of charges for seasonal flu and whether there would be any difference in the price of the H1N1 flu shots.", "answer": 0}, {"article": "Flavonoids have been found to relax blood vessels and thereby improve blood flow, inhibit platelets from sticking together in the blood, and have a beneficial antioxidant effect. What still is not known is whether regularly eating dark chocolate, especially with its high sugar and fat content, eventually will lead to an unhealthy weight gain that would erase the beneficial effects of the flavonoids found in the cocoa.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Thought there was no discussion of cost, most people have a general idea how much cocoa costs.", "answer": 2}, {"article": "For an early version of the study abstract, click on \u201cContents,\u201d then \u201cVolume 44, No.\nCAVEATS The study involved a relatively small number of participants and lasted a short time; a larger and longer study would be needed to adequately test effectiveness and safety.\nThe research described in Quick Study comes from credible, peer-reviewed journals.\nNonetheless, conclusive evidence about a treatment's effectiveness is rarely found in a single study.\nAlso, among those in the 40-milligram group, people carrying what is sometimes called the Alzheimer\u2019s gene (APOE-e4) showed more improvement than non-carriers.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Neither this story nor a competing story by Fox News discussed costs. The product being studied, Levemir delivered through Kurve Technology\u2019s ViaNase, has been written about for about a decade, and so cost information could have been found and reported.", "answer": 0}, {"article": "\u201cOur cancer trap works just like a roach motel, where you put in some bait and the roach goes there and dies,\u201d said Liping Tang, UTA bioengineering professor and leader of the research.\n\u201cThis method is effective for both diagnosing and treating metastasis cancer and can be used in combination with traditional chemotherapy and radiation therapy,\u201d he added.\n\u201cSo the cancer trap is really complementary to current cancer treatments and especially beneficial at the early stages when it is difficult to see if the cancer is spreading as there are few cancer cells.\nThis cancer trap can be used for early diagnosis and treatment of metastasized cancer.\nWe have also found it very effective in late stage cancers to stop the spread of the disease and to prolong lifespan,\u201d he added.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Cost is not mentioned. While it can be extremely difficult to place a precise cost on early stage medical technologies, the issue can be addressed in broader terms. Is the technology difficult to make? Can it be produced on a large scale? Are those questions that still need to be explored? This release neglects to do so, which is particularly problematic in a news release that is focused on the announcement of a patent. Patents are designed to secure intellectual property, allowing people and institutions to profit from their discoveries. As such, this release is effectively about business. Failing to address potential costs, even in the most general terms, is a significant oversight.", "answer": 0}, {"article": "Espiritu started work at Henry Ford just as the program was starting, and she remembers the initial staff meetings: \"There was a lot of, 'How can you do this?\nThe story of the health system's success is a story of persistence, confidence, hope and a strict adherence to a very specific approach.\nThe behavioral health provider in Nashville implemented the Henry Ford approach for nearly 200 patients who'd already made a suicide attempt.\nFifteen years ago, suicide prevention care at Henry Ford, like in many places, was mostly reactive.\nWhen patients came in talking about suicide, health providers took notice.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "At issue in the story is the health system\u2019s so-called \u201cperfect depression care,\u201d which incorporates depression screening into primary care. Patients deemed to have, or be at risk of, depression are then given appropriate treatment. It\u2019s difficult to pin a specific cost to this. The matter is further complicated by the fact that treating depression can also save money by driving down costs related to associated health problems. However, the story notes that Centerstone \u2014 a separate health system that has adopted the Henry Ford Health System\u2019s model for a smaller cohort of patients \u2014 did do a cost/benefit analysis and found that it resulted in savings of more than $400,000 per year. While we\u2019ll award a Satisfactory, we think there was a muddling here of Henry Ford\u2019s global screening strategy with the intense care provision in the Centerstone model. It is not appropriate to apply the cost analysis of the latter to the former. In addition, it can be argued that\u00a0screening every patient at every visit it wasteful. The story reads/sounds somewhat like a paean to doing as much as you can and adopting a kitchen-sink approach rather than a carefully honed and efficient one.", "answer": 1}, {"article": "Air is suctioned through the side channels to emulate breathing.\nMore often than not, these studies produce mixed data that don\u2019t tell researchers much about whether it is safe and effective for humans.\n\u201cBiology is very complex.\u201d\n\nIncorporating the chips into drug testing could save millions of dollars and years of time on research.\nThis proved the chips could provide real world information to scientists studying the effects of new drug compounds.\nThe chips will also provide researchers with information on dosing at a much earlier stage in drug studies\u2014particularly helpful because animals metabolize chemical substances at a different rate than humans.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The Newsweek report generally addresses the costs to put a new drug on the market, and it states that \u201cIncorporating the chips into drug testing could save millions of dollars and years of time on research.\u201d\nWe\u2019ll reward the story\u2019s impulse to address cost with a Satisfactory rating, but we\u2019d note that the issue is more complicated than readers may appreciate based on the coverage.\u00a0The article starts by projecting benefits \u2013 cost of drug development and time to FDA approval. And only later does it imply that the new technology initially will add to the cost because it will be done along with the old technology (animal studies). Only if it is as good or better may it be a substitute. Then the question is whether it will indeed be cheaper. It may be cheaper if the chips are less expensive than animal studies or if they better identify agents that do or don\u2019t work in humans. But\u00a0costs are difficult to predict and the totals can add up quickly \u2014 for example, a vial of human lung cells costs over $700. This all seems very speculative at this point.", "answer": 1}, {"article": "Vaginal and vulvar cancers are usually caused by the human papillomavirus, which also causes cervical cancer.\nBut raloxifene's edge in blood-clot and uterine-cancer avoidance was not statistically significant, and tamoxifen proved better at reducing the rate of noninvasive breast cancer.\nWhile both drugs reduced cases of breast cancer by about half from what would have been expected for the women in the study, raloxifene caused fewer cases of blood clots, cataracts and uterine cancers, making it initially appear the winner.\nBut Dr. Ganz said that side effects of both drugs were generally mild and that it was important that women at high risk of breast cancer take one of them.\nThe editorial in the journal said the new data \"still may not be enough to convince primary care physicians to be more aggressive than they have been to date in breast cancer chemoprevention.\"\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There is no mention of the costs of either drug, nor of the overall cost-effectiveness of this approach to preventing breast cancer, including savings on cancers prevented compared with no treatment. This would also have included an estimate of the costs of monitoring and treatment for the possible side effects, particularly uterine problems\u2013which led to hysterectomy in more than 350 women during the trial.", "answer": 0}, {"article": "First, help with work or school such as assistance in deciding which classes or opportunities are most appropriate, given a person\u2019s symptoms.\n\u201cI\u2019m very favorably impressed they were able to pull this study off so successfully, and it clearly shows the importance of early intervention,\u201d said Dr. William T. Carpenter, a professor of psychiatry at the University of Maryland School of Medicine, who was not involved in the study.\nIn the new study, doctors used the medications as part of a package of treatments and worked to keep the doses as low as possible minimizing their bad effects.\nThe sprawling research team, led by Dr. John M. Kane, chairman of the psychiatry department at Hofstra North Shore-LIJ School of Medicine, randomly assigned 34 community care clinics in 21 states to provide either treatment as usual, or the combined package.\nDr. Mary E. Olson, an assistant professor of psychiatry at the University of Massachusetts Medical School, who has worked to promote approaches to psychosis that are less reliant on drugs, said the combined treatment had a lot in common with Open Dialogue, a Finnish program developed in the 1980s.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not touch on costs for the more comprehensive treatment \u2014 including educating families and providing more counseling for patients.\u00a0True costs and potential savings would be very hard to quantify, and would accrue over time as people hopefully stay in school and jobs, and have fewer admissions to the hospital etc. Even if the story couldn\u2019t address these issues precisely, some mention of them would have been helpful. We do applaud the story for exploring the political and reimbursement context. This was especially good:\nIts [study] findings have already trickled out to government agencies: On Friday, the Centers for Medicare & Medicaid Services published in its influential guidelines a strong endorsement of the combined-therapy approach.Mental health reform bills now being circulated in Congress \u201cmention the study by name,\u201d said Dr. Robert K. Heinssen, the director of services and intervention research at the centers, who oversaw the research.", "answer": 0}, {"article": "\u201cI tell my patients, \u2018buyer beware,\u2019\u201d Shepard said in an email.\nIn addition, U.S.-based studies of chondroitin have had mixed results, said Shepard, who wasn\u2019t involved in the study.\nDr. Michael Shepard of Hoag Orthopedic Institute in Orange, California, noted that the study had a relatively low number of participants and that most U.S. studies of this type would run two years rather than six months.\n\u201cChondroitin is not a miracle pill, but if it allows people to feel less pain and be more active, thereby losing weight and strengthening muscles, then I think there may benefit,\u201d Wolfe told Reuters Health by email.\nHe stressed that pharmaceutical-grade chondroitin is not the same as over-the-counter supplements, which are made differently and can\u2019t get into the joint in high enough concentrations to combat the causes of cartilage degradation and pain.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The article makes no\u00a0mention of how much pharmaceutical-grade chondroitin costs.", "answer": 0}, {"article": "Delyth Morgan, chief executive at Breast Cancer Now, which funded the research, said: \u201cThis is a really crucial discovery.\nOur study also demonstrates that statins could be a valuable addition to breast cancer treatment, and that this warrants investigation in clinical trials.\u201d\n\nThe research has not yet been tested in humans.\nCholesterol production by the tumour will not be the only reason why ER-positive breast cancers recur, but campaigners are excited by the possibilities for a treatment if further research corroborates these findings.\n\u201cThis study breaks new ground in uncovering how some breast cancers continue to survive without oestrogen and suggests that women could benefit from adding statins to standard anti-hormone treatments.\nFar too many women have to deal with the potentially devastating consequences of their breast cancer coming back and this research presents an important opportunity to improve the effectiveness of today\u2019s most commonly used treatments.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There\u2019s no discussion of the cost of statins, which is readily available data.", "answer": 0}, {"article": "CHICAGO\u2014For patients facing a choice between bypass surgery and a popular, less-invasive procedure to treat heart blockages, surgery improves chances of long-term survival, researchers said Tuesday.\n\nIn a study that analyzed data on nearly 190,000 Medicare patients treated between 2003 and 2007, 16.4% of surgery patients had died after four years, compared with 20.8% treated with angioplasty and a stent to prop open diseased vessels.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Like its counterparts, this story fails to say a word about costs of the two procedures.\u00a0 Based on our calculations, the two procedures have about a $44,000 price difference and with a Number Needed to Treat of 23, the costs of avoiding a death in this patient population at 4 years exceeds $1 Million.\u00a0 We think that is an important health policy consideration.", "answer": 0}, {"article": "Anticipating wide interest in the psilocybin research from scientists, clinicians and the public, the journal solicited 11 commentaries to be co-published with the study results written by luminaries in psychiatry, palliative care and drug regulation, including two past presidents of the American Psychiatric Association, a past president of the European College of Neuropsychopharmacology, the former deputy director of the U.S. Office of National Drug Control Policy, and the former head of the U.K.\nThe researchers cautioned that the drug was given in tightly controlled conditions in the presence of two clinically trained monitors and said they do not recommend use of the compound outside of such a research or patient care setting.\nThe study was designed to see if psilocybin could produce similar results in psychologically distressed cancer patients.\nSix months after the final session of treatment, about 80 percent of participants continued to show clinically significant decreases in depressed mood and anxiety, with about 60 percent showing symptom remission into the normal range.\nThe study was funded by grants from the Heffter Research Institute, the RiverStyx Foundation, William Linton, the Betsy Gordon Foundation, the McCormick family, the Fetzer Institute, George Goldsmith, Ekaterina Malievskaia and the National Institute on Drug Abuse (R01DA03889).\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Cost is not addressed at all.\nThe costs associated with cancer treatments has been the topic of discussion for some time. So, cost of palliative treatments are important. \u00a0While there may not be any good estimates of a commercially available product at the moment, the regulatory issues associated with psilocybin are considerable and are likely to have a large impact on cost. The release could have addressed this in a general way, even if specific cost figures are not available.\u00a0", "answer": 0}, {"article": "\"It is very big.\nVeridex launched the first commercial test using circulating tumor cell technology in 2004, the company said.\nCapturing and counting those cells can provide information to patients and doctors about prognoses with certain types of metastatic cancers, the statement said.\nResearchers hope the test will be used by oncologists as a diagnostic tool aimed at discovering as early as possible if a cancer has spread, as well as by researchers in coming up with new drug therapies.\nToner says the test is like a liquid biopsy and targets almost all solid cancers -- cancers found in \"solid\" organs like the breast or prostate.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not offer any information about costs. It refers to an early technology for detecting circulating tumor cells marketed by the same company, but then doesn\u2019t tell readers how much the existing test costs.", "answer": 0}, {"article": "Most recently, the F.D.A.\nIf the vaccine helps smokers quit, Dr. Reus said, a central question will be whether booster shots could help prevent relapse.\nBecause the compound is too big to cross the blood-brain barrier, the vaccine is expected to diminish or eliminate the pleasure associated with puffing a cigarette.\nAn effective vaccine could play a major role in reducing smoking around the world, said Dr. Vocci, who estimated that current rates of smoking would lead to one billion deaths in the 21st century.\nThomas E. Rathjen, a spokesman for Nabi Biopharmaceuticals, said the results of the study should be available sometime next year.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not provide even an estimate of the cost of the vaccine. There is the suggestion that if the vaccine were approved it could be a financial boon for Nabi Biopharmaceuticals. Consumers want to know what it may cost them. ", "answer": 0}, {"article": "There have been many attempts over the decades to develop blood tests to screen for cancers.\nFirst, he notes, the Hopkins team will need to demonstrate that the test will be useful in patients without symptoms.\nOf course, the ultimate goal of this test is to find cancer in people who haven't already been diagnosed.\nAn effective screening test would hold lots of potential for cancer patients, Prasad says.\nThen the researchers will need to show that the rate of false alarms remains very low, otherwise people will be sent on needless and expensive medical odysseys.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story makes it clear that cost of the test is currently speculative (\u201ccould cost about $500\u201d) and goes even further to caution that: \u201cJohns Hopkins holds the patent and has not licensed it as yet to a company that would ultimately set the price.\u201d", "answer": 1}, {"article": "Although no one can pinpoint a reason for the link with certainty, \"essentially we think that alcohol may be having an effect by reducing the immune response, which leads to joint inflammation, and also that it may have a mild pain-killing effect,\" said Maxwell.\nNor do the study authors advise drinking as a cure for arthritis.\n\"We would therefore recommend that a future prospective study should be performed to further assess the impact of alcohol consumption on rheumatoid arthritis, a study recording alcohol consumption at the time rather than asking about it later.\"\nThis finding is slightly different than what is reported in the current study (that the severity of the disease decreased with more alcohol).\n\"There are limitations to any research which asks patients to report their exposure to something (such as alcohol) over a period of time,\" Maxwell added.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Not applicable. The cost of alcohol is not in question. ", "answer": 2}, {"article": "Enlarged prostate is characterized by a host of unpleasant symptoms, including weak or slow urine flow, an urgent need to urinate frequently, incomplete bladder emptying and having to get up repeatedly at night to urinate.\n\"PAE is potentially fraught with complications,\" Lowe said, adding that the study follow-up of less than one year was short for a disease that lasts decades.\nDr. Franklin Lowe, associate director of urology at St. Luke's-Roosevelt Hospital in New York City, said PAE was \"unlikely\" to be used much to treat enlarged prostate.\nAnd while this study showed some symptomatic improvement, it didn't have enough objective data to show that the new technique would surpass surgery, she said.\nSince the study is being presented at a medical meeting and has not yet been published in a peer-reviewed journal, the findings should be considered preliminary.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There was no discussion of costs. Why not?\u00a0 You can let a researcher say it\u2019s ready to be used in certain patients, yet you can\u2019t estimate a cost?", "answer": 0}, {"article": "(image: transmission electron micrograph of Zika virus, NIAID)\n\n\"If we could find a way to specifically target those GSCs that are the source of recurrence, then that might provide an option to prevent recurrence or even a cure,\" says Qin.\nIn a study published this week in mBio\u00ae, an open-access journal of the American Society for Microbiology, the team shows that a live, attenuated version of the Zika virus could form the basis of a new treatment option for this fatal brain cancer.\nIn addition, the Zika virus was much less efficient at attacking the differentiated, healthy brain cells.\nComparing those profiles, the team found that in the treated cells, the virus triggered a strong antiviral response in the cells, which induced inflammation and eventually cell death.\nShi's lab has developed a promising live-attenuated Zika vaccine candidate called ZIKV-LAV that had been shown to be safe, non-virulent, and effective in protecting against infection in mice and non-human primates.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "This release reports results of a clinical trial in mice. It\u2019s too early to estimate costs for human treatment.", "answer": 2}, {"article": "But high blood pressure also appears to increase a person's risk of developing Alzheimer's disease, which is associated with the accumulation of plaques and tangles in the brain.\nAnd he says other people with high blood pressure should follow his lead.\nAt least two large studies have revealed an alarming trend among stroke patients, Koroshetz says.\nWhen blood pressure rises, it strains the tiny blood vessels that keep brain cells alive, Koroshetz says.\nIf people knew about the link between dementia and high blood pressure, they might be more inclined to do something about it, Koroshetz says.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No specific brand name interventions mentioned, though it\u2019s implied that medication is frequently used.\nWhile we wouldn\u2019t expect the story to list the prices of the many drugs for high blood pressure, we do think the story could have discussed this aspect of seeking treatment. Is it a factor in why so many people don\u2019t treat their high blood pressure?", "answer": 2}, {"article": "\u201cFor young people they don\u2019t want to commit themselves to a treatment which they might need to take for the next five to ten years,\u201d he said.\nSeventy-six of the 81 study participants, or 94 percent, completed the trial, Amminger noted, which underscores the safety and tolerability of fish oil.\nThe effect of fish oil capsules, Amminger noted, was similar to that seen in two trials of antipsychotic drugs in at-risk individuals.\n\u201cAt the moment there\u2019s no state-of-the-art guideline (on) how to treat those people.\u201d\n\nPrescribing antipsychotic medications may be helpful, Amminger added, but these medications have serious side effects, and can also be stigmatizing.\nThere are a number of mechanisms through which omega-3s could protect the brain, Amminger said; they are a major component of brain cells.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not mention costs.\u00a0 Fish oil supplements are relatively inexpensive and can cost as little as $0.25 per day for the amount given in the study.", "answer": 0}, {"article": "The study comes a month after Gov.\nThey say the test's value is limited because it doesn't identify which plaque are stable and which could rupture and cause a heart attack.\nDr. William Zoghbi, director of Methodist Hospital's Cardiovascular Imaging Institute, said the cancer risk numbers reported in the study are actually fairly low compared to other tests that take X-rays of the chest area, such as a regular CAT scan or coronary angiography.\nThe Texas law will require insurance companies pay $200 of the bill for patients to get the test every five years.\nIt eventually attracted attention in cardiology circles, where the scans' costs and benefits are the subject of much debate.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "\n\n\n \nThe story not only mentions the cost of a scan to individuals ($100 to $500), it also notes that about $50 million dollars was spent on this type of scanning nationwide in 2008. A longer story could have also reported on the costs of additional testing and treatments triggered by screening apparently healthy individuals.", "answer": 1}, {"article": "The Journal of Medical Entomology is published by the Entomological Society of America, the largest organization in the world serving the professional and scientific needs of entomologists and people in related disciplines.\nClip-On caused high mosquito mortality and knockdown rates up to 0.3 meters from the device, enough to protect a single person wearing the device.\nThe effectiveness of the device came as a pleasant surprise to the researchers.\nA product called the OFF!\u00ae Clip-On\u2122 repellent device could be an effective tool for preventing bites from the Aedes aegypti mosquito -- the primary vector of Zika, chikungunya, dengue, and yellow fever -- according to an article in the Journal of Medical Entomology.\nSkepticism is inherent to the trade.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release doesn\u2019t provide any information about the device\u2019s cost. A quick online search found the OFF! Clip-On starter pack going for $9.49 at Target. After the initial purchase, consumers must continue to buy refills and batteries. The monetary impact is huge if you consider the the volume of potential sales.", "answer": 0}, {"article": "B vitamins, including B12 and folate, have been shown to help lower homocysteine levels, so high levels of the amino acid suggest low levels of B12.\nThe relationship between vitamin B12 and Alzheimer's risk is \"complex,\" says Dr. Sudha Seshadri, M.D., an associate professor of neurology at the Boston University School of Medicine and the author of an editorial accompanying the study.\n\"Lowering these in general is important for cardiovascular health, and this study strengthens our knowledge about its role in risk for Alzheimer's disease.\"\nDr. Sam Gandy, M.D., the associate director of the Alzheimer's Disease Research Center at the Mount Sinai School of Medicine, in New York City, says that it may make sense for people to get blood tests to measure their levels of B12 and folate.\nHealth.com: 9 foods that may help save your memory\n\nOver the next seven years, 17 study participants were diagnosed with Alzheimer's disease.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "", "answer": 0}, {"article": "HIV infects the body by corrupting T cells that are mobilized by the immune system when the virus enters a person's body.\nThe tool, a vaginal implant, decreases the number of cells that the HIV virus can target in a woman's genital tract.\nUnlike conventional methods of HIV prevention, such as condoms or anti-HIV drugs, the implant takes advantage of some people's natural immunity to the virus.\nWhen the T cells stay resting, it's referred to as being immune quiescent.\nThe article recently appeared in the Journal of Controlled Release.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The lead author is quoted as stating the implant could prevent HIV infection \u201cmore reliably and cheaply,\u201d but the cost is not provided in the release.\nThe cost may well be unknown since the treatment is experimental and in development. However, the published research states that the active ingredient \u2014 hydroxychloroquine, or HCQ \u2014 \u201cis an inexpensive drug.\u201d Perhaps that price could have been included.\nAnd cost is relevant since the vast majority of HIV infections occur in the developing world where cost could have a major influence on compliance with prevention measures.", "answer": 0}, {"article": "In general, the risk of developing colorectal cancer varies with age, race, ethnicity and lifestyle.\nDr. Friis emphasized that people should not start taking aspirin or NSAIDs on the basis of the new findings.\nThey didn\u2019t include patients who made over-the-counter purchases of the medicines.\nNonaspirin NSAIDs were also protective against colorectal cancer with consistent long-term use, \u201cand there was some indication that even non-continuous use of these agents may be (marginally) effective for the prevention of colorectal cancer,\u201d Dr. Friis said.\nOn the other hand, merely having taken aspirin did not alter the colorectal cancer risk, they reported in Annals of Internal Medicine.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No mention was made of costs, but anyone who has been to a drugstore knows that aspirin is cheap.", "answer": 2}, {"article": "\u201cThere\u2019s definitely a major need for a permanent, total artificial heart,\u201d Laman A.\nIts device, powered by a small air compressor that can be carried in a backpack, has been implanted in more than 800 patients as a bridge before transplant.\nCarmat estimates its device will cost $176,000 to $226,000.\nThe device was developed over 15 years by a team that included Alain F. Carpentier, the French surgeon-scientist who, along with Albert Starr, received the 2007 Albert Lasker Award for Clinical Medical Research.\nCiting World Health Organization data that shows heart disease is the world\u2019s leading cause of death, Mr. Conviti, the Carmat chief executive, estimated the potential market at \u201ca minimum\u201d of 100,000 patients a year in the United States and Europe.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story explains that the company \"estimates its device will cost $176,000 to $226,000. When all expenses are considered, including hospital and surgical expenses, it says it will cost just over $315,000, about the same as a transplant.\"", "answer": 1}, {"article": "Anthony's asthma diminished over time, and he says he can still play soccer, run fast and breathe \"just fine.\"\nThe severity of this and the other two problems that turned up as a result of the abnormal EKGs are reason enough, Debauche says, to screen all school athletes nationwide.\nThere's no official policy from the American College of Cardiology, but officials say most members support screening student athletes.\nThese surprise attacks are due to inherited problems that children are born with.\nDebauche says the heart screening turned out to be life-saving for this student athlete.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "1clip_filelist.xml\" rel=\"File-List\"/>1clip_themedata.thmx\" rel=\"themeData\"/>1clip_colorschememapping.xml\" rel=\"colorSchemeMapping\"/>\n\n\n\n\nThe story cites unnamed experts who make the vague claim that EKG screening would be \u201ctoo costly.\u201d However, an estimate of the cost of the equipment and the cost per test would have been easy to include and would have provided valuable context to the discussion. Notably, the authors of the study discussed in this article have suggested that the cost of an EKG is as low as $3 under the research protocol they used.\u00a0 However, the cost skyrockets to over $100 if the customary physician billing process is used. The story presents this tension in a one-sided and biased fashion without ever discussing the cost implications sufficiently.\u00a0\n", "answer": 0}, {"article": "The requested URL /usnews/health/articles/061008/16healthwatch.htm was not found on this server.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The price of cola products is well known. ", "answer": 2}, {"article": "American veterans coping with PTSD are traveling to lodges in the Amazon that offer ayahuasca, a hallucinogenic brew. Some say it has helped them manage emotional trauma from war, but others say it\u2019s not worth the journey. Photo: Ryan Dube/WSJ\n\nAfter surviving firefights and a roadside bomb in Afghanistan, U.S. Army veteran Asa Barrett tried antidepressant drugs and therapy to overcome depression and bouts of anger. Nothing worked.\n\nBut then, like many other foreigners, he journeyed to Peru\u2019s remote Amazonian jungle to drink ayahuasca, a centuries-old, sacred indigenous brew that some Western scientists think can help to heal psychological traumas.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story says foreigners are \u201cpaying up to $2,500 a week to drink the elixir,\u201d though it does not say whether this is typical. The story could have elaborated by describing the costs of travel and living expenses while taking the substance, too. There are hidden costs to think about, too, such as treating the negative adverse effects of the drug", "answer": 1}, {"article": "For more information on bisphosphonates, visit U.S. Food and Drug Administration.\nSaid Coleman: \"Zoledronic acid cannot be routinely recommended for prevention of cancer returning, but it remains a very good drug for patients where the cancer has already spread to the bone.\"\nTHURSDAY, Dec. 9, 2010 (HealthDay News) -- The bone drug zoledronic acid (Zometa), considered a potentially promising weapon against breast cancer recurrence, has flopped in a new study involving more than 3,360 patients.\nAnderson Cancer Center, was not involved in the study but put it in perspective.\nOther studies underway may provide a clearer answer, she said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "We won\u2019t require a discussion of costs in this story because the use of zoledronic acid for early stage breast cancer is still up in the air. However, since the drug is already being sold for other indications, the story would have been better if it had told readers something about the costs of using the drug for approved indications.", "answer": 1}, {"article": "\"We need people to swim against the stream.\nThe goal of the project is to develop a simple, accurate, noninvasive, and reproducible method for early identification of chronic heart failure, he tells WebMD.\nThe new device was about that accurate at differentiating between severe and less severe heart failure patients.\n\"Still, much more work is needed before we will know if the electronic nose will make it to the clinic,\" says Ruschitzka, who moderated a news briefing to discuss the findings.\nAug. 30, 2011 (Paris) -- German researchers say they\u2019re a step closer to developing an electronic nose that can distinguish between people who have heart failure and those who don't.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not discuss costs. Because the research is in its infancy and there does not appear to be a comparable device, we don\u2019t think the cost question applies here.", "answer": 2}, {"article": "Still, it\u2019s impossible to rule out that big fiber eaters had healthier habits overall that would cut their risk, Jia-Yi Dong of Soochow University in Suzhou and his colleagues write in the American Journal of Clinical Nutrition.\nKnown benefits of a high-fiber diet include lower cholesterol and weight loss.\n\u201cIncreasing dietary fiber intake in the general public is of great public health significance,\u201d the Chinese team concludes.\nTheir findings don\u2019t prove fiber itself lowers cancer risk, however, because women who consume a lot of it might be healthier overall than those who don\u2019t.\nAnd those in the top fifth of fiber intake were 11 percent less likely to do so than women in the bottom fifth.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Not applicable.\u00a0 The cost of fiber in the diet is not in question.", "answer": 2}, {"article": "\"Certainly, however, this solid paper adds to the literature and paves the way for additional research on this interesting topic.\"\n\"For the past decade, the importance of fish oil and the omega-3 fatty acids have been stressed to patients,\" explained Wu, who was not involved in the study.\nHowever, the findings only showed an association and did not prove that fish oil pills caused healthier growth in children.\nAccording to Dr. Jill Rabin, co-chief of the division of ambulatory care, Women's Health Programs-PCAP Services at Northwell Health, in New Hyde Park, N.Y., \"In pregnancy and beyond, adequate intake of fish is important for normal human development, and this paper certainly adds to the literature.\"\nThose whose mothers took the fish oil supplements during pregnancy sustained a higher body mass index (BMI) from the age of 1 to 6 years.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "This story doesn\u2019t mention the costs of the fish oil supplements it appears to support. However, the cost of such supplements is reasonable and the period in which they\u2019re recommended is short \u2014 the last trimester of pregnancy \u2014 making cost a lesser concern than in some cases.", "answer": 2}, {"article": "During the luteal phase, estrogen and progesterone levels are at their highest, which may help a woman keep addictive cravings at bay and reduce feelings of cigarette withdrawal.\nThe brain scans showed that during the follicular stage, cigarette imagery activated five areas of the brain which the researchers say are linked to higher-level cravings.\nThey called for more studies to help understand all the factors that contribute to sex and gender differences in smoking.\nA new study finds hormone fluctuations that occur over the course of a woman's menstrual cycle may impact her ability to kick the cigarette habit.\nResearchers asked each participant to smoke one cigarette 30 to 40 minutes before undergoing an fMRI, or brain scan.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Since the story let the researchers get away with saying, \u201cThis result emphasizes the need for gender-specific programs to quit smoking\u2026\u201d, we might have dinged it for not projecting what the costs of such programs might be. \u00a0But we\u2019re going to rule this Not Applicable because it would be difficult at this point to think about all that might be involved in costs of such an approach, even if this research was close to true real-world application, which it is not.", "answer": 2}, {"article": "Dr. Sonia Friedman is an associate professor of medicine at Harvard Medical School.\n\"Treatment with oral tofacitinib is potentially a new treatment option for patients with moderate to severe ulcerative colitis, pending review by the [U.S. Food and Drug Administration],\" Sandborn said.\nWhether Xeljanz should be used as a first treatment is still not clear, said Dr. Arun Swaminath, director of the inflammatory bowel disease program at Lenox Hill Hospital in New York City.\nForty percent of those taking a 10-mg dose of the drug had remission at a year.\nIn the first trial, nearly 19 percent of the patients taking Xeljanz experienced a remission of their condition in eight weeks.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story doesn\u2019t mention cost. This is a significant oversight, given that a glance at online pricing guides indicate the drug costs around $4,000 per month (treatment for the bulk of the clinical trial patients was for two months, though some patients took lower \u201cmaintenance\u201d doses for a year).", "answer": 0}, {"article": ".\nThe contraceptive method was effective in nearly 96 percent of continuing users.\nDespite the adverse effects, more than 75 percent of participants reported being willing to use this method of contraception at the conclusion of the trial.\nThe prospective Phase II single arm, multi-center study tested the safety and effectiveness of injectable contraceptives in 320 healthy men ages 18 to 45.\nOnly four pregnancies occurred among the men's partners during the efficacy phase of the study.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The cost of these hormone injections isn\u2019t mentioned, and there\u2019s no assessment of how the cost might compare with other forms of birth control. It should be noted that people interested in using this injection for birth control would also need to factor in clinic visit costs and potential treatment of side effects.", "answer": 0}, {"article": "Cocoa or cacao beans are not beans but the seeds of the fruit of the Theobroma cacao tree.\nA new study suggests that dark chocolate and cocoa powder may be the next \"super foods\" thanks to their high antioxidant content.\nTwo groups of antioxidants in particular, polyphenols and flavonols, which are found in various fruits and seeds, have been the focus of much research due to their potentially healthy effects.\nFoods and fruits high in these antioxidants have been dubbed as \"super foods\" or \"super fruits\" by the media.\nAntioxidants are a group of compounds known to fight the damaging effects of oxidative stress on cells within the body and are increasingly thought to have many heart-healthy properties.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story should have pointed out that the dark chocolate associated with health benefits is generally more expensive than other chocolates due to its high cocoa content.", "answer": 0}, {"article": "The requested URL /usnews/health/articles/060723/31robot.htm was not found on this server.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The article\u2019s main focus is about robotic surgery for prostate cancer, although other applications are mentioned. Comparitive costs are given for a robotic radical prostatectomy, laparoscopic prostatectomy, and open prostatectomy. ", "answer": 1}, {"article": "Research has shown that vitamin D plays a key role in maintaining muscle integrity and strength and some studies suggest vitamin D may reduce the risk of falls.\n\"Falls in homebound older people often lead to disability and placement in a nursing home,\" said Denise Houston, Ph.D., R.D., associate professor of gerontology and geriatric medicine at Wake Forest Baptist and lead author of the study.\nThe study showed that the monthly vitamin D supplement was effective in increasing the concentrations of vitamin D in the blood from insufficient to sufficient levels in all but one of the 34 people who received it, and to optimal levels in all but five people.\nFunding for the study was provided by the Wake Forest Translational Science Institute and Center for Integrative Medicine and the Claude Pepper Older Americans Independence Center of Wake Forest Baptist.\nSixty-eight study participants received either a monthly vitamin D supplement of 100,000 international units or placebo delivered with their MOW meal.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The news release makes no mention of the cost of Vitamin D supplements, which would likely be important to the elderly population, many of whom live on fixed incomes.\u00a0Nor does it mention a key fact about the Older Americans Act that was cited in the study itself: \u201cAlthough OAA nutrition programs can provide education and counseling to encourage the use of vitamin-mineral supplements, the provision of vitamin-mineral supplements is currently not a fundable OAA service.\u201d Relatively speaking, the cost of such supplements is minimal, but readers may not be aware of that.", "answer": 0}, {"article": "Sept. 17, 2010 -- The FDA has approved Krystexxa (pegloticase) for the treatment of gout.\nThe drug is administered to patients every two weeks as an intravenous infusion.\nThe drug is associated with some serious side effects.\nTwo six-month clinical trials of 212 total patients showed that the drug lowered uric acid levels and reduced deposits of uric acid crystals in joints and soft tissue.\nSavient expects Krystexxa to be available by prescription later this year.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No mention of costs.\u00a0 Why not?\u00a0 And, since the drug must be administered every two weeks as an intravenous infusion, cost of delivery could be another substantial issue. (Our medical editor on this story says such biologic infusions tend to cost more than $1,000 per infusion.) How could this be excluded from such a story? ", "answer": 0}, {"article": "\"There are many gaps in the evidence,\" Reiss said.\n\"This is a very preliminary study with a small number of subjects and the results are far from conclusive,\" said Dr. Allison Reiss, head of the Inflammation Section at Winthrop-University Hospital in Mineola, N.Y.\n\nShe believes the current study lacks information on possible confounding factors -- things such as \"coexisting illnesses, medications, hydration state, tobacco use and multiple other variables\" that could influence what's found in the saliva samples.\n\"It is uncertain whether the strength and consistency of the relationship between these metabolites [in saliva] and Alzheimer's risk will be maintained in a large multicenter study.\"\n\"Saliva is easily obtained, safe and affordable, and has promising potential for predicting and tracking cognitive decline, but we're in the very early stages of this work and much more research is needed,\" study author Shraddha Sapkota, a neuroscience graduate student at the University of Alberta in Canada, said in a news release from the Alzheimer's Association.\nStill, Dr. Paul Wright, chair of neurology at North Shore University Hospital in Manhasset, N.Y., said the research \"is still in its infancy but very promising.\"\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There is no mention in this short story about the potential costs of such a test, if it proved to be viable. Of course, it\u2019s too early to say anything definitive about cost, and offering a specific number might mislead readers by implying that the test is anywhere near ready to be used. But we think the story could have offered some sense of the technology behind the test and whether it\u2019s advanced/expensive or cheap/widely available. Other tests using saliva are in use today and could offer a general comparison point to suggest the costs of a new test.", "answer": 0}, {"article": "\u2022 Khin NA, et.al.\nEsketamine nasal spray has an acceptable safety and tolerability profile, based on the adverse event data from both Phase 3 studies.\nIf approved by the U.S. Food and Drug Administration (FDA), esketamine would be one of the first new approaches to treat refractory major depressive disorder available to patients in the last 50 years.\nThe results from these studies will inform regulatory filings for esketamine nasal spray in treatment-resistant depression, for which Janssen has received Breakthrough Therapy Designations from the U.S. FDA.\nThese findings represent two of the five Phase 3 studies that comprise Janssen's treatment-resistant depression program with esketamine nasal spray.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Costs are not addressed and they should be. While esketamine spray is a newer version of ketamine, which has been in use as a general anesthetic for 50 years, that drug has been off-patent for many years. A new version of the drug, presented in a nasal spray formula, is eligible for patent protection once it is approved by the FDA.", "answer": 0}, {"article": "... Then a lot of guys eventually were like, 'I'll go.\n\"To a certain extent, I was surprised by the magnitude of the effect of the intervention,\" said Ciantel Blyler, a clinical pharmacist at Cedars-Sinai Medical Center in Los Angeles who was a co-author of the study.\nBy the end of the study, the researchers found that the barbers' role in encouraging the men to monitor and improve their health resulted in a significant reduction in blood pressure, when coupled with medication from the pharmacists.\nAdditionally, more research is needed to determine whether similar study results would occur on a national level, since the study was conducted only in the Los Angeles area.\n'Medical mistrust has been an important barrier'\n\nThe study had some limitations, including that it was not blind, because both participants and researchers knew who was assigned to the pharmacist-led program and who was in the control group.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There was no mention of costs in this story although the costs of some antihypertensive drugs can be moderately high. Neither did the story disclose that study participants received vouchers for monthly haircuts as well as a small monetary payment to offset the costs of drugs and transportation as enticements to continue with the program, information that was contained in the journal paper but excluded in the story.\u00a0 Regardless, we don\u2019t believe that information is that important to readers in this case so we\u2019ll rate this category as non-applicable.", "answer": 2}, {"article": "We know from our own anecdotes that we have saved a lot of lives.\u201d\n\nDr. Lepor said that he had just met a woman who had smoked for 50 years and was concerned about her risk.\nBut because the study was stopped early, a full analysis of the harms caused by screening scans is still months away.\nIn the study, even experienced radiologists at major cancer centers had a high rate of false positives, suggesting that the rate would be even higher in the real world.\nThe wording of the ad seemed to be aimed at a broad group, ranging from heavy smokers to women who had never smoked, Dr. Brawley said.\nIn the release, Dr. Norman E. Lepor said the scans were an \u201cindispensable\u201d part of annual exams for patients who have smoked for 10 years.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Good job on this.\u00a0 The story stated:\n\u00a0However, it could have also included at least a line about the costs of following testing and possible treatment of false positives.", "answer": 1}, {"article": "This news-agency article is no longer available on nytimes.com.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Although the story does include some discussion of costs, the specifics implied that smartphone app systems are inherently less expensive than alternatives. However, as the story points out, the actual costs and effectiveness of the apps discussed are still being studied. The hoped-for cost savings might not materialize. It\u2019s possible that the apps might be cheaper, but also less effective, perhaps leading to more expensive remedial interventions or poorer health outcomes. The story did not address several important cost questions. Even if insurers or public programs paid for the apps, who would pay for the smartphones, data plans and other costs? For people with low incomes, these costs could create barriers to treatment.", "answer": 0}, {"article": "\"Historically, patients with chronic systolic heart failure were considered too frail to exercise and, through the late 1980s, avoidance of physical activity was a standard recommendation,\" the study's authors write.\nThe study authors say there's a usually a strong relationship between depression and heart failure, so the fact that tai chi helped cheer people up was an especially good sign.\nThe researchers recruited 100 people with the chronic condition from heart clinics in Boston.\nThe Archives of Internal Medicine study is the first large clinical trial to look at whether a tai chi program can do anything for people with heart failure.\nIn a quality of life questionnaire the researchers gave out, those who practiced tai chi scored significantly higher than those who hadn't been doing the movement.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "How much would it cost to replicate the\u00a0experience of participants in this study who received tai chi training? And would the classes be covered by insurance? These are important questions for people with heart failure, who tend to be older and are\u00a0often living on fixed incomes. But the story doesn\u2019t tell us.\u00a0It wouldn\u2019t have been hard to estimate\u00a0cost ranges for a 12 week course that meets twice weekly as in the intervention.", "answer": 0}, {"article": "The requested URL /2011-08-30/business/29945941_1_mark-kris-cancer-cases-lung was not found on this server.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "\n\n\nThe story clearly states near the top that this treatment is \u201cvery expensive.\u201d It reports that crizotinib treatment costs about $9,600 per month and that patients may continue to be treated until the cancer resumes spreading. There is also a reference to an assistance plan offered by Pfizer. The story also reports that tumors \u201cshrank or stopped growing in just over half of patients for nearly two years on average.\u201d From this information, careful readers could calculate that the drug cost (not including associated medical care and tests) would routinely approach a quarter of a million dollars per patient. It would have been helpful if the story had provided this calculation. The story also reports that the test needed to identify appropriate patients costs $250.", "answer": 1}, {"article": "Dr. Steve Hicks, senior author of the study and an assistant professor of pediatrics at Penn State College of Medicine, said the \"five microRNAs in saliva could predict with approximately 85% accuracy which concussed children would have symptoms one month later.\nHe added that creating an actual test for use by doctors will require collaboration on the part of researchers.\nDr. Jeffrey Kutcher, a neurologist and National Director of The Sports Neurology Clinic at The CORE Institute, said that \"work like this is important because it does provide potential for tests that can be helpful in the clinical setting.\"\nPossibly, then, the drugs may be a potential 'confounding' variable, they wrote, meaning that medication may influence test results and symptoms, adding an element of confusion to the study and its possible interpretation.\n\"Because the markers we identified in this study are not correlated with patient age, we are hopeful they may be applied in adult populations, as well,\" he said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story provides no discussion of how much this test might cost if and when it comes to market.", "answer": 0}, {"article": "Dr Davide Pellacani, who began these studies in York, before moving to the University of British Columbia, said: \"Using this computer analysis, not only could we see which tissue samples had cancer and which didn't, but also which cancers were dangerous and which ones less so.\nIt is now understood that to find the different levels of cancer, scientists have to identify genes that have been altered in different cancer types.\nThe team needed to eliminate the 'noise' of the genetic patterns that make individuals unique, to leave them with the patterns that indicate cancer.\nA team at the University of York and the University of British Columbia, Canada, however, have designed a test that can pick out life-threatening prostate cancers, with up to 92% accuracy.\nTo take this method out of the laboratory, the team are now investigating a further trial with new cancer samples, and hope to involve a commercial partner to allow this to be used for patients being treated in the NHS.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "This news release does not mention costs. This is likely because, as we said above, the test is still experimental, and not something available to the general public.\nIn comparison, available genomic tests run around $4,000.", "answer": 0}, {"article": "Macular edema can arise during any stage of diabetic retinopathy and is the most common cause of diabetes-related vision loss.\nThe three drugs yielded similar gains in vision for patients with 20/32 or 20/40 vision at the start of treatment.\nAdditionally, laser treatment was given if DME persisted without continual improvement after six months of injections.\nDRCR.net investigators enrolled 660 people with DME at 89 clinical trial sites across the United States.\nBy two years, 41 percent of participants in the Eylea group received laser treatment to treat their macular edema, compared with 64 percent of participants in the Avastin group and 52 percent in the Lucentis group.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release states that based on Medicare allowable charges, each injection of Eylea costs $1,850, Lucentis is $1,200 per injection and Avastin is $60 per injection. Patients received nine monthly injections, on average. This is good detail, although total costs of all treatments (medication plus laser) would have been even more helpful.", "answer": 1}, {"article": "NASHVILLE -- Sick with depression, Harriet Bruce spent her days lying in bed for months at a time.\nIt's an alternative to electroconvulsive therapy \u2014 shock treatments \u2014 for patients who have not responded to drugs or psychotherapy.\nThe devices cost around $100,000, Cochran said, who has treated 45 patients with the therapy.\nThe cost, however, is less than an extended hospital stay.\nThe NeuroStar system resembles a dentist's chair.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story provides the reader with information on the cost so it meets the criterion. \u00a0We would have liked a bit more information. \u00a0For example, how durable is the response and will patients need repeated treatments? Based on the literature to date, patients may need to undergo treatment every 2-3 months. \u00a0We are told that each treatment costs about $400 and the total cost is $8-12,000. \u00a0That means each patients receives 20-30 treatments. \u00a0There are ancillary costs associated with each trip that we would have liked to have included. Nonetheless, we\u2019ll give the story the benefit of the doubt.", "answer": 1}, {"article": "Sunlight's ultraviolet (UV) rays can damage the DNA in skin cells, increasing the risk for skin cancer.\nBut she said more reserach is needed to see if everyone benefits from it.\nIt doesn't involve any high-priced new pharmaceuticals -- the key may be an over-the-counter vitamin supplement that costs less than $10 a month.\nDoctors involved in the study are excited by their findings on vitamin B3 nicotinamide.\nWiese thinks the vitamin study sounds promising.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "We\u2019re told right off the bat that twice-daily nicotinamide supplements cost about $10 a month.", "answer": 1}, {"article": "Chronic rhinosinusitis (CRS) affects a sizable minority -- 14 percent to 16 percent -- of U.S. residents.\nThis second finding is probably explained by the fact that people going for second or further surgeries were probably sicker to begin with, Josephson said.\n\"These were patients who have chronic sinusitis so, by definition, they have at least three months of symptoms and they have evidence of an ongoing inflammation or infection of their nose and sinuses on either a CT scan or an examination of the nose and sinuses,\" Smith said.\nThe condition, marked by symptoms such as sinus pain and pressure, headache, stuffy nose and sneezing, can compromise quality of life more than even congestive heart failure, back pain or chronic obstructive pulmonary disease, the study authors said.\nFRIDAY, Jan. 1, 2010 (HealthDay News) -- Three-quarters of patients undergoing surgery for stubborn sinusitis saw significant improvements in their quality of life, new research shows.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "", "answer": 0}, {"article": "In an outpatient procedure under local anesthesia, doctors funneled a catheter into the patient's heart and removed peppercorn-sized bits of tissue from the part of the patient's heart that was unaffected by the heart attack.\nMarb\u00e1n and his colleagues first presented this research at an American Heart Association conference in November.\nMarb\u00e1n says when the first patient data came in, he and his colleagues were relieved to see the procedure was safe.\nShe is hopeful further studies will confirm these early results.\nFurther research will hopefully also help answer those questions, she says.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "It\u2019s too early to have a meaningful discussion of costs.\n\u00a0", "answer": 2}, {"article": "After her mother unexpectedly died from a tear in the wall of her heart at age 63, Patricia Walters talked to her doctor, Leslie Cho, about how to better monitor her own heart health.\n\nPregnant at the time with her own daughter, Ms. Walters, now 46, says she was \"a nervous wreck\" worrying that she, too, might face serious cardiac risk.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Any story about a screening test should not only include the cost of the test (which this story did not), but more importantly, the costs of preventive care.\u00a0 In this case, the use of a statin drug simply based on a rather controversial laboratory test", "answer": 0}, {"article": "[It's 3 a.m. and you're depressed.\nThe researchers said enough clinical evidence now supports mental health professionals recommending light therapy as a treatment for depression.\nAlthough the light therapy helped many patients, it provided the most benefit to those who were also taking the antidepressant.\nBut now a study has found that light therapy also works in treating non-seasonal depression.\nExperts have known for some time that light therapy can improve the mood of people who feel especially down when the days get shorter and gloomier.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story squeaks by on this with mention that light therapy is \u201ccheap\u201d and easy to use. We would have preferred some numbers giving prices for the light sources that patients typically use at home and some estimate for a therapeutic course of psychotherapy (which is often provided in combination with light therapy).", "answer": 1}, {"article": "\u201cWith medicine, you always want to optimize a patient\u2019s outcome,\u201d Shastri said.\nIVM has the potential to improve the chances for women to have babies without a long course of hormones.\nPlus, the American Society for Reproductive Medicine (ASRM) committee opinion on IVM states that implantation rates for IVM\u2014between 5.5 and 21.6 percent\u2014 are a more reliable indicator of IVM success and are lower than expected for women of the same age who use IVF.\nFor starters, since there is less time involved with IVM, women who are undergoing chemotherapy, radiation or plan to have surgery may be good candidates.\nAlthough IVF is considered the standard of care, experts say some women may benefit from IVM.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Although the article states that IVM is less expensive than standard IVF because women undergo fewer hormone injections, it does not cite any cost figures for either procedure, or other assisted reproductive technologies. And it should.", "answer": 0}, {"article": "Oct. 17, 2010 -- Women aged 65 and older are advised to undergo bone mineral density (BMD) screening every two years, but those with normal results at age 67 may be able to wait 10 years before their next screening test, a new study suggests.\nTheir findings are based on the women's T-score, which is a measure of bone density.\nThe new findings are slated to be presented at the annual meeting of the American Society for Bone Mineral Research in Toronto.\nResearchers analyzed bone mineral density data from 5,035 women aged 67 or older who had their BMD tested at least twice during the 15-year study period.\n\"Our study found it would take about 16 years for 10 percent of women in the highest bone density ranges to develop osteoporosis.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "This story makes no mention of costs.", "answer": 0}, {"article": "That accounts for a small percentage of people.\nThe prescription-free test is the first to report on three specific BRCA1 and BRCA2 breast cancer gene mutations, according to the FDA.\nStill, the company, which already tests DNA for other health risks as well as ancestry, said this cancer test is \"a step in the right direction.\"\nBy analyzing DNA collected through a saliva sample, the test detects increased risk of developing breast, ovarian or prostate cancer.\n\u201cThe test should not be used as a substitute for seeing your doctor for cancer screenings or counseling on genetic and lifestyle factors that can increase or decrease cancer risk,\u201d he said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Cost isn\u2019t mentioned. The BRCA testing appears to be part of the $199 \u201chealth + ancestry service\u201d package provided by 23andMe \u2014 though the package description on the company website did not include BRCA at the time of this writing. While this is a significant out-of-pocket expense for most people, it is somewhat less expensive than some other genetic testing options. However, those other testing options are significantly more extensive. In other words, as one genetic counselor notes in a related article in The Atlantic, \u201c[23andMe] is not an inexpensive way to get your testing done more cheaply.\u201d", "answer": 0}, {"article": "Aug. 4, 2010 -- The plant extract resveratrol, found in the skin of red grapes, appears to suppress inflammation and may fight aging in humans, according to a new study.\nNow, Ghanim and colleagues say they have found that resveratrol reduces inflammation in humans that could lead to heart disease, stroke, and type 2 diabetes.\nThe volunteers took pills once a day for six weeks.\nBlood samples from those on placebo showed no significant change in pro-inflammatory markers.\nStudy author Husam Ghanim, PhD, of the University of Buffalo says the popular plant extract has been shown to prolong life and reduce the rate of aging in roundworms, fruit flies, and yeast, apparently because resveratrol affects a gene associated with longevity.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No discussion of the cost of the supplements used in the study. Doesn\u2019t cost matter? ", "answer": 0}, {"article": "The 12 poses, by their English names, were tree, triangle, warrior II, side-angle, twisted triangle, locust, bridge, supine hand-to-foot I, supine hand-to-foot II, straight-legged twist, bent-knee twist and corpse pose.\nEven if bone density did not increase, improvements in posture and balance that can accrue from the practice of yoga can be protective, Dr. Fishman said.\nBut all told, the team concluded, the results may lend support to Dr. Fishman\u2019s long-held belief that yoga can help reverse bone loss.\nAt the time the study was submitted for publication, \u201cwith more than 90,000 hours of yoga practiced largely by people with osteoporosis or osteopenia, there have been no reported or X-ray detected fractures or serious injuries of any kind related to the practice of yoga in any of the 741 participants,\u201d Dr. Fishman and his colleagues wrote.\nA pharmaceutical company is unlikely to fund a study that doesn\u2019t involve a drug, and in any event, the research requires a large group of volunteers tracked over a very long time.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "While the article did not specifically state how much it costs to do a 12 minute yoga session everyday, one can assume it is relatively inexpensive and cost is not really an issue here. \u00a0Where it becomes an issue is when yoga practitioners attend expensive classes, feel compelled to buy expensive yoga accessories, travel to India to spend time with yoga gurus, and generally spend lots of personal time practicing it, all which could lead to considerable costs.", "answer": 2}, {"article": "Your office thermostat is set for men's comfort.\nBased on other studies in the past that seemed to allude to marijuana use and later development of psychotic symptoms such as delusions or hallucinations, the researchers had thought they might find some associations to disease or other health conditions.\nThe researchers found no links to physical or mental health issues -- including depression, psychotic symptoms or asthma -- in any group, even those with very high use.\nUpdate: The study's findings generated significant controversy along with requests for supplemental analysis, according to the editors of the Psychology of Addictive Behaviors.\nThe participants fell into four groups: those with no use or low use of marijuana, early chronic users, those who only smoked during their teens and those who began using it later and continued using the drug.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "We\u2019ll rule this Not Applicable. \u00a0The story didn\u2019t discuss costs, and we acknowledge it would be difficult to pin down marijuana costs from different sources \u2013 from the time period in question in the analysis \u2013 or today.", "answer": 2}, {"article": "\"She had a persistent boil on her buttocks,\" he explained.\nRose Cooper, a microbiologist and honey expert at the University of Wales Institute at Cardiff, remains cautiously optimistic that the increased use of honey dressings will help better information to emerge.\nA 250-gram jar with UMF16, which is in the midrange, sells for about $28.95 on the Internet.\nThe most promising research, he and many other scientists say, focuses instead on bioactive honey's potency as a topical application.\nFor biochemist Peter Molan, honey's ancient power to heal is not a matter of faith.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does mention the cost of one jar of manuka that can be bought over the internet.", "answer": 1}, {"article": "That's the tantalizing premise behind Deplin, a prescription form of the B-vitamin folate. Although it has been on the market since 2006, Deplin is generating growing buzz at psychiatric conferences and among clinicians and patients, particularly those who haven't responded to antidepressants or did for a while only to have their depression return.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Good job here. The story notes that the monthly cost of Deplin can run as high as $98 and may not be covered by insurance.", "answer": 1}, {"article": "George Bray, an obesity researcher at Pennington Biomedical Research Center in Baton Rouge who has also studied this topic and who wrote the accompanying editorial in JAMA, says that other studies \"show that you can do well on any diet as long as you stick to it.\nMore research is needed to show that interesting results like these are applicable in real life, she says.\nOn a low-glycemic index diet, you would avoid highly processed carbs such as white bread, white rice, many snack foods, prepared breakfast cereals, sugary desserts and sugary beverages, she says.\nA new study is raising questions about the age-old belief that a calorie is a calorie.\n\"We think the low-carb and low-glycemic index diets, by not causing the surge and crash in blood sugar, don't trigger the starvation response.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The cost of these diets is not really in question. We\u2019ll call it not applicable.", "answer": 2}, {"article": "(Adenoids, glands at the roof of the mouth, are often removed along with tonsils.)\nThere aren't strong guidelines regarding the use of tonsillectomy to treat sleep disorders, so the doctors reviewed the evidence to see whether the surgery outperformed so-called watchful waiting -- monitoring the situation.\nTo qualify for the surgery, a child must have many recurring throat infections within a short span of time or severe sleep disturbances, said Dr. Sivakumar Chinnadurai, a co-author of the reviews.\nHowever, this strong benefit only applies to the first couple of years following surgery, Chinnadurai said.\nThe study results showed \"there may be new evidence that supports expanding the criteria and opening up the procedure to more individuals,\" said Dr. Alyssa Hackett, an otolaryngologist with the New York Eye and Ear Infirmary of Mount Sinai in New York City.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Nowhere in this HealthDay story is the subject of costs mentioned. While tonsillectomy is considered a common treatment, it is still surgery, and therefore somewhat expensive.\u00a0 One source online, insurer Blue Cross Blue Shield, quotes the average cost of the procedure as $5,442, although some or all of that may be covered by insurance. Even considering the cost of multiple doctors\u2019 visits and prescribed medication for throat infections over a year or two, the surgical cost still is higher, and that point should have been made in this story.", "answer": 0}, {"article": "Newsday's coverage of the Class of 2019, led by Mariano Rivera and Mike Mussina.\nFrom a Catholic school uniform to a hijab, LIers talk about their religious clothing.\nA hijab, a turban, a beard: What aren\u2019t you seeing?\nAt 14, MS-13 was his family.\nOver 24,000 employees at 116 LI companies were polled on what makes their employers great.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No mention of the costs associated with the type of physical therapy discussed or whether such therapy is covered by insurance or Medicare.", "answer": 0}, {"article": "We are excited to announce that FibromyalgiaTreating.com is now part of RedOrbit.com. All of the same great people, writers and editors but now with more firepower. We now have access to an enormous amount of additional research information from doctors and scientists. We can now extend to other conditions that may be part of your everyday lives and help you on a broad level if that is what you need. We are here for you and now, better than ever so sit back and enjoy the new Fibromyalgia Treating by RedOrbit!", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story notes the an additional $20 per mammogram with CAD when billed to Medicare. With the newer technology, costs to public health would increase via additional screening and unnecessary biopsies, and treatment would increase for cancers that may never become problematic (i.e. some forms of DCIS or ductal carcinoma in situ). ", "answer": 1}, {"article": "Graphic artist Colleen Kelly decided in 2000 that she had nothing to lose by enrolling in an experimental study of VNS.\nRobert \"Skip\" Cummins, Cyberonics's CEO, dismissed such criticism and said his company, whose sole product is VNS, faced similar skepticism after the device was approved for epilepsy in 1997.\nA report by Harvard Pilgrim Health Care, an influential mental health insurer in Boston, called it \"experimental, investigational and unproven.\"\nBecause that study lacked a control group and because patients received other depression treatments after the device was implanted, there is no way to know whether the device was responsible.\nHe noted that VNS is now accepted by insurers as a treatment for intractable seizures, which can be fatal if they are not controlled.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story explains the cost of the device and of the implantation procedure. It also explains that some insurers are reluctant to reimburse for this technology. ", "answer": 1}, {"article": "A study shows that not all good fats are the same when it comes to protecting your health\n\nA study shows that not all good fats are the same when it comes to protecting your health.\nReviewing the dietary advice as a whole is important, says Alice Lichtenstein, a spokesperson for the association, since changes in one area could have unexpected, and potentially harmful, effects on other eating habits.\nThe AHA further breaks down the unsaturated-fat advice by suggesting that people devote about 5% to 10% of their daily calories to foods containing linoleic acid.\nRamsden says the findings provide some refined understanding of unsaturated fats, which come in different chemical forms that may have varying benefits or risks.\nRamsden says the results highlight the need to study dietary ingredients in more detail, rather than lumping them together and assuming they have the same effect on the body.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The cost of vegetable oil with linoleic acid is not in question.", "answer": 2}, {"article": "Most are still of the opinion that sunscreens with an SPF of up to 50, and containing avobenzone and oxybenzone, efficiently protect the skin from both UVA and UVB ultraviolet rays.\nOur two cents' worth:There's no reason not to take a flyer on Fernblock \u2014 actress Reese Witherspoon gives it a hearty endorsement - but keep slathering up, too.\nIf you're squeamish about vitamin A, there are a number of alternatives.\nAs an alternative, there's a relatively new product called Fernblock, which claims to protect the skin internally by systemically inhibiting the absorption of ultraviolet rays.\nYour skin vs. the sun: A sunscreen pill?\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "\u00a0The costs of Fernblock are not discussed. For all we know, it might be free. As the story says, \"There\u2019s no reason\" not to try it.", "answer": 0}, {"article": "Dozens of biotechnology and pharmaceutical companies including Alnylam, Merck, Pfizer, Novartis and Roche are looking for ways to manipulate RNA to block genes that make disease-causing proteins involved in cancer, blindness or AIDS.\nThe finding, reported in the journal Nature on Sunday, offers early proof that a new treatment approach called RNA interference or RNAi might work in people.\nBut getting the treatment to the right target in the body has presented a challenge.\nOther teams are using fats or lipids to deliver the therapy to the treatment target.\nDavis could not say whether the therapy helped shrink tumors in the patients, but one patient did get a second cycle of treatment, suggesting it might be.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No costs discussed, but we can understand why given the very early stage of this research. Not applicable in this case.", "answer": 2}, {"article": "Wu says in a news release: \u201cThe system we have is portable and as soon as you lie down you can get a scan -- it\u2019s real-time.\nThe real-time imaging minimizes the chance of missing a breast tumor during scanning.\u201d Wu says it will even work through a bra.\nCurrent mammography testing works well for detecting breast cancer in women over 50 with results of up to 95% accuracy.\n\u201cAlthough there is still research to be done, the system has great potential to bring a new way for breast cancer diagnosis.\u201d\n\nCarolyn Rogers, clinical nurse specialist at Breast Cancer Care in the U.K., says in an emailed statement: \u201cEvidence is needed to demonstrate the accuracy and uses of this device.\nRadiofrequency or microwave technology for breast cancer detection is not new, but what Zhipeng Wu, PhD, from Manchester\u2019s School of Electrical and Electronic Engineering has achieved is the speed of results and portability.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "We wouldn\u2019t expect a discussion of cost implications for a technique still in its formative years. But since the article states that \u201ccosts are reduced,\u201d we have to address it. \nFirst of all, costs compared to what? Mammography? The other investigational techniques using RF or microwaves just mentioned?\nLet\u2019s assume the comparator is mammography. It may be that, if and once there\u2019s an available product, costs for each screening visit can be reduced. But the total costs depend on how effective it is. Without knowing how good it is at picking up breast cancer (sensitivity) and excluding signals that aren\u2019t breast cancer (specificity), we don\u2019t know its role. It might be too unreliable to replace mammography. Poor sensitivity leads to missing cancers, which cost life and money. Poor specificity leads to more unnecessary biopsies and treatments; if indeed people would screen themselves at home, poor specificity also means more unnecessary doctor visits. Also, will clinic and home uses be covered by insurance?\n As the independent sources says, we don\u2019t know how the new device will be used. Until trials determine whether it will replace mammography, supplement it, or sink out of memory, we can\u2019t know the total costs. To say vaguely that \u201ccosts are reduced\u201d may not, therefore, be correct.", "answer": 0}, {"article": "In the United States, the Affordable Care Act designates HIV testing as a preventive service, meaning that all insurers must cover it without charging a co-pay.\nAnd because the incidence of other sexually transmitted infections declined for these men, after the diagnosis, the scientists had reason to believe the self-reports of condom usage were accurate.\nAdopting some version of the British at-home test could help Americans who have already been tested keep up their screening schedule.\nA sizable fraction of the undiagnosed may be people who have been tested, just not recently enough.\nOraQuick, on the other hand, is an oral-based at-home test that does let users see their results immediately, but it has an 8.3 percent chance of a false negative.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story lists the test cost of $45. However, the story would have offered a more complete picture of cost if it had estimated the annual cost of regular screening and provided costs for other tests.", "answer": 1}, {"article": "RELATED: What we know about how cancer starts could all be wrong\n\nIn January 2013, nearly four months after Landon\u2019s initial diagnosis, the two went from Utah to Colorado, where Riddle purchased an alternative treatment fraught with complicated politics and plenty of skepticism\u2014especially when it comes to saving the life of a preschooler with a potentially fatal disease.\nBut Landon appeared to be among a small percentage of children with leukemia for whom the treatment was unbearable, excruciating.\nShe was willing to do whatever it took to keep him on cannabis.\nBut to do that, the family would need to leave Utah, where all cannabis is illegal.\nThe chemo had compromised his immune system so severely that he caught every bug in the hospital, just about every strain of stomach viruses, influenza and the common cold.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There is no discussion of the cost of the cannabis treatment.", "answer": 0}, {"article": "Previous research has also shown activity in the endocannabinoid system declines as we get older, indicating it plays a role in the progression of aging.\n\u201cTogether, these results reveal a profound, long-lasting improvement of cognitive performance resulting from a low dose of THC treatment in mature and old animals,\u201d the scientists write.\nWith a cannabinoid like THC, which does have adverse effects in certain individuals, there would be worries about the chronic dosing of this kind of medicine.\nMoving this research forward, however, will be problematic: \u201cTesting in humans is going to be difficult.\nMany scientists are currently looking at its potential use as a treatment for neurological conditions, including multiple sclerosis, epilepsy and Parkinson\u2019s disease.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Although the story describes mouse experiments, it draws parallels to human marijuana use and some mention of the cost of its use\u2013recreationally or medicinally\u2013would have been useful.", "answer": 0}, {"article": "Stephen Buckley, head of information at the mental health charity Mind, said: \u201cWe welcome research which adds to our understanding of treatments and medications that may work for people experiencing mental health problems.\nIf the test proves effective it is hoped that by measuring patients\u2019 level of blood inflammation it would identify which of them would benefit from receiving antidepressants soon after their diagnosis to stop their condition worsening.\n\u201cThis study provides a clinically suitable approach for personalising antidepressants therapy.\nThe experts involved believe the breakthrough could lead to depressed patients receiving personalised treatments that are more likely to relieve their symptoms.\n\u201cSuch a finding and a test to back it up would be critical to advancing our understanding of the biological causes of depression.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Costs were not included. If it\u2019s not too soon to speculate that \u201cthis\u00a0breakthrough could lead to depressed patients receiving personalized treatments that are more likely to relieve their symptoms,\u201d then it\u2019s not too soon to think about what that test might cost.\u00a0", "answer": 0}, {"article": "And the paper made no mention of the costs attached to long-term pharmacotherapy,\" Katz added.\nIt helped patients in clinical trials lose as much as 13 percent to 15 percent of body weight.\nHowever, one expert was not sold on this new drug.\nAfter one year, 47.5 percent of those taking lorcaserin had lost 5 percent or more of their body weight.\nA potential player in fighting the obesity epidemic, lorcaserin is a new type of weight-loss drug that works by acting on serotonin, a chemical associated with feelings of well-being and feeling full, and does not appear to increase blood pressure or cause any other heart problems, according to the researchers, whose work was sponsored by the drug manufacturer.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There is a passing reference to costs, which is more than the other two stories provided. But it would not have taken much effort to gather some basic cost ranges for a drug that has to be taken twice a day for at least a year to see results.", "answer": 0}, {"article": ".\n\"Many would have predicted that tendon healing is inflammation-linked,\" said Thoru Pederson, Ph.D., Editor-in-Chief of The FASEB Journal, \"but that the anti-inflammatory roles of TSCs could be so potent, and so amplifiable, is a striking finding.\"\nIn vivo, the researchers evaluated inflammatory responses by TSCs, including infiltration of macrophages (white blood cells that consume damaged or dead cells) and expression of anti-/proinflammatory cytokines, at different time points.\n\"Our findings represent an important foundation for the development of a new treatment that would regulate overwhelmed inflammation for tendon ruptures and tears, tendonitis, tendinopathy, and other tendon injuries and diseases.\"\nIn their study, Lee and colleagues used both in vitro human models and in vivo rat models.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "This is basic research, so no one is in a position to talk about specific costs. But when a release broaches therapy as a likely goal, as is the case, then it indeed needs to speak to cost. Such treatments run into the thousands of dollars, with iffy participation by insurance companies.", "answer": 0}, {"article": "Watching her patients undergo bone marrow transplant ?\nOf the 12 AML patients who received this experimental T-cell therapy after a transplant put their disease in remission, all are still in remission after a median follow-up of more than two years.\nBecause it was the first study of this particular approach, the researchers focused on a high-risk group -- AML patients undergoing bone marrow transplant who had certain genetic or disease characteristics that decrease the chance of long-term transplant success -- \"a hard population of patients,\" Chapuis said, many of whom \"were horribly sick.\"\nThis is the team's first trial of this strategy, which was initially developed in the lab of Dr. Phil Greenberg, one of the study's leaders and the head of Fred Hutch's Program in Immunology.\nChapuis's role in this trial is on the laboratory side of the research, ensuring the quality of the genetically engineered cell products and monitoring the activity of the cells after infusion.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Although this research in still in early stages, the release could have noted that immunotherapy can be very expensive. Some courses of treatment cost $100,000, while others need to be given continually at a cost that can exceed $10,000/month.", "answer": 0}, {"article": "Publicity in recent years about emotional, cognitive, and memory problems in aging football and hockey players who suffered multiple concussions during their careers has raised the anxiety level around the topic. A lawsuit by thousands of NFL players who claim the league did not keep them well enough informed about the long-term risks of concussion - dementia is one of them - is based in Philadelphia and has raised even higher the profile of what doctors call mild traumatic brain injury.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "As one of the experts in the story points out, \u201cthe treatment needs to be individualized.\u201d\u00a0 All therapies have costs.\u00a0 Some stab at estimating a range of time/costs could have been made. With the story discussing hospitals adopting protocols, it certainly seems a cost could be identified for a protocol.", "answer": 0}, {"article": "Professor Paul Workman, Chief Executive of The Institute of Cancer Research, London, said:\n\n\"If we're going to drive further improvements in survival from cancer, it's essential that we find ways of prolonging life in people whose cancers have evolved and become resistant to treatment.\nWe hope our results lead to the adoption of this drug combination in breast cancer, where it delays the need to start chemotherapy by an average of nine months.\nThe new research, published today (Thursday) in The Lancet Oncology, shows that even women with specific genetic changes conveying resistance to hormone therapy can benefit from the new drug combination.\nThe combination allowed many women with metastatic hormone-receptor-positive, HER2-negative cancer to delay the start of chemotherapy, which is the traditional treatment option in these patients once hormone drugs have stopped working.\nThe research showed that using 'liquid biopsies' that measure cancer DNA circulating in the blood to detect PIK3CA, and tests for blood hormone levels, the palbociclib combination worked in all types of hormone-receptor positive, HER2 negative breast cancer.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The news release does not mention cost. The wholesale cost for fulvestrant 500 MG is $1,845/month and palbociclib is approximately $9,850. A 2015 report on palbociclib\u2019s cost by a pharmacy benefits manager stated it could potentially be one of the top 10 most costly cancer drugs.", "answer": 0}, {"article": "WASHINGTON -- A U.S. Food and Drug Administration panel of outside medical experts backed a Novartis AG drug, Exelon, for treatment of dementia in patients with Parkinson's disease.\n\nExelon is currently on the market to treat mild to moderate Alzheimer's disease. The FDA said it wasn't sure whether dementia associated with Parkinson's was much different than dementia associated with Alzheimer's. Dementia is a condition that typically first presents itself as memory loss greater than what would be expected as part of the normal...", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not mention any cost information for Exelon (rivastigmine). ", "answer": 0}, {"article": "But another found that the stroke rate was 22 percent lower in people who ate chocolate once a week, and a third reported that death from stroke was 46 percent lower in those who ate 50 grams of chocolate once a week.\nThe health benefit may come from antioxidants called flavonoids that are present in chocolate, Saposnik said.\nAnd dietitians say too much chocolate can be harmful.\nFor now, said registered dietitian Katie Clark, \"caution should be taken not to promote chocolate as a health food,\" even though it's fine in moderation.\nBut Keith-Thomas Ayoob, an associate professor at Albert Einstein College of Medicine in New York City who studies nutrition, said chocolate does have its benefits.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The cost of chocolate is not in question.", "answer": 2}, {"article": "June 7, 2012 -- Drinking three cups of coffee per day may help turn the tide against Alzheimer's disease among older adults who are already showing signs of memory problems, a new study shows.\nCoffee was the main, or only source, of caffeine among people in the study.\nThe findings will appear in the Journal of Alzheimer's Disease.\nThis is equivalent to drinking several cups of coffee a few hours before giving blood.\nThe new study included 124 people aged 65 to 88 who had mild cognitive impairment, which is the medical term for mild memory loss.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The cost of coffee is not in question.", "answer": 2}, {"article": "For further information please contact:\nOnce the pharmacokinetic study and an additional safety and efficacy Phase 3 trial in adults currently under way are complete later this year, Shire plans to add these study results to its existing SHP465 data set to submit a Class 2 resubmission for FDA approval of the medicine for treatment of ADHD.\n\n\u2022 Study addresses key U.S. Food and Drug Administration (FDA) requirement, keeping SHP465 on track for potential 2017 U.S. launch\n\u2022 Key secondary endpoint also met, showing higher proportion of patients were rated improved (p<0.001)\n\u2022 Data add to overall robust clinical development program for SHP465\n\nShire plc (LSE: SHP,NASDAQ: SHPG) today announces positive topline results from a four-week Phase 3, randomized, double-blind, multi-center, placebo-controlled, dose-optimization, safety and efficacy study, SHP465-305, in children and adolescents aged 6-17 years with Attention-Deficit/Hyperactivity Disorder (ADHD).\nIncluding study 305 and previous studies, Shire now has a robust database of 15 clinical studies evaluating SHP465 in more than 1,100 subjects.\nThe completion of SHP465-305 addresses an FDA requirement to evaluate the safety and efficacy of SHP465 in children and adolescents prior to filing a Class 2 resubmission of the medicine for FDA approval.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There is no discussion of the eventual price point of this drug. This is important if commonly used drugs like Adderall are becoming available as a generic and subsequently much less expensive. According to GoodRx.com, the cost for a 30-day supply of Adderall ranges from $75 to $150. Costs for Vyvanse, a newer stimulant for ADHD, costs around $250 for 30 pills. Concerta, which came on the market around the same time as Vyvanse, costs about $250 for 30 pills. Generic Ritalin (one of the oldest ADHD stimulant drugs) averages around $45 for a month\u2019s supply.\nCompanies sometimes develop new, yet no more effective or safe, formulations because they can sell them at higher costs as a new patented drug.", "answer": 0}, {"article": "In a study published in the Jan. 19 issue of Neurology, Carlesimo and colleagues found that DTI scanning predicted declines in memory performance with more accuracy than traditional MRI.\n\"This type of brain scan appears to be a better way to measure how healthy the brain is in people who are experiencing memory loss,\" Carlesimo says in a news release.\nBut it is increasingly clear that DTI can also be used to identify very small structural changes in the gray matter of the brain, which is critical for learning and memory, researcher Giovanni A. Carlesimo, MD, PhD, of Italy's Tor Vergata University tells WebMD.\n\"This might help doctors when trying to differentiate between normal aging and diseases like Alzheimer's.\"\nThe technique, known as diffusion tensor imaging (DTI) or diffusion MRI, is used to assess changes in the white matter regions of the brain.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "\u00a0There was no discussion about direct costs for this test.", "answer": 0}, {"article": "Plaque psoriasis is an autoimmune condition that causes cells to build up on the surface of the skin, forming thick red patches and flaky silver-white scales.\nHe adds that the data on Siliq suggests that it is not only effective in treating psoriasis, but that many patients experience improvement in anxiety and depression, as well.\nBecause of these events, the labeling for Siliq will include a Boxed Warning, and the drug will only be available through a restricted REMS (Risk Evaluation and Mitigation Strategy) program.\nIn order to prescribe it, doctors must be certified with the program and must counsel patients about this risk.\nIn the three clinical trials considered for drug approval, more than 50% of patients who used Siliq achieved total skin clearance\u2014the ultimate goal of psoriasis treatments\u2014within a year.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "We\u2019ll give this story credit for mentioning cost, when it states\u00a0\u201cpricing information is not available at this time.\u201d However, the story would have been stronger if it had explained the known costs of similar injectable drugs, as we mention in our review of the FDA news release on this drug, and\u00a0as discussed here. It\u2019s likely this new drug would be in a similar price range.", "answer": 1}, {"article": "Their median age was 63.\nBut with better therapies to control the cancer systemically and improved imaging that finds ever-smaller deposits of cancer in other parts of the body, it may be time to see whether surgery also can help increase the length of survival times, they said.\nTwo small prospective studies have suggested no survival difference among women with Stage 4 breast cancer who have surgery and those who don't, he said.\nIn retrospective research, it's impossible to filter out the countless reasons that a woman and her doctor might have made the decision to treat the cancer with or without surgery, leaving the conclusions unreliable for clinical decision-making, he said.\nStill there may be reasons to remove the cancer in the breast.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The cost of breast surgery in the US varies widely depending on the type, hospital and region, and so we acknowledge that it would have been difficult to provide solid numbers here. Nevertheless, we feel\u00a0that cost remains relevant for this piece. This study basically argues that surgery plus other aggressive non-surgical treatment vs. non-surgical treatment alone may lead to longer survival. Since this isn\u2019t proven, one could reasonably ask about the costs of these two approaches. This may be analogous to the prior use of autologous bone marrow transplantation (BMT) in women with metastatic breast cancer. The high cost of this treatment led to fights with insurers over coverage and finally to a randomized trial that showed no benefit. We don\u2019t do autologous BMT anymore. Could a similar scenario play out here? The question seems worth asking and addressing.", "answer": 0}, {"article": "\"I think there\u2019s no one answer,\u2019\u2019 Goldstein said.\nThe drug, which is being developed by the giant German drug maker Boehringer Ingelheim, could become the first treatment approved by U.S. regulators for women who suffer from hypoactive sexual desire disorder.\nIt could take two to three years to come to market in the United States, the company said.\n\"I\u2019m hoping this will help the women who need it.\u2019\u2019\n\nOne expert, Andrew Goldstein who runs the Sexual Wellness Center in Annapolis, Md., described a \"huge\u2019\u2019 unmet need for a medical treatment.\nThe issue of a woman\u2019s libido is more complicated than the dysfunction treated by the well-known little blue pill, according to women\u2019s sexual health experts.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No cost data was provided for flibanserin.\u00a0 But an estimate of the potential U.S. market, up to $100 million in sales, was given.\u00a0 Those sales estimates had to be based on some price assumptions.\u00a0 What where they? \u00a0 It doesn\u2019t seem that you should provide the one number without providing the other. How might the cost of flibanserin compare to the cost of drugs to treat erectile dysfunction? ", "answer": 0}, {"article": "A little bit of current may calm the tremors of Parkinson\ufffds disease, ease depression and epilepsy, and awaken those with terrible injuries.\nA glimpse of Mom must first register on your occipital lobes as a pattern of light and shadow.\nIt's harder than you think to say hello to your mother--at least in terms of the work your brain has to do.\nFrom there it is relayed to your memory center, where it is identified by comparison with every other face you've ever seen.\nYou must then summon the speech centers in your frontal lobes, which recruit your breath and muscles and at last allow you to utter the words Hi, Mom.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No estimates of the cost of this treatment were provided.", "answer": 0}, {"article": "Behavioral counseling is widely recommended, with medication, to help smokers quit.\nBetter strategies are needed to prevent relapse, he tells WebMD.\nThe findings are at odds with clinical trials, Connolly says.\nSmoking cessation experts and a maker of nicotine replacement therapies took issue with the findings.\nThe results of the new study are published online in Tobacco Control.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "This story discussed costs in the context of overall sales figures. \u201cDeciding how best to get smokers to quit for good is a public health challenge. Sales of the nicotine replacement products have risen, Connolly says. Sales totaled $45 million in 1984, when nicotine gum was introduced. Since 1997, sales have totaled more than $800 million annually.\u201d We wish the story had included some examples of the costs of the individual products compared to cigarettes.\nThe cost of 8 weeks of the nicotine patch is approximately $160-200.", "answer": 1}, {"article": "test found a small cancer, and he does not want to take a chance that it will grow slowly and not cause him problems.\nYet changing medical practice can be difficult.\nOften it is easier to just order the test.\nAnd doctors, he added, have many inducements to screen.\n\u201cIt is not all pure data that is promoting aggressive screening.\u201d Dr. Andriole is directing a National Cancer Institute study of 76,000 men that failed to find a screening benefit after 10 years.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There was no discussion of costs, either in terms of the actual dollar value involved in routine PSA testing or for follow-up biopsy and treatment.", "answer": 0}, {"article": "Platelets, the blood cells that promote clotting, contain hundreds of proteins, called growth factors, that are important in repairing injuries.\nThose who seek this treatment must look for a clinician with considerable PRP experience \u2014 someone who does the procedure several times a day, not once or twice a month \u2014 and who has a good success rate, Ferrell says.\nFerrell told me not to use nonsteroidal anti-inflammatories, such as ibuprofen, for a week after the injection because the goal is to encourage, not stifle, inflammation.\nStill, \u201cit has significant cost savings\u201d compared with surgery, Ferrell says.\nThe outcome was excellent, but the recovery was long and horrible.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story attempted to discuss cost by citing the difference in price\u00a0between shoulder surgery ($13,000) and the PRP treatment ($1,000, in this case for two injections). This is sufficient enough for a Satisfactory rating, but barely.\nWhile this does give readers some idea of the possible cost difference in treatments, there is no assurance that the charges in the author\u2019s case are typical for those for the general\u00a0public. It is simply one single data point which is fairly useless to the public. And, since there is no evidence of benefit or how many shots one might require, cost could be all over the place.", "answer": 1}, {"article": "Presenting at the meeting, Shraddha Sapkota, a graduate student in neuroscience at University of Alberta, and her colleagues described how they carefully analyzed the saliva of a group of volunteers participating in an aging study.\nThe results aren\u2019t conclusive enough yet for doctors to start using them to distinguish people who are more likely to develop Alzheimer\u2019s, but that\u2019s the goal, says Sapkota.\nExperts now believe that the biological processes behind the neurodegenerative condition begin years, if not decades, before memory problems and confusion become noticeable.\nBy comparing their saliva components, the scientists found that each of the three groups showed slightly different patterns of compounds, which could form the basis of a relatively easy and non-invasive way to determine which people are at higher risk of developing more serious degenerative brain conditions.\nIdeally, for example, isolating those with MCI might help doctors to focus in on a group of patients who might be at higher risk of developing Alzheimer\u2019s and therefore might need more intensive and regular testing.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There is no mention in this short story about the potential costs of such a test, if it proved to be viable. Of course, it\u2019s too early to say anything definitive about cost, and offering a specific number might mislead readers by implying that the test is anywhere near ready to be used. But we think the story could have offered some sense of the technology behind the test and whether it\u2019s advanced/expensive or cheap/widely available. Other tests using saliva are in use today and could offer a general comparison point to suggest the costs of a new test.", "answer": 0}, {"article": "Stay in touch on Linkedin, on Twitter @EpicSciences or on Facebook.com/EpicSciences.\nIt is estimated that 50,000 patients a year may be eligible for and benefit from the Oncotype DX\u00ae AR-V7 Nucleus Detect\u2122 test.\nEpic Sciences' goal is to increase the success rate of cancer drugs in clinical trials and improve patient outcomes by providing physicians real-time information to guide treatment choices.\nThrough a blood draw, the test detects AR-V7 protein in the nucleus of circulating tumor cells utilizing Epic Sciences' No Cell Left Behind\u00ae platform to accurately identify patients who are resistant to androgen receptor (AR)-targeted therapies and who should instead switch to chemotherapy.\nThe blood test called, Oncotype DX\u00ae AR-V7 Nucleus Detect\u2122 is commercially available in the U.S. through Epic Science's partnership with Genomic Health, Inc. (NASDAQ: GHDX).\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The $3,980 price tag for this test wasn\u2019t mentioned. The release notes that the Centers for Medicare and Medicaid Services (CMS) are currently evaluating whether the test will be covered in the future. In other words, it is not currently covered by Medicare.\u00a0 We aren\u2019t told whether other insurers cover the test.\nThere was also no information about the costs of the treatments involved. Hormone therapies for prostate cancer are especially pricey, running more than $10,000 a month, according to published reports.", "answer": 0}, {"article": "People with painfully damaged knees and hips have increasingly turned to \"minimally invasive\" joint-replacement surgery. But these relatively new procedures, though they promise shorter recuperation times, are raising concerns about potential complications.\n\nMany surgeons in recent years have performed joint replacements with ever smaller incisions. In minimally invasive surgery, the incision is typically about three to four inches long, roughly half that of traditional surgery. By cutting less of the surrounding tissue...", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "\nThe story cites a cost of ~$40,000 exclusive of hospital costs, and says this is roughly the same as traditional total joint replacement.", "answer": 1}, {"article": "Genetic factors that increase prostate cancer risk include inheritable variations in genes known as BRCA1 and BRCA2.\nThe ICR-led study is aiming to find out whether screening men who have genetic variants that increase their prostate cancer risk could lead to earlier diagnosis.\nThe study found that the predictive value of screening these men \u2014 expressed as the number of cancers detected relative to the number of tissue samples taken \u2014 was 48 percent, far higher than the 24 percent achieved in population-wide screening.\nThe findings suggest that by narrowing the focus of prostate cancer screening to those whose genes put them at most risk, doctors would catch more cancers early as well as reducing the potential for costly and damaging overdiagnosis.\n\u201cAlthough these are early results, it appears that (prostate cancer) screening is reasonably accurate at predicting potentially aggressive prostate cancer among men at higher risk of the disease due to a genetic predisposition,\u201d said Ros Eeles, who led a research team from Britain\u2019s Institute of Cancer Research (ICR) and Royal Marsden hospital.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story makes no mention of the costs of the test, associated follow-up procedures or the tests for BRCA mutations.", "answer": 0}, {"article": "In the United States, an estimated 42,000 corneal grafts a year are performed using tissue from posthumous donors, but there are sometimes problems with rejection and experts say failure rates are significant.\nThe scientists, whose work was published Wednesday in the Science Translational Medicine journal, said their findings offered hope for the millions of people who go blind each year because of a worldwide shortage of corneas for donation.\nFagerholm said the patients in this trial had no problems with rejection and did not need long-term immune suppression drugs to help their bodies accept the corneas.\nThe biosynthetic corneas also became sensitive to touch and the treated eyes began producing normal tears, the researchers said.\nAfter the patients were also fitted with contact lenses, which is common after corneal transplants, their vision was comparable with that of patients who undergo regular human corneal tissue transplants.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There is no discussion of costs. Again, charitiable organizations who work in this area could have provided some ballpark figures for human corneal transplants. The researchers claim in another story that this option would be cheaper. At a minimum, a dollar figure would have been good context.", "answer": 0}, {"article": "Letters being mailed to study participants advise them to discuss with their doctors whether they should have additional scans or not.\nMany smokers already had sought out spiral CTs, even though the American Cancer Society hasn't recommended the test - citing a lack of clear evidence that they work - and most insurance doesn't cover the $300 to $400 cost.\nThe massive National Lung Screening Trial enrolled 53,000 current or former smokers to try to settle the debate.\nNor is it clear if the study results are applicable to all smokers.\nIt found 20 percent fewer deaths from lung cancer among those screened with spiral CTs than among those given chest X-rays, the NCI said Thursday, a difference significant enough that it ended the study early.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "\n\n\nThe story reports that these scans typically cost $300-400 and are not generally covered by insurance. The story would have been better if it had clearly pointed out that the potentially huge cost of such a screening program, because hundreds of smokers had to be scanned to extend one life in this trial and follow-up tests and treatments cost much more than the initial scan. Nonetheless, we\u2019ll give it the benefit of the doubt on this criterion. The New York Times never specified the scans\u2019 costs.\n", "answer": 1}, {"article": "scans on 991 people ages 50 to 90.\nThe question, though, was whether it helped the patients and their doctors to know what the M.R.I.\u2019s had found.\nHe told her bluntly that her pain was caused by arthritis, not the torn cartilage.\nAnd the answer, Dr. Modic reported, is that it did not.\nscan, he said, radiologists should put the findings in context.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story adequately describes what insurers pay for the scans.", "answer": 1}, {"article": "\u201cIt\u2019s very muddy now exactly how long we need to treat patients,\u201d George said.\nBased on the results, George and his team say, it would be necessary to treat 12 depressed patients with TMS in order to have one patient recover.\n\u201cIt looks as if from this trial you at least need to try three weeks and maybe even six weeks before you would give up.\u201d\n\nPatients who got better were prescribed venlafaxine - marketed as Effexor \u2014 and a small dose of lithium, noted George, a combination that\u2019s been shown to help people stay well after their depression has remitted.\nGeorge said he and his colleagues would like to study whether giving people TMS intermittently instead of putting them on antidepressants would produce equally durable effects.\nIn a second phase of the study, all patients were given the real TMS treatment.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story doesn\u2019t discuss the cost of the TMS machine or the cost of a typical course of treatment. This is a significant\u00a0oversight considering that many health insurance plans offer limited coverage for mental health expenses.\u00a0Does a patient who pays\u00a0out of pocket have any hope of\u00a0affording\u00a0TMS treatment? The article\u00a0doesn\u2019t say.\u00a0", "answer": 0}, {"article": "All of these study participants \u2014 largely people in their 70s, all with a diagnosis of either \"mild cognitive impairment\" or atypical dementia \u2014 are living with the unconfirmed suspicion that they have Alzheimer's. The study is underwritten by the Centers for Medicare & Medicaid Services and the Alzheimer's Assn. It set out to find out whether knowing \u2014 getting the costly test that would offer either confirmation or reprieve \u2014 would change the way that patients with cognitive troubles are treated, or the way that they plan their lives.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "A close call here. The story does discuss costs, but perhaps not adequately. It cites a range of costs early on \u2014 \u201c$3,000-5,000\u201d \u2014 but it\u2019s not clear whether that\u2019s for PET scans or transcranial magnetic stimulation or whether that range covers both.", "answer": 1}]